doi,model_number,stratified,stratgrp,subanalysis,subgrp,outcome,measure,measure_comments,covariates,comparison,ref,compare,point,lower,upper
10.1097/AOG.0000000000003552,1,Yes,Achieved sterilization at time of cesarean delivery,No,NA,Sterilization at the time of cesarean delivery,Percent,NA,None,1,N/A,Black or African American,44.5,-99,-99
10.1097/AOG.0000000000003552,1,Yes,Achieved sterilization at time of cesarean delivery,No,NA,Sterilization at the time of cesarean delivery,Percent,NA,None,2,N/A,White,34.4,-99,-99
10.1097/AOG.0000000000003552,1,Yes,Achieved sterilization at time of cesarean delivery,No,NA,Sterilization at the time of cesarean delivery,Percent,NA,None,3,N/A,Hispanic,16.4,-99,-99
10.1097/AOG.0000000000003552,1,Yes,Achieved sterilization at time of cesarean delivery,No,NA,Sterilization at the time of cesarean delivery,Percent,NA,None,4,N/A,Asian,1.6,-99,-99
10.1097/AOG.0000000000003552,1,Yes,Achieved sterilization at time of cesarean delivery,No,NA,Sterilization at the time of cesarean delivery,Percent,NA,None,5,N/A,Other,3.1,-99,-99
10.1097/AOG.0000000000003552,2,Yes,Did not achieve sterilization at time of cesarean delivery,No,NA,Nonachievement of sterilization at time of cesarean delivery,Percent,NA,None,1,N/A,Black or African American,63,-99,-99
10.1097/AOG.0000000000003552,2,Yes,Did not achieve sterilization at time of cesarean delivery,No,NA,Nonachievement of sterilization at time of cesarean delivery,Percent,NA,None,2,N/A,White,26,-99,-99
10.1097/AOG.0000000000003552,2,Yes,Did not achieve sterilization at time of cesarean delivery,No,NA,Nonachievement of sterilization at time of cesarean delivery,Percent,NA,None,3,N/A,Hispanic,7,-99,-99
10.1097/AOG.0000000000003552,2,Yes,Did not achieve sterilization at time of cesarean delivery,No,NA,Nonachievement of sterilization at time of cesarean delivery,Percent,NA,None,4,N/A,Asian,0,-99,-99
10.1097/AOG.0000000000003552,2,Yes,Did not achieve sterilization at time of cesarean delivery,No,NA,Nonachievement of sterilization at time of cesarean delivery,Percent,NA,None,5,N/A,Other,4,-99,-99
10.1097/AOG.0000000000003552,5,No,NA,Yes,Black or African American,Sterilization at the time of cesarean delivery,OR,NA,"Age, gestational age at delivery, adequate prenatal care, Hispanic, Asian, other race or ethnicity, married",1,White,Black or African American,0.95,0.87,1.03
10.1097/AOG.0000000000003552,6,No,NA,Yes,"Hispanic, Asian, other race or ethnicity",Sterilization at the time of cesarean delivery,OR,NA,"Age, gestational age at delivery, adequate prenatal care, Black or African American, Married",1,White,"Hispanic, Asian, other race or ethnicity",1.04,0.94,1.15
10.1097/AOG.0000000000003552,3,No,NA,Yes,Black or African American,Sterilization at the time of cesarean delivery,OR,NA,None,1,White,Black or African American,0.53,0.31,0.89
10.1097/AOG.0000000000003552,4,No,NA,Yes,"Hispanic, Asian, other race or ethnicity",Sterilization at the time of cesarean delivery,OR,NA,None,1,White,"Hispanic, Asian, other race or ethnicity",1.4,0.67,3.09
10.1016/j.ygyno.2019.03.007,1,No,NA,No,NA,germline testing performed,Percent,NA,None,1,N/A,Black,40,-99,-99
10.1016/j.ygyno.2019.03.007,1,No,NA,No,NA,germline testing performed,Percent,NA,None,2,N/A,Hispanic White,56.63,-99,-99
10.1016/j.ygyno.2019.03.007,1,No,NA,No,NA,germline testing performed,Percent,NA,None,3,N/A,Non-Hispanic White,59.72,-99,-99
10.1016/j.ygyno.2019.03.007,1,No,NA,No,NA,germline testing performed,Percent,NA,None,4,N/A,Other/unknown,41.18,-99,-99
10.1016/j.ygyno.2019.03.007,2,No,NA,No,NA,Somatic testing performed,Percent,NA,None,1,N/A,Black,27.5,-99,-99
10.1016/j.ygyno.2019.03.007,2,No,NA,No,NA,Somatic testing performed,Percent,NA,None,2,N/A,Hispanic White,24.1,-99,-99
10.1016/j.ygyno.2019.03.007,2,No,NA,No,NA,Somatic testing performed,Percent,NA,None,3,N/A,Non-Hispanic White,31.25,-99,-99
10.1016/j.ygyno.2019.03.007,2,No,NA,No,NA,Somatic testing performed,Percent,NA,None,4,N/A,Other/unknown,17.65,-99,-99
10.1016/j.ygyno.2019.03.007,3,No,NA,No,NA,Germline testing performed,OR,NA,"Age, treating medical center, Insurance type, family history of cancer, personal history of cancers, year of diagnosis, lines of treatment, FIGO stage, type of patient",1,Non-Hispanic White,Black,0.58,0.25,1.36
10.1016/j.ygyno.2019.03.007,3,No,NA,No,NA,Germline testing performed,OR,NA,"Age, treating medical center, Insurance type, family history of cancer, personal history of cancers, year of diagnosis, lines of treatment, FIGO stage, type of patient",2,Non-Hispanic White,Hispanic White,0.99,0.57,1.71
10.1016/j.ygyno.2019.03.007,3,No,NA,No,NA,Germline testing performed,OR,NA,"Age, treating medical center, Insurance type, family history of cancer, personal history of cancers, year of diagnosis, lines of treatment, FIGO stage, type of patient",3,Non-Hispanic White,Other/Unknown,0.61,0.19,2
10.1016/j.ygyno.2019.03.007,4,No,NA,No,NA,Somatic testing performed,OR,NA,"Age, treating medical center, Insurance type, family history of cancer, personal history of cancers, year of diagnosis, lines of treatment, FIGO stage, type of patient",1,Non-Hispanic White,Black,2.39,0.81,6.38
10.1016/j.ygyno.2019.03.007,4,No,NA,No,NA,Somatic testing performed,OR,NA,"Age, treating medical center, Insurance type, family history of cancer, personal history of cancers, year of diagnosis, lines of treatment, FIGO stage, type of patient",2,Non-Hispanic White,Hispanic White,1.48,0.81,2.72
10.1016/j.ygyno.2019.03.007,4,No,NA,No,NA,Somatic testing performed,OR,NA,"Age, treating medical center, Insurance type, family history of cancer, personal history of cancers, year of diagnosis, lines of treatment, FIGO stage, type of patient",3,Non-Hispanic White,Other/Unknown,0.71,0.16,3.06
10.1016/j.ygyno.2017.11.012,1,No,NA,No,NA,advanced ovarian cancer,Median overall survial,NA,NA,1,NA,Non-Hispanic White,55.25,51.84,58.49
10.1016/j.ygyno.2017.11.012,1,No,NA,No,NA,advanced ovarian cancer,Median overall survial,NA,NA,2,NA,Non-Hispanic Black,40,19.54,78.82
10.1016/j.ygyno.2017.11.012,1,No,NA,No,NA,advanced ovarian cancer,Median overall survial,NA,NA,3,NA,Asian,80.79,50.89,114.59
10.1016/j.ygyno.2017.11.012,1,No,NA,No,NA,advanced ovarian cancer,Median overall survial,NA,NA,4,NA,Hispanic,38.1,24.95,94.72
10.1016/j.ygyno.2017.11.012,2,No,NA,No,NA,advanced ovarian cancer,HR,NA,"Age, race, body mass index, BRCA status, ASA results, tumor grade, presence of carcinoomatosis or upper abdominal disease, and PDS outcome",1,Non-Hispanic White,Non-Hispanic Black,0.795,0.5,1.27
10.1016/j.ygyno.2017.11.012,2,No,NA,No,NA,advanced ovarian cancer,HR,NA,"Age, race, body mass index, BRCA status, ASA results, tumor grade, presence of carcinoomatosis or upper abdominal disease, and PDS outcome",2,Non-Hispanic White,Asian,1.21,0.78,1.89
10.1016/j.ygyno.2017.11.012,2,No,NA,No,NA,advanced ovarian cancer,HR,NA,"Age, race, body mass index, BRCA status, ASA results, tumor grade, presence of carcinoomatosis or upper abdominal disease, and PDS outcome",3,Non-Hispanic White,Hispanic,1.1,0.68,1.76
10.1016/j.ygyno.2017.07.145,1,No,NA,No,NA,endometrioid endometrial cancer survival,HR,NA,"Stage, tumor grade, year of diagnosis",1,White,Black,1.54,1.45,1.62
10.1016/j.ygyno.2017.07.145,2,No,NA,No,NA,non-endometrioid endometrial cancer survival,HR,NA,"Stage, tumor grade, year of diagnosis",1,White,Black,1.55,1.48,1.62
10.1016/j.ygyno.2017.07.145,3,Yes,<65 years old,No,NA,endometrioid endometrial cancer survival,HR,NA,"Stage, tumor grade, year of diagnosis",1,White,Black,1.8,1.65,1.96
10.1016/j.ygyno.2017.07.145,4,Yes,<65 years old,No,NA,non-endometrioid endometrial cancer survival,HR,NA,"Stage, tumor grade, year of diagnosis",1,White,Black,1.89,1.75,2.04
10.1016/j.ygyno.2017.07.145,5,Yes,≥65 years old,No,NA,endometrioid endometrial cancer survival,HR,NA,"Stage, tumor grade, year of diagnosis",1,White,Black,1.21,1.13,1.3
10.1016/j.ygyno.2017.07.145,6,Yes,≥65 years old,No,NA,non-endometrioid endometrial cancer survival,HR,NA,"Stage, tumor grade, year of diagnosis",1,White,Black,1.3,1.23,1.37
10.1016/j.ygyno.2016.09.026,1,No,NA,No,NA,Ovarian cancer trial accrual,Absolute difference,NA,None,1,N/A,White,8.8,-99,-99
10.1016/j.ygyno.2016.09.026,1,No,NA,No,NA,Ovarian cancer trial accrual,Absolute difference,NA,None,2,N/A,Black,-7.1,-99,-99
10.1016/j.ygyno.2016.09.026,1,No,NA,No,NA,Ovarian cancer trial accrual,Absolute difference,NA,None,3,N/A,American Indian/Alaska Native,-0.1,-99,-99
10.1016/j.ygyno.2016.09.026,1,No,NA,No,NA,Ovarian cancer trial accrual,Absolute difference,NA,None,4,N/A,Asian/Pacific Islander,-1.6,-99,-99
10.1016/j.ygyno.2016.09.026,2,No,NA,Yes,Ethnicity,Ovarian cancer trial accrual,Absolute difference,NA,None,1,N/A,Hispanic,-9.8,-99,-99
10.1016/j.ygyno.2016.09.026,2,No,NA,Yes,Ethnicity,Ovarian cancer trial accrual,Absolute difference,NA,None,2,N/A,Not Hispanic,9.8,-99,-99
10.1016/j.ygyno.2016.09.026,3,No,NA,No,NA,Uterine cancer trial accrual,Absolute difference,NA,None,1,N/A,White,1.7,-99,-99
10.1016/j.ygyno.2016.09.026,3,No,NA,No,NA,Uterine cancer trial accrual,Absolute difference,NA,None,2,N/A,Black,-1.2,-99,-99
10.1016/j.ygyno.2016.09.026,3,No,NA,No,NA,Uterine cancer trial accrual,Absolute difference,NA,None,3,N/A,American Indian/Alaska Native,0.6,-99,-99
10.1016/j.ygyno.2016.09.026,3,No,NA,No,NA,Uterine cancer trial accrual,Absolute difference,NA,None,4,N/A,Asian/Pacific Islander,1.1,-99,-99
10.1016/j.ygyno.2016.09.026,4,No,NA,Yes,Ethnicity,Uterine cancer trial accrual,Absolute difference,NA,None,1,N/A,Hispanic,-7.9,-99,-99
10.1016/j.ygyno.2016.09.026,4,No,NA,Yes,Ethnicity,Uterine cancer trial accrual,Absolute difference,NA,None,2,N/A,Not Hispanic,7.9,-99,-99
10.1016/j.ygyno.2016.09.026,5,No,NA,No,NA,Cervical cancer trial accrual,Absolute difference,NA,None,1,N/A,White,0.7,-99,-99
10.1016/j.ygyno.2016.09.026,5,No,NA,No,NA,Cervical cancer trial accrual,Absolute difference,NA,None,2,N/A,Black,-1.2,-99,-99
10.1016/j.ygyno.2016.09.026,5,No,NA,No,NA,Cervical cancer trial accrual,Absolute difference,NA,None,3,N/A,American Indian/Alaska Native,1.1,-99,-99
10.1016/j.ygyno.2016.09.026,5,No,NA,No,NA,Cervical cancer trial accrual,Absolute difference,NA,None,4,N/A,Asian/Pacific Islander,-0.6,-99,-99
10.1016/j.ygyno.2016.09.026,6,No,NA,No,Ethnicity,Cervical cancer trial accrual,Absolute difference,NA,None,1,N/A,Hispanic,-7.3,-99,-99
10.1016/j.ygyno.2016.09.026,6,No,NA,No,Ethnicity,Cervical cancer trial accrual,Absolute difference,NA,None,2,N/A,Not Hispanic,7.4,-99,-99
10.1016/j.ygyno.2016.09.026,7,No,NA,No,NA,All gynecological cancers,Absolute difference,NA,None,1,N/A,White,6.1,-99,-99
10.1016/j.ygyno.2016.09.026,7,No,NA,No,NA,All gynecological cancers,Absolute difference,NA,None,2,N/A,Black,-5.1,-99,-99
10.1016/j.ygyno.2016.09.026,7,No,NA,No,NA,All gynecological cancers,Absolute difference,NA,None,3,N/A,American Indian/Alaska Native,0.3,-99,-99
10.1016/j.ygyno.2016.09.026,7,No,NA,No,NA,All gynecological cancers,Absolute difference,NA,None,4,N/A,Asian/Pacific Islander,-1.3,-99,-99
10.1016/j.ygyno.2016.09.026,8,No,NA,Yes,Ethnicity,All gynecological cancers,Absolute difference,NA,None,1,N/A,Hispanic,-8.8,-99,-99
10.1016/j.ygyno.2016.09.026,8,No,NA,Yes,Ethnicity,All gynecological cancers,Absolute difference,NA,None,2,N/A,Not Hispanic,8.8,-99,-99
10.1016/j.ygyno.2016.09.026,9,No,NA,No,NA,Ovarian cancer trial accrual,Absolute difference,NA,None,1,N/A,Privately insured,9.7,-99,-99
10.1016/j.ygyno.2016.09.026,9,No,NA,No,NA,Ovarian cancer trial accrual,Absolute difference,NA,None,2,N/A,Insured-Medicaid,-9.9,-99,-99
10.1016/j.ygyno.2016.09.026,9,No,NA,No,NA,Ovarian cancer trial accrual,Absolute difference,NA,None,3,N/A,Uninsured,-2.2,-99,-99
10.1016/j.ygyno.2016.09.026,9,No,NA,No,NA,Ovarian cancer trial accrual,Absolute difference,NA,None,4,N/A,Unknown,0.8,-99,-99
10.1016/j.ygyno.2016.09.026,10,No,NA,Yes,White,Ovarian cancer trial accrual,Absolute difference,NA,None,1,N/A,Privately insured,14,-99,-99
10.1016/j.ygyno.2016.09.026,10,No,NA,Yes,White,Ovarian cancer trial accrual,Absolute difference,NA,None,2,N/A,Insured-Medicaid,-7.4,-99,-99
10.1016/j.ygyno.2016.09.026,10,No,NA,Yes,White,Ovarian cancer trial accrual,Absolute difference,NA,None,3,N/A,Uninsured,-4.9,-99,-99
10.1016/j.ygyno.2016.09.026,10,No,NA,Yes,White,Ovarian cancer trial accrual,Absolute difference,NA,None,4,N/A,Unknown,0,-99,-99
10.1016/j.ygyno.2016.09.026,11,No,NA,Yes,Black,Ovarian cancer trial accrual,Absolute difference,NA,None,1,N/A,Privately insured,-0.9,-99,-99
10.1016/j.ygyno.2016.09.026,11,No,NA,Yes,Black,Ovarian cancer trial accrual,Absolute difference,NA,None,2,N/A,Insured-Medicaid,-2.5,-99,-99
10.1016/j.ygyno.2016.09.026,11,No,NA,Yes,Black,Ovarian cancer trial accrual,Absolute difference,NA,None,3,N/A,Uninsured,1.8,-99,-99
10.1016/j.ygyno.2016.09.026,11,No,NA,Yes,Black,Ovarian cancer trial accrual,Absolute difference,NA,None,4,N/A,Unknown,1.2,-99,-99
10.1016/j.ygyno.2016.09.026,12,No,NA,No,NA,Uterine cancer trial accural,Absolute difference,NA,None,1,N/A,Privately insured,-2.8,-99,-99
10.1016/j.ygyno.2016.09.026,12,No,NA,No,NA,Uterine cancer trial accural,Absolute difference,NA,None,2,N/A,Insured-Medicaid,-2.6,-99,-99
10.1016/j.ygyno.2016.09.026,12,No,NA,No,NA,Uterine cancer trial accural,Absolute difference,NA,None,3,N/A,Uninsured,3.3,-99,-99
10.1016/j.ygyno.2016.09.026,12,No,NA,No,NA,Uterine cancer trial accural,Absolute difference,NA,None,4,N/A,Unknown,2,-99,-99
10.1016/j.ygyno.2016.09.026,13,No,NA,Yes,White,Uterine cancer trial accural,Absolute difference,NA,None,1,N/A,Privately insured,5.9,-99,-99
10.1016/j.ygyno.2016.09.026,13,No,NA,Yes,White,Uterine cancer trial accural,Absolute difference,NA,None,2,N/A,Insured-Medicaid,-2.5,-99,-99
10.1016/j.ygyno.2016.09.026,13,No,NA,Yes,White,Uterine cancer trial accural,Absolute difference,NA,None,3,N/A,Uninsured,-0.6,-99,-99
10.1016/j.ygyno.2016.09.026,13,No,NA,Yes,White,Uterine cancer trial accural,Absolute difference,NA,None,4,N/A,Unknown,0.7,-99,-99
10.1016/j.ygyno.2016.09.026,14,No,NA,Yes,Black,Uterine cancer trial accural,Absolute difference,NA,None,1,N/A,Privately insured,-15.3,-99,-99
10.1016/j.ygyno.2016.09.026,14,No,NA,Yes,Black,Uterine cancer trial accural,Absolute difference,NA,None,2,N/A,Insured-Medicaid,8.2,-99,-99
10.1016/j.ygyno.2016.09.026,14,No,NA,Yes,Black,Uterine cancer trial accural,Absolute difference,NA,None,3,N/A,Uninsured,3.2,-99,-99
10.1016/j.ygyno.2016.09.026,14,No,NA,Yes,Black,Uterine cancer trial accural,Absolute difference,NA,None,4,N/A,Unknown,2.4,-99,-99
10.1016/j.ygyno.2016.09.026,15,No,NA,No,NA,Cervical cancer trial accural,Absolute difference,NA,None,1,N/A,Privately insured,-7.4,-99,-99
10.1016/j.ygyno.2016.09.026,15,No,NA,No,NA,Cervical cancer trial accural,Absolute difference,NA,None,2,N/A,Insured-Medicaid,-2.7,-99,-99
10.1016/j.ygyno.2016.09.026,15,No,NA,No,NA,Cervical cancer trial accural,Absolute difference,NA,None,3,N/A,Uninsured,6.9,-99,-99
10.1016/j.ygyno.2016.09.026,15,No,NA,No,NA,Cervical cancer trial accural,Absolute difference,NA,None,4,N/A,Unknown,3.2,-99,-99
10.1016/j.ygyno.2016.09.026,16,No,NA,Yes,White,Cervical cancer trial accural,Absolute difference,NA,None,1,N/A,Privately insured,1.6,-99,-99
10.1016/j.ygyno.2016.09.026,16,No,NA,Yes,White,Cervical cancer trial accural,Absolute difference,NA,None,2,N/A,Insured-Medicaid,-8.5,-99,-99
10.1016/j.ygyno.2016.09.026,16,No,NA,Yes,White,Cervical cancer trial accural,Absolute difference,NA,None,3,N/A,Uninsured,0,-99,-99
10.1016/j.ygyno.2016.09.026,16,No,NA,Yes,White,Cervical cancer trial accural,Absolute difference,NA,None,4,N/A,Unknown,2,-99,-99
10.1016/j.ygyno.2016.09.026,17,No,NA,Yes,Black,Cervical cancer trial accural,Absolute difference,NA,None,1,N/A,Privately insured,-22.2,-99,-99
10.1016/j.ygyno.2016.09.026,17,No,NA,Yes,Black,Cervical cancer trial accural,Absolute difference,NA,None,2,N/A,Insured-Medicaid,13.4,-99,-99
10.1016/j.ygyno.2016.09.026,17,No,NA,Yes,Black,Cervical cancer trial accural,Absolute difference,NA,None,3,N/A,Uninsured,0,-99,-99
10.1016/j.ygyno.2016.09.026,17,No,NA,Yes,Black,Cervical cancer trial accural,Absolute difference,NA,None,4,N/A,Unknown,3.7,-99,-99
10.1016/j.ygyno.2016.09.026,18,No,NA,Yes,Race,Difference in clinical trial accruals and population incidence for ovarian cancer,Absolute difference,NA,None,1,N/A,White,8.8,-99,-99
10.1016/j.ygyno.2016.09.026,18,No,NA,Yes,Race,Difference in clinical trial accruals and population incidence for ovarian cancer,Absolute difference,NA,None,2,N/A,Black,-7.1,-99,-99
10.1016/j.ygyno.2016.09.026,18,No,NA,Yes,Race,Difference in clinical trial accruals and population incidence for ovarian cancer,Absolute difference,NA,None,3,N/A,American Indian/Alaska Native,-0.1,-99,-99
10.1016/j.ygyno.2016.09.026,18,No,NA,Yes,Race,Difference in clinical trial accruals and population incidence for ovarian cancer,Absolute difference,NA,None,4,N/A,Asian/Pasific Islander,-1.6,-99,-99
10.1016/j.ygyno.2016.09.026,19,No,NA,Yes,Ethnicity,Difference in clinical trial accruals and population incidence for ovarian cancer,Absolute difference,NA,None,1,N/A,Not hispanic,13.4,-99,-99
10.1016/j.ygyno.2016.09.026,19,No,NA,Yes,Ethnicity,Difference in clinical trial accruals and population incidence for ovarian cancer,Absolute difference,NA,None,2,N/A,Hispanic,-13.4,-99,-99
10.1016/j.ygyno.2016.09.026,20,Yes,2003-2007,Yes,Race,Difference in clinical trial accruals and population incidence for ovarian cancer,Absolute difference,NA,None,1,N/A,White,9.5,-99,-99
10.1016/j.ygyno.2016.09.026,20,Yes,2003-2007,Yes,Race,Difference in clinical trial accruals and population incidence for ovarian cancer,Absolute difference,NA,None,2,N/A,Black,-7.23,-99,-99
10.1016/j.ygyno.2016.09.026,20,Yes,2003-2007,Yes,Race,Difference in clinical trial accruals and population incidence for ovarian cancer,Absolute difference,NA,None,3,N/A,American Indian/Alaska Native,-2.2,-99,-99
10.1016/j.ygyno.2016.09.026,20,Yes,2003-2007,Yes,Race,Difference in clinical trial accruals and population incidence for ovarian cancer,Absolute difference,NA,None,4,N/A,Asian/Pacific Islander,-2.2,-99,-99
10.1016/j.ygyno.2016.09.026,21,Yes,2003-2007,Yes,Ethnicity,Difference in clinical trial accruals and population incidence for ovarian cancer,Absolute difference,NA,None,1,N/A,Not hispanic,13.39,-99,-99
10.1016/j.ygyno.2016.09.026,21,Yes,2003-2007,Yes,Ethnicity,Difference in clinical trial accruals and population incidence for ovarian cancer,Absolute difference,NA,None,2,N/A,Hispanic,-13.99,-99,-99
10.1016/j.ygyno.2016.09.026,22,Yes,2008-2012,Yes,Race,Difference in clinical trial accruals and population incidence for ovarian cancer,Absolute difference,NA,None,1,N/A,White,8.28,-99,-99
10.1016/j.ygyno.2016.09.026,22,Yes,2008-2012,Yes,Race,Difference in clinical trial accruals and population incidence for ovarian cancer,Absolute difference,NA,None,2,N/A,Black,-6.99,-99,-99
10.1016/j.ygyno.2016.09.026,22,Yes,2008-2012,Yes,Race,Difference in clinical trial accruals and population incidence for ovarian cancer,Absolute difference,NA,None,3,N/A,American Indian/Alaska Native,-0.13,-99,-99
10.1016/j.ygyno.2016.09.026,22,Yes,2008-2012,Yes,Race,Difference in clinical trial accruals and population incidence for ovarian cancer,Absolute difference,NA,None,4,N/A,Asian/Pacific Islander,-1.25,-99,-99
10.1016/j.ygyno.2016.09.026,23,Yes,2008-2012,Yes,Ethnicity,Difference in clinical trial accruals and population incidence for ovarian cancer,Absolute difference,NA,None,1,N/A,Not hispanic,12.96,-99,-99
10.1016/j.ygyno.2016.09.026,23,Yes,2008-2012,Yes,Ethnicity,Difference in clinical trial accruals and population incidence for ovarian cancer,Absolute difference,NA,None,2,N/A,Hispanic,-12.96,-99,-99
10.1016/j.ygyno.2016.09.026,24,Yes,Change over time,Yes,Race,Difference in clinical trial accruals and population incidence for ovarian cancer,Absolute difference,NA,None,1,N/A,White,-1.23,-99,-99
10.1016/j.ygyno.2016.09.026,24,Yes,Change over time,Yes,Race,Difference in clinical trial accruals and population incidence for ovarian cancer,Absolute difference,NA,None,2,N/A,Black,0.24,-99,-99
10.1016/j.ygyno.2016.09.026,24,Yes,Change over time,Yes,Race,Difference in clinical trial accruals and population incidence for ovarian cancer,Absolute difference,NA,None,3,N/A,American Indian/Alaska Native,0.04,-99,-99
10.1016/j.ygyno.2016.09.026,24,Yes,Change over time,Yes,Race,Difference in clinical trial accruals and population incidence for ovarian cancer,Absolute difference,NA,None,4,N/A,Asian/Pacific Islander,0.95,-99,-99
10.1016/j.ygyno.2016.09.026,25,Yes,Change over time,Yes,Ethnicity,Difference in clinical trial accruals and population incidence for ovarian cancer,Absolute difference,NA,None,1,N/A,Not hispanic,-0.98,-99,-99
10.1016/j.ygyno.2016.09.026,25,Yes,Change over time,Yes,Ethnicity,Difference in clinical trial accruals and population incidence for ovarian cancer,Absolute difference,NA,None,2,N/A,Hispanic,0.98,-99,-99
10.1016/j.ygyno.2016.09.026,26,Yes,NA,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,1,N/A,White,1.7,-99,-99
10.1016/j.ygyno.2016.09.026,26,Yes,NA,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,2,N/A,Black,-1.2,-99,-99
10.1016/j.ygyno.2016.09.026,26,Yes,NA,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,3,N/A,American Indian/Alaska Native,0.6,-99,-99
10.1016/j.ygyno.2016.09.026,26,Yes,NA,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,4,N/A,Asian/Pacific Islander,-1.1,-99,-99
10.1016/j.ygyno.2016.09.026,27,Yes,NA,Yes,Ethnicity,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,1,N/A,Not hispanic,14.1,-99,-99
10.1016/j.ygyno.2016.09.026,27,Yes,NA,Yes,Ethnicity,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,2,N/A,Hispanic,-14.1,-99,-99
10.1016/j.ygyno.2016.09.026,28,Yes,2003-2007,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,1,N/A,White,3.37,-99,-99
10.1016/j.ygyno.2016.09.026,28,Yes,2003-2007,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,2,N/A,Black,-2.98,-99,-99
10.1016/j.ygyno.2016.09.026,28,Yes,2003-2007,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,3,N/A,American Indian/Alaska Native,0.86,-99,-99
10.1016/j.ygyno.2016.09.026,28,Yes,2003-2007,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,4,N/A,Asian/Pacific Islander,-1.25,-99,-99
10.1016/j.ygyno.2016.09.026,29,Yes,2003-2007,Yes,Ethnicity,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,1,N/A,Not hispanic,13.91,-99,-99
10.1016/j.ygyno.2016.09.026,29,Yes,2003-2007,Yes,Ethnicity,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,2,N/A,Hispanic,14.01,-99,-99
10.1016/j.ygyno.2016.09.026,30,Yes,2008-2012,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,1,N/A,White,0.17,-99,-99
10.1016/j.ygyno.2016.09.026,30,Yes,2008-2012,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,2,N/A,Black,0.43,-99,-99
10.1016/j.ygyno.2016.09.026,30,Yes,2008-2012,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,3,N/A,American Indian/Alaska Native,0.37,-99,-99
10.1016/j.ygyno.2016.09.026,30,Yes,2008-2012,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,4,N/A,Asian/Pacific Islander,-0.97,-99,-99
10.1016/j.ygyno.2016.09.026,31,Yes,2008-2012,Yes,Ethnicity,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,1,N/A,Not hispanic,14.17,-99,-99
10.1016/j.ygyno.2016.09.026,31,Yes,2008-2012,Yes,Ethnicity,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,2,N/A,Hispanic,-14.27,-99,-99
10.1016/j.ygyno.2016.09.026,32,Yes,Change over time,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,1,N/A,White,-3.21,-99,-99
10.1016/j.ygyno.2016.09.026,32,Yes,Change over time,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,2,N/A,Black,3.41,-99,-99
10.1016/j.ygyno.2016.09.026,32,Yes,Change over time,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,3,N/A,American Indian/Alaska Native,-0.49,-99,-99
10.1016/j.ygyno.2016.09.026,32,Yes,Change over time,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,4,N/A,Asian/Pacific Islander,0.29,-99,-99
10.1016/j.ygyno.2016.09.026,33,Yes,Change over time,Yes,Ethnicity,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,1,N/A,Not hispanic,0.26,-99,-99
10.1016/j.ygyno.2016.09.026,33,Yes,Change over time,Yes,Ethnicity,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,2,N/A,Hispanic,-0.26,-99,-99
10.1016/j.ygyno.2016.09.026,34,Yes,NA,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,1,N/A,White,0.7,-99,-99
10.1016/j.ygyno.2016.09.026,34,Yes,NA,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,2,N/A,Black,-1.2,-99,-99
10.1016/j.ygyno.2016.09.026,34,Yes,NA,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,3,N/A,American Indian/Alaska Native,1.1,-99,-99
10.1016/j.ygyno.2016.09.026,34,Yes,NA,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,4,N/A,Asian/Pacific Islander,-0.6,-99,-99
10.1016/j.ygyno.2016.09.026,35,Yes,NA,Yes,Ethnicity,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,1,N/A,Not hispanic,14.1,-99,-99
10.1016/j.ygyno.2016.09.026,35,Yes,NA,Yes,Ethnicity,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,2,N/A,Hispanic,-14.1,-99,-99
10.1016/j.ygyno.2016.09.026,36,Yes,2003-2007,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,1,N/A,White,1.15,-99,-99
10.1016/j.ygyno.2016.09.026,36,Yes,2003-2007,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,2,N/A,Black,-1.49,-99,-99
10.1016/j.ygyno.2016.09.026,36,Yes,2003-2007,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,3,N/A,American Indian/Alaska Native,1.33,-99,-99
10.1016/j.ygyno.2016.09.026,36,Yes,2003-2007,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,4,N/A,-0.98,NA,NA,NA
10.1016/j.ygyno.2016.09.026,37,Yes,2003-2007,Yes,Ethnicity,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,1,N/A,Not hispanic,-3.32,-99,-99
10.1016/j.ygyno.2016.09.026,37,Yes,2003-2007,Yes,Ethnicity,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,2,N/A,Hispanic,3.32,-99,-99
10.1016/j.ygyno.2016.09.026,38,Yes,2008-2012,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,1,N/A,White,0.18,-99,-99
10.1016/j.ygyno.2016.09.026,38,Yes,2008-2012,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,2,N/A,Black,-0.87,-99,-99
10.1016/j.ygyno.2016.09.026,38,Yes,2008-2012,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,3,N/A,American Indian/Alaska Native,0.85,-99,-99
10.1016/j.ygyno.2016.09.026,38,Yes,2008-2012,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,4,N/A,Asian/Pacific Islander,-0.16,-99,-99
10.1016/j.ygyno.2016.09.026,39,Yes,2008-2012,Yes,Ethnicity,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,1,N/A,Not hispanic,-2.49,-99,-99
10.1016/j.ygyno.2016.09.026,39,Yes,2008-2012,Yes,Ethnicity,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,2,N/A,Hispanic,2.49,-99,-99
10.1016/j.ygyno.2016.09.026,40,Yes,Change over time,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,1,N/A,White,-0.96,-99,-99
10.1016/j.ygyno.2016.09.026,40,Yes,Change over time,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,2,N/A,Black,0.62,-99,-99
10.1016/j.ygyno.2016.09.026,40,Yes,Change over time,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,3,N/A,American Indian/Alaska Native,-0.48,-99,-99
10.1016/j.ygyno.2016.09.026,40,Yes,Change over time,Yes,Race,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,4,N/A,Asian/Pacific Islander,0.82,-99,-99
10.1016/j.ygyno.2016.09.026,41,Yes,Change over time,Yes,Ethnicity,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,1,N/A,Not hispanic,0.84,-99,-99
10.1016/j.ygyno.2016.09.026,41,Yes,Change over time,Yes,Ethnicity,Difference in clinical trial accruals and population incidence for uterine cancer,Absolute difference,NA,None,2,N/A,Hispanic,-0.85,-99,-99
10.1016/j.ygyno.2016.04.014,1,No,NA,No,NA,likelihood of late treatment,Incident rate ratio,NA,None,1,Non-Hispanic White,Non-Hispanic Black,1.35,1.28,1.42
10.1016/j.ygyno.2016.04.014,1,No,NA,No,NA,likelihood of late treatment,Incident rate ratio,NA,None,2,Non-Hispanic White,Hispanic,1.31,1.2,1.43
10.1016/j.ygyno.2016.04.014,1,No,NA,No,NA,likelihood of late treatment,Incident rate ratio,NA,None,3,Non-Hispanic White,Asian,1.15,1.01,1.3
10.1016/j.ygyno.2016.04.014,1,No,NA,No,NA,likelihood of late treatment,Incident rate ratio,NA,None,4,Non-Hispanic White,Other/Unknown,1.05,0.97,1.15
10.1016/j.ygyno.2016.04.014,2,No,NA,No,NA,all-cause mortality for patients diagnosed with uterine cancer,HR,NA,None,1,Non-Hispanic White,Non-Hispanic Black,1.17,1.08,1.27
10.1016/j.ygyno.2016.04.014,2,No,NA,No,NA,all-cause mortality for patients diagnosed with uterine cancer,HR,NA,None,2,Non-Hispanic White,Hispanic,0.8,0.71,0.9
10.1016/j.ygyno.2016.04.014,2,No,NA,No,NA,all-cause mortality for patients diagnosed with uterine cancer,HR,NA,None,3,Non-Hispanic White,Asian,0.63,0.52,0.76
10.1016/j.ygyno.2016.04.014,2,No,NA,No,NA,all-cause mortality for patients diagnosed with uterine cancer,HR,NA,None,4,Non-Hispanic White,Other/Unknown,0.97,0.83,1.14
10.1016/j.ygyno.2017.01.024,1,No,NA,No,NA,Sugery,OR,NA,"date of diagnosis, age, facility type, area of residence, region, income, insurance, education, charlson score, histology, pathologic stage",1,White,african american,0.65,0.51,0.83
10.1016/j.ygyno.2017.01.024,1,No,NA,No,NA,Sugery,OR,NA,"date of diagnosis, age, facility type, area of residence, region, income, insurance, education, charlson score, histology, pathologic stage",2,White,Hispanic,0.88,0.57,1.37
10.1016/j.ygyno.2017.01.024,2,No,NA,No,NA,Chemotherapy,OR,NA,"date of diagnosis, age, facility type, area of residence, region, income, insurance, education, charlson score, histology, pathologic stage",1,White,african american,1.02,0.95,1.09
10.1016/j.ygyno.2017.01.024,2,No,NA,No,NA,Chemotherapy,OR,NA,"date of diagnosis, age, facility type, area of residence, region, income, insurance, education, charlson score, histology, pathologic stage",2,White,Hispanic,1.01,0.9,1.13
10.1016/j.ygyno.2017.01.024,3,No,NA,No,NA,Radiation,OR,NA,"date of diagnosis, age, facility type, area of residence, region, income, insurance, education, charlson score, histology, pathologic stage",1,White,african american,0.99,0.93,1.06
10.1016/j.ygyno.2017.01.024,3,No,NA,No,NA,Radiation,OR,NA,"date of diagnosis, age, facility type, area of residence, region, income, insurance, education, charlson score, histology, pathologic stage",2,White,Hispanic,0.94,0.85,1.04
10.1016/j.ygyno.2017.01.024,4,No,NA,No,NA,Overall mortality,HR,NA,"date of diagnosis, age, facility type, area of residence, region, income, insurance, education, charlson score, histology, pathologic stage",1,White,african american,1.21,1.16,1.26
10.1016/j.ygyno.2017.01.024,4,No,NA,No,NA,Overall mortality,HR,NA,"date of diagnosis, age, facility type, area of residence, region, income, insurance, education, charlson score, histology, pathologic stage",2,White,Hispanic,0.87,0.8,0.93
10.1016/j.ygyno.2017.01.024,5,No,NA,Yes,Early Stage (1 and 2),Overall mortality,HR,NA,"date of diagnosis, age, facility type, area of residence, region, income, insurance, education, charlson score, histology, pathologic stage",1,White,african american,1.22,1.13,1.33
10.1016/j.ygyno.2017.01.024,5,No,NA,Yes,Early Stage (1 and 2),Overall mortality,HR,NA,"date of diagnosis, age, facility type, area of residence, region, income, insurance, education, charlson score, histology, pathologic stage",2,White,Hispanic,0.8,0.68,0.94
10.1016/j.ygyno.2017.01.024,6,No,NA,Yes,Advanced stage (3 and 4),Overall mortality,HR,NA,"date of diagnosis, age, facility type, area of residence, region, income, insurance, education, charlson score, histology, pathologic stage",1,White,african american,1.27,1.2,1.34
10.1016/j.ygyno.2017.01.024,6,No,NA,Yes,Advanced stage (3 and 4),Overall mortality,HR,NA,"date of diagnosis, age, facility type, area of residence, region, income, insurance, education, charlson score, histology, pathologic stage",2,White,Hispanic,0.92,0.83,1.02
10.1016/j.ygyno.2015.12.012,1,No,NA,No,NA,Dying without Hospice,OR,NA,None,1,White,Non-white,2.04,0.94,4.43
10.1016/j.ygyno.2015.12.012,2,No,NA,No,NA,Dying without Hospice,OR,NA,education,1,White,Non-white,3.07,1.27,7.46
10.1016/j.ygyno.2015.12.012,3,No,NA,No,NA,having a medical power of attorney or living will,OR,NA,None,1,White,Non-White,0.37,0.18,0.79
10.1016/j.ygyno.2015.12.012,4,No,NA,No,NA,having a medical power of attorney or living will,OR,NA,age,1,White,Non-White,0.4,0.18,0.85
10.1016/j.ygyno.2015.08.019,1,No,NA,Yes,Race,Sexual activity,OR,NA,NA,1,White,Other,0.65,0.34,1.22
10.1016/j.ygyno.2015.08.019,2,No,NA,Yes,Race,Sexual dysfunction in sexually active women,OR,NA,NA,1,White,Other,0.66,0.16,2.79
10.1016/j.ygyno.2015.05.024,1,No,NA,No,NA,A Haplotype frequency,Percent,NA,NA,1,NA,African-American,10,-99,-99
10.1016/j.ygyno.2015.05.024,1,No,NA,No,NA,A Haplotype frequency,Percent,NA,NA,2,NA,European American,40,-99,-99
10.1016/j.ygyno.2015.05.024,2,No,NA,No,NA,B Haplotype frequency,Percent,NA,NA,1,NA,African-American,0,-99,-99
10.1016/j.ygyno.2015.05.024,2,No,NA,No,NA,B Haplotype frequency,Percent,NA,NA,2,NA,European American,2,-99,-99
10.1016/j.ygyno.2015.05.024,3,No,NA,No,NA,C Haplotype frequency,Percent,NA,NA,1,NA,African-American,14,-99,-99
10.1016/j.ygyno.2015.05.024,3,No,NA,No,NA,C Haplotype frequency,Percent,NA,NA,2,NA,European American,30,-99,-99
10.1016/j.ygyno.2015.05.024,4,No,NA,No,NA,D Haplotype frequency,Percent,NA,NA,1,NA,African-American,12,-99,-99
10.1016/j.ygyno.2015.05.024,4,No,NA,No,NA,D Haplotype frequency,Percent,NA,NA,2,NA,European American,0,-99,-99
10.1016/j.ygyno.2015.05.024,5,No,NA,No,NA,E Haplotype frequency,Percent,NA,NA,1,NA,African-American,18,-99,-99
10.1016/j.ygyno.2015.05.024,5,No,NA,No,NA,E Haplotype frequency,Percent,NA,NA,2,NA,European American,0,-99,-99
10.1016/j.ygyno.2015.05.024,6,No,NA,No,NA,F Haplotype frequency,Percent,NA,NA,1,NA,African-American,8,-99,-99
10.1016/j.ygyno.2015.05.024,6,No,NA,No,NA,F Haplotype frequency,Percent,NA,NA,2,NA,European American,21,-99,-99
10.1016/j.ygyno.2015.05.024,7,No,NA,No,NA,G Haplotype frequency,Percent,NA,NA,1,NA,African-American,10,-99,-99
10.1016/j.ygyno.2015.05.024,7,No,NA,No,NA,G Haplotype frequency,Percent,NA,NA,2,NA,European American,8,-99,-99
10.1016/j.ygyno.2015.05.024,8,No,NA,No,NA,H Haplotype frequency,Percent,NA,NA,1,NA,African-American,25,-99,-99
10.1016/j.ygyno.2015.05.024,8,No,NA,No,NA,H Haplotype frequency,Percent,NA,NA,2,NA,European American,28,-99,-99
10.1016/j.ygyno.2015.05.024,9,No,NA,No,NA,I Haplotype frequency,Percent,NA,NA,1,NA,African-American,31,-99,-99
10.1016/j.ygyno.2015.05.024,9,No,NA,No,NA,I Haplotype frequency,Percent,NA,NA,2,NA,European American,15,-99,-99
10.1016/j.ygyno.2015.05.024,10,No,NA,No,NA,J Haplotype frequency,Percent,NA,NA,1,NA,African-American,14,-99,-99
10.1016/j.ygyno.2015.05.024,10,No,NA,No,NA,J Haplotype frequency,Percent,NA,NA,2,NA,European American,4,-99,-99
10.1016/j.ygyno.2015.05.024,11,No,NA,No,NA,K Haplotype frequency,Percent,NA,NA,1,NA,African-American,10,-99,-99
10.1016/j.ygyno.2015.05.024,11,No,NA,No,NA,K Haplotype frequency,Percent,NA,NA,2,NA,European American,2,-99,-99
10.1016/j.ygyno.2015.05.024,12,No,NA,Yes,Race,Presence of Haplotype A,Percent,NA,NA,1,NA,African-American,19,-99,-99
10.1016/j.ygyno.2015.05.024,12,No,NA,Yes,Race,Presence of Haplotype A,Percent,NA,NA,2,NA,European American,81,-99,-99
10.1016/j.ygyno.2015.05.024,13,No,NA,Yes,Race,Absence of Haplotype B,Percent,NA,NA,1,NA,African-American,59,-99,-99
10.1016/j.ygyno.2015.05.024,13,No,NA,Yes,Race,Absence of Haplotype B,Percent,NA,NA,2,NA,European American,41,-99,-99
10.1016/j.ygyno.2015.05.024,14,No,NA,Yes,Race,Presence of Haplotype C,Percent,NA,NA,1,NA,African-American,30,-99,-99
10.1016/j.ygyno.2015.05.024,14,No,NA,Yes,Race,Presence of Haplotype C,Percent,NA,NA,2,NA,European American,70,-99,-99
10.1016/j.ygyno.2015.05.024,15,No,NA,Yes,Race,Absence of Haplotype C,Percent,NA,NA,1,NA,African-American,54,-99,-99
10.1016/j.ygyno.2015.05.024,15,No,NA,Yes,Race,Absence of Haplotype C,Percent,NA,NA,2,NA,European American,46,-99,-99
10.1016/j.ygyno.2015.05.024,16,No,NA,Yes,Race,Presence of Haplotype D,Percent,NA,NA,1,NA,African-American,100,-99,-99
10.1016/j.ygyno.2015.05.024,16,No,NA,Yes,Race,Presence of Haplotype D,Percent,NA,NA,2,NA,European American,0,-99,-99
10.1016/j.ygyno.2015.05.024,17,No,NA,Yes,Race,Absence of Haplotype E,Percent,NA,NA,1,NA,African-American,44,-99,-99
10.1016/j.ygyno.2015.05.024,17,No,NA,Yes,Race,Absence of Haplotype E,Percent,NA,NA,2,NA,European American,56,-99,-99
10.1016/j.ygyno.2015.05.024,18,No,NA,Yes,Race,Presence of Haplotype F,Percent,NA,NA,1,NA,African-American,27,-99,-99
10.1016/j.ygyno.2015.05.024,18,No,NA,Yes,Race,Presence of Haplotype F,Percent,NA,NA,2,NA,European American,73,-99,-99
10.1016/j.ygyno.2015.05.024,19,No,NA,Yes,Race,Absence of Haplotype F,Percent,NA,NA,1,NA,African-American,53,-99,-99
10.1016/j.ygyno.2015.05.024,19,No,NA,Yes,Race,Absence of Haplotype F,Percent,NA,NA,2,NA,European American,47,-99,-99
10.1016/j.ygyno.2015.05.024,20,No,NA,Yes,Race,Presence of Haplotype G,Percent,NA,NA,1,NA,African-American,50,-99,-99
10.1016/j.ygyno.2015.05.024,20,No,NA,Yes,Race,Presence of Haplotype G,Percent,NA,NA,2,NA,European American,50,-99,-99
10.1016/j.ygyno.2015.05.024,21,No,NA,Yes,Race,Absence of Haplotype G,Percent,NA,NA,1,NA,African-American,49,-99,-99
10.1016/j.ygyno.2015.05.024,21,No,NA,Yes,Race,Absence of Haplotype G,Percent,NA,NA,2,NA,European American,51,-99,-99
10.1016/j.ygyno.2015.05.024,22,No,NA,Yes,Race,Presence of Haplotype H,Percent,NA,NA,1,NA,African-American,46,-99,-99
10.1016/j.ygyno.2015.05.024,22,No,NA,Yes,Race,Presence of Haplotype H,Percent,NA,NA,2,NA,European American,54,-99,-99
10.1016/j.ygyno.2015.05.024,23,No,NA,Yes,Race,Absence of Haplotype H,Percent,NA,NA,1,NA,African-American,50,-99,-99
10.1016/j.ygyno.2015.05.024,23,No,NA,Yes,Race,Absence of Haplotype H,Percent,NA,NA,2,NA,European American,50,-99,-99
10.1016/j.ygyno.2015.05.024,24,No,NA,Yes,Race,Presence of Haplotype I,Percent,NA,NA,1,NA,African-American,67,-99,-99
10.1016/j.ygyno.2015.05.024,24,No,NA,Yes,Race,Presence of Haplotype I,Percent,NA,NA,2,NA,European American,33,-99,-99
10.1016/j.ygyno.2015.05.024,25,No,NA,Yes,Race,Absence of Haplotype I,Percent,NA,NA,1,NA,African-American,44,-99,-99
10.1016/j.ygyno.2015.05.024,25,No,NA,Yes,Race,Absence of Haplotype I,Percent,NA,NA,2,NA,European American,56,-99,-99
10.1016/j.ygyno.2015.05.024,26,No,NA,Yes,Race,Presence of Haplotype J,Percent,NA,NA,1,NA,African-American,64,-99,-99
10.1016/j.ygyno.2015.05.024,26,No,NA,Yes,Race,Presence of Haplotype J,Percent,NA,NA,2,NA,European American,36,-99,-99
10.1016/j.ygyno.2015.05.024,27,No,NA,Yes,Race,Absence of Haplotype J,Percent,NA,NA,1,NA,African-American,47,-99,-99
10.1016/j.ygyno.2015.05.024,27,No,NA,Yes,Race,Absence of Haplotype J,Percent,NA,NA,2,NA,European American,53,-99,-99
10.1016/j.ygyno.2015.05.024,28,No,NA,Yes,Race,Presence of Haplotype K,Percent,NA,NA,1,NA,African-American,83,-99,-99
10.1016/j.ygyno.2015.05.024,28,No,NA,Yes,Race,Presence of Haplotype K,Percent,NA,NA,2,NA,European American,17,-99,-99
10.1016/j.ygyno.2015.05.024,29,No,NA,Yes,Race,Absence of Haplotype K,Percent,NA,NA,1,NA,African-American,47,-99,-99
10.1016/j.ygyno.2015.05.024,29,No,NA,Yes,Race,Absence of Haplotype K,Percent,NA,NA,2,NA,European American,53,-99,-99
10.1016/j.ygyno.2015.05.024,30,No,NA,Yes,Race,Presence of Haplotype BCF,Percent,NA,NA,1,NA,African-American,31,-99,-99
10.1016/j.ygyno.2015.05.024,30,No,NA,Yes,Race,Presence of Haplotype BCF,Percent,NA,NA,2,NA,European American,69,-99,-99
10.1016/j.ygyno.2015.05.024,31,No,NA,Yes,Race,Absence of Haplotype BCF,Percent,NA,NA,1,NA,African-American,58,-99,-99
10.1016/j.ygyno.2015.05.024,31,No,NA,Yes,Race,Absence of Haplotype BCF,Percent,NA,NA,2,NA,European American,42,-99,-99
10.1016/j.ygyno.2015.05.024,32,No,NA,Yes,Race,Presence of Haplotype DE,Percent,NA,NA,1,NA,African-American,100,-99,-99
10.1016/j.ygyno.2015.05.024,32,No,NA,Yes,Race,Presence of Haplotype DE,Percent,NA,NA,2,NA,European American,0,-99,-99
10.1016/j.ygyno.2015.05.024,33,No,NA,Yes,Race,Absence of Haplotype DE,Percent,NA,NA,1,NA,African-American,42,-99,-99
10.1016/j.ygyno.2015.05.024,33,No,NA,Yes,Race,Absence of Haplotype DE,Percent,NA,NA,2,NA,European American,58,-99,-99
10.1016/j.ygyno.2015.04.033,1,No,NA,No,NA,"Eligible, not enrolled among patients with a trial available",Percent,NA,None,1,N/A,White,40,-99,-99
10.1016/j.ygyno.2015.04.033,1,No,NA,No,NA,"Eligible, not enrolled among patients with a trial available",Percent,NA,None,2,N/A,Black,7,-99,-99
10.1016/j.ygyno.2015.04.033,1,No,NA,No,NA,"Eligible, not enrolled among patients with a trial available",Percent,NA,None,3,N/A,Asian/Asian/White,14.2,-99,-99
10.1016/j.ygyno.2015.04.033,1,No,NA,No,NA,"Eligible, not enrolled among patients with a trial available",Percent,NA,None,4,N/A,Native American,12.5,-99,-99
10.1016/j.ygyno.2015.04.033,1,No,NA,No,NA,"Eligible, not enrolled among patients with a trial available",Percent,NA,None,5,N/A,Hawaiian/PI,100,-99,-99
10.1016/j.ygyno.2015.04.033,1,No,NA,No,NA,"Eligible, not enrolled among patients with a trial available",Percent,NA,None,6,N/A,Unknown,50,-99,NA
10.1016/j.ygyno.2015.04.033,1,No,NA,No,NA,"Eligible, not enrolled among patients with a trial available",Percent,NA,None,7,N/A,NA,NA,NA,-99
10.1016/j.ygyno.2015.04.033,2,No,NA,No,NA,Enrolled among patients with a trial available,Percent,NA,None,1,N/A,White,45,-99,-99
10.1016/j.ygyno.2015.04.033,2,No,NA,No,NA,Enrolled among patients with a trial available,Percent,NA,None,2,N/A,Black,83,-99,-99
10.1016/j.ygyno.2015.04.033,2,No,NA,No,NA,Enrolled among patients with a trial available,Percent,NA,None,3,N/A,Asian/Asian/White,78.6,-99,-99
10.1016/j.ygyno.2015.04.033,2,No,NA,No,NA,Enrolled among patients with a trial available,Percent,NA,None,4,N/A,Native American,75,-99,-99
10.1016/j.ygyno.2015.04.033,2,No,NA,No,NA,Enrolled among patients with a trial available,Percent,NA,None,5,N/A,Hawaiian/PI,0,-99,-99
10.1016/j.ygyno.2015.04.033,2,No,NA,No,NA,Enrolled among patients with a trial available,Percent,NA,None,6,N/A,Unknown,50,-99,NA
10.1016/j.ygyno.2015.04.033,2,No,NA,No,NA,Enrolled among patients with a trial available,Percent,NA,None,7,N/A,NA,NA,NA,-99
10.1016/j.ygyno.2015.04.033,3,No,NA,No,NA,Not eligible among patients with a trial available,Percent,NA,None,1,N/A,White,14,-99,-99
10.1016/j.ygyno.2015.04.033,3,No,NA,No,NA,Not eligible among patients with a trial available,Percent,NA,None,2,N/A,Black,10,-99,-99
10.1016/j.ygyno.2015.04.033,3,No,NA,No,NA,Not eligible among patients with a trial available,Percent,NA,None,3,N/A,Asian/Asian/White,7,-99,-99
10.1016/j.ygyno.2015.04.033,3,No,NA,No,NA,Not eligible among patients with a trial available,Percent,NA,None,4,N/A,Native American,12.5,-99,-99
10.1016/j.ygyno.2015.04.033,3,No,NA,No,NA,Not eligible among patients with a trial available,Percent,NA,None,5,N/A,Hawaiian/PI,0,-99,-99
10.1016/j.ygyno.2015.04.033,3,No,NA,No,NA,Not eligible among patients with a trial available,Percent,NA,None,6,N/A,Unknown,0,-99,NA
10.1016/j.ygyno.2015.04.033,3,No,NA,No,NA,Not eligible among patients with a trial available,Percent,NA,None,7,N/A,NA,NA,NA,-99
10.1016/j.ygyno.2015.04.033,4,No,NA,No,NA,Race of women with a trial available,Percent,NA,None,1,N/A,White,81,-99,-99
10.1016/j.ygyno.2015.04.033,4,No,NA,No,NA,Race of women with a trial available,Percent,NA,None,2,N/A,Black,10,-99,-99
10.1016/j.ygyno.2015.04.033,4,No,NA,No,NA,Race of women with a trial available,Percent,NA,None,3,N/A,Asian/Asian/White,4.8,-99,-99
10.1016/j.ygyno.2015.04.033,4,No,NA,No,NA,Race of women with a trial available,Percent,NA,None,4,N/A,Native American,2.7,-99,-99
10.1016/j.ygyno.2015.04.033,4,No,NA,No,NA,Race of women with a trial available,Percent,NA,None,5,N/A,Hawaiian/PI,0.03,-99,-99
10.1016/j.ygyno.2015.04.033,4,No,NA,No,NA,Race of women with a trial available,Percent,NA,None,6,N/A,Unknown,1.3,-99,NA
10.1016/j.ygyno.2015.04.033,4,No,NA,No,NA,Race of women with a trial available,Percent,NA,None,7,N/A,NA,NA,NA,-99
10.1016/j.ygyno.2015.04.033,5,No,NA,No,NA,Variables associated with trial eligibility/ineligibity,OR,NA,None,1,N/A,Ethnicity of physician non-Hispanic,28.87,2.32,358.86
10.1016/j.ygyno.2015.04.033,6,No,NA,No,NA,Race doctor,OR,NA,None,1,White,Asian,0.03,0.005,0.22
10.1016/j.ygyno.2015.04.033,7,No,NA,No,NA,Race doctor,OR,NA,None,1,White,Black,56.5,1.06,NA
10.1016/j.ygyno.2015.04.033,8,No,NA,No,NA,Patient race,OR,NA,None,1,White,non-White,7.893,1.35,46.19
10.1097/AOG.0000000000000843,1,No,NA,Yes,"Race, ethnicity and language",Recall of screening discussion,OR,NA,None,1,Caucasian or white,African American or Black,0.74,0.3,1.84
10.1097/AOG.0000000000000843,1,No,NA,Yes,"Race, ethnicity and language",Recall of screening discussion,OR,NA,None,2,Caucasian or white,Latina,0.96,0.5,2.06
10.1097/AOG.0000000000000843,1,No,NA,Yes,"Race, ethnicity and language",Recall of screening discussion,OR,NA,None,3,Caucasian or white,"Other (asian, pacific islander, native american, mixed, other)",0.77,0.3,1.99
10.1097/AOG.0000000000000843,2,No,NA,Yes,"Race, ethnicity and language",Clear understanding that screening was optional,OR,NA,None,1,Caucasian or white,African American or Black,0.5,0.28,0.9
10.1097/AOG.0000000000000843,2,No,NA,Yes,"Race, ethnicity and language",Clear understanding that screening was optional,OR,NA,None,2,Caucasian or white,Latina (English speaking),0.27,0.14,0.52
10.1097/AOG.0000000000000843,2,No,NA,Yes,"Race, ethnicity and language",Clear understanding that screening was optional,OR,NA,None,3,Caucasian or white,Latina (Spanish speaking),0.8,0.51,1.27
10.1097/AOG.0000000000000843,2,No,NA,Yes,"Race, ethnicity and language",Clear understanding that screening was optional,OR,NA,None,4,Caucasian or white,"Other (Asian, Pacific Islander, Native American, Mixed, other)",0.63,0.36,1.1
10.1097/AOG.0000000000000843,3,No,NA,No,NA,Clear understanding that screening was optional,OR,NA,"Maternal age <35 years, multiparity, highest level of education, single marital status, low literacy, low numeracy, prenatal care site serving primarily low income women, assignment to intervention group",1,Caucasian or white,African American or Black,0.75,0.38,1.46
10.1097/AOG.0000000000000843,3,No,NA,No,NA,Clear understanding that screening was optional,OR,NA,"Maternal age <35 years, multiparity, highest level of education, single marital status, low literacy, low numeracy, prenatal care site serving primarily low income women, assignment to intervention group",2,Caucasian or white,Latina (English speaking),0.35,0.18,0.7
10.1097/AOG.0000000000000843,3,No,NA,No,NA,Clear understanding that screening was optional,OR,NA,"Maternal age <35 years, multiparity, highest level of education, single marital status, low literacy, low numeracy, prenatal care site serving primarily low income women, assignment to intervention group",3,Caucasian or white,Latina (Spanish speaking),1.17,0.64,2.15
10.1097/AOG.0000000000000843,3,No,NA,No,NA,Clear understanding that screening was optional,OR,NA,"Maternal age <35 years, multiparity, highest level of education, single marital status, low literacy, low numeracy, prenatal care site serving primarily low income women, assignment to intervention group",4,Caucasian or white,"Other (Asian, Pacific Islander, Native American, Mixed, other)",0.75,0.41,1.35
10.1097/AOG.0000000000000843,4,No,NA,Yes,"Race, ethnicity and language",Correct recall of whether screening was done,OR,NA,None,1,Caucasian or white,African American or Black,0.29,0.12,0.68
10.1097/AOG.0000000000000843,4,No,NA,Yes,"Race, ethnicity and language",Correct recall of whether screening was done,OR,NA,None,2,Caucasian or white,Latina (English speaking),0.49,0.18,1.33
10.1097/AOG.0000000000000843,4,No,NA,Yes,"Race, ethnicity and language",Correct recall of whether screening was done,OR,NA,None,3,Caucasian or white,Latina (Spanish speaking),0.58,0.27,1.23
10.1097/AOG.0000000000000843,4,No,NA,Yes,"Race, ethnicity and language",Correct recall of whether screening was done,OR,NA,None,4,Caucasian or white,"Other (Asian, Pacific Islander, Native American, Mixed, other)",0.86,0.28,2.64
10.1097/AOG.0000000000000843,5,No,NA,No,NA,Correct recall of whether screening was done,OR,NA,"Maternal age <35 years, multiparity, highest level of education, single marital status, low literacy, low numeracy, prenatal care site serving primarily low income women, assignment to intervention group",1,Caucasian or white,African American or Black,0.66,0.23,1.89
10.1097/AOG.0000000000000843,5,No,NA,No,NA,Correct recall of whether screening was done,OR,NA,"Maternal age <35 years, multiparity, highest level of education, single marital status, low literacy, low numeracy, prenatal care site serving primarily low income women, assignment to intervention group",2,Caucasian or white,Latina (English speaking),0.93,0.3,2.94
10.1097/AOG.0000000000000843,5,No,NA,No,NA,Correct recall of whether screening was done,OR,NA,"Maternal age <35 years, multiparity, highest level of education, single marital status, low literacy, low numeracy, prenatal care site serving primarily low income women, assignment to intervention group",3,Caucasian or white,Latina (Spanish speaking),1.74,0.62,4.93
10.1097/AOG.0000000000000843,5,No,NA,No,NA,Correct recall of whether screening was done,OR,NA,"Maternal age <35 years, multiparity, highest level of education, single marital status, low literacy, low numeracy, prenatal care site serving primarily low income women, assignment to intervention group",4,Caucasian or white,"Other (Asian, Pacific Islander, Native American, Mixed, other)",1.36,0.42,4.45
10.1097/AOG.0000000000000843,6,No,NA,Yes,"Race, ethnicity and language",Recall of diagnostic testing discussion,OR,NA,None,1,Caucasian or white,African American or Black,0.62,0.37,1.05
10.1097/AOG.0000000000000843,6,No,NA,Yes,"Race, ethnicity and language",Recall of diagnostic testing discussion,OR,NA,None,2,Caucasian or white,Latina (English speaking),0.65,0.34,1.25
10.1097/AOG.0000000000000843,6,No,NA,Yes,"Race, ethnicity and language",Recall of diagnostic testing discussion,OR,NA,None,3,Caucasian or white,Latina (Spanish speaking),0.44,0.29,0.67
10.1097/AOG.0000000000000843,6,No,NA,Yes,"Race, ethnicity and language",Recall of diagnostic testing discussion,OR,NA,None,4,Caucasian or white,"Other (Asian, Pacific Islander, Native American, Mixed, other)",0.58,0.33,1.02
10.1097/AOG.0000000000000843,7,No,NA,Yes,"Race, ethnicity and language",Clear understanding that diagnostic testing was optional,OR,NA,None,1,Caucasian or white,African American or Black,0.2,0.11,0.36
10.1097/AOG.0000000000000843,7,No,NA,Yes,"Race, ethnicity and language",Clear understanding that diagnostic testing was optional,OR,NA,None,2,Caucasian or white,Latina (English speaking),0.28,0.13,0.61
10.1097/AOG.0000000000000843,7,No,NA,Yes,"Race, ethnicity and language",Clear understanding that diagnostic testing was optional,OR,NA,None,3,Caucasian or white,Latina (Spanish speaking),0.42,0.24,0.72
10.1097/AOG.0000000000000843,7,No,NA,Yes,"Race, ethnicity and language",Clear understanding that diagnostic testing was optional,OR,NA,None,4,Caucasian or white,"other (Asian, Pacific Islander, Native American, Mixed, other)",0.35,0.19,0.66
10.1097/AOG.0000000000000843,8,No,NA,No,NA,Clear understanding that diagnostic testing was optional,OR,NA,"Maternal age <35 years, multiparity, highest level of education, single marital status, low literacy, low numeracy, prenatal care site serving primarily low income women, assignment to intervention group",1,Caucasian or white,African American or Black,0.44,0.22,0.91
10.1097/AOG.0000000000000843,8,No,NA,No,NA,Clear understanding that diagnostic testing was optional,OR,NA,"Maternal age <35 years, multiparity, highest level of education, single marital status, low literacy, low numeracy, prenatal care site serving primarily low income women, assignment to intervention group",2,Caucasian or white,Latina (English speaking),0.53,0.23,1.22
10.1097/AOG.0000000000000843,8,No,NA,No,NA,Clear understanding that diagnostic testing was optional,OR,NA,"Maternal age <35 years, multiparity, highest level of education, single marital status, low literacy, low numeracy, prenatal care site serving primarily low income women, assignment to intervention group",3,Caucasian or white,Latina (Spanish speaking),1.16,0.58,2.34
10.1097/AOG.0000000000000843,8,No,NA,No,NA,Clear understanding that diagnostic testing was optional,OR,NA,"Maternal age <35 years, multiparity, highest level of education, single marital status, low literacy, low numeracy, prenatal care site serving primarily low income women, assignment to intervention group",4,Caucasian or white,"other (Asian, Pacific Islander, Native American, Mixed, other)",0.5,0.25,0.99
10.1097/AOG.0000000000000843,9,No,NA,Yes,"Race, ethnicity and language",Correct recall of whether diagnostic testing was done,OR,NA,None,1,Caucasian or white,African American or Black,0.27,0.03,2.92
10.1097/AOG.0000000000000843,9,No,NA,Yes,"Race, ethnicity and language",Correct recall of whether diagnostic testing was done,OR,NA,None,2,Caucasian or white,Latina (Spanish speaking),0.86,0.07,10.17
10.1097/AOG.0000000000000843,9,No,NA,Yes,"Race, ethnicity and language",Correct recall of whether diagnostic testing was done,OR,NA,None,3,Caucasian or white,"other (Asian, Pacific Islander, Native American, Mixed, other)",0.37,0.02,6.26
10.1097/AOG.0000000000000808,1,No,NA,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,White,Black,1.25,0.77,2.04
10.1097/AOG.0000000000000808,1,No,NA,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",2,White,Asian,0.74,0.42,1.33
10.1097/AOG.0000000000000808,2,Yes,White,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,difficulty paying for basics: Not hard at all,difficulty paying for basics: Somewhat hard,1.14,0.57,2.28
10.1097/AOG.0000000000000808,2,Yes,White,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",2,difficulty paying for basics: Not hard at all,difficulty paying for basics: Very hard,1.1,0.26,4.54
10.1097/AOG.0000000000000808,3,Yes,Black,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,difficulty paying for basics: Not hard at all,difficulty paying for basics: Somewhat hard,1.77,0.77,4.07
10.1097/AOG.0000000000000808,3,Yes,Black,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",2,difficulty paying for basics: Not hard at all,difficulty paying for basics: Very hard,1.93,0.56,6.65
10.1097/AOG.0000000000000808,4,Yes,Asian,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,difficulty paying for basics: Not hard at all,difficulty paying for basics: somewhat hard,0.88,0.23,3.36
10.1097/AOG.0000000000000808,4,Yes,Asian,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",2,difficulty paying for basics: Not hard at all,difficulty paying for basics: Very hard,1.61,0.08,31.5
10.1097/AOG.0000000000000808,5,Yes,White,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,High school or less,some college or greater,0.9,0.38,2.16
10.1097/AOG.0000000000000808,6,Yes,Black,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,High school or less,some college or greater,1.17,0.49,2.8
10.1097/AOG.0000000000000808,7,Yes,Asian,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,High school or less,some college or greater,1.42,0.3,6.73
10.1097/AOG.0000000000000808,8,Yes,White,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level,  number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,nulliparous,parous,1.61,0.79,3.3
10.1097/AOG.0000000000000808,9,Yes,Black,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level,  number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,nulliparous,parous,1.34,0.37,4.88
10.1097/AOG.0000000000000808,10,Yes,Asian,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level,  number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,nulliparous,parous,0.88,0.19,4.18
10.1097/AOG.0000000000000808,11,Yes,White,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,n/a,number of years with anxiety,1.07,0.79,1.22
10.1097/AOG.0000000000000808,12,Yes,Black,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,n/a,number of years with anxiety,0.96,0.82,1.12
10.1097/AOG.0000000000000808,13,Yes,Asian,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,n/a,number of years with anxiety,0.96,0.75,1.24
10.1097/AOG.0000000000000808,14,Yes,White,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,n/a,sf-36 vitality score,1.02,1.01,1.03
10.1097/AOG.0000000000000808,15,Yes,Black,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,n/a,sf-36 vitality score,1.01,0.99,1.03
10.1097/AOG.0000000000000808,16,Yes,Asian,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,n/a,sf-36 vitality score,0.99,0.97,1.02
10.1097/AOG.0000000000000808,17,Yes,White,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,n/a,number of women's health visits,1.2,1.04,1.38
10.1097/AOG.0000000000000808,18,Yes,Black,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,n/a,number of women's health visits,1.12,0.94,1.34
10.1097/AOG.0000000000000808,19,Yes,Asian,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,n/a,number of women's health visits,1.3,0.99,1.72
10.1097/AOG.0000000000000808,20,Yes,White,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,n/a,average number md visits,1.07,1,1.14
10.1097/AOG.0000000000000808,21,Yes,Black,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,n/a,average number md visits,1.09,0.99,1.2
10.1097/AOG.0000000000000808,22,Yes,Asian,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,n/a,average number md visits,1.04,0.92,1.18
10.1097/AOG.0000000000000808,23,Yes,White,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits,  frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,no diabetes,diabetes,0.94,0.18,5.03
10.1097/AOG.0000000000000808,24,Yes,Black,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits,  frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,no diabetes,diabetes,0.51,0.13,1.99
10.1097/AOG.0000000000000808,25,Yes,Asian,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits,  frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,no diabetes,diabetes,0.58,0.05,7.02
10.1097/AOG.0000000000000808,26,Yes,White,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,Monthly,frequency of ui at first report: Weekly,1.85,0.75,4.55
10.1097/AOG.0000000000000808,26,Yes,White,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",2,Monthly,frequency of ui at first report: Daily,3.43,0.79,14.8
10.1097/AOG.0000000000000808,27,Yes,Black,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,Monthly,frequency of ui at first report: Weekly,1.22,0.4,3.67
10.1097/AOG.0000000000000808,27,Yes,Black,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",2,Monthly,frequency of ui at first report: Daily,1.5,0.31,7.15
10.1097/AOG.0000000000000808,28,Yes,Asian,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,Monthly,frequency of ui at first report: Weekly,2.26,0.45,11.4
10.1097/AOG.0000000000000808,28,Yes,Asian,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",2,Monthly,frequency of ui at first report: Daily,3.49,0.21,57.3
10.1097/AOG.0000000000000808,29,Yes,White,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,None,frequency of ui in year prior to report: Monthly,1.66,0.67,4.12
10.1097/AOG.0000000000000808,29,Yes,White,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",2,None,frequency of ui in year prior to report: Weekly,2.2,0.67,7.24
10.1097/AOG.0000000000000808,29,Yes,White,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",3,None,frequency of ui in year prior to report: Daily,3.67,0.83,16.3
10.1097/AOG.0000000000000808,30,Yes,Black,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,None,frequency of ui in year prior to report: Monthly,1.75,0.67,4.56
10.1097/AOG.0000000000000808,30,Yes,Black,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",2,None,frequency of ui in year prior to report: Weekly,1.93,0.54,6.94
10.1097/AOG.0000000000000808,30,Yes,Black,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",3,None,frequency of ui in year prior to report: Daily,2.57,0.51,12.9
10.1097/AOG.0000000000000808,31,Yes,Asian,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,None,frequency of ui in year prior to report: Monthly,2.08,0.47,9.24
10.1097/AOG.0000000000000808,31,Yes,Asian,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",2,None,frequency of ui in year prior to report: Weekly,2.89,0.32,26.4
10.1097/AOG.0000000000000808,31,Yes,Asian,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, duration of UI, UI improve in year prior, UI worse in year prior, bothersomeness of UI",3,None,frequency of ui in year prior to report: Daily,1.66,0.05,52.2
10.1097/AOG.0000000000000808,32,Yes,White,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report,  UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,duration of ui: Present at baseline (> 7 years),duration of ui: Less than 4 years,0.39,0.1,1.53
10.1097/AOG.0000000000000808,32,Yes,White,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report,  UI improve in year prior, UI worse in year prior, bothersomeness of UI",2,duration of ui: Present at baseline (> 7 years),duration of ui: 4-7 years,0.31,0.13,0.72
10.1097/AOG.0000000000000808,33,Yes,Black,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report,  UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,duration of ui: Present at baseline (> 7 years),duration of ui: Less than 4 years,0.5,0.1,2.53
10.1097/AOG.0000000000000808,33,Yes,Black,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report,  UI improve in year prior, UI worse in year prior, bothersomeness of UI",2,duration of ui: Present at baseline (> 7 years),duration of ui: 4-7 years,0.38,0.15,1.01
10.1097/AOG.0000000000000808,34,Yes,Asian,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report,  UI improve in year prior, UI worse in year prior, bothersomeness of UI",1,duration of ui: Present at baseline (> 7 years),duration of ui: Less than 4 years,0.15,0.01,6.72
10.1097/AOG.0000000000000808,34,Yes,Asian,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report,  UI improve in year prior, UI worse in year prior, bothersomeness of UI",2,duration of ui: Present at baseline (> 7 years),duration of ui: 4-7 years,0.58,0.13,2.64
10.1097/AOG.0000000000000808,35,Yes,White,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI worse in year prior, bothersomeness of UI",1,n/a,ui improve in year prior,0.54,0.22,1.35
10.1097/AOG.0000000000000808,36,Yes,Black,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI worse in year prior, bothersomeness of UI",1,n/a,ui improve in year prior,0.85,0.26,2.83
10.1097/AOG.0000000000000808,37,Yes,Asian,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI worse in year prior, bothersomeness of UI",1,n/a,ui improve in year prior,0.51,0.1,2.64
10.1097/AOG.0000000000000808,38,Yes,White,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, bothersomeness of UI",1,n/a,ui worse in year prior,1.9,0.87,4.13
10.1097/AOG.0000000000000808,39,Yes,Black,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, bothersomeness of UI",1,n/a,ui worse in year prior,1.94,0.75,4.99
10.1097/AOG.0000000000000808,40,Yes,Asian,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, bothersomeness of UI",1,n/a,ui worse in year prior,1.19,0.26,5.56
10.1097/AOG.0000000000000808,41,Yes,White,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior",1,n/a,bothersomeness of ui,1.1,0.98,1.23
10.1097/AOG.0000000000000808,42,Yes,Black,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior",1,n/a,bothersomeness of ui,1.12,0.98,1.29
10.1097/AOG.0000000000000808,43,Yes,Asian,No,NA,"Seeking treatment for urinary incontinence in visits 7, 8, or 9",OR,NA,"Difficulty paying for basics, education level, parity, number of years with anxiety, SF-36 vitality score, number women's health visits, average number MD visits, diabetes, frequency of UI at first report, frequency of UI in year prior to report, duration of UI, UI improve in year prior, UI worse in year prior",1,n/a,bothersomeness of ui,1.05,0.85,1.28
10.1016/j.ygyno.2014.10.021,1,Yes,2000-2005,No,NA,endometrial cancer survival,HR,NA,"age at diagnosis, marital status, seer region",1,Non hispanic white,US born hispanics,1.92,1.72,2.14
10.1016/j.ygyno.2014.10.021,1,Yes,2000-2005,No,NA,endometrial cancer survival,HR,NA,"age at diagnosis, marital status, seer region",2,Non hispanic white,Foreign born hispanics,1.69,1.5,1.9
10.1016/j.ygyno.2014.10.021,1,Yes,2000-2005,No,NA,endometrial cancer survival,HR,NA,"age at diagnosis, marital status, seer region",3,Non hispanic white,Birthplace unknown hispanics,0.75,0.66,0.86
10.1016/j.ygyno.2014.10.021,2,Yes,2000-2005,No,NA,endometrial cancer survival,HR,NA,"age at diagnosis, marital status, seer region, stage, histologybased risk, grade, lymphadenectomy",1,Non hispanic white,US born hispanics,1.61,1.44,1.79
10.1016/j.ygyno.2014.10.021,2,Yes,2000-2005,No,NA,endometrial cancer survival,HR,NA,"age at diagnosis, marital status, seer region, stage, histologybased risk, grade, lymphadenectomy",2,Non hispanic white,Foreign born hispanics,1.35,1.2,1.52
10.1016/j.ygyno.2014.10.021,2,Yes,2000-2005,No,NA,endometrial cancer survival,HR,NA,"age at diagnosis, marital status, seer region, stage, histologybased risk, grade, lymphadenectomy",3,Non hispanic white,Birthplace unknown hispanics,0.71,0.62,0.81
10.1016/j.ygyno.2014.10.021,3,Yes,2000-2005,No,NA,endometrial cancer survival,HR,NA,"Age at diagnosis, marital status, SEER region, stage, histology-based risk, grade, lymphadenectomy, treatment",1,Non hispanic white,US born hispanics,1.61,1.44,1.79
10.1016/j.ygyno.2014.10.021,3,Yes,2000-2005,No,NA,endometrial cancer survival,HR,NA,"Age at diagnosis, marital status, SEER region, stage, histology-based risk, grade, lymphadenectomy, treatment",2,Non hispanic white,Foreign born hispanics,1.27,1.13,1.43
10.1016/j.ygyno.2014.10.021,3,Yes,2000-2005,No,NA,endometrial cancer survival,HR,NA,"Age at diagnosis, marital status, SEER region, stage, histology-based risk, grade, lymphadenectomy, treatment",3,Non hispanic white,Birthplace unknown hispanics,0.69,0.6,0.78
10.1016/j.ygyno.2014.10.021,4,Yes,2006-2010,No,NA,endometrial cancer survival,HR,NA,"age at diagnosis, marital status, seer region",1,Non hispanic white,US born hispanics,2.09,1.78,2.45
10.1016/j.ygyno.2014.10.021,4,Yes,2006-2010,No,NA,endometrial cancer survival,HR,NA,"age at diagnosis, marital status, seer region",2,Non hispanic white,Foreign born hispanics,2.05,1.76,2.38
10.1016/j.ygyno.2014.10.021,4,Yes,2006-2010,No,NA,endometrial cancer survival,HR,NA,"age at diagnosis, marital status, seer region",3,Non hispanic white,Birthplace unknown hispanics,0.83,0.7,0.97
10.1016/j.ygyno.2014.10.021,5,Yes,2006-2010,No,NA,endometrial cancer survival,HR,NA,"age at diagnosis, marital status, seer region, stage, histologybased risk, grade, lymphadenectomy",1,Non hispanic white,US born hispanics,1.41,1.2,1.65
10.1016/j.ygyno.2014.10.021,5,Yes,2006-2010,No,NA,endometrial cancer survival,HR,NA,"age at diagnosis, marital status, seer region, stage, histologybased risk, grade, lymphadenectomy",2,Non hispanic white,Foreign born hispanics,1.35,1.16,1.57
10.1016/j.ygyno.2014.10.021,5,Yes,2006-2010,No,NA,endometrial cancer survival,HR,NA,"age at diagnosis, marital status, seer region, stage, histologybased risk, grade, lymphadenectomy",3,Non hispanic white,Birthplace unknown hispanics,1.31,1.12,1.52
10.1016/j.ygyno.2014.10.021,6,Yes,2006-2010,No,NA,endometrial cancer survival,HR,NA,"Age at diagnosis, marital status, SEER region, stage, histology-based risk, grade, lymphadenectomy, treatment",1,Non hispanic white,US born hispanics,1.16,0.99,1.36
10.1016/j.ygyno.2014.10.021,6,Yes,2006-2010,No,NA,endometrial cancer survival,HR,NA,"Age at diagnosis, marital status, SEER region, stage, histology-based risk, grade, lymphadenectomy, treatment",2,Non hispanic white,Foreign born hispanics,1.31,1.12,1.52
10.1016/j.ygyno.2014.10.021,6,Yes,2006-2010,No,NA,endometrial cancer survival,HR,NA,"Age at diagnosis, marital status, SEER region, stage, histology-based risk, grade, lymphadenectomy, treatment",3,Non hispanic white,Birthplace unknown hispanics,0.75,0.64,0.88
10.1016/j.ygyno.2014.10.021,7,No,NA,Yes,2000-2005,Mortality differences,OR,NA,None,1,Non hispanic white,US born hispanics,1.92,1.72,2.14
10.1016/j.ygyno.2014.10.021,7,No,NA,Yes,2000-2005,Mortality differences,OR,NA,None,2,Non hispanic white,Foreign born hispanics,1.69,1.5,1.9
10.1016/j.ygyno.2014.10.021,7,No,NA,Yes,2000-2005,Mortality differences,OR,NA,None,3,Non hispanic white,Birthplace unknown hispanics,0.75,0.66,0.86
10.1016/j.ygyno.2014.10.021,8,No,NA,Yes,2000-2005,Mortality differences,OR,NA,Early diagnosis,1,Non hispanic white,US born hispanics,1.63,1.47,1.82
10.1016/j.ygyno.2014.10.021,8,No,NA,Yes,2000-2005,Mortality differences,OR,NA,Early diagnosis,2,Non hispanic white,Foreign born hispanics,1.44,1.28,1.62
10.1016/j.ygyno.2014.10.021,8,No,NA,Yes,2000-2005,Mortality differences,OR,NA,Early diagnosis,3,Non hispanic white,Birthplace unknown hispanics,0.73,0.64,0.83
10.1016/j.ygyno.2014.10.021,9,No,NA,Yes,2000-2005,Mortality differences,OR,NA,Disease severity,1,Non hispanic white,US born hispanics,1.83,1.64,2.04
10.1016/j.ygyno.2014.10.021,9,No,NA,Yes,2000-2005,Mortality differences,OR,NA,Disease severity,2,Non hispanic white,Foreign born hispanics,1.48,1.31,1.67
10.1016/j.ygyno.2014.10.021,9,No,NA,Yes,2000-2005,Mortality differences,OR,NA,Disease severity,3,Non hispanic white,Birthplace unknown hispanics,0.74,0.65,0.84
10.1016/j.ygyno.2014.10.021,10,No,NA,Yes,2000-2005,Mortality differences,OR,NA,All cancer characteristics,1,Non hispanic white,US born hispanics,1.61,1.44,1.79
10.1016/j.ygyno.2014.10.021,10,No,NA,Yes,2000-2005,Mortality differences,OR,NA,All cancer characteristics,2,Non hispanic white,Foreign born hispanics,1.35,1.2,1.52
10.1016/j.ygyno.2014.10.021,10,No,NA,Yes,2000-2005,Mortality differences,OR,NA,All cancer characteristics,3,Non hispanic white,Birthplace unknown hispanics,0.71,0.62,0.81
10.1016/j.ygyno.2014.10.021,11,No,NA,Yes,2000-2005,Mortality differences,OR,NA,Treatment including all other factors,1,Non hispanic white,US born hispanics,1.61,1.44,1.79
10.1016/j.ygyno.2014.10.021,11,No,NA,Yes,2000-2005,Mortality differences,OR,NA,Treatment including all other factors,2,Non hispanic white,Foreign born hispanics,1.27,1.13,1.43
10.1016/j.ygyno.2014.10.021,11,No,NA,Yes,2000-2005,Mortality differences,OR,NA,Treatment including all other factors,3,Non hispanic white,Birthplace unknown hispanics,0.69,0.6,0.78
10.1016/j.ygyno.2014.10.021,12,No,NA,Yes,2000-2005,Mortality differences,OR,NA,Treatment only,1,Non hispanic white,us born hispanics,1.83,1.64,2.04
10.1016/j.ygyno.2014.10.021,12,No,NA,Yes,2000-2005,Mortality differences,OR,NA,Treatment only,2,Non hispanic white,Foreign born hispanics,1.5,1.33,1.69
10.1016/j.ygyno.2014.10.021,12,No,NA,Yes,2000-2005,Mortality differences,OR,NA,Treatment only,3,Non hispanic white,Birthplace unknown hispanics,0.71,0.62,0.81
10.1016/j.ygyno.2014.10.021,13,No,NA,Yes,2006-2010,Mortality differences,OR,NA,None,1,Non hispanic white,us born hispanics,2.09,1.78,2.45
10.1016/j.ygyno.2014.10.021,13,No,NA,Yes,2006-2010,Mortality differences,OR,NA,None,2,Non hispanic white,Foreign born hispanics,2.05,1.76,2.38
10.1016/j.ygyno.2014.10.021,13,No,NA,Yes,2006-2010,Mortality differences,OR,NA,None,3,Non hispanic white,Birthplace unknown hispanics,0.83,0.7,0.97
10.1016/j.ygyno.2014.10.021,14,No,NA,Yes,2006-2010,Mortality differences,OR,NA,early diagnosis,1,Non hispanic white,us born hispanics,1.57,1.34,1.84
10.1016/j.ygyno.2014.10.021,14,No,NA,Yes,2006-2010,Mortality differences,OR,NA,early diagnosis,2,Non hispanic white,Foreign born hispanics,1.59,1.37,1.85
10.1016/j.ygyno.2014.10.021,14,No,NA,Yes,2006-2010,Mortality differences,OR,NA,early diagnosis,3,Non hispanic white,Birthplace unknown hispanics,0.79,0.67,0.92
10.1016/j.ygyno.2014.10.021,15,No,NA,Yes,2006-2010,Mortality differences,OR,NA,disease severity,1,Non hispanic white,us born hispanics,1.72,1.47,2.02
10.1016/j.ygyno.2014.10.021,15,No,NA,Yes,2006-2010,Mortality differences,OR,NA,disease severity,2,Non hispanic white,Foreign born hispanics,1.61,1.38,1.87
10.1016/j.ygyno.2014.10.021,15,No,NA,Yes,2006-2010,Mortality differences,OR,NA,disease severity,3,Non hispanic white,Birthplace unknown hispanics,0.81,0.69,0.94
10.1016/j.ygyno.2014.10.021,16,No,NA,Yes,2006-2010,Mortality differences,OR,NA,all cancer characteristics,1,Non hispanic white,us born hispanics,1.41,1.2,1.65
10.1016/j.ygyno.2014.10.021,16,No,NA,Yes,2006-2010,Mortality differences,OR,NA,all cancer characteristics,2,Non hispanic white,Foreign born hispanics,1.35,1.16,1.57
10.1016/j.ygyno.2014.10.021,16,No,NA,Yes,2006-2010,Mortality differences,OR,NA,all cancer characteristics,3,Non hispanic white,Birthplace unknown hispanics,0.75,0.64,0.88
10.1016/j.ygyno.2014.10.021,17,No,NA,Yes,2006-2010,Mortality differences,OR,NA,treatment including all other factors,1,Non hispanic white,us born hispanics,1.16,0.99,1.36
10.1016/j.ygyno.2014.10.021,17,No,NA,Yes,2006-2010,Mortality differences,OR,NA,treatment including all other factors,2,Non hispanic white,Foreign born hispanics,1.31,1.12,1.52
10.1016/j.ygyno.2014.10.021,17,No,NA,Yes,2006-2010,Mortality differences,OR,NA,treatment including all other factors,3,Non hispanic white,Birthplace unknown hispanics,0.75,0.64,0.88
10.1016/j.ygyno.2014.10.021,18,No,NA,Yes,2006-2010,Mortality differences,OR,NA,treatment only,1,Non hispanic white,us born hispanics,1.64,1.4,1.93
10.1016/j.ygyno.2014.10.021,18,No,NA,Yes,2006-2010,Mortality differences,OR,NA,treatment only,2,Non hispanic white,Foreign born hispanics,1.81,1.56,2.11
10.1016/j.ygyno.2014.10.021,18,No,NA,Yes,2006-2010,Mortality differences,OR,NA,treatment only,3,Non hispanic white,Birthplace unknown hispanics,0.74,0.64,0.87
10.1016/j.ygyno.2014.10.021,19,No,NA,No,NA,Mortality differences,OR,NA,None,1,Non hispanic white,us born hispanics,1.97,1.8,2.15
10.1016/j.ygyno.2014.10.021,19,No,NA,No,NA,Mortality differences,OR,NA,None,2,Non hispanic white,Foreign born hispanics,1.81,1.65,1.99
10.1016/j.ygyno.2014.10.021,19,No,NA,No,NA,Mortality differences,OR,NA,None,3,Non hispanic white,Birthplace unknown hispanics,0.78,0.71,0.86
10.1016/j.ygyno.2014.10.021,20,No,NA,No,NA,Mortality differences,OR,NA,early diagnosis,1,Non hispanic white,us born hispanics,1.63,1.49,1.78
10.1016/j.ygyno.2014.10.021,20,No,NA,No,NA,Mortality differences,OR,NA,early diagnosis,2,Non hispanic white,Foreign born hispanics,1.51,1.38,1.66
10.1016/j.ygyno.2014.10.021,20,No,NA,No,NA,Mortality differences,OR,NA,early diagnosis,3,Non hispanic white,Birthplace unknown hispanics,0.76,0.68,0.83
10.1016/j.ygyno.2014.10.021,21,No,NA,No,NA,Mortality differences,OR,NA,disease severity,1,Non hispanic white,us born hispanics,1.81,1.65,1.98
10.1016/j.ygyno.2014.10.021,21,No,NA,No,NA,Mortality differences,OR,NA,disease severity,2,Non hispanic white,Foreign born hispanics,1.54,1.41,1.69
10.1016/j.ygyno.2014.10.021,21,No,NA,No,NA,Mortality differences,OR,NA,disease severity,3,Non hispanic white,Birthplace unknown hispanics,0.77,0.69,0.85
10.1016/j.ygyno.2014.10.021,22,No,NA,No,NA,Mortality differences,OR,NA,all cancer characteristics,1,Non hispanic white,us born hispanics,1.57,1.43,1.71
10.1016/j.ygyno.2014.10.021,22,No,NA,No,NA,Mortality differences,OR,NA,all cancer characteristics,2,Non hispanic white,Foreign born hispanics,1.37,1.25,1.5
10.1016/j.ygyno.2014.10.021,22,No,NA,No,NA,Mortality differences,OR,NA,all cancer characteristics,3,Non hispanic white,Birthplace unknown hispanics,0.74,0.67,0.82
10.1016/j.ygyno.2014.10.021,23,No,NA,No,NA,Mortality differences,OR,NA,treatment including all other factors,1,Non hispanic white,us born hispanics,1.54,1.4,1.68
10.1016/j.ygyno.2014.10.021,23,No,NA,No,NA,Mortality differences,OR,NA,treatment including all other factors,2,Non hispanic white,Foreign born hispanics,1.32,1.2,1.45
10.1016/j.ygyno.2014.10.021,23,No,NA,No,NA,Mortality differences,OR,NA,treatment including all other factors,3,Non hispanic white,Birthplace unknown hispanics,0.73,0.66,0.81
10.1016/j.ygyno.2014.10.021,24,No,NA,No,NA,Mortality differences,OR,NA,treatment only,1,Non hispanic white,us born hispanics,1.8,1.64,1.97
10.1016/j.ygyno.2014.10.021,24,No,NA,No,NA,Mortality differences,OR,NA,treatment only,2,Non hispanic white,Foreign born hispanics,1.61,1.46,1.76
10.1016/j.ygyno.2014.10.021,24,No,NA,No,NA,Mortality differences,OR,NA,treatment only,3,Non hispanic white,Birthplace unknown hispanics,0.73,0.66,0.81
10.1016/j.ygyno.2014.10.009,1,No,NA,No,NA,5 year disease specific survival,Percent,NA,none,1,n/a,asian,59.1,-99,-99
10.1016/j.ygyno.2014.10.009,1,No,NA,No,NA,5 year disease specific survival,Percent,NA,none,2,n/a,white,47.3,-99,-99
10.1016/j.ygyno.2014.10.009,2,Yes,≤ 63,No,NA,5 year disease specific survival,Percent,NA,none,1,n/a,asian,66.4,-99,-99
10.1016/j.ygyno.2014.10.009,2,Yes,≤ 63,No,NA,5 year disease specific survival,Percent,NA,none,2,n/a,white,60,-99,-99
10.1016/j.ygyno.2014.10.009,3,Yes,> 63 years,No,NA,5 year disease specific survival,Percent,NA,none,1,n/a,asian,43.8,-99,-99
10.1016/j.ygyno.2014.10.009,3,Yes,> 63 years,No,NA,5 year disease specific survival,Percent,NA,none,2,n/a,white,35,-99,-99
10.1016/j.ygyno.2014.10.009,4,Yes,year of diagnosis 1988-1993,No,NA,5 year disease specific survival,Percent,NA,none,1,n/a,asian,50.8,-99,-99
10.1016/j.ygyno.2014.10.009,4,Yes,year of diagnosis 1988-1993,No,NA,5 year disease specific survival,Percent,NA,none,2,n/a,white,43.4,-99,-99
10.1016/j.ygyno.2014.10.009,5,Yes,year of diagnosis 1994-1999,No,NA,5 year disease specific survival,Percent,NA,none,1,n/a,asian,58,-99,-99
10.1016/j.ygyno.2014.10.009,5,Yes,year of diagnosis 1994-1999,No,NA,5 year disease specific survival,Percent,NA,none,2,n/a,white,46.3,-99,-99
10.1016/j.ygyno.2014.10.009,6,Yes,year of diagnosis 2000-2004,No,NA,5 year disease specific survival,Percent,NA,none,1,n/a,asian,60.6,-99,-99
10.1016/j.ygyno.2014.10.009,6,Yes,year of diagnosis 2000-2004,No,NA,5 year disease specific survival,Percent,NA,none,2,n/a,white,47.8,-99,-99
10.1016/j.ygyno.2014.10.009,7,Yes,serous,No,NA,5 year disease specific survival,Percent,NA,none,1,n/a,asian,49.3,-99,-99
10.1016/j.ygyno.2014.10.009,7,Yes,serous,No,NA,5 year disease specific survival,Percent,NA,none,2,n/a,white,41.1,-99,-99
10.1016/j.ygyno.2014.10.009,8,Yes,clear cell,No,NA,5 year disease specific survival,Percent,NA,none,1,n/a,asian,71.6,-99,-99
10.1016/j.ygyno.2014.10.009,8,Yes,clear cell,No,NA,5 year disease specific survival,Percent,NA,none,2,n/a,white,65.5,-99,-99
10.1016/j.ygyno.2014.10.009,9,Yes,endometrioid,No,NA,5 year disease specific survival,Percent,NA,none,1,n/a,asian,81,-99,-99
10.1016/j.ygyno.2014.10.009,9,Yes,endometrioid,No,NA,5 year disease specific survival,Percent,NA,none,2,n/a,white,76.9,-99,-99
10.1016/j.ygyno.2014.10.009,10,Yes,mucinous,No,NA,5 year disease specific survival,Percent,NA,none,1,n/a,asian,77.1,-99,-99
10.1016/j.ygyno.2014.10.009,10,Yes,mucinous,No,NA,5 year disease specific survival,Percent,NA,none,2,n/a,white,68.9,-99,-99
10.1016/j.ygyno.2014.10.009,11,Yes,adenocarcinoma,No,NA,5 year disease specific survival,Percent,NA,none,1,n/a,asian,27.9,-99,-99
10.1016/j.ygyno.2014.10.009,11,Yes,adenocarcinoma,No,NA,5 year disease specific survival,Percent,NA,none,2,n/a,white,22.5,-99,-99
10.1016/j.ygyno.2014.10.009,12,Yes,surgery yes,No,NA,5 year disease specific survival,Percent,NA,none,1,n/a,asian,64.4,-99,-99
10.1016/j.ygyno.2014.10.009,12,Yes,surgery yes,No,NA,5 year disease specific survival,Percent,NA,none,2,n/a,white,52.8,-99,-99
10.1016/j.ygyno.2014.10.009,13,Yes,surgery no,No,NA,5 year disease specific survival,Percent,NA,none,1,n/a,asian,10.6,-99,-99
10.1016/j.ygyno.2014.10.009,13,Yes,surgery no,No,NA,5 year disease specific survival,Percent,NA,none,2,n/a,white,9.4,-99,-99
10.1016/j.ygyno.2014.10.009,14,Yes,surgery unknown,No,NA,5 year disease specific survival,Percent,NA,none,1,n/a,asian,35.2,-99,-99
10.1016/j.ygyno.2014.10.009,14,Yes,surgery unknown,No,NA,5 year disease specific survival,Percent,NA,none,2,n/a,white,16.6,-99,-99
10.1016/j.ygyno.2014.10.009,15,Yes,stage 1,No,NA,5 year disease specific survival,Percent,NA,none,1,n/a,asian,90.7,-99,-99
10.1016/j.ygyno.2014.10.009,15,Yes,stage 1,No,NA,5 year disease specific survival,Percent,NA,none,2,n/a,white,89.2,-99,-99
10.1016/j.ygyno.2014.10.009,16,Yes,stage 2,No,NA,5 year disease specific survival,Percent,NA,none,1,n/a,asian,76,-99,-99
10.1016/j.ygyno.2014.10.009,16,Yes,stage 2,No,NA,5 year disease specific survival,Percent,NA,none,2,n/a,white,68.5,-99,-99
10.1016/j.ygyno.2014.10.009,17,Yes,stage 3,No,NA,5 year disease specific survival,Percent,NA,none,1,n/a,asian,44.5,-99,-99
10.1016/j.ygyno.2014.10.009,17,Yes,stage 3,No,NA,5 year disease specific survival,Percent,NA,none,2,n/a,white,37,-99,-99
10.1016/j.ygyno.2014.10.009,18,Yes,stage 4,No,NA,5 year disease specific survival,Percent,NA,none,1,n/a,asian,23.3,-99,-99
10.1016/j.ygyno.2014.10.009,18,Yes,stage 4,No,NA,5 year disease specific survival,Percent,NA,none,2,n/a,white,21,-99,-99
10.1016/j.ygyno.2014.10.009,19,Yes,grade 1,No,NA,5 year disease specific survival,Percent,NA,none,1,n/a,asian,90.6,-99,-99
10.1016/j.ygyno.2014.10.009,19,Yes,grade 1,No,NA,5 year disease specific survival,Percent,NA,none,2,n/a,white,84.2,-99,-99
10.1016/j.ygyno.2014.10.009,20,Yes,grade 2,No,NA,5 year disease specific survival,Percent,NA,none,1,n/a,asian,74.6,-99,-99
10.1016/j.ygyno.2014.10.009,20,Yes,grade 2,No,NA,5 year disease specific survival,Percent,NA,none,2,n/a,white,59.1,-99,-99
10.1016/j.ygyno.2014.10.009,21,Yes,grade 3,No,NA,5 year disease specific survival,Percent,NA,none,1,n/a,asian,49.6,-99,-99
10.1016/j.ygyno.2014.10.009,21,Yes,grade 3,No,NA,5 year disease specific survival,Percent,NA,none,2,n/a,white,40.7,-99,-99
10.1016/j.ygyno.2014.10.009,22,Yes,grade unknown,No,NA,5 year disease specific survival,Percent,NA,none,1,n/a,asian,51.8,-99,-99
10.1016/j.ygyno.2014.10.009,22,Yes,grade unknown,No,NA,5 year disease specific survival,Percent,NA,none,2,n/a,white,38.1,-99,-99
10.1016/j.ygyno.2014.10.009,23,No,NA,No,NA,5 year disease-specific survival,HR,NA,"Age at diagnosis, year of diagnosis, surgery, stage, grade",1,White,Asian,0.96,0.93,0.98
10.1016/j.ygyno.2014.10.009,24,No,NA,Yes,Asian ethnicities,5 year disease specific survival,Percent,NA,none,1,n/a,vietnamese,62.1,-99,-99
10.1016/j.ygyno.2014.10.009,24,No,NA,Yes,Asian ethnicities,5 year disease specific survival,Percent,NA,none,2,n/a,filipino,61.5,-99,-99
10.1016/j.ygyno.2014.10.009,24,No,NA,Yes,Asian ethnicities,5 year disease specific survival,Percent,NA,none,3,n/a,chinese,61,-99,-99
10.1016/j.ygyno.2014.10.009,24,No,NA,Yes,Asian ethnicities,5 year disease specific survival,Percent,NA,none,4,n/a,korean,59,-99,-99
10.1016/j.ygyno.2014.10.009,24,No,NA,Yes,Asian ethnicities,5 year disease specific survival,Percent,NA,none,5,n/a,japanese,54.6,-99,-99
10.1016/j.ygyno.2014.10.009,24,No,NA,Yes,Asian ethnicities,5 year disease specific survival,Percent,NA,none,6,n/a,"asian indian/pakistani, nos",48.2,-99,NA
10.1016/j.ygyno.2014.10.009,24,No,NA,Yes,Asian ethnicities,5 year disease specific survival,Percent,NA,none,7,n/a,NA,NA,NA,-99
10.1016/j.ygyno.2014.10.009,25,No,NA,Yes,Asian ethnicity,5 year disease-specific survival,HR,NA,"Age at diagnosis, surgery, stage, grade",1,"Chinese, filipino, korean, vietnamese","Asian Indian/Pakistani, Japanese",1.19,1.04,1.35
10.1097/AOG.0000000000000470,1,No,NA,No,NA,Preterm birth,OR,NA,none,1,White or asian race,Non-white or asian race,2.11,1.19,3.74
10.1016/j.ygyno.2014.08.029,1,No,NA,Yes,Debulking surgery,Ovarian cancer treatment,OR,NA,none,1,Non-Hispanic White,Non-Hispanic Black,0.42,0.33,0.54
10.1016/j.ygyno.2014.08.029,2,No,NA,Yes,Any surgery,Ovarian cancer treatment,OR,NA,none,1,Non-Hispanic White,Non-Hispanic Black,0.41,0.34,0.5
10.1016/j.ygyno.2014.08.029,3,No,NA,Yes,multi-agent chemotherapy,ovarian cancer treatment,OR,NA,none,1,Non-Hispanic White,Non-Hispanic Black,0.62,0.52,0.74
10.1016/j.ygyno.2014.08.029,4,No,NA,Yes,any chemotherapy,ovarian cancer treatment,OR,NA,none,1,Non-Hispanic White,Non-Hispanic Black,0.67,0.55,0.81
10.1016/j.ygyno.2014.08.029,5,No,NA,Yes,Debulking surgery,ovarian cancer treatment,OR,NA,"age, stage at diagnosis, tumor grade",1,Non-Hispanic White,Non-Hispanic Black,0.38,0.29,0.49
10.1016/j.ygyno.2014.08.029,6,No,NA,Yes,Any surgery,ovarian cancer treatment,OR,NA,"age, stage at diagnosis, tumor grade",1,Non-Hispanic White,Non-Hispanic Black,0.38,0.29,0.49
10.1016/j.ygyno.2014.08.029,7,No,NA,Yes,multi-agent chemotherapy,ovarian cancer treatment,OR,NA,"age, stage at diagnosis, tumor grade",1,Non-Hispanic White,Non-Hispanic Black,0.5,0.41,0.61
10.1016/j.ygyno.2014.08.029,8,No,NA,Yes,any chemotherapy,ovarian cancer treatment,OR,NA,"age, stage at diagnosis, tumor grade",1,Non-Hispanic White,Non-Hispanic Black,0.51,0.41,0.63
10.1016/j.ygyno.2014.08.029,9,No,NA,Yes,Debulking surgery,ovarian cancer treatment,OR,NA,"age, stage at diagnosis, tumor grade, year of diagnosis",1,Non-Hispanic White,Non-Hispanic Black,0.39,0.3,0.5
10.1016/j.ygyno.2014.08.029,10,No,NA,Yes,Any surgery,ovarian cancer treatment,OR,NA,"age, stage at diagnosis, tumor grade, year of diagnosis",1,Non-Hispanic White,Non-Hispanic Black,0.37,0.29,0.49
10.1016/j.ygyno.2014.08.029,11,No,NA,Yes,multi-agent chemotherapy,ovarian cancer treatment,OR,NA,"age, stage at diagnosis, tumor grade, year of diagnosis",1,Non-Hispanic White,Non-Hispanic Black,0.48,0.39,0.59
10.1016/j.ygyno.2014.08.029,12,No,NA,Yes,any chemotherapy,ovarian cancer treatment,OR,NA,"age, stage at diagnosis, tumor grade, year of diagnosis",1,Non-Hispanic White,Non-Hispanic Black,0.49,0.39,0.61
10.1016/j.ygyno.2014.08.029,13,No,NA,Yes,Debulking surgery,ovarian cancer treatment,OR,NA,"age, stage at diagnosis, tumor grade, year of diagnosis, concentrated affluence",1,Non-Hispanic White,Non-Hispanic Black,0.44,0.33,0.58
10.1016/j.ygyno.2014.08.029,14,No,NA,Yes,Any surgery,ovarian cancer treatment,OR,NA,"age, stage at diagnosis, tumor grade, year of diagnosis, concentrated affluence",1,Non-Hispanic White,Non-Hispanic Black,0.39,0.29,0.53
10.1016/j.ygyno.2014.08.029,15,No,NA,Yes,multi-agent chemotherapy,ovarian cancer treatment,OR,NA,"age, stage at diagnosis, tumor grade, year of diagnosis, concentrated affluence",1,Non-Hispanic White,Non-Hispanic Black,0.56,0.45,0.71
10.1016/j.ygyno.2014.08.029,16,No,NA,Yes,any chemotherapy,ovarian cancer treatment,OR,NA,"age, stage at diagnosis, tumor grade, year of diagnosis, concentrated affluence",1,Non-Hispanic White,Non-Hispanic Black,0.58,0.45,0.74
10.1016/j.ygyno.2014.08.029,17,No,NA,Yes,Debulking surgery,ovarian cancer treatment,OR,NA,"(nested by Census tract) age, stage at diagnosis, tumor grade, year of diagnosis, concentrated affluence, concentrated disadvantage",1,Non-Hispanic White,Non-Hispanic Black,0.43,0.32,0.59
10.1016/j.ygyno.2014.08.029,18,No,NA,Yes,Any surgery,ovarian cancer treatment,OR,NA,"(nested by Census tract) age, stage at diagnosis, tumor grade, year of diagnosis, concentrated affluence, concentrated disadvantage",1,Non-Hispanic White,Non-Hispanic Black,0.43,0.3,0.6
10.1016/j.ygyno.2014.08.029,19,No,NA,Yes,multi-agent chemotherapy,ovarian cancer treatment,OR,NA,"(nested by Census tract) age, stage at diagnosis, tumor grade, year of diagnosis, concentrated affluence, concentrated disadvantage",1,Non-Hispanic White,Non-Hispanic Black,0.53,0.41,0.68
10.1016/j.ygyno.2014.08.029,20,No,NA,Yes,any chemotherapy,ovarian cancer treatment,OR,NA,"(nested by Census tract) age, stage at diagnosis, tumor grade, year of diagnosis, concentrated affluence, concentrated disadvantage",1,Non-Hispanic White,Non-Hispanic Black,0.57,0.44,0.75
10.1016/j.ygyno.2014.08.029,21,No,NA,Yes,Debulking surgery,ovarian cancer treatment,OR,NA,"(nested by Census tract) age, stage at diagnosis, tumor grade, year of diagnosis, concentrated affluence, concentrated disadvantage",1,Non-Hispanic White,Non-Hispanic Black,0.47,0.34,0.65
10.1016/j.ygyno.2014.08.029,22,No,NA,Yes,Any surgery,ovarian cancer treatment,OR,NA,"(nested by Census tract) age, stage at diagnosis, tumor grade, year of diagnosis, concentrated affluence, concentrated disadvantage",1,Non-Hispanic White,Non-Hispanic Black,0.42,0.3,0.61
10.1016/j.ygyno.2014.08.029,23,No,NA,Yes,multi-agent chemotherapy,ovarian cancer treatment,OR,NA,"(nested by Census tract) age, stage at diagnosis, tumor grade, year of diagnosis, concentrated affluence, concentrated disadvantage",1,Non-Hispanic White,Non-Hispanic Black,0.51,0.39,0.67
10.1016/j.ygyno.2014.08.029,24,No,NA,Yes,any chemotherapy,ovarian cancer treatment,OR,NA,"(nested by Census tract) age, stage at diagnosis, tumor grade, year of diagnosis, concentrated affluence, concentrated disadvantage",1,Non-Hispanic White,Non-Hispanic Black,0.56,0.42,0.75
10.1016/j.ygyno.2014.08.029,25,No,NA,Yes,Debulking surgery,ovarian cancer treatment,OR,NA,outcome-specific covariates significant in each final multivariable logical regression model,1,Non-Hispanic White,Non-Hispanic Black,0.39,0.3,0.51
10.1016/j.ygyno.2014.08.029,26,No,NA,Yes,Any surgery,ovarian cancer treatment,OR,NA,outcome-specific covariates significant in each final multivariable logical regression model,1,Non-Hispanic White,Non-Hispanic Black,0.38,0.29,0.5
10.1016/j.ygyno.2014.08.029,27,No,NA,Yes,multi-agent chemotherapy,ovarian cancer treatment,OR,NA,outcome-specific covariates significant in each final multivariable logical regression model,1,Non-Hispanic White,Non-Hispanic Black,0.56,0.44,0.7
10.1016/j.ygyno.2014.08.029,28,No,NA,Yes,any chemotherapy,ovarian cancer treatment,OR,NA,outcome-specific covariates significant in each final multivariable logical regression model,1,Non-Hispanic White,Non-Hispanic Black,0.56,0.44,0.72
10.1016/j.ygyno.2014.03.561,1,No,NA,No,NA,non-adherence to national comprehensive cancer network guidelines,OR,NA,"hospital volume, distance to care, distance to high volume hospital, insurance status, socioeconomic status, age, stage, tumor grade, tumor histology",1,white,black,1.49,1.21,1.83
10.1016/j.ygyno.2014.03.561,1,No,NA,No,NA,non-adherence to national comprehensive cancer network guidelines,OR,NA,"hospital volume, distance to care, distance to high volume hospital, insurance status, socioeconomic status, age, stage, tumor grade, tumor histology",2,white,hispanic,0.97,0.85,1.1
10.1016/j.ygyno.2014.03.561,1,No,NA,No,NA,non-adherence to national comprehensive cancer network guidelines,OR,NA,"hospital volume, distance to care, distance to high volume hospital, insurance status, socioeconomic status, age, stage, tumor grade, tumor histology",3,white,asian/pacific islander,1.05,0.9,1.22
10.1016/j.ajog.2014.01.037,1,No,NA,No,NA,contraceptive use: any method vs. no method,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",1,White,Hispanic,0.94,0.76,1.17
10.1016/j.ajog.2014.01.037,1,No,NA,No,NA,contraceptive use: any method vs. no method,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",2,White,Black,0.65,0.51,0.83
10.1016/j.ajog.2014.01.037,1,No,NA,No,NA,contraceptive use: any method vs. no method,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",3,White,Other,0.59,0.45,0.77
10.1016/j.ajog.2014.01.037,2,No,NA,Yes,contraceptive users,contraceptive use: highly/moderately vs. less-effective method,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",1,White,Hispanic,0.57,0.43,0.76
10.1016/j.ajog.2014.01.037,2,No,NA,Yes,contraceptive users,contraceptive use: highly/moderately vs. less-effective method,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",2,White,Black,0.49,0.37,0.65
10.1016/j.ajog.2014.01.037,2,No,NA,Yes,contraceptive users,contraceptive use: highly/moderately vs. less-effective method,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",3,White,Other,0.41,0.28,0.61
10.1016/j.ajog.2014.01.037,3,No,NA,Yes,contraceptive users,contraceptive use: highly vs. moderately/less-effective method,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",1,White,Hispanic,0.59,0.46,0.77
10.1016/j.ajog.2014.01.037,3,No,NA,Yes,contraceptive users,contraceptive use: highly vs. moderately/less-effective method,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",2,White,Black,0.63,0.46,0.84
10.1016/j.ajog.2014.01.037,3,No,NA,Yes,contraceptive users,contraceptive use: highly vs. moderately/less-effective method,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",3,White,Other,0.58,0.38,0.88
10.1016/j.ajog.2014.01.037,4,Yes,age (15-19),No,NA,any method of contraceptive use,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",1,white,hispanic,0.83,0.46,1.47
10.1016/j.ajog.2014.01.037,4,Yes,age (15-19),No,NA,any method of contraceptive use,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",2,white,black,0.98,0.52,1.86
10.1016/j.ajog.2014.01.037,5,Yes,age (15-19),No,NA,high/moderate vs least effective contraceptive,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",1,white,hispanic,0.7,0.34,1.42
10.1016/j.ajog.2014.01.037,5,Yes,age (15-19),No,NA,high/moderate vs least effective contraceptive,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",2,white,black,0.32,0.16,0.62
10.1016/j.ajog.2014.01.037,6,Yes,age (15-19),No,NA,high vs moderate/least effective contraceptive,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",1,white,hispanic,5.03,1.43,17.7
10.1016/j.ajog.2014.01.037,6,Yes,age (15-19),No,NA,high vs moderate/least effective contraceptive,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",2,white,black,0.1,0.01,1.46
10.1016/j.ajog.2014.01.037,7,Yes,age (20-29),No,NA,any method of contraceptive use,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",1,white,hispanic,0.93,0.63,1.38
10.1016/j.ajog.2014.01.037,7,Yes,age (20-29),No,NA,any method of contraceptive use,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",2,white,black,0.59,0.42,0.83
10.1016/j.ajog.2014.01.037,8,Yes,age (20-29),No,NA,high/moderate vs least effective contraceptive,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",1,white,hispanic,0.5,0.33,0.75
10.1016/j.ajog.2014.01.037,8,Yes,age (20-29),No,NA,high/moderate vs least effective contraceptive,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",2,white,black,0.39,0.27,0.56
10.1016/j.ajog.2014.01.037,9,Yes,age (20-29),No,NA,high vs moderate/least effective contraceptive,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",1,white,hispanic,0.31,0.2,0.48
10.1016/j.ajog.2014.01.037,9,Yes,age (20-29),No,NA,high vs moderate/least effective contraceptive,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",2,white,black,0.38,0.24,0.61
10.1016/j.ajog.2014.01.037,10,Yes,age (30-39),No,NA,any method of contraceptive use,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",1,white,hispanic,0.98,0.64,1.51
10.1016/j.ajog.2014.01.037,10,Yes,age (30-39),No,NA,any method of contraceptive use,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",2,white,black,0.67,0.4,1.1
10.1016/j.ajog.2014.01.037,11,Yes,age (30-39),No,NA,high/moderate vs least effective contraceptive,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",1,white,hispanic,0.53,0.34,0.82
10.1016/j.ajog.2014.01.037,11,Yes,age (30-39),No,NA,high/moderate vs least effective contraceptive,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",2,white,black,0.78,0.45,1.34
10.1016/j.ajog.2014.01.037,12,Yes,age (30-39),No,NA,high vs moderate/least effective contracetive,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",1,white,hispanic,0.64,0.45,0.9
10.1016/j.ajog.2014.01.037,12,Yes,age (30-39),No,NA,high vs moderate/least effective contracetive,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",2,white,black,0.79,0.51,1.22
10.1016/j.ajog.2014.01.037,13,Yes,age (40+),No,NA,any method of contraceptive use,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",1,white,hispanic,0.94,0.46,1.94
10.1016/j.ajog.2014.01.037,13,Yes,age (40+),No,NA,any method of contraceptive use,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",2,white,black,0.76,0.38,1.49
10.1016/j.ajog.2014.01.037,14,Yes,age (40+),No,NA,high/moderate vs least effective contraceptive,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",1,white,hispanic,0.79,0.37,1.73
10.1016/j.ajog.2014.01.037,14,Yes,age (40+),No,NA,high/moderate vs least effective contraceptive,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",2,white,black,1.06,0.37,3.01
10.1016/j.ajog.2014.01.037,15,Yes,age (40+),No,NA,high vs moderate/least effective contracetive,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",1,white,hispanic,0.9,0.45,1.78
10.1016/j.ajog.2014.01.037,15,Yes,age (40+),No,NA,high vs moderate/least effective contracetive,OR,NA,"age, income, education, insurance status, marital status, religion, parity, unintended pregnancies",2,white,black,0.77,0.37,1.59
10.1016/j.ygyno.2014.01.013,1,No,NA,No,NA,Death from any cause,HR,NA,none,1,white,black,1.77,0.9,3.46
10.1016/j.ygyno.2014.01.013,2,No,NA,No,NA,Death from any cause,HR,NA,"age, histology type, FIGO stage, FIGO grade",1,white,black,1.19,0.55,2.54
10.1016/j.ygyno.2014.01.013,3,No,NA,No,NA,death from any cause,HR,NA,"age, histology type, FIGO stage, FIGO grade, surgery type, chemotherapy, radiation therapy",1,white,black,1.35,0.62,2.95
10.1016/j.ygyno.2014.01.013,4,No,NA,No,NA,death from any cause,HR,NA,"age, histology type, FIGO stage, FIGO grade, surgery type, chemotherapy, radiation therapy, BMI, hypertension, diabetes, and the occurrence of any surgical complication",1,white,black,0.85,0.36,2.03
10.1016/j.ygyno.2014.01.013,5,No,NA,No,NA,death from endometrial cancer,HR,NA,none,1,white,black,2.17,0.87,5.44
10.1016/j.ygyno.2014.01.013,6,No,NA,No,NA,death from endometrial cancer,HR,NA,"age, histology type, FIGO stage, FIGO grade",1,white,black,1.44,0.5,4.17
10.1016/j.ygyno.2014.01.013,7,No,NA,No,NA,death from endometrial cancer,HR,NA,"age, histology type, FIGO stage, FIGO grade, surgery type, chemotherapy, radiation therapy",1,white,black,1.49,0.49,4.51
10.1016/j.ygyno.2014.01.013,8,No,NA,No,NA,death from endometrial cancer,HR,NA,"age, histology type, FIGO stage, FIGO grade, surgery type, chemotherapy, radiation therapy, BMI, hypertension, diabetes, and the occurrence of any surgical complication",1,white,black,0.95,0.26,3.52
10.1016/j.ygyno.2014.01.013,9,No,NA,No,NA,death from other causes,HR,NA,none,1,white,black,1.38,0.51,3.71
10.1016/j.ygyno.2014.01.013,10,No,NA,No,NA,death from other causes,HR,NA,"age, histology type, FIGO stage, FIGO grade",1,white,black,0.95,0.31,2.92
10.1016/j.ygyno.2014.01.013,11,No,NA,No,NA,death from other causes,HR,NA,"age, histology type, FIGO stage, FIGO grade, surgery type, chemotherapy, radiation therapy",1,white,black,1.06,0.33,3.4
10.1016/j.ygyno.2014.01.013,12,No,NA,No,NA,death from other causes,HR,NA,"age, histology type, FIGO stage, FIGO grade, surgery type, chemotherapy, radiation therapy, BMI, hypertension, diabetes, and the occurrence of any surgical complication",1,white,black,0.51,0.14,1.82
10.1016/j.fertnstert.2013.09.015,1,No,NA,No,NA,Antimullerian hormone levels,factor change,NA,linear age,1,White,African American,0.756,0.65,0.878
10.1016/j.fertnstert.2013.09.015,1,No,NA,No,NA,Antimullerian hormone levels,factor change,NA,linear age,2,White,Latina,0.63,0.541,0.735
10.1016/j.fertnstert.2013.09.015,1,No,NA,No,NA,Antimullerian hormone levels,factor change,NA,linear age,3,White,Chinese,0.78,0.668,0.911
10.1016/j.fertnstert.2013.09.015,2,No,NA,No,NA,Antimullerian hormone levels,factor change,NA,"linear age, quadratic age, BMI, smoking, parity, hormonal BC, menarcheal age, psychological stress, education, household income",1,White,African American,0.909,0.771,1.073
10.1016/j.fertnstert.2013.09.015,2,No,NA,No,NA,Antimullerian hormone levels,factor change,NA,"linear age, quadratic age, BMI, smoking, parity, hormonal BC, menarcheal age, psychological stress, education, household income",2,White,Latina,0.694,0.593,0.812
10.1016/j.fertnstert.2013.09.015,2,No,NA,No,NA,Antimullerian hormone levels,factor change,NA,"linear age, quadratic age, BMI, smoking, parity, hormonal BC, menarcheal age, psychological stress, education, household income",3,White,Chinese,0.796,0.683,0.927
10.1016/j.fertnstert.2013.09.015,3,No,NA,No,NA,Antimullerian hormone levels,factor change,NA,linear age,1,Latina,African American,1.199,1.023,1.406
10.1016/j.fertnstert.2013.09.015,4,No,NA,No,NA,Antimullerian hormone levels,factor change,NA,"linear age, quadratic age, BMI, smoking, parity, hormonal BC, menarcheal age, psychological stress, education, household income",1,Latina,African American,1.31,1.118,1.536
10.1016/j.fertnstert.2013.09.015,5,No,NA,No,NA,Antimullerian hormone levels,factor change,NA,linear age,1,Chinese,African American,0.969,0.825,1.137
10.1016/j.fertnstert.2013.09.015,5,No,NA,No,NA,Antimullerian hormone levels,factor change,NA,linear age,2,Chinese,Latina,1.143,0.956,1.367
10.1016/j.fertnstert.2013.09.015,6,No,NA,No,NA,Antimullerian hormone levels,factor change,NA,"linear age, quadratic age, BMI, smoking, parity, hormonal BC, menarcheal age, psychological stress, education, household income",1,Chinese,African American,0.808,0.686,0.951
10.1016/j.fertnstert.2013.09.015,6,No,NA,No,NA,Antimullerian hormone levels,factor change,NA,"linear age, quadratic age, BMI, smoking, parity, hormonal BC, menarcheal age, psychological stress, education, household income",2,Chinese,Latina,0.872,0.735,1.035
10.1016/j.fertnstert.2013.09.015,7,Yes,age 25,No,NA,Contrasts between predicted geometric mean Antimullerian hormone (ng/mL) values,ng/mL,NA,None,1,N/A,White,4.7,-99,-99
10.1016/j.fertnstert.2013.09.015,7,Yes,age 25,No,NA,Contrasts between predicted geometric mean Antimullerian hormone (ng/mL) values,ng/mL,NA,None,2,N/A,African American,2.84,-99,-99
10.1016/j.fertnstert.2013.09.015,7,Yes,age 25,No,NA,Contrasts between predicted geometric mean Antimullerian hormone (ng/mL) values,ng/mL,NA,None,3,N/A,Latina,3.26,-99,-99
10.1016/j.fertnstert.2013.09.015,7,Yes,age 25,No,NA,Contrasts between predicted geometric mean Antimullerian hormone (ng/mL) values,ng/mL,NA,None,4,N/A,Chinese,3.84,-99,-99
10.1016/j.fertnstert.2013.09.015,8,Yes,age 30,No,NA,Contrasts between predicted geometric mean Antimullerian hormone (ng/mL) values,ng/mL,NA,None,1,N/A,White,4.26,-99,-99
10.1016/j.fertnstert.2013.09.015,8,Yes,age 30,No,NA,Contrasts between predicted geometric mean Antimullerian hormone (ng/mL) values,ng/mL,NA,None,2,N/A,African American,3.14,-99,-99
10.1016/j.fertnstert.2013.09.015,8,Yes,age 30,No,NA,Contrasts between predicted geometric mean Antimullerian hormone (ng/mL) values,ng/mL,NA,None,3,N/A,Latina,2.95,-99,-99
10.1016/j.fertnstert.2013.09.015,8,Yes,age 30,No,NA,Contrasts between predicted geometric mean Antimullerian hormone (ng/mL) values,ng/mL,NA,None,4,N/A,Chinese,3.44,-99,-99
10.1016/j.fertnstert.2013.09.015,9,Yes,age 35,No,NA,Contrasts between predicted geometric mean Antimullerian hormone (ng/mL) values,ng/mL,NA,None,1,N/A,White,2.94,-99,-99
10.1016/j.fertnstert.2013.09.015,9,Yes,age 35,No,NA,Contrasts between predicted geometric mean Antimullerian hormone (ng/mL) values,ng/mL,NA,None,2,N/A,African American,2.64,-99,-99
10.1016/j.fertnstert.2013.09.015,9,Yes,age 35,No,NA,Contrasts between predicted geometric mean Antimullerian hormone (ng/mL) values,ng/mL,NA,None,3,N/A,Latina,2.04,-99,-99
10.1016/j.fertnstert.2013.09.015,9,Yes,age 35,No,NA,Contrasts between predicted geometric mean Antimullerian hormone (ng/mL) values,ng/mL,NA,None,4,N/A,Chinese,2.34,-99,-99
10.1016/j.fertnstert.2013.09.015,10,Yes,age 40,No,NA,Contrasts between predicted geometric mean Antimullerian hormone (ng/mL) values,ng/mL,NA,None,1,N/A,White,1.54,-99,-99
10.1016/j.fertnstert.2013.09.015,10,Yes,age 40,No,NA,Contrasts between predicted geometric mean Antimullerian hormone (ng/mL) values,ng/mL,NA,None,2,N/A,African American,1.69,-99,-99
10.1016/j.fertnstert.2013.09.015,10,Yes,age 40,No,NA,Contrasts between predicted geometric mean Antimullerian hormone (ng/mL) values,ng/mL,NA,None,3,N/A,Latina,1.07,-99,-99
10.1016/j.fertnstert.2013.09.015,10,Yes,age 40,No,NA,Contrasts between predicted geometric mean Antimullerian hormone (ng/mL) values,ng/mL,NA,None,4,N/A,Chinese,1.21,-99,-99
10.1016/j.fertnstert.2013.09.015,11,Yes,age 45,No,NA,Contrasts between predicted geometric mean Antimullerian hormone (ng/mL) values,ng/mL,NA,None,1,N/A,White,0.62,-99,-99
10.1016/j.fertnstert.2013.09.015,11,Yes,age 45,No,NA,Contrasts between predicted geometric mean Antimullerian hormone (ng/mL) values,ng/mL,NA,None,2,N/A,African American,0.82,-99,-99
10.1016/j.fertnstert.2013.09.015,11,Yes,age 45,No,NA,Contrasts between predicted geometric mean Antimullerian hormone (ng/mL) values,ng/mL,NA,None,3,N/A,Latina,0.43,-99,-99
10.1016/j.fertnstert.2013.09.015,11,Yes,age 45,No,NA,Contrasts between predicted geometric mean Antimullerian hormone (ng/mL) values,ng/mL,NA,None,4,N/A,Chinese,0.48,-99,-99
10.1097/AOG.0000000000000583,1,Yes,Year (1983),No,NA,observed infant deaths resulting from anomalies,Prevalence,"per 100,000",none,1,n/a,black,269.3,-99,-99
10.1097/AOG.0000000000000583,1,Yes,Year (1983),No,NA,observed infant deaths resulting from anomalies,Prevalence,"per 100,000",none,2,n/a,white,251.7,-99,-99
10.1097/AOG.0000000000000583,2,Yes,Year (2004),No,NA,"observed infant deaths resulting from anomalies/100,000",Prevalence,"per 100,000",none,1,n/a,black,167.3,-99,-99
10.1097/AOG.0000000000000583,2,Yes,Year (2004),No,NA,"observed infant deaths resulting from anomalies/100,000",Prevalence,"per 100,000",none,2,n/a,white,131.1,-99,-99
10.1097/AOG.0000000000000583,3,Yes,Year (1983),No,NA,estimated differennce in nfant dealths resulting from anomalies,Absolute difference,"number of excess cases per 100,000",none,1,white,black,16.4,9.9,22.9
10.1097/AOG.0000000000000583,4,Yes,Year (2004),No,NA,estimated differennce in nfant dealths resulting from anomalies,Absolute difference,"number of excess cases per 100,000",none,1,white,black,34.1,29.6,38.6
10.1097/AOG.0000000000000583,5,Yes,Year (1983),No,NA,estimated differennce in nfant dealths resulting from anomalies,Relative rate ratio,NA,none,1,white,black,1.07,1.04,1.09
10.1097/AOG.0000000000000583,6,Yes,Year (2004),No,NA,estimated differennce in nfant dealths resulting from anomalies,Relative rate ratio,NA,none,1,white,black,1.26,1.23,1.3
10.1097/AOG.0000000000000583,7,Yes,Year (1983),Yes,Blacks,observed infant deaths resulting from anomalies,Prevalence,"per 100,000",none,1,n/a,state does not fund pregnancy termination for women on medicaid,268.5,-99,-99
10.1097/AOG.0000000000000583,7,Yes,Year (1983),Yes,Blacks,observed infant deaths resulting from anomalies,Prevalence,"per 100,000",none,2,n/a,state funds pregancy termination for women on medicaid,270.7,-99,-99
10.1097/AOG.0000000000000583,8,Yes,Year (2004),Yes,Blacks,observed infant deaths resulting from anomalies,Prevalence,"per 100,000",none,1,n/a,state does not fund pregnancy termination for women on medicaid,182.5,-99,-99
10.1097/AOG.0000000000000583,8,Yes,Year (2004),Yes,Blacks,observed infant deaths resulting from anomalies,Prevalence,"per 100,000",none,2,n/a,state funds pregancy termination for women on medicaid,141.6,-99,-99
10.1097/AOG.0000000000000583,9,Yes,Year (1983),Yes,Whites,observed infant deaths resulting from anomalies,Prevalence,"per 100,000",none,1,n/a,state does not fund pregnancy termination for women on medicaid,249.4,-99,-99
10.1097/AOG.0000000000000583,9,Yes,Year (1983),Yes,Whites,observed infant deaths resulting from anomalies,Prevalence,"per 100,000",none,2,n/a,state funds pregancy termination for women on medicaid,254.8,-99,-99
10.1097/AOG.0000000000000583,10,Yes,Year (2004),Yes,Whites,observed infant deaths resulting from anomalies,Prevalence,"per 100,000",none,1,n/a,state does not fund pregnancy termination for women on medicaid,140.5,-99,-99
10.1097/AOG.0000000000000583,10,Yes,Year (2004),Yes,Whites,observed infant deaths resulting from anomalies,Prevalence,"per 100,000",none,2,n/a,state funds pregancy termination for women on medicaid,119.2,-99,-99
10.1097/AOG.0000000000000583,11,Yes,Year (1983),Yes,Blacks,estimated differennce in nfant dealths resulting from anomalies,Absolute difference,"number of excess cases per 100,000",none,1,states that do not fund pregnancy termination,states that fund pregancy termination for women on medicaid,2.9,-9.9,15.7
10.1097/AOG.0000000000000583,12,Yes,Year (2004),Yes,Blacks,estimated differennce in nfant dealths resulting from anomalies,Absolute difference,"number of excess cases per 100,000",none,1,states that do not fund pregnancy termination,states that fund pregancy termination for women on medicaid,33.4,24.9,41.8
10.1097/AOG.0000000000000583,13,Yes,Year (1983),Yes,Whites,estimated differennce in nfant dealths resulting from anomalies,Absolute difference,"number of excess cases per 100,000",none,1,states that do not fund pregnancy termination,states that fund pregancy termination for women on medicaid,7.9,2.6,13.3
10.1097/AOG.0000000000000583,14,Yes,Year (2004),Yes,Whites,estimated differennce in nfant dealths resulting from anomalies,Absolute difference,"number of excess cases per 100,000",none,1,states that do not fund pregnancy termination,states that fund pregancy termination for women on medicaid,22.4,19.2,25.6
10.1097/AOG.0000000000000583,15,Yes,Year (1983),Yes,Blacks,estimated differennce in nfant dealths resulting from anomalies,Relative rate ratio,NA,none,1,states that do not fund pregnancy termination,states that fund pregancy termination for women on medicaid,1.01,0.96,1.06
10.1097/AOG.0000000000000583,16,Yes,Year (2004),Yes,Blacks,estimated differennce in nfant dealths resulting from anomalies,Relative rate ratio,NA,none,1,states that do not fund pregnancy termination,states that fund pregancy termination for women on medicaid,1.23,1.17,1.3
10.1097/AOG.0000000000000583,17,Yes,Year (1983),Yes,whites,estimated differennce in nfant dealths resulting from anomalies,Relative rate ratio,NA,none,1,states that do not fund pregnancy termination,states that fund pregancy termination for women on medicaid,1.03,1.01,1.06
10.1097/AOG.0000000000000583,18,Yes,Year (2004),Yes,whites,estimated differennce in nfant dealths resulting from anomalies,Relative rate ratio,NA,none,1,states that do not fund pregnancy termination,states that fund pregancy termination for women on medicaid,1.19,1.16,1.22
10.1097/AOG.0000000000000583,19,Yes,On medicaid,Yes,Non-Hispanic Blacks,observed infant death with anomalies,Prevalence,"per 100,000",none,1,n/a,states that do not fund pregnancy termination,245.5,-99,-99
10.1097/AOG.0000000000000583,19,Yes,On medicaid,Yes,Non-Hispanic Blacks,observed infant death with anomalies,Prevalence,"per 100,000",none,2,n/a,state funds pregancy termination for women on medicaid,129.3,-99,-99
10.1097/AOG.0000000000000583,20,Yes,Not on medicaid,Yes,Non-Hispanic Blacks,observed infant death with anomalies,Prevalence,"per 100,000",none,1,n/a,states that do not fund pregnancy termination,184.1,-99,-99
10.1097/AOG.0000000000000583,20,Yes,Not on medicaid,Yes,Non-Hispanic Blacks,observed infant death with anomalies,Prevalence,"per 100,000",none,2,n/a,state funds pregancy termination for women on medicaid,204.9,-99,-99
10.1097/AOG.0000000000000583,21,Yes,On medicaid,Yes,Non-hispanic whites,observed infant death with anomalies,Prevalence,"per 100,000",none,1,n/a,states that do not fund pregnancy termination,196.4,-99,-99
10.1097/AOG.0000000000000583,21,Yes,On medicaid,Yes,Non-hispanic whites,observed infant death with anomalies,Prevalence,"per 100,000",none,2,n/a,state funds pregancy termination for women on medicaid,134.3,-99,-99
10.1097/AOG.0000000000000583,22,Yes,Not on medicaid,Yes,Non-hispanic whites,observed infant death with anomalies,Prevalence,"per 100,000",none,1,n/a,states that do not fund pregnancy termination,129.2,-99,-99
10.1097/AOG.0000000000000583,22,Yes,Not on medicaid,Yes,Non-hispanic whites,observed infant death with anomalies,Prevalence,"per 100,000",none,2,n/a,state funds pregancy termination for women on medicaid,87,-99,-99
10.1097/AOG.0000000000000583,23,Yes,On medicaid,Yes,Non-Hispanic Blacks,estimated difference in mortality,Absolute difference,"number of excess cases per 100,000",none,1,states that do not fund pregnancy termination,states that fund pregancy termination for women on medicaid,120,85.7,154.2
10.1097/AOG.0000000000000583,24,Yes,Not on medicaid,Yes,Non-Hispanic Blacks,estimated difference in mortality,Absolute difference,"number of excess cases per 100,000",none,1,states that do not fund pregnancy termination,states that fund pregancy termination for women on medicaid,-20.3,-62.6,22
10.1097/AOG.0000000000000583,25,Yes,On medicaid,Yes,non-hispanic whites,estimated difference in mortality,Absolute difference,"number of excess cases per 100,000",none,1,states that do not fund pregnancy termination,states that fund pregancy termination for women on medicaid,63.9,-99,-99
10.1097/AOG.0000000000000583,26,Yes,Not on medicaid,Yes,non-hispanic whites,estimated difference in mortality,Absolute difference,"number of excess cases per 100,000",none,1,states that do not fund pregnancy termination,states that fund pregancy termination for women on medicaid,42.1,30.3,53.9
10.1097/AOG.0000000000000583,27,Yes,On medicaid,Yes,Non-Hispanic Blacks,estimated difference in mortality,Relative rate ratio,NA,none,1,states that do not fund pregnancy termination,states that fund pregancy termination for women on medicaid,1.94,1.52,2.36
10.1097/AOG.0000000000000583,28,Yes,not on medicaid,Yes,Non-Hispanic Blacks,estimated difference in mortality,Relative rate ratio,NA,none,1,states that do not fund pregnancy termination,states that fund pregancy termination for women on medicaid,0.9,0.7,1.1
10.1097/AOG.0000000000000583,29,Yes,On medicaid,Yes,non-hispanic whites,estimated difference in mortality,Relative rate ratio,NA,none,1,states that do not fund pregnancy termination,states that fund pregancy termination for women on medicaid,1.48,1.25,1.7
10.1097/AOG.0000000000000583,30,Yes,not on medicaid,Yes,non-hispanic whites,estimated difference in mortality,Relative rate ratio,NA,none,1,states that do not fund pregnancy termination,states that fund pregancy termination for women on medicaid,1.49,1.32,1.65
10.1016/j.ajog.2013.04.012,1,Yes,gestational age (<28 wks),Yes,singletons,preterm birth,Percent,NA,none,1,n/a,white,1.2,-99,-99
10.1016/j.ajog.2013.04.012,1,Yes,gestational age (<28 wks),Yes,singletons,preterm birth,Percent,NA,none,2,n/a,black,5.5,-99,-99
10.1016/j.ajog.2013.04.012,1,Yes,gestational age (<28 wks),Yes,singletons,preterm birth,Percent,NA,none,3,n/a,hispanic,1.9,-99,-99
10.1016/j.ajog.2013.04.012,1,Yes,gestational age (<28 wks),Yes,singletons,preterm birth,Percent,NA,none,4,n/a,asian,1.3,-99,-99
10.1016/j.ajog.2013.04.012,1,Yes,gestational age (<28 wks),Yes,singletons,preterm birth,Percent,NA,none,5,n/a,native,1.6,-99,-99
10.1016/j.ajog.2013.04.012,2,Yes,gestational age (<32 wks),Yes,singletons,preterm birth,Percent,NA,none,1,n/a,white,2.3,-99,-99
10.1016/j.ajog.2013.04.012,2,Yes,gestational age (<32 wks),Yes,singletons,preterm birth,Percent,NA,none,2,n/a,black,8.6,-99,-99
10.1016/j.ajog.2013.04.012,2,Yes,gestational age (<32 wks),Yes,singletons,preterm birth,Percent,NA,none,3,n/a,hispanic,3.5,-99,-99
10.1016/j.ajog.2013.04.012,2,Yes,gestational age (<32 wks),Yes,singletons,preterm birth,Percent,NA,none,4,n/a,asian,2.5,-99,-99
10.1016/j.ajog.2013.04.012,2,Yes,gestational age (<32 wks),Yes,singletons,preterm birth,Percent,NA,none,5,n/a,native,3,-99,-99
10.1016/j.ajog.2013.04.012,3,Yes,gestational age (<37 wks),Yes,singletons,preterm birth,Percent,NA,none,1,n/a,white,12.9,-99,-99
10.1016/j.ajog.2013.04.012,3,Yes,gestational age (<37 wks),Yes,singletons,preterm birth,Percent,NA,none,2,n/a,black,24,-99,-99
10.1016/j.ajog.2013.04.012,3,Yes,gestational age (<37 wks),Yes,singletons,preterm birth,Percent,NA,none,3,n/a,hispanic,15.3,-99,-99
10.1016/j.ajog.2013.04.012,3,Yes,gestational age (<37 wks),Yes,singletons,preterm birth,Percent,NA,none,4,n/a,asian,12,-99,-99
10.1016/j.ajog.2013.04.012,3,Yes,gestational age (<37 wks),Yes,singletons,preterm birth,Percent,NA,none,5,n/a,native,12.7,-99,-99
10.1016/j.ajog.2013.04.012,4,Yes,gesational age (<28),Yes,singletons,preterm birth,OR,NA,"maternal age, gravidity, smoking, body mass index, number of sacs with heart rate, male factor, day of embryoo traansfer, number of emmbryo transfer, prior spontaneous abortion, utterine factor, and uunkown factor",1,white,black,4.8,4.1,5.7
10.1016/j.ajog.2013.04.012,4,Yes,gesational age (<28),Yes,singletons,preterm birth,OR,NA,"maternal age, gravidity, smoking, body mass index, number of sacs with heart rate, male factor, day of embryoo traansfer, number of emmbryo transfer, prior spontaneous abortion, utterine factor, and uunkown factor",2,white,hispanic,1.6,1.3,2.1
10.1016/j.ajog.2013.04.012,4,Yes,gesational age (<28),Yes,singletons,preterm birth,OR,NA,"maternal age, gravidity, smoking, body mass index, number of sacs with heart rate, male factor, day of embryoo traansfer, number of emmbryo transfer, prior spontaneous abortion, utterine factor, and uunkown factor",3,white,asian,1.1,0.9,1.4
10.1016/j.ajog.2013.04.012,4,Yes,gesational age (<28),Yes,singletons,preterm birth,OR,NA,"maternal age, gravidity, smoking, body mass index, number of sacs with heart rate, male factor, day of embryoo traansfer, number of emmbryo transfer, prior spontaneous abortion, utterine factor, and uunkown factor",4,white,native,1.4,0.6,3.1
10.1016/j.ajog.2013.04.012,5,Yes,gestational age (<37 wks),Yes,singletons,preterm birth,OR,NA,"maternal age, gravidity, smoking, body mass index, number of sacs with heart rate, male factor, day of embryoo traansfer, number of emmbryo transfer, prior spontaneous abortion, utterine factor, and uunkown factor",1,white,black,3.9,3.4,4.4
10.1016/j.ajog.2013.04.012,5,Yes,gestational age (<37 wks),Yes,singletons,preterm birth,OR,NA,"maternal age, gravidity, smoking, body mass index, number of sacs with heart rate, male factor, day of embryoo traansfer, number of emmbryo transfer, prior spontaneous abortion, utterine factor, and uunkown factor",2,white,hispanic,1.5,1.3,1.8
10.1016/j.ajog.2013.04.012,5,Yes,gestational age (<37 wks),Yes,singletons,preterm birth,OR,NA,"maternal age, gravidity, smoking, body mass index, number of sacs with heart rate, male factor, day of embryoo traansfer, number of emmbryo transfer, prior spontaneous abortion, utterine factor, and uunkown factor",3,white,asian,1.1,0.9,1.3
10.1016/j.ajog.2013.04.012,5,Yes,gestational age (<37 wks),Yes,singletons,preterm birth,OR,NA,"maternal age, gravidity, smoking, body mass index, number of sacs with heart rate, male factor, day of embryoo traansfer, number of emmbryo transfer, prior spontaneous abortion, utterine factor, and uunkown factor",4,white,native,1.3,0.7,2.3
10.1016/j.ajog.2013.04.012,6,Yes,gesational age (<28),Yes,singletons,preterm birth,OR,NA,"maternal age, gravidity, smoking, body mass index, number of sacs with heart rate, male factor, day of embryoo traansfer, number of emmbryo transfer, prior spontaneous abortion, utterine factor, and uunkown factor",1,white,black,2.1,1.9,2.3
10.1016/j.ajog.2013.04.012,6,Yes,gesational age (<28),Yes,singletons,preterm birth,OR,NA,"maternal age, gravidity, smoking, body mass index, number of sacs with heart rate, male factor, day of embryoo traansfer, number of emmbryo transfer, prior spontaneous abortion, utterine factor, and uunkown factor",2,white,hispanic,1.2,1.1,1.3
10.1016/j.ajog.2013.04.012,6,Yes,gesational age (<28),Yes,singletons,preterm birth,OR,NA,"maternal age, gravidity, smoking, body mass index, number of sacs with heart rate, male factor, day of embryoo traansfer, number of emmbryo transfer, prior spontaneous abortion, utterine factor, and uunkown factor",3,white,asian,0.9,0.9,1
10.1016/j.ajog.2013.04.012,6,Yes,gesational age (<28),Yes,singletons,preterm birth,OR,NA,"maternal age, gravidity, smoking, body mass index, number of sacs with heart rate, male factor, day of embryoo traansfer, number of emmbryo transfer, prior spontaneous abortion, utterine factor, and uunkown factor",4,white,native,1,0.7,1.3
10.1016/j.ajog.2013.04.012,7,Yes,gesational age (<28),Yes,twins,preterm birth,Percent,NA,none,1,n/a,white,4.2,-99,-99
10.1016/j.ajog.2013.04.012,7,Yes,gesational age (<28),Yes,twins,preterm birth,Percent,NA,none,2,n/a,black,12.7,-99,-99
10.1016/j.ajog.2013.04.012,7,Yes,gesational age (<28),Yes,twins,preterm birth,Percent,NA,none,3,n/a,hispanic,5.9,-99,-99
10.1016/j.ajog.2013.04.012,7,Yes,gesational age (<28),Yes,twins,preterm birth,Percent,NA,none,4,n/a,asian,3.9,-99,-99
10.1016/j.ajog.2013.04.012,7,Yes,gesational age (<28),Yes,twins,preterm birth,Percent,NA,none,5,n/a,native,4.5,-99,-99
10.1016/j.ajog.2013.04.012,8,Yes,gestational age (<37 wks),Yes,twins,preterm birth,Percent,NA,none,1,n/a,white,10.3,-99,-99
10.1016/j.ajog.2013.04.012,8,Yes,gestational age (<37 wks),Yes,twins,preterm birth,Percent,NA,none,2,n/a,black,21.5,-99,-99
10.1016/j.ajog.2013.04.012,8,Yes,gestational age (<37 wks),Yes,twins,preterm birth,Percent,NA,none,3,n/a,hispanic,12.2,-99,-99
10.1016/j.ajog.2013.04.012,8,Yes,gestational age (<37 wks),Yes,twins,preterm birth,Percent,NA,none,4,n/a,asian,9.1,-99,-99
10.1016/j.ajog.2013.04.012,8,Yes,gestational age (<37 wks),Yes,twins,preterm birth,Percent,NA,none,5,n/a,native,13.4,-99,-99
10.1016/j.ajog.2013.04.012,9,Yes,gesational age (<28),Yes,twins,preterm birth,Percent,NA,none,1,n/a,white,62.4,-99,-99
10.1016/j.ajog.2013.04.012,9,Yes,gesational age (<28),Yes,twins,preterm birth,Percent,NA,none,2,n/a,black,69.8,-99,-99
10.1016/j.ajog.2013.04.012,9,Yes,gesational age (<28),Yes,twins,preterm birth,Percent,NA,none,3,n/a,hispanic,63.9,-99,-99
10.1016/j.ajog.2013.04.012,9,Yes,gesational age (<28),Yes,twins,preterm birth,Percent,NA,none,4,n/a,asian,55.9,-99,-99
10.1016/j.ajog.2013.04.012,9,Yes,gesational age (<28),Yes,twins,preterm birth,Percent,NA,none,5,n/a,native,63.9,-99,-99
10.1016/j.ajog.2013.04.012,10,Yes,gesational age (<28),Yes,twins,preterm birth,OR,NA,"maternal age, gravidity, smoking, body mass index, number of sacs with heart rate, male factor, day of embryoo traansfer, number of emmbryo transfer, prior spontaneous abortion, utterine factor, and uunkown factor",1,white,black,3.3,2.7,3.9
10.1016/j.ajog.2013.04.012,10,Yes,gesational age (<28),Yes,twins,preterm birth,OR,NA,"maternal age, gravidity, smoking, body mass index, number of sacs with heart rate, male factor, day of embryoo traansfer, number of emmbryo transfer, prior spontaneous abortion, utterine factor, and uunkown factor",2,white,hispanic,1.4,1.2,1.8
10.1016/j.ajog.2013.04.012,10,Yes,gesational age (<28),Yes,twins,preterm birth,OR,NA,"maternal age, gravidity, smoking, body mass index, number of sacs with heart rate, male factor, day of embryoo traansfer, number of emmbryo transfer, prior spontaneous abortion, utterine factor, and uunkown factor",3,white,asian,0.9,0.8,1.2
10.1016/j.ajog.2013.04.012,10,Yes,gesational age (<28),Yes,twins,preterm birth,OR,NA,"maternal age, gravidity, smoking, body mass index, number of sacs with heart rate, male factor, day of embryoo traansfer, number of emmbryo transfer, prior spontaneous abortion, utterine factor, and uunkown factor",4,white,native,1.1,0.5,2.3
10.1016/j.ajog.2013.04.012,11,Yes,gestational age (<37 wks),Yes,twins,preterm birth,OR,NA,"maternal age, gravidity, smoking, body mass index, number of sacs with heart rate, male factor, day of embryoo traansfer, number of emmbryo transfer, prior spontaneous abortion, utterine factor, and uunkown factor",1,white,black,2.4,2.1,2.7
10.1016/j.ajog.2013.04.012,11,Yes,gestational age (<37 wks),Yes,twins,preterm birth,OR,NA,"maternal age, gravidity, smoking, body mass index, number of sacs with heart rate, male factor, day of embryoo traansfer, number of emmbryo transfer, prior spontaneous abortion, utterine factor, and uunkown factor",2,white,hispanic,1.2,1,1.4
10.1016/j.ajog.2013.04.012,11,Yes,gestational age (<37 wks),Yes,twins,preterm birth,OR,NA,"maternal age, gravidity, smoking, body mass index, number of sacs with heart rate, male factor, day of embryoo traansfer, number of emmbryo transfer, prior spontaneous abortion, utterine factor, and uunkown factor",3,white,asian,0.9,0.8,1
10.1016/j.ajog.2013.04.012,11,Yes,gestational age (<37 wks),Yes,twins,preterm birth,OR,NA,"maternal age, gravidity, smoking, body mass index, number of sacs with heart rate, male factor, day of embryoo traansfer, number of emmbryo transfer, prior spontaneous abortion, utterine factor, and uunkown factor",4,white,native,1.3,0.8,2.1
10.1016/j.ajog.2013.04.012,12,Yes,gesational age (<28),Yes,twins,preterm birth,OR,NA,"maternal age, gravidity, smoking, body mass index, number of sacs with heart rate, male factor, day of embryoo traansfer, number of emmbryo transfer, prior spontaneous abortion, utterine factor, and uunkown factor",1,white,black,1.4,1.2,1.6
10.1016/j.ajog.2013.04.012,12,Yes,gesational age (<28),Yes,twins,preterm birth,OR,NA,"maternal age, gravidity, smoking, body mass index, number of sacs with heart rate, male factor, day of embryoo traansfer, number of emmbryo transfer, prior spontaneous abortion, utterine factor, and uunkown factor",2,white,hispanic,1.1,1,1.2
10.1016/j.ajog.2013.04.012,12,Yes,gesational age (<28),Yes,twins,preterm birth,OR,NA,"maternal age, gravidity, smoking, body mass index, number of sacs with heart rate, male factor, day of embryoo traansfer, number of emmbryo transfer, prior spontaneous abortion, utterine factor, and uunkown factor",3,white,asian,0.8,0.7,0.9
10.1016/j.ajog.2013.04.012,12,Yes,gesational age (<28),Yes,twins,preterm birth,OR,NA,"maternal age, gravidity, smoking, body mass index, number of sacs with heart rate, male factor, day of embryoo traansfer, number of emmbryo transfer, prior spontaneous abortion, utterine factor, and uunkown factor",4,white,native,1.1,0.8,1.7
10.1016/j.ygyno.2012.05.035,1,Yes,Year (1973-1989),No,NA,diagnosed with invasive cervical cancer,Percent,NA,none,1,n/a,white,77.1,76.5,77.7
10.1016/j.ygyno.2012.05.035,1,Yes,Year (1973-1989),No,NA,diagnosed with invasive cervical cancer,Percent,NA,none,2,n/a,black,15.5,15,16
10.1016/j.ygyno.2012.05.035,1,Yes,Year (1973-1989),No,NA,diagnosed with invasive cervical cancer,Percent,NA,none,3,n/a,asian/pacific islander,5.8,5.5,6.1
10.1016/j.ygyno.2012.05.035,1,Yes,Year (1973-1989),No,NA,diagnosed with invasive cervical cancer,Percent,NA,none,4,n/a,american indian/alaskan native,1.01,0.9,1.2
10.1016/j.ygyno.2012.05.035,1,Yes,Year (1973-1989),No,NA,diagnosed with invasive cervical cancer,Percent,NA,none,5,n/a,other,0.5,0.4,0.6
10.1016/j.ygyno.2012.05.035,2,Yes,Year (1990-2008),No,NA,diagnosed with invasive cervical cancer,Percent,NA,none,1,n/a,white,73.7,73.1,74.3
10.1016/j.ygyno.2012.05.035,2,Yes,Year (1990-2008),No,NA,diagnosed with invasive cervical cancer,Percent,NA,none,2,n/a,black,14.8,14.3,15.3
10.1016/j.ygyno.2012.05.035,2,Yes,Year (1990-2008),No,NA,diagnosed with invasive cervical cancer,Percent,NA,none,3,n/a,asian/pacific islander,9.4,9,9.8
10.1016/j.ygyno.2012.05.035,2,Yes,Year (1990-2008),No,NA,diagnosed with invasive cervical cancer,Percent,NA,none,4,n/a,american indian/alaskan native,1.1,1,1.3
10.1016/j.ygyno.2012.05.035,2,Yes,Year (1990-2008),No,NA,diagnosed with invasive cervical cancer,Percent,NA,none,5,n/a,other,1.1,0.9,1.2
10.1016/j.ygyno.2012.05.035,3,Yes,Year (1973),No,NA,diagnosed with invasive cervical cancer,Percent,NA,none,1,n/a,white,78.8,76.4,81.1
10.1016/j.ygyno.2012.05.035,3,Yes,Year (1973),No,NA,diagnosed with invasive cervical cancer,Percent,NA,none,2,n/a,black,15.4,13.4,17.6
10.1016/j.ygyno.2012.05.035,3,Yes,Year (1973),No,NA,diagnosed with invasive cervical cancer,Percent,NA,none,3,n/a,asian/pacific islander,4.5,3.4,5.8
10.1016/j.ygyno.2012.05.035,3,Yes,Year (1973),No,NA,diagnosed with invasive cervical cancer,Percent,NA,none,4,n/a,american indian/alaskan native,0.8,0.3,1.4
10.1016/j.ygyno.2012.05.035,3,Yes,Year (1973),No,NA,diagnosed with invasive cervical cancer,Percent,NA,none,5,n/a,other,0.5,0.2,1.1
10.1016/j.ygyno.2012.05.035,4,Yes,Year (2008),No,NA,diagnosed with invasive cervical cancer,Percent,NA,none,1,n/a,white,71.6,68.6,74.7
10.1016/j.ygyno.2012.05.035,4,Yes,Year (2008),No,NA,diagnosed with invasive cervical cancer,Percent,NA,none,2,n/a,black,16.3,14,18.8
10.1016/j.ygyno.2012.05.035,4,Yes,Year (2008),No,NA,diagnosed with invasive cervical cancer,Percent,NA,none,3,n/a,asian/pacific islander,8.9,7.2,10.9
10.1016/j.ygyno.2012.05.035,4,Yes,Year (2008),No,NA,diagnosed with invasive cervical cancer,Percent,NA,none,4,n/a,american indian/alaskan native,1.2,0.6,2.1
10.1016/j.ygyno.2012.05.035,4,Yes,Year (2008),No,NA,diagnosed with invasive cervical cancer,Percent,NA,none,5,n/a,other,2,1.2,3.2
10.1097/AOG.0b013e3182460d9f,1,No,NA,Yes,Race,Vaccination History,Percent,NA,none,1,n/a,white,47.6,-99,-99
10.1097/AOG.0b013e3182460d9f,1,No,NA,Yes,Race,Vaccination History,Percent,NA,none,2,n/a,african american,30.6,-99,-99
10.1097/AOG.0b013e3182460d9f,1,No,NA,Yes,Race,Vaccination History,Percent,NA,none,3,n/a,other,27.3,-99,-99
10.1097/AOG.0b013e3182460d9f,2,No,NA,Yes,Race,no vaccination history,Percent,NA,none,1,n/a,white,52.4,-99,-99
10.1097/AOG.0b013e3182460d9f,2,No,NA,Yes,Race,no vaccination history,Percent,NA,none,2,n/a,african american,69.4,-99,-99
10.1097/AOG.0b013e3182460d9f,2,No,NA,Yes,Race,no vaccination history,Percent,NA,none,3,n/a,other,72.7,-99,-99
10.1097/AOG.0b013e3182460d9f,3,No,NA,Yes,Race,no vaccination history,OR,NA,none,1,white,african american,2.07,0.96,4.44
10.1097/AOG.0b013e3182460d9f,3,No,NA,Yes,Race,no vaccination history,OR,NA,none,2,white,other,2.43,0.91,6.47
10.1097/AOG.0b013e3182460d9f,4,No,NA,Yes,Race,no vaccination history,OR,NA,"age, ethnicity, and insurance type",1,white,african american,1.31,0.56,3.04
10.1097/AOG.0b013e3182460d9f,4,No,NA,Yes,Race,no vaccination history,OR,NA,"age, ethnicity, and insurance type",2,white,other,9.09,0.65,6.76
10.1097/AOG.0b013e3182460d9f,5,No,NA,Yes,Ethnicity,Vaccination History,Percent,NA,none,1,n/a,non-hispanic,44.8,-99,-99
10.1097/AOG.0b013e3182460d9f,5,No,NA,Yes,Ethnicity,Vaccination History,Percent,NA,none,2,n/a,hispanic,35.6,-99,-99
10.1097/AOG.0b013e3182460d9f,6,No,NA,Yes,Ethnicity,no vaccination history,Percent,NA,none,1,n/a,non-hispanic,55.2,-99,-99
10.1097/AOG.0b013e3182460d9f,6,No,NA,Yes,Ethnicity,no vaccination history,Percent,NA,none,2,n/a,hispanic,64.4,-99,-99
10.1097/AOG.0b013e3182460d9f,7,No,NA,Yes,Ethnicity,no vaccination history,OR,NA,none,1,Non-Hispanic,hispanic,1.47,0.76,2.86
10.1097/AOG.0b013e3182460d9f,8,No,NA,Yes,Ethnicity,no vaccination history,OR,NA,"age, race, insurance type",1,non-hispanic,hispanic,0.96,0.36,2.62
10.1097/AOG.0b013e3182460d9f,9,No,NA,Yes,race,Heard of HPV Vaccine (Yes),Percent,NA,none,1,n/a,white,90.9,-99,-99
10.1097/AOG.0b013e3182460d9f,9,No,NA,Yes,race,Heard of HPV Vaccine (Yes),Percent,NA,none,2,n/a,african american,76,-99,-99
10.1097/AOG.0b013e3182460d9f,9,No,NA,Yes,race,Heard of HPV Vaccine (Yes),Percent,NA,none,3,n/a,other,60,NA,NA
10.1097/AOG.0b013e3182460d9f,10,No,NA,Yes,race,heard of HPV Vaccine (No),Percent,NA,none,1,n/a,white,9.1,-99,-99
10.1097/AOG.0b013e3182460d9f,10,No,NA,Yes,race,heard of HPV Vaccine (No),Percent,NA,none,2,n/a,african american,24,-99,-99
10.1097/AOG.0b013e3182460d9f,10,No,NA,Yes,race,heard of HPV Vaccine (No),Percent,NA,none,3,n/a,other,40,-99,-99
10.1097/AOG.0b013e3182460d9f,11,No,NA,Yes,race,provider has talked with patient about vaccine (yes),Percent,NA,none,1,n/a,white,78.1,-99,-99
10.1097/AOG.0b013e3182460d9f,11,No,NA,Yes,race,provider has talked with patient about vaccine (yes),Percent,NA,none,2,n/a,african american,72.2,-99,-99
10.1097/AOG.0b013e3182460d9f,11,No,NA,Yes,race,provider has talked with patient about vaccine (yes),Percent,NA,none,3,n/a,other,59.1,-99,-99
10.1097/AOG.0b013e3182460d9f,12,No,NA,Yes,race,provider has talked with patient about vaccine (no),Percent,NA,none,1,n/a,white,21.9,-99,-99
10.1097/AOG.0b013e3182460d9f,12,No,NA,Yes,race,provider has talked with patient about vaccine (no),Percent,NA,none,2,n/a,african american,27.8,-99,-99
10.1097/AOG.0b013e3182460d9f,12,No,NA,Yes,race,provider has talked with patient about vaccine (no),Percent,NA,none,3,n/a,other,40.9,-99,-99
10.1097/AOG.0b013e3182460d9f,13,No,NA,Yes,ethnicity,Heard of HPV Vaccine (Yes),Percent,NA,none,1,n/a,non-hispanic,87.5,-99,-99
10.1097/AOG.0b013e3182460d9f,13,No,NA,Yes,ethnicity,Heard of HPV Vaccine (Yes),Percent,NA,none,2,n/a,hispanic,69,-99,-99
10.1097/AOG.0b013e3182460d9f,14,No,NA,Yes,ethnicity,heard of HPV Vaccine (No),Percent,NA,none,1,n/a,non-hispanic,12.5,-99,-99
10.1097/AOG.0b013e3182460d9f,14,No,NA,Yes,ethnicity,heard of HPV Vaccine (No),Percent,NA,none,2,n/a,hispanic,31,-99,-99
10.1097/AOG.0b013e3182460d9f,15,No,NA,Yes,ethnicity,provider has talked with patient about vaccine (yes),Percent,NA,none,1,n/a,non-hispanic,77.1,-99,-99
10.1097/AOG.0b013e3182460d9f,15,No,NA,Yes,ethnicity,provider has talked with patient about vaccine (yes),Percent,NA,none,2,n/a,hispanic,63.6,-99,-99
10.1097/AOG.0b013e3182460d9f,16,No,NA,Yes,ethnicity,provider has talked with patient about vaccine (no),Percent,NA,none,1,n/a,non-hispanic,22.9,-99,-99
10.1097/AOG.0b013e3182460d9f,16,No,NA,Yes,ethnicity,provider has talked with patient about vaccine (no),Percent,NA,none,2,n/a,hispanic,36.4,-99,-99
10.1097/AOG.0b013e3182460d9f,17,No,NA,Yes,race,vaccination before abnormal pap test result,Percent,NA,none,1,n/a,white,61.4,-99,-99
10.1097/AOG.0b013e3182460d9f,17,No,NA,Yes,race,vaccination before abnormal pap test result,Percent,NA,none,2,n/a,african american,20,-99,-99
10.1097/AOG.0b013e3182460d9f,17,No,NA,Yes,race,vaccination before abnormal pap test result,Percent,NA,none,3,n/a,other,50,-99,-99
10.1097/AOG.0b013e3182460d9f,18,No,NA,Yes,race,vaccination in same month as abnormal pap test result,Percent,NA,none,1,n/a,white,9.1,-99,-99
10.1097/AOG.0b013e3182460d9f,18,No,NA,Yes,race,vaccination in same month as abnormal pap test result,Percent,NA,none,2,n/a,african american,0,-99,-99
10.1097/AOG.0b013e3182460d9f,18,No,NA,Yes,race,vaccination in same month as abnormal pap test result,Percent,NA,none,3,n/a,other,16.7,-99,-99
10.1097/AOG.0b013e3182460d9f,19,No,NA,Yes,race,vaccination after abnormal pap test result,Percent,NA,none,1,n/a,white,29.5,-99,-99
10.1097/AOG.0b013e3182460d9f,19,No,NA,Yes,race,vaccination after abnormal pap test result,Percent,NA,none,2,n/a,african american,80,-99,-99
10.1097/AOG.0b013e3182460d9f,19,No,NA,Yes,race,vaccination after abnormal pap test result,Percent,NA,none,3,n/a,other,33.3,-99,-99
10.1097/AOG.0b013e3182460d9f,20,No,NA,Yes,ethnicity,vaccination before abnormal pap test result,Percent,NA,none,1,n/a,non-hispanic,55.6,-99,-99
10.1097/AOG.0b013e3182460d9f,20,No,NA,Yes,ethnicity,vaccination before abnormal pap test result,Percent,NA,none,2,n/a,hispanic,77.8,NA,NA
10.1097/AOG.0b013e3182460d9f,21,No,NA,Yes,ethnicity,vaccination in same month as abnormal pap test result,Percent,NA,none,1,n/a,non-hispanic,9.1,-99,-99
10.1097/AOG.0b013e3182460d9f,21,No,NA,Yes,ethnicity,vaccination in same month as abnormal pap test result,Percent,NA,none,2,n/a,hispanic,0,-99,-99
10.1097/AOG.0b013e3182460d9f,22,No,NA,Yes,ethnicity,vaccination after abnormal pap test result,Percent,NA,none,1,n/a,non-hispanic,35.4,-99,-99
10.1097/AOG.0b013e3182460d9f,22,No,NA,Yes,ethnicity,vaccination after abnormal pap test result,Percent,NA,none,2,n/a,hispanic,22.2,-99,-99
10.1016/j.ajog.2011.01.054,1,No,NA,No,NA,Persistent Bacterial Vaginosis,Percent,NA,none,1,n/a,non-hispanic white,4,-99,-99
10.1016/j.ajog.2011.01.054,1,No,NA,No,NA,Persistent Bacterial Vaginosis,Percent,NA,none,2,n/a,african american,35.9,-99,-99
10.1016/j.ajog.2011.01.054,1,No,NA,No,NA,Persistent Bacterial Vaginosis,Percent,NA,none,3,n/a,hispanic,12.5,-99,-99
10.1016/j.ygyno.2012.10.016,1,No,NA,No,NA,tumor recurrence rates,Percent,NA,None,1,N/A,Non-African American,6.8,-99,-99
10.1016/j.ygyno.2012.10.016,1,No,NA,No,NA,tumor recurrence rates,Percent,NA,None,2,N/A,African American,11.6,-99,-99
10.1016/j.ygyno.2012.10.016,2,No,NA,No,NA,recurrence free survival,Percent,NA,None,1,N/A,Non-African American,91,-99,-99
10.1016/j.ygyno.2012.10.016,2,No,NA,No,NA,recurrence free survival,Percent,NA,None,2,N/A,African American,85,-99,-99
10.1016/j.ygyno.2012.10.016,3,No,NA,No,NA,disease specific survival,Percent,NA,None,1,N/A,Non-African American,97,-99,-99
10.1016/j.ygyno.2012.10.016,3,No,NA,No,NA,disease specific survival,Percent,NA,None,2,N/A,African American,93,-99,-99
10.1016/j.ygyno.2012.10.016,4,No,NA,No,NA,5-year overall survival,Percent,NA,None,1,N/A,Non-African American,85,-99,-99
10.1016/j.ygyno.2012.10.016,4,No,NA,No,NA,5-year overall survival,Percent,NA,None,2,N/A,African American,84,-99,-99
10.1016/j.fertnstert.2011.04.054,1,No,NA,No,NA,Infertility treatment use ($),Mean,NA,None,1,N/A,White,14807,-99,-99
10.1016/j.fertnstert.2011.04.054,1,No,NA,No,NA,Infertility treatment use ($),Mean,NA,None,2,N/A,white female,19182,-99,-99
10.1016/j.fertnstert.2011.04.054,2,No,NA,No,NA,Cumulative pregnancy,Percent,NA,None,1,N/A,White,45.1,-99,-99
10.1016/j.fertnstert.2011.04.054,2,No,NA,No,NA,Cumulative pregnancy,Percent,NA,None,2,N/A,white female,53.6,-99,-99
10.1016/j.fertnstert.2011.04.054,3,No,NA,No,NA,Any pregnancy,OR,NA,None,1,Nonwhite,White,1.4,-99,-99
10.1016/j.fertnstert.2011.04.054,4,No,NA,No,NA,Medications only vs. no treatment,OR,NA,"female age, marital status, previous children, insurance coverage for fertility care, duration of infertility, and couple infertility diagnosis",1,Nonwhite,White,0.38,0.12,1.24
10.1016/j.fertnstert.2011.04.054,5,No,NA,No,NA,IUI vs. no treatment,OR,NA,"female age, marital status, previous children, insurance coverage for fertility care, duration of infertility, and couple infertility diagnosis",1,Nonwhite,White,1.09,0.53,2.27
10.1016/j.fertnstert.2011.04.054,6,No,NA,No,NA,IVF vs. no treatment,OR,NA,"female age, marital status, previous children, insurance coverage for fertility care, duration of infertility, and couple infertility diagnosis",1,Nonwhite,White,1.19,0.63,2.24
10.1016/j.fertnstert.2011.04.054,7,No,NA,No,NA,1-2 cycles vs. 0 cycles,OR,NA,"female age, marital status, previous children, insurance coverage for fertility care, duration of infertility, and couple infertility diagnosis",1,Nonwhite,White,0.85,0.44,1.64
10.1016/j.fertnstert.2011.04.054,8,No,NA,No,NA,3-4 cycles vs. 0 cycles,OR,NA,"female age, marital status, previous children, insurance coverage for fertility care, duration of infertility, and couple infertility diagnosis",1,Nonwhite,White,0.99,0.48,2.06
10.1016/j.fertnstert.2011.04.054,9,No,NA,No,NA,>= 5 cycles vs. 0 cycles,OR,NA,"female age, marital status, previous children, insurance coverage for fertility care, duration of infertility, and couple infertility diagnosis",1,Nonwhite,White,1.64,0.77,3.48
10.1016/j.fertnstert.2011.04.054,10,No,NA,No,NA,Infertility treatment use ($),Mean,NA,"female age, marital status, previous children, insurance coverage for infertility, duration of infertility, and couple infertility diagnosis",1,Nonwhite,White,NA,NA,NA
10.1016/j.fertnstert.2011.04.054,11,No,NA,No,NA,Any pregnancy,OR,NA,"female age, marital status, previous children, insurance coverage for infertility, duration of infertility, and couple infertility diagnosis",1,Nonwhite,White,NA,NA,NA
10.1016/j.fertnstert.2011.04.054,12,No,NA,No,NA,Infertility treatment use ($),Mean,NA,"number of cycles (i.e., 0, 1–2, 3–4, R5) and types of treatment (i.e., ovulation induction medications, IUI, or IVF), female age, marital status, previous children, insurance coverage for infertility, duration of infertility, and couple infertility diagnosis",1,Nonwhite,White,NA,NA,NA
10.1016/j.fertnstert.2011.04.054,13,No,NA,No,NA,Any pregnancy,OR,NA,"number of cycles (i.e., 0, 1–2, 3–4, R5) and types of treatment (i.e., ovulation induction medications, IUI, or IVF), female age, marital status, previous children, insurance coverage for infertility, duration of infertility, and couple infertility diagnosis",1,Nonwhite,White,NA,NA,NA
10.1016/j.fertnstert.2011.04.054,14,No,NA,No,NA,Any pregnancy,OR,NA,"total cost of fertility diagnosis and treatment, types of treatment (i.e., ovulation induction medications, IUI, or IVF), female age, marital status, previous children, insurance coverage for infertility, duration of infertility, and couple infertility diagnosis",1,Nonwhite,White,NA,NA,NA
10.1016/j.fertnstert.2013.02.017,1,Yes,Black,No,NA,Mean cycle day,Mean,NA,None,1,N/A,Black,8.3,-99,-99
10.1016/j.fertnstert.2013.02.017,2,Yes,White,No,NA,Mean cycle day,Mean,NA,None,1,N/A,White,7.8,-99,-99
10.1016/j.fertnstert.2013.02.017,3,Yes,Black,No,NA,Presence of fibroid,Percent,NA,None,1,N/A,Black,25.6,-99,-99
10.1016/j.fertnstert.2013.02.017,4,Yes,White,No,NA,Presence of fibroid,Percent,NA,None,1,N/A,White,6.9,-99,-99
10.1016/j.fertnstert.2013.02.017,5,Yes,Black,Yes,Intramural,Presence of fibroid,Percent,NA,None,1,N/A,Black,18.2,-99,-99
10.1016/j.fertnstert.2013.02.017,6,Yes,White,Yes,Intramural,Presence of fibroid,Percent,NA,None,1,N/A,White,50,-99,-99
10.1016/j.fertnstert.2013.02.017,7,Yes,Black,Yes,Subserosal,Presence of fibroid,Percent,NA,None,1,N/A,Black,72.7,-99,-99
10.1016/j.fertnstert.2013.02.017,8,Yes,White,Yes,Subserosal,Presence of fibroid,Percent,NA,None,1,N/A,White,50,-99,-99
10.1016/j.fertnstert.2013.02.017,9,Yes,Black,Yes,Pedunculated,Presence of fibroid,Percent,NA,None,1,N/A,Black,9.1,-99,-99
10.1016/j.fertnstert.2013.02.017,10,Yes,White,Yes,Pedunculated,Presence of fibroid,Percent,NA,None,1,N/A,White,0,-99,-99
10.1016/j.fertnstert.2013.02.017,11,Yes,Black,No,NA,Largest diameter of fibroid,Mean,NA,None,1,N/A,Black,2.6,-99,-99
10.1016/j.fertnstert.2013.02.017,12,Yes,White,No,NA,Largest diameter of fibroid,Mean,NA,None,1,N/A,White,1.7,-99,-99
10.1016/j.fertnstert.2013.02.017,13,Yes,Black,No,NA,Uterine volume,Mean,NA,None,1,N/A,Black,64.4,-99,-99
10.1016/j.fertnstert.2013.02.017,14,Yes,White,No,NA,Uterine volume,Mean,NA,None,1,N/A,White,41.1,-99,-99
10.1016/j.fertnstert.2013.02.017,15,Yes,Black,No,NA,Endometrial thickness,Mean,NA,None,1,N/A,Black,6,-99,-99
10.1016/j.fertnstert.2013.02.017,16,Yes,White,No,NA,Endometrial thickness,Mean,NA,None,1,N/A,White,4.3,-99,-99
10.1016/j.fertnstert.2013.02.017,17,Yes,Black,No,NA,Volume of right ovary,Mean,NA,None,1,N/A,Black,10.4,-99,-99
10.1016/j.fertnstert.2013.02.017,18,Yes,White,No,NA,Volume of right ovary,Mean,NA,None,1,N/A,White,5.5,-99,-99
10.1016/j.fertnstert.2013.02.017,19,Yes,Black,No,NA,Volume of left ovary,Mean,NA,None,1,N/A,Black,6.2,-99,-99
10.1016/j.fertnstert.2013.02.017,20,Yes,White,No,NA,Volume of left ovary,Mean,NA,None,1,N/A,White,4.5,-99,-99
10.1016/j.ajog.2019.09.009,1,No,NA,No,NA,Intention to provide abortion,OR,NA,None,1,White,Black,0.63,0.37,1.06
10.1016/j.ajog.2019.09.009,1,No,NA,No,NA,Intention to provide abortion,OR,NA,None,2,White,Latino,1.18,0.55,2.5
10.1016/j.ajog.2019.09.009,1,No,NA,No,NA,Intention to provide abortion,OR,NA,None,3,White,Asian,1.69,1.13,2.53
10.1016/j.ajog.2019.09.009,1,No,NA,No,NA,Intention to provide abortion,OR,NA,None,4,White,Other,1.41,0.64,3.12
10.1016/j.ajog.2019.09.009,2,Yes,None,No,NA,Number of abortions done in residency rotation,Percent,NA,None,1,N/A,White,4.8,-99,-99
10.1016/j.ajog.2019.09.009,2,Yes,None,No,NA,Number of abortions done in residency rotation,Percent,NA,None,2,N/A,Black,3.2,-99,-99
10.1016/j.ajog.2019.09.009,2,Yes,None,No,NA,Number of abortions done in residency rotation,Percent,NA,None,3,N/A,Latino,3.3,-99,-99
10.1016/j.ajog.2019.09.009,2,Yes,None,No,NA,Number of abortions done in residency rotation,Percent,NA,None,4,N/A,Asian,5,-99,-99
10.1016/j.ajog.2019.09.009,2,Yes,None,No,NA,Number of abortions done in residency rotation,Percent,NA,None,5,N/A,Other,10.7,-99,-99
10.1016/j.ajog.2019.09.009,3,Yes,Below mean,No,NA,Number of abortions done in residency rotation,Percent,NA,None,1,N/A,White,54.4,-99,-99
10.1016/j.ajog.2019.09.009,3,Yes,Below mean,No,NA,Number of abortions done in residency rotation,Percent,NA,None,2,N/A,Black,65.1,-99,-99
10.1016/j.ajog.2019.09.009,3,Yes,Below mean,No,NA,Number of abortions done in residency rotation,Percent,NA,None,3,N/A,Latino,60,-99,-99
10.1016/j.ajog.2019.09.009,3,Yes,Below mean,No,NA,Number of abortions done in residency rotation,Percent,NA,None,4,N/A,Asian,46.8,-99,-99
10.1016/j.ajog.2019.09.009,3,Yes,Below mean,No,NA,Number of abortions done in residency rotation,Percent,NA,None,5,N/A,Other,57.1,-99,-99
10.1016/j.ajog.2019.09.009,4,Yes,Above mean,No,NA,Number of abortions done in residency rotation,Percent,NA,None,1,N/A,White,40.8,-99,-99
10.1016/j.ajog.2019.09.009,4,Yes,Above mean,No,NA,Number of abortions done in residency rotation,Percent,NA,None,2,N/A,Black,31.8,-99,-99
10.1016/j.ajog.2019.09.009,4,Yes,Above mean,No,NA,Number of abortions done in residency rotation,Percent,NA,None,3,N/A,Latino,36.7,-99,-99
10.1016/j.ajog.2019.09.009,4,Yes,Above mean,No,NA,Number of abortions done in residency rotation,Percent,NA,None,4,N/A,Asian,48.2,-99,-99
10.1016/j.ajog.2019.09.009,4,Yes,Above mean,No,NA,Number of abortions done in residency rotation,Percent,NA,None,5,N/A,Other,32.1,-99,-99
10.1016/j.ajog.2019.09.009,5,Yes,Partial opt-out,No,NA,Partial opt-out,Percent,NA,None,1,N/A,White,18.3,-99,-99
10.1016/j.ajog.2019.09.009,5,Yes,Partial opt-out,No,NA,Partial opt-out,Percent,NA,None,2,N/A,Black,23.8,-99,-99
10.1016/j.ajog.2019.09.009,5,Yes,Partial opt-out,No,NA,Partial opt-out,Percent,NA,None,3,N/A,Latino,3.3,-99,-99
10.1016/j.ajog.2019.09.009,5,Yes,Partial opt-out,No,NA,Partial opt-out,Percent,NA,None,4,N/A,Asian,7.2,-99,-99
10.1016/j.ajog.2019.09.009,5,Yes,Partial opt-out,No,NA,Partial opt-out,Percent,NA,None,5,N/A,Other,10.7,-99,-99
10.1016/j.ajog.2019.09.009,6,Yes,Average abortion attitude score,No,NA,Average abortion attitude score,"0-5, higher numbers indicating more favorable abortion atittudes",NA,None,1,N/A,White,4.86,-99,-99
10.1016/j.ajog.2019.09.009,6,Yes,Average abortion attitude score,No,NA,Average abortion attitude score,"0-5, higher numbers indicating more favorable abortion atittudes",NA,None,2,N/A,Black,4.77,-99,-99
10.1016/j.ajog.2019.09.009,6,Yes,Average abortion attitude score,No,NA,Average abortion attitude score,"0-5, higher numbers indicating more favorable abortion atittudes",NA,None,3,N/A,Latino,5.13,-99,-99
10.1016/j.ajog.2019.09.009,6,Yes,Average abortion attitude score,No,NA,Average abortion attitude score,"0-5, higher numbers indicating more favorable abortion atittudes",NA,None,4,N/A,Asian,5.11,-99,-99
10.1016/j.ajog.2019.09.009,6,Yes,Average abortion attitude score,No,NA,Average abortion attitude score,"0-5, higher numbers indicating more favorable abortion atittudes",NA,None,5,N/A,Other,4.98,-99,-99
10.1016/j.ajog.2019.09.009,7,No,NA,No,NA,Intention to provide abortion for any indication among us obstetrics and gynecology residents,OR,NA,None,1,White,Black,0.63,0.37,1.06
10.1016/j.ajog.2019.09.009,7,No,NA,No,NA,Intention to provide abortion for any indication among us obstetrics and gynecology residents,OR,NA,None,2,White,Latino/Hispanic,1.18,0.55,2.5
10.1016/j.ajog.2019.09.009,7,No,NA,No,NA,Intention to provide abortion for any indication among us obstetrics and gynecology residents,OR,NA,None,3,White,Asian,1.69,1.13,2.53
10.1016/j.ajog.2019.09.009,8,No,NA,No,NA,Intention to provide abortion for any indication among us obstetrics and gynecology residents,OR,NA,religiosity,1,White,Black,1.1,0.59,2.02
10.1016/j.ajog.2019.09.009,8,No,NA,No,NA,Intention to provide abortion for any indication among us obstetrics and gynecology residents,OR,NA,religiosity,2,White,Latino/Hispanic,0.95,0.43,2.08
10.1016/j.ajog.2019.09.009,8,No,NA,No,NA,Intention to provide abortion for any indication among us obstetrics and gynecology residents,OR,NA,religiosity,3,White,Asian,1.61,1.03,2.52
10.1016/j.ajog.2019.09.009,9,No,NA,No,NA,Intention to provide abortion for any indication among us obstetrics and gynecology residents,OR,NA,abortion attitude,1,White,Black,0.76,0.42,1.39
10.1016/j.ajog.2019.09.009,9,No,NA,No,NA,Intention to provide abortion for any indication among us obstetrics and gynecology residents,OR,NA,abortion attitude,2,White,Latino/Hispanic,0.99,0.43,2.24
10.1016/j.ajog.2019.09.009,9,No,NA,No,NA,Intention to provide abortion for any indication among us obstetrics and gynecology residents,OR,NA,abortion attitude,3,White,Asian,1.36,0.87,2.11
10.1016/j.ajog.2019.09.009,10,No,NA,No,NA,Intention to provide abortion for any indication among us obstetrics and gynecology residents,OR,NA,"religiosity, abortion attitude",1,White,Black,1.06,0.54,2.07
10.1016/j.ajog.2019.09.009,10,No,NA,No,NA,Intention to provide abortion for any indication among us obstetrics and gynecology residents,OR,NA,"religiosity, abortion attitude",2,White,Latino/Hispanic,0.9,0.39,2.12
10.1016/j.ajog.2019.09.009,10,No,NA,No,NA,Intention to provide abortion for any indication among us obstetrics and gynecology residents,OR,NA,"religiosity, abortion attitude",3,White,Asian,1.29,0.81,2.07
10.1097/AOG.0000000000003401,1,No,NA,No,NA,Predictors of Brachytherapy,OR,NA,"Age, insurance, charlson/deyo score, residence, year of diagnosis, treatment facility location, FIGO clinical stage",1,non-Hispanic White,Hispanic,0.93,0.85,1.02
10.1097/AOG.0000000000003401,1,No,NA,No,NA,Predictors of Brachytherapy,OR,NA,"Age, insurance, charlson/deyo score, residence, year of diagnosis, treatment facility location, FIGO clinical stage",2,non-Hispanic White,Non-Hispanic Black,0.93,0.86,0.99
10.1097/AOG.0000000000003401,1,No,NA,No,NA,Predictors of Brachytherapy,OR,NA,"Age, insurance, charlson/deyo score, residence, year of diagnosis, treatment facility location, FIGO clinical stage",3,non-Hispanic White,Asian,1.13,0.99,1.29
10.1097/AOG.0000000000003401,1,No,NA,No,NA,Predictors of Brachytherapy,OR,NA,"Age, insurance, charlson/deyo score, residence, year of diagnosis, treatment facility location, FIGO clinical stage",4,non-Hispanic White,Other,1.12,0.91,1.39
10.1097/AOG.0000000000003401,2,Yes,56 d or Less,No,NA,Duration of Radiation Therapy,Percent,NA,None,1,N/A,Non-Hispanic White,58,-99,-99
10.1097/AOG.0000000000003401,2,Yes,56 d or Less,No,NA,Duration of Radiation Therapy,Percent,NA,None,2,N/A,Hispanic,57,-99,-99
10.1097/AOG.0000000000003401,2,Yes,56 d or Less,No,NA,Duration of Radiation Therapy,Percent,NA,None,3,N/A,Non-Hispanic Black,55,-99,-99
10.1097/AOG.0000000000003401,2,Yes,56 d or Less,No,NA,Duration of Radiation Therapy,Percent,NA,None,4,N/A,Asian,59,-99,-99
10.1097/AOG.0000000000003401,2,Yes,56 d or Less,No,NA,Duration of Radiation Therapy,Percent,NA,None,5,N/A,Other,60,-99,-99
10.1097/AOG.0000000000003401,3,Yes,Not planned or contraindicated,No,NA,Reason patient did not receive radiation therapy for treatment of cervical cancer,Percent,NA,None,1,N/A,Non-Hispanic White,84,-99,-99
10.1097/AOG.0000000000003401,3,Yes,Not planned or contraindicated,No,NA,Reason patient did not receive radiation therapy for treatment of cervical cancer,Percent,NA,None,2,N/A,Hispanic,84,-99,-99
10.1097/AOG.0000000000003401,3,Yes,Not planned or contraindicated,No,NA,Reason patient did not receive radiation therapy for treatment of cervical cancer,Percent,NA,None,3,N/A,Non-Hispanic Black,80,-99,-99
10.1097/AOG.0000000000003401,3,Yes,Not planned or contraindicated,No,NA,Reason patient did not receive radiation therapy for treatment of cervical cancer,Percent,NA,None,4,N/A,Asian,76,-99,-99
10.1097/AOG.0000000000003401,3,Yes,Not planned or contraindicated,No,NA,Reason patient did not receive radiation therapy for treatment of cervical cancer,Percent,NA,None,5,N/A,Other,81,-99,-99
10.1097/AOG.0000000000003401,4,Yes,FIGO IB2,No,NA,Overall Survival,HR,NA,"Age, insurance, charlson/deyo score, residence, year of diagnosis, treatment facility location, brachytherapy",1,non-Hispanic White,Hispanic,0.641,0.36,1.14
10.1097/AOG.0000000000003401,4,Yes,FIGO IB2,No,NA,Overall Survival,HR,NA,"Age, insurance, charlson/deyo score, residence, year of diagnosis, treatment facility location, brachytherapy",2,non-Hispanic White,Non-Hispanic Black,1.189,0.84,1.69
10.1097/AOG.0000000000003401,4,Yes,FIGO IB2,No,NA,Overall Survival,HR,NA,"Age, insurance, charlson/deyo score, residence, year of diagnosis, treatment facility location, brachytherapy",3,non-Hispanic White,Asian,0.618,0.25,1.52
10.1097/AOG.0000000000003401,4,Yes,FIGO IB2,No,NA,Overall Survival,HR,NA,"Age, insurance, charlson/deyo score, residence, year of diagnosis, treatment facility location, brachytherapy",4,non-Hispanic White,Other,0.676,0.19,2.43
10.1097/AOG.0000000000003401,5,Yes,FIGO II,No,NA,Overall Survival,HR,NA,"Age, insurance, charlson/deyo score, residence, year of diagnosis, treatment facility location, brachytherapy",1,non-Hispanic White,Hispanic,0.63,0.5,0.79
10.1097/AOG.0000000000003401,5,Yes,FIGO II,No,NA,Overall Survival,HR,NA,"Age, insurance, charlson/deyo score, residence, year of diagnosis, treatment facility location, brachytherapy",2,non-Hispanic White,Non-Hispanic Black,1.006,0.87,1.17
10.1097/AOG.0000000000003401,5,Yes,FIGO II,No,NA,Overall Survival,HR,NA,"Age, insurance, charlson/deyo score, residence, year of diagnosis, treatment facility location, brachytherapy",3,non-Hispanic White,Asian,0.661,0.48,0.91
10.1097/AOG.0000000000003401,5,Yes,FIGO II,No,NA,Overall Survival,HR,NA,"Age, insurance, charlson/deyo score, residence, year of diagnosis, treatment facility location, brachytherapy",4,non-Hispanic White,Other,0.869,0.52,1.46
10.1097/AOG.0000000000003401,6,Yes,FIGO III,No,NA,Overall Survival,HR,NA,"Age, insurance, charlson/deyo score, residence, year of diagnosis, treatment facility location, brachytherapy",1,non-Hispanic White,Hispanic,0.676,0.57,0.8
10.1097/AOG.0000000000003401,6,Yes,FIGO III,No,NA,Overall Survival,HR,NA,"Age, insurance, charlson/deyo score, residence, year of diagnosis, treatment facility location, brachytherapy",2,non-Hispanic White,Non-Hispanic Black,0.981,0.88,1.1
10.1097/AOG.0000000000003401,6,Yes,FIGO III,No,NA,Overall Survival,HR,NA,"Age, insurance, charlson/deyo score, residence, year of diagnosis, treatment facility location, brachytherapy",3,non-Hispanic White,Asian,0.774,0.61,0.98
10.1097/AOG.0000000000003401,6,Yes,FIGO III,No,NA,Overall Survival,HR,NA,"Age, insurance, charlson/deyo score, residence, year of diagnosis, treatment facility location, brachytherapy",4,non-Hispanic White,Other,0.725,0.48,1.09
10.1097/AOG.0000000000003401,7,Yes,FIGO IVA,No,NA,Overall Survival,HR,NA,"Age, insurance, charlson/deyo score, residence, year of diagnosis, treatment facility location, brachytherapy",1,non-Hispanic White,Hispanic,0.682,0.44,1.05
10.1097/AOG.0000000000003401,7,Yes,FIGO IVA,No,NA,Overall Survival,HR,NA,"Age, insurance, charlson/deyo score, residence, year of diagnosis, treatment facility location, brachytherapy",2,non-Hispanic White,Non-Hispanic Black,1.062,0.81,1.39
10.1097/AOG.0000000000003401,7,Yes,FIGO IVA,No,NA,Overall Survival,HR,NA,"Age, insurance, charlson/deyo score, residence, year of diagnosis, treatment facility location, brachytherapy",3,non-Hispanic White,Asian,0.75,0.4,1.41
10.1097/AOG.0000000000003401,7,Yes,FIGO IVA,No,NA,Overall Survival,HR,NA,"Age, insurance, charlson/deyo score, residence, year of diagnosis, treatment facility location, brachytherapy",4,non-Hispanic White,Other,0.988,0.34,2.84
10.1016/j.ajog.2017.11.602,1,No,NA,No,NA,Association between patient characteristics and missed opportunities,OR,NA,None,1,Non-Hispanic White,Hispanic,1.31,0.88,1.94
10.1016/j.ajog.2017.11.602,1,No,NA,No,NA,Association between patient characteristics and missed opportunities,OR,NA,None,2,Non-Hispanic White,Non-Hispanic Black,1.62,1.09,2.42
10.1016/j.ajog.2017.11.602,1,No,NA,No,NA,Association between patient characteristics and missed opportunities,OR,NA,None,3,Non-Hispanic White,Non-Hispanic other,1.08,0.37,3.16
10.1016/j.ajog.2017.11.602,2,No,NA,No,NA,Association between patient characteristics and missed opportunities,OR,NA,"preferred language, insurance",1,Non-Hispanic White,Hispanic,1.23,0.81,1.9
10.1016/j.ajog.2017.11.602,2,No,NA,No,NA,Association between patient characteristics and missed opportunities,OR,NA,"preferred language, insurance",2,Non-Hispanic White,Non-Hispanic Black,1.61,1.08,2.41
10.1016/j.ajog.2017.11.602,2,No,NA,No,NA,Association between patient characteristics and missed opportunities,OR,NA,"preferred language, insurance",3,Non-Hispanic White,Non-Hispanic other,1.45,0.47,4.48
10.1016/j.ygyno.2017.08.005,1,No,NA,No,NA,adjuvant radiotherapy,OR,NA,"age, charlson, facility type, census region, zipcode income, % residents without HS diploma, distance to treatment facility, urban density, insurance status, FIGO substage, tumor size, grade, lymph node surgery, number of LN removed, surgery type, chemotherapy",1,White,Black,0.94,-99,-99
10.1016/j.ygyno.2017.08.005,1,No,NA,No,NA,adjuvant radiotherapy,OR,NA,"age, charlson, facility type, census region, zipcode income, % residents without HS diploma, distance to treatment facility, urban density, insurance status, FIGO substage, tumor size, grade, lymph node surgery, number of LN removed, surgery type, chemotherapy",2,White,Hispanic,0.93,-99,-99
10.1016/j.ygyno.2017.08.005,1,No,NA,No,NA,adjuvant radiotherapy,OR,NA,"age, charlson, facility type, census region, zipcode income, % residents without HS diploma, distance to treatment facility, urban density, insurance status, FIGO substage, tumor size, grade, lymph node surgery, number of LN removed, surgery type, chemotherapy",3,White,Other,0.92,-99,-99
10.1016/j.ygyno.2017.08.005,2,No,NA,No,NA,oncologic surgery,OR,NA,"age, charlson, facility type, census region, zipcode income, % residents without HS diploma, distance to treatment facility, urban density, insurance status, FIGO substage, tumor size, grade, lymph node surgery, number of LN removed, surgery type, chemotherapy",1,White,Black,0.85,-99,-99
10.1016/j.ygyno.2017.08.005,2,No,NA,No,NA,oncologic surgery,OR,NA,"age, charlson, facility type, census region, zipcode income, % residents without HS diploma, distance to treatment facility, urban density, insurance status, FIGO substage, tumor size, grade, lymph node surgery, number of LN removed, surgery type, chemotherapy",2,White,Hispanic,0.86,-99,-99
10.1016/j.ygyno.2017.08.005,2,No,NA,No,NA,oncologic surgery,OR,NA,"age, charlson, facility type, census region, zipcode income, % residents without HS diploma, distance to treatment facility, urban density, insurance status, FIGO substage, tumor size, grade, lymph node surgery, number of LN removed, surgery type, chemotherapy",3,White,Other,1.33,-99,-99
10.1016/j.ygyno.2017.08.005,3,No,NA,Yes,Eldery patients,Death,HR,NA,"radiotherapy, income (zip code), % residents w/o hs diploma, census region, charlson comorbidity score, figo stage, tumor size, grade, lymph node surgery, number of ln removed, chemotherapy, margin status",1,White,Black,1.09,-99,-99
10.1016/j.ygyno.2017.08.005,3,No,NA,Yes,Eldery patients,Death,HR,NA,"radiotherapy, income (zip code), % residents w/o hs diploma, census region, charlson comorbidity score, figo stage, tumor size, grade, lymph node surgery, number of ln removed, chemotherapy, margin status",2,White,Hispanic,1.05,-99,-99
10.1016/j.ygyno.2017.08.005,3,No,NA,Yes,Eldery patients,Death,HR,NA,"radiotherapy, income (zip code), % residents w/o hs diploma, census region, charlson comorbidity score, figo stage, tumor size, grade, lymph node surgery, number of ln removed, chemotherapy, margin status",3,White,Other,0.99,-99,-99
10.1016/j.ajog.2016.03.022,1,No,NA,No,NA,Human papillomavirus vaccination rate,RR,NA,None,1,N/A,Non-Hispanic white,0.74,0.64,0.85
10.1016/j.ajog.2016.03.022,1,No,NA,No,NA,Human papillomavirus vaccination rate,RR,NA,None,2,N/A,African American,1.35,1.17,1.55
10.1016/j.ajog.2016.03.022,2,No,NA,No,NA,Difference of human papillomavirus vaccination rates before and after the mandate,Percent difference,NA,None,1,N/A,Non-Hispanic white,5.1,-99,-99
10.1016/j.ajog.2016.03.022,2,No,NA,No,NA,Difference of human papillomavirus vaccination rates before and after the mandate,Percent difference,NA,None,2,N/A,African American,4.9,-99,-99
10.1016/j.ajog.2016.03.022,2,No,NA,No,NA,Difference of human papillomavirus vaccination rates before and after the mandate,Percent difference,NA,None,3,N/A,Other,-15,-99,-99
10.1016/j.ajog.2016.03.022,3,No,NA,No,NA,initiation of the human papillomavirus vaccine series,OR,NA,"public insurance, safety concerns, perceived susceptibility",1,Non-Hispanic White,Black,5.3,1.4,20
10.1016/j.ajog.2016.03.022,3,No,NA,No,NA,initiation of the human papillomavirus vaccine series,OR,NA,"public insurance, safety concerns, perceived susceptibility",2,Non-Hispanic White,Other,1.2,0.39,4.06
10.1016/j.ygyno.2016.09.009,1,No,NA,No,NA,Overall survival,HR,NA,"age, CDCC, histology, stage, location of radiation, radiation treatment",1,Caucasian (non-Hispanic),Black,1.069,1.008,1.134
10.1016/j.ygyno.2016.09.009,1,No,NA,No,NA,Overall survival,HR,NA,"age, CDCC, histology, stage, location of radiation, radiation treatment",2,Caucasian (non-Hispanic),Hispanic,0.689,0.634,0.749
10.1016/j.ygyno.2016.09.009,1,No,NA,No,NA,Overall survival,HR,NA,"age, CDCC, histology, stage, location of radiation, radiation treatment",3,Caucasian (non-Hispanic),Other,0.8,0.718,0.891
10.1016/j.ygyno.2016.09.009,2,No,NA,No,NA,Receiving standard of care therapy,OR,NA,"age, CDCC, stage, tumor size, insurance status, median household income, urban/rural, distance to hospital, facility volume, facility type, facility location, location of radiation",1,Caucasian (non-Hispanic),Black,0.856,0.766,0.957
10.1016/j.ygyno.2016.09.009,2,No,NA,No,NA,Receiving standard of care therapy,OR,NA,"age, CDCC, stage, tumor size, insurance status, median household income, urban/rural, distance to hospital, facility volume, facility type, facility location, location of radiation",2,Caucasian (non-Hispanic),Hispanic,0.891,0.779,1.019
10.1016/j.ygyno.2016.09.009,2,No,NA,No,NA,Receiving standard of care therapy,OR,NA,"age, CDCC, stage, tumor size, insurance status, median household income, urban/rural, distance to hospital, facility volume, facility type, facility location, location of radiation",3,Caucasian (non-Hispanic),Other,1.185,1.002,1.401
10.1016/j.ygyno.2016.09.009,3,No,NA,No,NA,Not receiving any radiotherapy boost,OR,NA,"age, CDCC, stage, tumor size, insurance status, median household income, urban/rural, distance to hospital, facility volume, facility type, facility location",1,Caucasian (non-Hispanic),Black,1.053,0.939,1.18
10.1016/j.ygyno.2016.09.009,3,No,NA,No,NA,Not receiving any radiotherapy boost,OR,NA,"age, CDCC, stage, tumor size, insurance status, median household income, urban/rural, distance to hospital, facility volume, facility type, facility location",2,Caucasian (non-Hispanic),Hispanic,1.036,0.889,1.194
10.1016/j.ygyno.2016.09.009,3,No,NA,No,NA,Not receiving any radiotherapy boost,OR,NA,"age, CDCC, stage, tumor size, insurance status, median household income, urban/rural, distance to hospital, facility volume, facility type, facility location",3,Caucasian (non-Hispanic),Other,0.769,0.634,0.932
10.1016/j.ygyno.2016.02.013,1,No,NA,No,NA,Overall survival,HR,NA,None,1,Non-African Americans,African Americans,1.228,1.076,1.402
10.1016/j.ygyno.2016.02.013,2,No,NA,No,NA,Cause-specific survival,HR,NA,None,1,Non-African Americans,African Americans,1.217,1.053,1.407
10.1097/AOG.0000000000001180,1,No,NA,No,NA,Undergoing Minimally Invasive Surgery Compared with Open Surgery,OR,NA,"Elixhauser comorbidity score, age, hospital type, region, teaching hospital, location of hospital, hospital bed size, hospital volume, median household income, expected payer, obese, year of diagnosis",1,White,Black,0.43,0.41,0.46
10.1097/AOG.0000000000001180,1,No,NA,No,NA,Undergoing Minimally Invasive Surgery Compared with Open Surgery,OR,NA,"Elixhauser comorbidity score, age, hospital type, region, teaching hospital, location of hospital, hospital bed size, hospital volume, median household income, expected payer, obese, year of diagnosis",2,White,Hispanic,0.77,0.72,0.82
10.1097/AOG.0000000000001180,1,No,NA,No,NA,Undergoing Minimally Invasive Surgery Compared with Open Surgery,OR,NA,"Elixhauser comorbidity score, age, hospital type, region, teaching hospital, location of hospital, hospital bed size, hospital volume, median household income, expected payer, obese, year of diagnosis",3,White,Asian or Pacific Islander,0.92,0.84,1
10.1097/AOG.0000000000001180,1,No,NA,No,NA,Undergoing Minimally Invasive Surgery Compared with Open Surgery,OR,NA,"Elixhauser comorbidity score, age, hospital type, region, teaching hospital, location of hospital, hospital bed size, hospital volume, median household income, expected payer, obese, year of diagnosis",4,White,Other,0.74,0.67,0.8
10.1097/AOG.0000000000001184,1,No,NA,No,NA,Health Professional Shortage Area; Medically Underserved Areas/Populations,Percent,NA,None,1,N/A,White,37.6,-99,-99
10.1097/AOG.0000000000001184,1,No,NA,No,NA,Health Professional Shortage Area; Medically Underserved Areas/Populations,Percent,NA,None,2,N/A,Black,45.2,-99,-99
10.1097/AOG.0000000000001184,1,No,NA,No,NA,Health Professional Shortage Area; Medically Underserved Areas/Populations,Percent,NA,None,3,N/A,Asian,30.9,-99,-99
10.1097/AOG.0000000000001184,1,No,NA,No,NA,Health Professional Shortage Area; Medically Underserved Areas/Populations,Percent,NA,None,4,N/A,Hispanic,46.8,-99,-99
10.1097/AOG.0000000000001184,1,No,NA,No,NA,Health Professional Shortage Area; Medically Underserved Areas/Populations,Percent,NA,None,5,N/A,Native,44.5,-99,-99
10.1097/AOG.0000000000001184,1,No,NA,No,NA,Health Professional Shortage Area; Medically Underserved Areas/Populations,Percent,NA,None,6,N/A,Other or unknown,37.5,-99,NA
10.1097/AOG.0000000000001184,1,No,NA,No,NA,Health Professional Shortage Area; Medically Underserved Areas/Populations,Percent,NA,None,7,N/A,NA,NA,NA,-99
10.1097/AOG.0000000000001184,2,No,NA,No,NA,Poverty Greater than 20%,Percent,NA,None,1,N/A,White,30.7,-99,-99
10.1097/AOG.0000000000001184,2,No,NA,No,NA,Poverty Greater than 20%,Percent,NA,None,2,N/A,Black,37.2,-99,-99
10.1097/AOG.0000000000001184,2,No,NA,No,NA,Poverty Greater than 20%,Percent,NA,None,3,N/A,Asian,29.6,-99,-99
10.1097/AOG.0000000000001184,2,No,NA,No,NA,Poverty Greater than 20%,Percent,NA,None,4,N/A,Hispanic,41.1,-99,-99
10.1097/AOG.0000000000001184,2,No,NA,No,NA,Poverty Greater than 20%,Percent,NA,None,5,N/A,Native,31.7,-99,-99
10.1097/AOG.0000000000001184,2,No,NA,No,NA,Poverty Greater than 20%,Percent,NA,None,6,N/A,Other or unknown,26.9,-99,NA
10.1097/AOG.0000000000001184,2,No,NA,No,NA,Poverty Greater than 20%,Percent,NA,None,7,N/A,NA,NA,NA,-99
10.1097/AOG.0000000000001184,3,No,NA,No,NA,Rural,Percent,NA,None,1,N/A,White,10.7,-99,-99
10.1097/AOG.0000000000001184,3,No,NA,No,NA,Rural,Percent,NA,None,2,N/A,Black,6.9,-99,-99
10.1097/AOG.0000000000001184,3,No,NA,No,NA,Rural,Percent,NA,None,3,N/A,Asian,3.6,-99,-99
10.1097/AOG.0000000000001184,3,No,NA,No,NA,Rural,Percent,NA,None,4,N/A,Hispanic,5.9,-99,-99
10.1097/AOG.0000000000001184,3,No,NA,No,NA,Rural,Percent,NA,None,5,N/A,Native,17.7,-99,-99
10.1097/AOG.0000000000001184,3,No,NA,No,NA,Rural,Percent,NA,None,6,N/A,Other or unknown,12.2,-99,NA
10.1097/AOG.0000000000001184,3,No,NA,No,NA,Rural,Percent,NA,None,7,N/A,NA,NA,NA,-99
10.1016/j.ygyno.2015.04.030,1,No,NA,No,NA,Need for 2nd line chemotherapy,Percent,NA,None,1,N/A,White,25.5,-99,-99
10.1016/j.ygyno.2015.04.030,1,No,NA,No,NA,Need for 2nd line chemotherapy,Percent,NA,None,2,N/A,African American,26.3,-99,-99
10.1016/j.ygyno.2015.04.030,1,No,NA,No,NA,Need for 2nd line chemotherapy,Percent,NA,None,3,N/A,Asian,52.2,-99,-99
10.1097/AOG.0000000000000735,1,No,NA,No,NA,Postpartum hemorrhage,OR,NA,None,1,Non-Hispanic White,Non-Hispanic Black,1.89,1.7,2.09
10.1097/AOG.0000000000000735,1,No,NA,No,NA,Postpartum hemorrhage,OR,NA,None,2,Non-Hispanic White,Hispanic,1.94,1.76,2.14
10.1097/AOG.0000000000000735,1,No,NA,No,NA,Postpartum hemorrhage,OR,NA,None,3,Non-Hispanic White,Asian,1.38,1.15,1.67
10.1097/AOG.0000000000000735,2,No,NA,No,NA,Postpartum hemorrhage,OR,NA,"age, diabetes mellitus, any hypertension, birth weight, prenatal care, obstetric history, multiple gestation, abruption, previa, accreta, anticoagulant use during pregnancy, insurance status",1,Non-Hispanic White,Non-Hispanic Black,1.87,1.65,2.12
10.1097/AOG.0000000000000735,2,No,NA,No,NA,Postpartum hemorrhage,OR,NA,"age, diabetes mellitus, any hypertension, birth weight, prenatal care, obstetric history, multiple gestation, abruption, previa, accreta, anticoagulant use during pregnancy, insurance status",2,Non-Hispanic White,Hispanic,2.07,1.83,2.36
10.1097/AOG.0000000000000735,2,No,NA,No,NA,Postpartum hemorrhage,OR,NA,"age, diabetes mellitus, any hypertension, birth weight, prenatal care, obstetric history, multiple gestation, abruption, previa, accreta, anticoagulant use during pregnancy, insurance status",3,Non-Hispanic White,Asian,1.49,1.21,1.84
10.1097/AOG.0000000000000735,3,No,NA,No,NA,Postpartum hemorrhage,OR,NA,"age, diabetes mellitus, any hypertension, birth weight, prenatal care, obstetric history, multiple gestation, abruption, previa, accreta, anticoagulant use during pregnancy, insurance status, hospital",1,Non-Hispanic White,Non-Hispanic Black,1.71,1.49,1.96
10.1097/AOG.0000000000000735,3,No,NA,No,NA,Postpartum hemorrhage,OR,NA,"age, diabetes mellitus, any hypertension, birth weight, prenatal care, obstetric history, multiple gestation, abruption, previa, accreta, anticoagulant use during pregnancy, insurance status, hospital",2,Non-Hispanic White,Hispanic,1.51,1.31,1.74
10.1097/AOG.0000000000000735,3,No,NA,No,NA,Postpartum hemorrhage,OR,NA,"age, diabetes mellitus, any hypertension, birth weight, prenatal care, obstetric history, multiple gestation, abruption, previa, accreta, anticoagulant use during pregnancy, insurance status, hospital",3,Non-Hispanic White,Asian,1.54,1.24,1.91
10.1097/AOG.0000000000000735,4,No,NA,No,NA,Peripartum infection,OR,NA,None,1,Non-Hispanic White,Non-Hispanic Black,1.21,1.13,1.31
10.1097/AOG.0000000000000735,4,No,NA,No,NA,Peripartum infection,OR,NA,None,2,Non-Hispanic White,Hispanic,1.61,1.51,1.72
10.1097/AOG.0000000000000735,4,No,NA,No,NA,Peripartum infection,OR,NA,None,3,Non-Hispanic White,Asian,1.57,1.4,1.75
10.1097/AOG.0000000000000735,5,No,NA,No,NA,Peripartum infection,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status",1,Non-Hispanic White,Non-Hispanic Black,1.13,1.03,1.23
10.1097/AOG.0000000000000735,5,No,NA,No,NA,Peripartum infection,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status",2,Non-Hispanic White,Hispanic,1.69,1.56,1.85
10.1097/AOG.0000000000000735,5,No,NA,No,NA,Peripartum infection,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status",3,Non-Hispanic White,Asian,1.59,1.41,1.79
10.1097/AOG.0000000000000735,6,No,NA,No,NA,Peripartum infection,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status, hospital",1,Non-Hispanic White,Non-Hispanic Black,1.25,1.14,1.38
10.1097/AOG.0000000000000735,6,No,NA,No,NA,Peripartum infection,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status, hospital",2,Non-Hispanic White,Hispanic,1.45,1.32,1.59
10.1097/AOG.0000000000000735,6,No,NA,No,NA,Peripartum infection,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status, hospital",3,Non-Hispanic White,Asian,1.62,1.43,1.84
10.1097/AOG.0000000000000735,7,No,NA,Yes,patients with a singleton delivery and no shoulder dystocia or placenta previa,Severe perineal laceration at spontaneous vaginal delivery,OR,NA,None,1,Non-Hispanic White,Non-Hispanic Black,0.47,0.4,0.56
10.1097/AOG.0000000000000735,7,No,NA,Yes,patients with a singleton delivery and no shoulder dystocia or placenta previa,Severe perineal laceration at spontaneous vaginal delivery,OR,NA,None,2,Non-Hispanic White,Hispanic,0.57,0.49,0.66
10.1097/AOG.0000000000000735,7,No,NA,Yes,patients with a singleton delivery and no shoulder dystocia or placenta previa,Severe perineal laceration at spontaneous vaginal delivery,OR,NA,None,3,Non-Hispanic White,Asian,2.26,1.92,2.67
10.1097/AOG.0000000000000735,8,No,NA,Yes,patients with a singleton delivery and no shoulder dystocia or placenta previa,Severe perineal laceration at spontaneous vaginal delivery,OR,NA,"age, body mass index at delivery, cigarette use during pregnancy, birth weight, prior vaginal delivery, insurance status",1,Non-Hispanic White,Non-Hispanic Black,0.79,0.65,0.95
10.1097/AOG.0000000000000735,8,No,NA,Yes,patients with a singleton delivery and no shoulder dystocia or placenta previa,Severe perineal laceration at spontaneous vaginal delivery,OR,NA,"age, body mass index at delivery, cigarette use during pregnancy, birth weight, prior vaginal delivery, insurance status",2,Non-Hispanic White,Hispanic,0.84,0.7,1.01
10.1097/AOG.0000000000000735,8,No,NA,Yes,patients with a singleton delivery and no shoulder dystocia or placenta previa,Severe perineal laceration at spontaneous vaginal delivery,OR,NA,"age, body mass index at delivery, cigarette use during pregnancy, birth weight, prior vaginal delivery, insurance status",3,Non-Hispanic White,Asian,1.97,1.66,2.34
10.1097/AOG.0000000000000735,9,No,NA,Yes,patients with a singleton delivery and no shoulder dystocia or placenta previa,Severe perineal laceration at spontaneous vaginal delivery,OR,NA,"age, body mass index at delivery, cigarette use during pregnancy, birth weight, prior vaginal delivery, insurance status, hospital",1,Non-Hispanic White,Non-Hispanic Black,0.76,0.62,0.93
10.1097/AOG.0000000000000735,9,No,NA,Yes,patients with a singleton delivery and no shoulder dystocia or placenta previa,Severe perineal laceration at spontaneous vaginal delivery,OR,NA,"age, body mass index at delivery, cigarette use during pregnancy, birth weight, prior vaginal delivery, insurance status, hospital",2,Non-Hispanic White,Hispanic,0.86,0.7,1.05
10.1097/AOG.0000000000000735,9,No,NA,Yes,patients with a singleton delivery and no shoulder dystocia or placenta previa,Severe perineal laceration at spontaneous vaginal delivery,OR,NA,"age, body mass index at delivery, cigarette use during pregnancy, birth weight, prior vaginal delivery, insurance status, hospital",3,Non-Hispanic White,Asian,2.06,1.72,2.47
10.1097/AOG.0000000000000735,10,No,NA,Yes,"patients with no previa and no history of classical, T, or J cesarean delivery",Labor induction,OR,NA,None,1,Non-Hispanic White,Non-Hispanic Black,0.83,0.8,0.86
10.1097/AOG.0000000000000735,10,No,NA,Yes,"patients with no previa and no history of classical, T, or J cesarean delivery",Labor induction,OR,NA,None,2,Non-Hispanic White,Hispanic,0.63,0.61,0.65
10.1097/AOG.0000000000000735,10,No,NA,Yes,"patients with no previa and no history of classical, T, or J cesarean delivery",Labor induction,OR,NA,None,3,Non-Hispanic White,Asian,0.66,0.62,0.7
10.1097/AOG.0000000000000735,11,No,NA,Yes,"patients with no previa and no history of classical, T, or J cesarean delivery",Labor induction,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status",1,Non-Hispanic White,Non-Hispanic Black,0.83,0.8,0.87
10.1097/AOG.0000000000000735,11,No,NA,Yes,"patients with no previa and no history of classical, T, or J cesarean delivery",Labor induction,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status",2,Non-Hispanic White,Hispanic,0.68,0.65,0.71
10.1097/AOG.0000000000000735,11,No,NA,Yes,"patients with no previa and no history of classical, T, or J cesarean delivery",Labor induction,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status",3,Non-Hispanic White,Asian,0.68,0.64,0.73
10.1097/AOG.0000000000000735,12,No,NA,Yes,"patients with no previa and no history of classical, T, or J cesarean delivery",Labor induction,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status, hospital",1,Non-Hispanic White,Non-Hispanic Black,0.88,0.84,0.92
10.1097/AOG.0000000000000735,12,No,NA,Yes,"patients with no previa and no history of classical, T, or J cesarean delivery",Labor induction,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status, hospital",2,Non-Hispanic White,Hispanic,0.67,0.64,0.7
10.1097/AOG.0000000000000735,12,No,NA,Yes,"patients with no previa and no history of classical, T, or J cesarean delivery",Labor induction,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status, hospital",3,Non-Hispanic White,Asian,0.74,0.69,0.8
10.1097/AOG.0000000000000735,13,No,NA,Yes,patients at term with intact membranes and spontaneous intended labor with no previa and cervical dilation measured within 1 hour before or after labor and delivery admission,Dilation 2 cm or less at admission,OR,NA,None,1,Non-Hispanic White,Non-Hispanic Black,0.94,0.88,1.01
10.1097/AOG.0000000000000735,13,No,NA,Yes,patients at term with intact membranes and spontaneous intended labor with no previa and cervical dilation measured within 1 hour before or after labor and delivery admission,Dilation 2 cm or less at admission,OR,NA,None,2,Non-Hispanic White,Hispanic,0.73,0.68,0.78
10.1097/AOG.0000000000000735,13,No,NA,Yes,patients at term with intact membranes and spontaneous intended labor with no previa and cervical dilation measured within 1 hour before or after labor and delivery admission,Dilation 2 cm or less at admission,OR,NA,None,3,Non-Hispanic White,Asian,1.07,0.95,1.19
10.1097/AOG.0000000000000735,14,No,NA,Yes,patients at term with intact membranes and spontaneous intended labor with no previa and cervical dilation measured within 1 hour before or after labor and delivery admission,Dilation 2 cm or less at admission,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status",1,Non-Hispanic White,Non-Hispanic Black,1.12,1.04,1.22
10.1097/AOG.0000000000000735,14,No,NA,Yes,patients at term with intact membranes and spontaneous intended labor with no previa and cervical dilation measured within 1 hour before or after labor and delivery admission,Dilation 2 cm or less at admission,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status",2,Non-Hispanic White,Hispanic,0.93,0.85,1.01
10.1097/AOG.0000000000000735,14,No,NA,Yes,patients at term with intact membranes and spontaneous intended labor with no previa and cervical dilation measured within 1 hour before or after labor and delivery admission,Dilation 2 cm or less at admission,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status",3,Non-Hispanic White,Asian,0.98,0.87,1.1
10.1097/AOG.0000000000000735,15,No,NA,Yes,patients at term with intact membranes and spontaneous intended labor with no previa and cervical dilation measured within 1 hour before or after labor and delivery admission,Dilation 2 cm or less at admission,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status, hospital",1,Non-Hispanic White,Non-Hispanic Black,1.1,1,1.21
10.1097/AOG.0000000000000735,15,No,NA,Yes,patients at term with intact membranes and spontaneous intended labor with no previa and cervical dilation measured within 1 hour before or after labor and delivery admission,Dilation 2 cm or less at admission,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status, hospital",2,Non-Hispanic White,Hispanic,0.87,0.79,0.96
10.1097/AOG.0000000000000735,15,No,NA,Yes,patients at term with intact membranes and spontaneous intended labor with no previa and cervical dilation measured within 1 hour before or after labor and delivery admission,Dilation 2 cm or less at admission,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status, hospital",3,Non-Hispanic White,Asian,0.8,0.71,0.91
10.1097/AOG.0000000000000735,16,No,NA,Yes,patients who received oxytocin in labor,Maximum oxytocin 20 milliunits/min or greater,OR,NA,None,1,Non-Hispanic White,Non-Hispanic Black,1.19,1.13,1.25
10.1097/AOG.0000000000000735,16,No,NA,Yes,patients who received oxytocin in labor,Maximum oxytocin 20 milliunits/min or greater,OR,NA,None,2,Non-Hispanic White,Hispanic,0.96,0.91,1.01
10.1097/AOG.0000000000000735,16,No,NA,Yes,patients who received oxytocin in labor,Maximum oxytocin 20 milliunits/min or greater,OR,NA,None,3,Non-Hispanic White,Asian,0.67,0.6,0.75
10.1097/AOG.0000000000000735,17,No,NA,Yes,patients who received oxytocin in labor,Maximum oxytocin 20 milliunits/min or greater,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status",1,Non-Hispanic White,Non-Hispanic Black,0.97,0.91,1.03
10.1097/AOG.0000000000000735,17,No,NA,Yes,patients who received oxytocin in labor,Maximum oxytocin 20 milliunits/min or greater,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status",2,Non-Hispanic White,Hispanic,0.84,0.79,0.9
10.1097/AOG.0000000000000735,17,No,NA,Yes,patients who received oxytocin in labor,Maximum oxytocin 20 milliunits/min or greater,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status",3,Non-Hispanic White,Asian,0.73,0.65,0.81
10.1097/AOG.0000000000000735,18,No,NA,Yes,patients who received oxytocin in labor,Maximum oxytocin 20 milliunits/min or greater,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status, hospital",1,Non-Hispanic White,Non-Hispanic Black,0.9,0.84,0.96
10.1097/AOG.0000000000000735,18,No,NA,Yes,patients who received oxytocin in labor,Maximum oxytocin 20 milliunits/min or greater,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status, hospital",2,Non-Hispanic White,Hispanic,0.79,0.73,0.85
10.1097/AOG.0000000000000735,18,No,NA,Yes,patients who received oxytocin in labor,Maximum oxytocin 20 milliunits/min or greater,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status, hospital",3,Non-Hispanic White,Asian,0.8,0.71,0.9
10.1097/AOG.0000000000000735,19,No,NA,Yes,patients with spontaneous intended labor admitted to labor and delivery before delivery,80% or more of labor augmented with oxytocin,OR,NA,None,1,Non-Hispanic White,Non-Hispanic Black,0.9,0.84,0.96
10.1097/AOG.0000000000000735,19,No,NA,Yes,patients with spontaneous intended labor admitted to labor and delivery before delivery,80% or more of labor augmented with oxytocin,OR,NA,None,2,Non-Hispanic White,Hispanic,0.67,0.63,0.72
10.1097/AOG.0000000000000735,19,No,NA,Yes,patients with spontaneous intended labor admitted to labor and delivery before delivery,80% or more of labor augmented with oxytocin,OR,NA,None,3,Non-Hispanic White,Asian,0.92,0.82,1.02
10.1097/AOG.0000000000000735,20,No,NA,Yes,patients with spontaneous intended labor admitted to labor and delivery before delivery,80% or more of labor augmented with oxytocin,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status",1,Non-Hispanic White,Non-Hispanic Black,0.95,0.87,1.02
10.1097/AOG.0000000000000735,20,No,NA,Yes,patients with spontaneous intended labor admitted to labor and delivery before delivery,80% or more of labor augmented with oxytocin,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status",2,Non-Hispanic White,Hispanic,0.89,0.81,0.97
10.1097/AOG.0000000000000735,20,No,NA,Yes,patients with spontaneous intended labor admitted to labor and delivery before delivery,80% or more of labor augmented with oxytocin,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status",3,Non-Hispanic White,Asian,0.97,0.86,1.09
10.1097/AOG.0000000000000735,21,No,NA,Yes,patients with spontaneous intended labor admitted to labor and delivery before delivery,80% or more of labor augmented with oxytocin,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status, hospital",1,Non-Hispanic White,Non-Hispanic Black,0.91,0.84,1
10.1097/AOG.0000000000000735,21,No,NA,Yes,patients with spontaneous intended labor admitted to labor and delivery before delivery,80% or more of labor augmented with oxytocin,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status, hospital",2,Non-Hispanic White,Hispanic,0.91,0.83,1
10.1097/AOG.0000000000000735,21,No,NA,Yes,patients with spontaneous intended labor admitted to labor and delivery before delivery,80% or more of labor augmented with oxytocin,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status, hospital",3,Non-Hispanic White,Asian,1.11,0.98,1.26
10.1097/AOG.0000000000000735,22,No,NA,Yes,patients who reached complete dilation after intended labor,1 h or more between complete dilation and initiation of pushing,OR,NA,None,1,Non-Hispanic White,Non-Hispanic Black,0.51,0.47,0.55
10.1097/AOG.0000000000000735,22,No,NA,Yes,patients who reached complete dilation after intended labor,1 h or more between complete dilation and initiation of pushing,OR,NA,None,2,Non-Hispanic White,Hispanic,0.54,0.5,0.58
10.1097/AOG.0000000000000735,22,No,NA,Yes,patients who reached complete dilation after intended labor,1 h or more between complete dilation and initiation of pushing,OR,NA,None,3,Non-Hispanic White,Asian,1.34,1.21,1.49
10.1097/AOG.0000000000000735,23,No,NA,Yes,patients who reached complete dilation after intended labor,1 h or more between complete dilation and initiation of pushing,OR,NA,"age, diabetes mellitus, any hypertension, birth weight, prenatal care, obstetric history, multiple gestation, abruption, previa, accreta, anticoagulant use during pregnancy, insurance status",1,Non-Hispanic White,Non-Hispanic Black,0.67,0.61,0.74
10.1097/AOG.0000000000000735,23,No,NA,Yes,patients who reached complete dilation after intended labor,1 h or more between complete dilation and initiation of pushing,OR,NA,"age, diabetes mellitus, any hypertension, birth weight, prenatal care, obstetric history, multiple gestation, abruption, previa, accreta, anticoagulant use during pregnancy, insurance status",2,Non-Hispanic White,Hispanic,0.82,0.74,0.9
10.1097/AOG.0000000000000735,23,No,NA,Yes,patients who reached complete dilation after intended labor,1 h or more between complete dilation and initiation of pushing,OR,NA,"age, diabetes mellitus, any hypertension, birth weight, prenatal care, obstetric history, multiple gestation, abruption, previa, accreta, anticoagulant use during pregnancy, insurance status",3,Non-Hispanic White,Asian,1.23,1.1,1.37
10.1097/AOG.0000000000000735,24,No,NA,Yes,patients who reached complete dilation after intended labor,1 h or more between complete dilation and initiation of pushing,OR,NA,"age, diabetes mellitus, any hypertension, birth weight, prenatal care, obstetric history, multiple gestation, abruption, previa, accreta, anticoagulant use during pregnancy, insurance status, hospital",1,Non-Hispanic White,Non-Hispanic Black,0.85,0.76,0.94
10.1097/AOG.0000000000000735,24,No,NA,Yes,patients who reached complete dilation after intended labor,1 h or more between complete dilation and initiation of pushing,OR,NA,"age, diabetes mellitus, any hypertension, birth weight, prenatal care, obstetric history, multiple gestation, abruption, previa, accreta, anticoagulant use during pregnancy, insurance status, hospital",2,Non-Hispanic White,Hispanic,0.92,0.83,1.02
10.1097/AOG.0000000000000735,24,No,NA,Yes,patients who reached complete dilation after intended labor,1 h or more between complete dilation and initiation of pushing,OR,NA,"age, diabetes mellitus, any hypertension, birth weight, prenatal care, obstetric history, multiple gestation, abruption, previa, accreta, anticoagulant use during pregnancy, insurance status, hospital",3,Non-Hispanic White,Asian,1.13,1,1.27
10.1097/AOG.0000000000000735,25,No,NA,Yes,patients with intended labor managed in hospital for more than 1 hour during first stage,Less than 1 vaginal examination/every 3 h in 1st stage,OR,NA,None,1,Non-Hispanic White,Non-Hispanic Black,1.44,1.38,1.51
10.1097/AOG.0000000000000735,25,No,NA,Yes,patients with intended labor managed in hospital for more than 1 hour during first stage,Less than 1 vaginal examination/every 3 h in 1st stage,OR,NA,None,2,Non-Hispanic White,Hispanic,1.09,1.04,1.14
10.1097/AOG.0000000000000735,25,No,NA,Yes,patients with intended labor managed in hospital for more than 1 hour during first stage,Less than 1 vaginal examination/every 3 h in 1st stage,OR,NA,None,3,Non-Hispanic White,Asian,1.11,1.03,1.2
10.1097/AOG.0000000000000735,26,No,NA,Yes,patients with intended labor managed in hospital for more than 1 hour during first stage,Less than 1 vaginal examination/every 3 h in 1st stage,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status",1,Non-Hispanic White,Non-Hispanic Black,1.42,1.34,1.5
10.1097/AOG.0000000000000735,26,No,NA,Yes,patients with intended labor managed in hospital for more than 1 hour during first stage,Less than 1 vaginal examination/every 3 h in 1st stage,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status",2,Non-Hispanic White,Hispanic,1.3,1.22,1.38
10.1097/AOG.0000000000000735,26,No,NA,Yes,patients with intended labor managed in hospital for more than 1 hour during first stage,Less than 1 vaginal examination/every 3 h in 1st stage,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status",3,Non-Hispanic White,Asian,1.15,1.05,1.25
10.1097/AOG.0000000000000735,27,No,NA,Yes,patients with intended labor managed in hospital for more than 1 hour during first stage,Less than 1 vaginal examination/every 3 h in 1st stage,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status, hospital",1,Non-Hispanic White,Non-Hispanic Black,1.03,0.97,1.1
10.1097/AOG.0000000000000735,27,No,NA,Yes,patients with intended labor managed in hospital for more than 1 hour during first stage,Less than 1 vaginal examination/every 3 h in 1st stage,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status, hospital",2,Non-Hispanic White,Hispanic,0.81,0.76,0.86
10.1097/AOG.0000000000000735,27,No,NA,Yes,patients with intended labor managed in hospital for more than 1 hour during first stage,Less than 1 vaginal examination/every 3 h in 1st stage,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status, hospital",3,Non-Hispanic White,Asian,0.9,0.83,0.99
10.1097/AOG.0000000000000735,28,No,NA,No,NA,Vaginal delivery,OR,NA,None,1,Non-Hispanic White,Non-Hispanic Black,0.95,0.92,0.98
10.1097/AOG.0000000000000735,28,No,NA,No,NA,Vaginal delivery,OR,NA,None,2,Non-Hispanic White,Hispanic,1.1,1.07,1.14
10.1097/AOG.0000000000000735,28,No,NA,No,NA,Vaginal delivery,OR,NA,None,3,Non-Hispanic White,Asian,0.92,0.87,0.97
10.1097/AOG.0000000000000735,29,No,NA,No,NA,Vaginal delivery,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status",1,Non-Hispanic White,Non-Hispanic Black,0.84,0.8,0.88
10.1097/AOG.0000000000000735,29,No,NA,No,NA,Vaginal delivery,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status",2,Non-Hispanic White,Hispanic,0.96,0.91,1.01
10.1097/AOG.0000000000000735,29,No,NA,No,NA,Vaginal delivery,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status",3,Non-Hispanic White,Asian,0.83,0.78,0.89
10.1097/AOG.0000000000000735,30,No,NA,No,NA,Vaginal delivery,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status, hospital",1,Non-Hispanic White,Non-Hispanic Black,0.87,0.83,0.91
10.1097/AOG.0000000000000735,30,No,NA,No,NA,Vaginal delivery,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status, hospital",2,Non-Hispanic White,Hispanic,1.06,1.01,1.12
10.1097/AOG.0000000000000735,30,No,NA,No,NA,Vaginal delivery,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status, hospital",3,Non-Hispanic White,Asian,0.96,0.89,1.03
10.1097/AOG.0000000000000735,31,No,NA,Yes,patients with a vaginal delivery and no shoulder dystocia,Episiotomy,OR,NA,None,1,Non-Hispanic White,Non-Hispanic Black,0.33,0.3,0.36
10.1097/AOG.0000000000000735,31,No,NA,Yes,patients with a vaginal delivery and no shoulder dystocia,Episiotomy,OR,NA,None,2,Non-Hispanic White,Hispanic,0.36,0.33,0.38
10.1097/AOG.0000000000000735,31,No,NA,Yes,patients with a vaginal delivery and no shoulder dystocia,Episiotomy,OR,NA,None,3,Non-Hispanic White,Asian,2.02,1.86,2.19
10.1097/AOG.0000000000000735,32,No,NA,Yes,patients with a vaginal delivery and no shoulder dystocia,Episiotomy,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status",1,Non-Hispanic White,Non-Hispanic Black,0.49,0.45,0.54
10.1097/AOG.0000000000000735,32,No,NA,Yes,patients with a vaginal delivery and no shoulder dystocia,Episiotomy,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status",2,Non-Hispanic White,Hispanic,0.62,0.57,0.68
10.1097/AOG.0000000000000735,32,No,NA,Yes,patients with a vaginal delivery and no shoulder dystocia,Episiotomy,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status",3,Non-Hispanic White,Asian,1.78,1.63,1.94
10.1097/AOG.0000000000000735,33,No,NA,Yes,patients with a vaginal delivery and no shoulder dystocia,Episiotomy,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status, hospital",1,Non-Hispanic White,Non-Hispanic Black,0.62,0.56,0.68
10.1097/AOG.0000000000000735,33,No,NA,Yes,patients with a vaginal delivery and no shoulder dystocia,Episiotomy,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status, hospital",2,Non-Hispanic White,Hispanic,0.63,0.58,0.7
10.1097/AOG.0000000000000735,33,No,NA,Yes,patients with a vaginal delivery and no shoulder dystocia,Episiotomy,OR,NA,"age, body mass index at delivery, diabetes mellitus, premature rupture of membranes or preterm premature rupture of membranes, cigarette use during pregnancy, gestational age at delivery, obstetric history, group B streptococcus status, insurance status, hospital",3,Non-Hispanic White,Asian,1.39,1.26,1.54
10.1097/AOG.0000000000000735,34,No,NA,Yes,patients with a cesarean delivery,General anesthesia at cesarean delivery,OR,NA,None,1,Non-Hispanic White,Non-Hispanic Black,1.97,1.77,2.2
10.1097/AOG.0000000000000735,34,No,NA,Yes,patients with a cesarean delivery,General anesthesia at cesarean delivery,OR,NA,None,2,Non-Hispanic White,Hispanic,1.1,0.97,1.25
10.1097/AOG.0000000000000735,34,No,NA,Yes,patients with a cesarean delivery,General anesthesia at cesarean delivery,OR,NA,None,3,Non-Hispanic White,Asian,0.88,0.69,1.11
10.1097/AOG.0000000000000735,35,No,NA,Yes,patients with a cesarean delivery,General anesthesia at cesarean delivery,OR,NA,"age, diabetes mellitus, any hypertension, birth weight, prenatal care, obstetric history, multiple gestation, abruption, previa, accreta, anticoagulant use during pregnancy, insurance status",1,Non-Hispanic White,Non-Hispanic Black,1.41,1.24,1.61
10.1097/AOG.0000000000000735,35,No,NA,Yes,patients with a cesarean delivery,General anesthesia at cesarean delivery,OR,NA,"age, diabetes mellitus, any hypertension, birth weight, prenatal care, obstetric history, multiple gestation, abruption, previa, accreta, anticoagulant use during pregnancy, insurance status",2,Non-Hispanic White,Hispanic,0.95,0.81,1.1
10.1097/AOG.0000000000000735,35,No,NA,Yes,patients with a cesarean delivery,General anesthesia at cesarean delivery,OR,NA,"age, diabetes mellitus, any hypertension, birth weight, prenatal care, obstetric history, multiple gestation, abruption, previa, accreta, anticoagulant use during pregnancy, insurance status",3,Non-Hispanic White,Asian,1.05,0.82,1.34
10.1097/AOG.0000000000000735,36,No,NA,Yes,patients with a cesarean delivery,General anesthesia at cesarean delivery,OR,NA,"age, diabetes mellitus, any hypertension, birth weight, prenatal care, obstetric history, multiple gestation, abruption, previa, accreta, anticoagulant use during pregnancy, insurance status, hospital",1,Non-Hispanic White,Non-Hispanic Black,1.19,1.04,1.37
10.1097/AOG.0000000000000735,36,No,NA,Yes,patients with a cesarean delivery,General anesthesia at cesarean delivery,OR,NA,"age, diabetes mellitus, any hypertension, birth weight, prenatal care, obstetric history, multiple gestation, abruption, previa, accreta, anticoagulant use during pregnancy, insurance status, hospital",2,Non-Hispanic White,Hispanic,0.87,0.73,1.03
10.1097/AOG.0000000000000735,36,No,NA,Yes,patients with a cesarean delivery,General anesthesia at cesarean delivery,OR,NA,"age, diabetes mellitus, any hypertension, birth weight, prenatal care, obstetric history, multiple gestation, abruption, previa, accreta, anticoagulant use during pregnancy, insurance status, hospital",3,Non-Hispanic White,Asian,1.08,0.83,1.39
10.1097/AOG.0000000000000643,1,No,NA,No,NA,nonadherence to national comprehensive cancer network treatment guidelines,OR,NA,"age at diagnosis, socioeconomic status, charlsondeyo score, figo-ajcc stage, tumor histology, tumor differentiation, tumor size",1,White,Black,1.53,1.22,1.92
10.1097/AOG.0000000000000643,1,No,NA,No,NA,nonadherence to national comprehensive cancer network treatment guidelines,OR,NA,"age at diagnosis, socioeconomic status, charlsondeyo score, figo-ajcc stage, tumor histology, tumor differentiation, tumor size",2,White,Asian or Pacific Islander,1.11,0.79,1.55
10.1097/AOG.0000000000000643,1,No,NA,No,NA,nonadherence to national comprehensive cancer network treatment guidelines,OR,NA,"age at diagnosis, socioeconomic status, charlsondeyo score, figo-ajcc stage, tumor histology, tumor differentiation, tumor size",3,White,Hispanic,1.31,0.81,2.11
10.1097/AOG.0000000000000643,1,No,NA,No,NA,nonadherence to national comprehensive cancer network treatment guidelines,OR,NA,"age at diagnosis, socioeconomic status, charlsondeyo score, figo-ajcc stage, tumor histology, tumor differentiation, tumor size",4,White,Other or unknown,1.57,1.09,2.26
10.1097/AOG.0000000000000643,2,No,NA,No,NA,Ovarian Cancer-Specific Survival,HR,NA,"age at diagnosis, socioeconomic status quartile, Charlson-Deyo score, FIGO-AJCC stage, tumor histology, tumor differentiation, tumor size, adherence to NCCN guidelines",1,White,Black,0.95,0.86,1.05
10.1097/AOG.0000000000000643,2,No,NA,No,NA,Ovarian Cancer-Specific Survival,HR,NA,"age at diagnosis, socioeconomic status quartile, Charlson-Deyo score, FIGO-AJCC stage, tumor histology, tumor differentiation, tumor size, adherence to NCCN guidelines",2,White,Asian or Pacific Islander,0.94,0.8,1.12
10.1097/AOG.0000000000000643,2,No,NA,No,NA,Ovarian Cancer-Specific Survival,HR,NA,"age at diagnosis, socioeconomic status quartile, Charlson-Deyo score, FIGO-AJCC stage, tumor histology, tumor differentiation, tumor size, adherence to NCCN guidelines",3,White,Hispanic,1.02,0.81,1.28
10.1097/AOG.0000000000000643,2,No,NA,No,NA,Ovarian Cancer-Specific Survival,HR,NA,"age at diagnosis, socioeconomic status quartile, Charlson-Deyo score, FIGO-AJCC stage, tumor histology, tumor differentiation, tumor size, adherence to NCCN guidelines",4,White,Other or unknown,1.24,1.05,1.46
10.1097/AOG.0000000000000643,3,Yes,White,Yes,Propensity score-matched sample,Effect of Adherence and Nonadherence to National Comprehensive Cancer Network Treatment Guidelines on Ovarian Cancer–Specific Survival,HR,NA,"Age at Diagnosis, Charlson-Deyo Comorbidity Score, Tumor Stage, Histology, Grade, Size",1,Adherent,Nonadherent,1.59,1.48,1.71
10.1097/AOG.0000000000000643,4,Yes,Black,Yes,Propensity score-matched sample,Effect of Adherence and Nonadherence to National Comprehensive Cancer Network Treatment Guidelines on Ovarian Cancer–Specific Survival,HR,NA,"Age at Diagnosis, Charlson-Deyo Comorbidity Score, Tumor Stage, Histology, Grade, Size",1,Adherent,Nonadherent,1.66,1.19,2.3
10.1097/AOG.0000000000000643,5,Yes,Asian or Pacific Islander,Yes,Propensity score-matched sample,Effect of Adherence and Nonadherence to National Comprehensive Cancer Network Treatment Guidelines on Ovarian Cancer–Specific Survival,HR,NA,"Age at Diagnosis, Charlson-Deyo Comorbidity Score, Tumor Stage, Histology, Grade, Size",1,Adherent,Nonadherent,1.52,0.99,1.92
10.1097/AOG.0000000000000643,6,Yes,Hispanic,Yes,Propensity score-matched sample,Effect of Adherence and Nonadherence to National Comprehensive Cancer Network Treatment Guidelines on Ovarian Cancer–Specific Survival,HR,NA,"Age at Diagnosis, Charlson-Deyo Comorbidity Score, Tumor Stage, Histology, Grade, Size",1,Adherent,Nonadherent,1.91,0.98,3.72
10.1097/AOG.0000000000000643,7,Yes,White,Yes,Study population cohort,Effect of Adherence and Nonadherence to National Comprehensive Cancer Network Treatment Guidelines on Ovarian Cancer–Specific Survival,HR,NA,"Age at Diagnosis, Charlson-Deyo Comorbidity Score, Tumor Stage, Histology, Grade, Size",1,Adherent,Nonadherent,1.69,1.59,1.8
10.1097/AOG.0000000000000643,8,Yes,Black,Yes,Study population cohort,Effect of Adherence and Nonadherence to National Comprehensive Cancer Network Treatment Guidelines on Ovarian Cancer–Specific Survival,HR,NA,"Age at Diagnosis, Charlson-Deyo Comorbidity Score, Tumor Stage, Histology, Grade, Size",1,Adherent,Nonadherent,1.62,1.23,2.14
10.1097/AOG.0000000000000643,9,Yes,Asian or Pacific Islander,Yes,Study population cohort,Effect of Adherence and Nonadherence to National Comprehensive Cancer Network Treatment Guidelines on Ovarian Cancer–Specific Survival,HR,NA,"Age at Diagnosis, Charlson-Deyo Comorbidity Score, Tumor Stage, Histology, Grade, Size",1,Adherent,Nonadherent,1.76,1.12,2.76
10.1097/AOG.0000000000000643,10,Yes,Hispanic,Yes,Study population cohort,Effect of Adherence and Nonadherence to National Comprehensive Cancer Network Treatment Guidelines on Ovarian Cancer–Specific Survival,HR,NA,"Age at Diagnosis, Charlson-Deyo Comorbidity Score, Tumor Stage, Histology, Grade, Size",1,Adherent,Nonadherent,2.73,1.4,5.3
10.1097/AOG.0000000000000643,11,Yes,White,Yes,Propensity score-matched sample,Median Disease-Specific Survival Time,months,NA,None,1,N/A,Adherent,35,34,37
10.1097/AOG.0000000000000643,11,Yes,White,Yes,Propensity score-matched sample,Median Disease-Specific Survival Time,months,NA,None,2,N/A,Nonadherent,20,18,22
10.1097/AOG.0000000000000643,12,Yes,Black,Yes,Propensity score-matched sample,Median Disease-Specific Survival Time,months,NA,None,1,N/A,Adherent,38,28,47
10.1097/AOG.0000000000000643,12,Yes,Black,Yes,Propensity score-matched sample,Median Disease-Specific Survival Time,months,NA,None,2,N/A,Nonadherent,18,8,29
10.1097/AOG.0000000000000643,13,Yes,Asian or Pacific Islander,Yes,Propensity score-matched sample,Median Disease-Specific Survival Time,months,NA,None,1,N/A,Adherent,39,23,59
10.1097/AOG.0000000000000643,13,Yes,Asian or Pacific Islander,Yes,Propensity score-matched sample,Median Disease-Specific Survival Time,months,NA,None,2,N/A,Nonadherent,31,11,42
10.1097/AOG.0000000000000643,14,Yes,Hispanic,Yes,Propensity score-matched sample,Median Disease-Specific Survival Time,months,NA,None,1,N/A,Adherent,35,24,85
10.1097/AOG.0000000000000643,14,Yes,Hispanic,Yes,Propensity score-matched sample,Median Disease-Specific Survival Time,months,NA,None,2,N/A,Nonadherent,14,5,70
10.1097/AOG.0000000000000643,15,Yes,White,Yes,Study population cohort,Median Disease-Specific Survival Time,months,NA,None,1,N/A,Adherent,36,35,38
10.1097/AOG.0000000000000643,15,Yes,White,Yes,Study population cohort,Median Disease-Specific Survival Time,months,NA,None,2,N/A,Nonadherent,10,9,10
10.1097/AOG.0000000000000643,16,Yes,Black,Yes,Study population cohort,Median Disease-Specific Survival Time,months,NA,None,1,N/A,Adherent,32,25,46
10.1097/AOG.0000000000000643,16,Yes,Black,Yes,Study population cohort,Median Disease-Specific Survival Time,months,NA,None,2,N/A,Nonadherent,8,1,10
10.1097/AOG.0000000000000643,17,Yes,Asian or Pacific Islander,Yes,Study population cohort,Median Disease-Specific Survival Time,months,NA,None,1,N/A,Adherent,42,32,61
10.1097/AOG.0000000000000643,17,Yes,Asian or Pacific Islander,Yes,Study population cohort,Median Disease-Specific Survival Time,months,NA,None,2,N/A,Nonadherent,8,6,17
10.1097/AOG.0000000000000643,18,Yes,Asian or Pacific Islander,Yes,Study population cohort,Median Disease-Specific Survival Time,months,NA,None,1,N/A,Adherent,31,24,85
10.1097/AOG.0000000000000643,18,Yes,Asian or Pacific Islander,Yes,Study population cohort,Median Disease-Specific Survival Time,months,NA,None,2,N/A,Nonadherent,9,5,14
10.1016/j.fertnstert.2014.08.031,1,Yes,Arizona,No,NA,Ectopic Pregnancy,RR,NA,None,1,White,Black,1.41,1.36,1.47
10.1016/j.fertnstert.2014.08.031,1,Yes,Arizona,No,NA,Ectopic Pregnancy,RR,NA,None,2,White,American Indian/Alaskan Native,0.45,0.42,0.47
10.1016/j.fertnstert.2014.08.031,1,Yes,Arizona,No,NA,Ectopic Pregnancy,RR,NA,None,3,White,Asian,0.66,0.6,0.74
10.1016/j.fertnstert.2014.08.031,1,Yes,Arizona,No,NA,Ectopic Pregnancy,RR,NA,None,4,White,Hispanic,0.67,0.65,0.69
10.1016/j.fertnstert.2014.08.031,2,Yes,California,No,NA,Ectopic Pregnancy,RR,NA,None,1,White,Black,1.47,1.45,1.49
10.1016/j.fertnstert.2014.08.031,2,Yes,California,No,NA,Ectopic Pregnancy,RR,NA,None,2,White,American Indian/Alaskan Native,0.94,0.88,1
10.1016/j.fertnstert.2014.08.031,2,Yes,California,No,NA,Ectopic Pregnancy,RR,NA,None,3,White,Asian,0.61,0.59,0.63
10.1016/j.fertnstert.2014.08.031,2,Yes,California,No,NA,Ectopic Pregnancy,RR,NA,None,4,White,Hispanic,0.79,0.78,0.8
10.1016/j.fertnstert.2014.08.031,2,Yes,California,No,NA,Ectopic Pregnancy,RR,NA,None,5,White,Native Hawaiian/Pacific Islander,0.62,0.6,0.65
10.1016/j.fertnstert.2014.08.031,3,Yes,Colorado,No,NA,Ectopic Pregnancy,RR,NA,None,1,White,Black,1.42,1.3,1.54
10.1016/j.fertnstert.2014.08.031,3,Yes,Colorado,No,NA,Ectopic Pregnancy,RR,NA,None,2,White,American Indian/Alaskan Native,1.01,0.81,1.25
10.1016/j.fertnstert.2014.08.031,3,Yes,Colorado,No,NA,Ectopic Pregnancy,RR,NA,None,3,White,Asian,0.43,0.33,0.55
10.1016/j.fertnstert.2014.08.031,3,Yes,Colorado,No,NA,Ectopic Pregnancy,RR,NA,None,4,White,Hispanic,0.78,0.74,0.82
10.1016/j.fertnstert.2014.08.031,3,Yes,Colorado,No,NA,Ectopic Pregnancy,RR,NA,None,5,White,Native Hawaiian/Pacific Islander,0.74,0.48,1.14
10.1016/j.fertnstert.2014.08.031,4,Yes,Florida,No,NA,Ectopic Pregnancy,RR,NA,None,1,White,Black,1.39,1.36,1.41
10.1016/j.fertnstert.2014.08.031,4,Yes,Florida,No,NA,Ectopic Pregnancy,RR,NA,None,2,White,American Indian/Alaskan Native,1.36,1.16,1.59
10.1016/j.fertnstert.2014.08.031,4,Yes,Florida,No,NA,Ectopic Pregnancy,RR,NA,None,3,White,Asian,0.58,0.54,0.63
10.1016/j.fertnstert.2014.08.031,4,Yes,Florida,No,NA,Ectopic Pregnancy,RR,NA,None,4,White,Hispanic,0.97,0.95,0.99
10.1016/j.fertnstert.2014.08.031,5,Yes,Iowa,No,NA,Ectopic Pregnancy,RR,NA,None,1,White,Black,1.46,1.37,1.56
10.1016/j.fertnstert.2014.08.031,5,Yes,Iowa,No,NA,Ectopic Pregnancy,RR,NA,None,2,White,American Indian/Alaskan Native,0.79,0.6,1.04
10.1016/j.fertnstert.2014.08.031,5,Yes,Iowa,No,NA,Ectopic Pregnancy,RR,NA,None,3,White,Asian,0.73,0.58,0.93
10.1016/j.fertnstert.2014.08.031,5,Yes,Iowa,No,NA,Ectopic Pregnancy,RR,NA,None,4,White,Hispanic,0.54,0.49,0.58
10.1016/j.fertnstert.2014.08.031,6,Yes,Illinois,No,NA,Ectopic Pregnancy,RR,NA,None,1,White,Black,1.95,1.91,2
10.1016/j.fertnstert.2014.08.031,6,Yes,Illinois,No,NA,Ectopic Pregnancy,RR,NA,None,2,White,American Indian/Alaskan Native,0.74,0.52,1.04
10.1016/j.fertnstert.2014.08.031,6,Yes,Illinois,No,NA,Ectopic Pregnancy,RR,NA,None,3,White,Asian,0.87,0.8,0.96
10.1016/j.fertnstert.2014.08.031,6,Yes,Illinois,No,NA,Ectopic Pregnancy,RR,NA,None,4,White,Hispanic,1.35,1.31,1.39
10.1016/j.fertnstert.2014.08.031,6,Yes,Illinois,No,NA,Ectopic Pregnancy,RR,NA,None,5,White,Native Hawaiian/Pacific Islander,1.43,1.05,1.97
10.1016/j.fertnstert.2014.08.031,7,Yes,Indiana,No,NA,Ectopic Pregnancy,RR,NA,None,1,White,Black,1.56,1.52,1.61
10.1016/j.fertnstert.2014.08.031,7,Yes,Indiana,No,NA,Ectopic Pregnancy,RR,NA,None,2,White,American Indian/Alaskan Native,1.96,1.32,2.88
10.1016/j.fertnstert.2014.08.031,7,Yes,Indiana,No,NA,Ectopic Pregnancy,RR,NA,None,3,White,Asian,0.55,0.46,0.66
10.1016/j.fertnstert.2014.08.031,7,Yes,Indiana,No,NA,Ectopic Pregnancy,RR,NA,None,4,White,Hispanic,0.49,0.46,0.51
10.1016/j.fertnstert.2014.08.031,8,Yes,Louisiana,No,NA,Ectopic Pregnancy,RR,NA,None,1,White,Black,1.65,1.6,1.69
10.1016/j.fertnstert.2014.08.031,8,Yes,Louisiana,No,NA,Ectopic Pregnancy,RR,NA,None,2,White,American Indian/Alaskan Native,1.08,0.88,1.34
10.1016/j.fertnstert.2014.08.031,8,Yes,Louisiana,No,NA,Ectopic Pregnancy,RR,NA,None,3,White,Asian,0.81,0.69,0.95
10.1016/j.fertnstert.2014.08.031,8,Yes,Louisiana,No,NA,Ectopic Pregnancy,RR,NA,None,4,White,Hispanic,0.72,0.65,0.81
10.1016/j.fertnstert.2014.08.031,8,Yes,Louisiana,No,NA,Ectopic Pregnancy,RR,NA,None,5,White,Native Hawaiian/Pacific Islander,0.71,0.34,1.51
10.1016/j.fertnstert.2014.08.031,9,Yes,Massachusetts,No,NA,Ectopic Pregnancy,RR,NA,None,1,White,Black,1.25,1.19,1.32
10.1016/j.fertnstert.2014.08.031,9,Yes,Massachusetts,No,NA,Ectopic Pregnancy,RR,NA,None,2,White,American Indian/Alaskan Native,0.86,0.56,1.31
10.1016/j.fertnstert.2014.08.031,9,Yes,Massachusetts,No,NA,Ectopic Pregnancy,RR,NA,None,3,White,Asian,0.77,0.69,0.84
10.1016/j.fertnstert.2014.08.031,9,Yes,Massachusetts,No,NA,Ectopic Pregnancy,RR,NA,None,4,White,Hispanic,1.04,0.88,1.09
10.1016/j.fertnstert.2014.08.031,10,Yes,Michigan,No,NA,Ectopic Pregnancy,RR,NA,None,1,White,Black,1.43,1.4,1.47
10.1016/j.fertnstert.2014.08.031,10,Yes,Michigan,No,NA,Ectopic Pregnancy,RR,NA,None,2,White,American Indian/Alaskan Native,0.59,0.5,0.71
10.1016/j.fertnstert.2014.08.031,10,Yes,Michigan,No,NA,Ectopic Pregnancy,RR,NA,None,3,White,Asian,0.88,0.79,0.97
10.1016/j.fertnstert.2014.08.031,10,Yes,Michigan,No,NA,Ectopic Pregnancy,RR,NA,None,4,White,Hispanic,0.98,0.93,1.03
10.1016/j.fertnstert.2014.08.031,11,Yes,Minnesota,No,NA,Ectopic Pregnancy,RR,NA,None,1,White,Black,1.46,1.41,1.51
10.1016/j.fertnstert.2014.08.031,11,Yes,Minnesota,No,NA,Ectopic Pregnancy,RR,NA,None,2,White,American Indian/Alaskan Native,1.04,0.96,1.12
10.1016/j.fertnstert.2014.08.031,11,Yes,Minnesota,No,NA,Ectopic Pregnancy,RR,NA,None,3,White,Asian,0.72,0.66,0.78
10.1016/j.fertnstert.2014.08.031,11,Yes,Minnesota,No,NA,Ectopic Pregnancy,RR,NA,None,4,White,Hispanic,1.06,1,1.13
10.1016/j.fertnstert.2014.08.031,12,Yes,Mississippi,No,NA,Ectopic Pregnancy,RR,NA,None,1,White,Black,1.51,1.46,1.56
10.1016/j.fertnstert.2014.08.031,12,Yes,Mississippi,No,NA,Ectopic Pregnancy,RR,NA,None,2,White,American Indian/Alaskan Native,1.54,1.31,1.81
10.1016/j.fertnstert.2014.08.031,12,Yes,Mississippi,No,NA,Ectopic Pregnancy,RR,NA,None,3,White,Asian,0.46,0.33,0.65
10.1016/j.fertnstert.2014.08.031,12,Yes,Mississippi,No,NA,Ectopic Pregnancy,RR,NA,None,4,White,Hispanic,0.64,0.55,0.75
10.1016/j.fertnstert.2014.08.031,13,Yes,New York,No,NA,Ectopic Pregnancy,RR,NA,None,1,White,Black,1.52,1.5,1.55
10.1016/j.fertnstert.2014.08.031,13,Yes,New York,No,NA,Ectopic Pregnancy,RR,NA,None,2,White,American Indian/Alaskan Native,0.81,0.75,0.89
10.1016/j.fertnstert.2014.08.031,13,Yes,New York,No,NA,Ectopic Pregnancy,RR,NA,None,3,White,Asian,1.01,0.98,1.04
10.1016/j.fertnstert.2014.08.031,13,Yes,New York,No,NA,Ectopic Pregnancy,RR,NA,None,4,White,Hispanic,1.21,1.19,1.23
10.1016/j.fertnstert.2014.08.031,13,Yes,New York,No,NA,Ectopic Pregnancy,RR,NA,None,5,White,Native Hawaiian/Pacific Islander,1.05,0.94,1.18
10.1016/j.fertnstert.2014.08.031,14,Yes,Texas,No,NA,Ectopic Pregnancy,RR,NA,None,1,White,Black,1.33,1.31,1.35
10.1016/j.fertnstert.2014.08.031,14,Yes,Texas,No,NA,Ectopic Pregnancy,RR,NA,None,2,White,American Indian/Alaskan Native,0.89,0.81,0.97
10.1016/j.fertnstert.2014.08.031,14,Yes,Texas,No,NA,Ectopic Pregnancy,RR,NA,None,3,White,Asian,0.72,0.68,0.76
10.1016/j.fertnstert.2014.08.031,14,Yes,Texas,No,NA,Ectopic Pregnancy,RR,NA,None,4,White,Hispanic,0.69,0.68,0.69
10.1016/j.fertnstert.2014.08.031,15,No,NA,No,NA,Ectopic Pregnancy,RR,NA,None,1,White,Black,1.46,1.45,1.47
10.1016/j.fertnstert.2014.08.031,15,No,NA,No,NA,Ectopic Pregnancy,RR,NA,None,2,White,American Indian/Alaskan Native,0.72,0.7,0.74
10.1016/j.fertnstert.2014.08.031,15,No,NA,No,NA,Ectopic Pregnancy,RR,NA,None,3,White,Asian,0.86,0.84,0.87
10.1016/j.fertnstert.2014.08.031,15,No,NA,No,NA,Ectopic Pregnancy,RR,NA,None,4,White,Hispanic,0.95,0.94,0.95
10.1016/j.fertnstert.2014.08.031,15,No,NA,No,NA,Ectopic Pregnancy,RR,NA,None,5,White,Native Hawaiian/Pacific Islander,0.92,0.9,0.95
10.1016/j.ajog.2014.02.014,1,No,NA,No,NA,Unplanned cesarean delivery,OR,NA,None,1,White,African American,1,0.8,1.3
10.1016/j.ajog.2014.02.014,1,No,NA,No,NA,Unplanned cesarean delivery,OR,NA,None,2,White,Hispanic,0.8,0.5,1.2
10.1016/j.ajog.2014.02.014,1,No,NA,No,NA,Unplanned cesarean delivery,OR,NA,None,3,White,Asian,1.1,0.6,2
10.1016/j.ajog.2014.02.014,1,No,NA,No,NA,Unplanned cesarean delivery,OR,NA,None,4,White,Other,1.3,0.7,2.2
10.1016/j.ajog.2014.02.014,2,No,NA,No,NA,Unplanned cesarean delivery,OR,NA,"gestational age, parity, age, body mass index, clinical sites, induction of labor, education",1,White,African American,0.9,0.5,1.4
10.1016/j.ajog.2014.02.014,2,No,NA,No,NA,Unplanned cesarean delivery,OR,NA,"gestational age, parity, age, body mass index, clinical sites, induction of labor, education",2,White,Hispanic,0.7,0.4,1.3
10.1016/j.ajog.2014.02.014,2,No,NA,No,NA,Unplanned cesarean delivery,OR,NA,"gestational age, parity, age, body mass index, clinical sites, induction of labor, education",3,White,Asian,1.7,0.6,4.3
10.1016/j.ajog.2014.02.014,2,No,NA,No,NA,Unplanned cesarean delivery,OR,NA,"gestational age, parity, age, body mass index, clinical sites, induction of labor, education",4,White,Other,1.2,0.4,2.9
10.1016/j.ajog.2014.02.014,3,No,NA,No,NA,Vaginal delivery,OR,NA,None,1,White,African American,1.1,1,1.3
10.1016/j.ajog.2014.02.014,3,No,NA,No,NA,Vaginal delivery,OR,NA,None,2,White,Hispanic,1.1,0.9,1.2
10.1016/j.ajog.2014.02.014,3,No,NA,No,NA,Vaginal delivery,OR,NA,None,3,White,Asian,0.8,0.5,1.2
10.1016/j.ajog.2014.02.014,3,No,NA,No,NA,Vaginal delivery,OR,NA,None,4,White,Other,0.9,0.6,1.3
10.1016/j.ajog.2014.02.014,4,No,NA,No,NA,Vaginal delivery,OR,NA,"gestational age, parity, age, body mass index, clinical sites, induction of labor, education",1,White,African American,1.2,0.8,2
10.1016/j.ajog.2014.02.014,4,No,NA,No,NA,Vaginal delivery,OR,NA,"gestational age, parity, age, body mass index, clinical sites, induction of labor, education",2,White,Hispanic,1.5,0.8,2.6
10.1016/j.ajog.2014.02.014,4,No,NA,No,NA,Vaginal delivery,OR,NA,"gestational age, parity, age, body mass index, clinical sites, induction of labor, education",3,White,Asian,0.8,0.3,2.1
10.1016/j.ajog.2014.02.014,4,No,NA,No,NA,Vaginal delivery,OR,NA,"gestational age, parity, age, body mass index, clinical sites, induction of labor, education",4,White,Other,0.7,0.3,1.6
10.1016/j.ajog.2014.02.014,5,No,NA,No,NA,Combined delivery,OR,NA,None,1,White,African American,1.3,0.8,2.1
10.1016/j.ajog.2014.02.014,5,No,NA,No,NA,Combined delivery,OR,NA,None,2,White,Hispanic,0.6,0.2,1.4
10.1016/j.ajog.2014.02.014,5,No,NA,No,NA,Combined delivery,OR,NA,None,3,White,Other,1.5,0.5,4.6
10.1016/j.ajog.2014.02.014,6,No,NA,No,NA,Combined delivery,OR,NA,"gestational age, parity, age, body mass index, clinical sites, induction of labor, education",1,White,African American,0.9,0.4,1.9
10.1016/j.ajog.2014.02.014,6,No,NA,No,NA,Combined delivery,OR,NA,"gestational age, parity, age, body mass index, clinical sites, induction of labor, education",2,White,Hispanic,0.8,0.3,2.4
10.1016/j.ajog.2014.02.014,6,No,NA,No,NA,Combined delivery,OR,NA,"gestational age, parity, age, body mass index, clinical sites, induction of labor, education",3,White,Other,2,0.5,7.8
10.1016/j.ajog.2014.02.014,7,No,NA,No,NA,Elective cesarean delivery,OR,NA,None,1,White,African American,0.5,0.3,0.8
10.1016/j.ajog.2014.02.014,7,No,NA,No,NA,Elective cesarean delivery,OR,NA,None,2,White,Hispanic,1.3,0.9,1.9
10.1016/j.ajog.2014.02.014,7,No,NA,No,NA,Elective cesarean delivery,OR,NA,None,3,White,Asian,2,1.2,3.4
10.1016/j.ajog.2014.02.014,7,No,NA,No,NA,Elective cesarean delivery,OR,NA,None,4,White,Other,0.6,0.2,1.8
10.1016/j.ajog.2014.02.014,8,No,NA,No,NA,Elective cesarean delivery,OR,NA,"gestational age, parity, age, body mass index, clinical sites, induction of labor, education",1,White,African American,0.7,0.3,0.9
10.1016/j.ajog.2014.02.014,8,No,NA,No,NA,Elective cesarean delivery,OR,NA,"gestational age, parity, age, body mass index, clinical sites, induction of labor, education",2,White,Hispanic,2.1,0.9,3.6
10.1016/j.ajog.2014.02.014,8,No,NA,No,NA,Elective cesarean delivery,OR,NA,"gestational age, parity, age, body mass index, clinical sites, induction of labor, education",3,White,Asian,2.7,1.1,6.2
10.1016/j.ajog.2014.02.014,8,No,NA,No,NA,Elective cesarean delivery,OR,NA,"gestational age, parity, age, body mass index, clinical sites, induction of labor, education",4,White,Other,0.9,0.3,3.4
10.1016/j.ajog.2014.02.014,9,No,NA,No,NA,Postpartum hemorrhage,OR,NA,None,1,White,African American,1.6,0.8,3
10.1016/j.ajog.2014.02.014,9,No,NA,No,NA,Postpartum hemorrhage,OR,NA,None,2,White,Hispanic,1.5,0.7,3.6
10.1016/j.ajog.2014.02.014,9,No,NA,No,NA,Postpartum hemorrhage,OR,NA,None,3,White,Asian,0.9,0.1,6.7
10.1016/j.ajog.2014.02.014,9,No,NA,No,NA,Postpartum hemorrhage,OR,NA,None,4,White,Other,1.9,0.5,7.8
10.1016/j.ajog.2014.02.014,10,No,NA,No,NA,Blood transfusion,OR,NA,None,1,White,African American,0.7,0.2,2.8
10.1016/j.ajog.2014.02.014,10,No,NA,No,NA,Blood transfusion,OR,NA,None,2,White,Hispanic,1.6,0.4,5.8
10.1016/j.ajog.2014.02.014,11,No,NA,No,NA,NICU admission 32-36 wks,OR,NA,None,1,White,African American,0.5,0.3,1
10.1016/j.ajog.2014.02.014,11,No,NA,No,NA,NICU admission 32-36 wks,OR,NA,None,2,White,Hispanic,0.9,0.8,1.1
10.1016/j.ajog.2014.02.014,11,No,NA,No,NA,NICU admission 32-36 wks,OR,NA,None,3,White,Asian,0.8,0.7,1.1
10.1016/j.ajog.2014.02.014,11,No,NA,No,NA,NICU admission 32-36 wks,OR,NA,None,4,White,Other,0.6,0.3,1
10.1016/j.ajog.2014.02.014,12,No,NA,No,NA,NICU >= 37 wks,OR,NA,None,1,White,African American,1.2,0.8,1.9
10.1016/j.ajog.2014.02.014,12,No,NA,No,NA,NICU >= 37 wks,OR,NA,None,2,White,Hispanic,0.7,0.3,1.5
10.1016/j.ajog.2014.02.014,12,No,NA,No,NA,NICU >= 37 wks,OR,NA,None,3,White,Asian,1.9,0.9,4.2
10.1016/j.ajog.2014.02.014,12,No,NA,No,NA,NICU >= 37 wks,OR,NA,None,4,White,Other,2.2,1.1,4.6
10.1016/j.ygyno.2014.02.006,1,No,NA,No,NA,national comprehensive cancer network adherent care,Percent,NA,None,1,N/A,Black,12.8,-99,-99
10.1016/j.ygyno.2014.02.006,1,No,NA,No,NA,national comprehensive cancer network adherent care,Percent,NA,None,2,N/A,White,85.8,-99,-99
10.1016/j.ygyno.2014.02.006,1,No,NA,No,NA,national comprehensive cancer network adherent care,Percent,NA,None,3,N/A,Other,1.4,-99,-99
10.1016/j.ygyno.2014.02.006,2,No,NA,No,NA,national comprehensive cancer network nonadherent care,Percent,NA,None,1,N/A,Black,21.5,-99,-99
10.1016/j.ygyno.2014.02.006,2,No,NA,No,NA,national comprehensive cancer network nonadherent care,Percent,NA,None,2,N/A,White,77.2,-99,-99
10.1016/j.ygyno.2014.02.006,2,No,NA,No,NA,national comprehensive cancer network nonadherent care,Percent,NA,None,3,N/A,Other,1.3,-99,-99
10.1016/j.ygyno.2014.01.013,13,Yes,Yes,No,NA,Wound infection,Percent,NA,None,1,N/A,White,16.5,-99,-99
10.1016/j.ygyno.2014.01.013,13,Yes,Yes,No,NA,Wound infection,Percent,NA,None,2,N/A,Black,14.4,-99,-99
10.1016/j.ygyno.2014.01.013,14,Yes,No,No,NA,Vaginal or pelvic infection,Percent,NA,None,1,N/A,White,97.9,-99,-99
10.1016/j.ygyno.2014.01.013,14,Yes,No,No,NA,Vaginal or pelvic infection,Percent,NA,None,2,N/A,Black,87.6,-99,-99
10.1016/j.ygyno.2014.01.013,15,Yes,Yes,No,NA,Vaginal or pelvic infection,Percent,NA,None,1,N/A,White,2.1,-99,-99
10.1016/j.ygyno.2014.01.013,15,Yes,Yes,No,NA,Vaginal or pelvic infection,Percent,NA,None,2,N/A,Black,4.1,-99,-99
10.1016/j.ygyno.2014.01.013,16,Yes,No,No,NA,Sepsis or other infection,Percent,NA,None,1,N/A,White,97.9,-99,-99
10.1016/j.ygyno.2014.01.013,16,Yes,No,No,NA,Sepsis or other infection,Percent,NA,None,2,N/A,Black,90.7,-99,-99
10.1016/j.ygyno.2014.01.013,17,Yes,Yes,No,NA,Sepsis or other infection,Percent,NA,None,1,N/A,White,2.1,-99,-99
10.1016/j.ygyno.2014.01.013,17,Yes,Yes,No,NA,Sepsis or other infection,Percent,NA,None,2,N/A,Black,1,-99,-99
10.1016/j.ygyno.2014.01.013,18,Yes,No,No,NA,Anemia or hemorrhage,Percent,NA,None,1,N/A,White,97.9,-99,-99
10.1016/j.ygyno.2014.01.013,18,Yes,No,No,NA,Anemia or hemorrhage,Percent,NA,None,2,N/A,Black,87.6,-99,-99
10.1016/j.ygyno.2014.01.013,19,Yes,Yes,No,NA,Anemia or hemorrhage,Percent,NA,None,1,N/A,White,2.1,-99,-99
10.1016/j.ygyno.2014.01.013,19,Yes,Yes,No,NA,Anemia or hemorrhage,Percent,NA,None,2,N/A,Black,4.1,-99,-99
10.1016/j.ygyno.2014.01.013,20,Yes,No,No,NA,Thromboembolism,Percent,NA,None,1,N/A,White,99,-99,-99
10.1016/j.ygyno.2014.01.013,20,Yes,No,No,NA,Thromboembolism,Percent,NA,None,2,N/A,Black,88.7,-99,-99
10.1016/j.ygyno.2014.01.013,21,Yes,Yes,No,NA,Thromboembolism,Percent,NA,None,1,N/A,White,1,-99,-99
10.1016/j.ygyno.2014.01.013,21,Yes,Yes,No,NA,Thromboembolism,Percent,NA,None,2,N/A,Black,3.1,-99,-99
10.1016/j.ygyno.2014.01.013,22,Yes,No,No,NA,Heart failure or MI,Percent,NA,None,1,N/A,White,100,-99,-99
10.1016/j.ygyno.2014.01.013,22,Yes,No,No,NA,Heart failure or MI,Percent,NA,None,2,N/A,Black,88.7,-99,-99
10.1016/j.ygyno.2014.01.013,23,Yes,Yes,No,NA,Heart failure or MI,Percent,NA,None,1,N/A,White,0,-99,-99
10.1016/j.ygyno.2014.01.013,23,Yes,Yes,No,NA,Heart failure or MI,Percent,NA,None,2,N/A,Black,3.1,-99,-99
10.1016/j.ygyno.2014.01.013,24,Yes,No,No,NA,Pulmonary,Percent,NA,None,1,N/A,White,96.9,-99,-99
10.1016/j.ygyno.2014.01.013,24,Yes,No,No,NA,Pulmonary,Percent,NA,None,2,N/A,Black,87.6,-99,-99
10.1016/j.ygyno.2014.01.013,25,Yes,Yes,No,NA,Pulmonary,Percent,NA,None,1,N/A,White,3.1,-99,-99
10.1016/j.ygyno.2014.01.013,25,Yes,Yes,No,NA,Pulmonary,Percent,NA,None,2,N/A,Black,4.1,-99,-99
10.1016/j.ygyno.2014.01.013,26,Yes,No,No,NA,Gastrointestinal,Percent,NA,None,1,N/A,White,96.9,-99,-99
10.1016/j.ygyno.2014.01.013,26,Yes,No,No,NA,Gastrointestinal,Percent,NA,None,2,N/A,Black,86.6,-99,-99
10.1016/j.ygyno.2014.01.013,27,Yes,Yes,No,NA,Gastrointestinal,Percent,NA,None,1,N/A,White,3.1,-99,-99
10.1016/j.ygyno.2014.01.013,27,Yes,Yes,No,NA,Gastrointestinal,Percent,NA,None,2,N/A,Black,5.2,-99,-99
10.1016/j.ygyno.2014.01.013,28,Yes,No,No,NA,Acute renal failure or insufficiency,Percent,NA,None,1,N/A,White,96.9,-99,-99
10.1016/j.ygyno.2014.01.013,28,Yes,No,No,NA,Acute renal failure or insufficiency,Percent,NA,None,2,N/A,Black,87.6,-99,-99
10.1016/j.ygyno.2014.01.013,29,Yes,Yes,No,NA,Acute renal failure or insufficiency,Percent,NA,None,1,N/A,White,3.1,-99,-99
10.1016/j.ygyno.2014.01.013,29,Yes,Yes,No,NA,Acute renal failure or insufficiency,Percent,NA,None,2,N/A,Black,4.1,-99,-99
10.1016/j.ygyno.2014.01.013,30,No,NA,No,NA,Death from any cause,HR,NA,None,1,White,Black,1.77,0.9,3.46
10.1016/j.ygyno.2014.01.013,32,No,NA,No,NA,Death from any cause,HR,NA,"age, histology type, FIGO stage, FIGO grade, surgery type, chemotherapy, and radiation therapy",1,White,Black,1.35,0.62,2.95
10.1016/j.ygyno.2014.01.013,33,No,NA,No,NA,Death from any cause,HR,NA,"age, histology type, FIGO stage, FIGO grade, surgery type, chemotherapy, radiation therapy, BMI, hypertension, diabetes, and the occurrence of any surgical complication",1,White,Black,0.85,0.36,2.03
10.1016/j.ygyno.2014.01.013,34,No,NA,No,NA,Death from endometrial cancer,HR,NA,None,1,White,Black,2.17,0.87,5.44
10.1016/j.ygyno.2014.01.013,35,No,NA,No,NA,Death from endometrial cancer,HR,NA,"age, histology type, FIGO stage, and FIGO grade",1,White,Black,1.44,0.5,4.17
10.1016/j.ygyno.2014.01.013,36,No,NA,No,NA,Death from endometrial cancer,HR,NA,"age, histology type, FIGO stage, FIGO grade, surgery type, chemotherapy, and radiation therapy",1,White,Black,1.49,0.49,4.51
10.1016/j.ygyno.2014.01.013,37,No,NA,No,NA,Death from endometrial cancer,HR,NA,"age, histology type, FIGO stage, FIGO grade, surgery type, chemotherapy, radiation therapy, BMI, hypertension, diabetes, and the occurrence of any surgical complication",1,White,Black,0.95,0.26,3.52
10.1016/j.ygyno.2014.01.013,38,No,NA,No,NA,Death from other causes,HR,NA,None,1,White,Black,1.38,0.51,3.71
10.1016/j.ygyno.2014.01.013,39,No,NA,No,NA,Death from other causes,HR,NA,"age, histology type, FIGO stage, and FIGO grade",1,White,Black,0.95,0.31,2.92
10.1016/j.ygyno.2014.01.013,40,No,NA,No,NA,Death from other causes,HR,NA,"age, histology type, FIGO stage, FIGO grade, surgery type, chemotherapy, and radiation therapy",1,White,Black,1.06,0.33,3.4
10.1016/j.ygyno.2014.01.013,41,No,NA,No,NA,Death from other causes,HR,NA,"age, histology type, FIGO stage, FIGO grade, surgery type, chemotherapy, radiation therapy, BMI, hypertension, diabetes, and the occurrence of any surgical complication",1,White,Black,0.51,0.14,1.82
10.1016/j.ygyno.2013.08.035,1,Yes,White,No,NA,Insurance coverage,Percent,NA,None,1,N/A,Private,51.7,-99,-99
10.1016/j.ygyno.2013.08.035,1,Yes,White,No,NA,Insurance coverage,Percent,NA,None,2,N/A,Medicare/other govt,39.7,-99,-99
10.1016/j.ygyno.2013.08.035,1,Yes,White,No,NA,Insurance coverage,Percent,NA,None,3,N/A,Public,7.1,-99,-99
10.1016/j.ygyno.2013.08.035,1,Yes,White,No,NA,Insurance coverage,Percent,NA,None,4,N/A,Self-pay,1.3,-99,-99
10.1016/j.ygyno.2013.08.035,1,Yes,White,No,NA,Insurance coverage,Percent,NA,None,5,N/A,Other,0.2,-99,-99
10.1016/j.ygyno.2013.08.035,2,Yes,Black,No,NA,Insurance coverage,Percent,NA,None,1,N/A,Private,43.1,-99,-99
10.1016/j.ygyno.2013.08.035,2,Yes,Black,No,NA,Insurance coverage,Percent,NA,None,2,N/A,Medicare/other govt,33.8,-99,-99
10.1016/j.ygyno.2013.08.035,2,Yes,Black,No,NA,Insurance coverage,Percent,NA,None,3,N/A,Public,22.1,-99,-99
10.1016/j.ygyno.2013.08.035,2,Yes,Black,No,NA,Insurance coverage,Percent,NA,None,4,N/A,Self-pay,1,-99,-99
10.1016/j.ygyno.2013.08.035,2,Yes,Black,No,NA,Insurance coverage,Percent,NA,None,5,N/A,Other,0,-99,-99
10.1016/j.ygyno.2013.08.035,3,Yes,Hispanic,No,NA,Insurance coverage,Percent,NA,None,1,N/A,Private,40.6,-99,-99
10.1016/j.ygyno.2013.08.035,3,Yes,Hispanic,No,NA,Insurance coverage,Percent,NA,None,2,N/A,Medicare/other govt,21.1,-99,-99
10.1016/j.ygyno.2013.08.035,3,Yes,Hispanic,No,NA,Insurance coverage,Percent,NA,None,3,N/A,Public,34.5,-99,-99
10.1016/j.ygyno.2013.08.035,3,Yes,Hispanic,No,NA,Insurance coverage,Percent,NA,None,4,N/A,Self-pay,3.6,-99,-99
10.1016/j.ygyno.2013.08.035,3,Yes,Hispanic,No,NA,Insurance coverage,Percent,NA,None,5,N/A,Other,0.2,-99,-99
10.1016/j.ygyno.2013.08.035,4,Yes,Asian/Pacific Islander,No,NA,Insurance coverage,Percent,NA,None,1,N/A,Private,62.9,-99,-99
10.1016/j.ygyno.2013.08.035,4,Yes,Asian/Pacific Islander,No,NA,Insurance coverage,Percent,NA,None,2,N/A,Medicare/other govt,19.3,-99,-99
10.1016/j.ygyno.2013.08.035,4,Yes,Asian/Pacific Islander,No,NA,Insurance coverage,Percent,NA,None,3,N/A,Public,15.4,-99,-99
10.1016/j.ygyno.2013.08.035,4,Yes,Asian/Pacific Islander,No,NA,Insurance coverage,Percent,NA,None,4,N/A,Self-pay,2.3,-99,-99
10.1016/j.ygyno.2013.08.035,4,Yes,Asian/Pacific Islander,No,NA,Insurance coverage,Percent,NA,None,5,N/A,Other,0.1,-99,-99
10.1016/j.ygyno.2013.08.035,5,Yes,Other,No,NA,Insurance coverage,Percent,NA,None,1,N/A,Private,48.1,-99,-99
10.1016/j.ygyno.2013.08.035,5,Yes,Other,No,NA,Insurance coverage,Percent,NA,None,2,N/A,Medicare/other govt,31.4,-99,-99
10.1016/j.ygyno.2013.08.035,5,Yes,Other,No,NA,Insurance coverage,Percent,NA,None,3,N/A,Public,18,-99,-99
10.1016/j.ygyno.2013.08.035,5,Yes,Other,No,NA,Insurance coverage,Percent,NA,None,4,N/A,Self-pay,2.6,-99,-99
10.1016/j.ygyno.2013.08.035,5,Yes,Other,No,NA,Insurance coverage,Percent,NA,None,5,N/A,Other,0,-99,-99
10.1016/j.ygyno.2013.08.035,6,Yes,White,No,NA,patients receiving ovarian cancer related Surgical procedures,Percent,NA,None,1,N/A,Hysterectomy,73.6,-99,-99
10.1016/j.ygyno.2013.08.035,6,Yes,White,No,NA,patients receiving ovarian cancer related Surgical procedures,Percent,NA,None,2,N/A,Lymphadenectomy,40,-99,-99
10.1016/j.ygyno.2013.08.035,6,Yes,White,No,NA,patients receiving ovarian cancer related Surgical procedures,Percent,NA,None,3,N/A,Bowel resection,47.2,-99,-99
10.1016/j.ygyno.2013.08.035,6,Yes,White,No,NA,patients receiving ovarian cancer related Surgical procedures,Percent,NA,None,4,N/A,Peritoneal/abdominal exicision,87.4,-99,-99
10.1016/j.ygyno.2013.08.035,7,Yes,Black,No,NA,patients receiving ovarian cancer related Surgical procedures,Percent,NA,None,1,N/A,Hysterectomy,69.3,-99,-99
10.1016/j.ygyno.2013.08.035,7,Yes,Black,No,NA,patients receiving ovarian cancer related Surgical procedures,Percent,NA,None,2,N/A,Lymphadenectomy,33.1,-99,-99
10.1016/j.ygyno.2013.08.035,7,Yes,Black,No,NA,patients receiving ovarian cancer related Surgical procedures,Percent,NA,None,3,N/A,Bowel resection,43.5,-99,-99
10.1016/j.ygyno.2013.08.035,7,Yes,Black,No,NA,patients receiving ovarian cancer related Surgical procedures,Percent,NA,None,4,N/A,Peritoneal/abdominal exicision,84.1,-99,-99
10.1016/j.ygyno.2013.08.035,8,Yes,Hispanic,No,NA,patients receiving ovarian cancer related Surgical procedures,Percent,NA,None,1,N/A,Hysterectomy,75.7,-99,-99
10.1016/j.ygyno.2013.08.035,8,Yes,Hispanic,No,NA,patients receiving ovarian cancer related Surgical procedures,Percent,NA,None,2,N/A,Lymphadenectomy,34.8,-99,-99
10.1016/j.ygyno.2013.08.035,8,Yes,Hispanic,No,NA,patients receiving ovarian cancer related Surgical procedures,Percent,NA,None,3,N/A,Bowel resection,40.7,-99,-99
10.1016/j.ygyno.2013.08.035,8,Yes,Hispanic,No,NA,patients receiving ovarian cancer related Surgical procedures,Percent,NA,None,4,N/A,Peritoneal/abdominal exicision,81.6,-99,-99
10.1016/j.ygyno.2013.08.035,9,Yes,Asian/Pacific Islander,No,NA,patients receiving ovarian cancer related Surgical procedures,Percent,NA,None,1,N/A,Hysterectomy,83.3,-99,-99
10.1016/j.ygyno.2013.08.035,9,Yes,Asian/Pacific Islander,No,NA,patients receiving ovarian cancer related Surgical procedures,Percent,NA,None,2,N/A,Lymphadenectomy,12.3,-99,-99
10.1016/j.ygyno.2013.08.035,9,Yes,Asian/Pacific Islander,No,NA,patients receiving ovarian cancer related Surgical procedures,Percent,NA,None,3,N/A,Bowel resection,45.8,-99,-99
10.1016/j.ygyno.2013.08.035,9,Yes,Asian/Pacific Islander,No,NA,patients receiving ovarian cancer related Surgical procedures,Percent,NA,None,4,N/A,Peritoneal/abdominal exicision,10.4,-99,-99
10.1016/j.ygyno.2013.08.035,10,Yes,Other,No,NA,patients receiving ovarian cancer related Surgical procedures,Percent,NA,None,1,N/A,Hysterectomy,79.2,-99,-99
10.1016/j.ygyno.2013.08.035,10,Yes,Other,No,NA,patients receiving ovarian cancer related Surgical procedures,Percent,NA,None,2,N/A,Lymphadenectomy,43,-99,-99
10.1016/j.ygyno.2013.08.035,10,Yes,Other,No,NA,patients receiving ovarian cancer related Surgical procedures,Percent,NA,None,3,N/A,Bowel resection,44.9,-99,-99
10.1016/j.ygyno.2013.08.035,10,Yes,Other,No,NA,patients receiving ovarian cancer related Surgical procedures,Percent,NA,None,4,N/A,Peritoneal/abdominal exicision,83.3,-99,-99
10.1016/j.ygyno.2013.08.035,11,No,NA,No,NA,Hysterectomy,OR,NA,"insurance coverage, modified charlson score, age, volume",1,White,Black,0.77,0.59,1
10.1016/j.ygyno.2013.08.035,11,No,NA,No,NA,Hysterectomy,OR,NA,"insurance coverage, modified charlson score, age, volume",2,White,Hispanic,0.98,0.84,1.13
10.1016/j.ygyno.2013.08.035,11,No,NA,No,NA,Hysterectomy,OR,NA,"insurance coverage, modified charlson score, age, volume",3,White,Asian/Pacific Islander,1.52,1.25,1.84
10.1016/j.ygyno.2013.08.035,12,Yes,High volume hospital,No,NA,Hysterectomy,OR,NA,"insurance coverage, modified charlson score, age, volume",1,White,Black,0.73,0.51,1.05
10.1016/j.ygyno.2013.08.035,12,Yes,High volume hospital,No,NA,Hysterectomy,OR,NA,"insurance coverage, modified charlson score, age, volume",2,White,Hispanic,0.84,0.66,1.05
10.1016/j.ygyno.2013.08.035,12,Yes,High volume hospital,No,NA,Hysterectomy,OR,NA,"insurance coverage, modified charlson score, age, volume",3,White,Asian/Pacific Islander,1.39,1.04,1.85
10.1016/j.ygyno.2013.08.035,13,Yes,Low volume hospital,No,NA,Hysterectomy,OR,NA,"insurance coverage, modified charlson score, age, volume",1,White,Black,0.81,0.55,1.19
10.1016/j.ygyno.2013.08.035,13,Yes,Low volume hospital,No,NA,Hysterectomy,OR,NA,"insurance coverage, modified charlson score, age, volume",2,White,Hispanic,1.08,0.89,1.31
10.1016/j.ygyno.2013.08.035,13,Yes,Low volume hospital,No,NA,Hysterectomy,OR,NA,"insurance coverage, modified charlson score, age, volume",3,White,Asian/Pacific Islander,1.62,1.24,2.12
10.1016/j.ygyno.2013.08.035,14,No,NA,No,NA,Lymphadenectomy,OR,NA,"insurance coverage, modified charlson score, age, volume",1,White,Black,0.76,0.59,0.99
10.1016/j.ygyno.2013.08.035,14,No,NA,No,NA,Lymphadenectomy,OR,NA,"insurance coverage, modified charlson score, age, volume",2,White,Hispanic,0.81,0.71,0.92
10.1016/j.ygyno.2013.08.035,14,No,NA,No,NA,Lymphadenectomy,OR,NA,"insurance coverage, modified charlson score, age, volume",3,White,Asian/Pacific Islander,1.2,1.04,1.4
10.1016/j.ygyno.2013.08.035,15,Yes,High volume hospital,No,NA,Lymphadenectomy,OR,NA,"insurance coverage, modified charlson score, age, volume",1,White,Black,0.77,0.54,1.09
10.1016/j.ygyno.2013.08.035,15,Yes,High volume hospital,No,NA,Lymphadenectomy,OR,NA,"insurance coverage, modified charlson score, age, volume",2,White,Hispanic,0.86,0.7,1.05
10.1016/j.ygyno.2013.08.035,15,Yes,High volume hospital,No,NA,Lymphadenectomy,OR,NA,"insurance coverage, modified charlson score, age, volume",3,White,Asian/Pacific Islander,1.28,1.03,1.6
10.1016/j.ygyno.2013.08.035,16,Yes,Low volume hospital,No,NA,Lymphadenectomy,OR,NA,"insurance coverage, modified charlson score, age, volume",1,White,Black,0.77,0.53,1.11
10.1016/j.ygyno.2013.08.035,16,Yes,Low volume hospital,No,NA,Lymphadenectomy,OR,NA,"insurance coverage, modified charlson score, age, volume",2,White,Hispanic,0.77,0.65,0.92
10.1016/j.ygyno.2013.08.035,16,Yes,Low volume hospital,No,NA,Lymphadenectomy,OR,NA,"insurance coverage, modified charlson score, age, volume",3,White,Asian/Pacific Islander,1.15,0.93,1.41
10.1016/j.ygyno.2013.08.035,17,No,NA,No,NA,Bowel resection,OR,NA,"insurance coverage, modified charlson score, age, volume",1,White,Black,0.87,0.68,1.1
10.1016/j.ygyno.2013.08.035,17,No,NA,No,NA,Bowel resection,OR,NA,"insurance coverage, modified charlson score, age, volume",2,White,Hispanic,0.8,0.71,0.91
10.1016/j.ygyno.2013.08.035,17,No,NA,No,NA,Bowel resection,OR,NA,"insurance coverage, modified charlson score, age, volume",3,White,Asian/Pacific Islander,0.95,0.82,1.1
10.1016/j.ygyno.2013.08.035,18,Yes,High volume hospital,No,NA,Bowel resection,OR,NA,"insurance coverage, modified charlson score, age, volume",1,White,Black,0.84,0.6,1.16
10.1016/j.ygyno.2013.08.035,18,Yes,High volume hospital,No,NA,Bowel resection,OR,NA,"insurance coverage, modified charlson score, age, volume",2,White,Hispanic,0.85,0.7,1.03
10.1016/j.ygyno.2013.08.035,18,Yes,High volume hospital,No,NA,Bowel resection,OR,NA,"insurance coverage, modified charlson score, age, volume",3,White,Asian/Pacific Islander,0.93,0.75,1.16
10.1016/j.ygyno.2013.08.035,19,Yes,Low volume hospital,No,NA,Bowel resection,OR,NA,"insurance coverage, modified charlson score, age, volume",1,White,Black,0.91,0.64,1.29
10.1016/j.ygyno.2013.08.035,19,Yes,Low volume hospital,No,NA,Bowel resection,OR,NA,"insurance coverage, modified charlson score, age, volume",2,White,Hispanic,0.77,0.65,0.91
10.1016/j.ygyno.2013.08.035,19,Yes,Low volume hospital,No,NA,Bowel resection,OR,NA,"insurance coverage, modified charlson score, age, volume",3,White,Asian/Pacific Islander,0.96,0.78,1.17
10.1016/j.ygyno.2013.08.035,20,No,NA,No,NA,Peritoneal excision,OR,NA,"insurance coverage, modified charlson score, age, volume",1,White,Black,0.78,0.56,1.08
10.1016/j.ygyno.2013.08.035,20,No,NA,No,NA,Peritoneal excision,OR,NA,"insurance coverage, modified charlson score, age, volume",2,White,Hispanic,0.7,0.59,0.82
10.1016/j.ygyno.2013.08.035,20,No,NA,No,NA,Peritoneal excision,OR,NA,"insurance coverage, modified charlson score, age, volume",3,White,Asian/Pacific Islander,0.81,0.66,1
10.1016/j.ygyno.2013.08.035,21,Yes,High volume hospital,No,NA,Peritoneal excision,OR,NA,"insurance coverage, modified charlson score, age, volume",1,White,Black,0.75,0.46,1.22
10.1016/j.ygyno.2013.08.035,21,Yes,High volume hospital,No,NA,Peritoneal excision,OR,NA,"insurance coverage, modified charlson score, age, volume",2,White,Hispanic,0.7,0.52,0.94
10.1016/j.ygyno.2013.08.035,21,Yes,High volume hospital,No,NA,Peritoneal excision,OR,NA,"insurance coverage, modified charlson score, age, volume",3,White,Asian/Pacific Islander,0.77,0.55,1.08
10.1016/j.ygyno.2013.08.035,22,Yes,Low volume hospital,No,NA,Peritoneal excision,OR,NA,"insurance coverage, modified charlson score, age, volume",1,White,Black,0.8,0.52,1.25
10.1016/j.ygyno.2013.08.035,22,Yes,Low volume hospital,No,NA,Peritoneal excision,OR,NA,"insurance coverage, modified charlson score, age, volume",2,White,Hispanic,0.7,0.57,0.86
10.1016/j.ygyno.2013.08.035,22,Yes,Low volume hospital,No,NA,Peritoneal excision,OR,NA,"insurance coverage, modified charlson score, age, volume",3,White,Asian/Pacific Islander,0.83,0.64,1.09
10.1016/j.ygyno.2013.08.035,23,No,NA,No,NA,receiving treatment at a High volume hospital,OR,NA,"insurance coverage, modified charlson score, age, volume",1,White,Black,1.16,0.92,1.48
10.1016/j.ygyno.2013.08.035,23,No,NA,No,NA,receiving treatment at a High volume hospital,OR,NA,"insurance coverage, modified charlson score, age, volume",2,White,Hispanic,0.72,0.64,0.82
10.1016/j.ygyno.2013.08.035,23,No,NA,No,NA,receiving treatment at a High volume hospital,OR,NA,"insurance coverage, modified charlson score, age, volume",3,White,Asian/Pacific Islander,0.85,0.73,0.99
10.1016/j.fertnstert.2013.10.055,1,Yes,< 20 y,No,NA,Metabolic syndrome,Percent,NA,None,1,N/A,PCOS White,15.9,-99,-99
10.1016/j.fertnstert.2013.10.055,1,Yes,< 20 y,No,NA,Metabolic syndrome,Percent,NA,None,2,N/A,PCOS Black,42.1,-99,-99
10.1016/j.fertnstert.2013.10.055,1,Yes,< 20 y,No,NA,Metabolic syndrome,Percent,NA,None,3,N/A,NHANES White,4.4,-99,-99
10.1016/j.fertnstert.2013.10.055,1,Yes,< 20 y,No,NA,Metabolic syndrome,Percent,NA,None,4,N/A,NHANES Black,4.2,-99,-99
10.1016/j.fertnstert.2013.10.055,2,Yes,< 20 y,No,NA,BMI,Percent,NA,None,1,N/A,PCOS White,49,-99,-99
10.1016/j.fertnstert.2013.10.055,2,Yes,< 20 y,No,NA,BMI,Percent,NA,None,2,N/A,PCOS Black,80,-99,-99
10.1016/j.fertnstert.2013.10.055,2,Yes,< 20 y,No,NA,BMI,Percent,NA,None,3,N/A,NHANES White,38.9,-99,-99
10.1016/j.fertnstert.2013.10.055,2,Yes,< 20 y,No,NA,BMI,Percent,NA,None,4,N/A,NHANES Black,44.2,-99,-99
10.1016/j.fertnstert.2013.10.055,3,Yes,< 20 y,No,NA,TG,Percent,NA,None,1,N/A,PCOS White,20.2,-99,-99
10.1016/j.fertnstert.2013.10.055,3,Yes,< 20 y,No,NA,TG,Percent,NA,None,2,N/A,PCOS Black,22.7,-99,-99
10.1016/j.fertnstert.2013.10.055,3,Yes,< 20 y,No,NA,TG,Percent,NA,None,3,N/A,NHANES White,8.1,-99,-99
10.1016/j.fertnstert.2013.10.055,3,Yes,< 20 y,No,NA,TG,Percent,NA,None,4,N/A,NHANES Black,3.5,-99,-99
10.1016/j.fertnstert.2013.10.055,4,Yes,< 20 y,No,NA,HDL,Percent,NA,None,1,N/A,PCOS White,28.3,-99,-99
10.1016/j.fertnstert.2013.10.055,4,Yes,< 20 y,No,NA,HDL,Percent,NA,None,2,N/A,PCOS Black,45.5,-99,-99
10.1016/j.fertnstert.2013.10.055,4,Yes,< 20 y,No,NA,HDL,Percent,NA,None,3,N/A,NHANES White,25.3,-99,-99
10.1016/j.fertnstert.2013.10.055,4,Yes,< 20 y,No,NA,HDL,Percent,NA,None,4,N/A,NHANES Black,21.6,-99,-99
10.1016/j.fertnstert.2013.10.055,5,Yes,< 20 y,No,NA,BP,Percent,NA,None,1,N/A,PCOS White,24.3,-99,-99
10.1016/j.fertnstert.2013.10.055,5,Yes,< 20 y,No,NA,BP,Percent,NA,None,2,N/A,PCOS Black,50,-99,-99
10.1016/j.fertnstert.2013.10.055,5,Yes,< 20 y,No,NA,BP,Percent,NA,None,3,N/A,NHANES White,1,-99,-99
10.1016/j.fertnstert.2013.10.055,5,Yes,< 20 y,No,NA,BP,Percent,NA,None,4,N/A,NHANES Black,3.5,-99,-99
10.1016/j.fertnstert.2013.10.055,6,Yes,< 20 y,No,NA,Glucose,Percent,NA,None,1,N/A,PCOS White,7.9,-99,-99
10.1016/j.fertnstert.2013.10.055,6,Yes,< 20 y,No,NA,Glucose,Percent,NA,None,2,N/A,PCOS Black,15,-99,-99
10.1016/j.fertnstert.2013.10.055,6,Yes,< 20 y,No,NA,Glucose,Percent,NA,None,3,N/A,NHANES White,6.7,-99,-99
10.1016/j.fertnstert.2013.10.055,6,Yes,< 20 y,No,NA,Glucose,Percent,NA,None,4,N/A,NHANES Black,4.7,-99,-99
10.1016/j.fertnstert.2013.10.055,7,Yes,20-34 y,No,NA,Metabolic syndrome,Percent,NA,None,1,N/A,PCOS White,22.6,-99,-99
10.1016/j.fertnstert.2013.10.055,7,Yes,20-34 y,No,NA,Metabolic syndrome,Percent,NA,None,2,N/A,PCOS Black,40,-99,-99
10.1016/j.fertnstert.2013.10.055,7,Yes,20-34 y,No,NA,Metabolic syndrome,Percent,NA,None,3,N/A,NHANES White,14.9,-99,-99
10.1016/j.fertnstert.2013.10.055,7,Yes,20-34 y,No,NA,Metabolic syndrome,Percent,NA,None,4,N/A,NHANES Black,16.6,-99,-99
10.1016/j.fertnstert.2013.10.055,8,Yes,20-34 y,No,NA,BMI,Percent,NA,None,1,N/A,PCOS White,51.7,-99,-99
10.1016/j.fertnstert.2013.10.055,8,Yes,20-34 y,No,NA,BMI,Percent,NA,None,2,N/A,PCOS Black,72.7,-99,-99
10.1016/j.fertnstert.2013.10.055,8,Yes,20-34 y,No,NA,BMI,Percent,NA,None,3,N/A,NHANES White,66.1,-99,-99
10.1016/j.fertnstert.2013.10.055,8,Yes,20-34 y,No,NA,BMI,Percent,NA,None,4,N/A,NHANES Black,75.4,-99,-99
10.1016/j.fertnstert.2013.10.055,9,Yes,20-34 y,No,NA,TG,Percent,NA,None,1,N/A,PCOS White,24.6,-99,-99
10.1016/j.fertnstert.2013.10.055,9,Yes,20-34 y,No,NA,TG,Percent,NA,None,2,N/A,PCOS Black,10.9,-99,-99
10.1016/j.fertnstert.2013.10.055,9,Yes,20-34 y,No,NA,TG,Percent,NA,None,3,N/A,NHANES White,15.5,-99,-99
10.1016/j.fertnstert.2013.10.055,9,Yes,20-34 y,No,NA,TG,Percent,NA,None,4,N/A,NHANES Black,9.9,-99,-99
10.1016/j.fertnstert.2013.10.055,10,Yes,20-34 y,No,NA,HDL,Percent,NA,None,1,N/A,PCOS White,35.6,-99,-99
10.1016/j.fertnstert.2013.10.055,10,Yes,20-34 y,No,NA,HDL,Percent,NA,None,2,N/A,PCOS Black,76.6,-99,-99
10.1016/j.fertnstert.2013.10.055,10,Yes,20-34 y,No,NA,HDL,Percent,NA,None,3,N/A,NHANES White,39.9,-99,-99
10.1016/j.fertnstert.2013.10.055,10,Yes,20-34 y,No,NA,HDL,Percent,NA,None,4,N/A,NHANES Black,42.9,-99,-99
10.1016/j.fertnstert.2013.10.055,11,Yes,20-34 y,No,NA,BP,Percent,NA,None,1,N/A,PCOS White,31.9,-99,-99
10.1016/j.fertnstert.2013.10.055,11,Yes,20-34 y,No,NA,BP,Percent,NA,None,2,N/A,PCOS Black,5.5,-99,-99
10.1016/j.fertnstert.2013.10.055,11,Yes,20-34 y,No,NA,BP,Percent,NA,None,3,N/A,NHANES White,3.3,-99,-99
10.1016/j.fertnstert.2013.10.055,11,Yes,20-34 y,No,NA,BP,Percent,NA,None,4,N/A,NHANES Black,10.6,-99,-99
10.1016/j.fertnstert.2013.10.055,12,Yes,20-34 y,No,NA,Glucose,Percent,NA,None,1,N/A,PCOS White,4.9,-99,-99
10.1016/j.fertnstert.2013.10.055,12,Yes,20-34 y,No,NA,Glucose,Percent,NA,None,2,N/A,PCOS Black,18.8,-99,-99
10.1016/j.fertnstert.2013.10.055,12,Yes,20-34 y,No,NA,Glucose,Percent,NA,None,3,N/A,NHANES White,9,-99,-99
10.1016/j.fertnstert.2013.10.055,12,Yes,20-34 y,No,NA,Glucose,Percent,NA,None,4,N/A,NHANES Black,8.3,-99,-99
10.1016/j.fertnstert.2013.10.055,13,Yes,< 20 y,No,NA,Metabolic syndrome,RR,NA,None,1,PCOS White,PCOS Black,2.65,1.29,5.4
10.1016/j.fertnstert.2013.10.055,14,Yes,20-34 y,No,NA,Metabolic syndrome,RR,NA,None,1,PCOS White,PCOS Black,1.44,1.21,2.6
10.1016/j.fertnstert.2013.10.055,15,Yes,< 20 y,No,NA,Metabolic syndrome,RR,NA,None,1,NHANES White,NHANES Black,0.95,0.4,2.25
10.1016/j.fertnstert.2013.10.055,16,Yes,20-34 y,No,NA,Metabolic syndrome,RR,NA,None,1,NHANES White,NHANES Black,1.13,0.58,2.21
10.1016/j.fertnstert.2013.10.055,17,Yes,< 20 y,No,NA,Metabolic syndrome,RR,NA,None,1,PCOS White,NHANES White,3.72,1.9,7.25
10.1016/j.fertnstert.2013.10.055,18,Yes,20-34 y,No,NA,Metabolic syndrome,RR,NA,None,1,PCOS White,NHANES White,1.52,1.04,2.24
10.1016/j.fertnstert.2013.10.055,19,Yes,< 20 y,No,NA,Metabolic syndrome,RR,NA,None,1,PCOS Black,NHANES Black,10.13,5.1,20.13
10.1016/j.fertnstert.2013.10.055,20,Yes,20-34 y,No,NA,Metabolic syndrome,RR,NA,None,1,PCOS Black,NHANES Black,2.42,1.52,3.83
10.1016/j.ygyno.2011.11.041,1,No,NA,No,NA,no hospice,Percent,NA,None,1,N/A,White,38.4,-99,-99
10.1016/j.ygyno.2011.11.041,1,No,NA,No,NA,no hospice,Percent,NA,None,2,N/A,Black,46.5,-99,-99
10.1016/j.ygyno.2011.11.041,1,No,NA,No,NA,no hospice,Percent,NA,None,3,N/A,Other,50.5,-99,-99
10.1016/j.ygyno.2011.11.041,2,No,NA,No,NA,late hospice,Percent,NA,None,1,N/A,White,11.3,-99,-99
10.1016/j.ygyno.2011.11.041,2,No,NA,No,NA,late hospice,Percent,NA,None,2,N/A,Black,11.5,-99,-99
10.1016/j.ygyno.2011.11.041,2,No,NA,No,NA,late hospice,Percent,NA,None,3,N/A,Other,9.3,-99,-99
10.1016/j.ygyno.2011.11.041,3,No,NA,No,NA,does not enroll in hospice,OR,NA,"Disease stage, age, marital status, urban/rural, income, medicare type",1,White,Nonwhite,1.44,1.26,1.65
10.1016/j.ygyno.2011.04.047,1,No,NA,No,NA,Overall survival,HR,NA,"age, tumor grade 3, nonserous histology, asa score = 3, surgical complexity score, serum albumin < 3.0 g/dl, platinum-based chemotherapy, gross residual disease, perioperative morbidity",1,White,African American,1.06,0.61,1.79
10.1016/j.ygyno.2011.03.010,1,No,NA,No,NA,Uterine cancer death at 4 years,HR,NA,"race, age, facility characteristics",1,White,Hispanic,1.31,1.16,1.5
10.1016/j.ygyno.2011.03.010,1,No,NA,No,NA,Uterine cancer death at 4 years,HR,NA,"race, age, facility characteristics",2,White,African American,2.35,2.2,2.51
10.1016/j.ygyno.2011.03.010,1,No,NA,No,NA,Uterine cancer death at 4 years,HR,NA,"race, age, facility characteristics",3,White,Other,1.06,0.86,1.3
10.1016/j.ygyno.2011.03.010,2,No,NA,No,NA,Uterine cancer death at 4 years,HR,NA,"race, age, facility characteristics, zip code level education",1,White,Hispanic,0.94,0.82,1.07
10.1016/j.ygyno.2011.03.010,2,No,NA,No,NA,Uterine cancer death at 4 years,HR,NA,"race, age, facility characteristics, zip code level education",2,White,African American,2.11,1.96,2.27
10.1016/j.ygyno.2011.03.010,2,No,NA,No,NA,Uterine cancer death at 4 years,HR,NA,"race, age, facility characteristics, zip code level education",3,White,Other,0.75,0.61,0.92
10.1016/j.ygyno.2011.03.010,3,No,NA,No,NA,Uterine cancer death at 4 years,HR,NA,"race, age, facility characteristics, zip code, level education, histology, stage, grade",1,White,Hispanic,1,0.86,1.17
10.1016/j.ygyno.2011.03.010,3,No,NA,No,NA,Uterine cancer death at 4 years,HR,NA,"race, age, facility characteristics, zip code, level education, histology, stage, grade",2,White,African American,1.44,1.31,1.57
10.1016/j.ygyno.2011.03.010,3,No,NA,No,NA,Uterine cancer death at 4 years,HR,NA,"race, age, facility characteristics, zip code, level education, histology, stage, grade",3,White,Other,0.8,0.62,1.03
10.1016/j.ygyno.2011.03.010,4,No,NA,No,NA,Uterine cancer death at 4 years,HR,NA,"race, age, facility characteristics, zip code, level education, histology, stage, grade, treatment",1,White,Hispanic,1,0.85,1.17
10.1016/j.ygyno.2011.03.010,4,No,NA,No,NA,Uterine cancer death at 4 years,HR,NA,"race, age, facility characteristics, zip code, level education, histology, stage, grade, treatment",2,White,African American,1.33,1.21,1.46
10.1016/j.ygyno.2011.03.010,4,No,NA,No,NA,Uterine cancer death at 4 years,HR,NA,"race, age, facility characteristics, zip code, level education, histology, stage, grade, treatment",3,White,Other,0.79,0.61,1.04
10.1016/j.ygyno.2011.03.010,5,No,NA,No,NA,Uterine cancer death at 4 years,HR,NA,"race, age, facility characteristics, zip code, level education, histology, stage, grade, insurance",1,White,Hispanic,0.96,0.82,1.13
10.1016/j.ygyno.2011.03.010,5,No,NA,No,NA,Uterine cancer death at 4 years,HR,NA,"race, age, facility characteristics, zip code, level education, histology, stage, grade, insurance",2,White,African American,1.28,1.17,1.4
10.1016/j.ygyno.2011.03.010,5,No,NA,No,NA,Uterine cancer death at 4 years,HR,NA,"race, age, facility characteristics, zip code, level education, histology, stage, grade, insurance",3,White,Other,0.81,0.62,1.05
10.1016/j.ygyno.2011.03.010,6,Yes,Stage 1,No,NA,4 year survival among surgical uterine cancer patients,HR,NA,"insurance, treatment, zip code, level education, age, facility characteristics, grade, histology",1,White,Hispanic,0.96,0.75,1.23
10.1016/j.ygyno.2011.03.010,6,Yes,Stage 1,No,NA,4 year survival among surgical uterine cancer patients,HR,NA,"insurance, treatment, zip code, level education, age, facility characteristics, grade, histology",2,White,Black,1.33,1.15,1.54
10.1016/j.ygyno.2011.03.010,6,Yes,Stage 1,No,NA,4 year survival among surgical uterine cancer patients,HR,NA,"insurance, treatment, zip code, level education, age, facility characteristics, grade, histology",3,White,Other,0.65,0.44,0.97
10.1016/j.ygyno.2011.03.010,7,Yes,Stage 2,No,NA,4 year survival among surgical uterine cancer patients,HR,NA,"insurance, treatment, zip code, level education, age, facility characteristics, grade, histology",1,White,Hispanic,1.52,1.03,2.24
10.1016/j.ygyno.2011.03.010,7,Yes,Stage 2,No,NA,4 year survival among surgical uterine cancer patients,HR,NA,"insurance, treatment, zip code, level education, age, facility characteristics, grade, histology",2,White,Black,1.42,1.1,1.83
10.1016/j.ygyno.2011.03.010,7,Yes,Stage 2,No,NA,4 year survival among surgical uterine cancer patients,HR,NA,"insurance, treatment, zip code, level education, age, facility characteristics, grade, histology",3,White,Other,1,0.59,1.68
10.1016/j.ygyno.2011.03.010,8,Yes,Stage 3,No,NA,4 year survival among surgical uterine cancer patients,HR,NA,"insurance, treatment, zip code, level education, age, facility characteristics, grade, histology",1,White,Hispanic,0.77,0.58,1.02
10.1016/j.ygyno.2011.03.010,8,Yes,Stage 3,No,NA,4 year survival among surgical uterine cancer patients,HR,NA,"insurance, treatment, zip code, level education, age, facility characteristics, grade, histology",2,White,Black,1.33,1.14,1.56
10.1016/j.ygyno.2011.03.010,8,Yes,Stage 3,No,NA,4 year survival among surgical uterine cancer patients,HR,NA,"insurance, treatment, zip code, level education, age, facility characteristics, grade, histology",3,White,Other,0.95,0.68,1.33
10.1016/j.ajog.2011.02.036,1,Yes,"Yes, got vaccine",No,NA,Vaccination,Percent,NA,None,1,N/A,Minority,28,-99,-99
10.1016/j.ajog.2011.02.036,1,Yes,"Yes, got vaccine",No,NA,Vaccination,Percent,NA,None,2,N/A,"White, non-Hispanic",50,-99,-99
10.1016/j.ajog.2011.02.036,2,Yes,"No, did not get",No,NA,Vaccination,Percent,NA,None,1,N/A,Minority,70,-99,-99
10.1016/j.ajog.2011.02.036,2,Yes,"No, did not get",No,NA,Vaccination,Percent,NA,None,2,N/A,"White, non-Hispanic",50,-99,-99
10.1016/j.ajog.2011.02.036,3,Yes,A lot,No,NA,Amount heard about 2009 H1N1 vaccine,Percent,NA,None,1,N/A,Minority,51,-99,-99
10.1016/j.ajog.2011.02.036,3,Yes,A lot,No,NA,Amount heard about 2009 H1N1 vaccine,Percent,NA,None,2,N/A,"White, non-Hispanic",35,-99,-99
10.1016/j.ajog.2011.02.036,4,Yes,"Heard some, little, or nothing at all",No,NA,Amount heard about 2009 H1N1 vaccine,Percent,NA,None,1,N/A,Minority,49,-99,-99
10.1016/j.ajog.2011.02.036,4,Yes,"Heard some, little, or nothing at all",No,NA,Amount heard about 2009 H1N1 vaccine,Percent,NA,None,2,N/A,"White, non-Hispanic",65,-99,-99
10.1016/j.ajog.2011.02.036,5,Yes,Concerned,No,NA,Concern about self getting 2009 H1N1 in next 12 mo,Percent,NA,None,1,N/A,Minority,42,-99,-99
10.1016/j.ajog.2011.02.036,5,Yes,Concerned,No,NA,Concern about self getting 2009 H1N1 in next 12 mo,Percent,NA,None,2,N/A,"White, non-Hispanic",29,-99,-99
10.1016/j.ajog.2011.02.036,6,Yes,Not concerned,No,NA,Concern about self getting 2009 H1N1 in next 12 mo,Percent,NA,None,1,N/A,Minority,58,-99,-99
10.1016/j.ajog.2011.02.036,6,Yes,Not concerned,No,NA,Concern about self getting 2009 H1N1 in next 12 mo,Percent,NA,None,2,N/A,"White, non-Hispanic",70,-99,-99
10.1016/j.ajog.2011.02.036,7,Yes,Concerned,No,NA,Concern about baby getting 2009 H1N1 in next 12 mo after baby is born,Percent,NA,None,1,N/A,Minority,52,-99,-99
10.1016/j.ajog.2011.02.036,7,Yes,Concerned,No,NA,Concern about baby getting 2009 H1N1 in next 12 mo after baby is born,Percent,NA,None,2,N/A,"White, non-Hispanic",47,-99,-99
10.1016/j.ajog.2011.02.036,8,Yes,Not concerned,No,NA,Concern about baby getting 2009 H1N1 in next 12 mo after baby is born,Percent,NA,None,1,N/A,Minority,48,-99,-99
10.1016/j.ajog.2011.02.036,8,Yes,Not concerned,No,NA,Concern about baby getting 2009 H1N1 in next 12 mo after baby is born,Percent,NA,None,2,N/A,"White, non-Hispanic",53,-99,-99
10.1016/j.ajog.2011.02.036,9,Yes,Believe,No,NA,Belief in greater risk of becoming seriously ill from 2009 H1N1 for pregnant women,Percent,NA,None,1,N/A,Minority,50,-99,-99
10.1016/j.ajog.2011.02.036,9,Yes,Believe,No,NA,Belief in greater risk of becoming seriously ill from 2009 H1N1 for pregnant women,Percent,NA,None,2,N/A,"White, non-Hispanic",54,-99,-99
10.1016/j.ajog.2011.02.036,10,Yes,Do not know or do not believe,No,NA,Belief in greater risk of becoming seriously ill from 2009 H1N1 for pregnant women,Percent,NA,None,1,N/A,Minority,50,-99,-99
10.1016/j.ajog.2011.02.036,10,Yes,Do not know or do not believe,No,NA,Belief in greater risk of becoming seriously ill from 2009 H1N1 for pregnant women,Percent,NA,None,2,N/A,"White, non-Hispanic",46,-99,-99
10.1016/j.ajog.2011.02.036,11,Yes,Very safe,No,NA,Safety of vaccine for pregnant women,Percent,NA,None,1,N/A,Minority,20,-99,-99
10.1016/j.ajog.2011.02.036,11,Yes,Very safe,No,NA,Safety of vaccine for pregnant women,Percent,NA,None,2,N/A,"White, non-Hispanic",29,-99,-99
10.1016/j.ajog.2011.02.036,12,Yes,Somewhat/not very/not at all safe,No,NA,Safety of vaccine for pregnant women,Percent,NA,None,1,N/A,Minority,79,-99,-99
10.1016/j.ajog.2011.02.036,12,Yes,Somewhat/not very/not at all safe,No,NA,Safety of vaccine for pregnant women,Percent,NA,None,2,N/A,"White, non-Hispanic",71,-99,-99
10.1016/j.ajog.2011.02.036,13,Yes,Believe,No,NA,Benefit of vaccine to fetus,Percent,NA,None,1,N/A,Minority,34,-99,-99
10.1016/j.ajog.2011.02.036,13,Yes,Believe,No,NA,Benefit of vaccine to fetus,Percent,NA,None,2,N/A,"White, non-Hispanic",30,-99,-99
10.1016/j.ajog.2011.02.036,14,Yes,Do not believe or are not sure,No,NA,Benefit of vaccine to fetus,Percent,NA,None,1,N/A,Minority,65,-99,-99
10.1016/j.ajog.2011.02.036,14,Yes,Do not believe or are not sure,No,NA,Benefit of vaccine to fetus,Percent,NA,None,2,N/A,"White, non-Hispanic",68,-99,-99
10.1016/j.ajog.2011.02.036,15,Yes,Received recommendation,No,NA,Recommendation from health care provider to get 2009 H1N1 vaccine while pregnant,Percent,NA,None,1,N/A,Minority,37,-99,-99
10.1016/j.ajog.2011.02.036,15,Yes,Received recommendation,No,NA,Recommendation from health care provider to get 2009 H1N1 vaccine while pregnant,Percent,NA,None,2,N/A,"White, non-Hispanic",57,-99,-99
10.1016/j.ajog.2011.02.036,16,Yes,Did not receive recommendation,No,NA,Recommendation from health care provider to get 2009 H1N1 vaccine while pregnant,Percent,NA,None,1,N/A,Minority,63,-99,-99
10.1016/j.ajog.2011.02.036,16,Yes,Did not receive recommendation,No,NA,Recommendation from health care provider to get 2009 H1N1 vaccine while pregnant,Percent,NA,None,2,N/A,"White, non-Hispanic",43,-99,-99
10.1016/j.ajog.2011.02.036,17,Yes,Received seasonal influenza vaccine,No,NA,Seasonal influenza vaccination,Percent,NA,None,1,N/A,Minority,37,-99,-99
10.1016/j.ajog.2011.02.036,17,Yes,Received seasonal influenza vaccine,No,NA,Seasonal influenza vaccination,Percent,NA,None,2,N/A,"White, non-Hispanic",41,-99,-99
10.1016/j.ajog.2011.02.036,18,Yes,Have not received seasonal influenza vaccine,No,NA,Seasonal influenza vaccination,Percent,NA,None,1,N/A,Minority,63,-99,-99
10.1016/j.ajog.2011.02.036,18,Yes,Have not received seasonal influenza vaccine,No,NA,Seasonal influenza vaccination,Percent,NA,None,2,N/A,"White, non-Hispanic",59,-99,-99
10.1016/j.ygyno.2010.11.041,1,No,NA,No,NA,Mean cervical cancer survival,Months,NA,None,1,N/A,European American,85.7,-99,-99
10.1016/j.ygyno.2010.11.041,1,No,NA,No,NA,Mean cervical cancer survival,Months,NA,None,2,N/A,African American,71.9,-99,-99
10.1016/j.ygyno.2010.11.041,1,No,NA,No,NA,Mean cervical cancer survival,Months,NA,None,3,N/A,Latino American,78.9,-99,-99
10.1016/j.ygyno.2010.11.041,1,No,NA,No,NA,Mean cervical cancer survival,Months,NA,None,4,N/A,Asian American,74.9,-99,-99
10.1016/j.ygyno.2010.11.041,2,No,NA,No,NA,Cervical cancer survival,HR,NA,None,1,European American,African American,1.7,1.22,2.38
10.1016/j.ygyno.2010.11.041,2,No,NA,No,NA,Cervical cancer survival,HR,NA,None,2,European American,Latino American,0.87,0.67,1.13
10.1016/j.ygyno.2010.11.041,2,No,NA,No,NA,Cervical cancer survival,HR,NA,None,3,European American,Asian American,1.04,1.03,1.05
10.1016/j.ygyno.2010.11.041,3,No,NA,No,NA,Individual level cervical cancer survival,HR,NA,None,1,European American,African American,0.9,0.48,1.69
10.1016/j.ygyno.2010.11.041,3,No,NA,No,NA,Individual level cervical cancer survival,HR,NA,None,2,European American,Latino American,0.59,0.38,0.93
10.1016/j.ygyno.2010.11.041,3,No,NA,No,NA,Individual level cervical cancer survival,HR,NA,None,3,European American,Asian American,0.7,0.43,1.15
10.1016/j.ygyno.2010.11.041,4,No,NA,No,NA,Neighborhood level cervical cancer survival,HR,NA,None,1,Median household income,Proportion of African American households,1.01,1.01,1.03
10.1016/j.ygyno.2010.11.041,4,No,NA,No,NA,Neighborhood level cervical cancer survival,HR,NA,None,2,Median household income,Proportion of Latino American households,1.01,0.99,1.02
10.1016/j.ygyno.2010.11.041,4,No,NA,No,NA,Neighborhood level cervical cancer survival,HR,NA,None,3,Median household income,Proportion of Asian American households,1.01,0.99,1.02
10.1016/j.ajog.2010.08.002,1,No,NA,No,NA,C-reactive protein,Median,NA,None,1,N/A,Non-Hispanic Black,1.7,-99,-99
10.1016/j.ajog.2010.08.002,1,No,NA,No,NA,C-reactive protein,Median,NA,None,2,N/A,Other,2.2,-99,-99
10.1016/j.ajog.2010.08.002,2,No,NA,No,NA,Epstein-Barr virus antibodies,Mean,NA,None,1,N/A,Non-Hispanic Black,140.9,-99,-99
10.1016/j.ajog.2010.08.002,2,No,NA,No,NA,Epstein-Barr virus antibodies,Mean,NA,None,2,N/A,Other,119.2,-99,-99
10.1097/AOG.0b013e3182a92011,1,No,NA,No,NA,mortality from advanced ovarian cancer,HR,NA,None,1,White,Black,1.27,1.1,1.46
10.1097/AOG.0b013e3182a92011,2,No,NA,No,NA,mortality from advanced ovarian cancer,HR,NA,"demographic, comorbidity, stage, tumor characteristics",1,White,Black,1.17,1.02,1.35
10.1097/AOG.0b013e3182a92011,3,No,NA,No,NA,mortality from advanced ovarian cancer,HR,NA,"demographic, comorbidity, stage, tumor characteristics",1,White,Black,1.1,0.95,1.26
10.1097/AOG.0b013e3182a92011,4,No,NA,No,NA,Propensity matched cohorts,HR,NA,None,1,White,Black,1.18,1,1.38
10.1097/AOG.0b013e3182a92011,5,No,NA,No,NA,Propensity matched cohorts,HR,NA,treatment,1,White,Black,1.06,0.84,1.34
10.1097/AOG.0b013e3182a92011,6,Yes,Received complete treatment - Yes,No,NA,mortality from advanced ovarian cancer,HR,NA,"Age at diagnosis, stage, charlson comorbidity score, histology, grade, region, year of diagnosis",1,White,Black,1.04,0.85,1.26
10.1097/AOG.0b013e3182a92011,7,Yes,Received complete treatment - No,No,NA,mortality from advanced ovarian cancer,HR,NA,"Age at diagnosis, stage, charlson comorbidity score, histology, grade, region, year of diagnosis",1,White,Black,1.09,0.89,1.34
10.1016/j.fertnstert.2008.10.061,2,No,NA,No,NA,Live birth,OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",1,White,Asian,0.9,0.82,0.97
10.1016/j.fertnstert.2008.10.061,2,No,NA,No,NA,Live birth,OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",2,White,Black,0.62,0.56,0.68
10.1016/j.fertnstert.2008.10.061,2,No,NA,No,NA,Live birth,OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",3,White,Hispanic,0.87,0.79,0.96
10.1016/j.fertnstert.2008.10.061,3,Yes,Singleton pregnancies,No,NA,Very early preterm birth (<29 weeks),OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",1,White,Asian,0.77,0.48,1.25
10.1016/j.fertnstert.2008.10.061,3,Yes,Singleton pregnancies,No,NA,Very early preterm birth (<29 weeks),OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",2,White,Black,4.25,3.14,5.76
10.1016/j.fertnstert.2008.10.061,3,Yes,Singleton pregnancies,No,NA,Very early preterm birth (<29 weeks),OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",3,White,Hispanic,1.38,0.91,2.09
10.1016/j.fertnstert.2008.10.061,4,Yes,Twin pregnancies,No,NA,Very early preterm birth (<29 weeks),OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",1,White,Asian,0.62,0.42,0.92
10.1016/j.fertnstert.2008.10.061,4,Yes,Twin pregnancies,No,NA,Very early preterm birth (<29 weeks),OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",2,White,Black,2.46,1.84,3.29
10.1016/j.fertnstert.2008.10.061,4,Yes,Twin pregnancies,No,NA,Very early preterm birth (<29 weeks),OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",3,White,Hispanic,1.36,1.01,1.82
10.1016/j.fertnstert.2008.10.061,5,Yes,Singleton pregnancies,No,NA,Early preterm birth (<32 weeks),OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",1,White,Asian,1.01,0.78,1.31
10.1016/j.fertnstert.2008.10.061,5,Yes,Singleton pregnancies,No,NA,Early preterm birth (<32 weeks),OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",2,White,Black,2.72,2.18,3.38
10.1016/j.fertnstert.2008.10.061,5,Yes,Singleton pregnancies,No,NA,Early preterm birth (<32 weeks),OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",3,White,Hispanic,1.19,0.91,1.56
10.1016/j.fertnstert.2008.10.061,6,Yes,Twin pregnancies,No,NA,Early preterm birth (<32 weeks),OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",1,White,Asian,0.83,0.69,1.01
10.1016/j.fertnstert.2008.10.061,6,Yes,Twin pregnancies,No,NA,Early preterm birth (<32 weeks),OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",2,White,Black,1.76,1.44,2.15
10.1016/j.fertnstert.2008.10.061,6,Yes,Twin pregnancies,No,NA,Early preterm birth (<32 weeks),OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",3,White,Hispanic,1.1,0.92,1.33
10.1016/j.fertnstert.2008.10.061,7,Yes,Singleton pregnancies,No,NA,Preterm birth (<37 weeks),OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",1,White,Asian,0.95,0.85,1.06
10.1016/j.fertnstert.2008.10.061,7,Yes,Singleton pregnancies,No,NA,Preterm birth (<37 weeks),OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",2,White,Black,1.79,1.59,2.03
10.1016/j.fertnstert.2008.10.061,7,Yes,Singleton pregnancies,No,NA,Preterm birth (<37 weeks),OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",3,White,Hispanic,1.22,1.08,1.37
10.1016/j.fertnstert.2008.10.061,8,Yes,Twin pregnancies,No,NA,Preterm birth (<37 weeks),OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",1,White,Asian,0.7,0.6,0.82
10.1016/j.fertnstert.2008.10.061,8,Yes,Twin pregnancies,No,NA,Preterm birth (<37 weeks),OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",2,White,Black,1.64,1.29,2.08
10.1016/j.fertnstert.2008.10.061,8,Yes,Twin pregnancies,No,NA,Preterm birth (<37 weeks),OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",3,White,Hispanic,1.14,0.95,1.37
10.1016/j.fertnstert.2008.10.061,9,Yes,Singleton pregnancies,No,NA,Term birth (>=37 weeks),OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",1,White,Asian,1.06,0.94,1.18
10.1016/j.fertnstert.2008.10.061,9,Yes,Singleton pregnancies,No,NA,Term birth (>=37 weeks),OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",2,White,Black,0.56,0.49,0.63
10.1016/j.fertnstert.2008.10.061,9,Yes,Singleton pregnancies,No,NA,Term birth (>=37 weeks),OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",3,White,Hispanic,0.82,0.73,0.93
10.1016/j.fertnstert.2008.10.061,10,Yes,Twin pregnancies,No,NA,Term birth (>=37 weeks),OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",1,White,Asian,1.42,1.22,1.65
10.1016/j.fertnstert.2008.10.061,10,Yes,Twin pregnancies,No,NA,Term birth (>=37 weeks),OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",2,White,Black,0.61,0.48,0.78
10.1016/j.fertnstert.2008.10.061,10,Yes,Twin pregnancies,No,NA,Term birth (>=37 weeks),OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",3,White,Hispanic,0.88,0.73,1.05
10.1016/j.fertnstert.2008.10.061,11,Yes,Singleton pregnancies,No,NA,Birth weight z-score <-1,OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",1,White,Asian,1.78,1.58,2.01
10.1016/j.fertnstert.2008.10.061,11,Yes,Singleton pregnancies,No,NA,Birth weight z-score <-1,OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",2,White,Black,1.81,1.56,2.11
10.1016/j.fertnstert.2008.10.061,11,Yes,Singleton pregnancies,No,NA,Birth weight z-score <-1,OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",3,White,Hispanic,1.36,1.17,1.58
10.1016/j.fertnstert.2008.10.061,12,Yes,Twin pregnancies,No,NA,Birth weight z-score <-1,OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",1,White,Asian,1.3,1.03,1.66
10.1016/j.fertnstert.2008.10.061,12,Yes,Twin pregnancies,No,NA,Birth weight z-score <-1,OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",2,White,Black,1.97,1.5,2.57
10.1016/j.fertnstert.2008.10.061,12,Yes,Twin pregnancies,No,NA,Birth weight z-score <-1,OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",3,White,Hispanic,1.26,0.97,1.64
10.1016/j.fertnstert.2008.10.061,13,Yes,Singleton pregnancies,No,NA,Birth weight z-score <-2,OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",1,White,Asian,2.05,1.5,2.8
10.1016/j.fertnstert.2008.10.061,13,Yes,Singleton pregnancies,No,NA,Birth weight z-score <-2,OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",2,White,Black,2.17,1.47,3.19
10.1016/j.fertnstert.2008.10.061,13,Yes,Singleton pregnancies,No,NA,Birth weight z-score <-2,OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",3,White,Hispanic,1.64,1.11,2.42
10.1016/j.fertnstert.2008.10.061,14,Yes,Twin pregnancies,No,NA,Birth weight z-score <-2,OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",1,White,Asian,1.29,0.76,2.17
10.1016/j.fertnstert.2008.10.061,14,Yes,Twin pregnancies,No,NA,Birth weight z-score <-2,OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",2,White,Black,3.21,2.02,5.11
10.1016/j.fertnstert.2008.10.061,14,Yes,Twin pregnancies,No,NA,Birth weight z-score <-2,OR,NA,"maternal age; number of embryos transferred; and diagnoses of male factor, endometriosis, polycystic ovarian syndrome, diminished ovarian reserve, tubal factors, uterine factors, and other factors.",3,White,Hispanic,1.57,0.94,2.62
10.1097/AOG.0b013e3182a7f3fc,1,No,NA,No,NA,Low Sexual Desire or Interest,OR,NA,"age, lack of a current spouse or sexual partner, poor, fair, or good vs. excellent or very good overall health, current diabetes mellitus vs. no diabetes, obstetric and deliveryspecific characteristics, parity, mode of delivery, ever birth after 40 weeks of gestation, ever oxytocin administration, ever had operative-assisted vaginal delivery, ever had episiotomy, ever had 3rd or 4th degree laceration, ever had spinal anesthesia, ever baby weight = 4000 grams",1,White,Black/African American,0.6,0.41,0.86
10.1097/AOG.0b013e3182a7f3fc,1,No,NA,No,NA,Low Sexual Desire or Interest,OR,NA,"age, lack of a current spouse or sexual partner, poor, fair, or good vs. excellent or very good overall health, current diabetes mellitus vs. no diabetes, obstetric and deliveryspecific characteristics, parity, mode of delivery, ever birth after 40 weeks of gestation, ever oxytocin administration, ever had operative-assisted vaginal delivery, ever had episiotomy, ever had 3rd or 4th degree laceration, ever had spinal anesthesia, ever baby weight = 4000 grams",2,White,Asian/Asian American,1.06,0.72,1.56
10.1097/AOG.0b013e3182a7f3fc,1,No,NA,No,NA,Low Sexual Desire or Interest,OR,NA,"age, lack of a current spouse or sexual partner, poor, fair, or good vs. excellent or very good overall health, current diabetes mellitus vs. no diabetes, obstetric and deliveryspecific characteristics, parity, mode of delivery, ever birth after 40 weeks of gestation, ever oxytocin administration, ever had operative-assisted vaginal delivery, ever had episiotomy, ever had 3rd or 4th degree laceration, ever had spinal anesthesia, ever baby weight = 4000 grams",3,White,Latina/Hispanic,0.9,0.61,1.31
10.1097/AOG.0b013e3182a7f3fc,2,No,NA,No,NA,Less than Monthly Sexual Activity,OR,NA,"age, lack of a current spouse or sexual partner, poor, fair, or good vs. excellent or very good overall health, current diabetes mellitus vs. no diabetes, obstetric and deliveryspecific characteristics, parity, mode of delivery, ever birth after 40 weeks of gestation, ever oxytocin administration, ever had operative-assisted vaginal delivery, ever had episiotomy, ever had 3rd or 4th degree laceration, ever had spinal anesthesia, ever baby weight = 4000 grams",1,White,Black/African American,1.8,1.19,2.71
10.1097/AOG.0b013e3182a7f3fc,2,No,NA,No,NA,Less than Monthly Sexual Activity,OR,NA,"age, lack of a current spouse or sexual partner, poor, fair, or good vs. excellent or very good overall health, current diabetes mellitus vs. no diabetes, obstetric and deliveryspecific characteristics, parity, mode of delivery, ever birth after 40 weeks of gestation, ever oxytocin administration, ever had operative-assisted vaginal delivery, ever had episiotomy, ever had 3rd or 4th degree laceration, ever had spinal anesthesia, ever baby weight = 4000 grams",2,White,Asian/Asian American,2.06,1.36,3.13
10.1097/AOG.0b013e3182a7f3fc,2,No,NA,No,NA,Less than Monthly Sexual Activity,OR,NA,"age, lack of a current spouse or sexual partner, poor, fair, or good vs. excellent or very good overall health, current diabetes mellitus vs. no diabetes, obstetric and deliveryspecific characteristics, parity, mode of delivery, ever birth after 40 weeks of gestation, ever oxytocin administration, ever had operative-assisted vaginal delivery, ever had episiotomy, ever had 3rd or 4th degree laceration, ever had spinal anesthesia, ever baby weight = 4000 grams",3,White,Latina/Hispanic,1.27,0.84,1.92
10.1097/AOG.0b013e3182a7f3fc,3,No,NA,No,NA,Low Sexual Satisfaction,OR,NA,"age, lack of a current spouse or sexual partner, poor, fair, or good vs. excellent or very good overall health, current diabetes mellitus vs. no diabetes, obstetric and deliveryspecific characteristics, parity, mode of delivery, ever birth after 40 weeks of gestation, ever oxytocin administration, ever had operative-assisted vaginal delivery, ever had episiotomy, ever had 3rd or 4th degree laceration, ever had spinal anesthesia, ever baby weight = 4000 grams",1,White,Black/African American,0.83,0.56,1.22
10.1097/AOG.0b013e3182a7f3fc,3,No,NA,No,NA,Low Sexual Satisfaction,OR,NA,"age, lack of a current spouse or sexual partner, poor, fair, or good vs. excellent or very good overall health, current diabetes mellitus vs. no diabetes, obstetric and deliveryspecific characteristics, parity, mode of delivery, ever birth after 40 weeks of gestation, ever oxytocin administration, ever had operative-assisted vaginal delivery, ever had episiotomy, ever had 3rd or 4th degree laceration, ever had spinal anesthesia, ever baby weight = 4000 grams",2,White,Asian/Asian American,0.98,0.66,1.45
10.1097/AOG.0b013e3182a7f3fc,3,No,NA,No,NA,Low Sexual Satisfaction,OR,NA,"age, lack of a current spouse or sexual partner, poor, fair, or good vs. excellent or very good overall health, current diabetes mellitus vs. no diabetes, obstetric and deliveryspecific characteristics, parity, mode of delivery, ever birth after 40 weeks of gestation, ever oxytocin administration, ever had operative-assisted vaginal delivery, ever had episiotomy, ever had 3rd or 4th degree laceration, ever had spinal anesthesia, ever baby weight = 4000 grams",3,White,Latina/Hispanic,0.62,0.41,0.93
10.1097/AOG.0b013e318220ebf3,1,No,NA,No,NA,human papillomavirus vaccination completion rates,OR,NA,None,1,White,African American,0.5,0.38,0.65
10.1097/AOG.0b013e318220ebf3,1,No,NA,No,NA,human papillomavirus vaccination completion rates,OR,NA,None,2,White,Hispanic,0.78,0.43,1.43
10.1097/AOG.0b013e318220ebf3,2,No,NA,No,NA,human papillomavirus vaccination completion rates,OR,NA,"age, insurance type, practice location, practice type",1,White,African American or Hispanic,0.64,0.49,0.83
10.1093/humrep/dev235,1,No,NA,No,NA,Hysterectomy,Percent,NA,None,1,N/A,Whites,45,-99,-99
10.1093/humrep/dev235,1,No,NA,No,NA,Hysterectomy,Percent,NA,None,2,N/A,African Americans,74,-99,-99
10.1093/humrep/dev235,2,No,NA,No,NA,Myomectomy,Percent,NA,None,1,N/A,Whites,31,-99,-99
10.1093/humrep/dev235,2,No,NA,No,NA,Myomectomy,Percent,NA,None,2,N/A,African Americans,5,-99,-99
10.1093/humrep/dev235,3,No,NA,No,NA,Hysteroscopic resection,Percent,NA,None,1,N/A,Whites,17,-99,-99
10.1093/humrep/dev235,3,No,NA,No,NA,Hysteroscopic resection,Percent,NA,None,2,N/A,African Americans,8,-99,-99
10.1093/humrep/dev235,4,No,NA,No,NA,Uterine artery embolization,Percent,NA,None,1,N/A,Whites,0,-99,-99
10.1093/humrep/dev235,4,No,NA,No,NA,Uterine artery embolization,Percent,NA,None,2,N/A,African Americans,11,-99,-99
10.1093/humrep/dev235,5,No,NA,No,NA,Endometrial ablation,Percent,NA,None,1,N/A,Whites,7,-99,-99
10.1093/humrep/dev235,5,No,NA,No,NA,Endometrial ablation,Percent,NA,None,2,N/A,African Americans,1,-99,-99
10.1093/humrep/dev235,6,No,NA,No,NA,Thermal balloon,Percent,NA,None,1,N/A,Whites,0,-99,-99
10.1093/humrep/dev235,6,No,NA,No,NA,Thermal balloon,Percent,NA,None,2,N/A,African Americans,1,-99,-99
10.1016/j.ajog.2015.02.010,1,No,NA,No,NA,Very early spontaneous preterm birth: 20.0-27.9 weeks gestation,Percent,NA,None,1,N/A,White,61.9,-99,-99
10.1016/j.ajog.2015.02.010,1,No,NA,No,NA,Very early spontaneous preterm birth: 20.0-27.9 weeks gestation,Percent,NA,None,2,N/A,Black,29.9,-99,-99
10.1016/j.ajog.2015.02.010,1,No,NA,No,NA,Very early spontaneous preterm birth: 20.0-27.9 weeks gestation,Percent,NA,None,3,N/A,Other,8.2,-99,-99
10.1016/j.ajog.2015.02.010,2,No,NA,No,NA,Early spontaneous preterm birth: 27.0-33.9 weeks gestation,Percent,NA,None,1,N/A,White,70.2,-99,-99
10.1016/j.ajog.2015.02.010,2,No,NA,No,NA,Early spontaneous preterm birth: 27.0-33.9 weeks gestation,Percent,NA,None,2,N/A,Black,20.2,-99,-99
10.1016/j.ajog.2015.02.010,2,No,NA,No,NA,Early spontaneous preterm birth: 27.0-33.9 weeks gestation,Percent,NA,None,3,N/A,Other,9.7,-99,-99
10.1097/AOG.0000000000000739,1,Yes,Underweight,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",1,White,Black,0.99,0.54,1.83
10.1097/AOG.0000000000000739,1,Yes,Underweight,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",2,White,Hispanic,1.38,0.8,2.4
10.1097/AOG.0000000000000739,1,Yes,Underweight,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",3,White,Asian,1.01,0.62,1.65
10.1097/AOG.0000000000000739,1,Yes,Underweight,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",4,White,Other,0.63,0.21,1.95
10.1097/AOG.0000000000000739,2,Yes,Underweight,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",1,White,Black,0.76,0.35,1.63
10.1097/AOG.0000000000000739,2,Yes,Underweight,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",2,White,Hispanic,0.71,0.29,1.75
10.1097/AOG.0000000000000739,2,Yes,Underweight,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",3,White,Asian,0.58,0.3,1.1
10.1097/AOG.0000000000000739,2,Yes,Underweight,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",4,White,Other,2,0.72,5.51
10.1097/AOG.0000000000000739,3,Yes,Normal Weight,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",1,White,Black,1.45,1.19,1.77
10.1097/AOG.0000000000000739,3,Yes,Normal Weight,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",2,White,Hispanic,1.29,1.07,1.56
10.1097/AOG.0000000000000739,3,Yes,Normal Weight,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",3,White,Asian,1.31,1.08,1.58
10.1097/AOG.0000000000000739,3,Yes,Normal Weight,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",4,White,American Indian,1.42,0.9,2.25
10.1097/AOG.0000000000000739,3,Yes,Normal Weight,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",5,White,Alaskan Native,1.46,0.9,2.35
10.1097/AOG.0000000000000739,3,Yes,Normal Weight,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",6,White,Hawaiian,1.29,0.85,NA
10.1097/AOG.0000000000000739,3,Yes,Normal Weight,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",7,White,NA,NA,NA,1.96
10.1097/AOG.0000000000000739,3,Yes,Normal Weight,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",8,White,Other,1.35,0.95,1.91
10.1097/AOG.0000000000000739,4,Yes,Normal Weight,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",1,White,Black,0.93,0.77,1.12
10.1097/AOG.0000000000000739,4,Yes,Normal Weight,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",2,White,Hispanic,0.84,0.69,1.01
10.1097/AOG.0000000000000739,4,Yes,Normal Weight,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",3,White,Asian,0.66,0.54,0.8
10.1097/AOG.0000000000000739,4,Yes,Normal Weight,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",4,White,American Indian,1.02,0.67,1.55
10.1097/AOG.0000000000000739,4,Yes,Normal Weight,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",5,White,Alaskan Native,0.85,0.54,1.35
10.1097/AOG.0000000000000739,4,Yes,Normal Weight,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",6,White,Hawaiian,0.96,0.67,NA
10.1097/AOG.0000000000000739,4,Yes,Normal Weight,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",7,White,NA,NA,NA,1.39
10.1097/AOG.0000000000000739,4,Yes,Normal Weight,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",8,White,Other,1.02,0.75,1.38
10.1097/AOG.0000000000000739,5,Yes,Overweight,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",1,White,Black,1.49,1.06,2.09
10.1097/AOG.0000000000000739,5,Yes,Overweight,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",2,White,Hispanic,0.91,0.64,1.28
10.1097/AOG.0000000000000739,5,Yes,Overweight,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",3,White,Asian,0.96,0.62,1.49
10.1097/AOG.0000000000000739,5,Yes,Overweight,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",4,White,American Indian,0.87,0.45,1.69
10.1097/AOG.0000000000000739,5,Yes,Overweight,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",5,White,Alaskan Native,2.26,1.08,4.73
10.1097/AOG.0000000000000739,5,Yes,Overweight,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",6,White,Hawaiian,0.88,0.37,NA
10.1097/AOG.0000000000000739,5,Yes,Overweight,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",7,White,NA,NA,NA,2.08
10.1097/AOG.0000000000000739,5,Yes,Overweight,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",8,White,Other,1.15,0.61,2.17
10.1097/AOG.0000000000000739,6,Yes,Overweight,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",1,White,Black,1.17,0.91,1.5
10.1097/AOG.0000000000000739,6,Yes,Overweight,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",2,White,Hispanic,0.85,0.67,1.08
10.1097/AOG.0000000000000739,6,Yes,Overweight,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",3,White,Asian,0.77,0.57,1.04
10.1097/AOG.0000000000000739,6,Yes,Overweight,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",4,White,American Indian,0.99,0.6,1.63
10.1097/AOG.0000000000000739,6,Yes,Overweight,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",5,White,Alaskan Native,0.86,0.45,1.63
10.1097/AOG.0000000000000739,6,Yes,Overweight,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",6,White,Hawaiian,0.75,0.44,NA
10.1097/AOG.0000000000000739,6,Yes,Overweight,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",7,White,NA,NA,NA,1.3
10.1097/AOG.0000000000000739,6,Yes,Overweight,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",8,White,Other,1,0.64,1.56
10.1097/AOG.0000000000000739,7,Yes,Obese,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",1,White,Black,0.99,0.72,1.34
10.1097/AOG.0000000000000739,7,Yes,Obese,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",2,White,Hispanic,0.79,0.55,1.13
10.1097/AOG.0000000000000739,7,Yes,Obese,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",3,White,Asian,0.45,0.22,0.9
10.1097/AOG.0000000000000739,7,Yes,Obese,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",4,White,American Indian,0.69,0.35,1.36
10.1097/AOG.0000000000000739,7,Yes,Obese,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",5,White,Alaskan Native,0.46,0.22,0.98
10.1097/AOG.0000000000000739,7,Yes,Obese,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",6,White,Hawaiian,0.46,0.2,NA
10.1097/AOG.0000000000000739,7,Yes,Obese,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",7,White,NA,NA,NA,1.09
10.1097/AOG.0000000000000739,7,Yes,Obese,No,NA,Inadequate Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",8,White,Other,1,0.54,1.87
10.1097/AOG.0000000000000739,8,Yes,Obese,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",1,White,Black,0.84,0.65,1.08
10.1097/AOG.0000000000000739,8,Yes,Obese,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",2,White,Hispanic,1.02,0.77,1.36
10.1097/AOG.0000000000000739,8,Yes,Obese,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",3,White,Asian,0.86,0.51,1.48
10.1097/AOG.0000000000000739,8,Yes,Obese,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",4,White,American Indian,0.72,0.37,1.41
10.1097/AOG.0000000000000739,8,Yes,Obese,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",5,White,Alaskan Native,0.57,0.33,0.99
10.1097/AOG.0000000000000739,8,Yes,Obese,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",6,White,Hawaiian,0.78,0.44,NA
10.1097/AOG.0000000000000739,8,Yes,Obese,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",7,White,NA,NA,NA,1.38
10.1097/AOG.0000000000000739,8,Yes,Obese,No,NA,Excessive Gestational Weight Gain,OR,NA,"age, education, parity, marital status, wic enrollment, medicaid enrollment, first trimester prenatal care, regular prepregnancy physical activity, alcohol consumption during pregnancy, smoking status during pregnancy, pre pregnancy depression, partner abuse before or during pregnancy, number of stressful life events, severe nausea during pregnancy, diabetic disease, hypertensive conditions",8,White,Other,1.23,0.76,2.01
10.1097/AOG.0b013e31823d4006,1,No,NA,No,NA,Standard treatment,RR,NA,"insurance status, age, charlson deyo score, clinical stage, median income, facility type",1,White,Hispanic,0.89,0.84,0.94
10.1097/AOG.0b013e31823d4006,1,No,NA,No,NA,Standard treatment,RR,NA,"insurance status, age, charlson deyo score, clinical stage, median income, facility type",2,White,African American,0.87,0.83,0.92
10.1097/AOG.0b013e31823d4006,1,No,NA,No,NA,Standard treatment,RR,NA,"insurance status, age, charlson deyo score, clinical stage, median income, facility type",3,White,Other,0.93,0.87,0.98
10.1097/AOG.0b013e31823d4006,1,No,NA,No,NA,Standard treatment,RR,NA,"insurance status, age, charlson deyo score, clinical stage, median income, facility type",4,White,Missing,0.98,0.95,1.02
10.1097/AOG.0000000000000605,1,No,NA,No,NA,Surgery,OR,NA,"stage, age, histology, period of diagnosis, race, marital status, region, urban setting, income level, Charlson score",1,White,African American,0.5,0.3,0.6
10.1097/AOG.0000000000000605,2,No,NA,No,NA,Chemotherapy,OR,NA,"stage, age, histology, period of diagnosis, race, marital status, region, urban setting, income level, Charlson score",1,White,African American,0.8,0.6,0.9
10.1097/AOG.0000000000000605,3,No,NA,No,NA,Radiotherapy,OR,NA,"stage, age, histology, period of diagnosis, race, marital status, region, urban setting, income level, Charlson score",1,White,African American,0.9,0.8,1.1
10.1097/AOG.0000000000000605,4,Yes,Stage I,No,NA,Disease-specific mortality,HR,NA,None,1,White,African American,1.4,1.1,1.8
10.1097/AOG.0000000000000605,5,Yes,Stage I,No,NA,All-cause mortality,HR,NA,None,1,White,African American,1.3,1.1,1.6
10.1097/AOG.0000000000000605,6,Yes,Stage II,No,NA,Disease-specific mortality,HR,NA,None,1,White,African American,1.4,1.06,2
10.1097/AOG.0000000000000605,7,Yes,Stage II,No,NA,All-cause mortality,HR,NA,None,1,White,African American,1.6,1.3,2
10.1097/AOG.0000000000000605,8,Yes,Stage III,No,NA,Disease-specific mortality,HR,NA,None,1,White,African American,1.2,1.002,1.5
10.1097/AOG.0000000000000605,9,Yes,Stage III,No,NA,All-cause mortality,HR,NA,None,1,White,African American,1.3,1.1,1.5
10.1097/AOG.0000000000000605,10,Yes,Stage IV,No,NA,Disease-specific mortality,HR,NA,None,1,White,African American,1.1,0.9,1.3
10.1097/AOG.0000000000000605,11,Yes,Stage IV,No,NA,All-cause mortality,HR,NA,None,1,White,African American,1.3,1.1,1.5
10.1097/AOG.0000000000000605,12,Yes,Stage Unknown,No,NA,Disease-specific mortality,HR,NA,None,1,White,African American,1.4,1.1,1.7
10.1097/AOG.0000000000000605,13,Yes,Stage Unknown,No,NA,All-cause mortality,HR,NA,None,1,White,African American,1.3,1.1,1.6
10.1097/AOG.0000000000000605,15,Yes,Histology,No,NA,Disease-specific mortality,HR,NA,None,1,White,African American,1.4,1.2,1.7
10.1097/AOG.0000000000000605,16,Yes,Histology,No,NA,Disease-specific mortality,HR,NA,None,1,White,African American,1.5,1.3,1.7
10.1097/AOG.0000000000000605,17,Yes,Histology Grade 3,No,NA,Disease-specific mortality,HR,NA,None,1,White,African American,1.2,1.07,1.5
10.1097/AOG.0000000000000605,18,Yes,Histology Grade 3,No,NA,All-cause mortality,HR,NA,None,1,White,African American,1.4,1.2,1.6
10.1097/AOG.0000000000000605,19,Yes,Histology Uterine carcinosarcoma clear clel,No,NA,Disease-specific mortality,HR,NA,None,1,White,African American,1.5,1.06,2.1
10.1097/AOG.0000000000000605,20,Yes,Histology Uterine carcinosarcoma clear cell,No,NA,All-cause mortality,HR,NA,None,1,White,African American,1.4,1.09,1.8
10.1097/AOG.0000000000000605,21,Yes,Histology Uterine carcinosarcoma serous,No,NA,Disease-specific mortality,HR,NA,None,1,White,African American,1.4,1.1,1.6
10.1097/AOG.0000000000000605,22,Yes,Histology Uterine carcinosarcoma serous,No,NA,All-cause mortality,HR,NA,None,1,White,African American,1.5,1.3,1.7
10.1097/AOG.0000000000000605,23,No,NA,No,NA,Disease-specific mortality,HR,NA,None,1,White,African American,1.1,1,1.2
10.1097/AOG.0000000000000605,24,No,NA,No,NA,Overall mortality,HR,NA,None,1,White,African American,1.2,1.1,1.3
10.1016/j.ygyno.2014.06.011,1,No,NA,No,NA,Receiving IP chemotherapy,OR,NA,"age group (years), stage at diagnosis, married, comorbidity score, urban/rural residence, median income of zip code for census tract, tertiles",1,Non white race,White,2.07,1.68,87
10.1016/j.ygyno.2014.03.562,1,No,NA,No,NA,Type ii endometrial cancer specific survival,HR,NA,"age at diagnosis, stage, histology, surgery, lymphadenectomy, radiation",1,Non Hispanic white,Hispanic,1.02,0.91,1.14
10.1016/j.ygyno.2014.03.562,2,No,NA,No,NA,overall survival,HR,NA,"age at diagnosis, stage, histology, surgery, lymphadenectomy, radiation",1,Non Hispanic white,Hispanic,1.06,0.97,1.16
10.1016/j.ygyno.2014.02.041,1,No,NA,No,NA,Death,HR,NA,"age, stage, BMI, lymphadenectomy, adjuvant treatment",1,White,Black,2,1.3,3.2
10.1016/j.ygyno.2014.02.041,2,No,NA,Yes,Early stage disease,Death,HR,NA,"age, stage, BMI, lymphadenectomy, adjuvant treatment",1,White,Black,3,1.5,5.8
10.1016/j.ajog.2013.07.021,1,Yes,1973-1979,No,NA,All-cause mortality,HR,NA,None,1,White,African American,0.83,0.64,1.08
10.1016/j.ajog.2013.07.021,2,Yes,1973-1979,No,NA,All-cause mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,1.05,0.78,1.42
10.1016/j.ajog.2013.07.021,3,Yes,1973-1979,No,NA,Vulvar cancer mortality,HR,NA,None,1,White,African American,0.78,0.48,1.26
10.1016/j.ajog.2013.07.021,4,Yes,1973-1979,No,NA,Vulvar cancer mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,0.89,0.51,1.53
10.1016/j.ajog.2013.07.021,5,Yes,1980-1989,No,NA,All-cause mortality,HR,NA,None,1,White,African American,0.98,0.77,1.25
10.1016/j.ajog.2013.07.021,6,Yes,1980-1989,No,NA,All-cause mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,1.55,1.18,2.03
10.1016/j.ajog.2013.07.021,7,Yes,1980-1989,No,NA,Vulvar cancer mortality,HR,NA,None,1,White,African American,0.77,0.49,1.22
10.1016/j.ajog.2013.07.021,8,Yes,1980-1989,No,NA,Vulvar cancer mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,0.74,0.43,1.26
10.1016/j.ajog.2013.07.021,9,Yes,1990-1999,No,NA,All-cause mortality,HR,NA,None,1,White,African American,0.77,0.62,0.96
10.1016/j.ajog.2013.07.021,10,Yes,1990-1999,No,NA,All-cause mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,0.9,0.71,1.15
10.1016/j.ajog.2013.07.021,11,Yes,1990-1999,No,NA,Vulvar cancer mortality,HR,NA,None,1,White,African American,0.56,0.37,0.83
10.1016/j.ajog.2013.07.021,12,Yes,1990-1999,No,NA,Vulvar cancer mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,0.62,0.41,0.95
10.1016/j.ajog.2013.07.021,13,Yes,2000-2009,No,NA,All-cause mortality,HR,NA,None,1,White,African American,0.82,0.62,1.07
10.1016/j.ajog.2013.07.021,14,Yes,2000-2009,No,NA,All-cause mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,0.75,0.55,1.01
10.1016/j.ajog.2013.07.021,15,Yes,2000-2009,No,NA,Vulvar cancer mortality,HR,NA,None,1,White,African American,0.65,0.43,0.97
10.1016/j.ajog.2013.07.021,16,Yes,2000-2009,No,NA,Vulvar cancer mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,0.46,0.3,0.72
10.1016/j.ajog.2013.07.021,17,Yes,All years,No,NA,All-cause mortality,HR,NA,None,1,White,African American,0.84,0.74,0.95
10.1016/j.ajog.2013.07.021,18,Yes,All years,No,NA,All-cause mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,1.03,0.9,1.17
10.1016/j.ajog.2013.07.021,19,Yes,All years,No,NA,Vulvar cancer mortality,HR,NA,None,1,White,African American,0.66,0.53,0.82
10.1016/j.ajog.2013.07.021,20,Yes,All years,No,NA,Vulvar cancer mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,0.67,0.53,0.84
10.1016/j.ajog.2013.07.021,21,Yes,1973-1979,Yes,<60 y,All-cause mortality,HR,NA,None,1,White,African American,1.1,0.75,1.64
10.1016/j.ajog.2013.07.021,22,Yes,1973-1979,Yes,<60 y,All-cause mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,1.11,0.69,1.79
10.1016/j.ajog.2013.07.021,23,Yes,1973-1979,Yes,<60 y,Vulvar cancer mortality,HR,NA,None,1,White,African American,1.28,0.62,2.64
10.1016/j.ajog.2013.07.021,24,Yes,1973-1979,Yes,<60 y,Vulvar cancer mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,1.2,0.48,3.01
10.1016/j.ajog.2013.07.021,25,Yes,1973-1979,Yes,>=60 y,All-cause mortality,HR,NA,None,1,White,African American,1.28,0.88,1.86
10.1016/j.ajog.2013.07.021,26,Yes,1973-1979,Yes,>=60 y,All-cause mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,1.05,0.69,1.59
10.1016/j.ajog.2013.07.021,27,Yes,1973-1979,Yes,>=60 y,Vulvar cancer mortality,HR,NA,None,1,White,African American,0.93,0.48,1.81
10.1016/j.ajog.2013.07.021,28,Yes,1973-1979,Yes,>=60 y,Vulvar cancer mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,0.72,0.34,1.52
10.1016/j.ajog.2013.07.021,29,Yes,1973-1979,Yes,All ages,All-cause mortality,HR,NA,None,1,White,African American,0.83,0.64,1.08
10.1016/j.ajog.2013.07.021,30,Yes,1973-1979,Yes,All ages,All-cause mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,1.05,0.78,1.42
10.1016/j.ajog.2013.07.021,31,Yes,1973-1979,Yes,All ages,Vulvar cancer mortality,HR,NA,None,1,White,African American,0.78,0.48,1.26
10.1016/j.ajog.2013.07.021,32,Yes,1973-1979,Yes,All ages,Vulvar cancer mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,0.89,0.51,1.53
10.1016/j.ajog.2013.07.021,33,Yes,1980-1989,Yes,<60 y,All-cause mortality,HR,NA,None,1,White,African American,1.96,1.35,2.85
10.1016/j.ajog.2013.07.021,34,Yes,1980-1989,Yes,<60 y,All-cause mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,1.62,1.06,2.47
10.1016/j.ajog.2013.07.021,35,Yes,1980-1989,Yes,<60 y,Vulvar cancer mortality,HR,NA,None,1,White,African American,1.73,0.84,3.56
10.1016/j.ajog.2013.07.021,36,Yes,1980-1989,Yes,<60 y,Vulvar cancer mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,0.72,0.26,1.99
10.1016/j.ajog.2013.07.021,37,Yes,1980-1989,Yes,>=60 y,All-cause mortality,HR,NA,None,1,White,African American,1.41,1,1.98
10.1016/j.ajog.2013.07.021,38,Yes,1980-1989,Yes,>=60 y,All-cause mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,1.37,0.94,2
10.1016/j.ajog.2013.07.021,39,Yes,1980-1989,Yes,>=60 y,Vulvar cancer mortality,HR,NA,None,1,White,African American,0.95,0.5,1.78
10.1016/j.ajog.2013.07.021,40,Yes,1980-1989,Yes,>=60 y,Vulvar cancer mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,0.59,0.29,1.21
10.1016/j.ajog.2013.07.021,41,Yes,1980-1989,Yes,All ages,All-cause mortality,HR,NA,None,1,White,African American,0.98,0.77,1.25
10.1016/j.ajog.2013.07.021,42,Yes,1980-1989,Yes,All ages,All-cause mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,1.55,1.18,2.03
10.1016/j.ajog.2013.07.021,43,Yes,1980-1989,Yes,All ages,Vulvar cancer mortality,HR,NA,None,1,White,African American,0.77,0.49,1.22
10.1016/j.ajog.2013.07.021,44,Yes,1980-1989,Yes,All ages,Vulvar cancer mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,0.74,0.43,1.26
10.1016/j.ajog.2013.07.021,45,Yes,1990-1999,Yes,<60 y,All-cause mortality,HR,NA,None,1,White,African American,1.53,1.04,2.24
10.1016/j.ajog.2013.07.021,46,Yes,1990-1999,Yes,<60 y,All-cause mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,1.22,0.79,1.89
10.1016/j.ajog.2013.07.021,47,Yes,1990-1999,Yes,<60 y,Vulvar cancer mortality,HR,NA,None,1,White,African American,0.86,0.39,1.89
10.1016/j.ajog.2013.07.021,48,Yes,1990-1999,Yes,<60 y,Vulvar cancer mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,0.65,0.27,1.57
10.1016/j.ajog.2013.07.021,49,Yes,1990-1999,Yes,>=60 y,All-cause mortality,HR,NA,None,1,White,African American,0.83,0.63,1.1
10.1016/j.ajog.2013.07.021,50,Yes,1990-1999,Yes,>=60 y,All-cause mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,0.77,0.57,1.03
10.1016/j.ajog.2013.07.021,51,Yes,1990-1999,Yes,>=60 y,Vulvar cancer mortality,HR,NA,None,1,White,African American,0.7,0.44,1.12
10.1016/j.ajog.2013.07.021,52,Yes,1990-1999,Yes,>=60 y,Vulvar cancer mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,0.59,0.36,0.96
10.1016/j.ajog.2013.07.021,53,Yes,1990-1999,Yes,All ages,All-cause mortality,HR,NA,None,1,White,African American,0.77,0.62,0.96
10.1016/j.ajog.2013.07.021,54,Yes,1990-1999,Yes,All ages,All-cause mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,0.9,0.71,1.15
10.1016/j.ajog.2013.07.021,55,Yes,1990-1999,Yes,All ages,Vulvar cancer mortality,HR,NA,None,1,White,African American,0.56,0.37,0.83
10.1016/j.ajog.2013.07.021,56,Yes,1990-1999,Yes,All ages,Vulvar cancer mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,0.62,0.41,0.95
10.1016/j.ajog.2013.07.021,57,Yes,2000-2009,Yes,<60 y,All-cause mortality,HR,NA,None,1,White,African American,1.91,1.26,2.91
10.1016/j.ajog.2013.07.021,58,Yes,2000-2009,Yes,<60 y,All-cause mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,1.74,1.05,2.88
10.1016/j.ajog.2013.07.021,59,Yes,2000-2009,Yes,<60 y,Vulvar cancer mortality,HR,NA,None,1,White,African American,1.32,0.68,2.53
10.1016/j.ajog.2013.07.021,60,Yes,2000-2009,Yes,<60 y,Vulvar cancer mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,1.18,0.53,2.64
10.1016/j.ajog.2013.07.021,61,Yes,2000-2009,Yes,>=60 y,All-cause mortality,HR,NA,None,1,White,African American,0.82,0.56,1.21
10.1016/j.ajog.2013.07.021,62,Yes,2000-2009,Yes,>=60 y,All-cause mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,0.46,0.3,0.71
10.1016/j.ajog.2013.07.021,63,Yes,2000-2009,Yes,>=60 y,Vulvar cancer mortality,HR,NA,None,1,White,African American,0.75,0.44,1.28
10.1016/j.ajog.2013.07.021,64,Yes,2000-2009,Yes,>=60 y,Vulvar cancer mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,0.32,0.18,0.57
10.1016/j.ajog.2013.07.021,65,Yes,2000-2009,Yes,All ages,All-cause mortality,HR,NA,None,1,White,African American,0.82,0.62,1.07
10.1016/j.ajog.2013.07.021,66,Yes,2000-2009,Yes,All ages,All-cause mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,0.75,0.55,1.01
10.1016/j.ajog.2013.07.021,67,Yes,2000-2009,Yes,All ages,Vulvar cancer mortality,HR,NA,None,1,White,African American,0.65,0.43,0.97
10.1016/j.ajog.2013.07.021,68,Yes,2000-2009,Yes,All ages,Vulvar cancer mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,0.46,0.3,0.72
10.1016/j.ajog.2013.07.021,69,Yes,All years,Yes,<60 y,All-cause mortality,HR,NA,None,1,White,African American,1.59,1.31,1.93
10.1016/j.ajog.2013.07.021,70,Yes,All years,Yes,<60 y,All-cause mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,1.45,1.17,1.8
10.1016/j.ajog.2013.07.021,71,Yes,All years,Yes,<60 y,Vulvar cancer mortality,HR,NA,None,1,White,African American,1.27,0.89,1.82
10.1016/j.ajog.2013.07.021,72,Yes,All years,Yes,<60 y,Vulvar cancer mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,1.04,0.69,1.55
10.1016/j.ajog.2013.07.021,73,Yes,All years,Yes,>=60 y,All-cause mortality,HR,NA,None,1,White,African American,1.01,0.86,1.2
10.1016/j.ajog.2013.07.021,74,Yes,All years,Yes,>=60 y,All-cause mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,0.85,0.71,1.01
10.1016/j.ajog.2013.07.021,75,Yes,All years,Yes,>=60 y,Vulvar cancer mortality,HR,NA,None,1,White,African American,0.79,0.6,1.05
10.1016/j.ajog.2013.07.021,76,Yes,All years,Yes,>=60 y,Vulvar cancer mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,0.54,0.41,0.73
10.1016/j.ajog.2013.07.021,77,Yes,All years,Yes,All ages,All-cause mortality,HR,NA,None,1,White,African American,0.84,0.74,0.95
10.1016/j.ajog.2013.07.021,78,Yes,All years,Yes,All ages,All-cause mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,1.03,0.9,1.17
10.1016/j.ajog.2013.07.021,79,Yes,All years,Yes,All ages,Vulvar cancer mortality,HR,NA,None,1,White,African American,0.66,0.53,0.82
10.1016/j.ajog.2013.07.021,80,Yes,All years,Yes,All ages,Vulvar cancer mortality,HR,NA,"Surveillance, Epidemiology, and End Results Registry, marital status, stage, age as a categorical variable, treatment, grade, lymph node status",1,White,African American,0.67,0.53,0.84
10.1016/j.ajog.2013.07.021,81,No,NA,No,NA,All-cause mortality,HR,NA,None,1,White,African American,1.03,0.9,1.17
10.1016/j.ajog.2013.07.021,82,No,NA,No,NA,Vulvar cancer mortality,HR,NA,None,1,White,African American,0.67,0.53,0.84
10.1016/j.ajog.2013.07.021,83,Yes,1973-1979,No,NA,Five year survival rate,HR,NA,None,1,White,African American,0.78,0.48,1.26
10.1016/j.ajog.2013.07.021,84,Yes,1980-1989,No,NA,Five year survival rate,HR,NA,None,1,White,African American,0.77,0.49,1.22
10.1016/j.ajog.2013.07.021,85,Yes,1990-1999,No,NA,Five year survival rate,HR,NA,None,1,White,African American,0.56,0.37,0.83
10.1016/j.ajog.2013.07.021,86,Yes,2000-2009,No,NA,Five year survival rate,HR,NA,None,1,White,African American,0.65,0.43,0.97
10.1016/j.ajog.2013.07.021,87,Yes,All years,No,NA,Five year survival rate,HR,NA,None,1,White,African American,0.66,0.53,0.82
10.1016/j.ajog.2012.12.038,1,Yes,New York,No,NA,Ectopic pregnancy rate,Percent,NA,None,1,N/A,White,2.26,-99,-99
10.1016/j.ajog.2012.12.038,1,Yes,New York,No,NA,Ectopic pregnancy rate,Percent,NA,None,2,N/A,Black,2.55,-99,-99
10.1016/j.ajog.2012.12.038,1,Yes,New York,No,NA,Ectopic pregnancy rate,Percent,NA,None,3,N/A,American Indian/Alaskan Native,1.21,-99,-99
10.1016/j.ajog.2012.12.038,1,Yes,New York,No,NA,Ectopic pregnancy rate,Percent,NA,None,4,N/A,Asian,1.19,-99,-99
10.1016/j.ajog.2012.12.038,1,Yes,New York,No,NA,Ectopic pregnancy rate,Percent,NA,None,5,N/A,Hispanic,2.76,-99,-99
10.1016/j.ajog.2012.12.038,1,Yes,New York,No,NA,Ectopic pregnancy rate,Percent,NA,None,6,N/A,Unknown/Missing,2.64,-99,NA
10.1016/j.ajog.2012.12.038,1,Yes,New York,No,NA,Ectopic pregnancy rate,Percent,NA,None,7,N/A,NA,NA,NA,-99
10.1016/j.ajog.2012.12.038,2,Yes,California,No,NA,Ectopic pregnancy rate,Percent,NA,None,1,N/A,White,2.29,-99,-99
10.1016/j.ajog.2012.12.038,2,Yes,California,No,NA,Ectopic pregnancy rate,Percent,NA,None,2,N/A,Black,3.12,-99,-99
10.1016/j.ajog.2012.12.038,2,Yes,California,No,NA,Ectopic pregnancy rate,Percent,NA,None,3,N/A,American Indian/Alaskan Native,2.33,-99,-99
10.1016/j.ajog.2012.12.038,2,Yes,California,No,NA,Ectopic pregnancy rate,Percent,NA,None,4,N/A,Asian,1.99,-99,-99
10.1016/j.ajog.2012.12.038,2,Yes,California,No,NA,Ectopic pregnancy rate,Percent,NA,None,5,N/A,Hispanic,1.93,-99,-99
10.1016/j.ajog.2012.12.038,2,Yes,California,No,NA,Ectopic pregnancy rate,Percent,NA,None,6,N/A,Native Hawaiian/Pacific Islander,2.1,-99,NA
10.1016/j.ajog.2012.12.038,2,Yes,California,No,NA,Ectopic pregnancy rate,Percent,NA,None,7,N/A,NA,NA,NA,-99
10.1016/j.ajog.2012.12.038,2,Yes,California,No,NA,Ectopic pregnancy rate,Percent,NA,None,8,N/A,Unknown/Missing,1.2,-99,-99
10.1016/j.ajog.2012.12.038,3,Yes,Illinois,No,NA,Ectopic pregnancy rate,Percent,NA,None,1,N/A,White,2.45,-99,-99
10.1016/j.ajog.2012.12.038,3,Yes,Illinois,No,NA,Ectopic pregnancy rate,Percent,NA,None,2,N/A,Black,3.51,-99,-99
10.1016/j.ajog.2012.12.038,3,Yes,Illinois,No,NA,Ectopic pregnancy rate,Percent,NA,None,3,N/A,American Indian/Alaskan Native,3.11,-99,-99
10.1016/j.ajog.2012.12.038,3,Yes,Illinois,No,NA,Ectopic pregnancy rate,Percent,NA,None,4,N/A,Asian,1.9,-99,-99
10.1016/j.ajog.2012.12.038,3,Yes,Illinois,No,NA,Ectopic pregnancy rate,Percent,NA,None,5,N/A,Hispanic,2.29,-99,-99
10.1016/j.ajog.2012.12.038,3,Yes,Illinois,No,NA,Ectopic pregnancy rate,Percent,NA,None,6,N/A,Multiracial,1.5,-99,NA
10.1016/j.ajog.2012.12.038,3,Yes,Illinois,No,NA,Ectopic pregnancy rate,Percent,NA,None,7,N/A,NA,NA,NA,-99
10.1016/j.ajog.2012.12.038,3,Yes,Illinois,No,NA,Ectopic pregnancy rate,Percent,NA,None,8,N/A,Unknown/Missing,1.21,-99,-99
10.1016/j.ajog.2012.12.038,4,Yes,New York,No,NA,Ectopic pregnancy rate,RR,NA,age,1,White,Black,1.12,1.1,1.14
10.1016/j.ajog.2012.12.038,4,Yes,New York,No,NA,Ectopic pregnancy rate,RR,NA,age,2,White,American Indian/Alaskan Native,0.56,0.5,0.56
10.1016/j.ajog.2012.12.038,4,Yes,New York,No,NA,Ectopic pregnancy rate,RR,NA,age,3,White,Asian,0.49,0.47,0.51
10.1016/j.ajog.2012.12.038,4,Yes,New York,No,NA,Ectopic pregnancy rate,RR,NA,age,4,White,Hispanic,1.21,1.19,1.24
10.1016/j.ajog.2012.12.038,4,Yes,New York,No,NA,Ectopic pregnancy rate,RR,NA,age,5,White,Unknown/Missing,1.07,1.05,1.1
10.1016/j.ajog.2012.12.038,5,Yes,California,No,NA,Ectopic pregnancy rate,RR,NA,age,1,White,Black,1.36,1.34,1.39
10.1016/j.ajog.2012.12.038,5,Yes,California,No,NA,Ectopic pregnancy rate,RR,NA,age,2,White,American Indian/Alaskan Native,1.04,0.96,1.12
10.1016/j.ajog.2012.12.038,5,Yes,California,No,NA,Ectopic pregnancy rate,RR,NA,age,3,White,Asian,0.79,0.77,0.81
10.1016/j.ajog.2012.12.038,5,Yes,California,No,NA,Ectopic pregnancy rate,RR,NA,age,4,White,Hispanic,0.83,0.82,0.84
10.1016/j.ajog.2012.12.038,5,Yes,California,No,NA,Ectopic pregnancy rate,RR,NA,age,5,White,Native Hawaiian/Pacific Islander,0.85,0.82,0.88
10.1016/j.ajog.2012.12.038,5,Yes,California,No,NA,Ectopic pregnancy rate,RR,NA,age,6,White,Unknown/Missing,0.71,-99,NA
10.1016/j.ajog.2012.12.038,5,Yes,California,No,NA,Ectopic pregnancy rate,RR,NA,age,7,White,NA,NA,NA,-99
10.1016/j.ajog.2012.12.038,6,Yes,Illinois,No,NA,Ectopic pregnancy rate,RR,NA,age,1,White,Black,1.45,1.42,1.48
10.1016/j.ajog.2012.12.038,6,Yes,Illinois,No,NA,Ectopic pregnancy rate,RR,NA,age,2,White,American Indian/Alaskan Native,1.27,1.05,1.55
10.1016/j.ajog.2012.12.038,6,Yes,Illinois,No,NA,Ectopic pregnancy rate,RR,NA,age,3,White,Asian,0.73,0.68,0.79
10.1016/j.ajog.2012.12.038,6,Yes,Illinois,No,NA,Ectopic pregnancy rate,RR,NA,age,4,White,Hispanic,0.9,0.88,0.93
10.1016/j.ajog.2012.12.038,6,Yes,Illinois,No,NA,Ectopic pregnancy rate,RR,NA,age,5,White,Multiracial,0.68,0.55,0.85
10.1016/j.ajog.2012.12.038,6,Yes,Illinois,No,NA,Ectopic pregnancy rate,RR,NA,age,6,White,Unknown/Missing,0.45,0.41,NA
10.1016/j.ajog.2012.12.038,6,Yes,Illinois,No,NA,Ectopic pregnancy rate,RR,NA,age,7,White,NA,NA,NA,0.49
10.1016/j.ygyno.2012.08.025,1,No,NA,No,NA,Death,HR,NA,None,1,White,Black,1.94,-99,-99
10.1016/j.ygyno.2012.08.025,1,No,NA,No,NA,Death,HR,NA,None,2,White,Hispanic,1.2,-99,-99
10.1016/j.ygyno.2012.08.025,2,No,NA,No,NA,Death,HR,NA,histology,1,White,Black,1.12,0.84,1.48
10.1016/j.ygyno.2012.08.025,2,No,NA,No,NA,Death,HR,NA,histology,2,White,Hispanic,0.93,0.67,1.29
10.1016/j.ajog.2012.01.040,1,No,NA,No,NA,Preterm delivery <37 weeks,OR,NA,"maternal age, marital status, kotelchuck index, month prenatal care began, parity, previous preterm birth, participation in group care",1,White,Black,1.2,0.95,1.5
10.1016/j.ajog.2012.01.040,1,No,NA,No,NA,Preterm delivery <37 weeks,OR,NA,"maternal age, marital status, kotelchuck index, month prenatal care began, parity, previous preterm birth, participation in group care",2,White,Hispanic,0.51,0.38,0.69
10.1016/j.ajog.2012.01.040,1,No,NA,No,NA,Preterm delivery <37 weeks,OR,NA,"maternal age, marital status, kotelchuck index, month prenatal care began, parity, previous preterm birth, participation in group care",3,White,Other,0.87,0.59,1.28
10.1016/j.ygyno.2011.11.025,1,Yes,1973-1977,No,NA,All cause mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status",1,White,African American,1.2,1.06,1.36
10.1016/j.ygyno.2011.11.025,2,Yes,1973-1977,No,NA,Ovarian cancer mortality,HR,NA,None,1,White,African American,0.95,0.82,1.11
10.1016/j.ygyno.2011.11.025,3,Yes,1973-1977,No,NA,Ovarian cancer mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status",1,White,African American,1.1,0.94,1.29
10.1016/j.ygyno.2011.11.025,4,Yes,1978-1982,No,NA,All cause mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status",1,White,African American,1.27,1.13,1.43
10.1016/j.ygyno.2011.11.025,5,Yes,1978-1982,No,NA,Ovarian cancer mortality,HR,NA,None,1,White,African American,0.9,0.79,1.04
10.1016/j.ygyno.2011.11.025,6,Yes,1978-1982,No,NA,Ovarian cancer mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status",1,White,African American,1.15,0.99,1.33
10.1016/j.ygyno.2011.11.025,7,Yes,1983-1987,No,NA,All cause mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status",1,White,African American,1.24,1.11,1.39
10.1016/j.ygyno.2011.11.025,8,Yes,1983-1987,No,NA,All cause mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status, receipt of surgery",1,White,African American,1.19,1.06,1.33
10.1016/j.ygyno.2011.11.025,9,Yes,1983-1987,No,NA,Ovarian cancer mortality,HR,NA,None,1,White,African American,1,0.87,1.14
10.1016/j.ygyno.2011.11.025,10,Yes,1983-1987,No,NA,Ovarian cancer mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status",1,White,African American,1.14,0.99,1.3
10.1016/j.ygyno.2011.11.025,11,Yes,1983-1987,No,NA,Ovarian cancer mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status, receipt of surgery",1,White,African American,1.08,0.94,1.23
10.1016/j.ygyno.2011.11.025,12,Yes,1988-1992,No,NA,All cause mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status",1,White,African American,1.28,1.14,1.43
10.1016/j.ygyno.2011.11.025,13,Yes,1988-1992,No,NA,All cause mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status, receipt of surgery",1,White,African American,1.29,1.15,1.44
10.1016/j.ygyno.2011.11.025,14,Yes,1988-1992,No,NA,Ovarian cancer mortality,HR,NA,None,1,White,African American,1,0.87,1.14
10.1016/j.ygyno.2011.11.025,15,Yes,1988-1992,No,NA,Ovarian cancer mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status",1,White,African American,1.05,0.92,1.21
10.1016/j.ygyno.2011.11.025,16,Yes,1988-1992,No,NA,Ovarian cancer mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status, receipt of surgery",1,White,African American,1.06,0.93,1.22
10.1016/j.ygyno.2011.11.025,17,Yes,1993-1997,No,NA,All cause mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status",1,White,African American,1.31,1.17,1.47
10.1016/j.ygyno.2011.11.025,18,Yes,1993-1997,No,NA,All cause mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status, receipt of surgery",1,White,African American,1.26,1.13,1.41
10.1016/j.ygyno.2011.11.025,19,Yes,1993-1997,No,NA,Ovarian cancer mortality,HR,NA,None,1,White,African American,0.95,0.84,1.08
10.1016/j.ygyno.2011.11.025,20,Yes,1993-1997,No,NA,Ovarian cancer mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status",1,White,African American,1.2,1.06,1.37
10.1016/j.ygyno.2011.11.025,21,Yes,1993-1997,No,NA,Ovarian cancer mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status, receipt of surgery",1,White,African American,1.15,1.01,1.31
10.1016/j.ygyno.2011.11.025,22,Yes,1998-2002,No,NA,All cause mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status",1,White,African American,1.34,1.2,1.5
10.1016/j.ygyno.2011.11.025,23,Yes,1998-2002,No,NA,All cause mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status, receipt of surgery",1,White,African American,1.26,1.13,1.41
10.1016/j.ygyno.2011.11.025,24,Yes,1998-2002,No,NA,Ovarian cancer mortality,HR,NA,None,1,White,African American,1.05,0.94,1.19
10.1016/j.ygyno.2011.11.025,25,Yes,1998-2002,No,NA,Ovarian cancer mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status",1,White,African American,1.22,1.07,1.38
10.1016/j.ygyno.2011.11.025,26,Yes,1998-2002,No,NA,Ovarian cancer mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status, receipt of surgery",1,White,African American,1.15,1.01,1.3
10.1016/j.ygyno.2011.11.025,27,Yes,2003-2007,No,NA,All cause mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status",1,White,African American,1.65,1.46,1.86
10.1016/j.ygyno.2011.11.025,28,Yes,2003-2007,No,NA,All cause mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status, receipt of surgery",1,White,African American,1.39,1.23,1.58
10.1016/j.ygyno.2011.11.025,29,Yes,2003-2007,No,NA,Ovarian cancer mortality,HR,NA,None,1,White,African American,1.2,1.05,1.4
10.1016/j.ygyno.2011.11.025,30,Yes,2003-2007,No,NA,Ovarian cancer mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status",1,White,African American,1.52,1.32,1.75
10.1016/j.ygyno.2011.11.025,31,Yes,2003-2007,No,NA,Ovarian cancer mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status, receipt of surgery",1,White,African American,1.29,1.12,1.49
10.1016/j.ygyno.2011.11.025,32,Yes,1973-2002,No,NA,All cause mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status",1,White,African American,1.27,1.21,1.33
10.1016/j.ygyno.2011.11.025,33,Yes,1973-2002,No,NA,All cause mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status, receipt of surgery",1,White,African American,1.25,1.18,1.32
10.1016/j.ygyno.2011.11.025,34,Yes,1973-2002,No,NA,Ovarian cancer mortality,HR,NA,None,1,White,African American,0.97,0.92,1.02
10.1016/j.ygyno.2011.11.025,35,Yes,1973-2002,No,NA,Ovarian cancer mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status",1,White,African American,1.14,1.08,1.21
10.1016/j.ygyno.2011.11.025,36,Yes,1973-2002,No,NA,Ovarian cancer mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status, receipt of surgery",1,White,African American,1.11,1.04,1.19
10.1016/j.ygyno.2011.11.025,37,Yes,1973-2007,No,NA,All cause mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status",1,White,African American,1.31,1.26,1.37
10.1016/j.ygyno.2011.11.025,38,Yes,1973-2007,No,NA,All cause mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status, receipt of surgery",1,White,African American,1.27,1.21,1.34
10.1016/j.ygyno.2011.11.025,39,Yes,1973-2007,No,NA,Ovarian cancer mortality,HR,NA,None,1,White,African American,0.99,0.94,1.04
10.1016/j.ygyno.2011.11.025,40,Yes,1973-2007,No,NA,Ovarian cancer mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status",1,White,African American,1.18,1.12,1.24
10.1016/j.ygyno.2011.11.025,41,Yes,1973-2007,No,NA,Ovarian cancer mortality,HR,NA,"five-year diagnosis cohort, registry, age, tumor stage, marital status, receipt of surgery",1,White,African American,1.14,1.07,1.21
10.1016/j.ygyno.2011.02.006,1,Yes,FIGO stage 1,No,NA,cesarean delivery,HR,NA,"age at diagnosis, angiolymphatic invasion, myometrial invasion, adjuvant chemotherapy, adjuvant radiation",1,Caucasian,African American,1.603,0.3641,0.579
10.1016/j.ygyno.2011.02.006,2,Yes,figo stage 24,No,NA,cesarean delivery,HR,NA,"age at diagnosis, angiolymphatic invasion, myometrial invasion, adjuvant chemotherapy, adjuvant radiation",1,Caucasian,African American,1.311,0.735,2.338
10.1016/j.ygyno.2011.02.004,1,No,NA,No,NA,Lymphadenectomy,OR,NA,"age, APR-DRG mortality risk score, payer status, surgeon volume",1,Caucasian,African American,1.1,0.94,1.27
10.1016/j.ygyno.2011.02.004,2,No,NA,No,NA,Minimally-invasive surgical approach,OR,NA,"age, APR-DRG mortality risk score, payer status, surgeon volume",1,Caucasian,African American,0.55,0.41,0.74
10.1016/j.ygyno.2011.02.004,3,No,NA,No,NA,In-hospital mortality,OR,NA,"age, APR-DRG mortality risk score, payer status",1,Caucasian,African American,1.12,0.42,3
10.1016/j.ygyno.2011.02.004,4,No,NA,No,NA,High-volume surgeon,OR,NA,"age, APR-DRG mortality risk score, payer status",1,Caucasian,African American,1.27,1.09,1.49
10.1016/j.fertnstert.2011.02.039,1,No,NA,No,NA,Self-reported barrier to infertility care: internet access,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,0.2,0.1,0.5
10.1016/j.fertnstert.2011.02.039,1,No,NA,No,NA,Self-reported barrier to infertility care: internet access,OR,NA,"age, education, income, religion, nulliparity",2,White,Hispanic,0.2,0.1,0.5
10.1016/j.fertnstert.2011.02.039,2,No,NA,No,NA,Self-reported barrier to infertility care: fertility tx insurance coverage,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,0.8,0.4,1.9
10.1016/j.fertnstert.2011.02.039,2,No,NA,No,NA,Self-reported barrier to infertility care: fertility tx insurance coverage,OR,NA,"age, education, income, religion, nulliparity",2,White,Asian American,1.7,0.5,5.6
10.1016/j.fertnstert.2011.02.039,2,No,NA,No,NA,Self-reported barrier to infertility care: fertility tx insurance coverage,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,2.1,0.9,5.3
10.1016/j.fertnstert.2011.02.039,3,No,NA,Yes,Self,Self-reported barrier to infertility care: referral source,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,4.6,1,22.3
10.1016/j.fertnstert.2011.02.039,3,No,NA,Yes,Self,Self-reported barrier to infertility care: referral source,OR,NA,"age, education, income, religion, nulliparity",2,White,Asian American,5.2,0.4,64
10.1016/j.fertnstert.2011.02.039,3,No,NA,Yes,Self,Self-reported barrier to infertility care: referral source,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,1.2,0.3,5
10.1016/j.fertnstert.2011.02.039,4,No,NA,Yes,Internet,Self-reported barrier to infertility care: referral source,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,0.5,0.2,1.8
10.1016/j.fertnstert.2011.02.039,4,No,NA,Yes,Internet,Self-reported barrier to infertility care: referral source,OR,NA,"age, education, income, religion, nulliparity",2,White,Asian American,0.4,0.1,2.1
10.1016/j.fertnstert.2011.02.039,4,No,NA,Yes,Internet,Self-reported barrier to infertility care: referral source,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,0.2,0,2.3
10.1016/j.fertnstert.2011.02.039,5,No,NA,Yes,Friend or family,Self-reported barrier to infertility care: referral source,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,0.9,0.4,2
10.1016/j.fertnstert.2011.02.039,5,No,NA,Yes,Friend or family,Self-reported barrier to infertility care: referral source,OR,NA,"age, education, income, religion, nulliparity",2,White,Asian American,1.6,0.5,5
10.1016/j.fertnstert.2011.02.039,5,No,NA,Yes,Friend or family,Self-reported barrier to infertility care: referral source,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,4.3,1.9,9.9
10.1016/j.fertnstert.2011.02.039,6,No,NA,Yes,Physician,Self-reported barrier to infertility care: referral source,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,1.8,1,3.3
10.1016/j.fertnstert.2011.02.039,6,No,NA,Yes,Physician,Self-reported barrier to infertility care: referral source,OR,NA,"age, education, income, religion, nulliparity",2,White,Asian American,0.8,0.3,1.9
10.1016/j.fertnstert.2011.02.039,6,No,NA,Yes,Physician,Self-reported barrier to infertility care: referral source,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,0.6,0.3,1.2
10.1016/j.fertnstert.2011.02.039,7,No,NA,Yes,age,Self-reported barrier to infertility care: harder to get treatment because of,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,38,11,129
10.1016/j.fertnstert.2011.02.039,7,No,NA,Yes,age,Self-reported barrier to infertility care: harder to get treatment because of,OR,NA,"age, education, income, religion, nulliparity",2,White,Asian American,4.9,1,25
10.1016/j.fertnstert.2011.02.039,7,No,NA,Yes,age,Self-reported barrier to infertility care: harder to get treatment because of,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,4.4,1.6,12
10.1016/j.fertnstert.2011.02.039,8,No,NA,Yes,race or ethnicity,Self-reported barrier to infertility care: harder to get treatment because of,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,72,14,378
10.1016/j.fertnstert.2011.02.039,8,No,NA,Yes,race or ethnicity,Self-reported barrier to infertility care: harder to get treatment because of,OR,NA,"age, education, income, religion, nulliparity",2,White,Asian American,0,0,0
10.1016/j.fertnstert.2011.02.039,8,No,NA,Yes,race or ethnicity,Self-reported barrier to infertility care: harder to get treatment because of,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,36,6.6,195
10.1016/j.fertnstert.2011.02.039,9,No,NA,Yes,income,Self-reported barrier to infertility care: harder to get treatment because of,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,8,3.6,18
10.1016/j.fertnstert.2011.02.039,9,No,NA,Yes,income,Self-reported barrier to infertility care: harder to get treatment because of,OR,NA,"age, education, income, religion, nulliparity",2,White,Asian American,0.5,0.1,4.6
10.1016/j.fertnstert.2011.02.039,9,No,NA,Yes,income,Self-reported barrier to infertility care: harder to get treatment because of,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,6.4,2.9,14
10.1016/j.fertnstert.2011.02.039,10,No,NA,Yes,insurance coverage,Self-reported barrier to infertility care: harder to get treatment because of,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,6.2,3.2,12
10.1016/j.fertnstert.2011.02.039,10,No,NA,Yes,insurance coverage,Self-reported barrier to infertility care: harder to get treatment because of,OR,NA,"age, education, income, religion, nulliparity",2,White,Asian American,0.5,0.1,1.9
10.1016/j.fertnstert.2011.02.039,10,No,NA,Yes,insurance coverage,Self-reported barrier to infertility care: harder to get treatment because of,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,4.1,2.1,8.1
10.1016/j.fertnstert.2011.02.039,11,No,NA,Yes,career,Self-reported barrier to infertility care: harder to get treatment because of,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,36,5.9,224
10.1016/j.fertnstert.2011.02.039,11,No,NA,Yes,career,Self-reported barrier to infertility care: harder to get treatment because of,OR,NA,"age, education, income, religion, nulliparity",2,White,Asian American,0,0,0
10.1016/j.fertnstert.2011.02.039,11,No,NA,Yes,career,Self-reported barrier to infertility care: harder to get treatment because of,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,20,1.8,111
10.1016/j.fertnstert.2011.02.039,12,No,NA,Yes,find a doctor with whom I'm comfortable,Self-reported barrier to infertility care: it was difficult to,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,6.6,2.8,15.4
10.1016/j.fertnstert.2011.02.039,12,No,NA,Yes,find a doctor with whom I'm comfortable,Self-reported barrier to infertility care: it was difficult to,OR,NA,"age, education, income, religion, nulliparity",2,White,Asian American,0.4,0.05,3.3
10.1016/j.fertnstert.2011.02.039,12,No,NA,Yes,find a doctor with whom I'm comfortable,Self-reported barrier to infertility care: it was difficult to,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,3.4,1.4,8.3
10.1016/j.fertnstert.2011.02.039,13,No,NA,Yes,get an appointment,Self-reported barrier to infertility care: it was difficult to,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,9.9,3.3,29.8
10.1016/j.fertnstert.2011.02.039,13,No,NA,Yes,get an appointment,Self-reported barrier to infertility care: it was difficult to,OR,NA,"age, education, income, religion, nulliparity",2,White,Asian American,2.3,0.4,12.7
10.1016/j.fertnstert.2011.02.039,13,No,NA,Yes,get an appointment,Self-reported barrier to infertility care: it was difficult to,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,7.2,2.5,21
10.1016/j.fertnstert.2011.02.039,14,No,NA,Yes,take time off for appointments,Self-reported barrier to infertility care: it was difficult to,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,4.6,2.4,9
10.1016/j.fertnstert.2011.02.039,14,No,NA,Yes,take time off for appointments,Self-reported barrier to infertility care: it was difficult to,OR,NA,"age, education, income, religion, nulliparity",2,White,Asian American,0.5,0.1,1.5
10.1016/j.fertnstert.2011.02.039,14,No,NA,Yes,take time off for appointments,Self-reported barrier to infertility care: it was difficult to,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,6.8,3.3,14
10.1016/j.fertnstert.2011.02.039,15,No,NA,Yes,pay for the treatment,Self-reported barrier to infertility care: it was difficult to,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,6.7,2.9,15.3
10.1016/j.fertnstert.2011.02.039,15,No,NA,Yes,pay for the treatment,Self-reported barrier to infertility care: it was difficult to,OR,NA,"age, education, income, religion, nulliparity",2,White,Asian American,0.4,0.1,1.9
10.1016/j.fertnstert.2011.02.039,15,No,NA,Yes,pay for the treatment,Self-reported barrier to infertility care: it was difficult to,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,9.4,4.1,21.7
10.1016/j.fertnstert.2011.02.039,16,No,NA,Yes,timing,Self-reported barrier to infertility care: ability to bear children rests on,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,5.2,2.5,10.7
10.1016/j.fertnstert.2011.02.039,16,No,NA,Yes,timing,Self-reported barrier to infertility care: ability to bear children rests on,OR,NA,"age, education, income, religion, nulliparity",2,White,Asian American,1.6,0.5,5.1
10.1016/j.fertnstert.2011.02.039,16,No,NA,Yes,timing,Self-reported barrier to infertility care: ability to bear children rests on,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,3.2,1.5,7.1
10.1016/j.fertnstert.2011.02.039,17,No,NA,Yes,personal control,Self-reported barrier to infertility care: ability to bear children rests on,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,4.3,2.3,8.1
10.1016/j.fertnstert.2011.02.039,17,No,NA,Yes,personal control,Self-reported barrier to infertility care: ability to bear children rests on,OR,NA,"age, education, income, religion, nulliparity",2,White,Asian American,1.5,0.6,3.6
10.1016/j.fertnstert.2011.02.039,17,No,NA,Yes,personal control,Self-reported barrier to infertility care: ability to bear children rests on,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,2.4,1.3,4.6
10.1016/j.fertnstert.2011.02.039,18,No,NA,Yes,god's will,Self-reported barrier to infertility care: ability to bear children rests on,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,3.1,1.5,6.1
10.1016/j.fertnstert.2011.02.039,18,No,NA,Yes,god's will,Self-reported barrier to infertility care: ability to bear children rests on,OR,NA,"age, education, income, religion, nulliparity",2,White,Asian American,0.3,0.1,0.9
10.1016/j.fertnstert.2011.02.039,18,No,NA,Yes,god's will,Self-reported barrier to infertility care: ability to bear children rests on,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,1.5,0.8,3
10.1016/j.fertnstert.2011.02.039,19,No,NA,Yes,a couple's physiology,Self-reported barrier to infertility care: ability to bear children rests on,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,0.1,0.1,0.3
10.1016/j.fertnstert.2011.02.039,19,No,NA,Yes,a couple's physiology,Self-reported barrier to infertility care: ability to bear children rests on,OR,NA,"age, education, income, religion, nulliparity",2,White,Asian American,1,0.1,8.6
10.1016/j.fertnstert.2011.02.039,19,No,NA,Yes,a couple's physiology,Self-reported barrier to infertility care: ability to bear children rests on,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,0.1,0.1,0.3
10.1016/j.fertnstert.2011.02.039,20,No,NA,Yes,chance,Self-reported barrier to infertility care: ability to bear children rests on,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,4.2,2.3,8.2
10.1016/j.fertnstert.2011.02.039,20,No,NA,Yes,chance,Self-reported barrier to infertility care: ability to bear children rests on,OR,NA,"age, education, income, religion, nulliparity",2,White,Asian American,0.6,0.2,1.6
10.1016/j.fertnstert.2011.02.039,20,No,NA,Yes,chance,Self-reported barrier to infertility care: ability to bear children rests on,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,4.2,2.2,8.4
10.1016/j.fertnstert.2011.02.039,21,No,NA,Yes,religious faith,Self-reported barrier to infertility care: ability to bear children rests on,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,2.8,1.5,5.4
10.1016/j.fertnstert.2011.02.039,21,No,NA,Yes,religious faith,Self-reported barrier to infertility care: ability to bear children rests on,OR,NA,"age, education, income, religion, nulliparity",2,White,Asian American,0.3,0.1,1.7
10.1016/j.fertnstert.2011.02.039,21,No,NA,Yes,religious faith,Self-reported barrier to infertility care: ability to bear children rests on,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,1.8,0.9,3.5
10.1016/j.fertnstert.2011.02.039,22,No,NA,Yes,trusting a medical provider,Self-reported barrier to infertility care: ability to bear children rests on,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,0.1,0.04,0.2
10.1016/j.fertnstert.2011.02.039,22,No,NA,Yes,trusting a medical provider,Self-reported barrier to infertility care: ability to bear children rests on,OR,NA,"age, education, income, religion, nulliparity",2,White,Asian American,5.7,1.7,18.4
10.1016/j.fertnstert.2011.02.039,22,No,NA,Yes,trusting a medical provider,Self-reported barrier to infertility care: ability to bear children rests on,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,0.7,0.3,1.4
10.1016/j.fertnstert.2011.02.039,23,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: historic misuse of medical treatment in my community,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,33.2,7.7,143
10.1016/j.fertnstert.2011.02.039,23,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: historic misuse of medical treatment in my community,OR,NA,"age, education, income, religion, nulliparity",2,White,Hispanic,3.2,1.1,9.7
10.1016/j.fertnstert.2011.02.039,24,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: need to consider adoption as alternative first,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,2.9,1.2,7.2
10.1016/j.fertnstert.2011.02.039,24,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: need to consider adoption as alternative first,OR,NA,"age, education, income, religion, nulliparity",2,White,Hispanic,3.7,1.4,10
10.1016/j.fertnstert.2011.02.039,25,No,NA,No,NA,"Points of worry and concern in seeking infertility treatment: personal sense of ""failing"" to conceive",OR,NA,"age, education, income, religion, nulliparity",1,White,African American,3.8,2,7.1
10.1016/j.fertnstert.2011.02.039,26,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: social stigma of infertility,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,3.7,1.8,6
10.1016/j.fertnstert.2011.02.039,26,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: social stigma of infertility,OR,NA,"age, education, income, religion, nulliparity",2,White,Asian American,7.3,2.8,19
10.1016/j.fertnstert.2011.02.039,26,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: social stigma of infertility,OR,NA,"age, education, income, religion, nulliparity",3,White,Chinese,59,6,579
10.1016/j.fertnstert.2011.02.039,27,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: disappointing spouse,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,4.3,2.2,8.4
10.1016/j.fertnstert.2011.02.039,28,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: friends or family finding out about treatment,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,6.6,2.8,15.4
10.1016/j.fertnstert.2011.02.039,28,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: friends or family finding out about treatment,OR,NA,"age, education, income, religion, nulliparity",2,White,Asian American,12.9,4.7,33.5
10.1016/j.fertnstert.2011.02.039,28,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: friends or family finding out about treatment,OR,NA,"age, education, income, religion, nulliparity",3,White,Chinese,18.4,3.5,96.2
10.1016/j.fertnstert.2011.02.039,28,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: friends or family finding out about treatment,OR,NA,"age, education, income, religion, nulliparity",4,White,Hispanic,7,3,15.9
10.1016/j.fertnstert.2011.02.039,29,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: using science or technology to conceive,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,4.1,1.8,9.2
10.1016/j.fertnstert.2011.02.039,29,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: using science or technology to conceive,OR,NA,"age, education, income, religion, nulliparity",2,White,Hispanic,5.3,2.2,12.9
10.1016/j.fertnstert.2011.02.039,30,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: short term side effects,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,3.8,2.1,7.1
10.1016/j.fertnstert.2011.02.039,30,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: short term side effects,OR,NA,"age, education, income, religion, nulliparity",2,White,Hispanic,4.8,2.4,9.7
10.1016/j.fertnstert.2011.02.039,30,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: short term side effects,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,NA,NA,NA
10.1016/j.fertnstert.2011.02.039,31,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: long term side effects,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,2.5,1.3,4.5
10.1016/j.fertnstert.2011.02.039,31,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: long term side effects,OR,NA,"age, education, income, religion, nulliparity",2,White,Hispanic,9.5,4.4,20.6
10.1016/j.fertnstert.2011.02.039,31,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: long term side effects,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,NA,NA,NA
10.1016/j.fertnstert.2011.02.039,32,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: having twins,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,4,1.5,10.5
10.1016/j.fertnstert.2011.02.039,32,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: having twins,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,NA,NA,NA
10.1016/j.fertnstert.2011.02.039,33,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: having triplets or greater,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,5.2,2.8,9.7
10.1016/j.fertnstert.2011.02.039,33,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: having triplets or greater,OR,NA,"age, education, income, religion, nulliparity",2,White,Hispanic,11,5.4,22.2
10.1016/j.fertnstert.2011.02.039,33,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: having triplets or greater,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,NA,NA,NA
10.1016/j.fertnstert.2011.02.039,34,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: having a miscarriage,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,2.6,1.3,5.1
10.1016/j.fertnstert.2011.02.039,34,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: having a miscarriage,OR,NA,"age, education, income, religion, nulliparity",2,White,Asian American,0.3,0.1,0.8
10.1016/j.fertnstert.2011.02.039,34,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: having a miscarriage,OR,NA,"age, education, income, religion, nulliparity",3,White,Hispanic,12.7,4.7,34.4
10.1016/j.fertnstert.2011.02.039,35,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: having an ectopic pregnancy,OR,NA,"age, education, income, religion, nulliparity",1,White,African American,5.6,2.8,11.2
10.1016/j.fertnstert.2011.02.039,35,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: having an ectopic pregnancy,OR,NA,"age, education, income, religion, nulliparity",2,White,Hispanic,11.3,4.9,25.6
10.1016/j.fertnstert.2011.02.039,36,No,NA,No,NA,Points of worry and concern in seeking infertility treatment: risk of birth defects,OR,NA,"age, education, income, religion, nulliparity",1,White,Hispanic,6.9,3.1,15.4
10.1016/j.ygyno.2011.01.027,1,Yes,White,No,NA,endometrial cancer,HR,NA,none,1,BMI < 25,BMI >= 30,1.8,1.44,2.27
10.1016/j.ygyno.2011.01.027,2,Yes,White,No,NA,endometrial cancer,HR,NA,none,1,Waist to Hip ratio < .7554,Waist to Hip ratio >= .8530,1.33,1.03,1.71
10.1016/j.ygyno.2011.01.027,3,Yes,Black,No,NA,endometrial cancer,HR,NA,none,1,BMI < 25,BMI >= 30,2.76,0.57,13.51
10.1016/j.ygyno.2011.01.027,4,Yes,Black,No,NA,endometrial cancer,HR,NA,none,1,Waist to Hip ratio < .7554,Waist to Hip ratio >= .8530,4.61,0.5,42.67
10.1016/j.ygyno.2010.12.347,1,No,NA,No,NA,Hysterectomy,OR,NA,"colon resection, lymphadenectomy, excision/destruction peritoneum/abdomen",1,White,African American,0.53,0.42,0.66
10.1016/j.ygyno.2010.12.347,1,No,NA,No,NA,Hysterectomy,OR,NA,"colon resection, lymphadenectomy, excision/destruction peritoneum/abdomen",2,White,Other races,0.97,0.69,1.36
10.1016/j.ygyno.2010.12.347,2,No,NA,No,NA,Colon resection,OR,NA,"hysterectomy, lymphadenectomy, excision/destruction peritoneum/abdomen",1,White,African American,0.65,0.48,0.87
10.1016/j.ygyno.2010.12.347,2,No,NA,No,NA,Colon resection,OR,NA,"hysterectomy, lymphadenectomy, excision/destruction peritoneum/abdomen",2,White,Other races,0.91,0.64,1.31
10.1016/j.ygyno.2010.12.347,3,No,NA,No,NA,Lymphadenectomy,OR,NA,"hysterectomy, colon resection, excision/destruction peritoneum/abdomen",1,White,African American,0.67,0.5,0.91
10.1016/j.ygyno.2010.12.347,3,No,NA,No,NA,Lymphadenectomy,OR,NA,"hysterectomy, colon resection, excision/destruction peritoneum/abdomen",2,White,Other races,0.74,0.5,1.09
10.1016/j.ygyno.2010.12.347,4,No,NA,No,NA,Excision/destruction peritoneum/abdomen,OR,NA,"hysterectomy, colon resection, lymphadenectomy",1,White,African American,0.98,0.74,1.3
10.1016/j.ygyno.2010.12.347,4,No,NA,No,NA,Excision/destruction peritoneum/abdomen,OR,NA,"hysterectomy, colon resection, lymphadenectomy",2,White,Other races,0.78,0.54,1.13
10.1016/j.ygyno.2010.12.347,5,No,NA,No,NA,High volume surgeon,OR,NA,high volume hospital,1,White,African American,0.55,0.44,0.69
10.1016/j.ygyno.2010.12.347,5,No,NA,No,NA,High volume surgeon,OR,NA,high volume hospital,2,White,Asian/Pacific Islander,0.82,0.47,1.42
10.1016/j.ygyno.2010.12.347,5,No,NA,No,NA,High volume surgeon,OR,NA,high volume hospital,3,White,Other races,1.2,0.83,1.73
10.1016/j.ygyno.2010.12.347,6,No,NA,No,NA,High volume hospital,OR,NA,high volume surgeon,1,White,African American,1.07,0.85,1.34
10.1016/j.ygyno.2010.12.347,6,No,NA,No,NA,High volume hospital,OR,NA,high volume surgeon,2,White,Asian/Pacific Islander,1.13,0.65,1.97
10.1016/j.ygyno.2010.12.347,6,No,NA,No,NA,High volume hospital,OR,NA,high volume surgeon,3,White,Other races,1.82,1.25,2.65
10.1016/j.ajog.2015.12.054,1,No,NA,No,NA,Documented provider counseling about 17-alpha hydroxyroprogesterone caproate,OR,NA,none,1,Non-hispanic white,Non-Hispanic Black,1.31,0.83,2.05
10.1016/j.ajog.2015.12.054,2,No,NA,No,NA,Documented provider counseling about 17-alpha hydroxyroprogesterone caproate,OR,NA,"maternal age, insurance status, pregnancy intendedness, GA of first prenatal visit, >1 prior PTB, GA at earliest PTB, prior term birth",1,Non-hispanic white,Non-Hispanic Black,1.64,0.8,3.37
10.1016/j.ajog.2015.12.054,3,No,NA,No,NA,Patient receipt of 17-alpha hydroxyroprogesterone caproate,OR,NA,none,1,Non-hispanic white,Non-Hispanic Black,1.09,0.75,1.59
10.1016/j.ajog.2015.12.054,4,No,NA,No,NA,Patient receipt of 17-alpha hydroxyroprogesterone caproate,OR,NA,"maternal age, insurance status, pregnancy intendedness, GA of first prenatal visit, >1 prior PTB, GA at earliest PTB, prior term birth",1,Non-hispanic white,Non-Hispanic Black,1.48,0.74,2.95
10.1016/j.ajog.2015.12.054,5,No,NA,No,NA,Adherence to 17-alpha hydroxyprogesterone caproate protocol,OR,NA,none,1,Non-hispanic white,Non-Hispanic Black,0.24,0.11,0.5
10.1016/j.ajog.2015.12.054,6,No,NA,No,NA,Adherence to 17-alpha hydroxyprogesterone caproate protocol,OR,NA,"maternal age, insurance status, pregnancy intendedness, GA of first prenatal visit, >1 prior PTB, GA at earliest PTB, prior term birth",1,Non-hispanic white,Non-Hispanic Black,0.16,0.04,0.65
10.1016/j.ygyno.2015.05.025,1,No,NA,No,NA,cervical insufficiency,LL,NA,none,1,n/a,white,0.19,-99,-99
10.1016/j.ygyno.2015.05.025,1,No,NA,No,NA,cervical insufficiency,LL,NA,none,2,n/a,Black,0.49,-99,-99
10.1016/j.ygyno.2015.05.025,1,No,NA,No,NA,cervical insufficiency,LL,NA,none,3,n/a,Asian/Pacific Islander,0.15,-99,-99
10.1016/j.ygyno.2015.05.025,1,No,NA,No,NA,cervical insufficiency,LL,NA,none,4,n/a,American Indian/Alaskan native,0.14,-99,-99
10.1016/j.ygyno.2015.05.025,2,No,NA,No,NA,cervical insufficiency,UL,NA,none,1,n/a,white,0.2,-99,-99
10.1016/j.ygyno.2015.05.025,2,No,NA,No,NA,cervical insufficiency,UL,NA,none,2,n/a,Black,0.56,-99,-99
10.1016/j.ygyno.2015.05.025,2,No,NA,No,NA,cervical insufficiency,UL,NA,none,3,n/a,Asian/Pacific Islander,0.15,-99,-99
10.1016/j.ygyno.2015.05.025,2,No,NA,No,NA,cervical insufficiency,UL,NA,none,4,n/a,American Indian/Alaskan native,0.14,-99,-99
10.1016/j.ygyno.2015.05.025,3,No,NA,No,NA,time to recurrence,HR,NA,none,1,White,Black,2.7,1.24,5.87
10.1016/j.ygyno.2015.05.025,4,No,NA,No,NA,recurrence free survival,HR,NA,none,1,White,Black,2.74,1.49,5.03
10.1016/j.ygyno.2015.05.025,5,No,NA,No,NA,overall survival,HR,NA,none,1,White,Black,2.83,1.4,5.69
10.1016/j.ygyno.2015.05.025,6,No,NA,No,NA,time to recurrence,HR,NA,"type, age",1,White,Black,2.51,1.1,5.73
10.1016/j.ygyno.2015.05.025,7,No,NA,No,NA,recurrence free survival,HR,NA,"type, age",1,White,Black,2.64,1.36,5.12
10.1016/j.ygyno.2015.05.025,8,No,NA,No,NA,overall survival,HR,NA,"type, age",1,White,Black,2.76,1.28,5.98
10.1016/j.ajog.2014.06.036,1,Yes,Death from any cause,No,NA,Diabetes mellitus,HR,NA,"year and age of diagnosis, Federation of International Gynecologists and Obstetricians stage, grade, histologic type, receipt of syrgery, chemotherapy, radiation therapy",1,n/a,White,1.62,1.13,2.35
10.1016/j.ajog.2014.06.036,1,Yes,Death from any cause,No,NA,Diabetes mellitus,HR,NA,"year and age of diagnosis, Federation of International Gynecologists and Obstetricians stage, grade, histologic type, receipt of syrgery, chemotherapy, radiation therapy",2,n/a,Black,1.17,0.8,1.71
10.1016/j.ajog.2014.06.036,2,Yes,Death from any cause,No,NA,hypertension,HR,NA,"year and age of diagnosis, Federation of International Gynecologists and Obstetricians stage, grade, histologic type, receipt of syrgery, chemotherapy, radiation therapy",1,n/a,White,0.96,0.7,1.32
10.1016/j.ajog.2014.06.036,2,Yes,Death from any cause,No,NA,hypertension,HR,NA,"year and age of diagnosis, Federation of International Gynecologists and Obstetricians stage, grade, histologic type, receipt of syrgery, chemotherapy, radiation therapy",2,n/a,Black,0.52,0.34,0.79
10.1016/j.ajog.2014.06.036,3,Yes,Death from any cause,No,NA,obesity,HR,NA,"year and age of diagnosis, Federation of International Gynecologists and Obstetricians stage, grade, histologic type, receipt of syrgery, chemotherapy, radiation therapy",1,n/a,White,1.04,0.75,1.43
10.1016/j.ajog.2014.06.036,3,Yes,Death from any cause,No,NA,obesity,HR,NA,"year and age of diagnosis, Federation of International Gynecologists and Obstetricians stage, grade, histologic type, receipt of syrgery, chemotherapy, radiation therapy",2,n/a,Black,1.04,0.69,1.56
10.1016/j.ajog.2014.06.036,4,Yes,Death from any cause,No,NA,morbid obesity,HR,NA,"year and age of diagnosis, Federation of International Gynecologists and Obstetricians stage, grade, histologic type, receipt of syrgery, chemotherapy, radiation therapy",1,n/a,White,1.33,0.86,2.06
10.1016/j.ajog.2014.06.036,4,Yes,Death from any cause,No,NA,morbid obesity,HR,NA,"year and age of diagnosis, Federation of International Gynecologists and Obstetricians stage, grade, histologic type, receipt of syrgery, chemotherapy, radiation therapy",2,n/a,Black,1.07,0.7,1.63
10.1016/j.ajog.2014.06.036,5,Yes,Death from any cause,No,NA,charlson comorbidity score 1,HR,NA,"year and age of diagnosis, Federation of International Gynecologists and Obstetricians stage, grade, histologic type, receipt of syrgery, chemotherapy, radiation therapy",1,n/a,White,1.89,1.24,2.9
10.1016/j.ajog.2014.06.036,5,Yes,Death from any cause,No,NA,charlson comorbidity score 1,HR,NA,"year and age of diagnosis, Federation of International Gynecologists and Obstetricians stage, grade, histologic type, receipt of syrgery, chemotherapy, radiation therapy",2,n/a,Black,1.07,0.66,1.72
10.1016/j.ajog.2014.06.036,6,Yes,Death from any cause,No,NA,charlson comorbidity score >= 2,HR,NA,"year and age of diagnosis, Federation of International Gynecologists and Obstetricians stage, grade, histologic type, receipt of syrgery, chemotherapy, radiation therapy",1,n/a,White,1.71,1.17,2.5
10.1016/j.ajog.2014.06.036,6,Yes,Death from any cause,No,NA,charlson comorbidity score >= 2,HR,NA,"year and age of diagnosis, Federation of International Gynecologists and Obstetricians stage, grade, histologic type, receipt of syrgery, chemotherapy, radiation therapy",2,n/a,Black,2.28,1.46,3.56
10.1016/j.ajog.2014.06.036,7,Yes,death from endometrial cancer,No,NA,Diabetes mellitus,HR,NA,"year and age of diagnosis, Federation of International Gynecologists and Obstetricians stage, grade, histologic type, receipt of syrgery, chemotherapy, radiation therapy",1,n/a,White,1,0.4,2.49
10.1016/j.ajog.2014.06.036,7,Yes,death from endometrial cancer,No,NA,Diabetes mellitus,HR,NA,"year and age of diagnosis, Federation of International Gynecologists and Obstetricians stage, grade, histologic type, receipt of syrgery, chemotherapy, radiation therapy",2,n/a,Black,0.71,0.36,1.37
10.1016/j.ajog.2014.06.036,8,Yes,death from endometrial cancer,No,NA,hypertension,HR,NA,"year and age of diagnosis, Federation of International Gynecologists and Obstetricians stage, grade, histologic type, receipt of syrgery, chemotherapy, radiation therapy",1,n/a,White,0.47,0.23,0.98
10.1016/j.ajog.2014.06.036,8,Yes,death from endometrial cancer,No,NA,hypertension,HR,NA,"year and age of diagnosis, Federation of International Gynecologists and Obstetricians stage, grade, histologic type, receipt of syrgery, chemotherapy, radiation therapy",2,n/a,Black,0.35,0.19,0.67
10.1016/j.ajog.2014.06.036,9,Yes,death from endometrial cancer,No,NA,obesity,HR,NA,"year and age of diagnosis, Federation of International Gynecologists and Obstetricians stage, grade, histologic type, receipt of syrgery, chemotherapy, radiation therapy",1,n/a,White,0.89,0.44,1.79
10.1016/j.ajog.2014.06.036,9,Yes,death from endometrial cancer,No,NA,obesity,HR,NA,"year and age of diagnosis, Federation of International Gynecologists and Obstetricians stage, grade, histologic type, receipt of syrgery, chemotherapy, radiation therapy",2,n/a,Black,0.81,0.44,1.51
10.1016/j.ajog.2014.06.036,10,Yes,death from endometrial cancer,No,NA,morbid obesity,HR,NA,"year and age of diagnosis, Federation of International Gynecologists and Obstetricians stage, grade, histologic type, receipt of syrgery, chemotherapy, radiation therapy",1,n/a,White,0.72,0.24,2.15
10.1016/j.ajog.2014.06.036,10,Yes,death from endometrial cancer,No,NA,morbid obesity,HR,NA,"year and age of diagnosis, Federation of International Gynecologists and Obstetricians stage, grade, histologic type, receipt of syrgery, chemotherapy, radiation therapy",2,n/a,Black,1.05,0.53,2.02
10.1016/j.ajog.2014.06.036,11,Yes,death from endometrial cancer,No,NA,charlson comorbidity score 1,HR,NA,"year and age of diagnosis, Federation of International Gynecologists and Obstetricians stage, grade, histologic type, receipt of syrgery, chemotherapy, radiation therapy",1,n/a,White,2.74,1.16,6.48
10.1016/j.ajog.2014.06.036,11,Yes,death from endometrial cancer,No,NA,charlson comorbidity score 1,HR,NA,"year and age of diagnosis, Federation of International Gynecologists and Obstetricians stage, grade, histologic type, receipt of syrgery, chemotherapy, radiation therapy",2,n/a,Black,1.1,0.51,2.36
10.1016/j.ajog.2014.06.036,12,Yes,death from endometrial cancer,No,NA,charlson comorbidity score >= 2,HR,NA,"year and age of diagnosis, Federation of International Gynecologists and Obstetricians stage, grade, histologic type, receipt of syrgery, chemotherapy, radiation therapy",1,n/a,White,0.92,0.35,2.41
10.1016/j.ajog.2014.06.036,12,Yes,death from endometrial cancer,No,NA,charlson comorbidity score >= 2,HR,NA,"year and age of diagnosis, Federation of International Gynecologists and Obstetricians stage, grade, histologic type, receipt of syrgery, chemotherapy, radiation therapy",2,n/a,Black,1.97,0.98,3.98
10.1016/j.ajog.2014.06.036,13,No,NA,No,NA,Overall death,HR,NA,none,1,White,Black,1.51,1.22,1.87
10.1016/j.ajog.2014.06.036,14,No,NA,No,NA,Overall death,HR,NA,none,1,White,Black,1.29,1.02,1.63
10.1016/j.ajog.2014.06.036,15,No,NA,No,NA,Overall death,HR,NA,none,1,White,Black,1.22,0.94,1.57
10.1016/j.ajog.2014.06.036,16,No,NA,No,NA,Disease-specific death,HR,NA,none,1,White,Black,2.42,1.63,3.6
10.1016/j.ajog.2014.06.036,17,No,NA,No,NA,Disease-specific death,HR,NA,none,1,White,Black,2.11,1.35,3.3
10.1016/j.ajog.2014.06.036,18,No,NA,No,NA,Disease-specific death,HR,NA,none,1,White,Black,2.27,1.39,3.68
10.1016/j.ajog.2014.06.036,19,No,NA,Yes,Surgically treated cases,Overall death,HR,NA,none,1,White,Black,1.39,1.11,1.75
10.1016/j.ajog.2014.06.036,20,No,NA,Yes,Surgically treated cases,Overall death,HR,NA,none,1,White,Black,1.28,1,1.64
10.1016/j.ajog.2014.06.036,21,No,NA,Yes,Surgically treated cases,Overall death,HR,NA,none,1,White,Black,1.26,0.97,1.64
10.1016/j.ajog.2014.06.036,22,No,NA,Yes,Surgically treated cases,Disease-specific death,HR,NA,none,1,White,Black,2.15,1.39,3.32
10.1016/j.ajog.2014.06.036,23,No,NA,Yes,Surgically treated cases,Disease-specific death,HR,NA,none,1,White,Black,2.03,1.27,3.24
10.1016/j.ajog.2014.06.036,24,No,NA,Yes,Surgically treated cases,Disease-specific death,HR,NA,none,1,White,Black,2.19,1.32,3.64
10.1016/j.ygyno.2011.03.018,1,Yes,1988-1994,No,NA,5 year survival,HR,NA,none,1,White,African American,1.1,0.9,1.5
10.1016/j.ygyno.2011.03.018,2,Yes,1988-1994,No,NA,5 year survival,HR,NA,"age, stage, treatment modality, modal metastasis",1,White,African American,1.1,0.8,1.4
10.1016/j.ygyno.2011.03.018,3,Yes,1995-1999,No,NA,5 year survival,HR,NA,none,1,White,African American,1.3,0.9,1.7
10.1016/j.ygyno.2011.03.018,4,Yes,1995-1999,No,NA,5 year survival,HR,NA,"age, stage, treatment modality, modal metastasis",1,White,African American,1.2,0.9,1.6
10.1016/j.ygyno.2011.03.018,5,Yes,2000-2007,No,NA,5 year survival,HR,NA,none,1,White,African American,1.2,1.01,1.5
10.1016/j.ygyno.2011.03.018,6,Yes,2000-2007,No,NA,5 year survival,HR,NA,"age, stage, treatment modality, modal metastasis",1,White,African American,1.3,1.1,1.6
10.1016/j.ygyno.2011.03.018,7,No,NA,No,NA,survival,HR,NA,"age, stage, treatment, lymphadenectomy, nodal metastasis",1,White,African American,1.2,1.1,1.4
10.1093/humrep/deq177,1,No,NA,No,NA,cervical insufficiency,OR,NA,none,1,White,Black,2.66,2.43,2.9
10.1093/humrep/deq177,1,No,NA,No,NA,cervical insufficiency,OR,NA,none,2,White,Asian/Pacific Islander,1.1,0.9,1.34
10.1093/humrep/deq177,1,No,NA,No,NA,cervical insufficiency,OR,NA,none,3,White,American Indian/Alaskan Native,1.16,0.79,1.7
10.1093/humrep/deq177,2,No,NA,Yes,primiparious-only,cervical insufficiency,OR,NA,none,1,White,Black,1.1,0.9,1.34
10.1093/humrep/deq177,2,No,NA,Yes,primiparious-only,cervical insufficiency,OR,NA,none,2,White,Asian/Pacific Islander,0.96,0.79,1.18
10.1093/humrep/deq177,2,No,NA,Yes,primiparious-only,cervical insufficiency,OR,NA,none,3,White,American Indian/Alaskan Native,1.62,1.1,2.37
10.1093/humrep/deq177,3,No,NA,Yes,multiparous women,cervical insufficiency,OR,NA,none,1,White,Black,2.18,2.02,2.36
10.1093/humrep/deq177,3,No,NA,Yes,multiparous women,cervical insufficiency,OR,NA,none,2,White,Asian/Pacific Islander,0.97,0.81,1.16
10.1093/humrep/deq177,3,No,NA,Yes,multiparous women,cervical insufficiency,OR,NA,none,3,White,American Indian/Alaskan Native,1.02,0.75,1.38
10.1016/j.fertnstert.2010.02.021,1,No,NA,No,NA,infertility diagnosis - tubal factor,RR,NA,none,1,White,African American,1.99,1.78,2.22
10.1016/j.fertnstert.2010.02.021,2,No,NA,No,NA,infertility diagnosis - male factor,RR,NA,none,1,White,African American,0.69,0.57,0.83
10.1016/j.fertnstert.2010.02.021,3,No,NA,No,NA,infertility diagnosis - endometriosis,RR,NA,none,1,White,African American,0.62,0.43,0.89
10.1016/j.fertnstert.2010.02.021,4,No,NA,No,NA,infertility diagnosis - anovulation,RR,NA,none,1,White,African American,0.58,0.37,0.92
10.1016/j.fertnstert.2010.02.021,5,No,NA,No,NA,infertility diagnosis - unexplained,RR,NA,none,1,White,African American,0.51,0.34,0.78
10.1016/j.fertnstert.2010.02.021,6,No,NA,No,NA,clinical pregnancy rate,RR,NA,none,1,White,African American,0.88,0.78,0.99
10.1016/j.fertnstert.2010.02.021,7,No,NA,No,NA,live birth rate,RR,NA,none,1,White,African American,0.74,0.63,0.91
10.1016/j.ajog.2014.06.006,1,Yes,white serving hospitals,No,NA,complicated vaginal delivery,RR,NA,none,1,Whites,Blacks,1.36,1.34,1.38
10.1016/j.ajog.2014.06.006,1,Yes,white serving hospitals,No,NA,complicated vaginal delivery,RR,NA,none,2,Whites,Hispanics,1.05,1.03,1.07
10.1016/j.ajog.2014.06.006,2,Yes,white serving hospitals,No,NA,complicated cesarean delivery,RR,NA,none,1,Whites,Blacks,1.37,1.35,1.39
10.1016/j.ajog.2014.06.006,2,Yes,white serving hospitals,No,NA,complicated cesarean delivery,RR,NA,none,2,Whites,Hispanics,0.94,0.92,0.95
10.1016/j.ajog.2014.06.006,3,Yes,white serving hospitals,No,NA,obstetric trauma,RR,NA,none,1,Whites,Blacks,0.68,0.66,0.7
10.1016/j.ajog.2014.06.006,3,Yes,white serving hospitals,No,NA,obstetric trauma,RR,NA,none,2,Whites,Hispanics,0.87,0.85,0.89
10.1016/j.ajog.2014.06.006,4,Yes,white serving hospitals,No,NA,blood transfusion,RR,NA,none,1,Whites,Blacks,2.14,2.04,2.25
10.1016/j.ajog.2014.06.006,4,Yes,white serving hospitals,No,NA,blood transfusion,RR,NA,none,2,Whites,Hispanics,1.36,1.29,1.43
10.1016/j.ajog.2014.06.006,5,Yes,white serving hospitals,No,NA,other obstetric complications,RR,NA,none,1,Whites,Blacks,1.19,1.12,1.26
10.1016/j.ajog.2014.06.006,5,Yes,white serving hospitals,No,NA,other obstetric complications,RR,NA,none,2,Whites,Hispanics,0.98,0.92,1.04
10.1016/j.ajog.2014.06.006,6,Yes,white serving hospitals,No,NA,obstetric wound complications postvaginal delivery,RR,NA,none,1,Whites,Blacks,0.95,0.88,1.03
10.1016/j.ajog.2014.06.006,6,Yes,white serving hospitals,No,NA,obstetric wound complications postvaginal delivery,RR,NA,none,2,Whites,Hispanics,0.92,0.86,0.99
10.1016/j.ajog.2014.06.006,7,Yes,white serving hospitals,No,NA,obstetric wound complications postcesarean delivery,RR,NA,none,1,Whites,Blacks,1.04,0.95,1.13
10.1016/j.ajog.2014.06.006,7,Yes,white serving hospitals,No,NA,obstetric wound complications postcesarean delivery,RR,NA,none,2,Whites,Hispanics,0.84,0.77,0.92
10.1016/j.ajog.2014.06.006,8,Yes,white serving hospitals,No,NA,puerperal infection,RR,NA,none,1,Whites,Blacks,2.85,2.53,3.2
10.1016/j.ajog.2014.06.006,8,Yes,white serving hospitals,No,NA,puerperal infection,RR,NA,none,2,Whites,Hispanics,1.94,1.72,2.2
10.1016/j.ajog.2014.06.006,9,Yes,white serving hospitals,No,NA,postpartum urinary tract infection,RR,NA,none,1,Whites,Blacks,2.62,2.34,2.94
10.1016/j.ajog.2014.06.006,9,Yes,white serving hospitals,No,NA,postpartum urinary tract infection,RR,NA,none,2,Whites,Hispanics,1.57,1.38,1.79
10.1016/j.ajog.2014.06.006,10,Yes,white serving hospitals,No,NA,peripartum hysterectomy if patients had PPH,RR,NA,none,1,Whites,Blacks,1.7,1.43,2.02
10.1016/j.ajog.2014.06.006,10,Yes,white serving hospitals,No,NA,peripartum hysterectomy if patients had PPH,RR,NA,none,2,Whites,Hispanics,1.33,1.11,1.58
10.1016/j.ajog.2014.06.006,11,Yes,white serving hospitals,No,NA,postpartum vascular complications,RR,NA,none,1,Whites,Blacks,2.21,1.76,2.79
10.1016/j.ajog.2014.06.006,11,Yes,white serving hospitals,No,NA,postpartum vascular complications,RR,NA,none,2,Whites,Hispanics,1.14,0.89,1.5
10.1016/j.ajog.2014.06.006,12,Yes,white serving hospitals,No,NA,obstetric thrombosis or embolism,RR,NA,none,1,Whites,Blacks,2.08,1.61,2.68
10.1016/j.ajog.2014.06.006,12,Yes,white serving hospitals,No,NA,obstetric thrombosis or embolism,RR,NA,none,2,Whites,Hispanics,1.11,0.82,1.5
10.1016/j.ajog.2014.06.006,13,Yes,white serving hospitals,No,NA,uterine rupture if patients had trial of labor,RR,NA,none,1,Whites,Blacks,1.22,0.83,1.79
10.1016/j.ajog.2014.06.006,13,Yes,white serving hospitals,No,NA,uterine rupture if patients had trial of labor,RR,NA,none,2,Whites,Hispanics,0.96,0.65,1.41
10.1016/j.ajog.2014.06.006,14,Yes,white serving hospitals,No,NA,puerperal cerebovascular disorders if patients had HDP,RR,NA,none,1,Whites,Blacks,3.27,2.27,4.72
10.1016/j.ajog.2014.06.006,14,Yes,white serving hospitals,No,NA,puerperal cerebovascular disorders if patients had HDP,RR,NA,none,2,Whites,Hispanics,1.96,1.3,2.95
10.1016/j.ajog.2014.06.006,15,Yes,white serving hospitals,No,NA,in hospital mortality,RR,NA,none,1,Whites,Blacks,3.05,1.8,5.15
10.1016/j.ajog.2014.06.006,15,Yes,white serving hospitals,No,NA,in hospital mortality,RR,NA,none,2,Whites,Hispanics,0.99,0.47,2.1
10.1016/j.ajog.2014.06.006,16,Yes,black serving hospitals,No,NA,complicated vaginal delivery,RR,NA,none,1,Whites,Blacks,1.19,1.13,1.26
10.1016/j.ajog.2014.06.006,16,Yes,black serving hospitals,No,NA,complicated vaginal delivery,RR,NA,none,2,Whites,Hispanics,0.75,0.69,0.81
10.1016/j.ajog.2014.06.006,17,Yes,black serving hospitals,No,NA,complicated cesarean delivery,RR,NA,none,1,Whites,Blacks,1.15,1.1,1.21
10.1016/j.ajog.2014.06.006,17,Yes,black serving hospitals,No,NA,complicated cesarean delivery,RR,NA,none,2,Whites,Hispanics,0.76,0.72,0.82
10.1016/j.ajog.2014.06.006,18,Yes,black serving hospitals,No,NA,obstetric trauma,RR,NA,none,1,Whites,Blacks,0.88,0.8,0.97
10.1016/j.ajog.2014.06.006,18,Yes,black serving hospitals,No,NA,obstetric trauma,RR,NA,none,2,Whites,Hispanics,0.87,0.76,0.98
10.1016/j.ajog.2014.06.006,19,Yes,black serving hospitals,No,NA,blood transfusion,RR,NA,none,1,Whites,Blacks,1.8,1.56,2.09
10.1016/j.ajog.2014.06.006,19,Yes,black serving hospitals,No,NA,blood transfusion,RR,NA,none,2,Whites,Hispanics,1.16,0.95,1.41
10.1016/j.ajog.2014.06.006,20,Yes,black serving hospitals,No,NA,other obstetric complications,RR,NA,none,1,Whites,Blacks,1.12,0.93,1.36
10.1016/j.ajog.2014.06.006,20,Yes,black serving hospitals,No,NA,other obstetric complications,RR,NA,none,2,Whites,Hispanics,0.7,0.53,0.92
10.1016/j.ajog.2014.06.006,21,Yes,black serving hospitals,No,NA,obstetric wound complications postvaginal delivery,RR,NA,none,1,Whites,Blacks,3.17,2.22,4.53
10.1016/j.ajog.2014.06.006,21,Yes,black serving hospitals,No,NA,obstetric wound complications postvaginal delivery,RR,NA,none,2,Whites,Hispanics,0.89,0.54,1.49
10.1016/j.ajog.2014.06.006,22,Yes,black serving hospitals,No,NA,obstetric wound complications postcesarean delivery,RR,NA,none,1,Whites,Blacks,1.11,0.75,1.33
10.1016/j.ajog.2014.06.006,22,Yes,black serving hospitals,No,NA,obstetric wound complications postcesarean delivery,RR,NA,none,2,Whites,Hispanics,0.72,0.48,1.08
10.1016/j.ajog.2014.06.006,23,Yes,black serving hospitals,No,NA,puerperal infection,RR,NA,none,1,Whites,Blacks,0.91,0.67,1.24
10.1016/j.ajog.2014.06.006,23,Yes,black serving hospitals,No,NA,puerperal infection,RR,NA,none,2,Whites,Hispanics,0.73,0.48,1.13
10.1016/j.ajog.2014.06.006,24,Yes,black serving hospitals,No,NA,postpartum urinary tract infection,RR,NA,none,1,Whites,Blacks,2.52,1.54,4.13
10.1016/j.ajog.2014.06.006,24,Yes,black serving hospitals,No,NA,postpartum urinary tract infection,RR,NA,none,2,Whites,Hispanics,1.33,0.71,2.5
10.1016/j.ajog.2014.06.006,25,Yes,black serving hospitals,No,NA,peripartum hysterectomy if patients had PPH,RR,NA,none,1,Whites,Blacks,0.99,0.59,1.63
10.1016/j.ajog.2014.06.006,25,Yes,black serving hospitals,No,NA,peripartum hysterectomy if patients had PPH,RR,NA,none,2,Whites,Hispanics,0.91,0.47,1.79
10.1016/j.ajog.2014.06.006,26,Yes,black serving hospitals,No,NA,postpartum vascular complications,RR,NA,none,1,Whites,Blacks,2.09,0.91,4.82
10.1016/j.ajog.2014.06.006,26,Yes,black serving hospitals,No,NA,postpartum vascular complications,RR,NA,none,2,Whites,Hispanics,0.86,0.26,2.81
10.1016/j.ajog.2014.06.006,27,Yes,black serving hospitals,No,NA,obstetric thrombosis or embolism,RR,NA,none,1,Whites,Blacks,1.9,0.82,4.39
10.1016/j.ajog.2014.06.006,27,Yes,black serving hospitals,No,NA,obstetric thrombosis or embolism,RR,NA,none,2,Whites,Hispanics,0.86,0.26,2.8
10.1016/j.ajog.2014.06.006,28,Yes,black serving hospitals,No,NA,uterine rupture if patients had trial of labor,RR,NA,none,1,Whites,Blacks,0.96,0.33,2.82
10.1016/j.ajog.2014.06.006,29,Yes,black serving hospitals,No,NA,puerperal cerebovascular disorders if patients had HDP,RR,NA,none,1,Whites,Blacks,0.73,0.27,1.96
10.1016/j.ajog.2014.06.006,29,Yes,black serving hospitals,No,NA,puerperal cerebovascular disorders if patients had HDP,RR,NA,none,2,Whites,Hispanics,0.21,0.02,1.76
10.1016/j.ajog.2014.06.006,30,Yes,black serving hospitals,No,NA,in hospital mortality,RR,NA,none,1,Whites,Blacks,0.54,0.19,1.5
10.1016/j.ajog.2014.06.006,31,Yes,hispanic serving hospitals,No,NA,complicated vaginal delivery,RR,NA,none,1,Whites,Blacks,1.15,1.12,1.19
10.1016/j.ajog.2014.06.006,31,Yes,hispanic serving hospitals,No,NA,complicated vaginal delivery,RR,NA,none,2,Whites,Hispanics,0.91,0.89,0.93
10.1016/j.ajog.2014.06.006,32,Yes,hispanic serving hospitals,No,NA,complicated cesarean delivery,RR,NA,none,1,Whites,Blacks,1.33,1.3,1.36
10.1016/j.ajog.2014.06.006,32,Yes,hispanic serving hospitals,No,NA,complicated cesarean delivery,RR,NA,none,2,Whites,Hispanics,0.84,0.82,0.85
10.1016/j.ajog.2014.06.006,33,Yes,hispanic serving hospitals,No,NA,obstetric trauma,RR,NA,none,1,Whites,Blacks,0.62,0.59,0.65
10.1016/j.ajog.2014.06.006,33,Yes,hispanic serving hospitals,No,NA,obstetric trauma,RR,NA,none,2,Whites,Hispanics,0.81,0.79,0.83
10.1016/j.ajog.2014.06.006,34,Yes,hispanic serving hospitals,No,NA,blood transfusion,RR,NA,none,1,Whites,Blacks,1.99,1.83,2.16
10.1016/j.ajog.2014.06.006,34,Yes,hispanic serving hospitals,No,NA,blood transfusion,RR,NA,none,2,Whites,Hispanics,1.14,1.07,1.2
10.1016/j.ajog.2014.06.006,35,Yes,hispanic serving hospitals,No,NA,other obstetric complications,RR,NA,none,1,Whites,Blacks,1.19,1.07,1.33
10.1016/j.ajog.2014.06.006,35,Yes,hispanic serving hospitals,No,NA,other obstetric complications,RR,NA,none,2,Whites,Hispanics,0.87,0.82,0.94
10.1016/j.ajog.2014.06.006,36,Yes,hispanic serving hospitals,No,NA,obstetric wound complications postvaginal delivery,RR,NA,none,1,Whites,Blacks,1.05,0.91,1.2
10.1016/j.ajog.2014.06.006,36,Yes,hispanic serving hospitals,No,NA,obstetric wound complications postvaginal delivery,RR,NA,none,2,Whites,Hispanics,1,0.93,1.09
10.1016/j.ajog.2014.06.006,37,Yes,hispanic serving hospitals,No,NA,obstetric wound complications postcesarean delivery,RR,NA,none,1,Whites,Blacks,1.2,1.03,1.39
10.1016/j.ajog.2014.06.006,37,Yes,hispanic serving hospitals,No,NA,obstetric wound complications postcesarean delivery,RR,NA,none,2,Whites,Hispanics,0.93,0.85,1.03
10.1016/j.ajog.2014.06.006,38,Yes,hispanic serving hospitals,No,NA,puerperal infection,RR,NA,none,1,Whites,Blacks,2.66,2.16,3.28
10.1016/j.ajog.2014.06.006,38,Yes,hispanic serving hospitals,No,NA,puerperal infection,RR,NA,none,2,Whites,Hispanics,1.5,1.28,1.75
10.1016/j.ajog.2014.06.006,39,Yes,hispanic serving hospitals,No,NA,postpartum urinary tract infection,RR,NA,none,1,Whites,Blacks,1.95,1.56,2.44
10.1016/j.ajog.2014.06.006,39,Yes,hispanic serving hospitals,No,NA,postpartum urinary tract infection,RR,NA,none,2,Whites,Hispanics,1.35,1.15,1.58
10.1016/j.ajog.2014.06.006,40,Yes,hispanic serving hospitals,No,NA,peripartum hysterectomy if patients had PPH,RR,NA,none,1,Whites,Blacks,1.51,1.13,2.01
10.1016/j.ajog.2014.06.006,40,Yes,hispanic serving hospitals,No,NA,peripartum hysterectomy if patients had PPH,RR,NA,none,2,Whites,Hispanics,1.09,0.9,1.32
10.1016/j.ajog.2014.06.006,41,Yes,hispanic serving hospitals,No,NA,postpartum vascular complications,RR,NA,none,1,Whites,Blacks,1.69,1.07,2.69
10.1016/j.ajog.2014.06.006,41,Yes,hispanic serving hospitals,No,NA,postpartum vascular complications,RR,NA,none,2,Whites,Hispanics,0.93,0.68,1.29
10.1016/j.ajog.2014.06.006,42,Yes,hispanic serving hospitals,No,NA,obstetric thrombosis or embolism,RR,NA,none,1,Whites,Blacks,1.5,0.9,2.5
10.1016/j.ajog.2014.06.006,42,Yes,hispanic serving hospitals,No,NA,obstetric thrombosis or embolism,RR,NA,none,2,Whites,Hispanics,0.85,0.6,1.21
10.1016/j.ajog.2014.06.006,43,Yes,hispanic serving hospitals,No,NA,uterine rupture if patients had trial of labor,RR,NA,none,1,Whites,Blacks,0.96,0.46,1.97
10.1016/j.ajog.2014.06.006,43,Yes,hispanic serving hospitals,No,NA,uterine rupture if patients had trial of labor,RR,NA,none,2,Whites,Hispanics,0.88,0.58,1.33
10.1016/j.ajog.2014.06.006,44,Yes,hispanic serving hospitals,No,NA,puerperal cerebovascular disorders if patients had HDP,RR,NA,none,1,Whites,Blacks,2.68,1.46,4.9
10.1016/j.ajog.2014.06.006,44,Yes,hispanic serving hospitals,No,NA,puerperal cerebovascular disorders if patients had HDP,RR,NA,none,2,Whites,Hispanics,0.93,0.58,1.51
10.1016/j.ajog.2014.06.006,45,Yes,hispanic serving hospitals,No,NA,in hospital mortality,RR,NA,none,1,Whites,Blacks,2.49,1.17,5.29
10.1016/j.ajog.2014.06.006,45,Yes,hispanic serving hospitals,No,NA,in hospital mortality,RR,NA,none,2,Whites,Hispanics,1.16,0.66,2.07
10.1016/j.ajog.2014.06.006,46,Yes,white serving hospitals,No,NA,complicated vaginal delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",1,Whites,Blacks,1.37,1.31,1.44
10.1016/j.ajog.2014.06.006,46,Yes,white serving hospitals,No,NA,complicated vaginal delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",2,Whites,Hispanics,1.02,0.96,1.07
10.1016/j.ajog.2014.06.006,47,Yes,white serving hospitals,No,NA,complicated vaginal delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",1,Whites,Blacks,1.25,1.2,1.31
10.1016/j.ajog.2014.06.006,47,Yes,white serving hospitals,No,NA,complicated vaginal delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",2,Whites,Hispanics,1.03,0.99,1.08
10.1016/j.ajog.2014.06.006,48,Yes,white serving hospitals,No,NA,complicated vaginal delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",1,Whites,Blacks,1.24,1.19,1.29
10.1016/j.ajog.2014.06.006,48,Yes,white serving hospitals,No,NA,complicated vaginal delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",2,Whites,Hispanics,1.04,0.99,1.08
10.1016/j.ajog.2014.06.006,49,Yes,white serving hospitals,No,NA,complicated cesarean delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",1,Whites,Blacks,1.25,1.22,1.28
10.1016/j.ajog.2014.06.006,49,Yes,white serving hospitals,No,NA,complicated cesarean delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",2,Whites,Hispanics,0.97,0.94,0.99
10.1016/j.ajog.2014.06.006,50,Yes,white serving hospitals,No,NA,complicated cesarean delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",1,Whites,Blacks,1.15,1.13,1.18
10.1016/j.ajog.2014.06.006,50,Yes,white serving hospitals,No,NA,complicated cesarean delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",2,Whites,Hispanics,0.96,0.93,0.98
10.1016/j.ajog.2014.06.006,51,Yes,white serving hospitals,No,NA,complicated cesarean delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",1,Whites,Blacks,1.15,1.12,1.17
10.1016/j.ajog.2014.06.006,51,Yes,white serving hospitals,No,NA,complicated cesarean delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",2,Whites,Hispanics,0.96,0.93,0.99
10.1016/j.ajog.2014.06.006,52,Yes,black serving hospitals,No,NA,complicated vaginal delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",1,Whites,Blacks,1.15,0.95,1.39
10.1016/j.ajog.2014.06.006,52,Yes,black serving hospitals,No,NA,complicated vaginal delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",2,Whites,Hispanics,0.73,0.54,0.98
10.1016/j.ajog.2014.06.006,53,Yes,black serving hospitals,No,NA,complicated vaginal delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",1,Whites,Blacks,1.12,1.01,1.27
10.1016/j.ajog.2014.06.006,53,Yes,black serving hospitals,No,NA,complicated vaginal delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",2,Whites,Hispanics,0.8,0.65,1
10.1016/j.ajog.2014.06.006,54,Yes,black serving hospitals,No,NA,complicated vaginal delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",1,Whites,Blacks,1.16,1.04,1.28
10.1016/j.ajog.2014.06.006,54,Yes,black serving hospitals,No,NA,complicated vaginal delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",2,Whites,Hispanics,0.82,0.68,0.99
10.1016/j.ajog.2014.06.006,55,Yes,black serving hospitals,No,NA,complicated cesarean delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",1,Whites,Blacks,1.16,1.03,1.3
10.1016/j.ajog.2014.06.006,55,Yes,black serving hospitals,No,NA,complicated cesarean delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",2,Whites,Hispanics,0.77,0.65,0.93
10.1016/j.ajog.2014.06.006,56,Yes,black serving hospitals,No,NA,complicated cesarean delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",1,Whites,Blacks,1.11,1,1.23
10.1016/j.ajog.2014.06.006,56,Yes,black serving hospitals,No,NA,complicated cesarean delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",2,Whites,Hispanics,0.79,0.68,0.92
10.1016/j.ajog.2014.06.006,57,Yes,black serving hospitals,No,NA,complicated cesarean delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",1,Whites,Blacks,1.09,1.02,1.17
10.1016/j.ajog.2014.06.006,57,Yes,black serving hospitals,No,NA,complicated cesarean delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",2,Whites,Hispanics,0.78,0.68,0.9
10.1016/j.ajog.2014.06.006,58,Yes,hispanic serving hospitals,No,NA,complicated vaginal delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",1,Whites,Blacks,1.25,1.15,1.37
10.1016/j.ajog.2014.06.006,58,Yes,hispanic serving hospitals,No,NA,complicated vaginal delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",2,Whites,Hispanics,0.91,0.85,0.97
10.1016/j.ajog.2014.06.006,59,Yes,hispanic serving hospitals,No,NA,complicated vaginal delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",1,Whites,Blacks,1.15,1.07,1.23
10.1016/j.ajog.2014.06.006,59,Yes,hispanic serving hospitals,No,NA,complicated vaginal delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",2,Whites,Hispanics,0.98,0.93,1.04
10.1016/j.ajog.2014.06.006,60,Yes,hispanic serving hospitals,No,NA,complicated vaginal delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",1,Whites,Blacks,1.13,1.08,1.19
10.1016/j.ajog.2014.06.006,60,Yes,hispanic serving hospitals,No,NA,complicated vaginal delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",2,Whites,Hispanics,0.99,0.96,1.03
10.1016/j.ajog.2014.06.006,61,Yes,hispanic serving hospitals,No,NA,complicated cesarean delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",1,Whites,Blacks,1.21,1.15,1.27
10.1016/j.ajog.2014.06.006,61,Yes,hispanic serving hospitals,No,NA,complicated cesarean delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",2,Whites,Hispanics,0.88,0.85,0.92
10.1016/j.ajog.2014.06.006,62,Yes,hispanic serving hospitals,No,NA,complicated cesarean delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",1,Whites,Blacks,1.15,1.11,1.21
10.1016/j.ajog.2014.06.006,62,Yes,hispanic serving hospitals,No,NA,complicated cesarean delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",2,Whites,Hispanics,0.93,0.89,0.96
10.1016/j.ajog.2014.06.006,63,Yes,hispanic serving hospitals,No,NA,complicated cesarean delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",1,Whites,Blacks,1.15,1.1,1.2
10.1016/j.ajog.2014.06.006,63,Yes,hispanic serving hospitals,No,NA,complicated cesarean delivery,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, statelevel household income quartile for patient zip code",2,Whites,Hispanics,0.94,0.91,0.97
10.1016/j.fertnstert.2010.05.031,1,No,NA,No,NA,rating concern about using hormones long term” as “very important” in sterilization decisions,OR,NA,none,1,White,African American,0.53,0.28,0.99
10.1016/j.fertnstert.2010.05.031,2,No,NA,No,NA,rating concern about using hormones long term” as “very important” in sterilization decisions,OR,NA,"age, marital status, education level, insurance status at the time of sterilization",1,White,African American,0.68,0.33,1.39
10.1016/j.fertnstert.2010.05.031,3,No,NA,No,NA,rating prior unwanted pregnancy” as “very important” in sterilization decisions,OR,NA,none,1,White,African American,2.79,1.38,5.67
10.1016/j.fertnstert.2010.05.031,4,No,NA,No,NA,rating prior unwanted pregnancy” as “very important” in sterilization decisions,OR,NA,"age, marital status, education level, insurance status at the time of sterilization",1,White,African American,1.94,0.85,4.41
10.1016/j.fertnstert.2010.05.031,5,No,NA,No,NA,rating didn’t want foreign object in body (ie. iud or implant)” as “very important” in sterilization decisions,OR,NA,none,1,White,African American,2.11,1.12,3.99
10.1016/j.fertnstert.2010.05.031,6,No,NA,No,NA,rating didn’t want foreign object in body (ie. iud or implant)” as “very important” in sterilization decisions,OR,NA,"age, marital status, education level, insurance status at the time of sterilization",1,White,African American,1.95,0.94,4.02
10.1016/j.fertnstert.2010.05.031,7,No,NA,No,NA,rating other methods decreased sexual pleasure” as “very important” in sterilization decisions,OR,NA,none,1,White,African American,3.07,1.09,8.7
10.1016/j.fertnstert.2010.05.031,8,No,NA,No,NA,rating other methods decreased sexual pleasure” as “very important” in sterilization decisions,OR,NA,"age, marital status, education level, insurance status at the time of sterilization",1,White,African American,3.98,1.14,13.86
10.1016/j.fertnstert.2010.05.031,9,No,NA,No,NA,rating likelihood of family members with ts” as “very important” in sterilization decisions,OR,NA,none,1,White,African American,2.36,1.33,4.17
10.1016/j.fertnstert.2010.05.031,10,No,NA,No,NA,rating likelihood of family members with ts” as “very important” in sterilization decisions,OR,NA,"age, marital status, education level, insurance status at the time of sterilization",1,White,African American,2.39,1.25,4.53
10.1016/j.fertnstert.2010.05.031,11,No,NA,No,NA,rating mother most influential person in sterilization decision” as “very important” in sterilization decisions,OR,NA,none,1,White,African American,5.83,1.45,23.46
10.1016/j.fertnstert.2010.05.031,12,No,NA,No,NA,rating mother most influential person in sterilization decision” as “very important” in sterilization decisions,OR,NA,"age, marital status, education level, insurance status at the time of sterilization",1,White,African American,4.34,0.99,18.94
10.1016/j.fertnstert.2010.05.031,13,No,NA,No,NA,rating doctor most influential person in sterilization decision” as “very important” in sterilization decisions,OR,NA,none,1,White,African American,0.35,0.14,0.9
10.1016/j.fertnstert.2010.05.031,14,No,NA,No,NA,rating doctor most influential person in sterilization decision” as “very important” in sterilization decisions,OR,NA,"age, marital status, education level, insurance status at the time of sterilization",1,White,African American,0.4,0.14,1.1
10.1016/j.fertnstert.2010.05.031,15,No,NA,No,NA,odds of answering ts reversal can easily restore fertility” correctly,OR,NA,none,1,White,African American,0.34,0.18,0.64
10.1016/j.fertnstert.2010.05.031,16,No,NA,No,NA,odds of answering ts reversal can easily restore fertility” correctly,OR,NA,"age, marital status, education level, insurance status at the time of sterilization",1,White,African American,0.44,0.22,0.91
10.1016/j.fertnstert.2010.05.031,17,No,NA,No,NA,odds of answering ts will reverse itself after 5 years” correctly,OR,NA,none,1,White,African American,0.21,0.11,0.4
10.1016/j.fertnstert.2010.05.031,18,No,NA,No,NA,odds of answering ts will reverse itself after 5 years” correctly,OR,NA,"age, marital status, education level, insurance status at the time of sterilization",1,White,African American,0.3,0.14,0.63
10.1016/j.fertnstert.2010.05.031,19,No,NA,No,NA,odds of answering a man can still ejaculate after vasectomy” correctly,OR,NA,none,1,White,African American,0.25,0.12,0.51
10.1016/j.fertnstert.2010.05.031,20,No,NA,No,NA,odds of answering a man can still ejaculate after vasectomy” correctly,OR,NA,"age, marital status, education level, insurance status at the time of sterilization",1,White,African American,0.29,0.12,0.68
10.1016/j.fertnstert.2010.05.031,21,No,NA,No,NA,odds of answering ovaries and uterus are removed during sterilization” correctly,OR,NA,none,1,White,African American,0.086,0.01,0.76
10.1016/j.fertnstert.2010.05.031,22,No,NA,No,NA,odds of answering ovaries and uterus are removed during sterilization” correctly,OR,NA,"age, marital status, education level, insurance status at the time of sterilization",1,White,African American,0.09,0.008,1.03
10.1016/j.fertnstert.2010.05.031,23,No,NA,No,NA,Have ever heard of IUDS,OR,NA,none,1,White,African American,0.14,0.028,0.072
10.1016/j.fertnstert.2010.05.031,24,No,NA,No,NA,Have ever heard of IUDS,OR,NA,"age, marital status, education level, insurance status at the time of sterilization",1,White,African American,0.11,0.015,0.83
10.1097/AOG.0000000000001567,1,No,NA,No,NA,open compared with minimally invasive surgery,OR,NA,"age, Elixhauser score, average annual hospital volume, hospital type, region, location, teaching status, bed size, median household income, expected payer, obesity, lymphadenectomy",1,White,Black,1.46,1.3,1.65
10.1097/AOG.0000000000001567,1,No,NA,No,NA,open compared with minimally invasive surgery,OR,NA,"age, Elixhauser score, average annual hospital volume, hospital type, region, location, teaching status, bed size, median household income, expected payer, obesity, lymphadenectomy",2,White,Hispanic,1.18,1.03,1.36
10.1097/AOG.0000000000001567,1,No,NA,No,NA,open compared with minimally invasive surgery,OR,NA,"age, Elixhauser score, average annual hospital volume, hospital type, region, location, teaching status, bed size, median household income, expected payer, obesity, lymphadenectomy",3,White,Asian or Pacific Islander,1.14,0.95,1.36
10.1097/AOG.0000000000001567,1,No,NA,No,NA,open compared with minimally invasive surgery,OR,NA,"age, Elixhauser score, average annual hospital volume, hospital type, region, location, teaching status, bed size, median household income, expected payer, obesity, lymphadenectomy",4,White,Other,2.39,1.99,2.87
10.1097/AOG.0000000000001567,1,No,NA,No,NA,open compared with minimally invasive surgery,OR,NA,"age, Elixhauser score, average annual hospital volume, hospital type, region, location, teaching status, bed size, median household income, expected payer, obesity, lymphadenectomy",5,White,Unknown,1.21,0.96,1.53
10.1097/AOG.0b013e31821c4071,1,No,NA,No,NA,cesarean delivery,OR,NA,none,1,White,African American,0.95,0.83,1.08
10.1097/AOG.0b013e31821c4071,1,No,NA,No,NA,cesarean delivery,OR,NA,none,2,White,Hispanic,0.99,0.89,1.11
10.1097/AOG.0b013e31821c4071,1,No,NA,No,NA,cesarean delivery,OR,NA,none,3,White,Other,0.96,0.82,1.13
10.1097/AOG.0b013e31821c4071,2,No,NA,No,NA,cesarean delivery,OR,NA,"age, parity, insurance, education, early prenatal care, income",1,White,African American,0.93,0.82,1.07
10.1097/AOG.0b013e31821c4071,2,No,NA,No,NA,cesarean delivery,OR,NA,"age, parity, insurance, education, early prenatal care, income",2,White,Hispanic,0.96,0.85,1.08
10.1097/AOG.0b013e31821c4071,2,No,NA,No,NA,cesarean delivery,OR,NA,"age, parity, insurance, education, early prenatal care, income",3,White,Other,0.96,0.82,1.13
10.1097/AOG.0b013e31821c4071,3,No,NA,No,NA,cesarean delivery,OR,NA,"age, parity, insurance, education, early prenatal care, income, gestational diabetes, pre-existing diabetes, pregnancy-induced hypertension, chronic hypertension",1,White,African American,0.88,0.76,1.01
10.1097/AOG.0b013e31821c4071,3,No,NA,No,NA,cesarean delivery,OR,NA,"age, parity, insurance, education, early prenatal care, income, gestational diabetes, pre-existing diabetes, pregnancy-induced hypertension, chronic hypertension",2,White,Hispanic,0.92,0.82,1.04
10.1097/AOG.0b013e31821c4071,3,No,NA,No,NA,cesarean delivery,OR,NA,"age, parity, insurance, education, early prenatal care, income, gestational diabetes, pre-existing diabetes, pregnancy-induced hypertension, chronic hypertension",3,White,Other,0.96,0.81,1.13
10.1097/AOG.0b013e31821c4071,4,No,NA,No,NA,cesarean delivery,OR,NA,"age, parity, insurance, education, early prenatal care, income, gestational diabetes, pre-existing diabetes, pregnancy-induced hypertension, chronic hypertension, gestational age, diagnosis or indication, including preterm labor, preterm premature rupture of membranes, abruption, previa, repeat cesarean delivery, malpresentation",1,White,African American,0.89,0.76,1.05
10.1097/AOG.0b013e31821c4071,4,No,NA,No,NA,cesarean delivery,OR,NA,"age, parity, insurance, education, early prenatal care, income, gestational diabetes, pre-existing diabetes, pregnancy-induced hypertension, chronic hypertension, gestational age, diagnosis or indication, including preterm labor, preterm premature rupture of membranes, abruption, previa, repeat cesarean delivery, malpresentation",2,White,Hispanic,0.95,0.83,1.09
10.1097/AOG.0b013e31821c4071,4,No,NA,No,NA,cesarean delivery,OR,NA,"age, parity, insurance, education, early prenatal care, income, gestational diabetes, pre-existing diabetes, pregnancy-induced hypertension, chronic hypertension, gestational age, diagnosis or indication, including preterm labor, preterm premature rupture of membranes, abruption, previa, repeat cesarean delivery, malpresentation",3,White,Other,0.87,0.72,1.06
10.1097/AOG.0b013e31821c4071,5,No,NA,No,NA,cesarean delivery,OR,NA,"age, parity, insurance, education, annual income, prenatal care, comorbidities, indication or diagnosis",1,White,African American,0.89,0.76,1.05
10.1097/AOG.0b013e31821c4071,5,No,NA,No,NA,cesarean delivery,OR,NA,"age, parity, insurance, education, annual income, prenatal care, comorbidities, indication or diagnosis",2,White,Hispanic,0.95,0.83,1.09
10.1097/AOG.0b013e31821c4071,5,No,NA,No,NA,cesarean delivery,OR,NA,"age, parity, insurance, education, annual income, prenatal care, comorbidities, indication or diagnosis",3,White,Other,0.87,0.72,1.06
10.1097/AOG.0b013e31821c4071,6,No,NA,No,NA,cesarean delivery,OR,NA,"age, parity, insurance, education, annual income, prenatal care, comorbidities, indication or diagnosis, hospital identification",1,White,African American,0.97,0.81,1.15
10.1097/AOG.0b013e31821c4071,6,No,NA,No,NA,cesarean delivery,OR,NA,"age, parity, insurance, education, annual income, prenatal care, comorbidities, indication or diagnosis, hospital identification",2,White,Hispanic,1.03,0.88,1.21
10.1097/AOG.0b013e31821c4071,6,No,NA,No,NA,cesarean delivery,OR,NA,"age, parity, insurance, education, annual income, prenatal care, comorbidities, indication or diagnosis, hospital identification",3,White,Other,0.92,0.75,1.13
10.1097/AOG.0000000000001033,1,No,NA,No,NA,Likelihood of diagnosis with advanced stage,OR,NA,"age at diagnosis, race ethnicity, insurance, diagnosis year, median income level, facility volume, facility type, census region",1,Non-Hispanic white,Hispanic,1.24,0.99,1.55
10.1097/AOG.0000000000001033,1,No,NA,No,NA,Likelihood of diagnosis with advanced stage,OR,NA,"age at diagnosis, race ethnicity, insurance, diagnosis year, median income level, facility volume, facility type, census region",2,Non-Hispanic white,Black,1.2,1.03,1.4
10.1097/AOG.0000000000001033,1,No,NA,No,NA,Likelihood of diagnosis with advanced stage,OR,NA,"age at diagnosis, race ethnicity, insurance, diagnosis year, median income level, facility volume, facility type, census region",3,Non-Hispanic white,Others,1.11,0.75,1.63
10.1097/AOG.0000000000001033,1,No,NA,No,NA,Likelihood of diagnosis with advanced stage,OR,NA,"age at diagnosis, race ethnicity, insurance, diagnosis year, median income level, facility volume, facility type, census region",4,Non-Hispanic white,Missing,0.98,0.84,1.13
10.1097/AOG.0000000000001033,2,Yes,Stage III,No,NA,Increased Hazard of Death Within 5 Years Among Patients with Advanced Stage Disease,HR,NA,none,1,Non-Hispanic white,Hispanic,1.04,0.75,1.43
10.1097/AOG.0000000000001033,2,Yes,Stage III,No,NA,Increased Hazard of Death Within 5 Years Among Patients with Advanced Stage Disease,HR,NA,none,2,Non-Hispanic white,Black,0.64,0.49,0.83
10.1097/AOG.0000000000001033,2,Yes,Stage III,No,NA,Increased Hazard of Death Within 5 Years Among Patients with Advanced Stage Disease,HR,NA,none,3,Non-Hispanic white,Others,1.07,0.6,1.89
10.1097/AOG.0000000000001033,2,Yes,Stage III,No,NA,Increased Hazard of Death Within 5 Years Among Patients with Advanced Stage Disease,HR,NA,none,4,Non-Hispanic white,Missing,1.03,0.84,1.26
10.1097/AOG.0000000000001033,3,Yes,Stage IV,No,NA,Increased Hazard of Death Within 5 Years Among Patients with Advanced Stage Disease,HR,NA,none,1,Non-Hispanic white,Hispanic,1.07,0.75,1.53
10.1097/AOG.0000000000001033,3,Yes,Stage IV,No,NA,Increased Hazard of Death Within 5 Years Among Patients with Advanced Stage Disease,HR,NA,none,2,Non-Hispanic white,Black,0.75,0.57,0.99
10.1097/AOG.0000000000001033,3,Yes,Stage IV,No,NA,Increased Hazard of Death Within 5 Years Among Patients with Advanced Stage Disease,HR,NA,none,3,Non-Hispanic white,Others,0.8,0.37,1.72
10.1097/AOG.0000000000001033,3,Yes,Stage IV,No,NA,Increased Hazard of Death Within 5 Years Among Patients with Advanced Stage Disease,HR,NA,none,4,Non-Hispanic white,Missing,1.22,0.95,1.57
10.1097/AOG.0000000000001033,4,Yes,Stage III,No,NA,Increased Hazard of Death Within 5 Years Among Patients with Advanced Stage Disease who underwent surgical treatment,HR,NA,none,1,Non-Hispanic white,Hispanic,0.97,0.66,1.43
10.1097/AOG.0000000000001033,4,Yes,Stage III,No,NA,Increased Hazard of Death Within 5 Years Among Patients with Advanced Stage Disease who underwent surgical treatment,HR,NA,none,2,Non-Hispanic white,Black,0.62,0.45,0.84
10.1097/AOG.0000000000001033,4,Yes,Stage III,No,NA,Increased Hazard of Death Within 5 Years Among Patients with Advanced Stage Disease who underwent surgical treatment,HR,NA,none,3,Non-Hispanic white,Others,1.16,0.57,2.33
10.1097/AOG.0000000000001033,4,Yes,Stage III,No,NA,Increased Hazard of Death Within 5 Years Among Patients with Advanced Stage Disease who underwent surgical treatment,HR,NA,none,4,Non-Hispanic white,Missing,1.24,0.99,1.54
10.1097/AOG.0000000000001033,5,Yes,Stage IV,No,NA,Increased Hazard of Death Within 5 Years Among Patients with Advanced Stage Disease who underwent surgical treatment,HR,NA,none,1,Non-Hispanic white,Hispanic,1.27,0.68,2.35
10.1097/AOG.0000000000001033,5,Yes,Stage IV,No,NA,Increased Hazard of Death Within 5 Years Among Patients with Advanced Stage Disease who underwent surgical treatment,HR,NA,none,2,Non-Hispanic white,Black,1.14,0.71,1.82
10.1097/AOG.0000000000001033,5,Yes,Stage IV,No,NA,Increased Hazard of Death Within 5 Years Among Patients with Advanced Stage Disease who underwent surgical treatment,HR,NA,none,3,Non-Hispanic white,Others,0.61,0.19,2.01
10.1097/AOG.0000000000001033,5,Yes,Stage IV,No,NA,Increased Hazard of Death Within 5 Years Among Patients with Advanced Stage Disease who underwent surgical treatment,HR,NA,none,4,Non-Hispanic white,Missing,1.05,0.73,1.51
10.1097/AOG.0000000000001033,6,No,NA,No,NA,5-year all cause mortality,HR,NA,all other covariates,1,white,Black,0.67,0.52,0.85
10.1016/j.ygyno.2012.08.021,1,Yes,1975-1979; <50 years,No,NA,localized cervical cancer,RR,NA,age,1,White,Black,1.8,1.6,2.1
10.1016/j.ygyno.2012.08.021,2,Yes,2005-2009; <50 years,No,NA,localized cervical cancer,RR,NA,age,1,White,Black,0.8,0.7,0.9
10.1016/j.ygyno.2012.08.021,3,Yes,1975-1979; <50 years,No,NA,regional cervical cancer,RR,NA,age,1,White,Black,2.1,1.6,2.7
10.1016/j.ygyno.2012.08.021,4,Yes,2005-2009; <50 years,No,NA,regional cervical cancer,RR,NA,age,1,White,Black,1.1,0.9,1.4
10.1016/j.ygyno.2012.08.021,5,Yes,1975-1979; <50 years,No,NA,distant cervical cancer,RR,NA,age,1,White,Black,2.6,1.4,4.5
10.1016/j.ygyno.2012.08.021,6,Yes,2005-2009; <50 years,No,NA,distant cervical cancer,RR,NA,age,1,White,Black,1.3,0.8,1.9
10.1016/j.ygyno.2012.08.021,7,Yes,1975-1979; <50 years,No,NA,unstaged cervical cancer,RR,NA,age,1,White,Black,2.2,1.3,3.6
10.1016/j.ygyno.2012.08.021,8,Yes,2005-2009; <50 years,No,NA,unstaged cervical cancer,RR,NA,age,1,White,Black,1.1,0.6,2.1
10.1016/j.ygyno.2012.08.021,9,Yes,1975-1979; 50-64 years,No,NA,localized cervical cancer,RR,NA,age,1,White,Black,2.3,1.8,2.8
10.1016/j.ygyno.2012.08.021,10,Yes,2005-2009; 50-64 years,No,NA,localized cervical cancer,RR,NA,age,1,White,Black,1.8,1.4,2.3
10.1016/j.ygyno.2012.08.021,11,Yes,1975-1979; 50-64 years,No,NA,regional cervical cancer,RR,NA,age,1,White,Black,2.1,1.6,2.7
10.1016/j.ygyno.2012.08.021,12,Yes,2005-2009; 50-64 years,No,NA,regional cervical cancer,RR,NA,age,1,White,Black,1.8,1.4,2.2
10.1016/j.ygyno.2012.08.021,13,Yes,1975-1979; 50-64 years,No,NA,distant cervical cancer,RR,NA,age,1,White,Black,2.9,1.8,4.3
10.1016/j.ygyno.2012.08.021,14,Yes,2005-2009; 50-64 years,No,NA,distant cervical cancer,RR,NA,age,1,White,Black,1.6,1.1,2.3
10.1016/j.ygyno.2012.08.021,15,Yes,1975-1979; 50-64 years,No,NA,unstaged cervical cancer,RR,NA,age,1,White,Black,2.1,1.1,3.8
10.1016/j.ygyno.2012.08.021,16,Yes,2005-2009; 50-64 years,No,NA,unstaged cervical cancer,RR,NA,age,1,White,Black,1.5,0.7,3.2
10.1016/j.ygyno.2012.08.021,17,Yes,1975-1979; >=65 years,No,NA,localized cervical cancer,RR,NA,age,1,White,Black,3.5,2.7,4.4
10.1016/j.ygyno.2012.08.021,18,Yes,2005-2009; >=65 years,No,NA,localized cervical cancer,RR,NA,age,1,White,Black,2.2,1.6,3
10.1016/j.ygyno.2012.08.021,19,Yes,1975-1979; >=65 years,No,NA,regional cervical cancer,RR,NA,age,1,White,Black,3.7,2.9,4.7
10.1016/j.ygyno.2012.08.021,20,Yes,2005-2009; >=65 years,No,NA,regional cervical cancer,RR,NA,age,1,White,Black,2.1,1.6,2.7
10.1016/j.ygyno.2012.08.021,21,Yes,1975-1979; >=65 years,No,NA,distant cervical cancer,RR,NA,age,1,White,Black,2.7,1.7,4.2
10.1016/j.ygyno.2012.08.021,22,Yes,2005-2009; >=65 years,No,NA,distant cervical cancer,RR,NA,age,1,White,Black,2.6,1.6,4
10.1016/j.ygyno.2012.08.021,23,Yes,1975-1979; >=65 years,No,NA,unstaged cervical cancer,RR,NA,age,1,White,Black,2.7,1.5,4.4
10.1016/j.ygyno.2012.08.021,24,Yes,2005-2009; >=65 years,No,NA,unstaged cervical cancer,RR,NA,age,1,White,Black,3,1.6,5.4
10.1016/j.ygyno.2012.08.021,25,Yes,1975-1979; <50 years; high area-level SES,No,NA,cervical cancer,RR,NA,age,1,White,Black,2.1,1.7,2.6
10.1016/j.ygyno.2012.08.021,26,Yes,2005-2009; <50 years; high area-level SES,No,NA,cervical cancer,RR,NA,age,1,White,Black,0.7,0.6,0.9
10.1016/j.ygyno.2012.08.021,27,Yes,1975-1979; <50 years; low area-level SES,No,NA,cervical cancer,RR,NA,age,1,White,Black,1.7,1.5,1.9
10.1016/j.ygyno.2012.08.021,28,Yes,2005-2009; <50 years; low area-level SES,No,NA,cervical cancer,RR,NA,age,1,White,Black,0.9,0.8,1.1
10.1016/j.ygyno.2012.08.021,29,Yes,1975-1979; 50-64 years; high area-level SES,No,NA,cervical cancer,RR,NA,age,1,White,Black,2.3,1.7,3
10.1016/j.ygyno.2012.08.021,30,Yes,2005-2009; 50-64 years; high area-level SES,No,NA,cervical cancer,RR,NA,age,1,White,Black,1.4,1,1.8
10.1016/j.ygyno.2012.08.021,31,Yes,1975-1979; 50-64 years; low area-level SES,No,NA,cervical cancer,RR,NA,age,1,White,Black,2.2,1.9,2.6
10.1016/j.ygyno.2012.08.021,32,Yes,2005-2009; 50-64 years; low area-level SES,No,NA,cervical cancer,RR,NA,age,1,White,Black,1.8,1.5,2.1
10.1016/j.ygyno.2012.08.021,33,Yes,1975-1979; >=65 years; high area-level SES,No,NA,cervical cancer,RR,NA,age,1,White,Black,2.5,1.7,3.5
10.1016/j.ygyno.2012.08.021,34,Yes,2005-2009; >=65 years; high area-level SES,No,NA,cervical cancer,RR,NA,age,1,White,Black,2.6,1.9,3.5
10.1016/j.ygyno.2012.08.021,35,Yes,1975-1979; >=65 years; low area-level SES,No,NA,cervical cancer,RR,NA,age,1,White,Black,3.2,2.7,3.7
10.1016/j.ygyno.2012.08.021,36,Yes,2005-2009; >=65 years; low area-level SES,No,NA,cervical cancer,RR,NA,age,1,White,Black,2,1.6,2.5
10.1016/j.ygyno.2012.08.021,37,Yes,1992-1996; <50 years,No,NA,cervical cancer,RR,NA,age,1,Non-Hispanic white,Non-Hispanic black,1.3,1.2,1.4
10.1016/j.ygyno.2012.08.021,37,Yes,1992-1996; <50 years,No,NA,cervical cancer,RR,NA,age,2,Non-Hispanic white,American Indian/Alaska Native,1.1,0.8,1.5
10.1016/j.ygyno.2012.08.021,37,Yes,1992-1996; <50 years,No,NA,cervical cancer,RR,NA,age,3,Non-Hispanic white,Asian/Pacific Islander,1,0.9,1.1
10.1016/j.ygyno.2012.08.021,37,Yes,1992-1996; <50 years,No,NA,cervical cancer,RR,NA,age,4,Non-Hispanic white,Hispanic (of any race),2,1.8,2.1
10.1016/j.ygyno.2012.08.021,38,Yes,2005-2009; <50 years,No,NA,cervical cancer,RR,NA,age,1,Non-Hispanic white,Non-Hispanic black,1,0.9,1.1
10.1016/j.ygyno.2012.08.021,38,Yes,2005-2009; <50 years,No,NA,cervical cancer,RR,NA,age,2,Non-Hispanic white,American Indian/Alaska Native,1.5,1.2,2
10.1016/j.ygyno.2012.08.021,38,Yes,2005-2009; <50 years,No,NA,cervical cancer,RR,NA,age,3,Non-Hispanic white,Asian/Pacific Islander,0.9,0.8,1
10.1016/j.ygyno.2012.08.021,38,Yes,2005-2009; <50 years,No,NA,cervical cancer,RR,NA,age,4,Non-Hispanic white,Hispanic (of any race),1.5,1.4,1.6
10.1016/j.ygyno.2012.08.021,39,Yes,1992-1996; 50-64 years,No,NA,cervical cancer,RR,NA,age,1,Non-Hispanic white,Non-Hispanic black,1.9,1.7,2.2
10.1016/j.ygyno.2012.08.021,39,Yes,1992-1996; 50-64 years,No,NA,cervical cancer,RR,NA,age,2,Non-Hispanic white,American Indian/Alaska Native,1.7,1,2.6
10.1016/j.ygyno.2012.08.021,39,Yes,1992-1996; 50-64 years,No,NA,cervical cancer,RR,NA,age,3,Non-Hispanic white,Asian/Pacific Islander,2,1.8,2.3
10.1016/j.ygyno.2012.08.021,39,Yes,1992-1996; 50-64 years,No,NA,cervical cancer,RR,NA,age,4,Non-Hispanic white,Hispanic (of any race),2.7,2.4,3
10.1016/j.ygyno.2012.08.021,40,Yes,2005-2009; 50-64 years,No,NA,cervical cancer,RR,NA,age,1,Non-Hispanic white,Non-Hispanic black,1.8,1.5,2
10.1016/j.ygyno.2012.08.021,40,Yes,2005-2009; 50-64 years,No,NA,cervical cancer,RR,NA,age,2,Non-Hispanic white,American Indian/Alaska Native,1.3,0.8,2.1
10.1016/j.ygyno.2012.08.021,40,Yes,2005-2009; 50-64 years,No,NA,cervical cancer,RR,NA,age,3,Non-Hispanic white,Asian/Pacific Islander,1.4,1.2,1.6
10.1016/j.ygyno.2012.08.021,40,Yes,2005-2009; 50-64 years,No,NA,cervical cancer,RR,NA,age,4,Non-Hispanic white,Hispanic (of any race),2.2,2,2.5
10.1016/j.ygyno.2012.08.021,41,Yes,1992-1996; >=65 years,No,NA,cervical cancer,RR,NA,age,1,Non-Hispanic white,Non-Hispanic black,2.8,2.4,3.1
10.1016/j.ygyno.2012.08.021,41,Yes,1992-1996; >=65 years,No,NA,cervical cancer,RR,NA,age,2,Non-Hispanic white,American Indian/Alaska Native,1.5,0.6,2.9
10.1016/j.ygyno.2012.08.021,41,Yes,1992-1996; >=65 years,No,NA,cervical cancer,RR,NA,age,3,Non-Hispanic white,Asian/Pacific Islander,2.3,2,2.7
10.1016/j.ygyno.2012.08.021,41,Yes,1992-1996; >=65 years,No,NA,cervical cancer,RR,NA,age,4,Non-Hispanic white,Hispanic (of any race),2.9,2.6,3.3
10.1016/j.ygyno.2012.08.021,42,Yes,2005-2009; >=65 years,No,NA,cervical cancer,RR,NA,age,1,Non-Hispanic white,Non-Hispanic black,2.1,1.8,2.5
10.1016/j.ygyno.2012.08.021,42,Yes,2005-2009; >=65 years,No,NA,cervical cancer,RR,NA,age,2,Non-Hispanic white,American Indian/Alaska Native,1.8,0.9,3.1
10.1016/j.ygyno.2012.08.021,42,Yes,2005-2009; >=65 years,No,NA,cervical cancer,RR,NA,age,3,Non-Hispanic white,Asian/Pacific Islander,1.5,1.3,1.8
10.1016/j.ygyno.2012.08.021,42,Yes,2005-2009; >=65 years,No,NA,cervical cancer,RR,NA,age,4,Non-Hispanic white,Hispanic (of any race),2.4,2.1,2.8
10.1016/j.ygyno.2012.08.021,43,Yes,1975-1979; <50 years,No,NA,cervical squamous cell carcinoma,RR,NA,age,1,White,Black,2.1,1.8,2.3
10.1016/j.ygyno.2012.08.021,44,Yes,2005-2009; <50 years,No,NA,cervical squamous cell carcinoma,RR,NA,age,1,White,Black,1.1,1,1.3
10.1016/j.ygyno.2012.08.021,45,Yes,1975-1979; <50 years,No,NA,cervical adenocarcinoma,RR,NA,age,1,White,Black,0.7,0.4,1.2
10.1016/j.ygyno.2012.08.021,46,Yes,2005-2009; <50 years,No,NA,cervical adenocarcinoma,RR,NA,age,1,White,Black,0.4,0.2,0.5
10.1016/j.ygyno.2012.08.021,47,Yes,1975-1979; 50-64 years,No,NA,cervical squamous cell carcinoma,RR,NA,age,1,White,Black,2.5,2.2,2.9
10.1016/j.ygyno.2012.08.021,48,Yes,2005-2009; 50-64 years,No,NA,cervical squamous cell carcinoma,RR,NA,age,1,White,Black,2.1,1.7,2.4
10.1016/j.ygyno.2012.08.021,49,Yes,1975-1979; 50-64 years,No,NA,cervical adenocarcinoma,RR,NA,age,1,White,Black,1,0.5,1.9
10.1016/j.ygyno.2012.08.021,50,Yes,2005-2009; 50-64 years,No,NA,cervical adenocarcinoma,RR,NA,age,1,White,Black,0.8,0.5,1.3
10.1016/j.ygyno.2012.08.021,51,Yes,1975-1979; >=65 years,No,NA,cervical squamous cell carcinoma,RR,NA,age,1,White,Black,3.6,3.1,4.2
10.1016/j.ygyno.2012.08.021,52,Yes,2005-2009; >=65 years,No,NA,cervical squamous cell carcinoma,RR,NA,age,1,White,Black,2.2,1.8,2.8
10.1016/j.ygyno.2012.08.021,53,Yes,1975-1979; >=65 years,No,NA,cervical adenocarcinoma,RR,NA,age,1,White,Black,1.8,1,3
10.1016/j.ygyno.2012.08.021,54,Yes,2005-2009; >=65 years,No,NA,cervical adenocarcinoma,RR,NA,age,1,White,Black,1.3,0.8,2.1
10.1016/j.ajog.2019.05.024,1,No,NA,No,NA,Total Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,88.42,86.1,90.8
10.1016/j.ajog.2019.05.024,1,No,NA,No,NA,Total Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,99.2,92.8,105.6
10.1016/j.ajog.2019.05.024,2,No,NA,Yes,1997-2001,Total Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,101.79,96.1,107.4
10.1016/j.ajog.2019.05.024,2,No,NA,Yes,1997-2001,Total Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,87.51,74,101
10.1016/j.ajog.2019.05.024,3,No,NA,Yes,2002-2006,Total Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,86.3,82.5,90.1
10.1016/j.ajog.2019.05.024,3,No,NA,Yes,2002-2006,Total Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,100.82,87.9,113.8
10.1016/j.ajog.2019.05.024,4,No,NA,Yes,2007-2011,Total Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,86.34,82.3,90.4
10.1016/j.ajog.2019.05.024,4,No,NA,Yes,2007-2011,Total Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,100.1,90.3,109.9
10.1016/j.ajog.2019.05.024,5,No,NA,Yes,2012-2014,Total Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,85.57,79.7,91.4
10.1016/j.ajog.2019.05.024,5,No,NA,Yes,2012-2014,Total Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,101.75,85.8,117.1
10.1016/j.ajog.2019.05.024,6,No,NA,No,NA,Low Risk Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,55.96,54.4,57.5
10.1016/j.ajog.2019.05.024,6,No,NA,No,NA,Low Risk Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,39.08,36.3,41.8
10.1016/j.ajog.2019.05.024,7,No,NA,Yes,1997-2001,Low Risk Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,78.71,73.24,84.18
10.1016/j.ajog.2019.05.024,7,No,NA,Yes,1997-2001,Low Risk Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,52.32,20.91,83.73
10.1016/j.ajog.2019.05.024,8,No,NA,Yes,2002-2006,Low Risk Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,71.74,67.73,75.74
10.1016/j.ajog.2019.05.024,8,No,NA,Yes,2002-2006,Low Risk Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,38.07,31.39,44.75
10.1016/j.ajog.2019.05.024,9,No,NA,Yes,2007-2011,Low Risk Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,56.69,54.16,59.22
10.1016/j.ajog.2019.05.024,9,No,NA,Yes,2007-2011,Low Risk Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,41.51,36.36,46.67
10.1016/j.ajog.2019.05.024,10,No,NA,Yes,2012-2014,Low Risk Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,53.86,51.26,56.47
10.1016/j.ajog.2019.05.024,10,No,NA,Yes,2012-2014,Low Risk Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,39.09,34.59,43.6
10.1016/j.ajog.2019.05.024,11,No,NA,No,NA,High Risk Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,26.71,25.8,27.6
10.1016/j.ajog.2019.05.024,11,No,NA,No,NA,High Risk Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,51.34,47.3,55.4
10.1016/j.ajog.2019.05.024,12,No,NA,Yes,1997-2001,High Risk Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,31.44,27.99,34.88
10.1016/j.ajog.2019.05.024,12,No,NA,Yes,1997-2001,High Risk Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,55.51,34.7,76.33
10.1016/j.ajog.2019.05.024,13,No,NA,Yes,2002-2006,High Risk Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,27.83,25.58,30.07
10.1016/j.ajog.2019.05.024,13,No,NA,Yes,2002-2006,High Risk Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,45.36,36.79,53.93
10.1016/j.ajog.2019.05.024,14,No,NA,Yes,2007-2011,High Risk Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,24.71,23.08,26.35
10.1016/j.ajog.2019.05.024,14,No,NA,Yes,2007-2011,High Risk Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,52.32,44.02,60.61
10.1016/j.ajog.2019.05.024,15,No,NA,Yes,2012-2014,High Risk Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,25.4,23.84,26.95
10.1016/j.ajog.2019.05.024,15,No,NA,Yes,2012-2014,High Risk Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,50.35,44.23,56.46
10.1016/j.ajog.2019.05.024,16,No,NA,No,NA,Serous Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,4.58,4.3,4.9
10.1016/j.ajog.2019.05.024,16,No,NA,No,NA,Serous Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,14.04,12.3,15.8
10.1016/j.ajog.2019.05.024,17,No,NA,Yes,1997-2001,Serous Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,4.59,3.77,5.4
10.1016/j.ajog.2019.05.024,17,No,NA,Yes,1997-2001,Serous Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,13.87,1.71,26.02
10.1016/j.ajog.2019.05.024,18,No,NA,Yes,2002-2006,Serous Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,4.79,4.16,5.42
10.1016/j.ajog.2019.05.024,18,No,NA,Yes,2002-2006,Serous Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,10.78,6.85,14.71
10.1016/j.ajog.2019.05.024,19,No,NA,Yes,2007-2011,Serous Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,4.01,3.56,4.47
10.1016/j.ajog.2019.05.024,19,No,NA,Yes,2007-2011,Serous Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,12.82,9.03,16.61
10.1016/j.ajog.2019.05.024,20,No,NA,Yes,2012-2014,Serous Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,4.24,3.78,4.7
10.1016/j.ajog.2019.05.024,20,No,NA,Yes,2012-2014,Serous Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,14.2,11.97,16.43
10.1016/j.ajog.2019.05.024,21,No,NA,No,NA,Carcinosarcoma Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,3.51,3.3,3.7
10.1016/j.ajog.2019.05.024,21,No,NA,No,NA,Carcinosarcoma Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,11.9,10.5,13.3
10.1016/j.ajog.2019.05.024,22,No,NA,Yes,1997-2001,Carcinosarcoma Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,4.21,3.36,5.05
10.1016/j.ajog.2019.05.024,22,No,NA,Yes,1997-2001,Carcinosarcoma Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,9.89,0.48,19.3
10.1016/j.ajog.2019.05.024,23,No,NA,Yes,2002-2006,Carcinosarcoma Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,3.49,3,3.97
10.1016/j.ajog.2019.05.024,23,No,NA,Yes,2002-2006,Carcinosarcoma Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,10.03,6.15,13.92
10.1016/j.ajog.2019.05.024,24,No,NA,Yes,2007-2011,Carcinosarcoma Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,3.53,3.18,3.89
10.1016/j.ajog.2019.05.024,24,No,NA,Yes,2007-2011,Carcinosarcoma Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,12.65,10.03,15.27
10.1016/j.ajog.2019.05.024,25,No,NA,Yes,2012-2014,Carcinosarcoma Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,3.48,3.11,3.85
10.1016/j.ajog.2019.05.024,25,No,NA,Yes,2012-2014,Carcinosarcoma Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,12.6,10.51,14.69
10.1016/j.ajog.2019.05.024,26,No,NA,No,NA,Endometrial G3 cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,17.54,16.9,18.1
10.1016/j.ajog.2019.05.024,26,No,NA,No,NA,Endometrial G3 cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,22.67,20.7,24.7
10.1016/j.ajog.2019.05.024,27,No,NA,Yes,1997-2001,Endometrial G3 cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,21.12,18.57,23.68
10.1016/j.ajog.2019.05.024,27,No,NA,Yes,1997-2001,Endometrial G3 cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,28.8,18.11,39.49
10.1016/j.ajog.2019.05.024,28,No,NA,Yes,2002-2006,Endometrial G3 cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,18.2,16.69,19.71
10.1016/j.ajog.2019.05.024,28,No,NA,Yes,2002-2006,Endometrial G3 cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,21.26,16.71,25.8
10.1016/j.ajog.2019.05.024,29,No,NA,Yes,2007-2011,Endometrial G3 cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,16.14,15.12,17.16
10.1016/j.ajog.2019.05.024,29,No,NA,Yes,2007-2011,Endometrial G3 cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,24.07,19.81,28.33
10.1016/j.ajog.2019.05.024,30,No,NA,Yes,2012-2014,Endometrial G3 cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,16.57,15.63,17.52
10.1016/j.ajog.2019.05.024,30,No,NA,Yes,2012-2014,Endometrial G3 cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,20.68,17.83,23.53
10.1016/j.ajog.2019.05.024,31,No,NA,No,NA,Other and mixed Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,5.75,5.4,6.1
10.1016/j.ajog.2019.05.024,31,No,NA,No,NA,Other and mixed Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,8.77,7.5,10.1
10.1016/j.ajog.2019.05.024,32,No,NA,Yes,1997-2001,Other and mixed Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,0.96,0.64,1.28
10.1016/j.ajog.2019.05.024,32,No,NA,Yes,1997-2001,Other and mixed Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,3.49,-6.13,13.1
10.1016/j.ajog.2019.05.024,33,No,NA,Yes,2002-2006,Other and mixed Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,2.23,1.89,2.56
10.1016/j.ajog.2019.05.024,33,No,NA,Yes,2002-2006,Other and mixed Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,4.08,2.29,5.87
10.1016/j.ajog.2019.05.024,34,No,NA,Yes,2007-2011,Other and mixed Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,4.9,4.48,5.32
10.1016/j.ajog.2019.05.024,34,No,NA,Yes,2007-2011,Other and mixed Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,6.99,5.28,8.7
10.1016/j.ajog.2019.05.024,35,No,NA,Yes,2012-2014,Other and mixed Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,1,N/A,White,7.08,6.5,7.66
10.1016/j.ajog.2019.05.024,35,No,NA,Yes,2012-2014,Other and mixed Endometrial cancer,Incidence,"per 100,000",prior hysterectomy,2,N/A,Black,10.66,8.69,12.63
10.1016/j.ajog.2015.01.029,1,No,NA,No,NA,Primary Cesarean Delivery,RR,NA,None,1,White,Black,1.11,1.06,1.17
10.1016/j.ajog.2015.01.030,2,No,NA,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,White,Black,1.23,1.17,1.29
10.1016/j.ajog.2015.01.031,3,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,Maternal Age: 20-29,<20,0.9,0.8,1.01
10.1016/j.ajog.2015.01.031,3,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",2,Maternal Age: 20-29,30-34,1.14,1.07,1.21
10.1016/j.ajog.2015.01.031,3,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",3,Maternal Age: 20-29,>= 35,1.37,1.27,1.47
10.1016/j.ajog.2015.01.032,4,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,Maternal Age: 20-29,<20,0.88,0.79,0.98
10.1016/j.ajog.2015.01.032,4,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",2,Maternal Age: 20-29,30-34,1.08,0.96,1.21
10.1016/j.ajog.2015.01.032,4,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",3,Maternal Age: 20-29,>= 35,1.66,1.49,1.86
10.1016/j.ajog.2015.01.033,5,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,Nulliparous,Multiparous,0.3,0.28,0.32
10.1016/j.ajog.2015.01.034,6,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,Nulliparous,Multiparous,0.37,0.34,0.4
10.1016/j.ajog.2015.01.035,7,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,Insurance type - Private,Medicaid/uninsured,0.92,0.85,1
10.1016/j.ajog.2015.01.036,8,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,Insurance type - Private,Medicaid/uninsured,0.98,0.89,1.07
10.1016/j.ajog.2015.01.037,9,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,marital status - Married,Unmarried,1,0.93,1.07
10.1016/j.ajog.2015.01.037,10,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,marital status - Married,Unmarried,1,0.91,1.1
10.1016/j.ajog.2015.01.037,11,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,N/A,Diabetes,1.21,1.03,1.42
10.1016/j.ajog.2015.01.037,12,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,N/A,Diabetes,1.15,0.99,1.33
10.1016/j.ajog.2015.01.037,13,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,N/A,Chronic Hypertension,1.16,1.03,1.3
10.1016/j.ajog.2015.01.037,14,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,N/A,Chronic Hypertension,1.15,0.99,1.33
10.1016/j.ajog.2015.01.037,15,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,"BMI, kg/m2 - 18.5-24.9",<18.5,0.72,0.59,0.9
10.1016/j.ajog.2015.01.037,15,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",2,"BMI, kg/m2 - 18.5-24.9",25.0-29.9,1.15,1.07,1.23
10.1016/j.ajog.2015.01.037,15,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",3,"BMI, kg/m2 - 18.5-24.9",>=30,1.61,1.51,1.71
10.1016/j.ajog.2015.01.037,16,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,"BMI, kg/m2 - 18.5-24.9",<18.5,0.81,0.61,1.07
10.1016/j.ajog.2015.01.037,16,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",2,"BMI, kg/m2 - 18.5-24.9",25.0-29.9,1.27,1.14,1.41
10.1016/j.ajog.2015.01.037,16,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",3,"BMI, kg/m2 - 18.5-24.9",>=30,1.51,1.36,1.66
10.1016/j.ajog.2015.01.037,17,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,N/A,Excess weight gain,1.32,1.24,1.4
10.1016/j.ajog.2015.01.037,18,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,N/A,Excess weight gain,1.19,1.09,1.29
10.1016/j.ajog.2015.01.037,19,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,N/A,Gestational Diabetes,1.27,1.16,1.4
10.1016/j.ajog.2015.01.037,20,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,N/A,Gestational Diabetes,1.23,1.07,1.42
10.1016/j.ajog.2015.01.037,21,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,N/A,Gestational hypertensive Diabetes,1.47,1.36,1.58
10.1016/j.ajog.2015.01.037,22,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,N/A,Gestational hypertensive Diabetes,1.39,1.24,1.55
10.1016/j.ajog.2015.01.037,23,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,N/A,Macrosomia,1.56,1.45,1.66
10.1016/j.ajog.2015.01.037,24,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,N/A,Macrosomia,1.63,1.43,1.85
10.1016/j.ajog.2015.01.037,25,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, premature rupture of membranes, patient type, year of delivery",1,"Gestational Age, wks; 39-40",<34,1.94,1.7,2.21
10.1016/j.ajog.2015.01.037,25,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, premature rupture of membranes, patient type, year of delivery",2,"Gestational Age, wks; 39-40",34-36,1.26,1.14,1.4
10.1016/j.ajog.2015.01.037,25,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, premature rupture of membranes, patient type, year of delivery",3,"Gestational Age, wks; 39-40",37-38,1.02,0.95,1.09
10.1016/j.ajog.2015.01.037,25,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, premature rupture of membranes, patient type, year of delivery",4,"Gestational Age, wks; 39-40",41,1.33,1.22,1.45
10.1016/j.ajog.2015.01.037,25,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, premature rupture of membranes, patient type, year of delivery",5,"Gestational Age, wks; 39-40",>=42,1.77,1.45,2.17
10.1016/j.ajog.2015.01.037,26,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, premature rupture of membranes, patient type, year of delivery",1,"Gestational Age, wks; 39-40",<34,1.79,1.53,0.209
10.1016/j.ajog.2015.01.037,26,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, premature rupture of membranes, patient type, year of delivery",2,"Gestational Age, wks; 39-40",34-36,1.24,1.08,1.42
10.1016/j.ajog.2015.01.037,26,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, premature rupture of membranes, patient type, year of delivery",3,"Gestational Age, wks; 39-40",37-38,0.86,0.77,0.95
10.1016/j.ajog.2015.01.037,26,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, premature rupture of membranes, patient type, year of delivery",4,"Gestational Age, wks; 39-40",41,1.42,1.37,1.58
10.1016/j.ajog.2015.01.037,26,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, premature rupture of membranes, patient type, year of delivery",5,"Gestational Age, wks; 39-40",>=42,1.46,0.88,2.41
10.1016/j.ajog.2015.01.037,27,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, premature rupture of membranes, patient type, year of delivery",1,N/A,Labor induction,0.98,0.93,1.04
10.1016/j.ajog.2015.01.037,28,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, premature rupture of membranes, patient type, year of delivery",1,N/A,Labor induction,1.24,1.14,1.34
10.1016/j.ajog.2015.01.037,29,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, patient type, year of delivery",1,N/A,premature rupture of membranes,1.09,0.89,1.33
10.1016/j.ajog.2015.01.038,30,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, patient type, year of delivery",1,N/A,premature rupture of membranes,1.07,0.79,1.44
10.1016/j.ajog.2015.01.037,31,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,Patient Type - Service,Private,1.08,0.98,1.18
10.1016/j.ajog.2015.01.037,32,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",1,Patient Type - Service,Private,1.09,1,1.19
10.1016/j.ajog.2015.01.038,33,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type",1,Year of Delivery - 2004,2005,0.93,0.84,1.02
10.1016/j.ajog.2015.01.038,33,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type",2,Year of Delivery - 2004,2006,0.99,0.9,1.09
10.1016/j.ajog.2015.01.038,33,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type",3,Year of Delivery - 2004,2007,1.11,1.01,1.21
10.1016/j.ajog.2015.01.038,33,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type",4,Year of Delivery - 2004,2008,1.07,0.97,1.18
10.1016/j.ajog.2015.01.038,33,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type",5,Year of Delivery - 2004,2009,1.15,1.05,1.26
10.1016/j.ajog.2015.01.038,33,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type",6,Year of Delivery - 2004,2010,1.08,0.98,NA
10.1016/j.ajog.2015.01.038,33,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type",7,Year of Delivery - 2004,NA,NA,NA,1.19
10.1016/j.ajog.2015.01.037,34,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type",1,Year of Delivery - 2004,2005,0.89,0.77,1.03
10.1016/j.ajog.2015.01.037,34,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type",2,Year of Delivery - 2004,2006,0.89,0.78,1.03
10.1016/j.ajog.2015.01.037,34,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type",3,Year of Delivery - 2004,2007,1,0.87,1.15
10.1016/j.ajog.2015.01.037,34,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type",4,Year of Delivery - 2004,2008,1.06,0.93,1.21
10.1016/j.ajog.2015.01.037,34,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type",5,Year of Delivery - 2004,2009,1.07,0.94,1.23
10.1016/j.ajog.2015.01.037,34,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type",6,Year of Delivery - 2004,2010,1.02,0.89,NA
10.1016/j.ajog.2015.01.037,34,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type",7,Year of Delivery - 2004,NA,NA,NA,1.17
10.1016/j.ajog.2015.01.037,35,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",1,Maternal Age: 20-29,<20,0.95,0.84,1.07
10.1016/j.ajog.2015.01.037,35,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",2,Maternal Age: 20-29,30-34,1.17,1.1,1.25
10.1016/j.ajog.2015.01.037,35,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",3,Maternal Age: 20-29,>=35,1.43,1.33,1.55
10.1016/j.ajog.2015.01.038,36,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",1,Maternal Age: 20-29,<20,0.83,0.74,0.93
10.1016/j.ajog.2015.01.038,36,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",2,Maternal Age: 20-29,30-34,1.21,1.06,1.37
10.1016/j.ajog.2015.01.038,36,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",3,Maternal Age: 20-29,>=35,1.56,1.37,1.78
10.1016/j.ajog.2015.01.037,37,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",1,Insurance type- private,Medicaid/uninsured,0.91,0.83,1
10.1016/j.ajog.2015.01.037,38,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",1,Insurance type- private,Medicaid/uninsured,0.99,0.9,1.1
10.1016/j.ajog.2015.01.038,39,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",1,Marital status - married,unmarried,0.94,0.88,1.02
10.1016/j.ajog.2015.01.037,40,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",1,Marital status - married,unmarried,0.93,0.83,1.03
10.1016/j.ajog.2015.01.037,41,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",1,N/A,Diabetes,1.28,1.09,1.49
10.1016/j.ajog.2015.01.038,42,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",1,N/A,Diabetes,1.1,0.87,1.38
10.1016/j.ajog.2015.01.037,43,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",1,N/A,Chronic hypertension,1.14,1.01,1.28
10.1016/j.ajog.2015.01.037,44,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",1,N/A,Chronic hypertension,1.19,1.01,1.4
10.1016/j.ajog.2015.01.038,45,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",1,"BMI, kg/m2 - 18.5-24.9",<18.5,0.68,0.53,0.87
10.1016/j.ajog.2015.01.038,45,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",2,"BMI, kg/m2 - 18.5-24.9",25.0-29.9,1.14,1.05,1.22
10.1016/j.ajog.2015.01.038,45,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",3,"BMI, kg/m2 - 18.5-24.9",>=30,1.55,1.45,1.66
10.1016/j.ajog.2015.01.037,46,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",1,"BMI, kg/m2 - 18.5-24.10",<18.6,0.89,0.66,1.21
10.1016/j.ajog.2015.01.037,46,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",2,"BMI, kg/m2 - 18.5-24.10",25.0-29.9,1.14,1.05,1.22
10.1016/j.ajog.2015.01.037,46,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",3,"BMI, kg/m2 - 18.5-24.10",>=30,1.52,1.37,1.7
10.1016/j.ajog.2015.01.037,47,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, BMI, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",1,N/A,Excess weigth gain,1.29,1.21,1.38
10.1016/j.ajog.2015.01.038,48,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, BMI, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",1,N/A,Excess weigth gain,1.17,1.06,1.29
10.1016/j.ajog.2015.01.037,49,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, BMI, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",1,N/A,Gestational Diabetes,1.26,1.13,1.39
10.1016/j.ajog.2015.01.037,50,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, BMI, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",1,N/A,Gestational Diabetes,1.2,1.03,1.4
10.1016/j.ajog.2015.01.038,51,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",1,N/A,Gestational hypertensive disorders,1.43,1.32,1.54
10.1016/j.ajog.2015.01.037,52,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, macrosomia, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",1,N/A,Gestational hypertensive disorders,1.36,1.2,1.54
10.1016/j.ajog.2015.01.037,53,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",1,N/A,Macrosomia,1.49,1.39,1.61
10.1016/j.ajog.2015.01.038,54,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, gestational age, labor induction, Premature rupture of the membranes, patient type, year of delivery",1,N/A,Macrosomia,1.34,1.16,1.56
10.1016/j.ajog.2015.01.037,55,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, Premature rupture of the membranes, patient type, year of delivery",1,"Gestational Age, wks; 39-40",<34,1.46,1.26,1.69
10.1016/j.ajog.2015.01.037,55,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, Premature rupture of the membranes, patient type, year of delivery",2,"Gestational Age, wks; 39-40",34-36,1.04,0.92,1.16
10.1016/j.ajog.2015.01.037,55,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, Premature rupture of the membranes, patient type, year of delivery",3,"Gestational Age, wks; 39-40",37-38,0.96,0.9,1.04
10.1016/j.ajog.2015.01.037,55,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, Premature rupture of the membranes, patient type, year of delivery",4,"Gestational Age, wks; 39-40",41,1.27,1.16,1.39
10.1016/j.ajog.2015.01.037,55,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, Premature rupture of the membranes, patient type, year of delivery",5,"Gestational Age, wks; 39-40",>=42,1.71,1.4,2.09
10.1016/j.ajog.2015.01.037,56,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, Premature rupture of the membranes, patient type, year of delivery",1,"Gestational Age, wks; 39-41",<34,1.3,1.07,1.58
10.1016/j.ajog.2015.01.037,56,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, Premature rupture of the membranes, patient type, year of delivery",2,"Gestational Age, wks; 39-41",34-36,1,0.85,1.18
10.1016/j.ajog.2015.01.037,56,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, Premature rupture of the membranes, patient type, year of delivery",3,"Gestational Age, wks; 39-41",37-38,0.82,0.73,0.92
10.1016/j.ajog.2015.01.037,56,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, Premature rupture of the membranes, patient type, year of delivery",4,"Gestational Age, wks; 39-41",41,1.31,1.17,1.47
10.1016/j.ajog.2015.01.037,56,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, Premature rupture of the membranes, patient type, year of delivery",5,"Gestational Age, wks; 39-41",>=42,1.1,0.62,1.96
10.1016/j.ajog.2015.01.038,57,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, Premature rupture of the membranes, patient type, year of delivery",1,N/A,Labor induction,1.13,1.07,1.2
10.1016/j.ajog.2015.01.039,58,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, Premature rupture of the membranes, patient type, year of delivery",1,N/A,Labor induction,1.32,1.2,1.44
10.1016/j.ajog.2015.01.037,59,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, patient type, year of delivery",1,N/A,Premature rupture of membranes,1.09,0.89,1.35
10.1016/j.ajog.2015.01.037,60,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, patient type, year of delivery",1,N/A,Premature rupture of membranes,0.95,0.67,1.34
10.1016/j.ajog.2015.01.038,61,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, year of delivery",1,Patient Type - Service,Private,1.15,1.03,1.27
10.1016/j.ajog.2015.01.039,62,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, year of delivery",1,Patient Type - Service,Private,1.04,0.95,1.15
10.1016/j.ajog.2015.01.037,63,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",1,Year of Delivery - 2004,2005,0.92,0.83,1.02
10.1016/j.ajog.2015.01.037,63,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",2,Year of Delivery - 2004,2006,1,0.91,1.11
10.1016/j.ajog.2015.01.037,63,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",3,Year of Delivery - 2004,2007,1.07,0.97,1.19
10.1016/j.ajog.2015.01.037,63,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",4,Year of Delivery - 2004,2008,0.95,0.86,1.05
10.1016/j.ajog.2015.01.037,63,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",5,Year of Delivery - 2004,2009,0.98,0.88,1.08
10.1016/j.ajog.2015.01.037,63,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",6,Year of Delivery - 2004,2010,0.98,0.89,NA
10.1016/j.ajog.2015.01.037,63,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",7,Year of Delivery - 2004,NA,NA,NA,1.09
10.1016/j.ajog.2015.01.037,64,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",1,Year of Delivery - 2005,2005,0.82,0.69,0.96
10.1016/j.ajog.2015.01.037,64,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",2,Year of Delivery - 2005,2006,0.91,0.78,1.06
10.1016/j.ajog.2015.01.037,64,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",3,Year of Delivery - 2005,2007,0.94,0.81,1.1
10.1016/j.ajog.2015.01.037,64,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",4,Year of Delivery - 2005,2008,0.94,0.81,1.09
10.1016/j.ajog.2015.01.037,64,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",5,Year of Delivery - 2005,2009,0.93,0.8,1.08
10.1016/j.ajog.2015.01.037,64,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",6,Year of Delivery - 2005,2010,0.93,0.8,NA
10.1016/j.ajog.2015.01.037,64,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Materal Age, Parity, Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",7,Year of Delivery - 2005,NA,NA,NA,1.08
10.1016/j.ajog.2015.01.038,65,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,Maternal Age: 20-29,<20,0.9,0.6,1.37
10.1016/j.ajog.2015.01.038,65,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",2,Maternal Age: 20-29,30-34,1.09,0.93,1.28
10.1016/j.ajog.2015.01.038,65,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",3,Maternal Age: 20-29,>=35,1.3,1.11,1.52
10.1016/j.ajog.2015.01.039,66,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,Maternal Age: 20-29,<20,1.36,1.02,1.81
10.1016/j.ajog.2015.01.039,66,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",2,Maternal Age: 20-29,30-34,0.92,0.75,1.13
10.1016/j.ajog.2015.01.039,66,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",3,Maternal Age: 20-29,>=35,1.72,1.43,2.08
10.1016/j.ajog.2015.01.037,67,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,Insurance type- private,Medicaid/uninsured,0.93,0.77,1.12
10.1016/j.ajog.2015.01.037,68,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,Insurance type- private,Medicaid/uninsured,0.97,0.81,1.16
10.1016/j.ajog.2015.01.038,69,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, insurance type, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,Marital status - married,Unmarried,1.18,0.99,1.39
10.1016/j.ajog.2015.01.039,70,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, insurance type, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,Marital status - married,Unmarried,1.13,0.95,1.35
10.1016/j.ajog.2015.01.037,71,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,N/A,Diabetes,1.11,0.71,1.74
10.1016/j.ajog.2015.01.037,72,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,N/A,Diabetes,1.27,0.77,2.08
10.1016/j.ajog.2015.01.038,73,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes,BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,N/A,Chronic Hypertension,1.27,0.94,1.7
10.1016/j.ajog.2015.01.039,74,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes,BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,N/A,Chronic Hypertension,1.13,0.87,1.47
10.1016/j.ajog.2015.01.037,75,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,"BMI, kg/m2 : 18.5-24.9",<18.5,0.87,0.57,1.31
10.1016/j.ajog.2015.01.037,75,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",2,"BMI, kg/m2 : 18.5-24.9",25.0-29.9,1.2,1.02,1.41
10.1016/j.ajog.2015.01.037,75,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",3,"BMI, kg/m2 : 18.5-24.9",>=30.0,1.81,1.56,2.11
10.1016/j.ajog.2015.01.037,76,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,"BMI, kg/m2 : 18.5-24.10",<18.5,0.54,0.25,1.17
10.1016/j.ajog.2015.01.037,76,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",2,"BMI, kg/m2 : 18.5-24.10",25.0 - 29-9,1.29,1.05,1.59
10.1016/j.ajog.2015.01.037,76,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",3,"BMI, kg/m2 : 18.5-24.10",>=30.0,1.44,1.18,1.77
10.1016/j.ajog.2015.01.038,77,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,N/A,Excess weight gain,1.36,1.19,1.56
10.1016/j.ajog.2015.01.039,78,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,N/A,Excess weight gain,1.2,1.02,1.41
10.1016/j.ajog.2015.01.037,79,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,N/A,Gestational diabetes,1.31,1.04,1.67
10.1016/j.ajog.2015.01.037,80,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,N/A,Gestational diabetes,1.31,0.99,1.75
10.1016/j.ajog.2015.01.037,81,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,N/A,Gestational hypertensive disorders,1.67,1.37,2.02
10.1016/j.ajog.2015.01.038,82,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,N/A,Gestational hypertensive disorders,1.5,1.2,1.87
10.1016/j.ajog.2015.01.039,83,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,N/A,Macrosomia,1.77,1.5,2.08
10.1016/j.ajog.2015.01.037,84,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, gestational age, labor induction, premature rupture of membranes, patient type, year of delivery",1,N/A,Macrosomia,2.31,1.84,2.9
10.1016/j.ajog.2015.01.037,85,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, premature rupture of membranes, patient type, year of delivery",1,"Gestational age, wks: 39-40",<34,3.91,3.09,4.94
10.1016/j.ajog.2015.01.037,85,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, premature rupture of membranes, patient type, year of delivery",2,"Gestational age, wks: 39-40",34-36,2.1,1.71,2.58
10.1016/j.ajog.2015.01.037,85,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, premature rupture of membranes, patient type, year of delivery",3,"Gestational age, wks: 39-40",37-38,1.19,1.01,1.38
10.1016/j.ajog.2015.01.037,85,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, premature rupture of membranes, patient type, year of delivery",4,"Gestational age, wks: 39-40",41,1.36,1.04,1.77
10.1016/j.ajog.2015.01.037,85,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, premature rupture of membranes, patient type, year of delivery",5,"Gestational age, wks: 39-40",>=42,1.27,0.42,3.88
10.1016/j.ajog.2015.01.037,86,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, premature rupture of membranes, patient type, year of delivery",1,"Gestational age, wks: 39-41",<34,3.23,2.52,4.13
10.1016/j.ajog.2015.01.037,86,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, premature rupture of membranes, patient type, year of delivery",2,"Gestational age, wks: 39-41",34-36,1.79,1.42,2.26
10.1016/j.ajog.2015.01.037,86,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, premature rupture of membranes, patient type, year of delivery",3,"Gestational age, wks: 39-41",37-38,0.96,0.79,1.16
10.1016/j.ajog.2015.01.037,86,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, premature rupture of membranes, patient type, year of delivery",4,"Gestational age, wks: 39-41",41,1.7,1.32,2.19
10.1016/j.ajog.2015.01.037,86,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, premature rupture of membranes, patient type, year of delivery",5,"Gestational age, wks: 39-41",>=42,2.85,1.35,6.04
10.1016/j.ajog.2015.01.038,87,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, premature rupture of membranes, patient type, year of delivery",1,N/A,labor induction,0.63,0.55,0.72
10.1016/j.ajog.2015.01.039,88,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, premature rupture of membranes, patient type, year of delivery",1,N/A,labor induction,1.08,0.92,1.28
10.1016/j.ajog.2015.01.037,89,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, patient type, year of delivery",1,N/A,Premature Rupture of Membrane,1.09,0.59,2.01
10.1016/j.ajog.2015.01.037,90,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, patient type, year of delivery",1,N/A,Premature Rupture of Membrane,1.43,0.89,2.3
10.1016/j.ajog.2015.01.037,91,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, year of delivery",1,Patient Type - Service,Private,0.97,0.8,1.17
10.1016/j.ajog.2015.01.038,92,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, year of delivery",1,Patient Type - Service,Private,1.24,1.05,1.47
10.1016/j.ajog.2015.01.039,93,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",1,Year of delivery. 2004,2005,1.05,0.82,1.35
10.1016/j.ajog.2015.01.039,93,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",2,Year of delivery. 2004,2006,0.98,0.75,1.26
10.1016/j.ajog.2015.01.039,93,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",3,Year of delivery. 2004,2007,1.31,1.03,1.67
10.1016/j.ajog.2015.01.039,93,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",4,Year of delivery. 2004,2008,1.62,1.28,2.04
10.1016/j.ajog.2015.01.039,93,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",5,Year of delivery. 2004,2009,1.83,1.46,2.3
10.1016/j.ajog.2015.01.039,93,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",6,Year of delivery. 2004,2010,1.48,1.16,NA
10.1016/j.ajog.2015.01.039,93,Yes,White,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",7,Year of delivery. 2004,NA,NA,NA,1.9
10.1016/j.ajog.2015.01.037,94,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",1,Year of delivery. 2004,2005,1.13,0.83,1.55
10.1016/j.ajog.2015.01.037,94,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",2,Year of delivery. 2004,2006,0.87,0.63,1.22
10.1016/j.ajog.2015.01.037,94,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",3,Year of delivery. 2004,2007,1.17,0.87,1.58
10.1016/j.ajog.2015.01.037,94,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",4,Year of delivery. 2004,2008,1.43,1.07,1.91
10.1016/j.ajog.2015.01.037,94,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",5,Year of delivery. 2004,2009,1.48,1.11,1.97
10.1016/j.ajog.2015.01.037,94,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",6,Year of delivery. 2004,2010,1.31,0.97,NA
10.1016/j.ajog.2015.01.037,94,Yes,Black,No,NA,Primary Cesarean Delivery,RR,NA,"Maternal Age, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, premature rupture of membranes, patient type",7,Year of delivery. 2004,NA,NA,NA,1.78
10.1016/j.ygyno.2017.12.010,1,No,NA,No,NA,Time to treatment initiation,Mean,NA,None,1,N/A,Non-Hispanic White,38.1,-99,-99
10.1016/j.ygyno.2017.12.010,1,No,NA,No,NA,Time to treatment initiation,Mean,NA,None,2,N/A,Non-Hispanic Black,45.3,-99,-99
10.1016/j.ygyno.2017.12.010,1,No,NA,No,NA,Time to treatment initiation,Mean,NA,None,3,N/A,Hispanic,49.4,-99,-99
10.1016/j.ygyno.2017.12.010,1,No,NA,No,NA,Time to treatment initiation,Mean,NA,None,4,N/A,Asian American and Pacific Islander,42.4,-99,-99
10.1016/j.ygyno.2017.12.010,1,No,NA,No,NA,Time to treatment initiation,Mean,NA,None,5,N/A,Other/Unknown,37.4,-99,-99
10.1016/j.ygyno.2017.12.010,2,No,NA,No,NA,Prolonged time to treatment initiation,RR,NA,None,1,Non-Hispanic White,Non-Hispanic Black,1.19,1.15,1.23
10.1016/j.ygyno.2017.12.010,2,No,NA,No,NA,Prolonged time to treatment initiation,RR,NA,None,2,Non-Hispanic White,Hispanic,1.3,1.25,1.35
10.1016/j.ygyno.2017.12.010,2,No,NA,No,NA,Prolonged time to treatment initiation,RR,NA,None,3,Non-Hispanic White,Asian American and Pacific Islander,1.11,1.05,1.18
10.1016/j.ygyno.2017.12.010,2,No,NA,No,NA,Prolonged time to treatment initiation,RR,NA,None,4,Non-Hispanic White,Other/Unknown,0.98,0.93,1.03
10.1016/j.ygyno.2017.12.010,3,No,NA,No,NA,Time to treatment initiation,Expected Value,NA,None,1,N/A,Non-Hispanic White,38.1,-99,-99
10.1016/j.ygyno.2017.12.010,3,No,NA,No,NA,Time to treatment initiation,Expected Value,NA,None,2,N/A,Non-Hispanic Black,45.2,-99,-99
10.1016/j.ygyno.2017.12.010,3,No,NA,No,NA,Time to treatment initiation,Expected Value,NA,None,3,N/A,Hispanic,49.4,-99,-99
10.1016/j.ygyno.2017.12.010,3,No,NA,No,NA,Time to treatment initiation,Expected Value,NA,None,4,N/A,Asian American and Pacific Islander,42.2,-99,-99
10.1016/j.ygyno.2017.12.010,3,No,NA,No,NA,Time to treatment initiation,Expected Value,NA,None,5,N/A,Other/Unknown,37.4,-99,-99
10.1016/j.ygyno.2017.12.010,4,No,NA,No,NA,Prolonged time to treatment initiation,RR,NA,"Year of diagnosis, Age, Insurance type, median household income, education status, urban/rural category, distance to reporting facility, reporting facility type, transitions in care, radiation plan type, radiation modality, primary treatment(s), charlson/deyo comorbidity score, ajcc clinical stage, tumor size, pelvic lymph node status, para-aortic lymph node status",1,Non-Hispanic White,Non-Hispanic Black,1.14,1.11,1.18
10.1016/j.ygyno.2017.12.010,4,No,NA,No,NA,Prolonged time to treatment initiation,RR,NA,"Year of diagnosis, Age, Insurance type, median household income, education status, urban/rural category, distance to reporting facility, reporting facility type, transitions in care, radiation plan type, radiation modality, primary treatment(s), charlson/deyo comorbidity score, ajcc clinical stage, tumor size, pelvic lymph node status, para-aortic lymph node status",2,Non-Hispanic White,Hispanic,1.19,1.15,1.24
10.1016/j.ygyno.2017.12.010,4,No,NA,No,NA,Prolonged time to treatment initiation,RR,NA,"Year of diagnosis, Age, Insurance type, median household income, education status, urban/rural category, distance to reporting facility, reporting facility type, transitions in care, radiation plan type, radiation modality, primary treatment(s), charlson/deyo comorbidity score, ajcc clinical stage, tumor size, pelvic lymph node status, para-aortic lymph node status",3,Non-Hispanic White,Asian American and Pacific Islander,1.02,0.96,1.07
10.1016/j.ygyno.2017.12.010,4,No,NA,No,NA,Prolonged time to treatment initiation,RR,NA,"Year of diagnosis, Age, Insurance type, median household income, education status, urban/rural category, distance to reporting facility, reporting facility type, transitions in care, radiation plan type, radiation modality, primary treatment(s), charlson/deyo comorbidity score, ajcc clinical stage, tumor size, pelvic lymph node status, para-aortic lymph node status",4,Non-Hispanic White,Other/Unknown,0.99,0.94,1.04
10.1016/j.ygyno.2017.12.010,5,No,NA,No,NA,Overall survival,HR,NA,"Time to treatment initiation (days), year of diagnosis, age, insurance type, median household income, education status, urban/rural category, distance to treating center, reporting facility type, transitions in care, radiation plan type, charlson/deyo comorbidity score, ajcc clinical stage, grade, tumor size, pelvic lymph node status, para-aortic lymph node status",1,Non-Hispanic White,Non-Hispanic Black,0.83,0.65,1.06
10.1016/j.ygyno.2017.12.010,5,No,NA,No,NA,Overall survival,HR,NA,"Time to treatment initiation (days), year of diagnosis, age, insurance type, median household income, education status, urban/rural category, distance to treating center, reporting facility type, transitions in care, radiation plan type, charlson/deyo comorbidity score, ajcc clinical stage, grade, tumor size, pelvic lymph node status, para-aortic lymph node status",2,Non-Hispanic White,Hispanic,0.68,0.49,0.95
10.1016/j.ygyno.2017.12.010,5,No,NA,No,NA,Overall survival,HR,NA,"Time to treatment initiation (days), year of diagnosis, age, insurance type, median household income, education status, urban/rural category, distance to treating center, reporting facility type, transitions in care, radiation plan type, charlson/deyo comorbidity score, ajcc clinical stage, grade, tumor size, pelvic lymph node status, para-aortic lymph node status",3,Non-Hispanic White,Asian American and Pacific Islander,0.63,0.4,1
10.1016/j.ygyno.2017.12.010,5,No,NA,No,NA,Overall survival,HR,NA,"Time to treatment initiation (days), year of diagnosis, age, insurance type, median household income, education status, urban/rural category, distance to treating center, reporting facility type, transitions in care, radiation plan type, charlson/deyo comorbidity score, ajcc clinical stage, grade, tumor size, pelvic lymph node status, para-aortic lymph node status",4,Non-Hispanic White,Other/Unknown,1.39,1.05,1.84
10.1016/j.ajog.2016.06.032,1,No,NA,Yes,low-risk patients,peripartum hysterectomy,RR,NA,"mode of delivery, labor induction, multiple gestation, stillbirth, placental abruption, fibroids, antepartum hemorrhage, polyhydramnios, preeclampsia/eclampsia, chorioamnionitis, placenta previa, age, discharge year, household income, insurance status, hospital bed size, annualized delivery volume, hospital location, hospital region, hospital teaching",1,White,Black,1.35,1.19,1.54
10.1016/j.ajog.2016.06.032,1,No,NA,Yes,low-risk patients,peripartum hysterectomy,RR,NA,"mode of delivery, labor induction, multiple gestation, stillbirth, placental abruption, fibroids, antepartum hemorrhage, polyhydramnios, preeclampsia/eclampsia, chorioamnionitis, placenta previa, age, discharge year, household income, insurance status, hospital bed size, annualized delivery volume, hospital location, hospital region, hospital teaching",2,White,Hispanic,1.19,1.05,1.35
10.1016/j.ajog.2016.06.032,1,No,NA,Yes,low-risk patients,peripartum hysterectomy,RR,NA,"mode of delivery, labor induction, multiple gestation, stillbirth, placental abruption, fibroids, antepartum hemorrhage, polyhydramnios, preeclampsia/eclampsia, chorioamnionitis, placenta previa, age, discharge year, household income, insurance status, hospital bed size, annualized delivery volume, hospital location, hospital region, hospital teaching",3,White,Other,1.34,1.18,1.53
10.1016/j.ajog.2016.06.032,1,No,NA,Yes,low-risk patients,peripartum hysterectomy,RR,NA,"mode of delivery, labor induction, multiple gestation, stillbirth, placental abruption, fibroids, antepartum hemorrhage, polyhydramnios, preeclampsia/eclampsia, chorioamnionitis, placenta previa, age, discharge year, household income, insurance status, hospital bed size, annualized delivery volume, hospital location, hospital region, hospital teaching",4,White,Unknown,1.36,0.79,2.34
10.1016/j.ajog.2016.06.032,2,No,NA,No,NA,peripartum hysterectomy,RR,NA,"mode of delivery, labor induction, multiple gestation, stillbirth, placental abruption, fibroids, antepartum hemorrhage, polyhydramnios, preeclampsia/eclampsia, chorioamnionitis, placenta previa, age, discharge year, household income, insurance status, hospital bed size, annualized delivery volume, hospital location, hospital region, hospital teaching",1,White,Black,1.27,1.15,1.41
10.1016/j.ajog.2016.06.032,2,No,NA,No,NA,peripartum hysterectomy,RR,NA,"mode of delivery, labor induction, multiple gestation, stillbirth, placental abruption, fibroids, antepartum hemorrhage, polyhydramnios, preeclampsia/eclampsia, chorioamnionitis, placenta previa, age, discharge year, household income, insurance status, hospital bed size, annualized delivery volume, hospital location, hospital region, hospital teaching",2,White,Hispanic,1.23,1.12,1.35
10.1016/j.ajog.2016.06.032,2,No,NA,No,NA,peripartum hysterectomy,RR,NA,"mode of delivery, labor induction, multiple gestation, stillbirth, placental abruption, fibroids, antepartum hemorrhage, polyhydramnios, preeclampsia/eclampsia, chorioamnionitis, placenta previa, age, discharge year, household income, insurance status, hospital bed size, annualized delivery volume, hospital location, hospital region, hospital teaching",3,White,Other,1.2,1.08,1.33
10.1016/j.ajog.2016.06.032,2,No,NA,No,NA,peripartum hysterectomy,RR,NA,"mode of delivery, labor induction, multiple gestation, stillbirth, placental abruption, fibroids, antepartum hemorrhage, polyhydramnios, preeclampsia/eclampsia, chorioamnionitis, placenta previa, age, discharge year, household income, insurance status, hospital bed size, annualized delivery volume, hospital location, hospital region, hospital teaching",4,White,Unknown,0.97,0.88,1.07
10.1016/j.ygyno.2016.07.107,1,No,NA,No,NA,stage 3/4 endometrial cancer at diagnosis,OR,NA,"income per year, facility location, primary payer category, age, tumor grade, histology",1,Non-Hispanic White,Hispanic White,1.06,0.99,1.14
10.1016/j.ygyno.2016.07.107,1,No,NA,No,NA,stage 3/4 endometrial cancer at diagnosis,OR,NA,"income per year, facility location, primary payer category, age, tumor grade, histology",2,Non-Hispanic White,Black,1.17,1.11,1.23
10.1016/j.ygyno.2016.07.107,1,No,NA,No,NA,stage 3/4 endometrial cancer at diagnosis,OR,NA,"income per year, facility location, primary payer category, age, tumor grade, histology",3,Non-Hispanic White,"American Indian, Aleutian, or Eskimo",1.03,0.77,1.38
10.1016/j.ygyno.2016.07.107,1,No,NA,No,NA,stage 3/4 endometrial cancer at diagnosis,OR,NA,"income per year, facility location, primary payer category, age, tumor grade, histology",4,Non-Hispanic White,Asian/pacific Islander,1.19,1.09,1.31
10.1016/j.ygyno.2016.07.107,1,No,NA,No,NA,stage 3/4 endometrial cancer at diagnosis,OR,NA,"income per year, facility location, primary payer category, age, tumor grade, histology",5,Non-Hispanic White,Other,0.91,0.75,1.1
10.1016/j.ygyno.2016.07.107,1,No,NA,No,NA,stage 3/4 endometrial cancer at diagnosis,OR,NA,"income per year, facility location, primary payer category, age, tumor grade, histology",6,Non-Hispanic White,Unknown,0.93,0.82,NA
10.1016/j.ygyno.2016.07.107,1,No,NA,No,NA,stage 3/4 endometrial cancer at diagnosis,OR,NA,"income per year, facility location, primary payer category, age, tumor grade, histology",7,Non-Hispanic White,NA,NA,NA,1.05
10.1016/j.ygyno.2016.07.107,2,No,NA,No,NA,inferior stage 3/4 overall survival,HR,NA,"Education, income per year, facility location, primary payer category, age, tumor grade, FIGO staging, Histology, Charlson-Deyo score, institution volume, treatment",1,Non-Hispanic White,Black,1.26,1.19,1.34
10.1016/j.ygyno.2018.02.019,1,Yes,Early-stage type 1,No,NA,endometrial cancer mortality,HR,NA,None,1,White,Black,1.23,1.13,1.34
10.1016/j.ygyno.2018.02.019,2,Yes,Early-stage type 2,No,NA,endometrial cancer mortality,HR,NA,None,1,White,Black,1.31,1.22,1.41
10.1016/j.ygyno.2018.02.019,3,Yes,Advanced-stage type 1,No,NA,endometrial cancer mortality,HR,NA,None,1,White,Black,1.3,1.08,1.57
10.1016/j.ygyno.2018.02.019,4,Yes,Advanced-stage type 2,No,NA,endometrial cancer mortality,HR,NA,None,1,White,Black,1.12,1.06,1.19
10.1016/j.ygyno.2018.02.019,5,Yes,Early-stage type 1; hospital volume <= 10,No,NA,endometrial cancer mortality,HR,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,White,Black,1.48,1.16,1.88
10.1016/j.ygyno.2018.02.019,6,Yes,Early-stage type 2; hospital volume <= 10,No,NA,endometrial cancer mortality,HR,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,White,Black,1.5,1.21,1.86
10.1016/j.ygyno.2018.02.019,7,Yes,Advanced-stage type 1; hospital volume <= 10,No,NA,endometrial cancer mortality,HR,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,White,Black,1.91,1.17,3.11
10.1016/j.ygyno.2018.02.019,8,Yes,Advanced-stage type 2; hospital volume <= 10,No,NA,endometrial cancer mortality,HR,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,White,Black,1.18,0.97,1.43
10.1016/j.ygyno.2018.02.019,9,Yes,Early-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer mortality,HR,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,White,Black,1.25,0.97,1.61
10.1016/j.ygyno.2018.02.019,10,Yes,Early-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer mortality,HR,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,White,Black,1.38,1.12,1.7
10.1016/j.ygyno.2018.02.019,11,Yes,Advanced-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer mortality,HR,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,White,Black,1.45,0.93,2.27
10.1016/j.ygyno.2018.02.019,12,Yes,Advanced-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer mortality,HR,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,White,Black,1.22,1.01,1.46
10.1016/j.ygyno.2018.02.019,13,Yes,Early-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer mortality,HR,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,White,Black,1.17,1.04,1.33
10.1016/j.ygyno.2018.02.019,14,Yes,Early-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer mortality,HR,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,White,Black,1.27,1.14,1.4
10.1016/j.ygyno.2018.02.019,15,Yes,Advanced-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer mortality,HR,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,White,Black,1.3,1,1.69
10.1016/j.ygyno.2018.02.019,16,Yes,Advanced-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer mortality,HR,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,White,Black,1.13,1.04,1.23
10.1016/j.ygyno.2018.02.019,17,Yes,Early-stage type 1; hospital volume >60,No,NA,endometrial cancer mortality,HR,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,White,Black,1.19,1.03,1.38
10.1016/j.ygyno.2018.02.019,18,Yes,Early-stage type 2; hospital volume >60,No,NA,endometrial cancer mortality,HR,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,White,Black,1.31,1.14,1.52
10.1016/j.ygyno.2018.02.019,19,Yes,Advanced-stage type 1; hospital volume >60,No,NA,endometrial cancer mortality,HR,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,White,Black,0.91,0.61,1.34
10.1016/j.ygyno.2018.02.019,20,Yes,Advanced-stage type 2; hospital volume >60,No,NA,endometrial cancer mortality,HR,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,White,Black,1.07,0.96,1.19
10.1016/j.ygyno.2018.02.019,21,Yes,Early-stage type 1; hospital volume <= 10,No,NA,endometrial cancer 2-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,93.9,91.5,95.6
10.1016/j.ygyno.2018.02.019,21,Yes,Early-stage type 1; hospital volume <= 10,No,NA,endometrial cancer 2-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,96.9,96.5,97.2
10.1016/j.ygyno.2018.02.019,22,Yes,Early-stage type 1; hospital volume <= 10,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,95.4,94.3,96.4
10.1016/j.ygyno.2018.02.019,22,Yes,Early-stage type 1; hospital volume <= 10,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,96.8,96.3,97.3
10.1016/j.ygyno.2018.02.019,23,Yes,Early-stage type 1; hospital volume <= 10,No,NA,endometrial cancer 2-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-3,-4.8,-1.2
10.1016/j.ygyno.2018.02.019,24,Yes,Early-stage type 1; hospital volume <= 10,No,NA,endometrial cancer 2-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-1.4,-2.4,-0.5
10.1016/j.ygyno.2018.02.019,25,Yes,Early-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer 2-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,96.4,94.8,97.5
10.1016/j.ygyno.2018.02.019,25,Yes,Early-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer 2-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,97.3,97,97.6
10.1016/j.ygyno.2018.02.019,26,Yes,Early-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,96.5,95.8,97.3
10.1016/j.ygyno.2018.02.019,26,Yes,Early-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,97.2,96.9,97.5
10.1016/j.ygyno.2018.02.019,27,Yes,Early-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer 2-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-0.9,-2.1,0.3
10.1016/j.ygyno.2018.02.019,28,Yes,Early-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer 2-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-0.7,-1.4,0.1
10.1016/j.ygyno.2018.02.019,29,Yes,Early-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer 2-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,96.5,95.8,97.1
10.1016/j.ygyno.2018.02.019,29,Yes,Early-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer 2-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,97.4,97.2,97.6
10.1016/j.ygyno.2018.02.019,30,Yes,Early-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,97,96.7,97.4
10.1016/j.ygyno.2018.02.019,30,Yes,Early-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,97.4,97.3,97.6
10.1016/j.ygyno.2018.02.019,31,Yes,Early-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer 2-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-0.9,-1.5,-0.3
10.1016/j.ygyno.2018.02.019,32,Yes,Early-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer 2-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-0.4,-0.7,-0.1
10.1016/j.ygyno.2018.02.019,33,Yes,Early-stage type 1; hospital volume >60,No,NA,endometrial cancer 2-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,96.7,95.6,97.5
10.1016/j.ygyno.2018.02.019,33,Yes,Early-stage type 1; hospital volume >60,No,NA,endometrial cancer 2-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,97.5,97.3,97.7
10.1016/j.ygyno.2018.02.019,34,Yes,Early-stage type 1; hospital volume >60,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,96.9,96.4,97.4
10.1016/j.ygyno.2018.02.019,34,Yes,Early-stage type 1; hospital volume >60,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,97.4,97.2,97.6
10.1016/j.ygyno.2018.02.019,35,Yes,Early-stage type 1; hospital volume >60,No,NA,endometrial cancer 2-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-0.8,-1.6,0
10.1016/j.ygyno.2018.02.019,36,Yes,Early-stage type 1; hospital volume >60,No,NA,endometrial cancer 2-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-0.5,-0.9,0
10.1016/j.ygyno.2018.02.019,37,Yes,Early-stage type 2; hospital volume <= 10,No,NA,endometrial cancer 2-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,77.5,72.6,81.6
10.1016/j.ygyno.2018.02.019,37,Yes,Early-stage type 2; hospital volume <= 10,No,NA,endometrial cancer 2-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,87,85.5,88.4
10.1016/j.ygyno.2018.02.019,38,Yes,Early-stage type 2; hospital volume <= 10,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,83.5,80.3,86.9
10.1016/j.ygyno.2018.02.019,38,Yes,Early-stage type 2; hospital volume <= 10,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,88.5,86.5,90.5
10.1016/j.ygyno.2018.02.019,39,Yes,Early-stage type 2; hospital volume <= 10,No,NA,endometrial cancer 2-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-9.5,-13.8,-5.2
10.1016/j.ygyno.2018.02.019,40,Yes,Early-stage type 2; hospital volume <= 10,No,NA,endometrial cancer 2-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-4.9,-7.6,-2.2
10.1016/j.ygyno.2018.02.019,41,Yes,Early-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer 2-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,79.4,75.6,82.6
10.1016/j.ygyno.2018.02.019,41,Yes,Early-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer 2-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,87.2,85.8,88.5
10.1016/j.ygyno.2018.02.019,42,Yes,Early-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,82.3,79.8,84.9
10.1016/j.ygyno.2018.02.019,42,Yes,Early-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,86.6,85.2,88
10.1016/j.ygyno.2018.02.019,43,Yes,Early-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer 2-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-7.8,-11.3,-4.3
10.1016/j.ygyno.2018.02.019,44,Yes,Early-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer 2-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-4.3,-7,-1.6
10.1016/j.ygyno.2018.02.019,45,Yes,Early-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer 2-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,81,79.2,82.7
10.1016/j.ygyno.2018.02.019,45,Yes,Early-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer 2-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,88,87.3,88.7
10.1016/j.ygyno.2018.02.019,46,Yes,Early-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,84.1,82.9,85.3
10.1016/j.ygyno.2018.02.019,46,Yes,Early-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,87.1,86.4,87.7
10.1016/j.ygyno.2018.02.019,47,Yes,Early-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer 2-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-7,-8.8,-5.2
10.1016/j.ygyno.2018.02.019,48,Yes,Early-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer 2-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-3,-4.2,-1.7
10.1016/j.ygyno.2018.02.019,49,Yes,Early-stage type 2; hospital volume >60,No,NA,endometrial cancer 2-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,84.6,82.3,86.6
10.1016/j.ygyno.2018.02.019,49,Yes,Early-stage type 2; hospital volume >60,No,NA,endometrial cancer 2-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,88.9,88.1,89.7
10.1016/j.ygyno.2018.02.019,50,Yes,Early-stage type 2; hospital volume >60,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,85.1,83.4,86.8
10.1016/j.ygyno.2018.02.019,50,Yes,Early-stage type 2; hospital volume >60,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,88.3,87.4,89.1
10.1016/j.ygyno.2018.02.019,51,Yes,Early-stage type 2; hospital volume >60,No,NA,endometrial cancer 2-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-4.3,-6.5,-2.1
10.1016/j.ygyno.2018.02.019,52,Yes,Early-stage type 2; hospital volume >60,No,NA,endometrial cancer 2-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-3.2,-4.9,-1.5
10.1016/j.ygyno.2018.02.019,53,Yes,Advanced-stage type 1; hospital volume <= 10,No,NA,endometrial cancer 2-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,61.8,42.4,76.4
10.1016/j.ygyno.2018.02.019,53,Yes,Advanced-stage type 1; hospital volume <= 10,No,NA,endometrial cancer 2-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,83.7,80.6,86.3
10.1016/j.ygyno.2018.02.019,54,Yes,Advanced-stage type 1; hospital volume <= 10,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,66.9,55.2,81.1
10.1016/j.ygyno.2018.02.019,54,Yes,Advanced-stage type 1; hospital volume <= 10,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,79.3,72.6,86.6
10.1016/j.ygyno.2018.02.019,55,Yes,Advanced-stage type 1; hospital volume <= 10,No,NA,endometrial cancer 2-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-21.9,-36.7,-7.1
10.1016/j.ygyno.2018.02.019,56,Yes,Advanced-stage type 1; hospital volume <= 10,No,NA,endometrial cancer 2-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-12.4,-24,-0.9
10.1016/j.ygyno.2018.02.019,57,Yes,Advanced-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer 2-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,73.1,61.1,81.9
10.1016/j.ygyno.2018.02.019,57,Yes,Advanced-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer 2-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,83.7,80.8,86.1
10.1016/j.ygyno.2018.02.019,58,Yes,Advanced-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,78.3,71.7,85.5
10.1016/j.ygyno.2018.02.019,58,Yes,Advanced-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,84.1,81.4,86.8
10.1016/j.ygyno.2018.02.019,59,Yes,Advanced-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer 2-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-10.6,-19.8,-1.4
10.1016/j.ygyno.2018.02.019,60,Yes,Advanced-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer 2-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-5.8,-12.8,1.3
10.1016/j.ygyno.2018.02.019,61,Yes,Advanced-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer 2-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,82.1,76.1,86.7
10.1016/j.ygyno.2018.02.019,61,Yes,Advanced-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer 2-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,83.8,82.3,85.1
10.1016/j.ygyno.2018.02.019,62,Yes,Advanced-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,79.6,75.9,83.6
10.1016/j.ygyno.2018.02.019,62,Yes,Advanced-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,83.6,82.3,85
10.1016/j.ygyno.2018.02.019,63,Yes,Advanced-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer 2-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-1.7,-6.5,3.1
10.1016/j.ygyno.2018.02.019,64,Yes,Advanced-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer 2-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-4,-7.8,-0.2
10.1016/j.ygyno.2018.02.019,65,Yes,Advanced-stage type 1; hospital volume >60,No,NA,endometrial cancer 2-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,82.9,74.1,88.9
10.1016/j.ygyno.2018.02.019,65,Yes,Advanced-stage type 1; hospital volume >60,No,NA,endometrial cancer 2-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,85.7,83.9,87.4
10.1016/j.ygyno.2018.02.019,66,Yes,Advanced-stage type 1; hospital volume >60,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,86.9,82.8,91.1
10.1016/j.ygyno.2018.02.019,66,Yes,Advanced-stage type 1; hospital volume >60,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,85.7,83.9,87.5
10.1016/j.ygyno.2018.02.019,67,Yes,Advanced-stage type 1; hospital volume >60,No,NA,endometrial cancer 2-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-2.8,-9,3.4
10.1016/j.ygyno.2018.02.019,68,Yes,Advanced-stage type 1; hospital volume >60,No,NA,endometrial cancer 2-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,1.2,-2.9,5.3
10.1016/j.ygyno.2018.02.019,69,Yes,Advanced-stage type 2; hospital volume <= 10,No,NA,endometrial cancer 2-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,40.6,43.6,46.5
10.1016/j.ygyno.2018.02.019,69,Yes,Advanced-stage type 2; hospital volume <= 10,No,NA,endometrial cancer 2-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,50.7,47.7,53.5
10.1016/j.ygyno.2018.02.019,70,Yes,Advanced-stage type 2; hospital volume <= 10,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,45.3,39.8,51.5
10.1016/j.ygyno.2018.02.019,70,Yes,Advanced-stage type 2; hospital volume <= 10,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,50.4,45.6,55.7
10.1016/j.ygyno.2018.02.019,71,Yes,Advanced-stage type 2; hospital volume <= 10,No,NA,endometrial cancer 2-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-10.1,-16.7,-3.5
10.1016/j.ygyno.2018.02.019,72,Yes,Advanced-stage type 2; hospital volume <= 10,No,NA,endometrial cancer 2-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-5.1,-10.6,0.3
10.1016/j.ygyno.2018.02.019,73,Yes,Advanced-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer 2-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,44.7,39.8,49.6
10.1016/j.ygyno.2018.02.019,73,Yes,Advanced-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer 2-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,54,51.3,56.6
10.1016/j.ygyno.2018.02.019,74,Yes,Advanced-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,46.7,42.6,51.2
10.1016/j.ygyno.2018.02.019,74,Yes,Advanced-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,52.7,49.9,55.7
10.1016/j.ygyno.2018.02.019,75,Yes,Advanced-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer 2-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-9.3,-14.8,-3.8
10.1016/j.ygyno.2018.02.019,76,Yes,Advanced-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer 2-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-6.1,-11,-1.1
10.1016/j.ygyno.2018.02.019,77,Yes,Advanced-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer 2-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,44.6,42,47.1
10.1016/j.ygyno.2018.02.019,77,Yes,Advanced-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer 2-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,52.4,51,53.8
10.1016/j.ygyno.2018.02.019,78,Yes,Advanced-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,47.3,45.1,49.5
10.1016/j.ygyno.2018.02.019,78,Yes,Advanced-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,51,49.8,52.4
10.1016/j.ygyno.2018.02.019,79,Yes,Advanced-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer 2-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-7.8,-10.7,-4.9
10.1016/j.ygyno.2018.02.019,80,Yes,Advanced-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer 2-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-3.8,-6.2,-1.4
10.1016/j.ygyno.2018.02.019,81,Yes,Advanced-stage type 2; hospital volume >60,No,NA,endometrial cancer 2-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,45.7,42,49.3
10.1016/j.ygyno.2018.02.019,81,Yes,Advanced-stage type 2; hospital volume >60,No,NA,endometrial cancer 2-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,52.8,51,54.5
10.1016/j.ygyno.2018.02.019,82,Yes,Advanced-stage type 2; hospital volume >60,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,48.1,45.1,51.3
10.1016/j.ygyno.2018.02.019,82,Yes,Advanced-stage type 2; hospital volume >60,No,NA,endometrial cancer 2-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,50.1,48.4,51.9
10.1016/j.ygyno.2018.02.019,83,Yes,Advanced-stage type 2; hospital volume >60,No,NA,endometrial cancer 2-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-7.1,-11.1,-3.1
10.1016/j.ygyno.2018.02.019,84,Yes,Advanced-stage type 2; hospital volume >60,No,NA,endometrial cancer 2-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-2,-5.3,1.2
10.1016/j.ygyno.2018.02.019,85,Yes,Early-stage type 1; hospital volume <= 10,No,NA,endometrial cancer 5-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,84.8,81.1,87.8
10.1016/j.ygyno.2018.02.019,85,Yes,Early-stage type 1; hospital volume <= 10,No,NA,endometrial cancer 5-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,90.9,90.3,91.5
10.1016/j.ygyno.2018.02.019,86,Yes,Early-stage type 1; hospital volume <= 10,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,87.4,85,89.8
10.1016/j.ygyno.2018.02.019,86,Yes,Early-stage type 1; hospital volume <= 10,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,91,89.9,92.1
10.1016/j.ygyno.2018.02.019,87,Yes,Early-stage type 1; hospital volume <= 10,No,NA,endometrial cancer 5-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-6.1,-9.2,-3
10.1016/j.ygyno.2018.02.019,88,Yes,Early-stage type 1; hospital volume <= 10,No,NA,endometrial cancer 5-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-3.6,-5.9,-1.4
10.1016/j.ygyno.2018.02.019,89,Yes,Early-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer 5-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,87.5,84.5,90
10.1016/j.ygyno.2018.02.019,89,Yes,Early-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer 5-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,91.5,90.9,92
10.1016/j.ygyno.2018.02.019,90,Yes,Early-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,89.4,87.4,91.4
10.1016/j.ygyno.2018.02.019,90,Yes,Early-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,91.3,90.6,92
10.1016/j.ygyno.2018.02.019,91,Yes,Early-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer 5-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-4,-6.6,-1.4
10.1016/j.ygyno.2018.02.019,92,Yes,Early-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer 5-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-1.9,-3.9,0.2
10.1016/j.ygyno.2018.02.019,93,Yes,Early-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer 5-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,87.9,86.5,89.3
10.1016/j.ygyno.2018.02.019,93,Yes,Early-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer 5-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,91.9,91.5,92.3
10.1016/j.ygyno.2018.02.019,94,Yes,Early-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,90.1,89.2,91.1
10.1016/j.ygyno.2018.02.019,94,Yes,Early-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,91.4,91.1,91.7
10.1016/j.ygyno.2018.02.019,95,Yes,Early-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer 5-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-3.6,-5,-2.2
10.1016/j.ygyno.2018.02.019,96,Yes,Early-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer 5-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-1.3,-2.2,-0.3
10.1016/j.ygyno.2018.02.019,97,Yes,Early-stage type 1; hospital volume >60,No,NA,endometrial cancer 5-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,88.2,86.1,90.1
10.1016/j.ygyno.2018.02.019,97,Yes,Early-stage type 1; hospital volume >60,No,NA,endometrial cancer 5-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,91.9,91.5,92.3
10.1016/j.ygyno.2018.02.019,98,Yes,Early-stage type 1; hospital volume >60,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,90.4,89,91.7
10.1016/j.ygyno.2018.02.019,98,Yes,Early-stage type 1; hospital volume >60,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,91.8,91.3,92.2
10.1016/j.ygyno.2018.02.019,99,Yes,Early-stage type 1; hospital volume >60,No,NA,endometrial cancer 5-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-3.7,-5.6,-1.8
10.1016/j.ygyno.2018.02.019,100,Yes,Early-stage type 1; hospital volume >60,No,NA,endometrial cancer 5-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-1.4,-2.7,0
10.1016/j.ygyno.2018.02.019,101,Yes,Early-stage type 2; hospital volume <= 10,No,NA,endometrial cancer 5-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,55.7,49.5,61.4
10.1016/j.ygyno.2018.02.019,101,Yes,Early-stage type 2; hospital volume <= 10,No,NA,endometrial cancer 5-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,71.4,69.3,73.5
10.1016/j.ygyno.2018.02.019,102,Yes,Early-stage type 2; hospital volume <= 10,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,65.7,60.4,71.4
10.1016/j.ygyno.2018.02.019,102,Yes,Early-stage type 2; hospital volume <= 10,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,74.5,71,78.3
10.1016/j.ygyno.2018.02.019,103,Yes,Early-stage type 2; hospital volume <= 10,No,NA,endometrial cancer 5-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-15.7,-21.8,-9.6
10.1016/j.ygyno.2018.02.019,104,Yes,Early-stage type 2; hospital volume <= 10,No,NA,endometrial cancer 5-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-8.9,-13.5,-4.2
10.1016/j.ygyno.2018.02.019,105,Yes,Early-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer 5-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,58.7,53.5,63.4
10.1016/j.ygyno.2018.02.019,105,Yes,Early-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer 5-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,71.3,69.3,73.2
10.1016/j.ygyno.2018.02.019,106,Yes,Early-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,63.4,59.4,67.8
10.1016/j.ygyno.2018.02.019,106,Yes,Early-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,71,68.8,73.2
10.1016/j.ygyno.2018.02.019,107,Yes,Early-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer 5-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-12.6,-17.7,-7.5
10.1016/j.ygyno.2018.02.019,108,Yes,Early-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer 5-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-7.5,-12.1,-3
10.1016/j.ygyno.2018.02.019,109,Yes,Early-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer 5-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,62.3,59.8,64.6
10.1016/j.ygyno.2018.02.019,109,Yes,Early-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer 5-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,73.4,72.3,74.4
10.1016/j.ygyno.2018.02.019,110,Yes,Early-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,66.9,64.9,68.9
10.1016/j.ygyno.2018.02.019,110,Yes,Early-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,72.2,71.2,73.2
10.1016/j.ygyno.2018.02.019,111,Yes,Early-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer 5-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-11.1,-13.7,-8.5
10.1016/j.ygyno.2018.02.019,112,Yes,Early-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer 5-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-5.3,-7.5,-3.1
10.1016/j.ygyno.2018.02.019,113,Yes,Early-stage type 2; hospital volume >60,No,NA,endometrial cancer 5-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,65.5,62.1,68.6
10.1016/j.ygyno.2018.02.019,113,Yes,Early-stage type 2; hospital volume >60,No,NA,endometrial cancer 5-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,75.7,74.3,76.9
10.1016/j.ygyno.2018.02.019,114,Yes,Early-stage type 2; hospital volume >60,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,68.4,65.6,71.3
10.1016/j.ygyno.2018.02.019,114,Yes,Early-stage type 2; hospital volume >60,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,74.3,72.9,75.7
10.1016/j.ygyno.2018.02.019,115,Yes,Early-stage type 2; hospital volume >60,No,NA,endometrial cancer 5-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-10.2,-13.6,-6.8
10.1016/j.ygyno.2018.02.019,116,Yes,Early-stage type 2; hospital volume >60,No,NA,endometrial cancer 5-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-5.9,-8.8,-2.9
10.1016/j.ygyno.2018.02.019,117,Yes,Advanced-stage type 1; hospital volume <= 10,No,NA,endometrial cancer 5-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,32.1,14,51.9
10.1016/j.ygyno.2018.02.019,117,Yes,Advanced-stage type 1; hospital volume <= 10,No,NA,endometrial cancer 5-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,64.1,59.8,68
10.1016/j.ygyno.2018.02.019,118,Yes,Advanced-stage type 1; hospital volume <= 10,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,40.4,27.9,58.6
10.1016/j.ygyno.2018.02.019,118,Yes,Advanced-stage type 1; hospital volume <= 10,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,57.6,48.8,67.9
10.1016/j.ygyno.2018.02.019,119,Yes,Advanced-stage type 1; hospital volume <= 10,No,NA,endometrial cancer 5-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-32,-52.2,-11.8
10.1016/j.ygyno.2018.02.019,120,Yes,Advanced-stage type 1; hospital volume <= 10,No,NA,endometrial cancer 5-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-17.1,-31.7,-2.6
10.1016/j.ygyno.2018.02.019,121,Yes,Advanced-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer 5-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,44.5,30.4,57.7
10.1016/j.ygyno.2018.02.019,121,Yes,Advanced-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer 5-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,63.2,59.2,67
10.1016/j.ygyno.2018.02.019,122,Yes,Advanced-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,55.9,46.2,67.6
10.1016/j.ygyno.2018.02.019,122,Yes,Advanced-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,65.4,61.2,70
10.1016/j.ygyno.2018.02.019,123,Yes,Advanced-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer 5-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-18.7,-32.4,-5
10.1016/j.ygyno.2018.02.019,124,Yes,Advanced-stage type 1; hospital volume 10.01 - 20,No,NA,endometrial cancer 5-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-9.5,-20.7,1.6
10.1016/j.ygyno.2018.02.019,125,Yes,Advanced-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer 5-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,52.2,44,59.8
10.1016/j.ygyno.2018.02.019,125,Yes,Advanced-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer 5-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,65.5,63.3,67.6
10.1016/j.ygyno.2018.02.019,126,Yes,Advanced-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,58.5,52.7,65
10.1016/j.ygyno.2018.02.019,126,Yes,Advanced-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,65.3,63.3,67.3
10.1016/j.ygyno.2018.02.019,127,Yes,Advanced-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer 5-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-13.3,-21.2,-5.4
10.1016/j.ygyno.2018.02.019,128,Yes,Advanced-stage type 1; hospital volume 20.01 - 60,No,NA,endometrial cancer 5-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-6.7,-13,-0.5
10.1016/j.ygyno.2018.02.019,129,Yes,Advanced-stage type 1; hospital volume >60,No,NA,endometrial cancer 5-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,69.8,58.9,78.3
10.1016/j.ygyno.2018.02.019,129,Yes,Advanced-stage type 1; hospital volume >60,No,NA,endometrial cancer 5-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,68.2,65.5,70.7
10.1016/j.ygyno.2018.02.019,130,Yes,Advanced-stage type 1; hospital volume >60,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,71.6,64.5,79.5
10.1016/j.ygyno.2018.02.019,130,Yes,Advanced-stage type 1; hospital volume >60,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,69.5,66.8,72.2
10.1016/j.ygyno.2018.02.019,131,Yes,Advanced-stage type 1; hospital volume >60,No,NA,endometrial cancer 5-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,1.6,-7.3,10.5
10.1016/j.ygyno.2018.02.019,132,Yes,Advanced-stage type 1; hospital volume >60,No,NA,endometrial cancer 5-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,2.2,-5.4,9.7
10.1016/j.ygyno.2018.02.019,133,Yes,Advanced-stage type 2; hospital volume <= 10,No,NA,endometrial cancer 5-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,20.5,15.2,26.3
10.1016/j.ygyno.2018.02.019,133,Yes,Advanced-stage type 2; hospital volume <= 10,No,NA,endometrial cancer 5-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,27.8,25,30.8
10.1016/j.ygyno.2018.02.019,134,Yes,Advanced-stage type 2; hospital volume <= 10,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,24.2,19.4,30.1
10.1016/j.ygyno.2018.02.019,134,Yes,Advanced-stage type 2; hospital volume <= 10,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,29,24.4,34.4
10.1016/j.ygyno.2018.02.019,135,Yes,Advanced-stage type 2; hospital volume <= 10,No,NA,endometrial cancer 5-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-7.3,-13.8,-0.8
10.1016/j.ygyno.2018.02.019,136,Yes,Advanced-stage type 2; hospital volume <= 10,No,NA,endometrial cancer 5-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-4.7,-9.7,0.3
10.1016/j.ygyno.2018.02.019,137,Yes,Advanced-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer 5-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,20.6,16,25.5
10.1016/j.ygyno.2018.02.019,137,Yes,Advanced-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer 5-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,31.3,28.5,34
10.1016/j.ygyno.2018.02.019,138,Yes,Advanced-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,25.1,21.4,29.4
10.1016/j.ygyno.2018.02.019,138,Yes,Advanced-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,30.9,28.1,34
10.1016/j.ygyno.2018.02.019,139,Yes,Advanced-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer 5-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-10.7,-16.4,-5
10.1016/j.ygyno.2018.02.019,140,Yes,Advanced-stage type 2; hospital volume 10.01 - 20,No,NA,endometrial cancer 5-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-5.8,-10.5,-1.2
10.1016/j.ygyno.2018.02.019,141,Yes,Advanced-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer 5-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,21.6,19.3,24.1
10.1016/j.ygyno.2018.02.019,141,Yes,Advanced-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer 5-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,29.4,28,30.9
10.1016/j.ygyno.2018.02.019,142,Yes,Advanced-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,25.5,23.6,27.7
10.1016/j.ygyno.2018.02.019,142,Yes,Advanced-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,29.1,27.9,30.5
10.1016/j.ygyno.2018.02.019,143,Yes,Advanced-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer 5-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-7.8,-10.7,-4.9
10.1016/j.ygyno.2018.02.019,144,Yes,Advanced-stage type 2; hospital volume 20.01 - 60,No,NA,endometrial cancer 5-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-3.6,-5.9,-1.3
10.1016/j.ygyno.2018.02.019,145,Yes,Advanced-stage type 2; hospital volume >60,No,NA,endometrial cancer 5-year survival,Percent,NA,None,1,N/A,Non-Hispanic: Black,20.8,17.5,24.3
10.1016/j.ygyno.2018.02.019,145,Yes,Advanced-stage type 2; hospital volume >60,No,NA,endometrial cancer 5-year survival,Percent,NA,None,2,N/A,Non-Hispanic: White,28.9,27.1,30.7
10.1016/j.ygyno.2018.02.019,146,Yes,Advanced-stage type 2; hospital volume >60,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,N/A,Non-Hispanic: Black,25.5,22.7,28.6
10.1016/j.ygyno.2018.02.019,146,Yes,Advanced-stage type 2; hospital volume >60,No,NA,endometrial cancer 5-year survival,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",2,N/A,Non-Hispanic: White,27.4,25.8,29.2
10.1016/j.ygyno.2018.02.019,147,Yes,Advanced-stage type 2; hospital volume >60,No,NA,endometrial cancer 5-year survival difference,Percent,NA,None,1,Non-Hispanic White,Non-Hispanic: Black,-8.1,-12.1,-4.1
10.1016/j.ygyno.2018.02.019,148,Yes,Advanced-stage type 2; hospital volume >60,No,NA,endometrial cancer 5-year survival difference,Percent,NA,"age of diagnosis, insurance status, median income of zip code residence area, patients' residence area (urban/rural), year of diagnosis, comorbidity score, tumor histology, grade, lymphadenectomy, facility location, facility type, overall radiation, chemotherapy",1,Non-Hispanic White,Non-Hispanic: Black,-1.9,-4.9,1.1
10.1097/AOG.0000000000001033,7,Yes,Stage 4 vulvar cancer,No,NA,5-year all cause mortality,HR,NA,"age group, insurance, diagnosis year, median income level, facility volume, facility type, region, lymph node examination, treatment",1,Non-Hispanic White,Black,0.75,0.57,0.99
10.1016/j.ajog.2015.01.029,2,No,NA,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disordres, macrosomia, gestational age, labor induction, PROM",1,White,Black,1.23,1.17,1.29
10.1016/j.ajog.2015.01.029,3,Yes,maternal age <20,No,NA,Primary cesarean delivery,RR,NA,"parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,maternal age 20-29,White,0.9,0.8,1.01
10.1016/j.ajog.2015.01.029,3,Yes,maternal age <20,No,NA,Primary cesarean delivery,RR,NA,"parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,maternal age 20-29,Black,0.88,0.79,0.98
10.1016/j.ajog.2015.01.029,4,Yes,maternal age 30-34,No,NA,Primary cesarean delivery,RR,NA,"parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,maternal age 20-29,White,1.14,1.07,1.21
10.1016/j.ajog.2015.01.029,4,Yes,maternal age 30-34,No,NA,Primary cesarean delivery,RR,NA,"parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,maternal age 20-29,Black,1.08,0.96,1.21
10.1016/j.ajog.2015.01.029,5,Yes,maternal age >=35,No,NA,Primary cesarean delivery,RR,NA,"parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,maternal age 20-29,White,1.37,1.27,1.47
10.1016/j.ajog.2015.01.029,5,Yes,maternal age >=35,No,NA,Primary cesarean delivery,RR,NA,"parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,maternal age 20-29,Black,1.66,1.49,1.86
10.1016/j.ajog.2015.01.029,6,Yes,multiparous,No,NA,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,nulliparous,White,0.3,0.28,0.32
10.1016/j.ajog.2015.01.029,6,Yes,multiparous,No,NA,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,nulliparous,Black,0.37,0.34,0.4
10.1016/j.ajog.2015.01.029,7,Yes,Medicaid/uninsured,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,private insurance,White,0.92,0.85,1
10.1016/j.ajog.2015.01.029,7,Yes,Medicaid/uninsured,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,private insurance,Black,0.98,0.89,1.07
10.1016/j.ajog.2015.01.029,8,Yes,unmarried,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,married,White,1,0.93,1.07
10.1016/j.ajog.2015.01.029,8,Yes,unmarried,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,married,Black,1,0.91,1.1
10.1016/j.ajog.2015.01.029,9,Yes,diabetes,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,N/A,White,1.21,1.03,1.42
10.1016/j.ajog.2015.01.029,9,Yes,diabetes,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,N/A,Black,1.15,0.92,1.43
10.1016/j.ajog.2015.01.029,10,Yes,chronic hypertension,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,N/A,White,1.16,1.03,1.3
10.1016/j.ajog.2015.01.029,10,Yes,chronic hypertension,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,N/A,Black,1.15,0.99,1.33
10.1016/j.ajog.2015.01.029,11,Yes,BMI <18.5,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,BMI 18.5-24.9,White,0.72,0.59,0.9
10.1016/j.ajog.2015.01.029,11,Yes,BMI <18.5,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,BMI 18.5-24.9,Black,0.81,0.61,1.07
10.1016/j.ajog.2015.01.029,12,Yes,BMI 25.0-29.9,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,BMI 18.5-24.9,White,1.15,1.07,1.23
10.1016/j.ajog.2015.01.029,12,Yes,BMI 25.0-29.9,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,BMI 18.5-24.9,Black,1.27,1.14,1.41
10.1016/j.ajog.2015.01.029,13,Yes,BMI >= 30.0,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,BMI 18.5-24.9,White,1.61,1.51,1.71
10.1016/j.ajog.2015.01.029,13,Yes,BMI >= 30.0,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,BMI 18.5-24.9,Black,1.51,1.36,1.66
10.1016/j.ajog.2015.01.029,14,Yes,excess weight gain,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,N/A,White,1.32,1.24,1.4
10.1016/j.ajog.2015.01.029,14,Yes,excess weight gain,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,N/A,Black,1.19,1.09,1.29
10.1016/j.ajog.2015.01.029,15,Yes,gestational diabetes,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,N/A,White,1.27,1.16,1.4
10.1016/j.ajog.2015.01.029,15,Yes,gestational diabetes,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,N/A,Black,1.23,1.07,1.42
10.1016/j.ajog.2015.01.029,16,Yes,gestational hypertensive disorders,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,N/A,White,1.47,1.36,1.58
10.1016/j.ajog.2015.01.029,16,Yes,gestational hypertensive disorders,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,N/A,Black,1.39,1.24,1.55
10.1016/j.ajog.2015.01.029,17,Yes,macrosomia,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, gestational age, labor induction, PROM, patient type, year of delivery",1,N/A,White,1.56,1.45,1.66
10.1016/j.ajog.2015.01.029,17,Yes,macrosomia,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, gestational age, labor induction, PROM, patient type, year of delivery",2,N/A,Black,1.63,1.43,1.85
10.1016/j.ajog.2015.01.029,18,Yes,gestational age <34,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, PROM, patient type, year of delivery",1,gestational age 39-40,White,1.94,1.7,2.21
10.1016/j.ajog.2015.01.029,18,Yes,gestational age <34,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, PROM, patient type, year of delivery",2,gestational age 39-40,Black,1.79,1.53,2.09
10.1016/j.ajog.2015.01.029,19,Yes,gestational age 34-36,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, PROM, patient type, year of delivery",1,gestational age 39-40,White,1.26,1.14,1.4
10.1016/j.ajog.2015.01.029,19,Yes,gestational age 34-36,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, PROM, patient type, year of delivery",2,gestational age 39-40,Black,1.24,1.08,1.42
10.1016/j.ajog.2015.01.029,20,Yes,gestational age 37-38,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, PROM, patient type, year of delivery",1,gestational age 39-40,White,1.02,0.95,1.09
10.1016/j.ajog.2015.01.029,20,Yes,gestational age 37-38,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, PROM, patient type, year of delivery",2,gestational age 39-40,Black,0.86,0.77,0.95
10.1016/j.ajog.2015.01.029,21,Yes,gestational age 41,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, PROM, patient type, year of delivery",1,gestational age 39-40,White,1.33,1.22,1.45
10.1016/j.ajog.2015.01.029,21,Yes,gestational age 41,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, PROM, patient type, year of delivery",2,gestational age 39-40,Black,1.42,1.27,1.58
10.1016/j.ajog.2015.01.029,22,Yes,gestational age >=42,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, PROM, patient type, year of delivery",1,gestational age 39-40,White,1.77,1.45,2.17
10.1016/j.ajog.2015.01.029,22,Yes,gestational age >=42,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, labor induction, PROM, patient type, year of delivery",2,gestational age 39-40,Black,1.46,0.88,2.41
10.1016/j.ajog.2015.01.029,23,Yes,labor induction,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, PROM, patient type, year of delivery",1,N/A,White,0.98,0.93,1.04
10.1016/j.ajog.2015.01.029,23,Yes,labor induction,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, PROM, patient type, year of delivery",2,N/A,Black,1.24,1.14,1.34
10.1016/j.ajog.2015.01.029,24,Yes,PROM,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, patient type, year of delivery",1,N/A,White,1.09,0.89,1.33
10.1016/j.ajog.2015.01.029,24,Yes,PROM,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, patient type, year of delivery",2,N/A,Black,1.07,0.79,1.44
10.1016/j.ajog.2015.01.029,25,Yes,private patient type,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, year of delivery",1,service patient type,White,1.08,0.98,1.18
10.1016/j.ajog.2015.01.029,25,Yes,private patient type,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, year of delivery",2,service patient type,Black,1.09,1,1.19
10.1016/j.ajog.2015.01.029,26,Yes,2005 year of delivery,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type",1,2004 year of delivery,White,0.93,0.84,1.02
10.1016/j.ajog.2015.01.029,26,Yes,2005 year of delivery,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type",2,2004 year of delivery,Black,0.89,0.77,1.03
10.1016/j.ajog.2015.01.029,27,Yes,2006 year of delivery,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type",1,2004 year of delivery,White,0.99,0.9,1.09
10.1016/j.ajog.2015.01.029,27,Yes,2006 year of delivery,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type",2,2004 year of delivery,Black,0.89,0.78,1.03
10.1016/j.ajog.2015.01.029,28,Yes,2007 year of delivery,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type",1,2004 year of delivery,White,1.11,1.01,1.21
10.1016/j.ajog.2015.01.029,28,Yes,2007 year of delivery,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type",2,2004 year of delivery,Black,1,0.87,1.15
10.1016/j.ajog.2015.01.029,29,Yes,2008 year of delivery,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type",1,2004 year of delivery,White,1.07,0.97,1.18
10.1016/j.ajog.2015.01.029,29,Yes,2008 year of delivery,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type",2,2004 year of delivery,Black,1.06,0.93,1.21
10.1016/j.ajog.2015.01.029,30,Yes,2009 year of delivery,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type",1,2004 year of delivery,White,1.15,1.05,1.26
10.1016/j.ajog.2015.01.029,30,Yes,2009 year of delivery,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type",2,2004 year of delivery,Black,1.07,0.94,1.23
10.1016/j.ajog.2015.01.029,31,Yes,2010 year of delivery,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type",1,2004 year of delivery,White,1.08,0.98,1.19
10.1016/j.ajog.2015.01.029,31,Yes,2010 year of delivery,No,NA,Primary cesarean delivery,RR,NA,"maternal age, parity, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type",2,2004 year of delivery,Black,1.02,0.89,1.17
10.1016/j.ajog.2015.01.029,32,Yes,maternal age <20,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,maternal age 20-29,White,0.95,0.84,1.07
10.1016/j.ajog.2015.01.029,32,Yes,maternal age <20,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,maternal age 20-29,Black,0.83,0.74,0.93
10.1016/j.ajog.2015.01.029,33,Yes,maternal age 30-34,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,maternal age 20-29,White,1.17,1.1,1.25
10.1016/j.ajog.2015.01.029,33,Yes,maternal age 30-34,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,maternal age 20-29,Black,1.21,1.06,1.37
10.1016/j.ajog.2015.01.029,34,Yes,maternal age >=35,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,maternal age 20-29,White,1.43,1.33,1.55
10.1016/j.ajog.2015.01.029,34,Yes,maternal age >=35,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,maternal age 20-29,Black,1.56,1.37,1.78
10.1016/j.ajog.2015.01.029,36,Yes,Medicaid/uninsured,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,private insurance,White,0.91,0.83,1
10.1016/j.ajog.2015.01.029,36,Yes,Medicaid/uninsured,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,private insurance,Black,0.99,0.9,1.1
10.1016/j.ajog.2015.01.029,37,Yes,unmarried,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,married,White,0.94,0.88,1.02
10.1016/j.ajog.2015.01.029,37,Yes,unmarried,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,married,Black,0.93,0.83,1.03
10.1016/j.ajog.2015.01.029,38,Yes,diabetes,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,N/A,White,1.28,1.09,1.49
10.1016/j.ajog.2015.01.029,38,Yes,diabetes,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,N/A,Black,1.1,0.87,1.38
10.1016/j.ajog.2015.01.029,39,Yes,chronic hypertension,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,N/A,White,1.14,1.01,1.28
10.1016/j.ajog.2015.01.029,39,Yes,chronic hypertension,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,N/A,Black,1.19,1.01,1.4
10.1016/j.ajog.2015.01.029,40,Yes,BMI <18.5,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,BMI 18.5-24.9,White,0.68,0.53,0.87
10.1016/j.ajog.2015.01.029,40,Yes,BMI <18.5,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,BMI 18.5-24.9,Black,0.89,0.66,1.21
10.1016/j.ajog.2015.01.029,41,Yes,BMI 25.0-29.9,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,BMI 18.5-24.9,White,1.14,1.05,1.22
10.1016/j.ajog.2015.01.029,41,Yes,BMI 25.0-29.9,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,BMI 18.5-24.9,Black,1.25,1.11,1.41
10.1016/j.ajog.2015.01.029,42,Yes,BMI >= 30.0,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,BMI 18.5-24.9,White,1.55,1.45,1.66
10.1016/j.ajog.2015.01.029,42,Yes,BMI >= 30.0,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,BMI 18.5-24.9,Black,1.52,1.37,1.7
10.1016/j.ajog.2015.01.029,43,Yes,excess weight gain,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,N/A,White,1.29,1.21,1.38
10.1016/j.ajog.2015.01.029,43,Yes,excess weight gain,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,N/A,Black,1.17,1.06,1.29
10.1016/j.ajog.2015.01.029,44,Yes,gestational diabetes,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,N/A,White,1.26,1.13,1.39
10.1016/j.ajog.2015.01.029,44,Yes,gestational diabetes,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,N/A,Black,1.2,1.03,1.4
10.1016/j.ajog.2015.01.029,45,Yes,gestational hypertensive disorders,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,N/A,White,1.43,1.32,1.54
10.1016/j.ajog.2015.01.029,45,Yes,gestational hypertensive disorders,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,N/A,Black,1.36,1.2,1.54
10.1016/j.ajog.2015.01.029,46,Yes,macrosomia,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,N/A,White,1.49,1.39,1.61
10.1016/j.ajog.2015.01.029,46,Yes,macrosomia,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,N/A,Black,1.34,1.16,1.56
10.1016/j.ajog.2015.01.029,47,Yes,gestational age <34,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,gestational age 39-40,White,1.46,1.26,1.69
10.1016/j.ajog.2015.01.029,47,Yes,gestational age <34,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,gestational age 39-40,Black,1.3,1.07,1.58
10.1016/j.ajog.2015.01.029,48,Yes,gestational age 34-36,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,gestational age 39-40,White,1.04,0.92,1.16
10.1016/j.ajog.2015.01.029,48,Yes,gestational age 34-36,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,gestational age 39-40,Black,1,0.85,1.18
10.1016/j.ajog.2015.01.029,49,Yes,gestational age 37-38,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,gestational age 39-40,White,0.96,0.9,1.04
10.1016/j.ajog.2015.01.029,49,Yes,gestational age 37-38,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,gestational age 39-40,Black,0.82,0.73,0.92
10.1016/j.ajog.2015.01.029,50,Yes,gestational age 41,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,gestational age 39-40,White,1.27,1.16,1.39
10.1016/j.ajog.2015.01.029,50,Yes,gestational age 41,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,gestational age 39-40,Black,1.31,1.17,1.47
10.1016/j.ajog.2015.01.029,51,Yes,gestational age >=42,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,gestational age 39-40,White,1.71,1.4,2.09
10.1016/j.ajog.2015.01.029,51,Yes,gestational age >=42,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,gestational age 39-40,Black,1.1,0.62,1.96
10.1016/j.ajog.2015.01.029,52,Yes,labor induction,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,N/A,White,1.13,1.07,1.2
10.1016/j.ajog.2015.01.029,52,Yes,labor induction,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,N/A,Black,1.32,1.2,1.44
10.1016/j.ajog.2015.01.029,53,Yes,PROM,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,N/A,White,1.09,0.89,1.35
10.1016/j.ajog.2015.01.029,53,Yes,PROM,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,N/A,Black,0.95,0.67,1.34
10.1016/j.ajog.2015.01.029,54,Yes,private patient type,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,service patient type,White,1.15,1.03,1.27
10.1016/j.ajog.2015.01.029,54,Yes,private patient type,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,service patient type,Black,1.04,0.95,1.15
10.1016/j.ajog.2015.01.029,55,Yes,2005 year of delivery,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,2004 year of delivery,White,0.92,0.83,1.02
10.1016/j.ajog.2015.01.029,55,Yes,2005 year of delivery,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,2004 year of delivery,Black,0.82,0.69,0.96
10.1016/j.ajog.2015.01.029,56,Yes,2006 year of delivery,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,2004 year of delivery,White,1,0.91,1.11
10.1016/j.ajog.2015.01.029,56,Yes,2006 year of delivery,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,2004 year of delivery,Black,0.91,0.78,1.06
10.1016/j.ajog.2015.01.029,57,Yes,2007 year of delivery,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,2004 year of delivery,White,1.07,0.97,1.19
10.1016/j.ajog.2015.01.029,57,Yes,2007 year of delivery,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,2004 year of delivery,Black,0.94,0.81,1.1
10.1016/j.ajog.2015.01.029,58,Yes,2008 year of delivery,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,2004 year of delivery,White,0.95,0.86,1.05
10.1016/j.ajog.2015.01.029,58,Yes,2008 year of delivery,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,2004 year of delivery,Black,0.94,0.81,1.09
10.1016/j.ajog.2015.01.029,59,Yes,2009 year of delivery,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,2004 year of delivery,White,0.98,0.88,1.08
10.1016/j.ajog.2015.01.029,59,Yes,2009 year of delivery,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,2004 year of delivery,Black,0.93,0.8,1.08
10.1016/j.ajog.2015.01.029,60,Yes,2010 year of delivery,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,2004 year of delivery,White,0.98,0.89,1.09
10.1016/j.ajog.2015.01.029,60,Yes,2010 year of delivery,Yes,nulliparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,2004 year of delivery,Black,0.93,0.8,1.08
10.1016/j.ajog.2015.01.029,61,Yes,maternal age <20,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,maternal age 20-29,White,0.9,0.6,1.37
10.1016/j.ajog.2015.01.029,61,Yes,maternal age <20,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,maternal age 20-29,Black,1.36,1.02,1.81
10.1016/j.ajog.2015.01.029,62,Yes,maternal age 30-34,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,maternal age 20-29,White,1.09,0.93,1.28
10.1016/j.ajog.2015.01.029,62,Yes,maternal age 30-34,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,maternal age 20-29,Black,0.92,0.75,1.13
10.1016/j.ajog.2015.01.029,63,Yes,maternal age >=35,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,maternal age 20-29,White,1.3,1.11,1.52
10.1016/j.ajog.2015.01.029,63,Yes,maternal age >=35,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,maternal age 20-29,Black,1.72,1.43,2.08
10.1016/j.ajog.2015.01.029,64,Yes,Medicaid/uninsured,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,private insurance,White,0.93,0.77,1.12
10.1016/j.ajog.2015.01.029,64,Yes,Medicaid/uninsured,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,private insurance,Black,0.97,0.81,1.16
10.1016/j.ajog.2015.01.029,65,Yes,unmarried,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,married,White,1.18,0.99,1.39
10.1016/j.ajog.2015.01.029,65,Yes,unmarried,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,married,Black,1.13,0.95,1.35
10.1016/j.ajog.2015.01.029,66,Yes,diabetes,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,N/A,White,1.11,0.71,1.74
10.1016/j.ajog.2015.01.029,66,Yes,diabetes,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,N/A,Black,1.27,0.77,2.08
10.1016/j.ajog.2015.01.029,67,Yes,chronic hypertension,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,N/A,White,1.27,0.94,1.7
10.1016/j.ajog.2015.01.029,67,Yes,chronic hypertension,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,N/A,Black,1.13,0.87,1.47
10.1016/j.ajog.2015.01.029,68,Yes,BMI <18.5,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,BMI 18.5-24.9,White,0.87,0.57,1.31
10.1016/j.ajog.2015.01.029,68,Yes,BMI <18.5,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,BMI 18.5-24.9,Black,0.54,0.25,1.17
10.1016/j.ajog.2015.01.029,69,Yes,BMI 25.0-29.9,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,BMI 18.5-24.9,White,1.2,1.02,1.41
10.1016/j.ajog.2015.01.029,69,Yes,BMI 25.0-29.9,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,BMI 18.5-24.9,Black,1.29,1.05,1.59
10.1016/j.ajog.2015.01.029,70,Yes,BMI >= 30.0,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,BMI 18.5-24.9,White,1.81,1.56,2.11
10.1016/j.ajog.2015.01.029,70,Yes,BMI >= 30.0,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,BMI 18.5-24.9,Black,1.44,1.18,1.77
10.1016/j.ajog.2015.01.029,71,Yes,excess weight gain,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,N/A,White,1.36,1.19,1.56
10.1016/j.ajog.2015.01.029,71,Yes,excess weight gain,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,N/A,Black,1,1.02,1.41
10.1016/j.ajog.2015.01.029,72,Yes,gestational diabetes,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,N/A,White,1.31,1.04,1.67
10.1016/j.ajog.2015.01.029,72,Yes,gestational diabetes,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,N/A,Black,1.31,0.99,1.75
10.1016/j.ajog.2015.01.029,73,Yes,gestational hypertensive disorders,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,N/A,White,1.67,1.37,2.02
10.1016/j.ajog.2015.01.029,73,Yes,gestational hypertensive disorders,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,N/A,Black,1.5,1.2,1.87
10.1016/j.ajog.2015.01.029,74,Yes,macrosomia,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,N/A,White,1.77,1.5,2.08
10.1016/j.ajog.2015.01.029,74,Yes,macrosomia,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,N/A,Black,2.31,1.84,2.9
10.1016/j.ajog.2015.01.029,75,Yes,gestational age <34,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,gestational age 39-40,White,3.91,3.09,4.94
10.1016/j.ajog.2015.01.029,75,Yes,gestational age <34,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,gestational age 39-40,Black,3.23,2.52,4.13
10.1016/j.ajog.2015.01.029,76,Yes,gestational age 34-36,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,gestational age 39-40,White,2.1,1.71,2.58
10.1016/j.ajog.2015.01.029,76,Yes,gestational age 34-36,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,gestational age 39-40,Black,1.79,1.42,2.26
10.1016/j.ajog.2015.01.029,77,Yes,gestational age 37-38,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,gestational age 39-40,White,1.19,1.02,1.38
10.1016/j.ajog.2015.01.029,77,Yes,gestational age 37-38,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,gestational age 39-40,Black,0.96,0.79,1.16
10.1016/j.ajog.2015.01.029,78,Yes,gestational age 41,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,gestational age 39-40,White,1.36,1.04,1.77
10.1016/j.ajog.2015.01.029,78,Yes,gestational age 41,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,gestational age 39-40,Black,1.7,1.32,2.19
10.1016/j.ajog.2015.01.029,79,Yes,gestational age >=42,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,gestational age 39-40,White,1.27,0.42,3.88
10.1016/j.ajog.2015.01.029,79,Yes,gestational age >=42,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,gestational age 39-40,Black,2.85,1.35,6.04
10.1016/j.ajog.2015.01.029,80,Yes,labor induction,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,N/A,White,0.63,0.55,0.72
10.1016/j.ajog.2015.01.029,80,Yes,labor induction,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,N/A,Black,1.08,0.92,1.28
10.1016/j.ajog.2015.01.029,81,Yes,PROM,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,N/A,White,1.09,0.59,2.01
10.1016/j.ajog.2015.01.029,81,Yes,PROM,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,N/A,Black,1.43,0.89,2.3
10.1016/j.ajog.2015.01.029,82,Yes,private patient type,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,service patient type,White,0.97,0.8,1.17
10.1016/j.ajog.2015.01.029,82,Yes,private patient type,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,service patient type,Black,1.24,1.05,1.47
10.1016/j.ajog.2015.01.029,83,Yes,2005 year of delivery,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,2004 year of delivery,White,1.05,0.82,1.35
10.1016/j.ajog.2015.01.029,83,Yes,2005 year of delivery,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,2004 year of delivery,Black,1.13,0.83,1.55
10.1016/j.ajog.2015.01.029,84,Yes,2006 year of delivery,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,2004 year of delivery,White,0.98,0.75,1.26
10.1016/j.ajog.2015.01.029,84,Yes,2006 year of delivery,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,2004 year of delivery,Black,0.87,0.63,1.22
10.1016/j.ajog.2015.01.029,85,Yes,2007 year of delivery,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,2004 year of delivery,White,1.31,1.03,1.67
10.1016/j.ajog.2015.01.029,85,Yes,2007 year of delivery,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,2004 year of delivery,Black,1.17,0.87,1.58
10.1016/j.ajog.2015.01.029,86,Yes,2008 year of delivery,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,2004 year of delivery,White,1.62,1.28,2.04
10.1016/j.ajog.2015.01.029,86,Yes,2008 year of delivery,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,2004 year of delivery,Black,1.43,1.07,1.91
10.1016/j.ajog.2015.01.029,87,Yes,2009 year of delivery,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,2004 year of delivery,White,1.83,1.46,2.3
10.1016/j.ajog.2015.01.029,87,Yes,2009 year of delivery,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,2004 year of delivery,Black,1.48,1.11,1.97
10.1016/j.ajog.2015.01.029,88,Yes,2010 year of delivery,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",1,2004 year of delivery,White,1.48,1.16,1.9
10.1016/j.ajog.2015.01.029,88,Yes,2010 year of delivery,Yes,multiparous,Primary cesarean delivery,RR,NA,"maternal age, insurance type, marital status, diabetes, chronic hypertension, BMI, excess weight gain, gestational diabetes, gestational hypertensive disorders, macrosomia, gestational age, labor induction, PROM, patient type, year of delivery",2,2004 year of delivery,Black,1.31,0.97,1.78
10.1016/j.ygyno.2015.05.025,9,No,NA,No,NA,recurrence free survival,HR,NA,"endometrial cancer type, age",1,White,Black,2.64,1.36,5.12
10.1016/j.ygyno.2015.05.025,10,No,NA,No,NA,overall surviva,HR,NA,"endometrial cancer type, age",1,White,Black,2.76,1.28,5.98
10.1016/j.ygyno.2014.10.021,25,No,NA,No,NA,endometrial cancer five-year survival,Percent,NA,None,1,N/A,Non Hispanic Whites,86.6,-99,-99
10.1016/j.ygyno.2014.10.021,25,No,NA,No,NA,endometrial cancer five-year survival,Percent,NA,None,2,N/A,U.S. born Hispanics,79.6,-99,-99
10.1016/j.ygyno.2014.10.021,25,No,NA,No,NA,endometrial cancer five-year survival,Percent,NA,None,3,N/A,Foreign born Hispanics,78.4,-99,-99
10.1016/j.ygyno.2014.10.021,25,No,NA,No,NA,endometrial cancer five-year survival,Percent,NA,None,4,N/A,Birthplace-unknown Hispanics,91.6,-99,-99
10.1016/j.ygyno.2014.10.021,26,No,NA,Yes,2000-2005,endometrial cancer five-year survival,Percent,NA,None,1,N/A,Non Hispanic Whites,86.5,-99,-99
10.1016/j.ygyno.2014.10.021,26,No,NA,Yes,2000-2005,endometrial cancer five-year survival,Percent,NA,None,2,N/A,U.S. born Hispanics,80.3,-99,-99
10.1016/j.ygyno.2014.10.021,26,No,NA,Yes,2000-2005,endometrial cancer five-year survival,Percent,NA,None,3,N/A,Foreign born Hispanics,80,-99,-99
10.1016/j.ygyno.2014.10.021,26,No,NA,Yes,2000-2005,endometrial cancer five-year survival,Percent,NA,None,4,N/A,Birthplace-unknown Hispanics,90.9,-99,-99
10.1016/j.ygyno.2014.10.021,27,No,NA,Yes,2006-2010,endometrial cancer five-year survival,Percent,NA,None,1,N/A,Non Hispanic Whites,87.4,-99,-99
10.1016/j.ygyno.2014.10.021,27,No,NA,Yes,2006-2010,endometrial cancer five-year survival,Percent,NA,None,2,N/A,U.S. born Hispanics,78.8,-99,-99
10.1016/j.ygyno.2014.10.021,27,No,NA,Yes,2006-2010,endometrial cancer five-year survival,Percent,NA,None,3,N/A,Foreign born Hispanics,76.9,-99,-99
10.1016/j.ygyno.2014.10.021,27,No,NA,Yes,2006-2010,endometrial cancer five-year survival,Percent,NA,None,4,N/A,Birthplace-unknown Hispanics,92.3,-99,-99
10.1016/j.ajog.2012.01.040,2,Yes,group care,No,NA,preterm delivery at 37 weeks' gestation,Percent,NA,None,1,N/A,White,6.5,-99,-99
10.1016/j.ajog.2012.01.040,2,Yes,group care,No,NA,preterm delivery at 37 weeks' gestation,Percent,NA,None,2,N/A,Black,7.5,-99,-99
10.1016/j.ajog.2012.01.040,2,Yes,group care,No,NA,preterm delivery at 37 weeks' gestation,Percent,NA,None,3,N/A,Hispanic,7.3,-99,-99
10.1016/j.ajog.2012.01.040,2,Yes,group care,No,NA,preterm delivery at 37 weeks' gestation,Percent,NA,None,4,N/A,Other,12.8,-99,-99
10.1016/j.ajog.2012.01.040,3,Yes,traditional care,No,NA,preterm delivery at 37 weeks' gestation,Percent,NA,None,1,N/A,White,13.7,-99,-99
10.1016/j.ajog.2012.01.040,3,Yes,traditional care,No,NA,preterm delivery at 37 weeks' gestation,Percent,NA,None,2,N/A,Black,16.1,-99,-99
10.1016/j.ajog.2012.01.040,3,Yes,traditional care,No,NA,preterm delivery at 37 weeks' gestation,Percent,NA,None,3,N/A,Hispanic,7,-99,-99
10.1016/j.ajog.2012.01.040,3,Yes,traditional care,No,NA,preterm delivery at 37 weeks' gestation,Percent,NA,None,4,N/A,Other,11.4,-99,-99
10.1016/j.ygyno.2011.02.006,3,Yes,advanced stage disease,No,NA,median survival,months,NA,None,1,N/A,Caucasian,32,NA,29
10.1016/j.ygyno.2011.03.018,8,Yes,1995-1999,No,NA,vaginal cancer survival,HR,NA,"age, stage, treatment modality, nodal metastasis",1,White,African American,1.2,0.9,1.6
10.1016/j.ygyno.2011.03.018,9,Yes,2000-2007,No,NA,vaginal cancer survival,HR,NA,"age, stage, treatment modality, nodal metastasis",1,White,African American,1.3,1.1,1.6
10.1016/j.ygyno.2011.03.018,10,No,NA,No,NA,vaginal cancer survival,HR,NA,"age, stage, treatment, lymphadenectomy, nodal metastasis",1,White,African American,1.2,1.1,1.4
10.1016/j.fertnstert.2013.10.055,21,Yes,age 20-34 y; NHANES,No,NA,triglyceride levels (>= 150 mg/dL),Prevalence,NA,None,1,N/A,White,15.5,-99,-99
10.1016/j.fertnstert.2013.10.055,21,Yes,age 20-34 y; NHANES,No,NA,triglyceride levels (>= 150 mg/dL),Prevalence,NA,None,2,N/A,Black,9.9,-99,-99
10.1016/j.fertnstert.2013.10.055,22,Yes,age 20-34 y; NHANES,No,NA,high density lipoprotein cholesterol levels (<= 50 mg/dL),Prevalence,NA,None,1,N/A,White,39.9,-99,-99
10.1016/j.fertnstert.2013.10.055,22,Yes,age 20-34 y; NHANES,No,NA,high density lipoprotein cholesterol levels (<= 50 mg/dL),Prevalence,NA,None,2,N/A,Black,42.9,-99,-99
10.1016/j.fertnstert.2013.10.055,23,Yes,age 20-34 y; NHANES,No,NA,blood pressure (mm Hg >= 130/85 mm Hg),Prevalence,NA,None,1,N/A,White,3.3,-99,-99
10.1016/j.fertnstert.2013.10.055,23,Yes,age 20-34 y; NHANES,No,NA,blood pressure (mm Hg >= 130/85 mm Hg),Prevalence,NA,None,2,N/A,Black,10.6,-99,-99
10.1016/j.fertnstert.2013.10.055,24,Yes,age 20-34 y; NHANES,No,NA,glucose (>= 100 mg/dL),Prevalence,NA,None,1,N/A,White,9,-99,-99
10.1016/j.fertnstert.2013.10.055,24,Yes,age 20-34 y; NHANES,No,NA,glucose (>= 100 mg/dL),Prevalence,NA,None,2,N/A,Black,8.3,-99,-99
10.1016/j.fertnstert.2013.10.055,25,Yes,age <20 y,No,NA,metabolic syndrome,RR,NA,None,1,PCOS white,PCOS black,2.65,1.29,5.4
10.1016/j.fertnstert.2013.10.055,26,Yes,age 20-34 y,No,NA,metabolic syndrome,RR,NA,None,1,PCOS white,PCOS black,1.44,1.21,2.6
10.1016/j.fertnstert.2013.10.055,27,Yes,age <20 y,No,NA,metabolic syndrome,RR,NA,None,1,NHANES white,NHANES black,0.95,0.4,2.25
10.1016/j.fertnstert.2013.10.055,28,Yes,age 20-34 y,No,NA,metabolic syndrome,RR,NA,None,1,NHANES white,NHANES black,1.13,0.58,2.21
10.1016/j.fertnstert.2013.10.055,29,Yes,age <20 y,No,NA,metabolic syndrome,RR,NA,None,1,PCOS white,NHANES white,3.72,1.9,7.25
10.1016/j.fertnstert.2013.10.055,30,Yes,age 20-34 y,No,NA,metabolic syndrome,RR,NA,None,1,PCOS white,NHANES white,1.52,1.04,2.24
10.1016/j.fertnstert.2013.10.055,31,Yes,age <20 y,No,NA,metabolic syndrome,RR,NA,None,1,PCOS black,NHANES black,10.13,5.1,20.13
10.1016/j.fertnstert.2013.10.055,32,Yes,age 20-34 y,No,NA,metabolic syndrome,RR,NA,None,1,PCOS black,NHANES black,2.42,1.52,3.83
10.1093/humrep/deq177,4,No,NA,No,NA,cervical insufficiency,OR,NA,"pregnancy terminations, mother's age, marital status, alcohol use, history of diabetes, pregnancy induced hypertension, anemia in pregnancy, genital herpes, renal disease, hydramnios/aligohydramnios, mother's education level, prenatal care adequacy, live births now living, live births now dead",1,White,Black,2.18,2.02,2.36
10.1093/humrep/deq177,4,No,NA,No,NA,cervical insufficiency,OR,NA,"pregnancy terminations, mother's age, marital status, alcohol use, history of diabetes, pregnancy induced hypertension, anemia in pregnancy, genital herpes, renal disease, hydramnios/aligohydramnios, mother's education level, prenatal care adequacy, live births now living, live births now dead",2,White,Asian/Pacific Islander,0.97,0.81,1.16
10.1093/humrep/deq177,4,No,NA,No,NA,cervical insufficiency,OR,NA,"pregnancy terminations, mother's age, marital status, alcohol use, history of diabetes, pregnancy induced hypertension, anemia in pregnancy, genital herpes, renal disease, hydramnios/aligohydramnios, mother's education level, prenatal care adequacy, live births now living, live births now dead",3,White,American Indian/Alaskan Native,1.02,0.75,1.38
10.1016/j.fertnstert.2010.02.054,1,No,NA,No,NA,Utilization of Complementary and Alternative Treatment,OR,NA,None,1,Non-White,White,0.9,0.57,1.41
10.1097/AOG.0b013e3181da9423,1,Yes,NIH,No,NA,BMI cut-off value sensitivity,Percent,NA,None,1,N/A,White,47.8,38.7,57
10.1097/AOG.0b013e3181da9423,1,Yes,NIH,No,NA,BMI cut-off value sensitivity,Percent,NA,None,2,N/A,Black,75,65.5,82.6
10.1097/AOG.0b013e3181da9423,1,Yes,NIH,No,NA,BMI cut-off value sensitivity,Percent,NA,None,3,N/A,Hispanic,53.9,45.7,61.8
10.1097/AOG.0b013e3181da9423,1,Yes,NIH,No,NA,BMI cut-off value sensitivity,Percent,NA,None,4,N/A,Overall,57.7,52.5,62.8
10.1097/AOG.0b013e3181da9423,2,Yes,NIH,No,NA,BMI cut-off value specificity,Percent,NA,None,1,N/A,White,100,95.3,100
10.1097/AOG.0b013e3181da9423,2,Yes,NIH,No,NA,BMI cut-off value specificity,Percent,NA,None,2,N/A,Black,96.8,89.1,99.1
10.1097/AOG.0b013e3181da9423,2,Yes,NIH,No,NA,BMI cut-off value specificity,Percent,NA,None,3,N/A,Hispanic,98.4,91.7,99.7
10.1097/AOG.0b013e3181da9423,2,Yes,NIH,No,NA,BMI cut-off value specificity,Percent,NA,None,4,N/A,Overall,98.5,95.8,99.5
10.1097/AOG.0b013e3181da9423,3,Yes,Rahman et al.,No,NA,BMI cut-off value sensitivity,Percent,NA,None,1,N/A,White,85.6,77.9,90.1
10.1097/AOG.0b013e3181da9423,3,Yes,Rahman et al.,No,NA,BMI cut-off value sensitivity,Percent,NA,None,2,N/A,Black,81.3,72.3,87.8
10.1097/AOG.0b013e3181da9423,3,Yes,Rahman et al.,No,NA,BMI cut-off value sensitivity,Percent,NA,None,3,N/A,Hispanic,83.2,76.2,88.5
10.1097/AOG.0b013e3181da9423,3,Yes,Rahman et al.,No,NA,BMI cut-off value sensitivity,Percent,NA,None,4,N/A,Overall,83.4,79.1,87
10.1097/AOG.0b013e3181da9423,4,Yes,Rahman et al.,No,NA,BMI cut-off value specificity,Percent,NA,None,1,N/A,White,93.6,85.9,97.2
10.1097/AOG.0b013e3181da9423,4,Yes,Rahman et al.,No,NA,BMI cut-off value specificity,Percent,NA,None,2,N/A,Black,90.5,80.7,95.6
10.1097/AOG.0b013e3181da9423,4,Yes,Rahman et al.,No,NA,BMI cut-off value specificity,Percent,NA,None,3,N/A,Hispanic,87.5,77.2,93.5
10.1097/AOG.0b013e3181da9423,4,Yes,Rahman et al.,No,NA,BMI cut-off value specificity,Percent,NA,None,4,N/A,Overall,90.7,86,94
10.1097/AOG.0b013e3181da9423,5,No,NA,No,NA,actual obesity rate based on WHO criterion standard,Percent,NA,None,1,N/A,White,58.7,51.4,65.8
10.1097/AOG.0b013e3181da9423,5,No,NA,No,NA,actual obesity rate based on WHO criterion standard,Percent,NA,None,2,N/A,Black,60.4,52.3,68
10.1097/AOG.0b013e3181da9423,5,No,NA,No,NA,actual obesity rate based on WHO criterion standard,Percent,NA,None,3,N/A,Hispanic,69.1,62.3,75.3
10.1097/AOG.0b013e3181da9423,5,No,NA,No,NA,actual obesity rate based on WHO criterion standard,Percent,NA,None,4,N/A,Overall,63.1,58.9,67.1
10.1097/AOG.0b013e3181da9423,6,No,NA,No,NA,obesity rate based on NIH's BMI cut off value,Percent,NA,None,1,N/A,White,28,21.8,35
10.1097/AOG.0b013e3181da9423,6,No,NA,No,NA,obesity rate based on NIH's BMI cut off value,Percent,NA,None,2,N/A,Black,46.5,38.6,54.6
10.1097/AOG.0b013e3181da9423,6,No,NA,No,NA,obesity rate based on NIH's BMI cut off value,Percent,NA,None,3,N/A,Hispanic,37.7,31.1,44.7
10.1097/AOG.0b013e3181da9423,6,No,NA,No,NA,obesity rate based on NIH's BMI cut off value,Percent,NA,None,4,N/A,Overall,36.9,32.9,41.1
10.1097/AOG.0b013e3181da9423,7,No,NA,No,NA,obesity rate based on rate/ethnicity specific BMI cut off value,Percent,NA,None,1,N/A,White,52.9,45.5,60.2
10.1097/AOG.0b013e3181da9423,7,No,NA,No,NA,obesity rate based on rate/ethnicity specific BMI cut off value,Percent,NA,None,2,N/A,Black,52.8,44.8,60.8
10.1097/AOG.0b013e3181da9423,7,No,NA,No,NA,obesity rate based on rate/ethnicity specific BMI cut off value,Percent,NA,None,3,N/A,Hispanic,61.4,54.4,68
10.1097/AOG.0b013e3181da9423,7,No,NA,No,NA,obesity rate based on rate/ethnicity specific BMI cut off value,Percent,NA,None,4,N/A,Overall,56,51.8,60.2
10.1016/j.ajog.2011.05.014,1,Yes,Natural menopause,No,NA,mean age at menopause,age,NA,None,1,N/A,White,49.2,-99,-99
10.1016/j.ajog.2011.05.014,1,Yes,Natural menopause,No,NA,mean age at menopause,age,NA,None,2,N/A,Black,48.8,-99,-99
10.1016/j.ajog.2011.05.014,2,Yes,Surgical menopause,No,NA,mean age at menopause,age,NA,None,1,N/A,White,39.5,-99,-99
10.1016/j.ajog.2011.05.014,2,Yes,Surgical menopause,No,NA,mean age at menopause,age,NA,None,2,N/A,Black,40,-99,-99
10.1016/j.ajog.2011.05.014,3,No,NA,No,NA,mean age at menopause,age,NA,"region, age, parity, annual income, education level, self-reported history of CVD, physical activity per week, smoking",1,N/A,White,48.1,-99,-99
10.1016/j.ajog.2011.05.014,3,No,NA,No,NA,mean age at menopause,age,NA,"region, age, parity, annual income, education level, self-reported history of CVD, physical activity per week, smoking",2,N/A,Black,48,-99,-99
10.1016/j.ajog.2014.06.006,64,Yes,White serving hospitals,No,NA,blood transfusion,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year",1,Whites,Blacks,2.16,1.97,2.38
10.1016/j.ajog.2014.06.006,64,Yes,White serving hospitals,No,NA,blood transfusion,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year",2,Whites,Hispanics,1.44,1.32,1.56
10.1016/j.ajog.2014.06.006,65,Yes,White serving hospitals,No,NA,blood transfusion,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, state-level household income quartile for patient ZIP code",1,Whites,Blacks,1.93,1.77,2.11
10.1016/j.ajog.2014.06.006,65,Yes,White serving hospitals,No,NA,blood transfusion,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, state-level household income quartile for patient ZIP code",2,Whites,Hispanics,1.32,1.22,1.44
10.1016/j.ajog.2014.06.006,66,Yes,White serving hospitals,No,NA,blood transfusion,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, state-level household income quartile for patient ZIP code, hospital location",1,Whites,Blacks,1.94,1.78,2.11
10.1016/j.ajog.2014.06.006,66,Yes,White serving hospitals,No,NA,blood transfusion,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, state-level household income quartile for patient ZIP code, hospital location",2,Whites,Hispanics,1.33,1.22,1.44
10.1016/j.ajog.2014.06.006,67,Yes,White serving hospitals,No,NA,in hospital mortality,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year",1,Whites,Blacks,3.15,1.68,5.9
10.1016/j.ajog.2014.06.006,67,Yes,White serving hospitals,No,NA,in hospital mortality,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year",2,Whites,Hispanics,0.97,0.44,2.13
10.1016/j.ajog.2014.06.006,68,Yes,White serving hospitals,No,NA,in hospital mortality,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, state-level household income quartile for patient ZIP code",1,Whites,Blacks,2.36,1.18,4.69
10.1016/j.ajog.2014.06.006,68,Yes,White serving hospitals,No,NA,in hospital mortality,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, state-level household income quartile for patient ZIP code",2,Whites,Hispanics,0.83,0.37,1.89
10.1016/j.ajog.2014.06.006,69,Yes,White serving hospitals,No,NA,in hospital mortality,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, state-level household income quartile for patient ZIP code, hospital location",1,Whites,Blacks,2.32,1.16,4.63
10.1016/j.ajog.2014.06.006,69,Yes,White serving hospitals,No,NA,in hospital mortality,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, state-level household income quartile for patient ZIP code, hospital location",2,Whites,Hispanics,0.83,0.37,1.87
10.1016/j.ajog.2014.06.006,70,Yes,Black serving hospitals,No,NA,blood transfusion,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year",1,Whites,Blacks,1.67,1.45,1.92
10.1016/j.ajog.2014.06.006,70,Yes,Black serving hospitals,No,NA,blood transfusion,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year",2,Whites,Hispanics,1.16,0.86,1.57
10.1016/j.ajog.2014.06.006,71,Yes,Black serving hospitals,No,NA,blood transfusion,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, state-level household income quartile for patient ZIP code",1,Whites,Blacks,1.7,1.47,1.97
10.1016/j.ajog.2014.06.006,71,Yes,Black serving hospitals,No,NA,blood transfusion,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, state-level household income quartile for patient ZIP code",2,Whites,Hispanics,1.16,0.87,1.54
10.1016/j.ajog.2014.06.006,72,Yes,Black serving hospitals,No,NA,blood transfusion,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, state-level household income quartile for patient ZIP code, hospital location",1,Whites,Blacks,1.65,1.41,1.93
10.1016/j.ajog.2014.06.006,72,Yes,Black serving hospitals,No,NA,blood transfusion,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, state-level household income quartile for patient ZIP code, hospital location",2,Whites,Hispanics,1.18,0.87,1.6
10.1016/j.ajog.2014.06.006,73,Yes,Black serving hospitals,No,NA,in hospital mortality,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year",1,Whites,Blacks,0.79,0.15,4.32
10.1016/j.ajog.2014.06.006,74,Yes,Black serving hospitals,No,NA,in hospital mortality,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, state-level household income quartile for patient ZIP code",1,Whites,Blacks,0.94,0.12,5.68
10.1016/j.ajog.2014.06.006,75,Yes,Black serving hospitals,No,NA,in hospital mortality,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, state-level household income quartile for patient ZIP code, hospital location",1,Whites,Blacks,1.1,0.12,9.94
10.1016/j.ajog.2014.06.006,76,Yes,Hispanic serving hospitals,No,NA,blood transfusion,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year",1,Whites,Blacks,1.89,1.65,2.16
10.1016/j.ajog.2014.06.006,76,Yes,Hispanic serving hospitals,No,NA,blood transfusion,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year",2,Whites,Hispanics,1.14,1.03,1.25
10.1016/j.ajog.2014.06.006,77,Yes,Hispanic serving hospitals,No,NA,blood transfusion,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, state-level household income quartile for patient ZIP code",1,Whites,Blacks,1.63,1.43,1.84
10.1016/j.ajog.2014.06.006,77,Yes,Hispanic serving hospitals,No,NA,blood transfusion,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, state-level household income quartile for patient ZIP code",2,Whites,Hispanics,1.04,0.95,1.14
10.1016/j.ajog.2014.06.006,78,Yes,Hispanic serving hospitals,No,NA,blood transfusion,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, state-level household income quartile for patient ZIP code, hospital location",1,Whites,Blacks,1.59,1.41,1.8
10.1016/j.ajog.2014.06.006,78,Yes,Hispanic serving hospitals,No,NA,blood transfusion,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, state-level household income quartile for patient ZIP code, hospital location",2,Whites,Hispanics,1.05,0.96,1.15
10.1016/j.ajog.2014.06.006,79,Yes,Hispanic serving hospitals,No,NA,in hospital mortality,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year",1,Whites,Blacks,2.45,1.09,5.51
10.1016/j.ajog.2014.06.006,79,Yes,Hispanic serving hospitals,No,NA,in hospital mortality,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year",2,Whites,Hispanics,1.14,0.6,2.16
10.1016/j.ajog.2014.06.006,80,Yes,Hispanic serving hospitals,No,NA,in hospital mortality,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, state-level household income quartile for patient ZIP code",1,Whites,Blacks,1.75,0.76,4.04
10.1016/j.ajog.2014.06.006,80,Yes,Hispanic serving hospitals,No,NA,in hospital mortality,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, state-level household income quartile for patient ZIP code",2,Whites,Hispanics,1.04,0.53,2.01
10.1016/j.ajog.2014.06.006,81,Yes,Hispanic serving hospitals,No,NA,in hospital mortality,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, state-level household income quartile for patient ZIP code, hospital location",1,Whites,Blacks,1.74,0.76,3.96
10.1016/j.ajog.2014.06.006,81,Yes,Hispanic serving hospitals,No,NA,in hospital mortality,RR,NA,"age, chronic condition, teaching hospital, multihospital system membership, hospital ownership, hospital delivery volume for index year, state, year, insurance coverage for delivery, state-level household income quartile for patient ZIP code, hospital location",2,Whites,Hispanics,1.06,0.55,2.04
10.1097/AOG.0b013e3182a92011,8,Yes,incomplete treatment,No,NA,mortality,HR,NA,None,1,White,Black,1.13,0.93,1.38
10.1097/AOG.0b013e3182a92011,9,Yes,complete treatment,No,NA,mortality,HR,NA,None,1,White,Black,1.11,0.91,1.34
10.1016/j.ygyno.2011.04.047,2,No,NA,No,NA,median overall survival,months,NA,None,1,N/A,White,50.5,43.2,57.9
10.1016/j.ygyno.2011.04.047,2,No,NA,No,NA,median overall survival,months,NA,None,2,N/A,African American,47,36.2,57.8
10.1097/AOG.0000000000003401,8,Yes,International Federation of Gynecology and Obstetrics Stage IVA Disease,No,NA,overall survival,HR,NA,None,1,Non-Hispanic White,Hispanic,0.682,0.44,1.05
10.1097/AOG.0000000000003401,8,Yes,International Federation of Gynecology and Obstetrics Stage IVA Disease,No,NA,overall survival,HR,NA,None,2,Non-Hispanic White,Non-Hispanic Black,1.062,0.81,1.39
10.1097/AOG.0000000000003401,8,Yes,International Federation of Gynecology and Obstetrics Stage IVA Disease,No,NA,overall survival,HR,NA,None,3,Non-Hispanic White,Asian,0.75,0.4,1.41
10.1097/AOG.0000000000003401,8,Yes,International Federation of Gynecology and Obstetrics Stage IVA Disease,No,NA,overall survival,HR,NA,None,4,Non-Hispanic White,Other,0.988,0.34,2.84
10.1097/AOG.0000000000000605,14,Yes,grade 3 endometrioid adenocarcinoma,No,NA,disease specific mortality,HR,NA,None,1,White,African American,1.4,1.2,1.7
10.1016/j.ajog.2010.08.028,1,Yes,BMI < 18.5,No,NA,baseline BMI,Percent,NA,None,1,N/A,African-American/Black,56.5,-99,-99
10.1016/j.ajog.2010.08.028,1,Yes,BMI < 18.5,No,NA,baseline BMI,Percent,NA,None,2,N/A,Latina/Hispanic,26.1,-99,-99
10.1016/j.ajog.2010.08.028,1,Yes,BMI < 18.5,No,NA,baseline BMI,Percent,NA,None,3,N/A,White,13,-99,-99
10.1016/j.ajog.2010.08.028,1,Yes,BMI < 18.5,No,NA,baseline BMI,Percent,NA,None,4,N/A,Other,4.4,-99,-99
10.1016/j.ajog.2010.08.028,2,Yes,BMI 18.5 - 24.9,No,NA,baseline BMI,Percent,NA,None,1,N/A,African-American/Black,60.9,-99,-99
10.1016/j.ajog.2010.08.028,2,Yes,BMI 18.5 - 24.9,No,NA,baseline BMI,Percent,NA,None,2,N/A,Latina/Hispanic,24.5,-99,-99
10.1016/j.ajog.2010.08.028,2,Yes,BMI 18.5 - 24.9,No,NA,baseline BMI,Percent,NA,None,3,N/A,White,13,-99,-99
10.1016/j.ajog.2010.08.028,2,Yes,BMI 18.5 - 24.9,No,NA,baseline BMI,Percent,NA,None,4,N/A,Other,1.6,-99,-99
10.1016/j.ajog.2010.08.028,3,Yes,BMI 25.0 - 29.9,No,NA,baseline BMI,Percent,NA,None,1,N/A,African-American/Black,58,-99,-99
10.1016/j.ajog.2010.08.028,3,Yes,BMI 25.0 - 29.9,No,NA,baseline BMI,Percent,NA,None,2,N/A,Latina/Hispanic,28,-99,-99
10.1016/j.ajog.2010.08.028,3,Yes,BMI 25.0 - 29.9,No,NA,baseline BMI,Percent,NA,None,3,N/A,White,11,-99,-99
10.1016/j.ajog.2010.08.028,3,Yes,BMI 25.0 - 29.9,No,NA,baseline BMI,Percent,NA,None,4,N/A,Other,3,-99,-99
10.1016/j.ajog.2010.08.028,4,Yes,BMI ≥ 30.0,No,NA,baseline BMI,Percent,NA,None,1,N/A,African-American/Black,56.7,-99,-99
10.1016/j.ajog.2010.08.028,4,Yes,BMI ≥ 30.0,No,NA,baseline BMI,Percent,NA,None,2,N/A,Latina/Hispanic,26.7,-99,-99
10.1016/j.ajog.2010.08.028,4,Yes,BMI ≥ 30.0,No,NA,baseline BMI,Percent,NA,None,3,N/A,White,15.8,-99,-99
10.1016/j.ajog.2010.08.028,4,Yes,BMI ≥ 30.0,No,NA,baseline BMI,Percent,NA,None,4,N/A,Other,0.8,-99,-99
10.1016/j.ygyno.2014.02.041,3,No,NA,Yes,advanted stage uterine carcinosarcoma,overall survival,months,NA,None,1,N/A,White,11.8,-99,-99
10.1016/j.ygyno.2014.02.041,3,No,NA,Yes,advanted stage uterine carcinosarcoma,overall survival,months,NA,None,2,N/A,Black,8.5,-99,-99
10.1016/j.ygyno.2014.02.041,4,No,NA,Yes,early stage uterine carcinosarcoma,progression free survival,months,NA,None,1,N/A,White,77.4,-99,-99
10.1016/j.ygyno.2014.02.041,4,No,NA,Yes,early stage uterine carcinosarcoma,progression free survival,months,NA,None,2,N/A,Black,13.6,-99,-99
10.1016/j.ygyno.2014.02.041,5,No,NA,Yes,early stage uterine carcinosarcoma,overall survival,months,NA,None,1,N/A,White,94.7,-99,-99
10.1016/j.ygyno.2014.02.041,5,No,NA,Yes,early stage uterine carcinosarcoma,overall survival,months,NA,None,2,N/A,Black,25.4,-99,-99
10.1016/j.ygyno.2014.02.041,6,No,NA,No,NA,death for all stages,HR,NA,"age, stage, BMI, lymphadenectomy, adjuvant treatment",1,White,Black,2,1.3,3.2
10.1016/j.ygyno.2014.02.041,7,No,NA,No,NA,early stage disease,HR,NA,"age, stage, BMI, lymphadenectomy, adjuvant treatment",1,White,Black,3,1.5,5.8
10.1097/AOG.0b013e3182a7f3fc,4,No,NA,No,NA,difficulty with arousal,OR,NA,"age, lack of a current spouse or sexual partner, poor, fair, or good vs. excellent or very good overall health, current diabetes mellitus vs. no diabetes, obstetric and delivery-specific characteristics, parity, mode of delivery, ever birth after 40 weeks of gestation, ever oxytocin administration, ever had operative-assisted vaginal delivery, ever had episiotomy, ever had 3rd or 4th degree laceration, ever had spinal anesthesia, ever baby weight ≥ 4000 grams",1,White,Black/African American,0.5,0.22,1.14
10.1097/AOG.0b013e3182a7f3fc,4,No,NA,No,NA,difficulty with arousal,OR,NA,"age, lack of a current spouse or sexual partner, poor, fair, or good vs. excellent or very good overall health, current diabetes mellitus vs. no diabetes, obstetric and delivery-specific characteristics, parity, mode of delivery, ever birth after 40 weeks of gestation, ever oxytocin administration, ever had operative-assisted vaginal delivery, ever had episiotomy, ever had 3rd or 4th degree laceration, ever had spinal anesthesia, ever baby weight ≥ 4000 grams",2,White,Asian/Asian American,1.22,0.63,2.37
10.1097/AOG.0b013e3182a7f3fc,4,No,NA,No,NA,difficulty with arousal,OR,NA,"age, lack of a current spouse or sexual partner, poor, fair, or good vs. excellent or very good overall health, current diabetes mellitus vs. no diabetes, obstetric and delivery-specific characteristics, parity, mode of delivery, ever birth after 40 weeks of gestation, ever oxytocin administration, ever had operative-assisted vaginal delivery, ever had episiotomy, ever had 3rd or 4th degree laceration, ever had spinal anesthesia, ever baby weight ≥ 4000 grams",3,White,Latina/Hispanic,1.52,0.85,2.73
10.1097/AOG.0b013e3182a7f3fc,5,No,NA,No,NA,difficulty with lubrication,OR,NA,"age, lack of a current spouse or sexual partner, poor, fair, or good vs. excellent or very good overall health, current diabetes mellitus vs. no diabetes, obstetric and delivery-specific characteristics, parity, mode of delivery, ever birth after 40 weeks of gestation, ever oxytocin administration, ever had operative-assisted vaginal delivery, ever had episiotomy, ever had 3rd or 4th degree laceration, ever had spinal anesthesia, ever baby weight ≥ 4000 grams",1,White,Black/African American,0.68,0.38,1.24
10.1097/AOG.0b013e3182a7f3fc,5,No,NA,No,NA,difficulty with lubrication,OR,NA,"age, lack of a current spouse or sexual partner, poor, fair, or good vs. excellent or very good overall health, current diabetes mellitus vs. no diabetes, obstetric and delivery-specific characteristics, parity, mode of delivery, ever birth after 40 weeks of gestation, ever oxytocin administration, ever had operative-assisted vaginal delivery, ever had episiotomy, ever had 3rd or 4th degree laceration, ever had spinal anesthesia, ever baby weight ≥ 4000 grams",2,White,Asian/Asian American,0.79,0.43,1.44
10.1097/AOG.0b013e3182a7f3fc,5,No,NA,No,NA,difficulty with lubrication,OR,NA,"age, lack of a current spouse or sexual partner, poor, fair, or good vs. excellent or very good overall health, current diabetes mellitus vs. no diabetes, obstetric and delivery-specific characteristics, parity, mode of delivery, ever birth after 40 weeks of gestation, ever oxytocin administration, ever had operative-assisted vaginal delivery, ever had episiotomy, ever had 3rd or 4th degree laceration, ever had spinal anesthesia, ever baby weight ≥ 4000 grams",3,White,Latina/Hispanic,1,0.58,1.7
10.1097/AOG.0b013e3182a7f3fc,6,No,NA,No,NA,difficulty with orgasm,OR,NA,"age, lack of a current spouse or sexual partner, poor, fair, or good vs. excellent or very good overall health, current diabetes mellitus vs. no diabetes, obstetric and delivery-specific characteristics, parity, mode of delivery, ever birth after 40 weeks of gestation, ever oxytocin administration, ever had operative-assisted vaginal delivery, ever had episiotomy, ever had 3rd or 4th degree laceration, ever had spinal anesthesia, ever baby weight ≥ 4000 grams",1,White,Black/African American,0.47,0.22,1.02
10.1097/AOG.0b013e3182a7f3fc,6,No,NA,No,NA,difficulty with orgasm,OR,NA,"age, lack of a current spouse or sexual partner, poor, fair, or good vs. excellent or very good overall health, current diabetes mellitus vs. no diabetes, obstetric and delivery-specific characteristics, parity, mode of delivery, ever birth after 40 weeks of gestation, ever oxytocin administration, ever had operative-assisted vaginal delivery, ever had episiotomy, ever had 3rd or 4th degree laceration, ever had spinal anesthesia, ever baby weight ≥ 4000 grams",2,White,Asian/Asian American,1.03,0.55,1.92
10.1097/AOG.0b013e3182a7f3fc,6,No,NA,No,NA,difficulty with orgasm,OR,NA,"age, lack of a current spouse or sexual partner, poor, fair, or good vs. excellent or very good overall health, current diabetes mellitus vs. no diabetes, obstetric and delivery-specific characteristics, parity, mode of delivery, ever birth after 40 weeks of gestation, ever oxytocin administration, ever had operative-assisted vaginal delivery, ever had episiotomy, ever had 3rd or 4th degree laceration, ever had spinal anesthesia, ever baby weight ≥ 4000 grams",3,White,Latina/Hispanic,1.26,0.72,2.2
10.1097/AOG.0b013e3182a7f3fc,7,No,NA,No,NA,pain/discomfort with intercourse,OR,NA,"age, lack of a current spouse or sexual partner, poor, fair, or good vs. excellent or very good overall health, current diabetes mellitus vs. no diabetes, obstetric and delivery-specific characteristics, parity, mode of delivery, ever birth after 40 weeks of gestation, ever oxytocin administration, ever had operative-assisted vaginal delivery, ever had episiotomy, ever had 3rd or 4th degree laceration, ever had spinal anesthesia, ever baby weight ≥ 4000 grams",1,White,Black/African American,0.69,0.33,1.44
10.1097/AOG.0b013e3182a7f3fc,7,No,NA,No,NA,pain/discomfort with intercourse,OR,NA,"age, lack of a current spouse or sexual partner, poor, fair, or good vs. excellent or very good overall health, current diabetes mellitus vs. no diabetes, obstetric and delivery-specific characteristics, parity, mode of delivery, ever birth after 40 weeks of gestation, ever oxytocin administration, ever had operative-assisted vaginal delivery, ever had episiotomy, ever had 3rd or 4th degree laceration, ever had spinal anesthesia, ever baby weight ≥ 4000 grams",2,White,Asian/Asian American,0.67,0.31,1.43
10.1097/AOG.0b013e3182a7f3fc,7,No,NA,No,NA,pain/discomfort with intercourse,OR,NA,"age, lack of a current spouse or sexual partner, poor, fair, or good vs. excellent or very good overall health, current diabetes mellitus vs. no diabetes, obstetric and delivery-specific characteristics, parity, mode of delivery, ever birth after 40 weeks of gestation, ever oxytocin administration, ever had operative-assisted vaginal delivery, ever had episiotomy, ever had 3rd or 4th degree laceration, ever had spinal anesthesia, ever baby weight ≥ 4000 grams",3,White,Latina/Hispanic,0.72,0.36,1.44
10.1016/j.ajog.2013.07.021,88,Yes,1990 - 1999,No,NA,disease specific mortality,HR,NA,None,1,White,African American,0.56,0.37,0.83
10.1016/j.ajog.2013.07.021,89,Yes,2000 - 2009,No,NA,five year survival rate,Percent,NA,None,1,N/A,White,77.1,-99,-99
10.1016/j.ajog.2013.07.021,89,Yes,2000 - 2009,No,NA,five year survival rate,Percent,NA,None,2,N/A,African American,84.48,-99,-99
10.1016/j.ajog.2013.07.021,90,Yes,2000 - 2009,No,NA,disease specific mortality,HR,NA,None,1,White,African American,0.65,0.43,0.97
10.1016/j.ajog.2013.07.021,91,Yes,All years,No,NA,five year survival rate,Percent,NA,None,1,N/A,White,75.39,-99,-99
10.1016/j.ajog.2013.07.021,91,Yes,All years,No,NA,five year survival rate,Percent,NA,None,2,N/A,African American,81.37,-99,-99
10.1016/j.ajog.2013.07.021,92,Yes,All years,No,NA,disease specific mortality,HR,NA,None,1,White,African American,0.66,0.53,0.82
10.1016/j.ygyno.2011.02.004,5,No,NA,No,NA,Lymphadenectomy,OR,NA,None,1,Caucasian,African American,1.13,0.98,1.3
10.1016/j.ygyno.2011.02.004,6,No,NA,No,NA,Minimally-invasive surgical approach,OR,NA,None,1,Caucasian,African American,0.56,0.42,0.74
10.1016/j.ygyno.2011.02.004,7,No,NA,No,NA,Minimally-invasive surgical approach,OR,NA,"age, payer status, APR-DRG mortality risk score",1,Caucasian,African American,0.6,0.45,0.8
10.1016/j.ygyno.2011.02.004,8,No,NA,No,NA,High-volume surgeon,OR,NA,None,1,Caucasian,African American,1.35,1.15,1.57
10.1016/j.fertnstert.2010.12.035,1,No,NA,No,NA,NA,OR,NA,"age, gravidity, oocyte source, oocyte state, day of embryo transfer, number of embryos transferred, infertility diagnoses, BMI",1,White,Asian,1.38,1.25,1.52
10.1016/j.fertnstert.2010.12.035,1,No,NA,No,NA,NA,OR,NA,"age, gravidity, oocyte source, oocyte state, day of embryo transfer, number of embryos transferred, infertility diagnoses, BMI",2,White,Hispanic,1.1,0.99,1.24
10.1016/j.fertnstert.2010.12.035,1,No,NA,No,NA,NA,OR,NA,"age, gravidity, oocyte source, oocyte state, day of embryo transfer, number of embryos transferred, infertility diagnoses, BMI",3,White,Black,1.43,1.27,1.61
10.1016/j.fertnstert.2010.12.035,2,Yes,normal weight,No,NA,assisted reproduction technology outcomes,OR,NA,"age, gravidity, oocyte source, oocyte state, day of embryo transfer, number of embryos transferred, infertility diagnoses",1,White,Asian,1.36,1.22,1.53
10.1016/j.fertnstert.2010.12.035,2,Yes,normal weight,No,NA,assisted reproduction technology outcomes,OR,NA,"age, gravidity, oocyte source, oocyte state, day of embryo transfer, number of embryos transferred, infertility diagnoses",2,White,Hispanic,1.21,1.03,1.42
10.1016/j.fertnstert.2010.12.035,2,Yes,normal weight,No,NA,assisted reproduction technology outcomes,OR,NA,"age, gravidity, oocyte source, oocyte state, day of embryo transfer, number of embryos transferred, infertility diagnoses",3,White,Black,1.18,0.97,1.44
10.1016/j.fertnstert.2010.12.035,3,Yes,overweight,No,NA,assisted reproduction technology outcomes,OR,NA,"age, gravidity, oocyte source, oocyte state, day of embryo transfer, number of embryos transferred, infertility diagnoses",1,White,Asian,1.21,0.98,1.5
10.1016/j.fertnstert.2010.12.035,3,Yes,overweight,No,NA,assisted reproduction technology outcomes,OR,NA,"age, gravidity, oocyte source, oocyte state, day of embryo transfer, number of embryos transferred, infertility diagnoses",2,White,Hispanic,0.92,0.75,1.13
10.1016/j.fertnstert.2010.12.035,3,Yes,overweight,No,NA,assisted reproduction technology outcomes,OR,NA,"age, gravidity, oocyte source, oocyte state, day of embryo transfer, number of embryos transferred, infertility diagnoses",3,White,Black,1.34,1.1,1.65
10.1016/j.fertnstert.2010.12.035,4,Yes,obese,No,NA,assisted reproduction technology outcomes,OR,NA,"age, gravidity, oocyte source, oocyte state, day of embryo transfer, number of embryos transferred, infertility diagnoses",1,White,Asian,1.73,1.21,2.47
10.1016/j.fertnstert.2010.12.035,4,Yes,obese,No,NA,assisted reproduction technology outcomes,OR,NA,"age, gravidity, oocyte source, oocyte state, day of embryo transfer, number of embryos transferred, infertility diagnoses",2,White,Hispanic,1.04,0.81,1.33
10.1016/j.fertnstert.2010.12.035,4,Yes,obese,No,NA,assisted reproduction technology outcomes,OR,NA,"age, gravidity, oocyte source, oocyte state, day of embryo transfer, number of embryos transferred, infertility diagnoses",3,White,Black,1.47,1.18,1.83
10.1016/j.fertnstert.2009.02.084,1,Yes,fresh cycles; no prior ART,No,NA,not achieving a live birth,RR,NA,"woman's age, nulliparous, prior spontaneous abortion, tubal disorder, male factor, uterine factor, diminished ovarian reserve, other ovarian disorder, endometriosis, ICSI",1,White,Black,1.31,1.26,1.37
10.1016/j.fertnstert.2009.02.084,2,Yes,fresh cycles; prior ART,No,NA,not achieving a live birth,RR,NA,"woman's age, nulliparous, prior spontaneous abortion, tubal disorder, male factor, uterine factor, diminished ovarian reserve, other ovarian disorder, endometriosis, ICSI",1,White,Black,1.33,1.24,1.42
10.1016/j.fertnstert.2009.02.084,3,Yes,cryopreserved cycles,No,NA,not achieving a live birth,RR,NA,"woman's age, nulliparous, prior spontaneous abortion, tubal disorder, male factor, uterine factor, diminished ovarian reserve, other ovarian disorder, endometriosis, ICSI",1,White,Black,1.1,1,1.21
10.1016/j.ygyno.2011.06.027,1,No,NA,No,NA,histology: endometrioid,Percent,NA,None,1,N/A,White,76.4,-99,-99
10.1016/j.ygyno.2011.06.027,1,No,NA,No,NA,histology: endometrioid,Percent,NA,None,2,N/A,Black,52.3,-99,-99
10.1016/j.ygyno.2011.06.027,2,No,NA,No,NA,histology: non-endometrioid,Percent,NA,None,1,N/A,White,23.5,-99,-99
10.1016/j.ygyno.2011.06.027,2,No,NA,No,NA,histology: non-endometrioid,Percent,NA,None,2,N/A,Black,47.7,-99,-99
10.1016/j.ygyno.2011.06.027,3,No,NA,No,NA,histology: unknown,Percent,NA,None,1,N/A,White,0.1,-99,-99
10.1016/j.ygyno.2011.06.027,3,No,NA,No,NA,histology: unknown,Percent,NA,None,2,N/A,Black,0,-99,-99
10.1016/j.ygyno.2011.06.027,4,No,NA,No,NA,stage: local,Percent,NA,None,1,N/A,White,75.6,-99,-99
10.1016/j.ygyno.2011.06.027,4,No,NA,No,NA,stage: local,Percent,NA,None,2,N/A,Black,68.2,-99,-99
10.1016/j.ygyno.2011.06.027,5,No,NA,No,NA,stage: regional,Percent,NA,None,1,N/A,White,12.7,-99,-99
10.1016/j.ygyno.2011.06.027,5,No,NA,No,NA,stage: regional,Percent,NA,None,2,N/A,Black,13.6,-99,-99
10.1016/j.ygyno.2011.06.027,6,No,NA,No,NA,stage: distant,Percent,NA,None,1,N/A,White,5.6,-99,-99
10.1016/j.ygyno.2011.06.027,6,No,NA,No,NA,stage: distant,Percent,NA,None,2,N/A,Black,11.4,-99,-99
10.1016/j.ygyno.2011.06.027,7,No,NA,No,NA,stage: unknown,Percent,NA,None,1,N/A,White,6.2,-99,-99
10.1016/j.ygyno.2011.06.027,7,No,NA,No,NA,stage: unknown,Percent,NA,None,2,N/A,Black,6.8,-99,-99
10.1016/j.ygyno.2011.06.027,8,No,NA,No,NA,grade: well differentiated,Percent,NA,None,1,N/A,White,45.2,-99,-99
10.1016/j.ygyno.2011.06.027,8,No,NA,No,NA,grade: well differentiated,Percent,NA,None,2,N/A,Black,34.7,-99,-99
10.1016/j.ygyno.2011.06.027,9,No,NA,No,NA,grade: moderately differentiated,Percent,NA,None,1,N/A,White,25.6,-99,-99
10.1016/j.ygyno.2011.06.027,9,No,NA,No,NA,grade: moderately differentiated,Percent,NA,None,2,N/A,Black,17.6,-99,-99
10.1016/j.ygyno.2011.06.027,10,No,NA,No,NA,grade: poorly differentiated,Percent,NA,None,1,N/A,White,15,-99,-99
10.1016/j.ygyno.2011.06.027,10,No,NA,No,NA,grade: poorly differentiated,Percent,NA,None,2,N/A,Black,20.5,-99,-99
10.1016/j.ygyno.2011.06.027,11,No,NA,No,NA,grade: undifferentiated,Percent,NA,None,1,N/A,White,0.8,-99,-99
10.1016/j.ygyno.2011.06.027,11,No,NA,No,NA,grade: undifferentiated,Percent,NA,None,2,N/A,Black,1.1,-99,-99
10.1016/j.ygyno.2011.06.027,12,No,NA,No,NA,grade: unknown,Percent,NA,None,1,N/A,White,13.4,-99,-99
10.1016/j.ygyno.2011.06.027,12,No,NA,No,NA,grade: unknown,Percent,NA,None,2,N/A,Black,26.1,-99,-99
10.1016/j.ygyno.2011.06.027,13,Yes,age <50,No,NA,histology: endometrioid,Percent,NA,None,1,N/A,White,73,-99,-99
10.1016/j.ygyno.2011.06.027,13,Yes,age <50,No,NA,histology: endometrioid,Percent,NA,None,2,N/A,Black,61.1,-99,-99
10.1016/j.ygyno.2011.06.027,14,Yes,age <50,No,NA,histology: non-endometrioid,Percent,NA,None,1,N/A,White,27,-99,-99
10.1016/j.ygyno.2011.06.027,14,Yes,age <50,No,NA,histology: non-endometrioid,Percent,NA,None,2,N/A,Black,38.9,-99,-99
10.1016/j.ygyno.2011.06.027,15,Yes,age <50,No,NA,histology: unknown,Percent,NA,None,1,N/A,White,0,-99,-99
10.1016/j.ygyno.2011.06.027,15,Yes,age <50,No,NA,histology: unknown,Percent,NA,None,2,N/A,Black,0,-99,-99
10.1016/j.ygyno.2011.06.027,16,Yes,age <50,No,NA,stage: local,Percent,NA,None,1,N/A,White,77.8,-99,-99
10.1016/j.ygyno.2011.06.027,16,Yes,age <50,No,NA,stage: local,Percent,NA,None,2,N/A,Black,77.8,-99,-99
10.1016/j.ygyno.2011.06.027,17,Yes,age <50,No,NA,stage: regional,Percent,NA,None,1,N/A,White,11.9,-99,-99
10.1016/j.ygyno.2011.06.027,17,Yes,age <50,No,NA,stage: regional,Percent,NA,None,2,N/A,Black,13.9,-99,-99
10.1016/j.ygyno.2011.06.027,18,Yes,age <50,No,NA,stage: distant,Percent,NA,None,1,N/A,White,4.6,-99,-99
10.1016/j.ygyno.2011.06.027,18,Yes,age <50,No,NA,stage: distant,Percent,NA,None,2,N/A,Black,2.8,-99,-99
10.1016/j.ygyno.2011.06.027,19,Yes,age <50,No,NA,stage: unknown,Percent,NA,None,1,N/A,White,5.7,-99,-99
10.1016/j.ygyno.2011.06.027,19,Yes,age <50,No,NA,stage: unknown,Percent,NA,None,2,N/A,Black,5.6,-99,-99
10.1016/j.ygyno.2011.06.027,20,Yes,age <50,No,NA,grade: well differentiated,Percent,NA,None,1,N/A,White,51.1,-99,-99
10.1016/j.ygyno.2011.06.027,20,Yes,age <50,No,NA,grade: well differentiated,Percent,NA,None,2,N/A,Black,55.6,-99,-99
10.1016/j.ygyno.2011.06.027,21,Yes,age <50,No,NA,grade: moderately differentiated,Percent,NA,None,1,N/A,White,22.7,-99,-99
10.1016/j.ygyno.2011.06.027,21,Yes,age <50,No,NA,grade: moderately differentiated,Percent,NA,None,2,N/A,Black,8.3,-99,-99
10.1016/j.ygyno.2011.06.027,22,Yes,age <50,No,NA,grade: poorly differentiated,Percent,NA,None,1,N/A,White,11.4,-99,-99
10.1016/j.ygyno.2011.06.027,22,Yes,age <50,No,NA,grade: poorly differentiated,Percent,NA,None,2,N/A,Black,16.7,-99,-99
10.1016/j.ygyno.2011.06.027,23,Yes,age <50,No,NA,grade: undifferentiated,Percent,NA,None,1,N/A,White,0.8,-99,-99
10.1016/j.ygyno.2011.06.027,23,Yes,age <50,No,NA,grade: undifferentiated,Percent,NA,None,2,N/A,Black,2.8,-99,-99
10.1016/j.ygyno.2011.06.027,24,Yes,age <50,No,NA,grade: unknown,Percent,NA,None,1,N/A,White,14.1,-99,-99
10.1016/j.ygyno.2011.06.027,24,Yes,age <50,No,NA,grade: unknown,Percent,NA,None,2,N/A,Black,16.7,-99,-99
10.1016/j.ygyno.2011.06.027,25,Yes,age ≥50,No,NA,histology: endometrioid,Percent,NA,None,1,N/A,White,77.2,-99,-99
10.1016/j.ygyno.2011.06.027,25,Yes,age ≥50,No,NA,histology: endometrioid,Percent,NA,None,2,N/A,Black,50,-99,-99
10.1016/j.ygyno.2011.06.027,26,Yes,age ≥50,No,NA,histology: non-endometrioid,Percent,NA,None,1,N/A,White,22.7,-99,-99
10.1016/j.ygyno.2011.06.027,26,Yes,age ≥50,No,NA,histology: non-endometrioid,Percent,NA,None,2,N/A,Black,50,-99,-99
10.1016/j.ygyno.2011.06.027,27,Yes,age ≥50,No,NA,histology: unknown,Percent,NA,None,1,N/A,White,0.1,-99,-99
10.1016/j.ygyno.2011.06.027,27,Yes,age ≥50,No,NA,histology: unknown,Percent,NA,None,2,N/A,Black,0,-99,-99
10.1016/j.ygyno.2011.06.027,28,Yes,age ≥50,No,NA,stage: local,Percent,NA,None,1,N/A,White,75.1,-99,-99
10.1016/j.ygyno.2011.06.027,28,Yes,age ≥50,No,NA,stage: local,Percent,NA,None,2,N/A,Black,65.7,-99,-99
10.1016/j.ygyno.2011.06.027,29,Yes,age ≥50,No,NA,stage: regional,Percent,NA,None,1,N/A,White,12.8,-99,-99
10.1016/j.ygyno.2011.06.027,29,Yes,age ≥50,No,NA,stage: regional,Percent,NA,None,2,N/A,Black,13.6,-99,-99
10.1016/j.ygyno.2011.06.027,30,Yes,age ≥50,No,NA,stage: distant,Percent,NA,None,1,N/A,White,5.8,-99,-99
10.1016/j.ygyno.2011.06.027,30,Yes,age ≥50,No,NA,stage: distant,Percent,NA,None,2,N/A,Black,13.6,-99,-99
10.1016/j.ygyno.2011.06.027,31,Yes,age ≥50,No,NA,stage: unknown,Percent,NA,None,1,N/A,White,6.3,-99,-99
10.1016/j.ygyno.2011.06.027,31,Yes,age ≥50,No,NA,stage: unknown,Percent,NA,None,2,N/A,Black,7.1,-99,-99
10.1016/j.ygyno.2011.06.027,32,Yes,age ≥50,No,NA,grade: well differentiated,Percent,NA,None,1,N/A,White,43.8,-99,-99
10.1016/j.ygyno.2011.06.027,32,Yes,age ≥50,No,NA,grade: well differentiated,Percent,NA,None,2,N/A,Black,29.3,-99,-99
10.1016/j.ygyno.2011.06.027,33,Yes,age ≥50,No,NA,grade: moderately differentiated,Percent,NA,None,1,N/A,White,26.3,-99,-99
10.1016/j.ygyno.2011.06.027,33,Yes,age ≥50,No,NA,grade: moderately differentiated,Percent,NA,None,2,N/A,Black,20,-99,-99
10.1016/j.ygyno.2011.06.027,34,Yes,age ≥50,No,NA,grade: poorly differentiated,Percent,NA,None,1,N/A,White,15.9,-99,-99
10.1016/j.ygyno.2011.06.027,34,Yes,age ≥50,No,NA,grade: poorly differentiated,Percent,NA,None,2,N/A,Black,21.4,-99,-99
10.1016/j.ygyno.2011.06.027,35,Yes,age ≥50,No,NA,grade: undifferentiated,Percent,NA,None,1,N/A,White,0.8,-99,-99
10.1016/j.ygyno.2011.06.027,35,Yes,age ≥50,No,NA,grade: undifferentiated,Percent,NA,None,2,N/A,Black,0.7,-99,-99
10.1016/j.ygyno.2011.06.027,36,Yes,age ≥50,No,NA,grade: unknown,Percent,NA,None,1,N/A,White,13.2,-99,-99
10.1016/j.ygyno.2011.06.027,36,Yes,age ≥50,No,NA,grade: unknown,Percent,NA,None,2,N/A,Black,28.6,-99,-99
10.1016/j.ygyno.2011.06.027,37,No,NA,No,NA,stage: local,Percent,NA,None,1,N/A,White,78.4,-99,-99
10.1016/j.ygyno.2011.06.027,37,No,NA,No,NA,stage: local,Percent,NA,None,2,N/A,Black,72.8,-99,-99
10.1016/j.ygyno.2011.06.027,38,No,NA,No,NA,stage: regional,Percent,NA,None,1,N/A,White,11.7,-99,-99
10.1016/j.ygyno.2011.06.027,38,No,NA,No,NA,stage: regional,Percent,NA,None,2,N/A,Black,10.9,-99,-99
10.1016/j.ygyno.2011.06.027,39,No,NA,No,NA,stage: distant,Percent,NA,None,1,N/A,White,3.7,-99,-99
10.1016/j.ygyno.2011.06.027,39,No,NA,No,NA,stage: distant,Percent,NA,None,2,N/A,Black,7.6,-99,-99
10.1016/j.ygyno.2011.06.027,40,No,NA,No,NA,stage: unknown,Percent,NA,None,1,N/A,White,6.2,-99,-99
10.1016/j.ygyno.2011.06.027,40,No,NA,No,NA,stage: unknown,Percent,NA,None,2,N/A,Black,8.7,-99,-99
10.1016/j.ygyno.2011.06.027,41,No,NA,No,NA,grade: well differentiated,Percent,NA,None,1,N/A,White,51.3,-99,-99
10.1016/j.ygyno.2011.06.027,41,No,NA,No,NA,grade: well differentiated,Percent,NA,None,2,N/A,Black,48.9,-99,-99
10.1016/j.ygyno.2011.06.027,42,No,NA,No,NA,grade: moderately differentiated,Percent,NA,None,1,N/A,White,28.2,-99,-99
10.1016/j.ygyno.2011.06.027,42,No,NA,No,NA,grade: moderately differentiated,Percent,NA,None,2,N/A,Black,20.7,-99,-99
10.1016/j.ygyno.2011.06.027,43,No,NA,No,NA,grade: poorly differentiated,Percent,NA,None,1,N/A,White,12.4,-99,-99
10.1016/j.ygyno.2011.06.027,43,No,NA,No,NA,grade: poorly differentiated,Percent,NA,None,2,N/A,Black,18.5,-99,-99
10.1016/j.ygyno.2011.06.027,44,No,NA,No,NA,grade: undifferentiated,Percent,NA,None,1,N/A,White,0.3,-99,-99
10.1016/j.ygyno.2011.06.027,44,No,NA,No,NA,grade: undifferentiated,Percent,NA,None,2,N/A,Black,0,-99,-99
10.1016/j.ygyno.2011.06.027,45,No,NA,No,NA,grade: unknown,Percent,NA,None,1,N/A,White,7.9,-99,-99
10.1016/j.ygyno.2011.06.027,45,No,NA,No,NA,grade: unknown,Percent,NA,None,2,N/A,Black,12,-99,-99
10.1016/j.ygyno.2011.06.027,46,Yes,age <50,No,NA,stage: local,Percent,NA,None,1,N/A,White,83,-99,-99
10.1016/j.ygyno.2011.06.027,46,Yes,age <50,No,NA,stage: local,Percent,NA,None,2,N/A,Black,72.7,-99,-99
10.1016/j.ygyno.2011.06.027,47,Yes,age <50,No,NA,stage: regional,Percent,NA,None,1,N/A,White,10,-99,-99
10.1016/j.ygyno.2011.06.027,47,Yes,age <50,No,NA,stage: regional,Percent,NA,None,2,N/A,Black,13.6,-99,-99
10.1016/j.ygyno.2011.06.027,48,Yes,age <50,No,NA,stage: distant,Percent,NA,None,1,N/A,White,2.2,-99,-99
10.1016/j.ygyno.2011.06.027,48,Yes,age <50,No,NA,stage: distant,Percent,NA,None,2,N/A,Black,4.5,-99,-99
10.1016/j.ygyno.2011.06.027,49,Yes,age <50,No,NA,stage: unknown,Percent,NA,None,1,N/A,White,4.8,-99,-99
10.1016/j.ygyno.2011.06.027,49,Yes,age <50,No,NA,stage: unknown,Percent,NA,None,2,N/A,Black,9.1,-99,-99
10.1016/j.ygyno.2011.06.027,50,Yes,age <50,No,NA,grade: well differentiated,Percent,NA,None,1,N/A,White,57.4,-99,-99
10.1016/j.ygyno.2011.06.027,50,Yes,age <50,No,NA,grade: well differentiated,Percent,NA,None,2,N/A,Black,77.3,-99,-99
10.1016/j.ygyno.2011.06.027,51,Yes,age <50,No,NA,grade: moderately differentiated,Percent,NA,None,1,N/A,White,25.2,-99,-99
10.1016/j.ygyno.2011.06.027,51,Yes,age <50,No,NA,grade: moderately differentiated,Percent,NA,None,2,N/A,Black,9.1,-99,-99
10.1016/j.ygyno.2011.06.027,52,Yes,age <50,No,NA,grade: poorly differentiated,Percent,NA,None,1,N/A,White,10.4,-99,-99
10.1016/j.ygyno.2011.06.027,52,Yes,age <50,No,NA,grade: poorly differentiated,Percent,NA,None,2,N/A,Black,13.6,-99,-99
10.1016/j.ygyno.2011.06.027,53,Yes,age <50,No,NA,grade: undifferentiated,Percent,NA,None,1,N/A,White,0.4,-99,-99
10.1016/j.ygyno.2011.06.027,53,Yes,age <50,No,NA,grade: undifferentiated,Percent,NA,None,2,N/A,Black,0,-99,-99
10.1016/j.ygyno.2011.06.027,54,Yes,age <50,No,NA,grade: unknown,Percent,NA,None,1,N/A,White,6.7,-99,-99
10.1016/j.ygyno.2011.06.027,54,Yes,age <50,No,NA,grade: unknown,Percent,NA,None,2,N/A,Black,0,-99,-99
10.1016/j.ygyno.2011.06.027,55,Yes,age ≥50,No,NA,stage: local,Percent,NA,None,1,N/A,White,77.4,-99,-99
10.1016/j.ygyno.2011.06.027,55,Yes,age ≥50,No,NA,stage: local,Percent,NA,None,2,N/A,Black,72.9,-99,-99
10.1016/j.ygyno.2011.06.027,56,Yes,age ≥50,No,NA,stage: regional,Percent,NA,None,1,N/A,White,12.1,-99,-99
10.1016/j.ygyno.2011.06.027,56,Yes,age ≥50,No,NA,stage: regional,Percent,NA,None,2,N/A,Black,10,-99,-99
10.1016/j.ygyno.2011.06.027,57,Yes,age ≥50,No,NA,stage: distant,Percent,NA,None,1,N/A,White,4,-99,-99
10.1016/j.ygyno.2011.06.027,57,Yes,age ≥50,No,NA,stage: distant,Percent,NA,None,2,N/A,Black,8.6,-99,-99
10.1016/j.ygyno.2011.06.027,58,Yes,age ≥50,No,NA,stage: unknown,Percent,NA,None,1,N/A,White,6.5,-99,-99
10.1016/j.ygyno.2011.06.027,58,Yes,age ≥50,No,NA,stage: unknown,Percent,NA,None,2,N/A,Black,8.6,-99,-99
10.1016/j.ygyno.2011.06.027,59,Yes,age ≥50,No,NA,grade: well differentiated,Percent,NA,None,1,N/A,White,50,-99,-99
10.1016/j.ygyno.2011.06.027,59,Yes,age ≥50,No,NA,grade: well differentiated,Percent,NA,None,2,N/A,Black,40,-99,-99
10.1016/j.ygyno.2011.06.027,60,Yes,age ≥50,No,NA,grade: moderately differentiated,Percent,NA,None,1,N/A,White,28.8,-99,-99
10.1016/j.ygyno.2011.06.027,60,Yes,age ≥50,No,NA,grade: moderately differentiated,Percent,NA,None,2,N/A,Black,24.3,-99,-99
10.1016/j.ygyno.2011.06.027,61,Yes,age ≥50,No,NA,grade: poorly differentiated,Percent,NA,None,1,N/A,White,12.9,-99,-99
10.1016/j.ygyno.2011.06.027,61,Yes,age ≥50,No,NA,grade: poorly differentiated,Percent,NA,None,2,N/A,Black,20,-99,-99
10.1016/j.ygyno.2011.06.027,62,Yes,age ≥50,No,NA,grade: undifferentiated,Percent,NA,None,1,N/A,White,0.2,-99,-99
10.1016/j.ygyno.2011.06.027,62,Yes,age ≥50,No,NA,grade: undifferentiated,Percent,NA,None,2,N/A,Black,0,-99,-99
10.1016/j.ygyno.2011.06.027,63,Yes,age ≥50,No,NA,grade: unknown,Percent,NA,None,1,N/A,White,8.2,-99,-99
10.1016/j.ygyno.2011.06.027,63,Yes,age ≥50,No,NA,grade: unknown,Percent,NA,None,2,N/A,Black,15.7,-99,-99
10.1016/j.ajog.2013.11.039,1,No,NA,No,NA,severe maternal morbidity with blood transfusion,RR,NA,"age, insurance coverage, state-level household income quartile for patient zip code, chronic medical conditions, hiv/aids, state",1,White,Black,2.1,2,2.2
10.1016/j.ajog.2013.11.039,1,No,NA,No,NA,severe maternal morbidity with blood transfusion,RR,NA,"age, insurance coverage, state-level household income quartile for patient zip code, chronic medical conditions, hiv/aids, state",2,White,Hispanic,1.3,1.2,1.3
10.1016/j.ajog.2013.11.039,1,No,NA,No,NA,severe maternal morbidity with blood transfusion,RR,NA,"age, insurance coverage, state-level household income quartile for patient zip code, chronic medical conditions, hiv/aids, state",3,White,Asian/Pacific Islander,1.2,1.2,1.3
10.1016/j.ajog.2013.11.039,1,No,NA,No,NA,severe maternal morbidity with blood transfusion,RR,NA,"age, insurance coverage, state-level household income quartile for patient zip code, chronic medical conditions, hiv/aids, state",4,White,American Indian/Alaska Native,1.7,1.5,1.8
10.1016/j.ajog.2013.11.039,2,No,NA,No,NA,severe maternal morbidity without blood transfusion,RR,NA,"age, insurance coverage, state-level household income quartile for patient zip code, chronic medical conditions, hiv/aids, state",1,White,Black,2.4,2.3,2.5
10.1016/j.ajog.2013.11.039,2,No,NA,No,NA,severe maternal morbidity without blood transfusion,RR,NA,"age, insurance coverage, state-level household income quartile for patient zip code, chronic medical conditions, hiv/aids, state",2,White,Hispanic,1.2,1.2,1.3
10.1016/j.ajog.2013.11.039,2,No,NA,No,NA,severe maternal morbidity without blood transfusion,RR,NA,"age, insurance coverage, state-level household income quartile for patient zip code, chronic medical conditions, hiv/aids, state",3,White,Asian/Pacific Islander,1.2,1.1,1.2
10.1016/j.ajog.2013.11.039,2,No,NA,No,NA,severe maternal morbidity without blood transfusion,RR,NA,"age, insurance coverage, state-level household income quartile for patient zip code, chronic medical conditions, hiv/aids, state",4,White,American Indian/Alaska Native,1.3,1.1,1.5
10.1016/j.ajog.2013.11.039,3,No,NA,No,NA,blood transfusion,"rate per 10,000 delivery hospitalizations",NA,none,1,N/A,Non-Hispanic White,78.94,-99,-99
10.1016/j.ajog.2013.11.039,3,No,NA,No,NA,blood transfusion,"rate per 10,000 delivery hospitalizations",NA,none,2,N/A,Non-Hispanic Black,187.03,-99,-99
10.1016/j.ajog.2013.11.039,3,No,NA,No,NA,blood transfusion,"rate per 10,000 delivery hospitalizations",NA,none,3,N/A,Hispanic,104.31,-99,-99
10.1016/j.ajog.2013.11.039,3,No,NA,No,NA,blood transfusion,"rate per 10,000 delivery hospitalizations",NA,none,4,N/A,Asian/Pacific Islander,97.92,-99,-99
10.1016/j.ajog.2013.11.039,3,No,NA,No,NA,blood transfusion,"rate per 10,000 delivery hospitalizations",NA,none,5,N/A,American Indian/Alaska Native,168.49,-99,-99
10.1016/j.ajog.2013.11.039,4,No,NA,No,NA,disseminated intravascular coagulation,"rate per 10,000 delivery hospitalizations",NA,none,1,N/A,Non-Hispanic White,12.81,-99,-99
10.1016/j.ajog.2013.11.039,4,No,NA,No,NA,disseminated intravascular coagulation,"rate per 10,000 delivery hospitalizations",NA,none,2,N/A,Non-Hispanic Black,21.96,-99,-99
10.1016/j.ajog.2013.11.039,4,No,NA,No,NA,disseminated intravascular coagulation,"rate per 10,000 delivery hospitalizations",NA,none,3,N/A,Hispanic,14.11,-99,-99
10.1016/j.ajog.2013.11.039,4,No,NA,No,NA,disseminated intravascular coagulation,"rate per 10,000 delivery hospitalizations",NA,none,4,N/A,Asian/Pacific Islander,16.1,-99,-99
10.1016/j.ajog.2013.11.039,4,No,NA,No,NA,disseminated intravascular coagulation,"rate per 10,000 delivery hospitalizations",NA,none,5,N/A,American Indian/Alaska Native,17.53,-99,-99
10.1016/j.ajog.2013.11.039,5,No,NA,No,NA,heart failure during procedure or surgery,"rate per 10,000 delivery hospitalizations",NA,none,1,N/A,Non-Hispanic White,8.93,-99,-99
10.1016/j.ajog.2013.11.039,5,No,NA,No,NA,heart failure during procedure or surgery,"rate per 10,000 delivery hospitalizations",NA,none,2,N/A,Non-Hispanic Black,23.87,-99,-99
10.1016/j.ajog.2013.11.039,5,No,NA,No,NA,heart failure during procedure or surgery,"rate per 10,000 delivery hospitalizations",NA,none,3,N/A,Hispanic,10.51,-99,-99
10.1016/j.ajog.2013.11.039,5,No,NA,No,NA,heart failure during procedure or surgery,"rate per 10,000 delivery hospitalizations",NA,none,4,N/A,Asian/Pacific Islander,10.89,-99,-99
10.1016/j.ajog.2013.11.039,5,No,NA,No,NA,heart failure during procedure or surgery,"rate per 10,000 delivery hospitalizations",NA,none,5,N/A,American Indian/Alaska Native,10.71,-99,-99
10.1016/j.ajog.2014.06.008,1,Yes,Gestational Age of 37 weeks,NA,NA,stillbirth,"rate per 10,000 ongoing pregnancies",NA,none,1,None,White,2,1.8,2.2
10.1016/j.ajog.2014.06.008,1,Yes,Gestational Age of 37 weeks,NA,NA,stillbirth,"rate per 10,000 ongoing pregnancies",NA,none,2,None,Black,3.9,3,4.8
10.1016/j.ajog.2014.06.008,1,Yes,Gestational Age of 37 weeks,NA,NA,stillbirth,"rate per 10,000 ongoing pregnancies",NA,none,3,None,Hispanic,2.3,2,2.5
10.1016/j.ajog.2014.06.008,1,Yes,Gestational Age of 37 weeks,NA,NA,stillbirth,"rate per 10,000 ongoing pregnancies",NA,none,4,None,Asian,2.2,1.7,2.7
10.1016/j.ajog.2014.06.008,2,Yes,Gestational Age of 38 weeks,No,NA,stillbirth,"rate per 10,000 ongoing pregnancies",NA,none,1,None,White,2.7,2.4,3
10.1016/j.ajog.2014.06.008,2,Yes,Gestational Age of 38 weeks,No,NA,stillbirth,"rate per 10,000 ongoing pregnancies",NA,none,2,None,Black,6.2,5,7.4
10.1016/j.ajog.2014.06.008,2,Yes,Gestational Age of 38 weeks,No,NA,stillbirth,"rate per 10,000 ongoing pregnancies",NA,none,3,None,Hispanic,3.1,2.8,3.4
10.1016/j.ajog.2014.06.008,2,Yes,Gestational Age of 38 weeks,No,NA,stillbirth,"rate per 10,000 ongoing pregnancies",NA,none,4,None,Asian,3,2.4,3.6
10.1016/j.ajog.2014.06.008,3,Yes,Gestational Age of 39 weeks,NA,NA,stillbirth,"rate per 10,000 ongoing pregnancies",NA,none,1,None,White,3.8,3.4,4.2
10.1016/j.ajog.2014.06.008,3,Yes,Gestational Age of 39 weeks,NA,NA,stillbirth,"rate per 10,000 ongoing pregnancies",NA,none,2,None,Black,8.2,6.6,9.9
10.1016/j.ajog.2014.06.008,3,Yes,Gestational Age of 39 weeks,NA,NA,stillbirth,"rate per 10,000 ongoing pregnancies",NA,none,3,None,Hispanic,4.6,4.2,5
10.1016/j.ajog.2014.06.008,3,Yes,Gestational Age of 39 weeks,NA,NA,stillbirth,"rate per 10,000 ongoing pregnancies",NA,none,4,None,Asian,3.8,3,4.6
10.1016/j.ajog.2014.06.008,4,Yes,Gestational Age of 40 weeks,No,NA,stillbirth,"rate per 10,000 ongoing pregnancies",NA,none,1,None,White,4.9,4.3,5.6
10.1016/j.ajog.2014.06.008,4,Yes,Gestational Age of 40 weeks,No,NA,stillbirth,"rate per 10,000 ongoing pregnancies",NA,none,2,None,Black,8.1,5.8,10.3
10.1016/j.ajog.2014.06.008,4,Yes,Gestational Age of 40 weeks,No,NA,stillbirth,"rate per 10,000 ongoing pregnancies",NA,none,3,None,Hispanic,6.6,5.9,7.4
10.1016/j.ajog.2014.06.008,4,Yes,Gestational Age of 40 weeks,No,NA,stillbirth,"rate per 10,000 ongoing pregnancies",NA,none,4,None,Asian,6.5,5,7.9
10.1016/j.ajog.2014.06.008,5,Yes,Gestational Age of 41 weeks,No,NA,stillbirth,"rate per 10,000 ongoing pregnancies",NA,none,1,None,White,8.5,7.1,9.9
10.1016/j.ajog.2014.06.008,5,Yes,Gestational Age of 41 weeks,No,NA,stillbirth,"rate per 10,000 ongoing pregnancies",NA,none,2,None,Black,15.5,10.4,20.6
10.1016/j.ajog.2014.06.008,5,Yes,Gestational Age of 41 weeks,No,NA,stillbirth,"rate per 10,000 ongoing pregnancies",NA,none,3,None,Hispanic,10.4,8.9,11.8
10.1016/j.ajog.2014.06.008,5,Yes,Gestational Age of 41 weeks,No,NA,stillbirth,"rate per 10,000 ongoing pregnancies",NA,none,4,None,Asian,10,6.8,13.1
10.1016/j.ajog.2014.10.1104,1,Yes,No surgery,No,NA,no surgery,OR,NA,"socioeconomic status, stage, hospital volume, physician volume",1,White,African American,2.04,1.45,2.87
10.1016/j.ajog.2014.10.1104,1,Yes,No surgery,No,NA,no surgery,OR,NA,"socioeconomic status, stage, hospital volume, physician volume",2,White,Hispanic,1.08,0.87,1.33
10.1016/j.ajog.2014.10.1104,1,Yes,No surgery,No,NA,no surgery,OR,NA,"socioeconomic status, stage, hospital volume, physician volume",3,White,Asian/Pacific Islander,1.14,0.87,1.48
10.1016/j.ajog.2014.10.1104,2,Yes,Removal of ovary +/- hysterectomy,No,NA,removal of ovary +/- hysterectomy,OR,NA,"socioeconomic status, stage, hospital volume, physician volume",1,White,African American,1.49,1.02,2.18
10.1016/j.ajog.2014.10.1104,2,Yes,Removal of ovary +/- hysterectomy,No,NA,removal of ovary +/- hysterectomy,OR,NA,"socioeconomic status, stage, hospital volume, physician volume",2,White,Hispanic,1.1,0.88,1.39
10.1016/j.ajog.2014.10.1104,2,Yes,Removal of ovary +/- hysterectomy,No,NA,removal of ovary +/- hysterectomy,OR,NA,"socioeconomic status, stage, hospital volume, physician volume",3,White,Asian/Pacific Islander,0.87,0.65,1.18
10.1016/j.ajog.2014.10.1104,3,Yes,Debulking,No,NA,debulking,OR,NA,"socioeconomic status, stage, hospital volume, physician volume",1,White,African American,0.99,0.76,1.28
10.1016/j.ajog.2014.10.1104,3,Yes,Debulking,No,NA,debulking,OR,NA,"socioeconomic status, stage, hospital volume, physician volume",2,White,Hispanic,0.86,0.74,0.99
10.1016/j.ajog.2014.10.1104,3,Yes,Debulking,No,NA,debulking,OR,NA,"socioeconomic status, stage, hospital volume, physician volume",3,White,Asian/Pacific Islander,0.79,0.66,0.94
10.1016/j.ajog.2014.10.1104,4,Yes,No chemotherapy - “other” reason,No,NA,no chemotherapy - “other” reason,OR,NA,"socioeconomic status, stage, hospital volume, physician volume",1,White,African American,1.55,1.24,1.93
10.1016/j.ajog.2014.10.1104,4,Yes,No chemotherapy - “other” reason,No,NA,no chemotherapy - “other” reason,OR,NA,"socioeconomic status, stage, hospital volume, physician volume",2,White,Hispanic,1.02,0.88,1.18
10.1016/j.ajog.2014.10.1104,4,Yes,No chemotherapy - “other” reason,No,NA,no chemotherapy - “other” reason,OR,NA,"socioeconomic status, stage, hospital volume, physician volume",3,White,Asian/Pacific Islander,1.11,0.93,1.34
10.1016/j.ajog.2014.10.1104,5,Yes,No chemotherapy despite recommendation,No,NA,no chemotherapy despite recommendation,OR,NA,"socioeconomic status, stage, hospital volume, physician volume",1,White,African American,0.76,0.5,1.17
10.1016/j.ajog.2014.10.1104,5,Yes,No chemotherapy despite recommendation,No,NA,no chemotherapy despite recommendation,OR,NA,"socioeconomic status, stage, hospital volume, physician volume",2,White,Hispanic,0.68,0.53,0.88
10.1016/j.ajog.2014.10.1104,5,Yes,No chemotherapy despite recommendation,No,NA,no chemotherapy despite recommendation,OR,NA,"socioeconomic status, stage, hospital volume, physician volume",3,White,Asian/Pacific Islander,1.23,0.94,1.61
10.1016/j.ajog.2015.05.008,1,No,NA,No,NA,cardiovascular pregnancy-related deaths,%,NA,none,1,N/A,"White, non-Hispanic",25,-99,-99
10.1016/j.ajog.2015.05.008,1,No,NA,No,NA,cardiovascular pregnancy-related deaths,%,NA,none,2,N/A,Hispanic,32.8,-99,-99
10.1016/j.ajog.2015.05.008,1,No,NA,No,NA,cardiovascular pregnancy-related deaths,%,NA,none,3,N/A,"African-American, non-Hispanic",39.1,-99,-99
10.1016/j.ajog.2015.05.008,1,No,NA,No,NA,cardiovascular pregnancy-related deaths,%,NA,none,4,N/A,All other/unknown or missing,3.1,-99,-99
10.1016/j.ajog.2015.05.008,2,No,NA,No,NA,cardiovascular pregnancy-related deaths,%,NA,none,1,N/A,"White, non-Hispanic",25.9,-99,-99
10.1016/j.ajog.2015.05.008,2,No,NA,No,NA,cardiovascular pregnancy-related deaths,%,NA,none,2,N/A,Hispanic,47.2,-99,-99
10.1016/j.ajog.2015.05.008,2,No,NA,No,NA,cardiovascular pregnancy-related deaths,%,NA,none,3,N/A,"African-American, non-Hispanic",16.1,-99,-99
10.1016/j.ajog.2015.05.008,2,No,NA,No,NA,cardiovascular pregnancy-related deaths,%,NA,none,4,N/A,All other/unknown or missing,9.8,-99,-99
10.1016/j.ajog.2015.08.019,1,No,NA,No,NA,severe maternal morbidity,rate per 1000 deliveries,NA,"age, insurance, zip code income, comorbidities, pregnancy complications",1,NA,White,13.3,12.5,14.1
10.1016/j.ajog.2015.08.019,1,No,NA,No,NA,severe maternal morbidity,rate per 1000 deliveries,NA,"age, insurance, zip code income, comorbidities, pregnancy complications",2,NA,Black,18.8,17.1,20.5
10.1016/j.ajog.2015.08.019,2,No,NA,No,NA,severe maternal morbidity,rate per 1000 deliveries,NA,"age, insurance, zip code income, comorbidities, pregnancy complications, site of care",1,NA,White,13.8,12.9,14.7
10.1016/j.ajog.2015.08.019,2,No,NA,No,NA,severe maternal morbidity,rate per 1000 deliveries,NA,"age, insurance, zip code income, comorbidities, pregnancy complications, site of care",2,NA,Black,17.3,16.1,18.5
10.1016/j.ajog.2015.08.019,3,No,NA,No,NA,severe maternal morbidity,rate per 1000 deliveries,NA,"age, insurance, zip code income, comorbidities, pregnancy complications, site of care, and hospital factors (teaching status, bed size, location, region, control, volume of deliveries, percentage of medicaid deliveries)",1,NA,White,13.8,12.9,14.7
10.1016/j.ajog.2015.08.019,3,No,NA,No,NA,severe maternal morbidity,rate per 1000 deliveries,NA,"age, insurance, zip code income, comorbidities, pregnancy complications, site of care, and hospital factors (teaching status, bed size, location, region, control, volume of deliveries, percentage of medicaid deliveries)",2,NA,Black,17.3,16.2,18.4
10.1016/j.ajog.2015.08.019,4,Yes,black-serving hospital status - Low-Black serving,No,NA,severe maternal morbidity,rate per 1000 deliveries,NA,none,1,NA,White,12.3,-99,-99
10.1016/j.ajog.2015.08.019,4,Yes,black-serving hospital status - Low-Black serving,No,NA,severe maternal morbidity,rate per 1000 deliveries,NA,none,2,NA,Black,16.9,-99,-99
10.1016/j.ajog.2015.08.019,5,No,NA,No,NA,severe maternal morbidity,rate per 1000 deliveries,NA,none,1,NA,White,11.8,11.2,12.5
10.1016/j.ajog.2015.08.019,5,No,NA,No,NA,severe maternal morbidity,rate per 1000 deliveries,NA,none,2,NA,Black,25.8,23.5,28
10.1016/j.ajog.2015.08.072,1,No,NA,No,NA,discussed incontinence with a clinician,OR,NA,"age, education level, household income, working full or part time for pay, clinical type of incontinence, clinical incontinence severity, cancer, asthma, chronic obstructive pulmonary disease, heart disease, hypertension, stroke, depression, irritable bowel syndrome, diabetes, arthritis, pelvic organ prolapse",1,Non-Latina white,Black,0.74,0.49,1.11
10.1016/j.ajog.2015.08.072,1,No,NA,No,NA,discussed incontinence with a clinician,OR,NA,"age, education level, household income, working full or part time for pay, clinical type of incontinence, clinical incontinence severity, cancer, asthma, chronic obstructive pulmonary disease, heart disease, hypertension, stroke, depression, irritable bowel syndrome, diabetes, arthritis, pelvic organ prolapse",2,Non-Latina white,Latina white,1.23,0.84,1.79
10.1016/j.ajog.2015.08.072,1,No,NA,No,NA,discussed incontinence with a clinician,OR,NA,"age, education level, household income, working full or part time for pay, clinical type of incontinence, clinical incontinence severity, cancer, asthma, chronic obstructive pulmonary disease, heart disease, hypertension, stroke, depression, irritable bowel syndrome, diabetes, arthritis, pelvic organ prolapse",3,Non-Latina white,Asian,0.74,0.47,1.14
10.1016/j.ajog.2015.08.072,2,No,NA,No,NA,discussed incontinence with a specialist,OR,NA,"age, education level, household income, working full or part time for pay, clinical type of incontinence, clinical incontinence severity, cancer, asthma, chronic obstructive pulmonary disease, heart disease, hypertension, stroke, depression, irritable bowel syndrome, diabetes, arthritis, pelvic organ prolapse",1,Non-Latina white,Black,0.55,0.35,0.84
10.1016/j.ajog.2015.08.072,2,No,NA,No,NA,discussed incontinence with a specialist,OR,NA,"age, education level, household income, working full or part time for pay, clinical type of incontinence, clinical incontinence severity, cancer, asthma, chronic obstructive pulmonary disease, heart disease, hypertension, stroke, depression, irritable bowel syndrome, diabetes, arthritis, pelvic organ prolapse",2,Non-Latina white,Latina white,0.97,0.67,1.4
10.1016/j.ajog.2015.08.072,2,No,NA,No,NA,discussed incontinence with a specialist,OR,NA,"age, education level, household income, working full or part time for pay, clinical type of incontinence, clinical incontinence severity, cancer, asthma, chronic obstructive pulmonary disease, heart disease, hypertension, stroke, depression, irritable bowel syndrome, diabetes, arthritis, pelvic organ prolapse",3,Non-Latina white,Asian,0.67,0.43,1.06
10.1016/j.ajog.2015.08.072,3,No,NA,No,NA,sought treatment in <1 year,OR,NA,"age, education level, household income, working full or part time for pay, clinical type of incontinence, clinical incontinence severity, cancer, asthma, chronic obstructive pulmonary disease, heart disease, hypertension, stroke, depression, irritable bowel syndrome, diabetes, arthritis, pelvic organ prolapse",1,Non-Latina White,Black,1.29,0.85,1.95
10.1016/j.ajog.2015.08.072,3,No,NA,No,NA,sought treatment in <1 year,OR,NA,"age, education level, household income, working full or part time for pay, clinical type of incontinence, clinical incontinence severity, cancer, asthma, chronic obstructive pulmonary disease, heart disease, hypertension, stroke, depression, irritable bowel syndrome, diabetes, arthritis, pelvic organ prolapse",2,Non-Latina White,Latina white,1.25,0.86,1.82
10.1016/j.ajog.2015.08.072,3,No,NA,No,NA,sought treatment in <1 year,OR,NA,"age, education level, household income, working full or part time for pay, clinical type of incontinence, clinical incontinence severity, cancer, asthma, chronic obstructive pulmonary disease, heart disease, hypertension, stroke, depression, irritable bowel syndrome, diabetes, arthritis, pelvic organ prolapse",3,Non-Latina White,Asian,0.74,0.47,1.18
10.1016/j.ajog.2015.08.072,4,No,NA,No,NA,provider recommended behavioral treatment for urinary incontinence,OR,NA,"age, education level, household income, working full or part time for pay, clinical type of incontinence, clinical incontinence severity, cancer, asthma, chronic obstructive pulmonary disease, heart disease, hypertension, stroke, depression, irritable bowel syndrome, diabetes, arthritis, pelvic organ prolapse",1,Non-Latina white,Black,2.75,1.23,6.17
10.1016/j.ajog.2015.08.072,4,No,NA,No,NA,provider recommended behavioral treatment for urinary incontinence,OR,NA,"age, education level, household income, working full or part time for pay, clinical type of incontinence, clinical incontinence severity, cancer, asthma, chronic obstructive pulmonary disease, heart disease, hypertension, stroke, depression, irritable bowel syndrome, diabetes, arthritis, pelvic organ prolapse",2,Non-Latina white,Latina white,0.96,0.55,1.66
10.1016/j.ajog.2015.08.072,4,No,NA,No,NA,provider recommended behavioral treatment for urinary incontinence,OR,NA,"age, education level, household income, working full or part time for pay, clinical type of incontinence, clinical incontinence severity, cancer, asthma, chronic obstructive pulmonary disease, heart disease, hypertension, stroke, depression, irritable bowel syndrome, diabetes, arthritis, pelvic organ prolapse",3,Non-Latina white,Asian,0.74,0.37,1.47
10.1016/j.ajog.2015.08.072,5,No,NA,No,NA,provider recommended pharmacologic treatment for urinary incontinence,OR,NA,"age, education level, household income, working full or part time for pay, clinical type of incontinence, clinical incontinence severity, cancer, asthma, chronic obstructive pulmonary disease, heart disease, hypertension, stroke, depression, irritable bowel syndrome, diabetes, arthritis, pelvic organ prolapse",1,Non-Latina white,Black,0.88,0.46,1.67
10.1016/j.ajog.2015.08.072,5,No,NA,No,NA,provider recommended pharmacologic treatment for urinary incontinence,OR,NA,"age, education level, household income, working full or part time for pay, clinical type of incontinence, clinical incontinence severity, cancer, asthma, chronic obstructive pulmonary disease, heart disease, hypertension, stroke, depression, irritable bowel syndrome, diabetes, arthritis, pelvic organ prolapse",2,Non-Latina white,Latina white,0.67,0.39,1.16
10.1016/j.ajog.2015.08.072,5,No,NA,No,NA,provider recommended pharmacologic treatment for urinary incontinence,OR,NA,"age, education level, household income, working full or part time for pay, clinical type of incontinence, clinical incontinence severity, cancer, asthma, chronic obstructive pulmonary disease, heart disease, hypertension, stroke, depression, irritable bowel syndrome, diabetes, arthritis, pelvic organ prolapse",3,Non-Latina white,Asian,0.46,0.22,1
10.1016/j.ajog.2015.12.034,1,No,NA,No,NA,previable live birth at 16 0/7 to 22 6/7 weeks of gestational age,RR,NA,"maternal age, unmarried, medicaid, education less than high school, tobacco use, prior preterm birth, interpregnancy interval <12 month, primiparous, plurality, congenital anomaly, genetic disorder",1,N/A,White (non-Hispanic),0.74,0.6,0.91
10.1016/j.ajog.2015.12.034,1,No,NA,No,NA,previable live birth at 16 0/7 to 22 6/7 weeks of gestational age,RR,NA,"maternal age, unmarried, medicaid, education less than high school, tobacco use, prior preterm birth, interpregnancy interval <12 month, primiparous, plurality, congenital anomaly, genetic disorder",2,N/A,Black (non-Hispanic),2.88,2.59,3.22
10.1016/j.ajog.2015.12.034,1,No,NA,No,NA,previable live birth at 16 0/7 to 22 6/7 weeks of gestational age,RR,NA,"maternal age, unmarried, medicaid, education less than high school, tobacco use, prior preterm birth, interpregnancy interval <12 month, primiparous, plurality, congenital anomaly, genetic disorder",3,N/A,Hispanic,1.29,0.77,2.17
10.1016/j.ajog.2016.04.049,1,No,NA,No,NA,disease specific survival,Prevalence,NA,none,1,None,White,85.7,-99,-99
10.1016/j.ajog.2016.04.049,1,No,NA,No,NA,disease specific survival,Prevalence,NA,none,2,None,Black,82.9,-99,-99
10.1016/j.ajog.2016.04.049,1,No,NA,No,NA,disease specific survival,Prevalence,NA,none,3,None,Hispanic,85.6,-99,-99
10.1016/j.ajog.2016.04.049,1,No,NA,No,NA,disease specific survival,Prevalence,NA,none,4,None,Asian,95.1,-99,-99
10.1016/j.ajog.2016.04.049,2,No,NA,No,NA,ovarian yolk sac tumor patients,Prevalence,NA,none,1,None,Asian,15.6,-99,-99
10.1016/j.ajog.2016.04.049,2,No,NA,No,NA,ovarian yolk sac tumor patients,Prevalence,NA,none,2,None,Black,16.5,-99,-99
10.1016/j.ajog.2016.04.049,2,No,NA,No,NA,ovarian yolk sac tumor patients,Prevalence,NA,none,3,None,Hispanic,15.6,-99,-99
10.1016/j.ajog.2016.04.049,2,No,NA,No,NA,ovarian yolk sac tumor patients,Prevalence,NA,none,4,None,White,51.3,-99,-99
10.1016/j.ajog.2016.05.007,1,No,NA,No,NA,severe maternal morbidity without hospital characteristics,OR,NA,"maternal age, maternal nativity, maternal education, insurance, prenatal visits, parity, type of pregnancy, pregnancy body mass index, smoked during pregnancy, alcohol use during pregnancy, previous cesarean, comorbidity",1,Non-Hispanic white,Hispanic,1.52,1.42,1.63
10.1016/j.ajog.2016.05.007,1,No,NA,No,NA,severe maternal morbidity without hospital characteristics,OR,NA,"maternal age, maternal nativity, maternal education, insurance, prenatal visits, parity, type of pregnancy, pregnancy body mass index, smoked during pregnancy, alcohol use during pregnancy, previous cesarean, comorbidity",2,Non-Hispanic white,Non-Hispanic black,2.02,1.89,2.17
10.1016/j.ajog.2016.05.007,1,No,NA,No,NA,severe maternal morbidity without hospital characteristics,OR,NA,"maternal age, maternal nativity, maternal education, insurance, prenatal visits, parity, type of pregnancy, pregnancy body mass index, smoked during pregnancy, alcohol use during pregnancy, previous cesarean, comorbidity",3,Non-Hispanic white,Asian,1.08,0.99,1.18
10.1016/j.ajog.2016.05.007,1,No,NA,No,NA,severe maternal morbidity without hospital characteristics,OR,NA,"maternal age, maternal nativity, maternal education, insurance, prenatal visits, parity, type of pregnancy, pregnancy body mass index, smoked during pregnancy, alcohol use during pregnancy, previous cesarean, comorbidity",4,Non-Hispanic white,Other,1.31,0.85,2.04
10.1016/j.ajog.2016.05.007,2,No,NA,No,NA,severe maternal morbidity with hospital characteristics,OR,NA,"maternal age, maternal nativity, maternal education, insurance, prenatal visits, parity, type of pregnancy, pregnancy body mass index, smoked during pregnancy, alcohol use during pregnancy, previous cesarean, comorbidity, hospital characteristics (hospital ownership, teaching status)",1,Non-Hispanic White,Hispanic,1.4,1.31,1.51
10.1016/j.ajog.2016.05.007,2,No,NA,No,NA,severe maternal morbidity with hospital characteristics,OR,NA,"maternal age, maternal nativity, maternal education, insurance, prenatal visits, parity, type of pregnancy, pregnancy body mass index, smoked during pregnancy, alcohol use during pregnancy, previous cesarean, comorbidity, hospital characteristics (hospital ownership, teaching status)",2,Non-Hispanic White,Non-Hispanic black,1.82,1.69,1.95
10.1016/j.ajog.2016.05.007,2,No,NA,No,NA,severe maternal morbidity with hospital characteristics,OR,NA,"maternal age, maternal nativity, maternal education, insurance, prenatal visits, parity, type of pregnancy, pregnancy body mass index, smoked during pregnancy, alcohol use during pregnancy, previous cesarean, comorbidity, hospital characteristics (hospital ownership, teaching status)",3,Non-Hispanic White,Asian,1.09,0.99,1.18
10.1016/j.ajog.2016.05.007,2,No,NA,No,NA,severe maternal morbidity with hospital characteristics,OR,NA,"maternal age, maternal nativity, maternal education, insurance, prenatal visits, parity, type of pregnancy, pregnancy body mass index, smoked during pregnancy, alcohol use during pregnancy, previous cesarean, comorbidity, hospital characteristics (hospital ownership, teaching status)",4,Non-Hispanic White,Other,1.43,1.31,1.51
10.1016/j.ajog.2016.08.019,1,No,NA,No,NA,preterm birth,OR,NA,none,1,White,African-American,1.54,1.33,1.79
10.1016/j.ajog.2016.08.019,1,No,NA,No,NA,preterm birth,OR,NA,none,2,White,Latina/Hispanic,1.27,1.1,1.45
10.1016/j.ajog.2016.08.019,1,No,NA,No,NA,preterm birth,OR,NA,none,3,White,Asian/Pacific Islander,0.95,0.83,1.08
10.1016/j.ajog.2016.08.019,1,No,NA,No,NA,preterm birth,OR,NA,none,4,White,Other,1.13,0.97,1.32
10.1016/j.ajog.2016.08.019,2,No,NA,No,NA,preterm birth,OR,NA,"maternal age, history of preterm birth, maternal body mass index, public insurance status, smoking, use of substances, history of pregestational diabetes mellitus, use of assisted reproductive technology",1,White,African-American,1.08,0.89,1.3
10.1016/j.ajog.2016.08.019,2,No,NA,No,NA,preterm birth,OR,NA,"maternal age, history of preterm birth, maternal body mass index, public insurance status, smoking, use of substances, history of pregestational diabetes mellitus, use of assisted reproductive technology",2,White,Latina/Hispanic,1.04,0.88,1.22
10.1016/j.ajog.2016.08.019,2,No,NA,No,NA,preterm birth,OR,NA,"maternal age, history of preterm birth, maternal body mass index, public insurance status, smoking, use of substances, history of pregestational diabetes mellitus, use of assisted reproductive technology",3,White,Asian/Pacific Islander,0.91,0.79,1.05
10.1016/j.ajog.2016.08.019,2,No,NA,No,NA,preterm birth,OR,NA,"maternal age, history of preterm birth, maternal body mass index, public insurance status, smoking, use of substances, history of pregestational diabetes mellitus, use of assisted reproductive technology",4,White,Other,0.92,0.77,1.1
10.1016/j.ajog.2016.08.019,3,No,NA,No,NA,total preterm birth,Chronic hypertension effect OR,NA,none,1,None,African-American,3.91,2.59,5.9
10.1016/j.ajog.2016.08.019,3,No,NA,No,NA,total preterm birth,Chronic hypertension effect OR,NA,none,2,None,Latina/Hispanic,2.58,1.61,NA
10.1016/j.ajog.2016.08.019,3,No,NA,No,NA,total preterm birth,Chronic hypertension effect OR,NA,none,3,None,Asian/Pacific Islander,3.51,2.39,5.15
10.1016/j.ajog.2016.08.019,3,No,NA,No,NA,total preterm birth,Chronic hypertension effect OR,NA,none,4,None,Other,2.71,1.46,5.06
10.1016/j.ajog.2016.08.019,3,No,NA,No,NA,total preterm birth,Chronic hypertension effect OR,NA,none,5,None,White,2.04,1.5,2.78
10.1016/j.ajog.2016.08.019,4,Yes,NA,Yes,NA,spontaneous preterm birth,Chronic hypertension effect OR,NA,none,1,None,African-American,1.31,0.68,2.53
10.1016/j.ajog.2016.08.019,4,Yes,NA,Yes,NA,spontaneous preterm birth,Chronic hypertension effect OR,NA,none,2,None,Latina/Hispanic,0.98,0.44,2.18
10.1016/j.ajog.2016.08.019,4,Yes,NA,Yes,NA,spontaneous preterm birth,Chronic hypertension effect OR,NA,none,3,None,Asian/Pacific Islander,0.77,0.37,1.61
10.1016/j.ajog.2016.08.019,4,Yes,NA,Yes,NA,spontaneous preterm birth,Chronic hypertension effect OR,NA,none,4,None,Other,0.72,0.22,2.38
10.1016/j.ajog.2016.08.019,4,Yes,NA,Yes,NA,spontaneous preterm birth,Chronic hypertension effect OR,NA,none,5,None,White,0.73,0.42,1.27
10.1016/j.ajog.2016.08.019,5,No,NA,No,NA,medically indicated preterm birth,Chronic hypertension effect OR,NA,none,1,None,African-American,6.85,4.23,11.1
10.1016/j.ajog.2016.08.019,5,No,NA,No,NA,medically indicated preterm birth,Chronic hypertension effect OR,NA,none,2,None,Latina/Hispanic,4.26,2.51,7.23
10.1016/j.ajog.2016.08.019,5,No,NA,No,NA,medically indicated preterm birth,Chronic hypertension effect OR,NA,none,3,None,Asian/Pacific Islander,9.87,6.01,16.21
10.1016/j.ajog.2016.08.019,5,No,NA,No,NA,medically indicated preterm birth,Chronic hypertension effect OR,NA,none,4,None,Other,4.82,2.02,11.5
10.1016/j.ajog.2016.08.019,5,No,NA,No,NA,medically indicated preterm birth,Chronic hypertension effect OR,NA,none,5,None,White,3.64,2.44,5.43
10.1016/j.ajog.2016.10.007,1,No,NA,No,NA,overall pregestational diabetes mellitus,change in rate per 100 deliveries,NA,none,1,None,Non-Hispanic white,59.2,-99,-99
10.1016/j.ajog.2016.10.007,1,No,NA,No,NA,overall pregestational diabetes mellitus,change in rate per 100 deliveries,NA,none,2,None,African American,95.3,-99,-99
10.1016/j.ajog.2016.10.007,1,No,NA,No,NA,overall pregestational diabetes mellitus,change in rate per 100 deliveries,NA,none,3,None,Asian,106,-99,-99
10.1016/j.ajog.2016.10.007,1,No,NA,No,NA,overall pregestational diabetes mellitus,change in rate per 100 deliveries,NA,none,4,None,Hispanic,161,-99,-99
10.1016/j.ajog.2016.10.007,2,No,NA,No,NA,overall pregestational diabetes mellitus,change in rate per 100 deliveries,NA,age,1,None,Non-Hispanic White,49.6,27.4,75.2
10.1016/j.ajog.2016.10.007,2,No,NA,No,NA,overall pregestational diabetes mellitus,change in rate per 100 deliveries,NA,age,2,None,African American,75.8,-99,-99
10.1016/j.ajog.2016.10.007,2,No,NA,No,NA,overall pregestational diabetes mellitus,change in rate per 100 deliveries,NA,age,3,None,Asian,73.8,-99,-99
10.1016/j.ajog.2016.10.007,2,No,NA,No,NA,overall pregestational diabetes mellitus,change in rate per 100 deliveries,NA,age,4,None,Hispanic,121.8,-99,-99
10.1016/j.ajog.2016.10.007,3,No,NA,No,NA,pregestational type 1 diabetes mellitus,change in rate per 100 deliveries,NA,none,1,None,Non-Hispanic White,124,-99,-99
10.1016/j.ajog.2016.10.007,3,No,NA,No,NA,pregestational type 1 diabetes mellitus,change in rate per 100 deliveries,NA,none,2,None,African American,20,-99,-99
10.1016/j.ajog.2016.10.007,3,No,NA,No,NA,pregestational type 1 diabetes mellitus,change in rate per 100 deliveries,NA,none,3,None,Asian,-20,-99,-99
10.1016/j.ajog.2016.10.007,3,No,NA,No,NA,pregestational type 1 diabetes mellitus,change in rate per 100 deliveries,NA,none,4,None,Hispanic,100,-99,-99
10.1016/j.ajog.2016.10.007,4,No,NA,No,NA,pregestational type 1 diabetes mellitus,change in rate per 100 deliveries,NA,age,1,None,Non-Hispanic White,118.4,70,180.5
10.1016/j.ajog.2016.10.007,4,No,NA,No,NA,pregestational type 1 diabetes mellitus,change in rate per 100 deliveries,NA,age,2,None,African American,17,-38.1,121.4
10.1016/j.ajog.2016.10.007,4,No,NA,No,NA,pregestational type 1 diabetes mellitus,change in rate per 100 deliveries,NA,age,3,None,Asian,-18.4,-57.2,55.4
10.1016/j.ajog.2016.10.007,4,No,NA,No,NA,pregestational type 1 diabetes mellitus,change in rate per 100 deliveries,NA,age,4,None,Hispanic,88.3,12.5,215.3
10.1016/j.ajog.2016.10.007,5,No,NA,No,NA,pregestational type 2 diabetes mellitus,change in rate per 100 deliveries,NA,none,1,None,Non-Hispanic White,29,-99,-99
10.1016/j.ajog.2016.10.007,5,No,NA,No,NA,pregestational type 2 diabetes mellitus,change in rate per 100 deliveries,NA,none,2,None,African American,129,-99,-99
10.1016/j.ajog.2016.10.007,5,No,NA,No,NA,pregestational type 2 diabetes mellitus,change in rate per 100 deliveries,NA,none,3,None,Asian,130,-99,-99
10.1016/j.ajog.2016.10.007,5,No,NA,No,NA,pregestational type 2 diabetes mellitus,change in rate per 100 deliveries,NA,none,4,None,Hispanic,173,-99,-99
10.1016/j.ajog.2016.11.1026,1,No,NA,No,NA,respiratory distress syndrome,RR,NA,study site,1,White,Black,0.99,0.91,1.08
10.1016/j.ajog.2016.11.1026,1,No,NA,No,NA,respiratory distress syndrome,RR,NA,study site,2,White,Hispanic,0.89,0.81,0.98
10.1016/j.ajog.2016.11.1026,2,No,NA,No,NA,respiratory distress syndrome,RR,NA,"study site, maternal age, squared maternal age, parity, insurance type, smoking and alcohol use during pregnancy, and marital status",1,White,Black,1.01,0.93,1.1
10.1016/j.ajog.2016.11.1026,2,No,NA,No,NA,respiratory distress syndrome,RR,NA,"study site, maternal age, squared maternal age, parity, insurance type, smoking and alcohol use during pregnancy, and marital status",2,White,Hispanic,0.88,0.8,0.96
10.1016/j.ajog.2016.11.1026,3,No,NA,No,NA,respiratory distress syndrome,RR,NA,"study site, maternal age, squared maternal age, parity, insurance type, smoking and alcohol use during pregnancy, marital status, maternal history of chronic diseases (asthma, depression, hypertension, renal disease, heart disease, diabetes mellitus, and thyroid disease), and prepregnancy body mass index",1,White,Black,0.99,0.91,1.08
10.1016/j.ajog.2016.11.1026,3,No,NA,No,NA,respiratory distress syndrome,RR,NA,"study site, maternal age, squared maternal age, parity, insurance type, smoking and alcohol use during pregnancy, marital status, maternal history of chronic diseases (asthma, depression, hypertension, renal disease, heart disease, diabetes mellitus, and thyroid disease), and prepregnancy body mass index",2,White,Hispanic,0.88,0.79,0.96
10.1016/j.ajog.2016.11.1026,4,No,NA,No,NA,sepsis,RR,NA,study site,1,White,Black,1.41,1.27,1.57
10.1016/j.ajog.2016.11.1026,4,No,NA,No,NA,sepsis,RR,NA,study site,2,White,Hispanic,1.13,1,1.27
10.1016/j.ajog.2016.11.1026,5,No,NA,No,NA,sepsis,RR,NA,"study site, maternal age, squared maternal age, parity, insurance type, smoking and alcohol use during pregnancy, and marital status",1,White,Black,1.43,1.29,1.61
10.1016/j.ajog.2016.11.1026,5,No,NA,No,NA,sepsis,RR,NA,"study site, maternal age, squared maternal age, parity, insurance type, smoking and alcohol use during pregnancy, and marital status",2,White,Hispanic,1.15,1.01,1.3
10.1016/j.ajog.2016.11.1027,1,No,NA,No,NA,"telomere length, as represented by the t/s ratio",Absolute Difference,NA,"placental tissue type (chorion, amnion, villus, cord)",1,White,Black,-0.09,-99,-99
10.1016/j.ajog.2016.11.1027,2,No,NA,No,NA,"placental tissue telomere length, as represented by the t/s ratio",Absolute Difference,NA,"placental tissue type (chorion, amnion, villus, cord), infant sex, maternal education, maternal age, gestational age, duration to sample collection",1,White,Black,-0.12,-99,-99
10.1016/j.ajog.2016.11.1027,3,No,NA,No,NA,amnion placental tissue telomere length,average,NA,none,1,N/A,white,0.919,-99,-99
10.1016/j.ajog.2016.11.1027,3,No,NA,No,NA,amnion placental tissue telomere length,average,NA,none,2,N/A,black,0.862,-99,-99
10.1016/j.ajog.2016.11.1027,4,No,NA,No,NA,cord placental tissue telomere length,average,NA,none,1,N/A,white,0.891,-99,-99
10.1016/j.ajog.2016.11.1027,4,No,NA,No,NA,cord placental tissue telomere length,average,NA,none,2,N/A,black,0.829,-99,-99
10.1016/j.ajog.2016.11.1027,5,No,NA,No,NA,villus placental tissue telomere length,average,NA,none,1,N/A,white,0.9,-99,-99
10.1016/j.ajog.2016.11.1027,5,No,NA,No,NA,villus placental tissue telomere length,average,NA,none,2,N/A,black,0.806,-99,-99
10.1016/j.ajog.2016.12.015,1,Yes,2008-2009,No,NA,pregnancy rate,pregnancies per 1000 person-years,NA,none,1,None,White,6.8,-99,-99
10.1016/j.ajog.2016.12.015,1,Yes,2008-2009,No,NA,pregnancy rate,pregnancies per 1000 person-years,NA,none,2,None,Black,25.1,-99,-99
10.1016/j.ajog.2016.12.015,2,Yes,2010-2011,No,NA,pregnancy rate,pregnancies per 1000 person-years,NA,none,1,None,White,27.2,-99,-99
10.1016/j.ajog.2016.12.015,2,Yes,2010-2011,No,NA,pregnancy rate,pregnancies per 1000 person-years,NA,none,2,None,Black,31.5,-99,-99
10.1016/j.ajog.2016.12.015,3,Yes,2012-2013,No,NA,pregnancy rate,pregnancies per 1000 person-years,NA,none,1,None,White,32,-99,-99
10.1016/j.ajog.2016.12.015,3,Yes,2012-2013,No,NA,pregnancy rate,pregnancies per 1000 person-years,NA,none,2,None,Black,30.5,-99,-99
10.1016/j.ajog.2016.12.020,1,No,NA,No,NA,minimally invasive procedure use,OR,NA,"surgeon hysterectomy volume, hospital hysterectomy volume, hospital bed size, surgeon practicing year, patient age, payer, elixhauser score, fibroids, endometriosis, abnormal menstruation bleeding, benign neoplasm or cyst, pelvic organ prolapse",1,White,Black,0.7,0.63,0.78
10.1016/j.ajog.2016.12.020,1,No,NA,No,NA,minimally invasive procedure use,OR,NA,"surgeon hysterectomy volume, hospital hysterectomy volume, hospital bed size, surgeon practicing year, patient age, payer, elixhauser score, fibroids, endometriosis, abnormal menstruation bleeding, benign neoplasm or cyst, pelvic organ prolapse",2,White,Hispanic ethnicity,0.62,0.48,0.8
10.1016/j.ajog.2016.12.020,1,No,NA,No,NA,minimally invasive procedure use,OR,NA,"surgeon hysterectomy volume, hospital hysterectomy volume, hospital bed size, surgeon practicing year, patient age, payer, elixhauser score, fibroids, endometriosis, abnormal menstruation bleeding, benign neoplasm or cyst, pelvic organ prolapse",3,White,Other,0.86,0.74,1
10.1016/j.ajog.2016.12.020,2,No,NA,No,NA,postoperative complications,OR,NA,"operative technique, surgeon hysterectomy volume, hospital hysterectomy volume, hospital bed size, surgeon practicing year, patient age, payer, elixhauser score, fibroids, endometriosis, abnormal menstruation bleeding, benign neoplasm or cyst, pelvic organ prolapse",1,White,Black,1.45,1.18,1.79
10.1016/j.ajog.2016.12.020,2,No,NA,No,NA,postoperative complications,OR,NA,"operative technique, surgeon hysterectomy volume, hospital hysterectomy volume, hospital bed size, surgeon practicing year, patient age, payer, elixhauser score, fibroids, endometriosis, abnormal menstruation bleeding, benign neoplasm or cyst, pelvic organ prolapse",2,White,Hispanic ethnicity,1.54,0.99,2.38
10.1016/j.ajog.2016.12.020,2,No,NA,No,NA,postoperative complications,OR,NA,"operative technique, surgeon hysterectomy volume, hospital hysterectomy volume, hospital bed size, surgeon practicing year, patient age, payer, elixhauser score, fibroids, endometriosis, abnormal menstruation bleeding, benign neoplasm or cyst, pelvic organ prolapse",3,White,Other,1.32,0.97,1.8
10.1016/j.ajog.2016.12.178,1,No,NA,No,NA,association of race/ethnicity with question responses regarding contraceptive preferences and attitudes - preferences (extremely important): method effectiveness,OR,NA,"age, marital status, income, education, parity, deployment history, medical condition, mental health condition",1,Non-Hispanic white,Non-Hispanic black,0.55,0.4,0.74
10.1016/j.ajog.2016.12.178,1,No,NA,No,NA,association of race/ethnicity with question responses regarding contraceptive preferences and attitudes - preferences (extremely important): method effectiveness,OR,NA,"age, marital status, income, education, parity, deployment history, medical condition, mental health condition",2,Non-Hispanic white,Hispanic,0.82,0.55,1.24
10.1016/j.ajog.2016.12.178,1,No,NA,No,NA,association of race/ethnicity with question responses regarding contraceptive preferences and attitudes - preferences (extremely important): method effectiveness,OR,NA,"age, marital status, income, education, parity, deployment history, medical condition, mental health condition",3,Non-Hispanic white,Other,0.65,0.4,1.05
10.1016/j.ajog.2016.12.178,2,No,NA,No,NA,association of race/ethnicity with question responses regarding contraceptive preferences and attitudes - preferences (extremely important): low cost,OR,NA,"age, marital status, income, education, parity, deployment history, medical condition, mental health condition",1,Non-Hispanic white,Non-Hispanic black,1.3,1.08,1.63
10.1016/j.ajog.2016.12.178,2,No,NA,No,NA,association of race/ethnicity with question responses regarding contraceptive preferences and attitudes - preferences (extremely important): low cost,OR,NA,"age, marital status, income, education, parity, deployment history, medical condition, mental health condition",2,Non-Hispanic white,Hispanic,1.38,1.05,1.82
10.1016/j.ajog.2016.12.178,2,No,NA,No,NA,association of race/ethnicity with question responses regarding contraceptive preferences and attitudes - preferences (extremely important): low cost,OR,NA,"age, marital status, income, education, parity, deployment history, medical condition, mental health condition",3,Non-Hispanic white,Other,1.11,0.79,1.55
10.1016/j.ajog.2016.12.178,3,No,NA,No,NA,association of race/ethnicity with question responses regarding contraceptive preferences and attitudes - preferences (extremely important): easy to use,OR,NA,"age, marital status, income, education, parity, deployment history, medical condition, mental health condition",1,Non-Hispanic white,Non-Hispanic black,1.35,1.04,1.75
10.1016/j.ajog.2016.12.178,3,No,NA,No,NA,association of race/ethnicity with question responses regarding contraceptive preferences and attitudes - preferences (extremely important): easy to use,OR,NA,"age, marital status, income, education, parity, deployment history, medical condition, mental health condition",2,Non-Hispanic white,Hispanic,1.22,0.87,1.71
10.1016/j.ajog.2016.12.178,3,No,NA,No,NA,association of race/ethnicity with question responses regarding contraceptive preferences and attitudes - preferences (extremely important): easy to use,OR,NA,"age, marital status, income, education, parity, deployment history, medical condition, mental health condition",3,Non-Hispanic white,Other,0.98,0.66,1.46
10.1016/j.ajog.2016.12.178,4,No,NA,No,NA,association of race/ethnicity with question responses regarding contraceptive preferences and attitudes - preferences (extremely important): does not contain hormones,OR,NA,"age, marital status, income, education, parity, deployment history, medical condition, mental health condition",1,Non-Hispanic white,Non-Hispanic black,1.94,1.56,2.41
10.1016/j.ajog.2016.12.178,4,No,NA,No,NA,association of race/ethnicity with question responses regarding contraceptive preferences and attitudes - preferences (extremely important): does not contain hormones,OR,NA,"age, marital status, income, education, parity, deployment history, medical condition, mental health condition",2,Non-Hispanic white,Hispanic,1.72,1.29,2.28
10.1016/j.ajog.2016.12.178,4,No,NA,No,NA,association of race/ethnicity with question responses regarding contraceptive preferences and attitudes - preferences (extremely important): does not contain hormones,OR,NA,"age, marital status, income, education, parity, deployment history, medical condition, mental health condition",3,Non-Hispanic white,Other,1.49,1.05,2.13
10.1016/j.ajog.2016.12.178,5,No,NA,No,NA,association of race/ethnicity with question responses regarding contraceptive preferences and attitudes - preferences (extremely important): acceptable to my partner,OR,NA,"age, marital status, income, education, parity, deployment history, medical condition, mental health condition",1,Non-Hispanic white,Non-Hispanic black,1.28,1.04,1.58
10.1016/j.ajog.2016.12.178,5,No,NA,No,NA,association of race/ethnicity with question responses regarding contraceptive preferences and attitudes - preferences (extremely important): acceptable to my partner,OR,NA,"age, marital status, income, education, parity, deployment history, medical condition, mental health condition",2,Non-Hispanic white,Hispanic,1.11,0.84,1.46
10.1016/j.ajog.2016.12.178,5,No,NA,No,NA,association of race/ethnicity with question responses regarding contraceptive preferences and attitudes - preferences (extremely important): acceptable to my partner,OR,NA,"age, marital status, income, education, parity, deployment history, medical condition, mental health condition",3,Non-Hispanic white,Other,1.01,0.71,1.42
10.1016/j.ajog.2017.02.040,1,No,NA,No,NA,"receipt of any postpartum care among low-income women ages 15-44 years delivering in california adjusted for select covariates, 2012",OR,NA,"race/ethnicity, primary language, age at delivery, ever resided in pcsa, delivery method, state-funded health care program at 99 days",1,White,Black,0.73,0.71,0.76
10.1016/j.ajog.2017.02.040,1,No,NA,No,NA,"receipt of any postpartum care among low-income women ages 15-44 years delivering in california adjusted for select covariates, 2012",OR,NA,"race/ethnicity, primary language, age at delivery, ever resided in pcsa, delivery method, state-funded health care program at 99 days",2,White,Latina,1.03,1,1.07
10.1016/j.ajog.2017.02.040,1,No,NA,No,NA,"receipt of any postpartum care among low-income women ages 15-44 years delivering in california adjusted for select covariates, 2012",OR,NA,"race/ethnicity, primary language, age at delivery, ever resided in pcsa, delivery method, state-funded health care program at 99 days",3,White,Asian/Pacific Islander,1.11,1.06,1.16
10.1016/j.ajog.2017.02.040,1,No,NA,No,NA,"receipt of any postpartum care among low-income women ages 15-44 years delivering in california adjusted for select covariates, 2012",OR,NA,"race/ethnicity, primary language, age at delivery, ever resided in pcsa, delivery method, state-funded health care program at 99 days",4,White,Other,1.06,1,1.13
10.1016/j.ajog.2017.02.040,2,No,NA,Yes,Received any contraception,"receipt of any postpartum contraception within 99 days, 2012",OR,NA,"race/ethnicity, primary language, age at delivery, ever resided in pcsa, delivery method, state-funded health care program at 99 days",1,White,Black,0.83,0.78,0.89
10.1016/j.ajog.2017.02.040,2,No,NA,Yes,Received any contraception,"receipt of any postpartum contraception within 99 days, 2012",OR,NA,"race/ethnicity, primary language, age at delivery, ever resided in pcsa, delivery method, state-funded health care program at 99 days",2,White,Latina,1.13,1.08,1.19
10.1016/j.ajog.2017.02.040,2,No,NA,Yes,Received any contraception,"receipt of any postpartum contraception within 99 days, 2012",OR,NA,"race/ethnicity, primary language, age at delivery, ever resided in pcsa, delivery method, state-funded health care program at 99 days",3,White,Asian/Pacific Islander,0.81,0.76,0.87
10.1016/j.ajog.2017.02.040,2,No,NA,Yes,Received any contraception,"receipt of any postpartum contraception within 99 days, 2012",OR,NA,"race/ethnicity, primary language, age at delivery, ever resided in pcsa, delivery method, state-funded health care program at 99 days",4,White,Other,0.8,0.73,0.88
10.1016/j.ajog.2017.02.040,3,No,NA,Yes,Received highly effective contraception,"receipt of any postpartum contraception within 99 days, 2012",OR,NA,"race/ethnicity, primary language, age at delivery, ever resided in pcsa, delivery method, state-funded health care program at 99 days",1,White,Black,0.64,0.58,0.71
10.1016/j.ajog.2017.02.040,3,No,NA,Yes,Received highly effective contraception,"receipt of any postpartum contraception within 99 days, 2012",OR,NA,"race/ethnicity, primary language, age at delivery, ever resided in pcsa, delivery method, state-funded health care program at 99 days",2,White,Latina,0.95,0.9,1
10.1016/j.ajog.2017.02.040,3,No,NA,Yes,Received highly effective contraception,"receipt of any postpartum contraception within 99 days, 2012",OR,NA,"race/ethnicity, primary language, age at delivery, ever resided in pcsa, delivery method, state-funded health care program at 99 days",3,White,Asian/Pacific Islander,0.65,0.59,0.72
10.1016/j.ajog.2017.02.040,3,No,NA,Yes,Received highly effective contraception,"receipt of any postpartum contraception within 99 days, 2012",OR,NA,"race/ethnicity, primary language, age at delivery, ever resided in pcsa, delivery method, state-funded health care program at 99 days",4,White,Other,0.89,0.78,1.01
10.1016/j.ajog.2017.03.001,1,No,NA,No,NA,complications among surgery (salpingectomy or salpingostomy) patients,RR,NA,"surgery, age, year, marital status, insurance status, hospital location, hospital teaching status, hospital bed size, hospital region, comorbidity, annualized hospital volume",1,White,Black,1.02,0.97,1.06
10.1016/j.ajog.2017.03.001,1,No,NA,No,NA,complications among surgery (salpingectomy or salpingostomy) patients,RR,NA,"surgery, age, year, marital status, insurance status, hospital location, hospital teaching status, hospital bed size, hospital region, comorbidity, annualized hospital volume",2,White,Hispanic,1.15,1.07,1.24
10.1016/j.ajog.2017.03.001,1,No,NA,No,NA,complications among surgery (salpingectomy or salpingostomy) patients,RR,NA,"surgery, age, year, marital status, insurance status, hospital location, hospital teaching status, hospital bed size, hospital region, comorbidity, annualized hospital volume",3,White,Other/Unknown,1.13,1.08,1.2
10.1016/j.ajog.2017.05.051,1,No,NA,No,NA,preterm infant delivery < 34 weeks,OR,NA,none,1,Non-Hispanic White mother born >= 37 weeks,Non-Hispanic White mother born 34-36 weeks,1.61,1.24,2.07
10.1016/j.ajog.2017.05.051,1,No,NA,No,NA,preterm infant delivery < 34 weeks,OR,NA,none,2,Non-Hispanic White mother born >= 37 weeks,Non-Hispanic White mother born < 34 weeks,2.15,1.4,3.32
10.1016/j.ajog.2017.05.051,1,No,NA,No,NA,preterm infant delivery < 34 weeks,OR,NA,none,3,Non-Hispanic White mother born >= 37 weeks,Non-Hispanic Black mother born >= 37 weeks,1.88,1.71,2.06
10.1016/j.ajog.2017.05.051,1,No,NA,No,NA,preterm infant delivery < 34 weeks,OR,NA,none,4,Non-Hispanic White mother born >= 37 weeks,Non-Hispanic Black mother born 34-36 weeks,2.43,1.91,3.09
10.1016/j.ajog.2017.05.051,1,No,NA,No,NA,preterm infant delivery < 34 weeks,OR,NA,none,5,Non-Hispanic White mother born >= 37 weeks,Non-Hispanic Black mother born < 34 weeks,2.78,1.96,3.93
10.1016/j.ajog.2017.05.051,2,No,NA,No,NA,preterm infant delivery < 34 weeks,OR,NA,"maternal education, maternal age, smoking, drug/alcohol use, infant gender",1,Non-Hispanic White mother born >= 37 weeks,Non-Hispanic White mother born 34-36 weeks,1.28,0.71,2.31
10.1016/j.ajog.2017.05.051,2,No,NA,No,NA,preterm infant delivery < 34 weeks,OR,NA,"maternal education, maternal age, smoking, drug/alcohol use, infant gender",2,Non-Hispanic White mother born >= 37 weeks,Non-Hispanic White mother born < 34 weeks,2.02,0.81,5.02
10.1016/j.ajog.2017.05.051,2,No,NA,No,NA,preterm infant delivery < 34 weeks,OR,NA,"maternal education, maternal age, smoking, drug/alcohol use, infant gender",3,Non-Hispanic White mother born >= 37 weeks,Non-Hispanic Black mother born >= 37 weeks,1.81,1.48,2.22
10.1016/j.ajog.2017.05.051,2,No,NA,No,NA,preterm infant delivery < 34 weeks,OR,NA,"maternal education, maternal age, smoking, drug/alcohol use, infant gender",4,Non-Hispanic White mother born >= 37 weeks,Non-Hispanic Black mother born 34-36 weeks,2,1.24,3.22
10.1016/j.ajog.2017.05.051,2,No,NA,No,NA,preterm infant delivery < 34 weeks,OR,NA,"maternal education, maternal age, smoking, drug/alcohol use, infant gender",5,Non-Hispanic White mother born >= 37 weeks,Non-Hispanic Black mother born <34 weeks,3.26,1.77,6.02
10.1016/j.ajog.2017.05.051,3,No,NA,No,NA,preterm infant delivery 34-36 weeks,OR,NA,none,1,Non-Hispanic White mother born >= 37 weeks,Non-Hispanic White mother born 34-36 weeks,1.08,0.9,1.31
10.1016/j.ajog.2017.05.051,3,No,NA,No,NA,preterm infant delivery 34-36 weeks,OR,NA,none,2,Non-Hispanic White mother born >= 37 weeks,Non-Hispanic White mother born < 34 weeks,1.21,0.86,1.72
10.1016/j.ajog.2017.05.051,3,No,NA,No,NA,preterm infant delivery 34-36 weeks,OR,NA,none,3,Non-Hispanic White mother born >= 37 weeks,Non-Hispanic Black mother born >= 37 weeks,1.2,1.12,1.28
10.1016/j.ajog.2017.05.051,3,No,NA,No,NA,preterm infant delivery 34-36 weeks,OR,NA,none,4,Non-Hispanic White mother born >= 37 weeks,Non-Hispanic Black mother born 34-36 weeks,1.49,1.23,1.79
10.1016/j.ajog.2017.05.051,3,No,NA,No,NA,preterm infant delivery 34-36 weeks,OR,NA,none,5,Non-Hispanic White mother born >= 37 weeks,Non-Hispanic Black mother born <34 weeks,1.18,0.86,1.62
10.1016/j.ajog.2017.05.051,4,No,NA,No,NA,preterm infant delivery 34-36 weeks,OR,NA,"maternal education, maternal age, smoking, alcohol/drug use, infant gender",1,Non-Hispanic White mother born >= 37 weeks,Non-Hispanic White mother born 34-36 weeks,1.03,0.68,1.54
10.1016/j.ajog.2017.05.051,4,No,NA,No,NA,preterm infant delivery 34-36 weeks,OR,NA,"maternal education, maternal age, smoking, alcohol/drug use, infant gender",2,Non-Hispanic White mother born >= 37 weeks,Non-Hispanic White mother born <34 weeks,1.07,0.5,2.33
10.1016/j.ajog.2017.05.051,4,No,NA,No,NA,preterm infant delivery 34-36 weeks,OR,NA,"maternal education, maternal age, smoking, alcohol/drug use, infant gender",3,Non-Hispanic White mother born >= 37 weeks,Non-Hispanic Black mother born >= 37 weeks,1.26,1.1,1.45
10.1016/j.ajog.2017.05.051,4,No,NA,No,NA,preterm infant delivery 34-36 weeks,OR,NA,"maternal education, maternal age, smoking, alcohol/drug use, infant gender",4,Non-Hispanic White mother born >= 37 weeks,Non-Hispanic Black mother born 34-36 weeks,1.47,1.03,2.1
10.1016/j.ajog.2017.05.051,4,No,NA,No,NA,preterm infant delivery 34-36 weeks,OR,NA,"maternal education, maternal age, smoking, alcohol/drug use, infant gender",5,Non-Hispanic White mother born >= 37 weeks,Non-Hispanic Black mother born < 34 weeks,1.1,0.57,2.11
10.1016/j.ajog.2017.05.051,5,No,NA,No,NA,spontaneous preterm infant delivery < 34 weeks,OR,NA,none,1,Non-Hispanic White mother born >= 37 weeks,Non-Hispanic White mother born 34-36 weeks,1.54,1.14,2.08
10.1016/j.ajog.2017.05.051,5,No,NA,No,NA,spontaneous preterm infant delivery < 34 weeks,OR,NA,none,2,Non-Hispanic White mother born >= 37 weeks,Non-Hispanic White mother born < 34 weeks,2.39,1.48,3.86
10.1016/j.ajog.2017.05.051,5,No,NA,No,NA,spontaneous preterm infant delivery < 34 weeks,OR,NA,none,3,Non-Hispanic White mother born >= 37 weeks,Non-Hispanic Black mother born >= 37 weeks,1.93,1.74,2.15
10.1016/j.ajog.2017.05.051,5,No,NA,No,NA,spontaneous preterm infant delivery < 34 weeks,OR,NA,none,4,Non-Hispanic White mother born >= 37 weeks,Non-Hispanic Black mother born 34-36 weeks,2.69,2.07,3.5
10.1016/j.ajog.2017.05.051,5,No,NA,No,NA,spontaneous preterm infant delivery < 34 weeks,OR,NA,none,5,Non-Hispanic White mother born >= 37 weeks,Non-Hispanic Black mother born < 34 weeks,3.14,2.15,4.6
10.1016/j.ajog.2017.07.036,1,No,NA,No,NA,"all minimally invasive hysterectomies (includes vaginal, laparoscopic, and robot-assisted hysterectomies) vs. abdominal hysterectomy",OR,NA,none,1,White,African American,0.8,0.65,0.97
10.1016/j.ajog.2017.07.036,1,No,NA,No,NA,"all minimally invasive hysterectomies (includes vaginal, laparoscopic, and robot-assisted hysterectomies) vs. abdominal hysterectomy",OR,NA,none,2,White,Other,0.83,0.51,1.34
10.1016/j.ajog.2017.07.036,2,No,NA,No,NA,vaginal hysterectomy vs. abdominal hysterectomy,OR,NA,none,1,White,African American,1.67,1.21,2.3
10.1016/j.ajog.2017.07.036,2,No,NA,No,NA,vaginal hysterectomy vs. abdominal hysterectomy,OR,NA,none,2,White,Other,0.9,0.38,2.11
10.1016/j.ajog.2017.07.036,3,No,NA,No,NA,laparoscopic vs. abdominal hysterectomy,OR,NA,none,1,White,African American,0.99,0.76,1.31
10.1016/j.ajog.2017.07.036,3,No,NA,No,NA,laparoscopic vs. abdominal hysterectomy,OR,NA,none,2,White,Other,0.72,0.35,1.49
10.1016/j.ajog.2017.07.036,4,No,NA,No,NA,robot-assisted hysterectomy vs abdominal hysterectomy,OR,NA,none,1,White,African American,0.38,0.29,0.5
10.1016/j.ajog.2017.07.036,4,No,NA,No,NA,robot-assisted hysterectomy vs abdominal hysterectomy,OR,NA,none,2,White,Other,0.87,0.49,1.54
10.1016/j.ajog.2017.07.036,5,No,NA,No,NA,"all minimally invasive hysterectomies (includes vaginal, laparoscopic, and robot-assisted hysterectomies) vs abdominal hysterectomy",OR,NA,none,1,Not Hispanic,Hispanic,0.63,0.39,1
10.1016/j.ajog.2018.04.052,1,Yes,Severe morbidity including transfusion,No,NA,severe morbidity among women with postpartum hemorrhage,%,NA,none,1,N/A,Black (Non-Hispanic),26.6,-99,-99
10.1016/j.ajog.2018.04.052,1,Yes,Severe morbidity including transfusion,No,NA,severe morbidity among women with postpartum hemorrhage,%,NA,none,2,N/A,White (Non-Hispanic),20.7,-99,-99
10.1016/j.ajog.2018.04.052,1,Yes,Severe morbidity including transfusion,No,NA,severe morbidity among women with postpartum hemorrhage,%,NA,none,3,N/A,Hispanic,22.5,-99,-99
10.1016/j.ajog.2018.04.052,1,Yes,Severe morbidity including transfusion,No,NA,severe morbidity among women with postpartum hemorrhage,%,NA,none,4,N/A,Asian or Pacific Islander,21.4,-99,-99
10.1016/j.ajog.2018.04.052,2,Yes,Severe morbidity excluding transfusion,No,NA,severe morbidity among women with postpartum hemorrhage,%,NA,none,1,N/A,Black (Non-Hispanic),12.1,-99,-99
10.1016/j.ajog.2018.04.052,2,Yes,Severe morbidity excluding transfusion,No,NA,severe morbidity among women with postpartum hemorrhage,%,NA,none,2,N/A,White (Non-Hispanic),9.5,-99,-99
10.1016/j.ajog.2018.04.052,2,Yes,Severe morbidity excluding transfusion,No,NA,severe morbidity among women with postpartum hemorrhage,%,NA,none,3,N/A,Hispanic,9.7,-99,-99
10.1016/j.ajog.2018.04.052,2,Yes,Severe morbidity excluding transfusion,No,NA,severe morbidity among women with postpartum hemorrhage,%,NA,none,4,N/A,Asian or Pacific Islander,10,-99,-99
10.1016/j.ajog.2018.04.052,3,No,NA,No,NA,risk for severe morbidity (including transfusion),RR,NA,none,1,Non-Hispanic white,Non-Hispanic black,1.28,1.25,1.31
10.1016/j.ajog.2018.04.052,3,No,NA,No,NA,risk for severe morbidity (including transfusion),RR,NA,none,2,Non-Hispanic white,Hispanic,1.09,1.06,1.11
10.1016/j.ajog.2018.04.052,3,No,NA,No,NA,risk for severe morbidity (including transfusion),RR,NA,none,3,Non-Hispanic white,Asian or Pacific Islander,1.03,1,1.06
10.1016/j.ajog.2018.04.052,3,No,NA,No,NA,risk for severe morbidity (including transfusion),RR,NA,none,4,Non-Hispanic white,Native American,0.98,0.92,1.04
10.1016/j.ajog.2018.04.052,3,No,NA,No,NA,risk for severe morbidity (including transfusion),RR,NA,none,5,Non-Hispanic white,Unknown,0.73,0.71,0.75
10.1016/j.ajog.2018.04.052,3,No,NA,No,NA,risk for severe morbidity (including transfusion),RR,NA,none,6,Non-Hispanic white,Other,1.17,1.13,1.21
10.1016/j.ajog.2018.04.052,4,No,NA,No,NA,risk for severe morbidity (including transfusion),RR,NA,"year, bed size, insurance status, hospital location, income quartile, hospital region, hospital teaching status, maternal age",1,Non-Hispanic White,Non-Hispanic black,1.24,1.22,1.27
10.1016/j.ajog.2018.04.052,4,No,NA,No,NA,risk for severe morbidity (including transfusion),RR,NA,"year, bed size, insurance status, hospital location, income quartile, hospital region, hospital teaching status, maternal age",2,Non-Hispanic White,Hispanic,1.08,1.06,1.1
10.1016/j.ajog.2018.04.052,4,No,NA,No,NA,risk for severe morbidity (including transfusion),RR,NA,"year, bed size, insurance status, hospital location, income quartile, hospital region, hospital teaching status, maternal age",3,Non-Hispanic White,Asian or Pacific Islander,1.05,1.02,1.08
10.1016/j.ajog.2018.04.052,4,No,NA,No,NA,risk for severe morbidity (including transfusion),RR,NA,"year, bed size, insurance status, hospital location, income quartile, hospital region, hospital teaching status, maternal age",4,Non-Hispanic White,Native American,1.02,0.95,1.09
10.1016/j.ajog.2018.04.052,4,No,NA,No,NA,risk for severe morbidity (including transfusion),RR,NA,"year, bed size, insurance status, hospital location, income quartile, hospital region, hospital teaching status, maternal age",5,Non-Hispanic White,Unknown,0.82,0.8,0.85
10.1016/j.ajog.2018.04.052,4,No,NA,No,NA,risk for severe morbidity (including transfusion),RR,NA,"year, bed size, insurance status, hospital location, income quartile, hospital region, hospital teaching status, maternal age",6,Non-Hispanic White,Other,1.14,1.1,1.17
10.1016/j.ajog.2018.04.052,5,No,NA,No,NA,risk for disseminated intravascular coagulation,%,NA,none,1,N/A,Black (non-Hispanic),8.4,-99,-99
10.1016/j.ajog.2018.04.052,5,No,NA,No,NA,risk for disseminated intravascular coagulation,%,NA,none,2,N/A,White (Non-Hispanic),7.1,-99,-99
10.1016/j.ajog.2018.04.052,5,No,NA,No,NA,risk for disseminated intravascular coagulation,%,NA,none,3,N/A,Hispanic,6.8,-99,-99
10.1016/j.ajog.2018.04.052,5,No,NA,No,NA,risk for disseminated intravascular coagulation,%,NA,none,4,N/A,Asian or Pacific Islander,6.8,-99,-99
10.1016/j.ajog.2018.08.002,1,Yes,Low-grade endometrioid,Yes,None,"association between race and adjuvent treatment in the nrg oncology/gynecologic oncology group 210 study, stratified by tumor subtype",%,NA,NA,1,NA,White,74.1,NA,NA
10.1016/j.ajog.2018.08.002,1,Yes,Low-grade endometrioid,Yes,None,"association between race and adjuvent treatment in the nrg oncology/gynecologic oncology group 210 study, stratified by tumor subtype",%,NA,NA,2,NA,Black,72.4,NA,NA
10.1016/j.ajog.2018.08.002,2,Yes,Low-grade endometrioid,Yes,RT-only,"association between race and adjuvent treatment in the nrg oncology/gynecologic oncology group 210 study, stratified by tumor subtype",%,NA,none,1,NA,White,16.1,NA,NA
10.1016/j.ajog.2018.08.002,2,Yes,Low-grade endometrioid,Yes,RT-only,"association between race and adjuvent treatment in the nrg oncology/gynecologic oncology group 210 study, stratified by tumor subtype",%,NA,none,2,NA,Black,14.5,NA,NA
10.1016/j.ajog.2018.08.002,3,Yes,Low-grade endometrioid,Yes,CT-only,"association between race and adjuvent treatment in the nrg oncology/gynecologic oncology group 210 study, stratified by tumor subtype",%,NA,none,1,NA,White,4.5,NA,NA
10.1016/j.ajog.2018.08.002,3,Yes,Low-grade endometrioid,Yes,CT-only,"association between race and adjuvent treatment in the nrg oncology/gynecologic oncology group 210 study, stratified by tumor subtype",%,NA,none,2,NA,Black,4.5,NA,NA
10.1016/j.ajog.2018.08.002,4,Yes,Low-grade endometrioid,Yes,RT Plus CT,"association between race and adjuvent treatment in the nrg oncology/gynecologic oncology group 210 study, stratified by tumor subtype",%,NA,none,1,NA,White,5.3,NA,NA
10.1016/j.ajog.2018.08.002,4,Yes,Low-grade endometrioid,Yes,RT Plus CT,"association between race and adjuvent treatment in the nrg oncology/gynecologic oncology group 210 study, stratified by tumor subtype",%,NA,none,2,NA,Black,8.6,NA,NA
10.1016/j.ajog.2018.08.002,5,Yes,High-grade endometrioid,Yes,None,"association between race and adjuvent treatment in the nrg oncology/gynecologic oncology group 210 study, stratified by tumor subtype",%,NA,none,1,NA,White,36.8,NA,NA
10.1016/j.ajog.2018.08.002,5,Yes,High-grade endometrioid,Yes,None,"association between race and adjuvent treatment in the nrg oncology/gynecologic oncology group 210 study, stratified by tumor subtype",%,NA,none,2,NA,Black,41.2,NA,NA
10.1016/j.ajog.2018.09.040,1,Yes,Guideline Concordant,No,NA,recognition and evaluation of postmenopausal bleeding and at least 1 diagnostic procedure,Prevalence,NA,none,1,None,White,79,-99,-99
10.1016/j.ajog.2018.09.040,1,Yes,Guideline Concordant,No,NA,recognition and evaluation of postmenopausal bleeding and at least 1 diagnostic procedure,Prevalence,NA,none,2,None,Black,70,-99,-99
10.1016/j.ajog.2018.09.040,2,Yes,Non-guideline Concordant,No,NA,recognition and evaluation of postmenopausal bleeding with no procedures,Prevalence,NA,none,1,None,White,5.4,-99,-99
10.1016/j.ajog.2018.09.040,2,Yes,Non-guideline Concordant,No,NA,recognition and evaluation of postmenopausal bleeding with no procedures,Prevalence,NA,none,2,None,Black,7.3,-99,-99
10.1016/j.ajog.2018.09.040,3,Yes,Non-Guideline Concordant,No,NA,classified with ab codes,Prevalence,NA,none,1,None,White,3.1,-99,-99
10.1016/j.ajog.2018.09.040,3,Yes,Non-Guideline Concordant,No,NA,classified with ab codes,Prevalence,NA,none,2,None,Black,3.7,-99,-99
10.1016/j.ajog.2018.09.040,4,Yes,Non-Guideline Concordant,No,NA,no documented bleeding with at least 1 diagnostic procedure,Prevalence,NA,none,1,None,White,7.5,-99,-99
10.1016/j.ajog.2018.09.040,4,Yes,Non-Guideline Concordant,No,NA,no documented bleeding with at least 1 diagnostic procedure,Prevalence,NA,none,2,None,Black,10.4,-99,-99
10.1016/j.ajog.2018.09.040,5,Yes,Non-Guideline Concordant,No,NA,neither bleeding nor diagnostic procedures,Prevalence,NA,none,1,None,White,5.3,-99,-99
10.1016/j.ajog.2018.09.040,5,Yes,Non-Guideline Concordant,No,NA,neither bleeding nor diagnostic procedures,Prevalence,NA,none,2,None,Black,8.6,-99,-99
10.1016/j.ajog.2019.01.229,1,Yes,BMI < 18.5,Yes,Black and White women,"nugent score, mean","Nugent score, mean",NA,none,1,N/A,Black women,5.08,-99,-99
10.1016/j.ajog.2019.01.229,1,Yes,BMI < 18.5,Yes,Black and White women,"nugent score, mean","Nugent score, mean",NA,none,2,N/A,White women,3.63,-99,-99
10.1016/j.ajog.2019.01.229,2,Yes,BMI 18.5 - 24.9,Yes,Black and White women,"nugent score, mean","Nugent score, mean",NA,none,1,N/A,Black women,4.98,-99,-99
10.1016/j.ajog.2019.01.229,2,Yes,BMI 18.5 - 24.9,Yes,Black and White women,"nugent score, mean","Nugent score, mean",NA,none,2,N/A,White women,3.21,-99,-99
10.1016/j.ajog.2019.01.229,3,Yes,BMI 25 - 29.9,Yes,Black and White women,"nugent score, mean","Nugent score, mean",NA,none,1,N/A,Black women,5.24,-99,-99
10.1016/j.ajog.2019.01.229,3,Yes,BMI 25 - 29.9,Yes,Black and White women,"nugent score, mean","Nugent score, mean",NA,none,2,N/A,White women,3.62,-99,-99
10.1016/j.ajog.2019.01.229,4,Yes,BMI 30 - 34.9,Yes,Black and White women,"nugent score, mean","Nugent score, mean",NA,none,1,N/A,Black women,5.37,-99,-99
10.1016/j.ajog.2019.01.229,4,Yes,BMI 30 - 34.9,Yes,Black and White women,"nugent score, mean","Nugent score, mean",NA,none,2,N/A,White women,3.99,-99,-99
10.1016/j.ajog.2019.01.229,5,Yes,BMI >= 35,Yes,Black and White women,"nugent score, mean","Nugent score, mean",NA,none,1,N/A,Black women,5.19,-99,-99
10.1016/j.ajog.2019.01.229,5,Yes,BMI >= 35,Yes,Black and White women,"nugent score, mean","Nugent score, mean",NA,none,2,N/A,White women,4.08,-99,-99
10.1016/j.ajog.2019.02.016,1,No,NA,No,NA,severe morbidity during postpartum readmissions,RR,NA,none,1,Non-Hispanic white,Non-Hispanic black,1.27,1.24,1.3
10.1016/j.ajog.2019.02.016,1,No,NA,No,NA,severe morbidity during postpartum readmissions,RR,NA,none,2,Non-Hispanic white,Hispanic,0.9,0.87,0.93
10.1016/j.ajog.2019.02.016,1,No,NA,No,NA,severe morbidity during postpartum readmissions,RR,NA,none,3,Non-Hispanic white,Asian or Pacific Islander,1.09,1.03,1.15
10.1016/j.ajog.2019.02.016,1,No,NA,No,NA,severe morbidity during postpartum readmissions,RR,NA,none,4,Non-Hispanic white,Native American,1.1,0.99,1.21
10.1016/j.ajog.2019.02.016,1,No,NA,No,NA,severe morbidity during postpartum readmissions,RR,NA,none,5,Non-Hispanic white,Other,1,0.95,1.05
10.1016/j.ajog.2019.02.016,1,No,NA,No,NA,severe morbidity during postpartum readmissions,RR,NA,none,6,Non-Hispanic white,Unknown,1.05,1.01,1.1
10.1016/j.ajog.2019.02.016,2,No,NA,No,NA,severe morbidity during postpartum readmissions,RR,NA,"year, hospital bed size, insurance status, hospital location, income quartile, hospital region, maternal age, comorbidity index",1,Non-Hispanic White,Non-Hispanic Black,1.16,1.1,1.22
10.1016/j.ajog.2019.02.016,2,No,NA,No,NA,severe morbidity during postpartum readmissions,RR,NA,"year, hospital bed size, insurance status, hospital location, income quartile, hospital region, maternal age, comorbidity index",2,Non-Hispanic White,Hispanic,0.93,0.88,0.99
10.1016/j.ajog.2019.02.016,2,No,NA,No,NA,severe morbidity during postpartum readmissions,RR,NA,"year, hospital bed size, insurance status, hospital location, income quartile, hospital region, maternal age, comorbidity index",3,Non-Hispanic White,Asian or Pacific Islander,1.05,0.95,1.17
10.1016/j.ajog.2019.02.016,2,No,NA,No,NA,severe morbidity during postpartum readmissions,RR,NA,"year, hospital bed size, insurance status, hospital location, income quartile, hospital region, maternal age, comorbidity index",4,Non-Hispanic White,Native American,1.08,0.89,1.32
10.1016/j.ajog.2019.02.016,2,No,NA,No,NA,severe morbidity during postpartum readmissions,RR,NA,"year, hospital bed size, insurance status, hospital location, income quartile, hospital region, maternal age, comorbidity index",5,Non-Hispanic White,Other,1.03,0.93,1.13
10.1016/j.ajog.2019.02.016,2,No,NA,No,NA,severe morbidity during postpartum readmissions,RR,NA,"year, hospital bed size, insurance status, hospital location, income quartile, hospital region, maternal age, comorbidity index",6,Non-Hispanic White,Unknown,1.02,0.94,1.11
10.1016/j.ajog.2019.05.011,1,Yes,Usual care setting,No,NA,postpartum blood pressure ascertainment,RR,NA,unclear,1,Nonblack,Black,1.95,1.3,2.93
10.1016/j.ajog.2019.05.011,2,Yes,text-messaging system,No,NA,postpartum blood pressure ascertainment,RR,NA,unclear,1,Nonblack,Black,0.99,0.87,1.11
10.1016/j.ajog.2019.05.011,3,Yes,Text-messaging system,NA,NA,postpartum blood pressure ascertainment,RR,NA,"unclear, at least texting arm",1,Nonblack,Black,0.51,0.33,0.78
10.1016/j.ajog.2019.07.026,1,Yes,2000,No,NA,travel distance over time based on sociodemographic characteristics,travel distance in miles,NA,n/a,1,N/A,White,6.9,NA,NA
10.1016/j.ajog.2019.07.026,1,Yes,2000,No,NA,travel distance over time based on sociodemographic characteristics,travel distance in miles,NA,n/a,2,N/A,Black,3.7,NA,NA
10.1016/j.ajog.2019.07.026,1,Yes,2000,No,NA,travel distance over time based on sociodemographic characteristics,travel distance in miles,NA,n/a,3,N/A,Hispanic,2.6,NA,NA
10.1016/j.ajog.2019.07.026,1,Yes,2000,No,NA,travel distance over time based on sociodemographic characteristics,travel distance in miles,NA,n/a,4,N/A,Other,4.8,NA,NA
10.1016/j.ajog.2019.07.026,2,Yes,2005,No,NA,travel distance based on sociodemographic characteristics,travel distance in miles,NA,n/a,1,N/A,White,7.9,NA,NA
10.1016/j.ajog.2019.07.026,2,Yes,2005,No,NA,travel distance based on sociodemographic characteristics,travel distance in miles,NA,n/a,2,N/A,Black,3.5,NA,NA
10.1016/j.ajog.2019.07.026,2,Yes,2005,No,NA,travel distance based on sociodemographic characteristics,travel distance in miles,NA,n/a,3,N/A,Hispanic,2.9,NA,NA
10.1016/j.ajog.2019.07.026,2,Yes,2005,No,NA,travel distance based on sociodemographic characteristics,travel distance in miles,NA,n/a,4,N/A,Other,7.1,NA,NA
10.1016/j.ajog.2019.07.026,3,Yes,2010,NA,NA,travel distance based on sociodemographic characteristics,travel distance in miles,NA,n/a,1,N/A,White,9.6,NA,NA
10.1016/j.ajog.2019.07.026,3,Yes,2010,NA,NA,travel distance based on sociodemographic characteristics,travel distance in miles,NA,n/a,2,N/A,Black,3.9,NA,NA
10.1016/j.ajog.2019.07.026,3,Yes,2010,NA,NA,travel distance based on sociodemographic characteristics,travel distance in miles,NA,n/a,3,N/A,Hispanic,3.5,NA,NA
10.1016/j.ajog.2019.07.026,3,Yes,2010,NA,NA,travel distance based on sociodemographic characteristics,travel distance in miles,NA,n/a,4,N/A,Other,5,NA,NA
10.1016/j.ajog.2019.07.026,4,Yes,2014,NA,NA,travel distance based on sociodemographic characteristics,travel distance in miles,NA,n/a,1,N/A,White,11.1,NA,NA
10.1016/j.ajog.2019.07.026,4,Yes,2014,NA,NA,travel distance based on sociodemographic characteristics,travel distance in miles,NA,n/a,2,N/A,Black,3.9,NA,NA
10.1016/j.ajog.2019.07.026,4,Yes,2014,NA,NA,travel distance based on sociodemographic characteristics,travel distance in miles,NA,n/a,3,N/A,Hispanic,3.8,NA,NA
10.1016/j.ajog.2019.07.026,4,Yes,2014,NA,NA,travel distance based on sociodemographic characteristics,travel distance in miles,NA,n/a,4,N/A,Other,6,NA,NA
10.1016/j.ajog.2019.07.026,5,No,NA,No,NA,travel distance based on sociodemographic characteristics,Difference in miles from 2000 to 2014,NA,n/a,1,N/A,White,4.2,3.4,5
10.1016/j.ajog.2019.07.026,5,No,NA,No,NA,travel distance based on sociodemographic characteristics,Difference in miles from 2000 to 2014,NA,n/a,2,N/A,Black,0.2,-0.4,0.8
10.1016/j.ajog.2019.07.026,5,No,NA,No,NA,travel distance based on sociodemographic characteristics,Difference in miles from 2000 to 2014,NA,n/a,3,N/A,Hispanic,1.2,0.03,2.37
10.1016/j.ajog.2019.07.026,5,No,NA,No,NA,travel distance based on sociodemographic characteristics,Difference in miles from 2000 to 2014,NA,n/a,4,N/A,Other,1.2,0.1,2.3
10.1016/j.ajog.2019.12.007,1,No,NA,No,NA,logistic regression model of the association between respondent demographics and residency program characteristics with low lac insertion experience among pgy4 residents,OR,NA,n/a,1,Non-Hispanic White,Other,1.49,1.31,1.68
10.1016/j.ajog.2019.12.007,2,No,NA,No,NA,logistic regression model of the association between respondent demographics and residency program characteristics with low larc insertion experience among pgy4 residents,OR,NA,"gender, race/ethnicity, relationship status, geographic region, type of residency program, size of residency program",1,Non-Hispanic white,Other,1.6,1.1,2.32
10.1016/j.ajog.2020.01.026,1,Yes,Baseline,No,NA,total severe maternal morbidity,RR,NA,none,1,White,Black,1.34,1.27,1.42
10.1016/j.ajog.2020.01.026,1,Yes,Baseline,No,NA,total severe maternal morbidity,RR,NA,none,2,White,Asian,1.03,0.95,1.11
10.1016/j.ajog.2020.01.026,1,Yes,Baseline,No,NA,total severe maternal morbidity,RR,NA,none,3,White,Hispanics,1.09,1.03,1.15
10.1016/j.ajog.2020.01.026,1,Yes,Baseline,No,NA,total severe maternal morbidity,RR,NA,none,4,White,Other,1.08,1,1.18
10.1016/j.ajog.2020.01.026,2,Yes,Postintervention,No,NA,total severe maternal morbidity,RR,NA,none,1,White,Black,1.22,1.05,1.4
10.1016/j.ajog.2020.01.026,2,Yes,Postintervention,No,NA,total severe maternal morbidity,RR,NA,none,2,White,Asian,1.13,1,1.28
10.1016/j.ajog.2020.01.026,2,Yes,Postintervention,No,NA,total severe maternal morbidity,RR,NA,none,3,White,Hispanics,1.1,0.99,1.23
10.1016/j.ajog.2020.01.026,2,Yes,Postintervention,No,NA,total severe maternal morbidity,RR,NA,none,4,White,Others,1.07,0.92,1.25
10.1016/j.ajog.2020.01.026,3,Yes,Baseline,No,NA,severe maternal morbidity excluding cases with transfusion alone,RR,NA,none,1,White,Black,1.46,1.3,1.65
10.1016/j.ajog.2020.01.026,3,Yes,Baseline,No,NA,severe maternal morbidity excluding cases with transfusion alone,RR,NA,none,2,White,Asian,1.15,1.05,1.25
10.1016/j.ajog.2020.01.026,3,Yes,Baseline,No,NA,severe maternal morbidity excluding cases with transfusion alone,RR,NA,none,3,White,Hispanics,1.05,0.95,1.15
10.1016/j.ajog.2020.01.026,3,Yes,Baseline,No,NA,severe maternal morbidity excluding cases with transfusion alone,RR,NA,none,4,White,Others,1.02,0.87,1.19
10.1016/j.ajog.2020.01.026,4,Yes,Postintervention,No,NA,severe maternal morbidity excluding cases with transfusion alone,RR,NA,none,1,White,Black,1.22,0.98,1.52
10.1016/j.ajog.2020.01.026,4,Yes,Postintervention,No,NA,severe maternal morbidity excluding cases with transfusion alone,RR,NA,none,2,White,Asian,1.09,0.9,1.32
10.1016/j.ajog.2020.01.026,4,Yes,Postintervention,No,NA,severe maternal morbidity excluding cases with transfusion alone,RR,NA,none,3,White,Hispanics,0.96,0.82,1.12
10.1016/j.ajog.2020.01.026,4,Yes,Postintervention,No,NA,severe maternal morbidity excluding cases with transfusion alone,RR,NA,none,4,White,Others,0.97,0.75,1.27
10.1016/j.ajog.2020.01.026,5,Yes,Baseline,No,NA,total severe maternal morbidity,RR,NA,"age at delivery, education levels, parity, and insurance status",1,White,Black,1.32,1.25,1.39
10.1016/j.ajog.2020.01.026,5,Yes,Baseline,No,NA,total severe maternal morbidity,RR,NA,"age at delivery, education levels, parity, and insurance status",2,White,Asian,1.02,0.96,1.09
10.1016/j.ajog.2020.01.026,5,Yes,Baseline,No,NA,total severe maternal morbidity,RR,NA,"age at delivery, education levels, parity, and insurance status",3,White,Hispanics,1.07,1.01,1.12
10.1016/j.ajog.2020.01.026,5,Yes,Baseline,No,NA,total severe maternal morbidity,RR,NA,"age at delivery, education levels, parity, and insurance status",4,White,Others,1.07,0.98,1.17
10.1016/j.ajog.2020.02.021,1,No,NA,No,NA,"racial difference in adherence to quality metrics - q1, time to surgery <6 weeks of diagnosis",RR,NA,"hospital clustering, year of diagnosis, stage, grade, histology, lymph vascular invasion, age, insurance status, average household income, urban/rural, comorbidity score, facility location, facility type, hospital volume",1,White,Black,0.89,0.87,0.9
10.1016/j.ajog.2020.02.021,2,No,NA,No,NA,"racial difference in adherence to quality metrics - q2, minimally invasive surgery",RR,NA,"hospital clustering, year of diagnosis, stage, grade, histology, lymph vascular invasion, age, insurance status, average household income, urban/rural, comorbidity score, facility location, facility type, hospital volume",1,White,Black,0.87,0.84,0.9
10.1016/j.ajog.2020.02.021,3,No,NA,No,NA,"racial difference in adherence to quality metrics - q3, pelvic lymphadenectomy",RR,NA,"hospital clustering, year of diagnosis, stage, grade, histology, lymph vascular invasion, age, insurance status, average household income, urban/rural, comorbidity score, facility location, facility type, hospital volume",1,White,Black,0.98,0.96,0.99
10.1016/j.ajog.2020.02.021,4,No,NA,No,NA,"racial difference in adherence to quality metrics - q4, adjuvant radiotherapy",RR,NA,"hospital clustering, year of diagnosis, stage, grade, histology, lymph vascular invasion, age, insurance status, average household income, urban/rural, comorbidity score, facility location, facility type, hospital volume",1,White,Black,1.02,0.98,1.06
10.1016/j.ajog.2020.02.021,5,No,NA,No,NA,"racial difference in adherence to quality metrics - q5, chemotherapy for stage iii/iv disease",RR,NA,"hospital clustering, year of diagnosis, stage, grade, histology, lymph vascular invasion, age, insurance status, average household income, urban/rural, comorbidity score, facility location, facility type, hospital volume",1,White,Black,0.97,0.95,0.99
10.1016/j.ajog.2020.02.027,1,Yes,Infertile,Yes,Treatment,severe maternal morbidity,OR,NA,none,1,Caucasian,Black,1.53,1.04,2.26
10.1016/j.ajog.2020.02.027,1,Yes,Infertile,Yes,Treatment,severe maternal morbidity,OR,NA,none,2,Caucasian,Hispanic,1.16,0.81,1.66
10.1016/j.ajog.2020.02.027,1,Yes,Infertile,Yes,Treatment,severe maternal morbidity,OR,NA,none,3,Caucasian,Asian,0.86,0.65,1.14
10.1016/j.ajog.2020.02.027,2,Yes,Infertile,Yes,Treatment,severe maternal morbidity,OR,NA,"maternal age, year of delivery, nulliparity, education, delivery mode, preterm birth, obesity, smoking, hypertension, diabetes, number of prenatal visits",1,Caucasian,Black,1.2,0.8,1.81
10.1016/j.ajog.2020.02.027,2,Yes,Infertile,Yes,Treatment,severe maternal morbidity,OR,NA,"maternal age, year of delivery, nulliparity, education, delivery mode, preterm birth, obesity, smoking, hypertension, diabetes, number of prenatal visits",2,Caucasian,Hispanic,1.05,0.72,1.52
10.1016/j.ajog.2020.02.027,2,Yes,Infertile,Yes,Treatment,severe maternal morbidity,OR,NA,"maternal age, year of delivery, nulliparity, education, delivery mode, preterm birth, obesity, smoking, hypertension, diabetes, number of prenatal visits",3,Caucasian,Asian,0.9,0.67,1.22
10.1016/j.ajog.2020.02.027,3,Yes,Infertile,Yes,Diagnosis,severe maternal morbidity,OR,NA,none,1,Caucasian,Black,1.63,1.27,2.11
10.1016/j.ajog.2020.02.027,3,Yes,Infertile,Yes,Diagnosis,severe maternal morbidity,OR,NA,none,2,Caucasian,Hispanic,1.17,0.91,1.49
10.1016/j.ajog.2020.02.027,3,Yes,Infertile,Yes,Diagnosis,severe maternal morbidity,OR,NA,none,3,Caucasian,Asian,0.68,0.51,0.9
10.1016/j.ajog.2020.02.027,4,Yes,Infertile,Yes,Diagnosis,severe meternal morbidity,OR,NA,"maternal age, year of delivery, nulliparity, education, delivery mode, preterm birth, obesity, smoking, hypertension, diabetes, number of prenatal visits",1,Caucasian,Black,1.3,0.99,1.7
10.1016/j.ajog.2020.02.027,4,Yes,Infertile,Yes,Diagnosis,severe meternal morbidity,OR,NA,"maternal age, year of delivery, nulliparity, education, delivery mode, preterm birth, obesity, smoking, hypertension, diabetes, number of prenatal visits",2,Caucasian,Hispanic,0.98,0.75,1.26
10.1016/j.ajog.2020.02.027,4,Yes,Infertile,Yes,Diagnosis,severe meternal morbidity,OR,NA,"maternal age, year of delivery, nulliparity, education, delivery mode, preterm birth, obesity, smoking, hypertension, diabetes, number of prenatal visits",3,Caucasian,Asian,0.69,0.51,0.93
10.1016/j.ajog.2020.02.027,5,Yes,Infertile,Yes,Testing,severe maternal morbidity,OR,NA,none,1,Caucasian,Black,0.88,0.2,3.79
10.1016/j.ajog.2020.02.027,5,Yes,Infertile,Yes,Testing,severe maternal morbidity,OR,NA,none,2,Caucasian,Hispanic,1.68,0.75,3.76
10.1016/j.ajog.2020.02.027,5,Yes,Infertile,Yes,Testing,severe maternal morbidity,OR,NA,none,3,Caucasian,Asian,1.54,0.66,3.59
10.1016/j.ajog.2020.02.041,1,No,NA,No,NA,odds ratios for associations between epidemiological and tumor characteristics and guideline-concordant treatment in the overall study population,OR,Univariable,n/a,1,Non-Hispanic white,Non-Hispanic black,0.77,0.72,0.81
10.1016/j.ajog.2020.02.041,1,No,NA,No,NA,odds ratios for associations between epidemiological and tumor characteristics and guideline-concordant treatment in the overall study population,OR,Univariable,n/a,2,Non-Hispanic white,Hispanic,0.8,0.75,0.86
10.1016/j.ajog.2020.02.041,1,No,NA,No,NA,odds ratios for associations between epidemiological and tumor characteristics and guideline-concordant treatment in the overall study population,OR,Univariable,n/a,3,Non-Hispanic white,Asian/Pacific Islander,0.87,0.79,0.95
10.1016/j.ajog.2020.02.041,2,No,NA,No,NA,odds ratios for associations between epidemiological and tumor characteristics and guideline-concordant treatment in overall study population,OR,Multivariable,"age at diagnosis, charlson comorbidity score, hospital type, hospital location, urban/rural, income, education, insurance, stage, grade",1,Non-Hispanic white,Non-Hispanic black,0.92,0.86,0.98
10.1016/j.ajog.2020.02.041,2,No,NA,No,NA,odds ratios for associations between epidemiological and tumor characteristics and guideline-concordant treatment in overall study population,OR,Multivariable,"age at diagnosis, charlson comorbidity score, hospital type, hospital location, urban/rural, income, education, insurance, stage, grade",2,Non-Hispanic white,Hispanic,0.9,0.83,0.97
10.1016/j.ajog.2020.02.041,2,No,NA,No,NA,odds ratios for associations between epidemiological and tumor characteristics and guideline-concordant treatment in overall study population,OR,Multivariable,"age at diagnosis, charlson comorbidity score, hospital type, hospital location, urban/rural, income, education, insurance, stage, grade",3,Non-Hispanic white,Asian/Pacific Islander,1.11,1,1.23
10.1016/j.ajog.2020.02.041,3,Yes,Non-Hispanic white,NA,NA,hazard rations for associations between guideline-concordant treatment and overall survival in the overall population and stratified by race/ethnicity,HR,NA,"age, charlson comorbidity score, hospital type, rurality, income, education, insurance, stage, grade",1,Guideline-concordant treatment Yes,Guideline-concordant treatment No,1.14,1.1,1.18
10.1016/j.ajog.2020.02.041,4,Yes,Non-Hispanic black,NA,NA,hazard ratios for associations between guideline-concordant treatment and overall survival in the overall population and stratified by race/ethnicity,HR,NA,"age, charlson comorbidity score, hospital type, rurality, income, education, insurance, stage, grade",1,Guideline-concordant treatment Yes,Guideline-concordant treatment No,1.09,0.98,1.21
10.1016/j.ajog.2020.02.041,5,Yes,Hispanic,No,NA,hazard ratios for associations between guideline-concordant treatment and overall survival in the overall population and stratified by race/ethnicity,HR,NA,"age, charlson comorbidity score, hospital type, rurality, income, education, insurance, stage, grade",1,Guideline-concordant treatment No,Guideline-concordant treatment No,0.92,0.78,1.09
10.1016/j.ajog.2020.02.042,1,No,NA,No,NA,associations between race/ethnicity and history of any unintended pregnancy,OR,Unadjusted,n/a,1,NH White,Hispanic,1.45,1.115,1.886
10.1016/j.ajog.2020.02.042,1,No,NA,No,NA,associations between race/ethnicity and history of any unintended pregnancy,OR,Unadjusted,n/a,2,NH White,NH Black,1.942,1.594,2.367
10.1016/j.ajog.2020.02.042,1,No,NA,No,NA,associations between race/ethnicity and history of any unintended pregnancy,OR,Unadjusted,n/a,3,NH White,NH other,1.473,1.056,2.054
10.1016/j.ajog.2020.02.042,2,No,NA,No,NA,associations between race/ethnicity and history of any unintended pregnancy,OR,Adjusted,"age, marital status, education, household income, parity, has additional non-va insurance, >1 medical condition, >1 mental health condition, history of military sexual trauma, geographic location",1,NH white,Hispanic,1.575,1.132,2.191
10.1016/j.ajog.2020.02.042,2,No,NA,No,NA,associations between race/ethnicity and history of any unintended pregnancy,OR,Adjusted,"age, marital status, education, household income, parity, has additional non-va insurance, >1 medical condition, >1 mental health condition, history of military sexual trauma, geographic location",2,NH white,NH black,1.805,1.393,2.364
10.1016/j.ajog.2020.02.042,2,No,NA,No,NA,associations between race/ethnicity and history of any unintended pregnancy,OR,Adjusted,"age, marital status, education, household income, parity, has additional non-va insurance, >1 medical condition, >1 mental health condition, history of military sexual trauma, geographic location",3,NH white,NH other,1.576,1.04,2.339
10.1016/j.ajog.2020.02.042,3,No,NA,No,NA,associations between race/ethnicity and any contraceptive use at last sex,OR,Unadjusted,n/a,1,NH white,Hispanic,0.708,0.36,1.393
10.1016/j.ajog.2020.02.042,3,No,NA,No,NA,associations between race/ethnicity and any contraceptive use at last sex,OR,Unadjusted,n/a,2,NH white,NH black,0.821,0.479,1.408
10.1016/j.ajog.2020.02.042,3,No,NA,No,NA,associations between race/ethnicity and any contraceptive use at last sex,OR,Unadjusted,n/a,3,NH white,NH other,1.259,0.438,3.617
10.1016/j.ajog.2020.02.042,4,No,NA,No,NA,associations between race/ethnicity and any contraceptive use at last sex,OR,Adjusted,"age, marital status, education, household income, parity, has additional non-va insurance, >1 medical condition, >1 mental health condition, history of military sexual trauma, geographic location",1,NH white,Hispanic,0.595,0.289,1.1223
10.1016/j.ajog.2020.02.042,4,No,NA,No,NA,associations between race/ethnicity and any contraceptive use at last sex,OR,Adjusted,"age, marital status, education, household income, parity, has additional non-va insurance, >1 medical condition, >1 mental health condition, history of military sexual trauma, geographic location",2,NH white,NH black,0.712,0.39,1.3
10.1016/j.ajog.2020.02.042,4,No,NA,No,NA,associations between race/ethnicity and any contraceptive use at last sex,OR,Adjusted,"age, marital status, education, household income, parity, has additional non-va insurance, >1 medical condition, >1 mental health condition, history of military sexual trauma, geographic location",3,NH white,NH other,1.108,0.371,3.311
10.1016/j.ajog.2020.07.015,1,No,NA,No,NA,rate of administration of antenatal corticosteroids,% of group administered,NA,none,1,None,Non-Hispanic White,44.5,-99,-99
10.1016/j.ajog.2020.07.015,1,No,NA,No,NA,rate of administration of antenatal corticosteroids,% of group administered,NA,none,2,None,Non-Hispanic White,37.8,-99,-99
10.1016/j.ajog.2020.07.015,1,No,NA,No,NA,rate of administration of antenatal corticosteroids,% of group administered,NA,none,3,None,Hispanic,36.8,-99,-99
10.1016/j.ajog.2020.07.015,2,No,NA,No,NA,rate of administration of antenatal corticosteroids,OR,NA,"proportion of women of age >35 years, nulliparity, marital status, higher education, private health insurance, no prenatal care, gestational or prepregnancy diabetes, history of preterm birth, tobacco use, infertility treatment, or birth by cesarean delivery",1,Non-Hispanic White,Non-Hispanic Black,0.83,0.81,0.85
10.1016/j.ajog.2020.07.015,2,No,NA,No,NA,rate of administration of antenatal corticosteroids,OR,NA,"proportion of women of age >35 years, nulliparity, marital status, higher education, private health insurance, no prenatal care, gestational or prepregnancy diabetes, history of preterm birth, tobacco use, infertility treatment, or birth by cesarean delivery",2,Non-Hispanic White,Hispanic,0.8,0.78,0.82
10.1016/j.ajog.2020.08.007,1,NA,NA,NA,NA,NA,NA,NA,n/a,1,NA,Nonwhite race,2.81,NA,NA
10.1016/j.ajog.2020.08.017,1,No,NA,No,NA,severe maternal morbidity,OR,NA,none,1,White,Black,1.99,1.92,2.07
10.1016/j.ajog.2020.08.017,1,No,NA,No,NA,severe maternal morbidity,OR,NA,none,2,White,US-born Hispanic,1.25,1.21,1.29
10.1016/j.ajog.2020.08.017,1,No,NA,No,NA,severe maternal morbidity,OR,NA,none,3,White,Foreign-born Hispanic,1.24,1.21,1.28
10.1016/j.ajog.2020.08.017,1,No,NA,No,NA,severe maternal morbidity,OR,NA,none,4,White,Asian and Pacific Islander,1.24,1.2,1.28
10.1016/j.ajog.2020.08.017,1,No,NA,No,NA,severe maternal morbidity,OR,NA,none,5,White,Other,1.55,1.37,1.75
10.1016/j.ajog.2020.08.017,1,No,NA,No,NA,severe maternal morbidity,OR,NA,none,6,White,Unknown,1.28,1.19,1.39
10.1016/j.ajog.2020.08.017,2,No,NA,No,NA,severe maternal morbidity,OR,NA,sociodemographic factors,1,White,Black,1.76,1.69,1.84
10.1016/j.ajog.2020.08.017,2,No,NA,No,NA,severe maternal morbidity,OR,NA,sociodemographic factors,2,White,US-born Hispanic,1.29,1.24,1.33
10.1016/j.ajog.2020.08.017,2,No,NA,No,NA,severe maternal morbidity,OR,NA,sociodemographic factors,3,White,Foreign-born Hispanic,1.12,1.07,1.18
10.1016/j.ajog.2020.08.017,2,No,NA,No,NA,severe maternal morbidity,OR,NA,sociodemographic factors,4,White,Asian and Pacific Islander,1.27,1.21,1.32
10.1016/j.ajog.2020.08.017,2,No,NA,No,NA,severe maternal morbidity,OR,NA,sociodemographic factors,5,White,Other,1.45,1.28,1.65
10.1016/j.ajog.2020.08.017,2,No,NA,No,NA,severe maternal morbidity,OR,NA,sociodemographic factors,6,White,Unknown,1.08,0.97,1.19
10.1016/j.ajog.2020.08.017,3,No,NA,No,NA,severe maternal morbidity,OR,NA,"sociodemographic factors, pregnancy-related behaviors",1,White,Black,1.68,1.61,1.75
10.1016/j.ajog.2020.08.017,3,No,NA,No,NA,severe maternal morbidity,OR,NA,"sociodemographic factors, pregnancy-related behaviors",2,White,US-born Hispanic,1.32,1.28,1.37
10.1016/j.ajog.2020.08.017,3,No,NA,No,NA,severe maternal morbidity,OR,NA,"sociodemographic factors, pregnancy-related behaviors",3,White,Foreign-born Hispanic,1.18,1.12,1.24
10.1016/j.ajog.2020.08.017,3,No,NA,No,NA,severe maternal morbidity,OR,NA,"sociodemographic factors, pregnancy-related behaviors",4,White,Asian and Pacific Islander,1.29,1.23,1.34
10.1016/j.ajog.2020.08.017,3,No,NA,No,NA,severe maternal morbidity,OR,NA,"sociodemographic factors, pregnancy-related behaviors",5,White,Other,1.44,1.27,1.63
10.1016/j.ajog.2020.08.017,3,No,NA,No,NA,severe maternal morbidity,OR,NA,"sociodemographic factors, pregnancy-related behaviors",6,White,Unknown,1.03,0.93,1.13
10.1016/j.ajog.2020.08.017,4,No,NA,No,NA,severe maternal morbidity,OR,NA,"sociodemographic factors, pregnancy-related behaviors, clinical factors",1,White,Black,1.25,1.19,1.31
10.1016/j.ajog.2020.08.017,4,No,NA,No,NA,severe maternal morbidity,OR,NA,"sociodemographic factors, pregnancy-related behaviors, clinical factors",2,White,US-born Hispanic,1.25,1.2,1.29
10.1016/j.ajog.2020.08.017,4,No,NA,No,NA,severe maternal morbidity,OR,NA,"sociodemographic factors, pregnancy-related behaviors, clinical factors",3,White,Foreign-born Hispanic,1.17,1.11,1.24
10.1016/j.ajog.2020.08.017,4,No,NA,No,NA,severe maternal morbidity,OR,NA,"sociodemographic factors, pregnancy-related behaviors, clinical factors",4,White,Asian and Pacific Islander,1.26,1.21,1.32
10.1016/j.ajog.2020.08.017,4,No,NA,No,NA,severe maternal morbidity,OR,NA,"sociodemographic factors, pregnancy-related behaviors, clinical factors",5,White,Other,1.31,1.15,1.49
10.1016/j.ajog.2020.08.017,4,No,NA,No,NA,severe maternal morbidity,OR,NA,"sociodemographic factors, pregnancy-related behaviors, clinical factors",6,White,Unknown,1,0.9,1.1
10.1016/j.ajog.2020.08.017,5,No,NA,No,NA,severe maternal morbidity,OR,NA,"sociodemographic factors, pregnancy-related behaviors, clinical factors, hospital factors",1,White,Black,1.25,1.19,1.31
10.1016/j.ajog.2020.08.017,5,No,NA,No,NA,severe maternal morbidity,OR,NA,"sociodemographic factors, pregnancy-related behaviors, clinical factors, hospital factors",2,White,US-born Hispanic,1.25,1.2,1.29
10.1016/j.ajog.2020.08.017,5,No,NA,No,NA,severe maternal morbidity,OR,NA,"sociodemographic factors, pregnancy-related behaviors, clinical factors, hospital factors",3,White,Foreign-born Hispanic,1.17,1.11,1.24
10.1016/j.ajog.2020.08.017,5,No,NA,No,NA,severe maternal morbidity,OR,NA,"sociodemographic factors, pregnancy-related behaviors, clinical factors, hospital factors",4,White,Asian and Pacific Islander,1.26,1.21,1.32
10.1016/j.ajog.2020.08.017,5,No,NA,No,NA,severe maternal morbidity,OR,NA,"sociodemographic factors, pregnancy-related behaviors, clinical factors, hospital factors",5,White,Other,1.31,1.15,1.5
10.1016/j.ajog.2020.08.017,5,No,NA,No,NA,severe maternal morbidity,OR,NA,"sociodemographic factors, pregnancy-related behaviors, clinical factors, hospital factors",6,White,Unknown,0.99,0.89,1.1
10.1016/j.ajog.2020.08.050,1,Yes,Did Pap test only,No,NA,abnormal pap test by pap test alone or cotesting,Prevalence,NA,none,1,N/A,Non-Hispanic white,11.71,10.45,13.09
10.1016/j.ajog.2020.08.050,1,Yes,Did Pap test only,No,NA,abnormal pap test by pap test alone or cotesting,Prevalence,NA,none,2,N/A,Non-Hispanic black,14.13,10.83,18.22
10.1016/j.ajog.2020.08.050,1,Yes,Did Pap test only,No,NA,abnormal pap test by pap test alone or cotesting,Prevalence,NA,none,3,N/A,Hispanic,15.88,12.85,19.46
10.1016/j.ajog.2020.08.050,1,Yes,Did Pap test only,No,NA,abnormal pap test by pap test alone or cotesting,Prevalence,NA,none,4,N/A,Other,7.76,5.43,10.96
10.1016/j.ajog.2020.08.050,2,Yes,Did HPV testing with Pap test,No,NA,abnormal hpv test,Prevalence,NA,none,1,N/A,Non-Hispanic white,12.65,10.64,14.98
10.1016/j.ajog.2020.08.050,2,Yes,Did HPV testing with Pap test,No,NA,abnormal hpv test,Prevalence,NA,none,2,N/A,Non-Hispanic black,13.03,9.19,18.14
10.1016/j.ajog.2020.08.050,2,Yes,Did HPV testing with Pap test,No,NA,abnormal hpv test,Prevalence,NA,none,3,N/A,Hispanic,14.59,10.33,20.22
10.1016/j.ajog.2020.08.050,2,Yes,Did HPV testing with Pap test,No,NA,abnormal hpv test,Prevalence,NA,none,4,N/A,Other,10.23,6,16.9
10.1016/j.ajog.2020.08.050,3,Yes,Did HPV testing with Pap test,No,NA,abnormal hpv and pap tests,Prevalence,NA,none,1,N/A,Non-Hispanic white,6.21,4.88,7.87
10.1016/j.ajog.2020.08.050,3,Yes,Did HPV testing with Pap test,No,NA,abnormal hpv and pap tests,Prevalence,NA,none,2,N/A,Non-Hispanic black,5.84,3.5,9.6
10.1016/j.ajog.2020.08.050,3,Yes,Did HPV testing with Pap test,No,NA,abnormal hpv and pap tests,Prevalence,NA,none,3,N/A,Hispanic,5.62,3.21,9.66
10.1016/j.ajog.2020.08.050,3,Yes,Did HPV testing with Pap test,No,NA,abnormal hpv and pap tests,Prevalence,NA,none,4,N/A,Other,3.9,1.73,8.55
10.1016/j.ajog.2020.09.013,1,No,NA,No,NA,positive pregnancy test,Prevalence,%,none,1,N/A,White Donor,72.1,-99,-99
10.1016/j.ajog.2020.09.013,1,No,NA,No,NA,positive pregnancy test,Prevalence,%,none,2,N/A,Black Donor,57.5,-99,-99
10.1016/j.ajog.2020.09.013,1,No,NA,No,NA,positive pregnancy test,Prevalence,%,none,3,N/A,Hispanic Donor,72.7,-99,-99
10.1016/j.ajog.2020.09.013,1,No,NA,No,NA,positive pregnancy test,Prevalence,%,none,4,N/A,Asian Donor,66.3,-99,-99
10.1016/j.ajog.2020.09.013,1,No,NA,No,NA,positive pregnancy test,Prevalence,%,none,5,N/A,Other Donor,65.9,-99,-99
10.1016/j.ajog.2020.09.013,2,No,NA,No,NA,positive pregnancy test,RR,NA,"donor age, donor bmi, recipient age, recipient bmi, tubal factor infertility, uterine factory infertility, and year of retrieval",1,White,Black Donor,0.85,0.75,0.96
10.1016/j.ajog.2020.09.013,2,No,NA,No,NA,positive pregnancy test,RR,NA,"donor age, donor bmi, recipient age, recipient bmi, tubal factor infertility, uterine factory infertility, and year of retrieval",2,White,Hispanic,1.1,1.01,1.2
10.1016/j.ajog.2020.09.013,2,No,NA,No,NA,positive pregnancy test,RR,NA,"donor age, donor bmi, recipient age, recipient bmi, tubal factor infertility, uterine factory infertility, and year of retrieval",3,White,Asian,0.91,0.82,1.02
10.1016/j.ajog.2020.09.013,2,No,NA,No,NA,positive pregnancy test,RR,NA,"donor age, donor bmi, recipient age, recipient bmi, tubal factor infertility, uterine factory infertility, and year of retrieval",4,White,Other,0.93,0.82,1.06
10.1016/j.ajog.2020.09.013,3,No,NA,No,NA,positive pregnancy test,Prevalence,NA,none,1,N/A,White Recipient,71.9,-99,-99
10.1016/j.ajog.2020.09.013,3,No,NA,No,NA,positive pregnancy test,Prevalence,NA,none,2,N/A,Black Recipient,59.7,-99,-99
10.1016/j.ajog.2020.09.013,3,No,NA,No,NA,positive pregnancy test,Prevalence,NA,none,3,N/A,Hispanic Recipient,72.9,-99,-99
10.1016/j.ajog.2020.09.013,3,No,NA,No,NA,positive pregnancy test,Prevalence,NA,none,4,N/A,Asian Recipient,69.2,-99,-99
10.1016/j.ajog.2020.09.013,3,No,NA,No,NA,positive pregnancy test,Prevalence,NA,none,5,N/A,Other Recipient,64.3,-99,-99
10.1016/j.ajog.2020.09.013,4,No,NA,No,NA,positive pregnancy test,RR,NA,"donor age, donor bmi, recipient age, recipient bmi, tubal factor infertility, and year of retrieval",1,White Recipient,Black Recipient,0.85,0.77,0.95
10.1016/j.ajog.2020.09.013,4,No,NA,No,NA,positive pregnancy test,RR,NA,"donor age, donor bmi, recipient age, recipient bmi, tubal factor infertility, and year of retrieval",2,White Recipient,Hispanic Recipient,1.07,0.97,1.17
10.1016/j.ajog.2020.09.013,4,No,NA,No,NA,positive pregnancy test,RR,NA,"donor age, donor bmi, recipient age, recipient bmi, tubal factor infertility, and year of retrieval",3,White Recipient,Asian Recipient,0.95,0.86,1.04
10.1016/j.ajog.2020.09.013,4,No,NA,No,NA,positive pregnancy test,RR,NA,"donor age, donor bmi, recipient age, recipient bmi, tubal factor infertility, and year of retrieval",4,White Recipient,Other Recipient,0.88,0.69,1.14
10.1016/j.ajog.2020.09.013,5,No,NA,No,NA,live birth,Prevalence,%,none,1,N/A,White Donor,50.4,-99,-99
10.1016/j.ajog.2020.09.013,5,No,NA,No,NA,live birth,Prevalence,%,none,2,N/A,Black Donor,40.1,-99,-99
10.1016/j.ajog.2020.09.013,5,No,NA,No,NA,live birth,Prevalence,%,none,3,N/A,Hispanic Donor,54.6,-99,-99
10.1016/j.ajog.2020.09.013,5,No,NA,No,NA,live birth,Prevalence,%,none,4,N/A,Asian Donor,45.3,-99,-99
10.1016/j.ajog.2020.09.013,5,No,NA,No,NA,live birth,Prevalence,%,none,5,N/A,Other Donor,39,-99,-99
10.1016/j.ajog.2020.12.018,1,No,NA,No,NA,contacting a papanicolaou test referral before 1 month of follow-up,OR,NA,none,1,White,Other,2,1.5,2.7
10.1016/j.ajog.2020.12.018,2,No,NA,No,NA,contacting a papanicolaou test referral before 1 month of follow-up,OR,NA,"age, insurance status, self-rated health, smoking, and study group",1,White,Other,2.04,1.5,2.8
10.1016/j.ajog.2020.12.018,3,No,NA,No,NA,in need of cervical cancer screening at baseline,OR,NA,"age, insurance status, self-rated health, and smoking status",1,White,nonwhite race,2.1,1.5,2.9
10.1016/j.ajog.2021.01.004,1,No,NA,No,NA,maternal in-hospital mortality,RR,NA,"maternal age, insurance, gestational age at delivery, multiple gestations, mode of delivery, rurality, year, pregnancy comorbid conditions (chronic hypertension, chronic cardiac disease, diabetes mellitus, chronic renal disease), and state of delivery",1,White,Black,1.44,1.17,1.79
10.1016/j.ajog.2021.01.004,2,Yes,Teaching status - Teaching,No,NA,maternal in-hospital mortality,RR,NA,"maternal age, insurance, gestational age at delivery, multiple gestations, mode of delivery, rurality, year, pregnancy comorbid conditions (chronic hypertension, chronic cardiac disease, diabetes mellitus, chronic renal disease), state of delivery",1,White,Black,1.42,0.9,2.15
10.1016/j.ajog.2021.01.004,3,Yes,Teaching status - Nonteaching,No,NA,maternal in-hospital mortality,RR,NA,"maternal age, insurance, gestational age at delivery, multiple gestations, mode of delivery, rurality, year, pregnancy comorbid conditions (chronic hypertension, chronic cardiac disease, diabetes mellitus, chronic renal disease), and state of delivery",1,White,Black,1.42,1.09,1.86
10.1016/j.ajog.2021.01.004,4,Yes,Black-serving status - Non Black-serving,No,NA,maternal in-hospital mortality,RR,NA,"maternal age, insurance, gestational age at delivery, multiple gestations, mode of delivery, rurality, year, pregnancy comorbid conditions (chronic hypertension, chronic cardiac disease, diabetes mellitus, chronic renal disease), state of delivery",1,White,Black,1.41,0.88,2.16
10.1016/j.ajog.2021.01.004,5,Yes,Black-serving status - Black-serving,No,NA,maternal in-hospital mortality,RR,NA,"maternal age, insurance, gestational age at delivery, multiple gestations, mode of delivery, rurality, year, pregnancy comorbid conditions (chronic hypertension, chronic cardiac disease, diabetes mellitus, chronic renal disease), and state of delivery",1,White,Black,1.23,0.95,1.69
10.1016/j.ajog.2021.02.015,1,Yes,Timing/age,NA,NA,"model-based average adjusted predictions of patient responses on visual analog scales expressing agreement with the following statement: “in general, the ability to bear children rests on timing/age",Mean point estimate (scale 0-100),NA,"respondent race or ethnicity, age, parity, household income, religion, education, fertility treatment status, and insurance coverage",1,N/A,White,28,26.4,29.6
10.1016/j.ajog.2021.02.015,1,Yes,Timing/age,NA,NA,"model-based average adjusted predictions of patient responses on visual analog scales expressing agreement with the following statement: “in general, the ability to bear children rests on timing/age",Mean point estimate (scale 0-100),NA,"respondent race or ethnicity, age, parity, household income, religion, education, fertility treatment status, and insurance coverage",2,N/A,Black,30.7,25.3,36.1
10.1016/j.ajog.2021.02.015,1,Yes,Timing/age,NA,NA,"model-based average adjusted predictions of patient responses on visual analog scales expressing agreement with the following statement: “in general, the ability to bear children rests on timing/age",Mean point estimate (scale 0-100),NA,"respondent race or ethnicity, age, parity, household income, religion, education, fertility treatment status, and insurance coverage",3,N/A,Latinx,27.4,21.3,33.4
10.1016/j.ajog.2021.02.015,1,Yes,Timing/age,NA,NA,"model-based average adjusted predictions of patient responses on visual analog scales expressing agreement with the following statement: “in general, the ability to bear children rests on timing/age",Mean point estimate (scale 0-100),NA,"respondent race or ethnicity, age, parity, household income, religion, education, fertility treatment status, and insurance coverage",4,N/A,Asian,24,18.8,29.1
10.1016/j.ajog.2021.02.015,1,Yes,Timing/age,NA,NA,"model-based average adjusted predictions of patient responses on visual analog scales expressing agreement with the following statement: “in general, the ability to bear children rests on timing/age",Mean point estimate (scale 0-100),NA,"respondent race or ethnicity, age, parity, household income, religion, education, fertility treatment status, and insurance coverage",5,N/A,Multiple or other,30.4,24.8,36.1
10.1016/j.ajog.2021.02.015,2,Yes,Stress,NA,NA,"model-based average adjusted predictions of patient responses on visual analog scales expressing agreement with the following statement: “in general, the ability to bear children rests on stress",Mean point estimate,NA,"respondent race or ethnicity, age, parity, household income, religion, education, fertility treatment status, and insurance coverage",1,N/A,White,52.8,50.9,54.8
10.1016/j.ajog.2021.02.015,2,Yes,Stress,NA,NA,"model-based average adjusted predictions of patient responses on visual analog scales expressing agreement with the following statement: “in general, the ability to bear children rests on stress",Mean point estimate,NA,"respondent race or ethnicity, age, parity, household income, religion, education, fertility treatment status, and insurance coverage",2,N/A,Black,40,33.3,46.7
10.1016/j.ajog.2021.02.015,2,Yes,Stress,NA,NA,"model-based average adjusted predictions of patient responses on visual analog scales expressing agreement with the following statement: “in general, the ability to bear children rests on stress",Mean point estimate,NA,"respondent race or ethnicity, age, parity, household income, religion, education, fertility treatment status, and insurance coverage",3,N/A,Latinx,42,34.6,49.5
10.1016/j.ajog.2021.02.015,2,Yes,Stress,NA,NA,"model-based average adjusted predictions of patient responses on visual analog scales expressing agreement with the following statement: “in general, the ability to bear children rests on stress",Mean point estimate,NA,"respondent race or ethnicity, age, parity, household income, religion, education, fertility treatment status, and insurance coverage",4,N/A,Asian,41.6,35.1,48.1
10.1016/j.ajog.2021.02.015,2,Yes,Stress,NA,NA,"model-based average adjusted predictions of patient responses on visual analog scales expressing agreement with the following statement: “in general, the ability to bear children rests on stress",Mean point estimate,NA,"respondent race or ethnicity, age, parity, household income, religion, education, fertility treatment status, and insurance coverage",5,N/A,Multiple or other,46.5,39.6,53.5
10.1016/j.ajog.2021.02.015,3,Yes,God's will,NA,NA,"model-based average adjusted predictions of patient responses on visual analog scales expressing agreement with the following statement: “in general, the ability to bear children rests on god's will",Mean point estimate,NA,"respondent race or ethnicity, age, parity, household income, religion, education, fertility treatment status, and insurance coverage",1,N/A,White,70.2,68.1,72.2
10.1016/j.ajog.2021.02.015,3,Yes,God's will,NA,NA,"model-based average adjusted predictions of patient responses on visual analog scales expressing agreement with the following statement: “in general, the ability to bear children rests on god's will",Mean point estimate,NA,"respondent race or ethnicity, age, parity, household income, religion, education, fertility treatment status, and insurance coverage",2,N/A,Black,41.4,34.5,48.4
10.1016/j.ajog.2021.02.015,3,Yes,God's will,NA,NA,"model-based average adjusted predictions of patient responses on visual analog scales expressing agreement with the following statement: “in general, the ability to bear children rests on god's will",Mean point estimate,NA,"respondent race or ethnicity, age, parity, household income, religion, education, fertility treatment status, and insurance coverage",3,N/A,Latinx,53.6,45.9,61.2
10.1016/j.ajog.2021.02.015,3,Yes,God's will,NA,NA,"model-based average adjusted predictions of patient responses on visual analog scales expressing agreement with the following statement: “in general, the ability to bear children rests on god's will",Mean point estimate,NA,"respondent race or ethnicity, age, parity, household income, religion, education, fertility treatment status, and insurance coverage",4,N/A,Asian,55.6,48.3,62.1
10.1016/j.ajog.2021.02.015,3,Yes,God's will,NA,NA,"model-based average adjusted predictions of patient responses on visual analog scales expressing agreement with the following statement: “in general, the ability to bear children rests on god's will",Mean point estimate,NA,"respondent race or ethnicity, age, parity, household income, religion, education, fertility treatment status, and insurance coverage",5,N/A,Multiple or other,66.3,59,73.6
10.1016/j.ajog.2021.02.015,4,Yes,Biology/physiology,NA,NA,"model-based average adjusted predictions of patient responses on visual analog scales expressing agreement with the following statement: “in general, the ability to bear children rests on biology/physiology",Mean point estimate,NA,"respondent race or ethnicity, age, parity, household income, religion, education, fertility treatment status, and insurance coverage",1,N/A,White,20.8,19.4,22.2
10.1016/j.ajog.2021.02.015,4,Yes,Biology/physiology,NA,NA,"model-based average adjusted predictions of patient responses on visual analog scales expressing agreement with the following statement: “in general, the ability to bear children rests on biology/physiology",Mean point estimate,NA,"respondent race or ethnicity, age, parity, household income, religion, education, fertility treatment status, and insurance coverage",2,N/A,Black,29.8,24.7,34.3
10.1016/j.ajog.2021.02.015,4,Yes,Biology/physiology,NA,NA,"model-based average adjusted predictions of patient responses on visual analog scales expressing agreement with the following statement: “in general, the ability to bear children rests on biology/physiology",Mean point estimate,NA,"respondent race or ethnicity, age, parity, household income, religion, education, fertility treatment status, and insurance coverage",3,N/A,Latinx,27.7,22.6,32.8
10.1016/j.ajog.2021.02.015,4,Yes,Biology/physiology,NA,NA,"model-based average adjusted predictions of patient responses on visual analog scales expressing agreement with the following statement: “in general, the ability to bear children rests on biology/physiology",Mean point estimate,NA,"respondent race or ethnicity, age, parity, household income, religion, education, fertility treatment status, and insurance coverage",4,N/A,Asian,19.1,14.5,23.6
10.1016/j.ajog.2021.02.015,4,Yes,Biology/physiology,NA,NA,"model-based average adjusted predictions of patient responses on visual analog scales expressing agreement with the following statement: “in general, the ability to bear children rests on biology/physiology",Mean point estimate,NA,"respondent race or ethnicity, age, parity, household income, religion, education, fertility treatment status, and insurance coverage",5,N/A,Multiple or other,19.6,14.7,24.4
10.1016/j.ajog.2021.02.015,5,Yes,Chance,NA,NA,"model-based average adjusted predictions of patient responses on visual analog scales expressing agreement with the following statement: “in general, the ability to bear children rests on chance",Mean point estimate,NA,"respondent race or ethnicity, age, parity, household income, religion, education, fertility treatment status, and insurance coverage",1,N/A,White,46.9,45,48.8
10.1016/j.ajog.2021.02.015,5,Yes,Chance,NA,NA,"model-based average adjusted predictions of patient responses on visual analog scales expressing agreement with the following statement: “in general, the ability to bear children rests on chance",Mean point estimate,NA,"respondent race or ethnicity, age, parity, household income, religion, education, fertility treatment status, and insurance coverage",2,N/A,Black,48.1,41.4,54.9
10.1016/j.ajog.2021.02.015,5,Yes,Chance,NA,NA,"model-based average adjusted predictions of patient responses on visual analog scales expressing agreement with the following statement: “in general, the ability to bear children rests on chance",Mean point estimate,NA,"respondent race or ethnicity, age, parity, household income, religion, education, fertility treatment status, and insurance coverage",3,N/A,Latinx,43.1,35.8,50.4
10.1016/j.ajog.2021.02.015,5,Yes,Chance,NA,NA,"model-based average adjusted predictions of patient responses on visual analog scales expressing agreement with the following statement: “in general, the ability to bear children rests on chance",Mean point estimate,NA,"respondent race or ethnicity, age, parity, household income, religion, education, fertility treatment status, and insurance coverage",4,N/A,Asian,45.7,39.4,52
10.1016/j.ajog.2021.02.015,5,Yes,Chance,NA,NA,"model-based average adjusted predictions of patient responses on visual analog scales expressing agreement with the following statement: “in general, the ability to bear children rests on chance",Mean point estimate,NA,"respondent race or ethnicity, age, parity, household income, religion, education, fertility treatment status, and insurance coverage",5,N/A,Multiple or other,41.3,34.4,48.1
10.1016/j.ajog.2021.02.017,1,No,NA,No,NA,cervical length cutoff < 15 mm,%,NA,none,1,N/A,White,0.2,NA,NA
10.1016/j.ajog.2021.02.017,1,No,NA,No,NA,cervical length cutoff < 15 mm,%,NA,none,2,N/A,Black,0.9,NA,NA
10.1016/j.ajog.2021.02.017,1,No,NA,No,NA,cervical length cutoff < 15 mm,%,NA,none,3,N/A,Hispanic,0.5,NA,NA
10.1016/j.ajog.2021.02.017,1,No,NA,No,NA,cervical length cutoff < 15 mm,%,NA,none,4,N/A,Other,0.5,NA,NA
10.1016/j.ajog.2021.02.017,2,No,NA,No,NA,cervical length cutoff < 25 mm,%,NA,none,1,N/A,White,1,NA,NA
10.1016/j.ajog.2021.02.017,2,No,NA,No,NA,cervical length cutoff < 25 mm,%,NA,none,2,N/A,Black,3.8,NA,NA
10.1016/j.ajog.2021.02.017,2,No,NA,No,NA,cervical length cutoff < 25 mm,%,NA,none,3,N/A,Hispanic,1.7,NA,NA
10.1016/j.ajog.2021.02.017,2,No,NA,No,NA,cervical length cutoff < 25 mm,%,NA,none,4,N/A,Other,1.2,NA,NA
10.1016/j.ajog.2021.02.017,3,No,NA,No,NA,cervical length cutoff > 30 mm,%,NA,none,1,N/A,White,3.9,NA,NA
10.1016/j.ajog.2021.02.017,3,No,NA,No,NA,cervical length cutoff > 30 mm,%,NA,none,2,N/A,Black,9,NA,NA
10.1016/j.ajog.2021.02.017,3,No,NA,No,NA,cervical length cutoff > 30 mm,%,NA,none,3,N/A,Hispanic,4.5,NA,NA
10.1016/j.ajog.2021.02.017,3,No,NA,No,NA,cervical length cutoff > 30 mm,%,NA,none,4,N/A,Other,4.5,NA,NA
10.1016/j.ajog.2021.02.017,4,No,NA,No,NA,funneling,%,NA,none,1,N/A,White,0.5,NA,NA
10.1016/j.ajog.2021.02.017,4,No,NA,No,NA,funneling,%,NA,none,2,N/A,Black,2.6,NA,NA
10.1016/j.ajog.2021.02.017,4,No,NA,No,NA,funneling,%,NA,none,3,N/A,Hispanic,1.8,NA,NA
10.1016/j.ajog.2021.02.017,4,No,NA,No,NA,funneling,%,NA,none,4,N/A,Other,1.9,NA,NA
10.1016/j.ajog.2021.02.017,5,No,NA,No,NA,debris,%,NA,none,1,N/A,White,0.5,NA,NA
10.1016/j.ajog.2021.02.017,5,No,NA,No,NA,debris,%,NA,none,2,N/A,Black,2.6,NA,NA
10.1016/j.ajog.2021.02.017,5,No,NA,No,NA,debris,%,NA,none,3,N/A,Hispanic,1.8,NA,NA
10.1016/j.ajog.2021.02.017,5,No,NA,No,NA,debris,%,NA,none,4,N/A,Other,1.9,NA,NA
10.1016/j.ajog.2021.02.028,1,No,NA,No,NA,total pregnancy-related mortality ratio,"number of pregnancy-related deaths per 100,000 live births",NA,none,1,N/A,White,12,11.4,12.6
10.1016/j.ajog.2021.02.028,1,No,NA,No,NA,total pregnancy-related mortality ratio,"number of pregnancy-related deaths per 100,000 live births",NA,none,2,N/A,Black,39.5,37.5,41.7
10.1016/j.ajog.2021.02.028,1,No,NA,No,NA,total pregnancy-related mortality ratio,"number of pregnancy-related deaths per 100,000 live births",NA,none,3,N/A,American Indian or Alaska Native,28.8,22.2,36.7
10.1016/j.ajog.2021.02.028,1,No,NA,No,NA,total pregnancy-related mortality ratio,"number of pregnancy-related deaths per 100,000 live births",NA,none,4,N/A,Asian or Pacific Islander,13.1,11.3,15
10.1016/j.ajog.2021.02.028,1,No,NA,No,NA,total pregnancy-related mortality ratio,"number of pregnancy-related deaths per 100,000 live births",NA,none,5,N/A,Hispanic,10.4,9.6,11.3
10.1016/j.ajog.2021.02.028,2,Yes,urban-rural category - large metro,No,NA,pregnancy-related mortality ratio,"number of pregnancy-related deaths per 100,000 live births",NA,none,1,N/A,White,9.5,8.8,10.3
10.1016/j.ajog.2021.02.028,2,Yes,urban-rural category - large metro,No,NA,pregnancy-related mortality ratio,"number of pregnancy-related deaths per 100,000 live births",NA,none,2,N/A,Black,36.7,34.3,39.3
10.1016/j.ajog.2021.02.028,2,Yes,urban-rural category - large metro,No,NA,pregnancy-related mortality ratio,"number of pregnancy-related deaths per 100,000 live births",NA,none,3,N/A,American Indian or Alaska Native,18.5,8.9,34.1
10.1016/j.ajog.2021.02.028,2,Yes,urban-rural category - large metro,No,NA,pregnancy-related mortality ratio,"number of pregnancy-related deaths per 100,000 live births",NA,none,4,N/A,Asian or Pacific Islander,12,10.1,14.1
10.1016/j.ajog.2021.02.028,2,Yes,urban-rural category - large metro,No,NA,pregnancy-related mortality ratio,"number of pregnancy-related deaths per 100,000 live births",NA,none,5,N/A,Hispanic,9.9,8.9,11
10.1016/j.ajog.2021.02.028,3,Yes,urban-rural category - medium metro,No,NA,pregnancy-related mortality ratio,"number of pregnancy-related deaths per 100,000 live births",NA,none,1,N/A,White,12.9,11.6,14.3
10.1016/j.ajog.2021.02.028,3,Yes,urban-rural category - medium metro,No,NA,pregnancy-related mortality ratio,"number of pregnancy-related deaths per 100,000 live births",NA,none,2,N/A,Black,40.3,35.6,45.5
10.1016/j.ajog.2021.02.028,3,Yes,urban-rural category - medium metro,No,NA,pregnancy-related mortality ratio,"number of pregnancy-related deaths per 100,000 live births",NA,none,3,N/A,American Indian or Alaska Native,20.3,9.3,38.6
10.1016/j.ajog.2021.02.028,3,Yes,urban-rural category - medium metro,No,NA,pregnancy-related mortality ratio,"number of pregnancy-related deaths per 100,000 live births",NA,none,4,N/A,Asian or Pacific Islander,14.8,10.4,20.5
10.1016/j.ajog.2021.02.028,3,Yes,urban-rural category - medium metro,No,NA,pregnancy-related mortality ratio,"number of pregnancy-related deaths per 100,000 live births",NA,none,5,N/A,Hispanic,11.1,9.2,13.2
10.1016/j.ajog.2021.02.028,4,Yes,urban-rural category - small metro,No,NA,pregnancy-related mortality ratio,"number of pregnancy-related deaths per 100,000 live births",NA,none,1,N/A,White,12.1,10.4,14
10.1016/j.ajog.2021.02.028,4,Yes,urban-rural category - small metro,No,NA,pregnancy-related mortality ratio,"number of pregnancy-related deaths per 100,000 live births",NA,none,2,N/A,Black,45.3,37.3,54.6
10.1016/j.ajog.2021.02.028,4,Yes,urban-rural category - small metro,No,NA,pregnancy-related mortality ratio,"number of pregnancy-related deaths per 100,000 live births",NA,none,3,N/A,American Indian or Alaska Native,39.2,20.2,68.4
10.1016/j.ajog.2021.02.028,4,Yes,urban-rural category - small metro,No,NA,pregnancy-related mortality ratio,"number of pregnancy-related deaths per 100,000 live births",NA,none,4,N/A,Asian or Pacific Islander,12.7,5.8,24.2
10.1016/j.ajog.2021.02.028,4,Yes,urban-rural category - small metro,No,NA,pregnancy-related mortality ratio,"number of pregnancy-related deaths per 100,000 live births",NA,none,5,N/A,Hispanic,11,7.7,15.3
10.1016/j.ajog.2021.02.028,5,Yes,urban-rural category - micropolitan,No,NA,pregnancy-related mortality ratio,"number of pregnancy-related deaths per 100,000 live births",NA,none,1,N/A,White,16.1,14.1,18.4
10.1016/j.ajog.2021.02.028,5,Yes,urban-rural category - micropolitan,No,NA,pregnancy-related mortality ratio,"number of pregnancy-related deaths per 100,000 live births",NA,none,2,N/A,Black,52.8,42.5,64.7
10.1016/j.ajog.2021.02.028,5,Yes,urban-rural category - micropolitan,No,NA,pregnancy-related mortality ratio,"number of pregnancy-related deaths per 100,000 live births",NA,none,3,N/A,American Indian or Alaska Native,32.3,18.1,53.2
10.1016/j.ajog.2021.02.028,5,Yes,urban-rural category - micropolitan,No,NA,pregnancy-related mortality ratio,"number of pregnancy-related deaths per 100,000 live births",NA,none,4,N/A,Asian or Pacific Islander,22.9,10.5,43.6
10.1016/j.ajog.2021.02.028,5,Yes,urban-rural category - micropolitan,No,NA,pregnancy-related mortality ratio,"number of pregnancy-related deaths per 100,000 live births",NA,none,5,N/A,Hispanic,14.1,9.8,19.6
10.1016/j.ajog.2021.02.036,1,No,NA,No,NA,cesarean section deliveries,OR,NA,none,1,White,Black,1.5,1.38,1.63
10.1016/j.ajog.2021.02.036,2,No,NA,No,NA,admitted to adult intensive care unit,OR,NA,none,1,White,Black,2.78,1.46,5.27
10.1016/j.ajog.2021.02.036,3,No,NA,No,NA,severe maternal morbidity,OR,NA,none,1,White,Black,1.67,1.3,2.15
10.1016/j.ajog.2021.02.036,4,No,NA,Yes,excluding blood transfusions,severe maternal morbidity,OR,NA,none,1,White,Black,1.99,1.17,3.36
10.1016/j.ajog.2021.02.036,5,No,NA,Yes,hemorrhage cases,severe maternal morbidity,OR,NA,none,1,White,Black,1.24,0.84,1.85
10.1016/j.ajog.2021.03.040,1,Yes,2009-2013,NA,NA,pregnancy-related mortality ratios for florida,"Pregnancy-related deaths per 100,000 live births",NA,n/a,1,N/A,Non-Hispanic White,15.8,NA,NA
10.1016/j.ajog.2021.03.040,1,Yes,2009-2013,NA,NA,pregnancy-related mortality ratios for florida,"Pregnancy-related deaths per 100,000 live births",NA,n/a,2,N/A,Non-Hispanic Black,46.6,NA,NA
10.1016/j.ajog.2021.03.040,1,Yes,2009-2013,NA,NA,pregnancy-related mortality ratios for florida,"Pregnancy-related deaths per 100,000 live births",NA,n/a,3,N/A,Hispanic,12.8,NA,NA
10.1016/j.ajog.2021.03.040,2,Yes,2014-2018,NA,NA,pregnancy-related mortality ratios for florida,"Pregnancy-related deaths per 100,000 live births",NA,n/a,1,N/A,Non-Hispanic White,14.5,NA,NA
10.1016/j.ajog.2021.03.040,2,Yes,2014-2018,NA,NA,pregnancy-related mortality ratios for florida,"Pregnancy-related deaths per 100,000 live births",NA,n/a,2,N/A,Non-Hispanic Black,29.4,NA,NA
10.1016/j.ajog.2021.03.040,2,Yes,2014-2018,NA,NA,pregnancy-related mortality ratios for florida,"Pregnancy-related deaths per 100,000 live births",NA,n/a,3,N/A,Hispanic,7.4,NA,NA
10.1016/j.ajog.2021.05.002,1,No,NA,No,NA,abdominal sacrocolpopexy vs vaginal colpopexy for treatment of apical prolapse by race and ethnicity,OR,NA,"age, comorbidities, asa classification, concurrent surgery",1,White,African American,1.07,0.94,1.22
10.1016/j.ajog.2021.05.002,1,No,NA,No,NA,abdominal sacrocolpopexy vs vaginal colpopexy for treatment of apical prolapse by race and ethnicity,OR,NA,"age, comorbidities, asa classification, concurrent surgery",2,White,Latina,0.92,0.83,1.02
10.1016/j.ajog.2021.05.002,1,No,NA,No,NA,abdominal sacrocolpopexy vs vaginal colpopexy for treatment of apical prolapse by race and ethnicity,OR,NA,"age, comorbidities, asa classification, concurrent surgery",3,White,Asian,0.82,0.68,0.99
10.1016/j.ajog.2021.05.002,1,No,NA,No,NA,abdominal sacrocolpopexy vs vaginal colpopexy for treatment of apical prolapse by race and ethnicity,OR,NA,"age, comorbidities, asa classification, concurrent surgery",4,White,American Indian or Alaska Native,0.89,0.55,1.45
10.1016/j.ajog.2021.05.002,1,No,NA,No,NA,abdominal sacrocolpopexy vs vaginal colpopexy for treatment of apical prolapse by race and ethnicity,OR,NA,"age, comorbidities, asa classification, concurrent surgery",5,White,Native Hawaiian or Pacific Islander,0.56,0.39,0.82
10.1016/j.ajog.2021.05.002,1,No,NA,No,NA,abdominal sacrocolpopexy vs vaginal colpopexy for treatment of apical prolapse by race and ethnicity,OR,NA,"age, comorbidities, asa classification, concurrent surgery",6,White,Unknown,0.47,0.43,0.52
10.1016/j.ajog.2021.05.002,2,No,NA,Yes,Abdominal sacrocolpopexy,laparoscopic vs open (laparotomy) abdominal sacrocolpopexy by race and ethnicity,OR,NA,"age, comorbidities, asa classification, concurrent surgery",1,White,African American,0.85,0.69,1.04
10.1016/j.ajog.2021.05.002,2,No,NA,Yes,Abdominal sacrocolpopexy,laparoscopic vs open (laparotomy) abdominal sacrocolpopexy by race and ethnicity,OR,NA,"age, comorbidities, asa classification, concurrent surgery",2,White,Latina,0.68,0.58,0.79
10.1016/j.ajog.2021.05.002,2,No,NA,Yes,Abdominal sacrocolpopexy,laparoscopic vs open (laparotomy) abdominal sacrocolpopexy by race and ethnicity,OR,NA,"age, comorbidities, asa classification, concurrent surgery",3,White,Asian,0.81,0.6,1.09
10.1016/j.ajog.2021.05.002,2,No,NA,Yes,Abdominal sacrocolpopexy,laparoscopic vs open (laparotomy) abdominal sacrocolpopexy by race and ethnicity,OR,NA,"age, comorbidities, asa classification, concurrent surgery",4,White,American Indian or Alaska Native,0.6,0.29,1.21
10.1016/j.ajog.2021.05.002,2,No,NA,Yes,Abdominal sacrocolpopexy,laparoscopic vs open (laparotomy) abdominal sacrocolpopexy by race and ethnicity,OR,NA,"age, comorbidities, asa classification, concurrent surgery",5,White,Native Hawaiian or Pacific Islander,0.31,0.17,0.56
10.1016/j.ajog.2021.05.002,2,No,NA,Yes,Abdominal sacrocolpopexy,laparoscopic vs open (laparotomy) abdominal sacrocolpopexy by race and ethnicity,OR,NA,"age, comorbidities, asa classification, concurrent surgery",6,White,Unknown,0.44,0.38,0.52
10.1016/j.ajog.2021.05.002,3,No,NA,No,NA,30-day postoperative complications - blood transfusion,OR,NA,"age, comorbidities, asa classification, concurrent surgery, surgical approach",1,White,African American,3.04,1.95,4.73
10.1016/j.ajog.2021.05.002,3,No,NA,No,NA,30-day postoperative complications - blood transfusion,OR,NA,"age, comorbidities, asa classification, concurrent surgery, surgical approach",2,White,Latina,2.65,1.82,3.87
10.1016/j.ajog.2021.05.002,3,No,NA,No,NA,30-day postoperative complications - blood transfusion,OR,NA,"age, comorbidities, asa classification, concurrent surgery, surgical approach",3,White,Asian,1.85,0.89,3.85
10.1016/j.ajog.2021.05.002,3,No,NA,No,NA,30-day postoperative complications - blood transfusion,OR,NA,"age, comorbidities, asa classification, concurrent surgery, surgical approach",4,White,American Indian or Alaska Native,1.52,0.21,11.12
10.1016/j.ajog.2021.05.002,3,No,NA,No,NA,30-day postoperative complications - blood transfusion,OR,NA,"age, comorbidities, asa classification, concurrent surgery, surgical approach",5,White,Native Hawaiian or Pacific Islander,-99,-99,-99
10.1016/j.ajog.2021.05.002,3,No,NA,No,NA,30-day postoperative complications - blood transfusion,OR,NA,"age, comorbidities, asa classification, concurrent surgery, surgical approach",6,White,Unknown,1.53,0.99,2.37
10.1016/j.ajog.2021.05.002,4,No,NA,No,NA,30-day postoperative complications - deep venous thrombosis and pulmonary embolism,OR,NA,"age, comorbidities, asa classification, concurrent surgery, surgical approach",1,White,African American,2.46,1.1,5.48
10.1016/j.ajog.2021.05.002,4,No,NA,No,NA,30-day postoperative complications - deep venous thrombosis and pulmonary embolism,OR,NA,"age, comorbidities, asa classification, concurrent surgery, surgical approach",2,White,Latina,0.59,0.18,1.94
10.1016/j.ajog.2021.05.002,4,No,NA,No,NA,30-day postoperative complications - deep venous thrombosis and pulmonary embolism,OR,NA,"age, comorbidities, asa classification, concurrent surgery, surgical approach",3,White,Asian,0.81,0.11,5.95
10.1016/j.ajog.2021.05.002,4,No,NA,No,NA,30-day postoperative complications - deep venous thrombosis and pulmonary embolism,OR,NA,"age, comorbidities, asa classification, concurrent surgery, surgical approach",4,White,American Indian or Alaska Native,-99,-99,-99
10.1016/j.ajog.2021.05.002,4,No,NA,No,NA,30-day postoperative complications - deep venous thrombosis and pulmonary embolism,OR,NA,"age, comorbidities, asa classification, concurrent surgery, surgical approach",5,White,Native Hawaiian or Pacific Islander,-99,-99,-99
10.1016/j.ajog.2021.05.002,4,No,NA,No,NA,30-day postoperative complications - deep venous thrombosis and pulmonary embolism,OR,NA,"age, comorbidities, asa classification, concurrent surgery, surgical approach",6,White,Unknown,-99,-99,-99
10.1016/j.ajog.2021.05.002,5,No,NA,No,NA,30-day postoperative complications - urinary tract infection,OR,NA,"age, comorbidities, asa classification, concurrent surgery, surgical approach",1,White,African American,0.68,0.49,0.96
10.1016/j.ajog.2021.05.002,5,No,NA,No,NA,30-day postoperative complications - urinary tract infection,OR,NA,"age, comorbidities, asa classification, concurrent surgery, surgical approach",2,White,Latina,1.08,0.87,1.34
10.1016/j.ajog.2021.05.002,5,No,NA,No,NA,30-day postoperative complications - urinary tract infection,OR,NA,"age, comorbidities, asa classification, concurrent surgery, surgical approach",3,White,Asian,1.05,0.7,1.56
10.1016/j.ajog.2021.05.002,5,No,NA,No,NA,30-day postoperative complications - urinary tract infection,OR,NA,"age, comorbidities, asa classification, concurrent surgery, surgical approach",4,White,American Indian or Alaska Native,0.24,0.03,1.71
10.1016/j.ajog.2021.05.002,5,No,NA,No,NA,30-day postoperative complications - urinary tract infection,OR,NA,"age, comorbidities, asa classification, concurrent surgery, surgical approach",5,White,Native Hawaiian or Pacific Islander,1.47,0.74,2.91
10.1016/j.ajog.2021.05.002,5,No,NA,No,NA,30-day postoperative complications - urinary tract infection,OR,NA,"age, comorbidities, asa classification, concurrent surgery, surgical approach",6,White,Unknown,1.57,1.32,1.86
10.1016/j.ajog.2021.05.045,1,No,NA,No,NA,bilateral oophorectomy alone in 2011,"rate per 10,000 women",NA,NA,1,Non-Hispanic White,Non-Hispanic Black,1.8,NA,NA
10.1016/j.ajog.2021.05.045,1,No,NA,No,NA,bilateral oophorectomy alone in 2011,"rate per 10,000 women",NA,NA,2,Non-Hispanic White,Non-Hispanic White,0.8,NA,NA
10.1016/j.ajog.2021.05.045,2,No,NA,No,NA,hysterectomy with bilateral oophorectomy in 2011,"rate per 10,000 women",NA,NA,1,Non-Hispanic White,Non-Hispanic Black,11.4,NA,NA
10.1016/j.ajog.2021.05.045,2,No,NA,No,NA,hysterectomy with bilateral oophorectomy in 2011,"rate per 10,000 women",NA,NA,2,Non-Hispanic White,Non-Hispanic White,16.8,NA,NA
10.1016/j.ajog.2021.05.045,3,No,NA,No,NA,overall bilateral oophorectomy in 2011,"rate per 10,000 women",NA,NA,1,Non-Hispanic White,Non-Hispanic Black,13.2,NA,NA
10.1016/j.ajog.2021.05.045,3,No,NA,No,NA,overall bilateral oophorectomy in 2011,"rate per 10,000 women",NA,NA,2,Non-Hispanic White,Non-Hispanic White,17.7,NA,NA
10.1016/j.ajog.2021.05.045,4,No,NA,No,NA,bilateral oophorectomy alone in 2012,"rate per 10,000 women",NA,NA,1,Non-Hispanic White,Non-Hispanic Black,1.1,NA,NA
10.1016/j.ajog.2021.05.045,4,No,NA,No,NA,bilateral oophorectomy alone in 2012,"rate per 10,000 women",NA,NA,2,Non-Hispanic White,Non-Hispanic White,1,NA,NA
10.1016/j.ajog.2021.05.045,5,No,NA,No,NA,hysterectomy with bilateral oophorectomy in 2012,"rate per 10,000 women",NA,NA,1,Non-Hispanic White,Non-Hispanic Black,11.4,NA,NA
10.1016/j.ajog.2021.05.045,5,No,NA,No,NA,hysterectomy with bilateral oophorectomy in 2012,"rate per 10,000 women",NA,NA,2,Non-Hispanic White,Non-Hispanic White,16.8,NA,NA
10.1016/j.fertnstert.2010.06.062,1,No,NA,No,NA,methotrexate treatment failure of ectopic pregnancy,RR,NA,none,1,White,African American,0.94,0.76,1.2
10.1016/j.fertnstert.2010.06.062,2,No,NA,No,NA,required public assistance,Prevalence,NA,none,1,None,African American,14.8,-99,-99
10.1016/j.fertnstert.2010.06.062,2,No,NA,No,NA,required public assistance,Prevalence,NA,none,2,None,White,5.7,-99,-99
10.1016/j.fertnstert.2010.06.062,3,No,NA,No,NA,tubal rupture,RR,NA,none,1,White,African American,0.88,0.19,4.07
10.1016/j.fertnstert.2015.05.012,1,No,NA,No,NA,clinical pregnancy,Rate (%),NA,none,1,N/A,White,36.2,-99,-99
10.1016/j.fertnstert.2015.05.012,1,No,NA,No,NA,clinical pregnancy,Rate (%),NA,none,2,N/A,Black,24.4,-99,-99
10.1016/j.fertnstert.2015.05.012,1,No,NA,No,NA,clinical pregnancy,Rate (%),NA,none,3,N/A,Asian,31.4,-99,-99
10.1016/j.fertnstert.2015.05.012,1,No,NA,No,NA,clinical pregnancy,Rate (%),NA,none,4,N/A,Hispanic,34,-99,-99
10.1016/j.fertnstert.2015.05.012,2,No,NA,No,NA,spontaneous abortion,Rate (%),NA,none,1,N/A,White,14.6,-99,-99
10.1016/j.fertnstert.2015.05.012,2,No,NA,No,NA,spontaneous abortion,Rate (%),NA,none,2,N/A,Black,28.9,-99,-99
10.1016/j.fertnstert.2015.05.012,2,No,NA,No,NA,spontaneous abortion,Rate (%),NA,none,3,N/A,Asian,20.6,-99,-99
10.1016/j.fertnstert.2015.05.012,2,No,NA,No,NA,spontaneous abortion,Rate (%),NA,none,4,N/A,Hispanic,15.3,-99,-99
10.1016/j.fertnstert.2015.05.012,3,No,NA,No,NA,multiple pregnancy,Rate (%),NA,none,1,N/A,White,21.9,-99,-99
10.1016/j.fertnstert.2015.05.012,3,No,NA,No,NA,multiple pregnancy,Rate (%),NA,none,2,N/A,Black,7.7,-99,-99
10.1016/j.fertnstert.2015.05.012,3,No,NA,No,NA,multiple pregnancy,Rate (%),NA,none,3,N/A,Asian,21.8,-99,-99
10.1016/j.fertnstert.2015.05.012,3,No,NA,No,NA,multiple pregnancy,Rate (%),NA,none,4,N/A,Hispanic,19.4,-99,-99
10.1016/j.fertnstert.2015.05.012,4,No,NA,No,NA,live birth,Rate (%),NA,none,1,N/A,White,30.7,-99,-99
10.1016/j.fertnstert.2015.05.012,4,No,NA,No,NA,live birth,Rate (%),NA,none,2,N/A,Black,16.9,-99,-99
10.1016/j.fertnstert.2015.05.012,4,No,NA,No,NA,live birth,Rate (%),NA,none,3,N/A,Asian,24,-99,-99
10.1016/j.fertnstert.2015.05.012,4,No,NA,No,NA,live birth,Rate (%),NA,none,4,N/A,Hispanic,28.5,-99,-99
10.1016/j.fertnstert.2015.05.012,5,No,NA,No,NA,clinical pregnancy,OR,NA,"age, body mass index, day 3 fsh, smoking, primary infertility diagnosis",1,White,Black,0.63,0.44,0.88
10.1016/j.fertnstert.2015.05.012,5,No,NA,No,NA,clinical pregnancy,OR,NA,"age, body mass index, day 3 fsh, smoking, primary infertility diagnosis",2,White,Asian,0.73,0.6,0.9
10.1016/j.fertnstert.2015.05.012,5,No,NA,No,NA,clinical pregnancy,OR,NA,"age, body mass index, day 3 fsh, smoking, primary infertility diagnosis",3,White,Hispanic,0.82,0.62,1.07
10.1016/j.fertnstert.2015.10.022,1,No,NA,No,NA,larc use vs. larc nonuse,OR,NA,none,1,White,Non-Hispanic black,0.66,0.35,1.26
10.1016/j.fertnstert.2015.10.022,1,No,NA,No,NA,larc use vs. larc nonuse,OR,NA,none,2,White,Non-Hispanic other,0.68,0.23,2.01
10.1016/j.fertnstert.2015.10.022,1,No,NA,No,NA,larc use vs. larc nonuse,OR,NA,none,3,White,Hispanic,1.07,0.56,2.06
10.1016/j.fertnstert.2015.10.022,2,No,NA,No,NA,larc use vs. high-efficacy use,OR,NA,none,1,White,Non-Hispanic black,0.78,0.38,1.64
10.1016/j.fertnstert.2015.10.022,2,No,NA,No,NA,larc use vs. high-efficacy use,OR,NA,none,2,White,Non-Hispanic other,0.69,0.29,1.64
10.1016/j.fertnstert.2015.10.022,2,No,NA,No,NA,larc use vs. high-efficacy use,OR,NA,none,3,White,Hispanic,1.37,0.64,2.92
10.1016/j.fertnstert.2015.10.022,3,No,NA,No,NA,larc use vs. low-efficacy use,OR,NA,none,1,White,Non-Hispanic black,0.41,0.14,1.21
10.1016/j.fertnstert.2015.10.022,3,No,NA,No,NA,larc use vs. low-efficacy use,OR,NA,none,2,White,Non-Hispanic white,0.41,0.04,4.24
10.1016/j.fertnstert.2015.10.022,3,No,NA,No,NA,larc use vs. low-efficacy use,OR,NA,none,3,White,Hispanic,0.64,0.25,1.67
10.1016/j.fertnstert.2016.08.034,1,No,NA,No,NA,received fertility counseling,Prevalence,NA,none,1,None,White,59.4,-99,-99
10.1016/j.fertnstert.2016.08.034,1,No,NA,No,NA,received fertility counseling,Prevalence,NA,none,2,None,Black,58.1,-99,-99
10.1016/j.fertnstert.2016.08.034,1,No,NA,No,NA,received fertility counseling,Prevalence,NA,none,3,None,Other,62.8,-99,-99
10.1016/j.fertnstert.2016.08.034,1,No,NA,No,NA,received fertility counseling,Prevalence,NA,none,4,None,Missing,0,-99,-99
10.1016/j.fertnstert.2016.08.034,2,No,NA,No,NA,not receiving fertility counseling,OR,NA,"age at diagnosis, education, insurance, married or cohabitating at time of diagnosis, place of residence at diagnosis, given birth to at least one child at diagnosis, fewer children than desired at time of interview, human papilloma virus before diagnosis, surgery on fallopian tubes before diagnosis, low birth weight or preterm birth before diagnosis, chemotherapy, radiation, cancer types",1,White,Black,0.97,0.67,1.39
10.1016/j.fertnstert.2016.08.034,2,No,NA,No,NA,not receiving fertility counseling,OR,NA,"age at diagnosis, education, insurance, married or cohabitating at time of diagnosis, place of residence at diagnosis, given birth to at least one child at diagnosis, fewer children than desired at time of interview, human papilloma virus before diagnosis, surgery on fallopian tubes before diagnosis, low birth weight or preterm birth before diagnosis, chemotherapy, radiation, cancer types",2,White,Other,1.01,0.49,2.08
10.1016/j.fertnstert.2016.08.034,3,No,NA,No,NA,not receiving fertility counseling,OR,NA,"age at diagnosis, education, insurance, married or cohabitating at time of diagnosis, place of residence at diagnosis, given birth to at least one child at diagnosis, chemotherapy, radiation, cancer types",1,White,Black,1.02,0.72,1.43
10.1016/j.fertnstert.2016.08.034,3,No,NA,No,NA,not receiving fertility counseling,OR,NA,"age at diagnosis, education, insurance, married or cohabitating at time of diagnosis, place of residence at diagnosis, given birth to at least one child at diagnosis, chemotherapy, radiation, cancer types",2,White,Other,0.86,0.44,1.68
10.1016/j.fertnstert.2019.04.044,1,No,NA,No,NA,rates of accessing infertility care among women who reported infertility by respondent characteristics,"Saw a medical provider because unable to become pregnant, % yes",NA,n/a,1,N/A,Mexican/American,44,24.4,63.6
10.1016/j.fertnstert.2019.04.044,1,No,NA,No,NA,rates of accessing infertility care among women who reported infertility by respondent characteristics,"Saw a medical provider because unable to become pregnant, % yes",NA,n/a,2,N/A,Other Hispanic,54.9,36.1,73.7
10.1016/j.fertnstert.2019.04.044,1,No,NA,No,NA,rates of accessing infertility care among women who reported infertility by respondent characteristics,"Saw a medical provider because unable to become pregnant, % yes",NA,n/a,3,N/A,Non-Hispanic white,65.3,57.8,72.9
10.1016/j.fertnstert.2019.04.044,1,No,NA,No,NA,rates of accessing infertility care among women who reported infertility by respondent characteristics,"Saw a medical provider because unable to become pregnant, % yes",NA,n/a,4,N/A,Non-Hispanic black,40.6,31.1,50
10.1016/j.fertnstert.2019.04.044,1,No,NA,No,NA,rates of accessing infertility care among women who reported infertility by respondent characteristics,"Saw a medical provider because unable to become pregnant, % yes",NA,n/a,5,N/A,Non-Hispanic Asian,79.8,63.1,96.6
10.1016/j.fertnstert.2019.04.044,1,No,NA,No,NA,rates of accessing infertility care among women who reported infertility by respondent characteristics,"Saw a medical provider because unable to become pregnant, % yes",NA,n/a,6,N/A,Other/multiracial,66,40.2,91.7
10.1016/j.fertnstert.2019.07.1323,1,No,NA,No,NA,assisted reproductive techonology births,RR,NA,unclear,1,White,Black,0.57,0.52,0.62
10.1016/j.fertnstert.2019.07.1323,1,No,NA,No,NA,assisted reproductive techonology births,RR,NA,unclear,2,White,Hispanic,0.62,0.57,0.68
10.1016/j.fertnstert.2019.07.1323,1,No,NA,No,NA,assisted reproductive techonology births,RR,NA,unclear,3,White,Asian/NHOPI,1.21,1.1,1.33
10.1016/j.fertnstert.2019.07.1323,1,No,NA,No,NA,assisted reproductive techonology births,RR,NA,unclear,4,White,Other,0.91,0.82,1.01
10.1016/j.fertnstert.2021.02.032,1,No,NA,No,NA,"gonadotropin dose >4,000 iu",RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",1,Non-Hispanic white,Non-Hispanic black,1,0.9,1.12
10.1016/j.fertnstert.2021.02.032,1,No,NA,No,NA,"gonadotropin dose >4,000 iu",RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",2,Non-Hispanic white,Asian/Pacific islander,0.87,0.79,0.96
10.1016/j.fertnstert.2021.02.032,1,No,NA,No,NA,"gonadotropin dose >4,000 iu",RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",3,Non-Hispanic white,Hispanic,0.95,0.88,1.04
10.1016/j.fertnstert.2021.02.032,1,No,NA,No,NA,"gonadotropin dose >4,000 iu",RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",4,Non-Hispanic white,Other,0.91,0.79,1.05
10.1016/j.fertnstert.2021.02.032,2,No,NA,No,NA,cycle cancellation,RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",1,Non-Hispanic white,Non-Hispanic black,1.03,0.87,1.23
10.1016/j.fertnstert.2021.02.032,2,No,NA,No,NA,cycle cancellation,RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",2,Non-Hispanic white,Asian/Pacific islander,0.83,0.74,0.94
10.1016/j.fertnstert.2021.02.032,2,No,NA,No,NA,cycle cancellation,RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",3,Non-Hispanic white,Hispanic,0.94,0.74,1.19
10.1016/j.fertnstert.2021.02.032,2,No,NA,No,NA,cycle cancellation,RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",4,Non-Hispanic white,Other,0.87,0.62,1.21
10.1016/j.fertnstert.2021.02.032,3,No,NA,No,NA,hyperstimulation,RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",1,Non-Hispanic white,Non-Hispanic black,1.78,0.88,3.6
10.1016/j.fertnstert.2021.02.032,3,No,NA,No,NA,hyperstimulation,RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",2,Non-Hispanic white,Asian/Pacific islander,0.73,0.34,1.58
10.1016/j.fertnstert.2021.02.032,3,No,NA,No,NA,hyperstimulation,RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",3,Non-Hispanic white,Hispanic,1.15,0.31,4.29
10.1016/j.fertnstert.2021.02.032,3,No,NA,No,NA,hyperstimulation,RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",4,Non-Hispanic white,Other,0.89,0.12,6.77
10.1016/j.fertnstert.2021.02.032,4,No,NA,No,NA,total no. of oocytes retrieved/poisson beta coefficient for no. of oocytes retrieved,RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",1,Non-Hispanic white,Non-Hispanic black,0.04,0.01,0.06
10.1016/j.fertnstert.2021.02.032,4,No,NA,No,NA,total no. of oocytes retrieved/poisson beta coefficient for no. of oocytes retrieved,RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",2,Non-Hispanic white,Asian/Pacific islander,-0.05,-0.07,-0.04
10.1016/j.fertnstert.2021.02.032,4,No,NA,No,NA,total no. of oocytes retrieved/poisson beta coefficient for no. of oocytes retrieved,RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",3,Non-Hispanic white,Hispanic,-0.03,-0.07,0.01
10.1016/j.fertnstert.2021.02.032,4,No,NA,No,NA,total no. of oocytes retrieved/poisson beta coefficient for no. of oocytes retrieved,RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",4,Non-Hispanic white,Other,0.02,-0.03,0.07
10.1016/j.fertnstert.2021.02.032,5,No,NA,No,NA,percentage of mature oocytes (does not include those who had their cycle cancelled or had no oocytes retrieved),RR,NA,none,1,N/A,Non-Hispanic white,78.3,77.1,80.8
10.1016/j.fertnstert.2021.02.032,5,No,NA,No,NA,percentage of mature oocytes (does not include those who had their cycle cancelled or had no oocytes retrieved),RR,NA,none,2,N/A,Non-Hispanic black,80,78.2,81.8
10.1016/j.fertnstert.2021.02.032,5,No,NA,No,NA,percentage of mature oocytes (does not include those who had their cycle cancelled or had no oocytes retrieved),RR,NA,none,3,N/A,Asian/Pacific islander,78.8,77,80.7
10.1016/j.fertnstert.2021.02.032,5,No,NA,No,NA,percentage of mature oocytes (does not include those who had their cycle cancelled or had no oocytes retrieved),RR,NA,none,4,N/A,Hispanic,79.2,77.6,80.9
10.1016/j.fertnstert.2021.02.032,5,No,NA,No,NA,percentage of mature oocytes (does not include those who had their cycle cancelled or had no oocytes retrieved),RR,NA,none,5,N/A,Other,79,77.5,80.5
10.1016/j.ygyno.2013.11.028,1,No,NA,No,NA,cancer specific survival,HR,NA,"age at diagnosis, stage, grade, histology, surgery, lymphadenectomy, radiation",1,Non-Hispanic white,Asian,0.92,0.84,1
10.1016/j.ygyno.2013.11.028,1,No,NA,No,NA,cancer specific survival,HR,NA,"age at diagnosis, stage, grade, histology, surgery, lymphadenectomy, radiation",2,Non-Hispanic white,American Indian/Alaskan Natives,1.06,0.8,1.4
10.1016/j.ygyno.2013.11.028,2,No,NA,No,NA,overal survival,HR,NA,"age at diagnosis, stage, grade, histology, surgery, lymphadenectomy, radiation",1,Non-Hispanic white,Asian,0.86,0.81,0.91
10.1016/j.ygyno.2013.11.028,2,No,NA,No,NA,overal survival,HR,NA,"age at diagnosis, stage, grade, histology, surgery, lymphadenectomy, radiation",2,Non-Hispanic white,American Indian/Alaskan Natives,1.35,1.15,1.59
10.1016/j.ygyno.2013.12.017,1,No,NA,No,NA,low-volume hospital care,OR,NA,"age, insurance, socioeconomic status, stage, tumor grade, histology, tumor size",1,White,Hispanic,1.03,0.88,1.2
10.1016/j.ygyno.2013.12.017,1,No,NA,No,NA,low-volume hospital care,OR,NA,"age, insurance, socioeconomic status, stage, tumor grade, histology, tumor size",2,White,Asian/Pacific Islander,0.96,0.81,1.14
10.1016/j.ygyno.2013.12.017,1,No,NA,No,NA,low-volume hospital care,OR,NA,"age, insurance, socioeconomic status, stage, tumor grade, histology, tumor size",3,White,Black,0.59,0.48,0.73
10.1016/j.ygyno.2013.12.017,2,No,NA,No,NA,low-volume physician,OR,NA,"age, insurance, socioeconomic status, stage, tumor grade, histology, tumor size",1,White,Hispanic,1.37,1.15,1.63
10.1016/j.ygyno.2013.12.017,2,No,NA,No,NA,low-volume physician,OR,NA,"age, insurance, socioeconomic status, stage, tumor grade, histology, tumor size",2,White,Asian/Pacific Islander,1.43,1.15,1.76
10.1016/j.ygyno.2013.12.017,2,No,NA,No,NA,low-volume physician,OR,NA,"age, insurance, socioeconomic status, stage, tumor grade, histology, tumor size",3,White,Black,1.35,1.01,1.81
10.1016/j.ygyno.2013.12.017,3,No,NA,No,NA,unknown physician volume,OR,NA,"age, insurance, socioeconomic status, stage, tumor grade, histology, tumor size",1,White,Hispanic,1.33,1.1,1.62
10.1016/j.ygyno.2013.12.017,3,No,NA,No,NA,unknown physician volume,OR,NA,"age, insurance, socioeconomic status, stage, tumor grade, histology, tumor size",2,White,Asian/Pacific Islander,1.53,1.21,1.93
10.1016/j.ygyno.2013.12.017,3,No,NA,No,NA,unknown physician volume,OR,NA,"age, insurance, socioeconomic status, stage, tumor grade, histology, tumor size",3,White,Black,1.38,0.98,1.88
10.1016/j.ygyno.2013.12.017,4,No,NA,No,NA,high-volume hospital/low-volume physician,OR,NA,"age, insurance, socioeconomic status, stage, tumor grade, histology, tumor size",1,White,Hispanic,1.63,1.11,2.39
10.1016/j.ygyno.2013.12.017,4,No,NA,No,NA,high-volume hospital/low-volume physician,OR,NA,"age, insurance, socioeconomic status, stage, tumor grade, histology, tumor size",2,White,Asian/Pacific Islander,1.75,1.14,2.69
10.1016/j.ygyno.2013.12.017,4,No,NA,No,NA,high-volume hospital/low-volume physician,OR,NA,"age, insurance, socioeconomic status, stage, tumor grade, histology, tumor size",3,White,Black,1.7,0.99,2.91
10.1016/j.ygyno.2013.12.017,5,No,NA,No,NA,low-volume hospital/high-volume physician,OR,NA,"age, insurance, socioeconomic status, stage, tumor grade, histology, tumor size",1,White,Hispanic,1.33,0.92,1.94
10.1016/j.ygyno.2013.12.017,5,No,NA,No,NA,low-volume hospital/high-volume physician,OR,NA,"age, insurance, socioeconomic status, stage, tumor grade, histology, tumor size",2,White,Asian/Pacific islander,1.19,0.77,1.83
10.1016/j.ygyno.2013.12.017,5,No,NA,No,NA,low-volume hospital/high-volume physician,OR,NA,"age, insurance, socioeconomic status, stage, tumor grade, histology, tumor size",3,White,Black,0.75,0.42,1.32
10.1016/j.ygyno.2015.11.018,1,Yes,stage,No,NA,progression-free survival,HR,NA,none,1,White,Black,1.49,1.13,1.98
10.1016/j.ygyno.2015.11.018,2,Yes,stage,Yes,randomized subcohort stratified by stage,progression-free survival,HR,NA,none,1,White,Black,1.36,0.76,2.42
10.1016/j.ygyno.2015.11.018,3,Yes,stage,No,NA,progression-free survival by racial genetic admixture,HR,NA,none,1,N/A,African,1.07,0.98,1.16
10.1016/j.ygyno.2015.11.018,3,Yes,stage,No,NA,progression-free survival by racial genetic admixture,HR,NA,none,2,N/A,American Indian,1.08,0.66,1.78
10.1016/j.ygyno.2015.11.018,3,Yes,stage,No,NA,progression-free survival by racial genetic admixture,HR,NA,none,3,N/A,European,0.93,0.85,1.02
10.1016/j.ygyno.2015.11.018,4,Yes,stage,No,NA,progression-free survival by racial genetic admixture,HR,NA,bmi,1,N/A,African,1.08,0.98,1.18
10.1016/j.ygyno.2015.11.018,4,Yes,stage,No,NA,progression-free survival by racial genetic admixture,HR,NA,bmi,2,N/A,American Indian,1.08,0.65,1.79
10.1016/j.ygyno.2015.11.018,4,Yes,stage,No,NA,progression-free survival by racial genetic admixture,HR,NA,bmi,3,N/A,European,0.92,0.84,1.01
10.1016/j.ygyno.2015.11.018,5,Yes,stage and race,No,NA,progression-free survival by racial genetic admixture,HR,NA,none,1,N/A,African,1.11,0.9,1.37
10.1016/j.ygyno.2015.11.018,5,Yes,stage and race,No,NA,progression-free survival by racial genetic admixture,HR,NA,none,2,N/A,American Indian,1.15,0.69,1.92
10.1016/j.ygyno.2015.11.018,5,Yes,stage and race,No,NA,progression-free survival by racial genetic admixture,HR,NA,none,3,N/A,European,0.86,0.69,1.07
10.1016/j.ygyno.2016.01.006,1,No,NA,No,NA,lymph node assessment,OR,NA,"age, period of diagnosis, facility type, insurance, charlson score, histology, stage",1,White,Black,1.03,0.78,1.35
10.1016/j.ygyno.2016.01.006,1,No,NA,No,NA,lymph node assessment,OR,NA,"age, period of diagnosis, facility type, insurance, charlson score, histology, stage",2,White,Other,1.11,0.78,1.6
10.1016/j.ygyno.2016.01.006,1,No,NA,No,NA,lymph node assessment,OR,NA,"age, period of diagnosis, facility type, insurance, charlson score, histology, stage",3,White,Unknown,1.29,0.67,2.47
10.1016/j.ygyno.2016.01.006,2,No,NA,No,NA,chemotherapy,OR,NA,"age, period of diagnosis, facility type, insurance, charlson score, histology, stage",1,White,Black,1.32,0.99,1.78
10.1016/j.ygyno.2016.01.006,2,No,NA,No,NA,chemotherapy,OR,NA,"age, period of diagnosis, facility type, insurance, charlson score, histology, stage",2,White,Other,0.9,0.61,1.32
10.1016/j.ygyno.2016.01.006,2,No,NA,No,NA,chemotherapy,OR,NA,"age, period of diagnosis, facility type, insurance, charlson score, histology, stage",3,White,Unknown,0.79,0.41,1.52
10.1016/j.ygyno.2016.01.006,3,No,NA,No,NA,radiation,OR,NA,"age, period of diagnosis, facility type, insurance, charlson score, histology, stage",1,White,Black,0.79,0.22,2.77
10.1016/j.ygyno.2016.01.006,3,No,NA,No,NA,radiation,OR,NA,"age, period of diagnosis, facility type, insurance, charlson score, histology, stage",2,White,Other,1.71,0.44,6.6
10.1016/j.ygyno.2016.01.006,3,No,NA,No,NA,radiation,OR,NA,"age, period of diagnosis, facility type, insurance, charlson score, histology, stage",3,White,Unknown,1.38,0.16,12.14
10.1016/j.ygyno.2016.01.006,4,No,NA,No,NA,surgery,OR,NA,"age, period of diagnosis, facility type, insurance, charlson score, histology, stage",1,White,Black,1.55,0.28,8.48
10.1016/j.ygyno.2016.01.006,4,No,NA,No,NA,surgery,OR,NA,"age, period of diagnosis, facility type, insurance, charlson score, histology, stage",2,White,Other,2.12,0.22,20.33
10.1016/j.ygyno.2016.01.006,4,No,NA,No,NA,surgery,OR,NA,"age, period of diagnosis, facility type, insurance, charlson score, histology, stage",3,White,Unknown,6239313.64,0,NA
10.1016/j.ygyno.2016.01.006,5,Yes,Stage - all,Yes,White and African American women,five-year survival,survival percentage,NA,none,1,N/A,White,0.91,0.89,0.93
10.1016/j.ygyno.2016.01.006,5,Yes,Stage - all,Yes,White and African American women,five-year survival,survival percentage,NA,none,2,N/A,African American,0.84,0.8,0.89
10.1016/j.ygyno.2016.03.002,1,Yes,Early stage; 1988-1997,No,NA,5-year overall survival,5-year overall survival rate (%),NA,none,1,N/A,White,58.6,-99,-99
10.1016/j.ygyno.2016.03.002,1,Yes,Early stage; 1988-1997,No,NA,5-year overall survival,5-year overall survival rate (%),NA,none,2,N/A,African American,47.8,-99,-99
10.1016/j.ygyno.2016.03.002,2,Yes,Early stage; 1988-1997,No,NA,5-year disease-specific survival,5-year disease-specific survival rate (%),NA,none,1,N/A,White,72.5,-99,-99
10.1016/j.ygyno.2016.03.002,2,Yes,Early stage; 1988-1997,No,NA,5-year disease-specific survival,5-year disease-specific survival rate (%),NA,none,2,N/A,African American,69.9,-99,-99
10.1016/j.ygyno.2016.03.002,3,Yes,Early stage; 1998-2004,No,NA,5-year overall survival,5-year overall survival rate (%),NA,none,1,N/A,White,62,-99,-99
10.1016/j.ygyno.2016.03.002,3,Yes,Early stage; 1998-2004,No,NA,5-year overall survival,5-year overall survival rate (%),NA,none,2,N/A,African American,54.5,-99,-99
10.1016/j.ygyno.2016.03.002,4,Yes,Early stage; 1998-2004,No,NA,5-year disease-specific survival,5-year disease-specific survival rate (%),NA,none,1,N/A,White,78.5,-99,-99
10.1016/j.ygyno.2016.03.002,4,Yes,Early stage; 1998-2004,No,NA,5-year disease-specific survival,5-year disease-specific survival rate (%),NA,none,2,N/A,African American,72.5,-99,-99
10.1016/j.ygyno.2016.03.002,5,Yes,Early stage; 2005-2011,No,NA,5-year overall survival,5-year overall survival rate (%),NA,none,1,N/A,White,68.1,-99,-99
10.1016/j.ygyno.2016.03.002,5,Yes,Early stage; 2005-2011,No,NA,5-year overall survival,5-year overall survival rate (%),NA,none,2,N/A,African American,60.6,-99,-99
10.1016/j.ygyno.2016.05.026,1,No,NA,No,NA,chemotherapy radiation with concurrent chemoradiation,Prevalence,NA,none,1,None,White,0.8,-99,-99
10.1016/j.ygyno.2016.05.026,1,No,NA,No,NA,chemotherapy radiation with concurrent chemoradiation,Prevalence,NA,none,2,None,African American,0.78,-99,-99
10.1016/j.ygyno.2016.05.026,1,No,NA,No,NA,chemotherapy radiation with concurrent chemoradiation,Prevalence,NA,none,3,None,Other,0.79,-99,-99
10.1016/j.ygyno.2016.05.026,2,No,NA,No,NA,chemotherapy radiation with concurrent chemoradiation,OR,NA,none,1,White,African American,0.88,0.8,0.96
10.1016/j.ygyno.2016.05.026,2,No,NA,No,NA,chemotherapy radiation with concurrent chemoradiation,OR,NA,none,2,White,Other,0.97,0.8,1.12
10.1016/j.ygyno.2016.05.026,3,No,NA,No,NA,chemotherapy radiation with concurrent chemoradiation,OR,NA,"age, income, charlson comorbidity index, insurance status, stage, histology, grade of disease, facility type, year of diagnosis",1,White,African American,0.87,0.78,0.97
10.1016/j.ygyno.2016.05.026,3,No,NA,No,NA,chemotherapy radiation with concurrent chemoradiation,OR,NA,"age, income, charlson comorbidity index, insurance status, stage, histology, grade of disease, facility type, year of diagnosis",2,White,Other,1.01,0.84,1.21
10.1016/j.ygyno.2016.05.026,4,No,NA,No,NA,mortality,HR,NA,none,1,White,Black,1.14,1.07,1.2
10.1016/j.ygyno.2016.05.026,4,No,NA,No,NA,mortality,HR,NA,none,2,White,Other,0.82,0.73,0.89
10.1016/j.ygyno.2016.05.026,5,No,NA,No,NA,mortality,HR,NA,"age, charlson score, year of diagnosis, insurance status, stage, histology, grade, concurrent chemo-radiation, brachytherapy, facility program type",1,White,Black,1.097,1.03,1.16
10.1016/j.ygyno.2016.05.026,5,No,NA,No,NA,mortality,HR,NA,"age, charlson score, year of diagnosis, insurance status, stage, histology, grade, concurrent chemo-radiation, brachytherapy, facility program type",2,White,Other,0.85,0.76,0.94
10.1016/j.ygyno.2016.06.009,1,No,NA,No,NA,satisfaction with interpersonal manner of physician,Prevalence,NA,none,1,None,White,0.65,-99,-99
10.1016/j.ygyno.2016.06.009,1,No,NA,No,NA,satisfaction with interpersonal manner of physician,Prevalence,NA,none,2,None,Racial/Ethnic Minority,0.86,-99,-99
10.1016/j.ygyno.2016.06.009,2,No,NA,No,NA,satisfaction with accessibility and convenience of care,Prevalence,NA,none,1,None,White,0.68,-99,-99
10.1016/j.ygyno.2016.06.009,2,No,NA,No,NA,satisfaction with accessibility and convenience of care,Prevalence,NA,none,2,None,Racial/Ethnic Minority,0.51,-99,-99
10.1016/j.ygyno.2016.06.009,3,No,NA,No,NA,NA,Prevalence,NA,none,1,Satisfaction with Financial Aspects of Care,White,0.61,-99,-99
10.1016/j.ygyno.2016.06.009,3,No,NA,No,NA,NA,Prevalence,NA,none,2,Satisfaction with Financial Aspects of Care,Racial/Ethnic Minority,0.49,-99,-99
10.1016/j.ygyno.2016.06.009,4,No,NA,No,NA,patient satisfaction,OR,NA,"age, bmi, education, insurance, time travelled to care, disease site, stage, charlson comorbidity index score",1,Black,White,2.9,1.1,7.3
10.1016/j.ygyno.2016.06.015,1,No,NA,No,NA,initial yes to randomized trials questionnaire,Prevalence,NA,none,1,None,Black,12,-99,-99
10.1016/j.ygyno.2016.06.015,1,No,NA,No,NA,initial yes to randomized trials questionnaire,Prevalence,NA,none,2,None,Hispanic,3,-99,-99
10.1016/j.ygyno.2016.06.015,1,No,NA,No,NA,initial yes to randomized trials questionnaire,Prevalence,NA,none,3,None,"White, non-Hispanic",14,-99,-99
10.1016/j.ygyno.2016.06.015,2,No,NA,No,NA,yes to randomized trials questionnaire after additional education,Prevalence,NA,none,1,None,Black,20,-99,-99
10.1016/j.ygyno.2016.06.015,2,No,NA,No,NA,yes to randomized trials questionnaire after additional education,Prevalence,NA,none,2,None,Hispanic,4,-99,-99
10.1016/j.ygyno.2016.06.015,2,No,NA,No,NA,yes to randomized trials questionnaire after additional education,Prevalence,NA,none,3,None,"White, non-Hispanic",9,-99,-99
10.1016/j.ygyno.2016.06.015,3,No,NA,No,NA,no to randomized trials questionnaire after additional education,Prevalence,NA,none,1,None,Black,8,-99,-99
10.1016/j.ygyno.2016.06.015,3,No,NA,No,NA,no to randomized trials questionnaire after additional education,Prevalence,NA,none,2,None,Hispanic,2,-99,-99
10.1016/j.ygyno.2016.06.015,3,No,NA,No,NA,no to randomized trials questionnaire after additional education,Prevalence,NA,none,3,None,"White, non-Hispanic",4,-99,-99
10.1016/j.ygyno.2016.06.015,4,No,NA,No,NA,unsure about randomized trials questionnaire after education,Prevalence,NA,none,1,None,Black,14,-99,-99
10.1016/j.ygyno.2016.06.015,4,No,NA,No,NA,unsure about randomized trials questionnaire after education,Prevalence,NA,none,2,None,Hispanic,5,-99,-99
10.1016/j.ygyno.2016.06.015,4,No,NA,No,NA,unsure about randomized trials questionnaire after education,Prevalence,NA,none,3,None,"White, non-Hispanic",4,-99,-99
10.1016/j.ygyno.2016.11.017,1,No,NA,No,NA,imrt usage,OR,NA,none,1,White,Black,0.59,0.44,0.78
10.1016/j.ygyno.2016.11.017,1,No,NA,No,NA,imrt usage,OR,NA,none,2,White,Other,0.87,0.77,0.99
10.1016/j.ygyno.2016.11.017,2,No,NA,No,NA,imrt usage,OR,NA,"age grouping, year of diagnosis, pathologic nodal status, dose grouping, facility type, insurance, income",1,White,Black,0.6,0.44,0.81
10.1016/j.ygyno.2016.11.017,2,No,NA,No,NA,imrt usage,OR,NA,"age grouping, year of diagnosis, pathologic nodal status, dose grouping, facility type, insurance, income",2,White,Other,0.9,0.79,1.03
10.1016/j.ygyno.2016.11.017,3,No,NA,No,NA,overall survival,HR,NA,none,1,White,Black,1.67,1.38,2.02
10.1016/j.ygyno.2016.11.017,3,No,NA,No,NA,overall survival,HR,NA,none,2,White,Other,1.06,0.95,1.17
10.1016/j.ygyno.2016.11.017,4,No,NA,No,NA,overall survival,HR,NA,"age grouping, year of diagnosis, pathologic nodal status, dose grouping, facility type, insurance, income, radiation technique",1,White,Black,1.44,1.17,1.76
10.1016/j.ygyno.2016.11.017,4,No,NA,No,NA,overall survival,HR,NA,"age grouping, year of diagnosis, pathologic nodal status, dose grouping, facility type, insurance, income, radiation technique",2,White,Other,1.05,0.94,1.17
10.1016/j.ygyno.2017.02.025,1,No,NA,No,NA,primary debulking surgical management type,Prevalence,NA,none,1,None,White,64.6,-99,-99
10.1016/j.ygyno.2017.02.025,1,No,NA,No,NA,primary debulking surgical management type,Prevalence,NA,none,2,None,Black,67.4,-99,-99
10.1016/j.ygyno.2017.02.025,2,No,NA,No,NA,interval debulking surgical management type,Prevalence,NA,none,1,None,White,23.4,-99,-99
10.1016/j.ygyno.2017.02.025,2,No,NA,No,NA,interval debulking surgical management type,Prevalence,NA,none,2,None,Black,39.4,-99,-99
10.1016/j.ygyno.2017.02.025,3,No,NA,No,NA,optimal debulking status,Prevalence,NA,none,1,None,White,89.8,-99,-99
10.1016/j.ygyno.2017.02.025,3,No,NA,No,NA,optimal debulking status,Prevalence,NA,none,2,None,Black,70.8,-99,-99
10.1016/j.ygyno.2017.02.025,4,No,NA,No,NA,iv chemo,Prevalence,NA,none,1,None,White,80.8,-99,-99
10.1016/j.ygyno.2017.02.025,4,No,NA,No,NA,iv chemo,Prevalence,NA,none,2,None,Black,89,-99,-99
10.1016/j.ygyno.2017.09.002,1,No,NA,No,NA,relative odds of type ii endometrial cancer among women in florida - type 2 (all),OR,NA,none,1,non-Hispanic White,non-Hispanic Black,2.64,2.38,2.92
10.1016/j.ygyno.2017.09.002,1,No,NA,No,NA,relative odds of type ii endometrial cancer among women in florida - type 2 (all),OR,NA,none,2,non-Hispanic White,Cuban,1.35,1.08,1.68
10.1016/j.ygyno.2017.09.002,1,No,NA,No,NA,relative odds of type ii endometrial cancer among women in florida - type 2 (all),OR,NA,none,3,non-Hispanic White,Mexican,1.27,0.64,2.5
10.1016/j.ygyno.2017.09.002,1,No,NA,No,NA,relative odds of type ii endometrial cancer among women in florida - type 2 (all),OR,NA,none,4,non-Hispanic White,Puerto Rican,1.29,0.92,1.8
10.1016/j.ygyno.2017.09.002,1,No,NA,No,NA,relative odds of type ii endometrial cancer among women in florida - type 2 (all),OR,NA,none,5,non-Hispanic White,South and Central American,1.84,1.4,2.43
10.1016/j.ygyno.2017.09.002,1,No,NA,No,NA,relative odds of type ii endometrial cancer among women in florida - type 2 (all),OR,NA,none,6,non-Hispanic White,"Hispanic, not otherwise specified",0.88,0.78,1
10.1016/j.ygyno.2017.09.002,2,No,NA,Yes,Adenocarcinoma (G3),relative odds of type ii endometrial cancer among women in florida,OR,NA,none,1,non-Hispanic White,non-Hispanic Black,1.6,1.42,1.81
10.1016/j.ygyno.2017.09.002,2,No,NA,Yes,Adenocarcinoma (G3),relative odds of type ii endometrial cancer among women in florida,OR,NA,none,2,non-Hispanic White,Cuban,1,0.75,1.32
10.1016/j.ygyno.2017.09.002,2,No,NA,Yes,Adenocarcinoma (G3),relative odds of type ii endometrial cancer among women in florida,OR,NA,none,3,non-Hispanic White,Mexican,-99,-99,-99
10.1016/j.ygyno.2017.09.002,2,No,NA,Yes,Adenocarcinoma (G3),relative odds of type ii endometrial cancer among women in florida,OR,NA,none,4,non-Hispanic White,Puerto Rican,1.05,0.7,1.59
10.1016/j.ygyno.2017.09.002,2,No,NA,Yes,Adenocarcinoma (G3),relative odds of type ii endometrial cancer among women in florida,OR,NA,none,5,non-Hispanic White,South and Central American,1.76,1.29,2.4
10.1016/j.ygyno.2017.09.002,2,No,NA,Yes,Adenocarcinoma (G3),relative odds of type ii endometrial cancer among women in florida,OR,NA,none,6,non-Hispanic White,"Hispanic, not otherwise specified",0.96,0.83,1.11
10.1016/j.ygyno.2017.09.002,3,No,NA,Yes,Carcinosarcoma,relative odds of type ii endometrial cancer among women in florida,OR,NA,none,1,non-Hispanic White,non-Hispanic Black,2.97,2.47,3.57
10.1016/j.ygyno.2017.09.002,3,No,NA,Yes,Carcinosarcoma,relative odds of type ii endometrial cancer among women in florida,OR,NA,none,2,non-Hispanic White,Cuban,1.22,0.73,2.02
10.1016/j.ygyno.2017.09.002,3,No,NA,Yes,Carcinosarcoma,relative odds of type ii endometrial cancer among women in florida,OR,NA,none,3,non-Hispanic White,Mexican,-99,-99,-99
10.1016/j.ygyno.2017.09.002,3,No,NA,Yes,Carcinosarcoma,relative odds of type ii endometrial cancer among women in florida,OR,NA,none,4,non-Hispanic White,Puerto Rican,2.35,1.32,4.17
10.1016/j.ygyno.2017.09.002,3,No,NA,Yes,Carcinosarcoma,relative odds of type ii endometrial cancer among women in florida,OR,NA,none,5,non-Hispanic White,South and Central American,-99,-99,-99
10.1016/j.ygyno.2017.09.002,3,No,NA,Yes,Carcinosarcoma,relative odds of type ii endometrial cancer among women in florida,OR,NA,none,6,non-Hispanic White,"Hispanic, not otherwise specified",0.75,0.54,1.04
10.1016/j.ygyno.2017.09.002,4,No,NA,Yes,Serous,relative odds of type ii endometrial cancer among women in florida,OR,NA,none,1,non-Hispanic White,non-Hispanic Black,2.51,2.11,2.97
10.1016/j.ygyno.2017.09.002,4,No,NA,Yes,Serous,relative odds of type ii endometrial cancer among women in florida,OR,NA,none,2,non-Hispanic White,Cuban,2.15,1.51,3.05
10.1016/j.ygyno.2017.09.002,4,No,NA,Yes,Serous,relative odds of type ii endometrial cancer among women in florida,OR,NA,none,3,non-Hispanic White,Mexican,-99,-99,-99
10.1016/j.ygyno.2017.09.002,4,No,NA,Yes,Serous,relative odds of type ii endometrial cancer among women in florida,OR,NA,none,4,non-Hispanic White,Puerto Rican,-99,-99,-99
10.1016/j.ygyno.2017.09.002,4,No,NA,Yes,Serous,relative odds of type ii endometrial cancer among women in florida,OR,NA,none,5,non-Hispanic White,South and Central American,-99,-99,-99
10.1016/j.ygyno.2017.09.002,4,No,NA,Yes,Serous,relative odds of type ii endometrial cancer among women in florida,OR,NA,none,6,non-Hispanic White,"Hispanic, not otherwise specified",0.8,0.61,1.05
10.1016/j.ygyno.2017.09.002,5,No,NA,Yes,Clear cell,relative odds of type ii endometrial cancer among women in florida,OR,NA,none,1,non-Hispanic White,non-Hispanic Black,2.7,1.99,3.66
10.1016/j.ygyno.2017.09.002,5,No,NA,Yes,Clear cell,relative odds of type ii endometrial cancer among women in florida,OR,NA,none,2,non-Hispanic White,Cuban,-99,-99,-99
10.1016/j.ygyno.2017.09.002,5,No,NA,Yes,Clear cell,relative odds of type ii endometrial cancer among women in florida,OR,NA,none,3,non-Hispanic White,Mexican,-99,-99,-99
10.1016/j.ygyno.2017.09.002,5,No,NA,Yes,Clear cell,relative odds of type ii endometrial cancer among women in florida,OR,NA,none,4,non-Hispanic White,Puerto Rican,-99,-99,-99
10.1016/j.ygyno.2017.09.002,5,No,NA,Yes,Clear cell,relative odds of type ii endometrial cancer among women in florida,OR,NA,none,5,non-Hispanic White,South and Central American,-99,-99,-99
10.1016/j.ygyno.2017.09.002,5,No,NA,Yes,Clear cell,relative odds of type ii endometrial cancer among women in florida,OR,NA,none,6,non-Hispanic White,"Hispanic, not otherwise specified",1.01,0.63,1.63
10.1016/j.ygyno.2017.10.033,1,Yes,Whites,Yes,All cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity % of,NA,n/a,1,N/A,Diabetes Yes,21.1,NA,NA
10.1016/j.ygyno.2017.10.033,1,Yes,Whites,Yes,All cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity % of,NA,n/a,2,N/A,Diabetes No,78.9,NA,NA
10.1016/j.ygyno.2017.10.033,1,Yes,Whites,Yes,All cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity % of,NA,n/a,3,N/A,COPD Yes,2.4,NA,NA
10.1016/j.ygyno.2017.10.033,1,Yes,Whites,Yes,All cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity % of,NA,n/a,4,N/A,COPD No,97.6,NA,NA
10.1016/j.ygyno.2017.10.033,1,Yes,Whites,Yes,All cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity % of,NA,n/a,5,N/A,Hypertension Yes,55.2,NA,NA
10.1016/j.ygyno.2017.10.033,1,Yes,Whites,Yes,All cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity % of,NA,n/a,6,N/A,Hypertension No,44.8,NA,NA
10.1016/j.ygyno.2017.10.033,1,Yes,Whites,Yes,All cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity % of,NA,n/a,7,N/A,Congestive heart failure Yes,0.4,NA,NA
10.1016/j.ygyno.2017.10.033,1,Yes,Whites,Yes,All cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity % of,NA,n/a,8,N/A,Congestive heart failure No,99.6,NA,NA
10.1016/j.ygyno.2017.10.033,2,Yes,Blacks,Yes,All cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity %,NA,n/a,1,N/A,Diabetes Yes,29.9,NA,NA
10.1016/j.ygyno.2017.10.033,2,Yes,Blacks,Yes,All cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity %,NA,n/a,2,N/A,Diabetes No,70.1,NA,NA
10.1016/j.ygyno.2017.10.033,2,Yes,Blacks,Yes,All cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity %,NA,n/a,3,N/A,COPD Yes,3,NA,NA
10.1016/j.ygyno.2017.10.033,2,Yes,Blacks,Yes,All cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity %,NA,n/a,4,N/A,COPD No,97,NA,NA
10.1016/j.ygyno.2017.10.033,2,Yes,Blacks,Yes,All cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity %,NA,n/a,5,N/A,Hypertension Yes,74.1,NA,NA
10.1016/j.ygyno.2017.10.033,2,Yes,Blacks,Yes,All cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity %,NA,n/a,6,N/A,Hypertension No,25.9,NA,NA
10.1016/j.ygyno.2017.10.033,2,Yes,Blacks,Yes,All cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity %,NA,n/a,7,N/A,Congestive heart failure Yes,1.2,NA,NA
10.1016/j.ygyno.2017.10.033,2,Yes,Blacks,Yes,All cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity %,NA,n/a,8,N/A,Congestive heart failure,98.8,NA,NA
10.1016/j.ygyno.2017.10.033,3,Yes,Whites,Yes,Laparoscopy cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity %,NA,n/a,1,N/A,Diabetes Yes,20.1,NA,NA
10.1016/j.ygyno.2017.10.033,3,Yes,Whites,Yes,Laparoscopy cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity %,NA,n/a,2,N/A,Diabetes No,79.9,NA,NA
10.1016/j.ygyno.2017.10.033,3,Yes,Whites,Yes,Laparoscopy cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity %,NA,n/a,3,N/A,COPD Yes,2.2,NA,NA
10.1016/j.ygyno.2017.10.033,3,Yes,Whites,Yes,Laparoscopy cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity %,NA,n/a,4,N/A,COPD No,97.8,NA,NA
10.1016/j.ygyno.2017.10.033,3,Yes,Whites,Yes,Laparoscopy cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity %,NA,n/a,5,N/A,Hypertension Yes,54.1,NA,NA
10.1016/j.ygyno.2017.10.033,3,Yes,Whites,Yes,Laparoscopy cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity %,NA,n/a,6,N/A,Hypertension No,45.9,NA,NA
10.1016/j.ygyno.2017.10.033,3,Yes,Whites,Yes,Laparoscopy cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity %,NA,n/a,7,N/A,Congestive heart failure Yes,0.3,NA,NA
10.1016/j.ygyno.2017.10.033,3,Yes,Whites,Yes,Laparoscopy cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity %,NA,n/a,8,N/A,Congestive heart failure No,99.7,NA,NA
10.1016/j.ygyno.2017.10.033,4,Yes,Blacks,Yes,Laparoscopy cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity %,NA,n/a,1,N/A,Diabetes Yes,30.5,NA,NA
10.1016/j.ygyno.2017.10.033,4,Yes,Blacks,Yes,Laparoscopy cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity %,NA,n/a,2,N/A,Diabetes No,69.5,NA,NA
10.1016/j.ygyno.2017.10.033,4,Yes,Blacks,Yes,Laparoscopy cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity %,NA,n/a,3,N/A,COPD Yes,3.3,NA,NA
10.1016/j.ygyno.2017.10.033,4,Yes,Blacks,Yes,Laparoscopy cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity %,NA,n/a,4,N/A,COPD No,96.7,NA,NA
10.1016/j.ygyno.2017.10.033,4,Yes,Blacks,Yes,Laparoscopy cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity %,NA,n/a,5,N/A,Hypertension Yes,75.2,NA,NA
10.1016/j.ygyno.2017.10.033,4,Yes,Blacks,Yes,Laparoscopy cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity %,NA,n/a,6,N/A,Hypertension No,24.8,NA,NA
10.1016/j.ygyno.2017.10.033,4,Yes,Blacks,Yes,Laparoscopy cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity %,NA,n/a,7,N/A,Congestive heart failure Yes,1.4,NA,NA
10.1016/j.ygyno.2017.10.033,4,Yes,Blacks,Yes,Laparoscopy cases,medical comorbidities of white and black women undergoing any hysterectomy and laparoscopic hysterectomy,Comorbidity %,NA,n/a,8,N/A,Congestive heart failure No,98.6,NA,NA
10.1016/j.ygyno.2017.10.034,1,No,NA,No,NA,received genetic counseling referrals,Prevalence,NA,none,1,None,Caucasian,67,-99,-99
10.1016/j.ygyno.2017.10.034,1,No,NA,No,NA,received genetic counseling referrals,Prevalence,NA,none,2,None,Latina,10,-99,-99
10.1016/j.ygyno.2017.10.034,1,No,NA,No,NA,received genetic counseling referrals,Prevalence,NA,none,3,None,Asian,10,-99,-99
10.1016/j.ygyno.2017.10.034,1,No,NA,No,NA,received genetic counseling referrals,Prevalence,NA,none,4,None,Black,2,-99,-99
10.1016/j.ygyno.2017.10.034,1,No,NA,No,NA,received genetic counseling referrals,Prevalence,NA,none,5,None,Other,8,-99,-99
10.1016/j.ygyno.2017.10.034,1,No,NA,No,NA,received genetic counseling referrals,Prevalence,NA,none,6,None,Unknown,2,-99,-99
10.1016/j.ygyno.2017.10.034,2,No,NA,No,NA,did not receive genetic counseling referrals,Prevalence,NA,none,1,None,Caucasian,51,-99,-99
10.1016/j.ygyno.2017.10.034,2,No,NA,No,NA,did not receive genetic counseling referrals,Prevalence,NA,none,2,None,Latina,18,-99,-99
10.1016/j.ygyno.2017.10.034,2,No,NA,No,NA,did not receive genetic counseling referrals,Prevalence,NA,none,3,None,Asian,17,-99,-99
10.1016/j.ygyno.2017.10.034,2,No,NA,No,NA,did not receive genetic counseling referrals,Prevalence,NA,none,4,None,Black,5,-99,-99
10.1016/j.ygyno.2017.10.034,2,No,NA,No,NA,did not receive genetic counseling referrals,Prevalence,NA,none,5,None,Other,5,-99,-99
10.1016/j.ygyno.2017.10.034,2,No,NA,No,NA,did not receive genetic counseling referrals,Prevalence,NA,none,6,None,Unknown,4,-99,-99
10.1016/j.ygyno.2017.10.034,3,No,NA,No,NA,"of referred patients, counseled",Prevalence,NA,none,1,None,Causasian,70,-99,-99
10.1016/j.ygyno.2017.10.034,3,No,NA,No,NA,"of referred patients, counseled",Prevalence,NA,none,2,None,Latina,10,-99,-99
10.1016/j.ygyno.2017.10.034,3,No,NA,No,NA,"of referred patients, counseled",Prevalence,NA,none,3,None,Asian,10,-99,-99
10.1016/j.ygyno.2017.10.034,3,No,NA,No,NA,"of referred patients, counseled",Prevalence,NA,none,4,None,Black,0,-99,-99
10.1016/j.ygyno.2017.10.034,3,No,NA,No,NA,"of referred patients, counseled",Prevalence,NA,none,5,None,Other,6,-99,-99
10.1016/j.ygyno.2017.10.034,3,No,NA,No,NA,"of referred patients, counseled",Prevalence,NA,none,6,None,Unknown,3,-99,-99
10.1016/j.ygyno.2017.10.034,4,No,NA,No,NA,"of referred patients, not counseled",Prevalence,NA,none,1,None,Caucasian,65,-99,-99
10.1016/j.ygyno.2017.10.034,4,No,NA,No,NA,"of referred patients, not counseled",Prevalence,NA,none,2,None,Latina,8,-99,-99
10.1016/j.ygyno.2017.10.034,4,No,NA,No,NA,"of referred patients, not counseled",Prevalence,NA,none,3,None,Asian,10,-99,-99
10.1016/j.ygyno.2017.10.034,4,No,NA,No,NA,"of referred patients, not counseled",Prevalence,NA,none,4,None,Black,8,-99,-99
10.1016/j.ygyno.2017.10.034,4,No,NA,No,NA,"of referred patients, not counseled",Prevalence,NA,none,5,None,Other,10,-99,-99
10.1016/j.ygyno.2017.10.034,4,No,NA,No,NA,"of referred patients, not counseled",Prevalence,NA,none,6,None,Unknown,0,-99,-99
10.1016/j.ygyno.2017.10.035,1,No,NA,No,NA,adjusted progression free survival analysis,HR,NA,"black race, age, stage, cci, suboptimal cytoreduction",1,White,Black race,1.21,0.82,1.77
10.1016/j.ygyno.2017.10.035,2,No,NA,No,NA,adjusted overall survival analysis,HR,NA,"black race, age, stage, cci, suboptimal cytoreduction",1,White,Black race,1.61,1.06,2.43
10.1016/j.ygyno.2017.12.021,1,No,NA,No,NA,death from endometrial cancer,Prevalence,NA,none,1,None,White,21.2,-99,-99
10.1016/j.ygyno.2017.12.021,1,No,NA,No,NA,death from endometrial cancer,Prevalence,NA,none,2,None,Black,41.2,-99,-99
10.1016/j.ygyno.2017.12.021,2,Yes,Diagnosed during time period I,No,NA,death from endometrial cancer,Prevalence,NA,none,1,None,White,25.1,-99,-99
10.1016/j.ygyno.2017.12.021,2,Yes,Diagnosed during time period I,No,NA,death from endometrial cancer,Prevalence,NA,none,2,None,Black,47.5,-99,-99
10.1016/j.ygyno.2017.12.021,3,No,Diagnosis during time period II,No,NA,death from endometrial cancer,Prevalence,NA,none,1,None,White,22.1,-99,-99
10.1016/j.ygyno.2017.12.021,3,No,Diagnosis during time period II,No,NA,death from endometrial cancer,Prevalence,NA,none,2,None,Black,42.3,-99,-99
10.1016/j.ygyno.2017.12.021,4,Yes,Diagnosed during time period III,No,NA,death from endometrial cancer,Prevalence,NA,none,1,None,WHite,20.7,-99,-99
10.1016/j.ygyno.2017.12.021,4,Yes,Diagnosed during time period III,No,NA,death from endometrial cancer,Prevalence,NA,none,2,None,Black,41.7,-99,-99
10.1016/j.ygyno.2017.12.021,5,Yes,Diagnosed during time period IV,No,NA,death from endometrial cancer,Prevalence,NA,none,1,None,White,18.1,-99,-99
10.1016/j.ygyno.2017.12.021,5,Yes,Diagnosed during time period IV,No,NA,death from endometrial cancer,Prevalence,NA,none,2,None,BLack,37.8,-99,-99
10.1016/j.ygyno.2017.12.032,1,No,NA,No,NA,mortality,HR,NA,"age, year of diagnosis, insurance status, income, location, comorbidity, facility type, region, stage, histology, chemotherapy",1,White,Black,1.19,1.08,1.32
10.1016/j.ygyno.2017.12.032,2,No,NA,No,NA,early stage mortality,HR,NA,"age, year of diagnosis, insurance status, income, location, comorbidity, facility type, region, stage, histology, grade, radiation",1,White,Black,1.24,1.04,1.49
10.1016/j.ygyno.2017.12.032,3,No,NA,No,NA,advanced stage mortality,HR,NA,"age, year of diagnosis, insurance status, income, location, comorbidity, facility type, region, stage, histology, chemotherapy",1,White,Black,1.12,0.89,1.41
10.1016/j.ygyno.2017.12.032,4,Yes,Stage IA,No,NA,survival rate,Prevalence,NA,none,1,None,White,97.2,96.9,97.5
10.1016/j.ygyno.2017.12.032,4,Yes,Stage IA,No,NA,survival rate,Prevalence,NA,none,2,None,Black,94.5,93,95.8
10.1016/j.ygyno.2017.12.032,5,Yes,Stage IB,No,NA,survival rate,Prevalence,NA,none,1,NA,White,90.6,88.6,92.3
10.1016/j.ygyno.2017.12.032,5,Yes,Stage IB,No,NA,survival rate,Prevalence,NA,none,2,NA,Black,81.5,73,87.5
10.1016/j.ygyno.2018.04.563,1,No,NA,No,NA,receiving brachytherapy radiation boost,Prevalence,NA,none,1,None,Non-Hispanic White,45.8,-99,-99
10.1016/j.ygyno.2018.04.563,1,No,NA,No,NA,receiving brachytherapy radiation boost,Prevalence,NA,none,2,None,Non-Hispanic Black,42.9,-99,-99
10.1016/j.ygyno.2018.04.563,1,No,NA,No,NA,receiving brachytherapy radiation boost,Prevalence,NA,none,3,None,Hispanic,43.9,-99,-99
10.1016/j.ygyno.2018.04.563,1,No,NA,No,NA,receiving brachytherapy radiation boost,Prevalence,NA,none,4,None,Asian/Pacific islander,45.4,-99,-99
10.1016/j.ygyno.2018.04.563,1,No,NA,No,NA,receiving brachytherapy radiation boost,Prevalence,NA,none,5,None,Other/unknown,48.1,-99,-99
10.1016/j.ygyno.2018.04.563,2,No,NA,No,NA,receiving external beam radiation radiation boost,Prevalence,NA,none,1,None,Non-Hispanic White,17.8,-99,-99
10.1016/j.ygyno.2018.04.563,2,No,NA,No,NA,receiving external beam radiation radiation boost,Prevalence,NA,none,2,None,Non-Hispanic Black,17.4,-99,-99
10.1016/j.ygyno.2018.04.563,2,No,NA,No,NA,receiving external beam radiation radiation boost,Prevalence,NA,none,3,None,Hispanic,18.8,-99,-99
10.1016/j.ygyno.2018.04.563,2,No,NA,No,NA,receiving external beam radiation radiation boost,Prevalence,NA,none,4,None,Asian/Pacific islander,16.8,-99,-99
10.1016/j.ygyno.2018.04.563,2,No,NA,No,NA,receiving external beam radiation radiation boost,Prevalence,NA,none,5,None,Other/unknown,19.2,-99,-99
10.1016/j.ygyno.2018.04.563,3,No,NA,No,NA,receiving brachytherapy boost,OR,NA,"radiation boost, age at diagnosis, socioeconomic status, stage at diagnosis, histology, tumor grade",1,Non-Hispanic White,Non-Hispanic Black,1.03,0.74,1.44
10.1016/j.ygyno.2018.04.563,3,No,NA,No,NA,receiving brachytherapy boost,OR,NA,"radiation boost, age at diagnosis, socioeconomic status, stage at diagnosis, histology, tumor grade",2,Non-Hispanic White,Hispanic,1.05,0.88,1.26
10.1016/j.ygyno.2018.04.563,3,No,NA,No,NA,receiving brachytherapy boost,OR,NA,"radiation boost, age at diagnosis, socioeconomic status, stage at diagnosis, histology, tumor grade",3,Non-Hispanic White,Asian/Pacific islander,1.06,0.84,1.33
10.1016/j.ygyno.2018.04.563,4,No,NA,No,NA,cervical cancer mortality,HR,NA,"radiation boost, age at diagnosis, socioeconomic status, stage at diagnosis, histology, tumor grade",1,Non-Hispanic White,Non-Hispanic Black,1.57,1.24,2
10.1016/j.ygyno.2018.04.563,4,No,NA,No,NA,cervical cancer mortality,HR,NA,"radiation boost, age at diagnosis, socioeconomic status, stage at diagnosis, histology, tumor grade",2,Non-Hispanic White,Hispanic,0.89,0.76,1.03
10.1016/j.ygyno.2018.04.563,4,No,NA,No,NA,cervical cancer mortality,HR,NA,"radiation boost, age at diagnosis, socioeconomic status, stage at diagnosis, histology, tumor grade",3,Non-Hispanic White,Asian/Pacific islander,0.86,0.7,1.05
10.1016/j.ygyno.2018.04.563,5,No,NA,No,NA,all-cause mortality,HR,NA,"radiation boost, age at diagnosis, socioeconomic status, stage at diagnosis, histology, tumor grade",1,Non-Hispanic White,Non-Hispanic Black,1.47,1.19,1.81
10.1016/j.ygyno.2018.04.563,5,No,NA,No,NA,all-cause mortality,HR,NA,"radiation boost, age at diagnosis, socioeconomic status, stage at diagnosis, histology, tumor grade",2,Non-Hispanic White,Hispanic,0.8,0.7,0.91
10.1016/j.ygyno.2018.04.563,5,No,NA,No,NA,all-cause mortality,HR,NA,"radiation boost, age at diagnosis, socioeconomic status, stage at diagnosis, histology, tumor grade",3,Non-Hispanic White,Asian/Pacific islander,0.81,0.68,0.96
10.1016/j.ygyno.2018.08.041,1,No,NA,No,NA,receipt of surgery and chemotherapy,OR,NA,"age at diagnosis, marital status, comorbidity index, % who did not graduate from high school, ajcc stage, histology groupings",1,White (non-Hispanic),African American (non-Hispanic),0.56,0.45,0.7
10.1016/j.ygyno.2018.08.041,1,No,NA,No,NA,receipt of surgery and chemotherapy,OR,NA,"age at diagnosis, marital status, comorbidity index, % who did not graduate from high school, ajcc stage, histology groupings",2,White (non-Hispanic),Hispanic,0.68,0.54,0.86
10.1016/j.ygyno.2018.08.041,1,No,NA,No,NA,receipt of surgery and chemotherapy,OR,NA,"age at diagnosis, marital status, comorbidity index, % who did not graduate from high school, ajcc stage, histology groupings",3,White (non-Hispanic),Other/Unknown,0.75,0.56,0.99
10.1016/j.ygyno.2018.08.041,2,No,NA,No,NA,overall survival,HR,NA,"treatment group, age at diagnosis, marital status, comorbidity index, ajcc stage, histology groupings",1,White (non-Hispanic),"Black, non-Hispanic",1.13,1.03,1.23
10.1016/j.ygyno.2018.08.041,2,No,NA,No,NA,overall survival,HR,NA,"treatment group, age at diagnosis, marital status, comorbidity index, ajcc stage, histology groupings",2,White (non-Hispanic),Hispanic,0.96,0.87,1.06
10.1016/j.ygyno.2018.08.041,2,No,NA,No,NA,overall survival,HR,NA,"treatment group, age at diagnosis, marital status, comorbidity index, ajcc stage, histology groupings",3,White (non-Hispanic),Other/unknown,0.91,0.8,1.03
10.1016/j.ygyno.2018.08.041,3,Yes,Standard treatment,No,NA,klabunde-modified charlson comorbidity score of 0,Prevalence,NA,none,1,None,Black,57,-99,-99
10.1016/j.ygyno.2018.08.041,3,Yes,Standard treatment,No,NA,klabunde-modified charlson comorbidity score of 0,Prevalence,NA,none,2,None,Hispanic,60.3,-99,-99
10.1016/j.ygyno.2018.08.041,3,Yes,Standard treatment,No,NA,klabunde-modified charlson comorbidity score of 0,Prevalence,NA,none,3,None,Other,65.1,-99,-99
10.1016/j.ygyno.2018.08.041,3,Yes,Standard treatment,No,NA,klabunde-modified charlson comorbidity score of 0,Prevalence,NA,none,4,None,White,70.2,-99,-99
10.1016/j.ygyno.2018.08.041,4,Yes,Standard Treatment,No,NA,klabunde-modified charlson comorbidity score of 1,Prevalence,NA,none,1,None,Black,25.9,-99,-99
10.1016/j.ygyno.2018.08.041,4,Yes,Standard Treatment,No,NA,klabunde-modified charlson comorbidity score of 1,Prevalence,NA,none,2,None,Hispanic,28.2,-99,-99
10.1016/j.ygyno.2018.08.041,4,Yes,Standard Treatment,No,NA,klabunde-modified charlson comorbidity score of 1,Prevalence,NA,none,3,None,Other,22.5,-99,-99
10.1016/j.ygyno.2018.08.041,4,Yes,Standard Treatment,No,NA,klabunde-modified charlson comorbidity score of 1,Prevalence,NA,none,4,None,White,20.7,-99,-99
10.1016/j.ygyno.2018.08.041,5,Yes,Standard Treatment,No,NA,klabunde-modified charlson comorbidity score of 2,Prevalence,NA,none,1,None,Black,17.1,-99,-99
10.1016/j.ygyno.2018.08.041,5,Yes,Standard Treatment,No,NA,klabunde-modified charlson comorbidity score of 2,Prevalence,NA,none,2,None,Hispanic,11.5,-99,-99
10.1016/j.ygyno.2018.08.041,5,Yes,Standard Treatment,No,NA,klabunde-modified charlson comorbidity score of 2,Prevalence,NA,none,3,None,Other,12.4,-99,-99
10.1016/j.ygyno.2018.08.041,5,Yes,Standard Treatment,No,NA,klabunde-modified charlson comorbidity score of 2,Prevalence,NA,none,4,None,White,9.1,-99,-99
10.1016/j.ygyno.2018.10.029,1,Yes,UVA cases,NA,NA,missing grade,OR,NA,"age, insurance, histology, stage, residual disease, neo-adjuvant chemotherapy",1,White,Black,3,1.57,5.72
10.1016/j.ygyno.2018.10.029,1,Yes,UVA cases,NA,NA,missing grade,OR,NA,"age, insurance, histology, stage, residual disease, neo-adjuvant chemotherapy",2,White,Other/NOS/unknown,2.42,0.67,8.73
10.1016/j.ygyno.2018.10.029,2,Yes,VDH cases,No,NA,missing grade,OR,NA,"age, histology, stage, residual disease, neo-adjuvant chemotherapy",1,White,Black,1.3,1.07,1.59
10.1016/j.ygyno.2018.10.029,2,Yes,VDH cases,No,NA,missing grade,OR,NA,"age, histology, stage, residual disease, neo-adjuvant chemotherapy",2,White,Other/NOS/unknown,0.78,0.57,1.08
10.1016/j.ygyno.2018.10.029,3,Yes,SEER cases,No,NA,missing grade,OR,NA,"age, insurance, histology, stage, residual disease, neo-adjuvant chemotherapy",1,White,Black,1.73,1.61,1.85
10.1016/j.ygyno.2018.10.029,3,Yes,SEER cases,No,NA,missing grade,OR,NA,"age, insurance, histology, stage, residual disease, neo-adjuvant chemotherapy",2,White,Other/NOS/unknown,0.8,0.74,0.86
10.1016/j.ygyno.2018.10.041,1,No,NA,No,NA,hospice unenrollment prior to death,OR,NA,"stage, comorbidities, age, year of death, time from diagnosis to death, geographic categorization, poverty level, educational level",1,Non-Hispanic White,Non-Hispanic Black,2.07,1.15,3.73
10.1016/j.ygyno.2018.10.041,1,No,NA,No,NA,hospice unenrollment prior to death,OR,NA,"stage, comorbidities, age, year of death, time from diagnosis to death, geographic categorization, poverty level, educational level",2,Non-Hispanic White,Hispanic,1.24,0.76,2.04
10.1016/j.ygyno.2018.10.041,1,No,NA,No,NA,hospice unenrollment prior to death,OR,NA,"stage, comorbidities, age, year of death, time from diagnosis to death, geographic categorization, poverty level, educational level",3,Non-Hispanic White,Other,0.54,0.12,2.43
10.1016/j.ygyno.2019.01.013,1,No,NA,No,NA,sample mean of implicit association test d-scores,Sample mean of implicit association test d-scores,NA,n/a,1,N/A,White,0.21,NA,NA
10.1016/j.ygyno.2019.01.013,1,No,NA,No,NA,sample mean of implicit association test d-scores,Sample mean of implicit association test d-scores,NA,n/a,2,N/A,Minority,0.08,NA,NA
10.1016/j.ygyno.2019.06.009,1,No,NA,No,NA,have you heard of brca testing? - adjusted odds ratio for positive response,OR,NA,"age, ethnicity, education level, family history of breast and/or ovarian cancer, willing to pay out of pocket",1,White,Black,0.11,0.05,0.28
10.1016/j.ygyno.2019.06.009,1,No,NA,No,NA,have you heard of brca testing? - adjusted odds ratio for positive response,OR,NA,"age, ethnicity, education level, family history of breast and/or ovarian cancer, willing to pay out of pocket",2,White,Other,0.48,0.17,1.32
10.1016/j.ygyno.2019.06.009,2,No,NA,No,NA,would you be interested in brca testing? adjusted odds ratio for positive response,OR,NA,"age, ethnicity, education level, family history of breast and/or ovarian cancer, willing to pay out of pocket",1,White,Black,1.38,0.6,3.15
10.1016/j.ygyno.2019.06.009,2,No,NA,No,NA,would you be interested in brca testing? adjusted odds ratio for positive response,OR,NA,"age, ethnicity, education level, family history of breast and/or ovarian cancer, willing to pay out of pocket",2,White,Other,1.13,0.41,3.11
10.1016/j.ygyno.2019.06.009,3,No,NA,No,NA,have you heard of brca testing? adjusted odds ratio for positive response,OR,NA,"age, race, education level, family history of breast and/or ovarian cancer, willing to pay out of pocket",1,Non-Hispanic,Hispanic,0.1,0.01,0.83
10.1016/j.ygyno.2019.06.009,4,No,NA,No,NA,would you be interested in brca testing? adjusted odds ratio for positive response,OR,NA,"age, race, education level, family history of breast and/or ovarian cancer, willing to pay out of pocket",1,Non-Hispanic,Hispanic,1.99,0.47,8.5
10.1016/j.ygyno.2019.06.022,1,No,NA,No,NA,brachytherapy use,OR,NA,"age, insurance type, income, stage, histology, facility type, facility location, facility distance, education (% who did not graduate high school), urban or rural, charlson/deyo score, clinical nodal status, year of diagnosis",1,Non-Black,Black,0.87,0.79,0.96
10.1016/j.ygyno.2019.06.022,2,Yes,Brachytherapy not administered,No,NA,overall survival,HR,NA,"age, insurance type, income, stage, histology, facility type, facility location, facility distance, education (% who did not graduate high school), urban or rural, charlson/deyo score, clinical nodal status, year of diagnosis, interaction term between race and boost modality",1,Non-Black,Black,1.14,1.05,1.24
10.1016/j.ygyno.2019.06.022,3,Yes,NA,NA,NA,brachytherapy administered,HR,NA,"age, insurance type, income, stage, histology, facility type, facility location, facility distance, education (% who did not graduate high school), urban or rural, charlson/deyo score, clinical nodal status, year of diagnosis, interaction term between race and boost modality",1,Non-Black,Black,1.04,0.95,1.13
10.1016/j.ygyno.2019.11.025,1,No,NA,No,NA,prognostic factor analysis in surgically managed vulvar cancer patients overall,HR,NA,"age, comorbidity score, clinical stage, tumor size, surgical margins, regional lymph node status, histologic subtype, tumor grade",1,White,Black,1,0.9,1.11
10.1016/j.ygyno.2019.11.025,1,No,NA,No,NA,prognostic factor analysis in surgically managed vulvar cancer patients overall,HR,NA,"age, comorbidity score, clinical stage, tumor size, surgical margins, regional lymph node status, histologic subtype, tumor grade",2,White,Others,0.83,0.71,0.98
10.1016/j.ygyno.2019.11.025,2,Yes,Non-elderly (<75 years old),No,NA,prognostic factor analysis in surgically managed vulvar cancer patients by age cohort,HR,NA,"age, comorbidity score, clinical stage, tumor size, surgical margins, regional lymph node status, histologic subtype, tumor grade",1,White,Black,1,0.88,1.14
10.1016/j.ygyno.2019.11.025,2,Yes,Non-elderly (<75 years old),No,NA,prognostic factor analysis in surgically managed vulvar cancer patients by age cohort,HR,NA,"age, comorbidity score, clinical stage, tumor size, surgical margins, regional lymph node status, histologic subtype, tumor grade",2,White,Other,0.9,0.72,1.13
10.1016/j.ygyno.2019.11.025,3,Yes,Elderly (≥75 years old),No,NA,prognostic factor analysis in surgically managed vulvar cancer patients by age cohort,HR,NA,"age, comorbidity score, clinical stage, tumor size, surgical margins, regional lymph node status, histologic subtype, tumor grade",1,White,Black,1.01,0.84,1.22
10.1016/j.ygyno.2019.11.025,3,Yes,Elderly (≥75 years old),No,NA,prognostic factor analysis in surgically managed vulvar cancer patients by age cohort,HR,NA,"age, comorbidity score, clinical stage, tumor size, surgical margins, regional lymph node status, histologic subtype, tumor grade",2,White,Others,0.79,0.63,0.99
10.1016/j.ygyno.2019.12.041,1,No,NA,No,NA,survival analysis for low-grade serous carcinoma,HR,NA,none,1,White,Black,1.07,0.79,1.43
10.1016/j.ygyno.2019.12.041,1,No,NA,No,NA,survival analysis for low-grade serous carcinoma,HR,NA,none,2,White,Other,0.69,0.45,1.08
10.1016/j.ygyno.2019.12.041,2,No,NA,No,NA,survival analysis for low-grade serous carcinoma,HR,NA,none,1,Non-Hispanic,Hispanic,0.94,0.69,1.28
10.1016/j.ygyno.2020.01.017,1,Yes,Uterine carcinosarcoma,No,NA,risk of death,HR,NA,"race, age, geographic region, year of diagnosis, comorbidity score, neighborhood income, insurance status, stage, surgery status including outcome, radiotherapy status, chemotherapy status",1,Non-Hispanic White,Non-Hispanic Black,1.17,1.1,1.24
10.1016/j.ygyno.2020.01.017,2,Yes,Ovarian Carcinosarcoma,No,NA,risk of death,HR,NA,"race, age, geographic region, year of diagnosis, comorbidity score, neighborhood income, insurance status, stage, surgery status including outcome, radiotherapy status, chemotherapy status",1,Non-Hispanic White,Non-Hispanic Black,0.99,0.85,1.15
10.1016/j.ygyno.2020.01.040,1,No,NA,Yes,Before education,willingness to participate before and after educational intervention,Percentage of sample willing to participate in clinical trials,NA,n/a,1,N/A,"White, non-Hispanic",33,NA,NA
10.1016/j.ygyno.2020.01.040,1,No,NA,Yes,Before education,willingness to participate before and after educational intervention,Percentage of sample willing to participate in clinical trials,NA,n/a,2,N/A,Non-white,36,NA,NA
10.1016/j.ygyno.2020.01.040,1,No,NA,Yes,Before education,willingness to participate before and after educational intervention,Percentage of sample willing to participate in clinical trials,NA,n/a,3,N/A,Black,33,NA,NA
10.1016/j.ygyno.2020.01.040,1,No,NA,Yes,Before education,willingness to participate before and after educational intervention,Percentage of sample willing to participate in clinical trials,NA,n/a,4,N/A,Hispanic,57,NA,NA
10.1016/j.ygyno.2020.01.040,1,No,NA,Yes,Before education,willingness to participate before and after educational intervention,Percentage of sample willing to participate in clinical trials,NA,n/a,5,N/A,Asian,14,NA,NA
10.1016/j.ygyno.2020.01.040,1,No,NA,Yes,Before education,willingness to participate before and after educational intervention,Percentage of sample willing to participate in clinical trials,NA,n/a,6,N/A,Other,33,NA,NA
10.1016/j.ygyno.2020.01.040,2,No,NA,Yes,After education,willingness to participate before and after educational intervention,Percentage of sample willing to participate in clinical trials,NA,n/a,1,N/A,"White, non-Hispanic",88,NA,NA
10.1016/j.ygyno.2020.01.040,2,No,NA,Yes,After education,willingness to participate before and after educational intervention,Percentage of sample willing to participate in clinical trials,NA,n/a,2,N/A,Non-white,75,NA,NA
10.1016/j.ygyno.2020.01.040,2,No,NA,Yes,After education,willingness to participate before and after educational intervention,Percentage of sample willing to participate in clinical trials,NA,n/a,3,N/A,Black,76,NA,NA
10.1016/j.ygyno.2020.01.040,2,No,NA,Yes,After education,willingness to participate before and after educational intervention,Percentage of sample willing to participate in clinical trials,NA,n/a,4,N/A,Hispanic,79,NA,NA
10.1016/j.ygyno.2020.01.040,2,No,NA,Yes,After education,willingness to participate before and after educational intervention,Percentage of sample willing to participate in clinical trials,NA,n/a,5,N/A,Asian,71,NA,NA
10.1016/j.ygyno.2020.01.040,2,No,NA,Yes,After education,willingness to participate before and after educational intervention,Percentage of sample willing to participate in clinical trials,NA,n/a,6,N/A,Other,66,NA,NA
10.1016/j.ygyno.2020.01.040,3,No,NA,No,NA,change in willingness to participate,Percentage point change in willingness to participate,NA,n/a,1,N/A,"White, non-Hispanic",55,NA,NA
10.1016/j.ygyno.2020.01.040,3,No,NA,No,NA,change in willingness to participate,Percentage point change in willingness to participate,NA,n/a,2,N/A,Non-white,39,NA,NA
10.1016/j.ygyno.2020.01.040,3,No,NA,No,NA,change in willingness to participate,Percentage point change in willingness to participate,NA,n/a,3,N/A,Black,43,NA,NA
10.1016/j.ygyno.2020.01.040,3,No,NA,No,NA,change in willingness to participate,Percentage point change in willingness to participate,NA,n/a,4,N/A,Hispanic,22,NA,NA
10.1016/j.ygyno.2020.01.040,3,No,NA,No,NA,change in willingness to participate,Percentage point change in willingness to participate,NA,n/a,5,N/A,Asian,57,NA,NA
10.1016/j.ygyno.2020.01.040,3,No,NA,No,NA,change in willingness to participate,Percentage point change in willingness to participate,NA,n/a,6,N/A,Other,33,NA,NA
10.1016/j.ygyno.2020.03.016,1,No,NA,No,NA,received guideline-concordant treatment,OR,NA,none,1,Non-Hispanic White,Non-Hispanic Black,1.02,0.97,1.08
10.1016/j.ygyno.2020.03.016,1,No,NA,No,NA,received guideline-concordant treatment,OR,NA,none,2,Non-Hispanic White,Hispanic,1,0.91,1.11
10.1016/j.ygyno.2020.03.016,1,No,NA,No,NA,received guideline-concordant treatment,OR,NA,none,3,Non-Hispanic White,Asian/Pacific Islander,1.1,0.97,1.26
10.1016/j.ygyno.2020.03.016,2,No,NA,No,NA,received guideline-concordant treatment,OR,NA,"age, stage, histology (carcinosarcoma, clear cell, serous), hospital type, insurance",1,Non-Hispanic White,Non-Hispanic Black,1.01,0.95,1.07
10.1016/j.ygyno.2020.03.016,2,No,NA,No,NA,received guideline-concordant treatment,OR,NA,"age, stage, histology (carcinosarcoma, clear cell, serous), hospital type, insurance",2,Non-Hispanic White,Hispanic,1.01,0.91,1.12
10.1016/j.ygyno.2020.03.016,2,No,NA,No,NA,received guideline-concordant treatment,OR,NA,"age, stage, histology (carcinosarcoma, clear cell, serous), hospital type, insurance",3,Non-Hispanic White,Asian/Pacific Islander,1.1,0.96,1.26
10.1016/j.ygyno.2020.03.016,3,Yes,Race/ethnicity - Non-Hispanic White,No,NA,death,HR,NA,"age, stage, histology, hospital type, and insurance status",1,did not receive guideline-concordant treatment,received guideline-concordant treatment,0.84,0.8,0.87
10.1016/j.ygyno.2020.03.016,4,Yes,Race/ethnicity - Non-Hispanic Black,No,NA,death,HR,NA,"age, stage, histology, hospital type, and insurance status",1,did not receive guideline-concordant treatment,received guideline-concordant treatment,0.85,0.8,0.91
10.1016/j.ygyno.2020.03.016,5,Yes,Race/ethnicity - Hispanic,No,NA,death,HR,NA,"age, stage, histology, hospital type, and insurance status",1,did not receive guideline-concordant treatment,received guideline-concordant treatment,0.84,0.72,0.98
10.1016/j.ygyno.2020.03.033,1,No,NA,No,NA,"age-adjusted cervical cancer incidence rates (per 100,000)",Incidence,NA,"age group, state at diagnosis, county of residence",1,N/A,AI/AN,10.5,NA,NA
10.1016/j.ygyno.2020.03.033,1,No,NA,No,NA,"age-adjusted cervical cancer incidence rates (per 100,000)",Incidence,NA,"age group, state at diagnosis, county of residence",2,N/A,NHW,6.8,NA,NA
10.1016/j.ygyno.2020.03.033,2,No,NA,No,NA,"age-adjusted uterine cancer incidence rates (per 100,000)",Incidence,NA,"age group, stage at diagnosis, county of residence",1,N/A,AI/AN,25.2,NA,NA
10.1016/j.ygyno.2020.03.033,2,No,NA,No,NA,"age-adjusted uterine cancer incidence rates (per 100,000)",Incidence,NA,"age group, stage at diagnosis, county of residence",2,N/A,NHW,25.9,NA,NA
10.1016/j.ygyno.2020.03.033,3,No,NA,No,NA,"age-adjusted ovarian cancer incidence rates (per 100,000)",Incidence,NA,"age group, state at diagnosis, county of residence",1,N/A,AI/AN,13.1,NA,NA
10.1016/j.ygyno.2020.03.033,3,No,NA,No,NA,"age-adjusted ovarian cancer incidence rates (per 100,000)",Incidence,NA,"age group, state at diagnosis, county of residence",2,N/A,NHW,14.5,NA,NA
10.1016/j.ygyno.2020.03.033,4,No,NA,No,NA,"age-adjusted other gynecologic cancer incidence rates (per 100,000)",Incidence,NA,"age group, stage at diagnosis, county of residence",1,N/A,AI/AN,4.6,NA,NA
10.1016/j.ygyno.2020.03.033,4,No,NA,No,NA,"age-adjusted other gynecologic cancer incidence rates (per 100,000)",Incidence,NA,"age group, stage at diagnosis, county of residence",2,N/A,NHW,4.5,NA,NA
10.1016/j.ygyno.2020.09.032,1,No,NA,No,NA,risk of conversion to open surgery for patients undergoing adequate minimally invasive staging for t1nxm0 endometrial carcinoma,OR,NA,"ln technique, surgical technique, omentectomy, co-morbidity, hispanic ethnicity, primary payer, zip code median income, county density, academic facility, facility region, hist-ology, year",1,White,Black,1.67,1.37,2.05
10.1016/j.ygyno.2020.09.032,1,No,NA,No,NA,risk of conversion to open surgery for patients undergoing adequate minimally invasive staging for t1nxm0 endometrial carcinoma,OR,NA,"ln technique, surgical technique, omentectomy, co-morbidity, hispanic ethnicity, primary payer, zip code median income, county density, academic facility, facility region, hist-ology, year",2,White,Asian,1.28,0.94,1.74
10.1016/j.ygyno.2020.09.032,1,No,NA,No,NA,risk of conversion to open surgery for patients undergoing adequate minimally invasive staging for t1nxm0 endometrial carcinoma,OR,NA,"ln technique, surgical technique, omentectomy, co-morbidity, hispanic ethnicity, primary payer, zip code median income, county density, academic facility, facility region, hist-ology, year",3,White,Other,1.15,0.76,1.75
10.1016/j.ygyno.2020.09.032,2,No,NA,No,NA,percent adequacy of lymph node assessment in patients with t1nxm0 endometrial carcinoma undergoing minimally invasive surgical staging,Prevalence,NA,none,1,None,Black,59.3,NA,NA
10.1016/j.ygyno.2020.09.032,2,No,NA,No,NA,percent adequacy of lymph node assessment in patients with t1nxm0 endometrial carcinoma undergoing minimally invasive surgical staging,Prevalence,NA,none,2,None,Asian/Pacific,62.9,NA,NA
10.1016/j.ygyno.2020.09.032,2,No,NA,No,NA,percent adequacy of lymph node assessment in patients with t1nxm0 endometrial carcinoma undergoing minimally invasive surgical staging,Prevalence,NA,none,3,None,White/Other,64.5,NA,NA
10.1016/j.ygyno.2020.10.033,1,No,NA,No,NA,endometrial hyperplasia symptoms,OR,NA,"age at first visit, bmi, obstetric history, medicaid, medicare, commercial insurance, family history of any female cancer, smoking/alcohol use history, diabetes, hypertension, hypothyroidism, birth control, menopausal status",1,Non-Hispanic White,Non-Hispanic Black,1.56,1.42,1.72
10.1016/j.ygyno.2020.10.033,1,No,NA,No,NA,endometrial hyperplasia symptoms,OR,NA,"age at first visit, bmi, obstetric history, medicaid, medicare, commercial insurance, family history of any female cancer, smoking/alcohol use history, diabetes, hypertension, hypothyroidism, birth control, menopausal status",2,Non-Hispanic White,Hispanic,1.35,1.22,1.49
10.1016/j.ygyno.2020.10.033,1,No,NA,No,NA,endometrial hyperplasia symptoms,OR,NA,"age at first visit, bmi, obstetric history, medicaid, medicare, commercial insurance, family history of any female cancer, smoking/alcohol use history, diabetes, hypertension, hypothyroidism, birth control, menopausal status",3,Non-Hispanic White,Other,1.09,0.88,1.34
10.1016/j.ygyno.2020.10.033,2,No,NA,No,NA,endometrial cancer,OR,NA,"age at first visit, bmi, obstetric history, medicaid, medicare, commercial insurance, family history of any female cancer, smoking/alcohol use history, diabetes, hypertension, hypothyroidism, birth control, menopausal status",1,Non-Hispanic White,Non-Hispanic Black,0.83,0.56,1.23
10.1016/j.ygyno.2020.10.033,2,No,NA,No,NA,endometrial cancer,OR,NA,"age at first visit, bmi, obstetric history, medicaid, medicare, commercial insurance, family history of any female cancer, smoking/alcohol use history, diabetes, hypertension, hypothyroidism, birth control, menopausal status",2,Non-Hispanic White,Hispanic,1.14,0.77,1.69
10.1016/j.ygyno.2020.10.033,2,No,NA,No,NA,endometrial cancer,OR,NA,"age at first visit, bmi, obstetric history, medicaid, medicare, commercial insurance, family history of any female cancer, smoking/alcohol use history, diabetes, hypertension, hypothyroidism, birth control, menopausal status",3,Non-Hispanic White,Other,1.17,0.5,2.74
10.1016/j.ygyno.2020.10.033,3,Yes,Medicare - No,No,NA,endometrial hyperplasia symptoms,OR,NA,"age at first visit, bmi, obstetric history, medicaid, commercial insurance, family history of any female cancer, smoking/alcohol use history, diabetes, hypertension, hypothyroidism, birth control, menopausal status",1,Non-Hispanic White,Hispanic,1.45,1.28,1.64
10.1016/j.ygyno.2020.10.033,3,Yes,Medicare - No,No,NA,endometrial hyperplasia symptoms,OR,NA,"age at first visit, bmi, obstetric history, medicaid, commercial insurance, family history of any female cancer, smoking/alcohol use history, diabetes, hypertension, hypothyroidism, birth control, menopausal status",2,Non-Hispanic White,Non-Hispanic Black,1.41,1.24,1.61
10.1016/j.ygyno.2020.10.033,3,Yes,Medicare - No,No,NA,endometrial hyperplasia symptoms,OR,NA,"age at first visit, bmi, obstetric history, medicaid, commercial insurance, family history of any female cancer, smoking/alcohol use history, diabetes, hypertension, hypothyroidism, birth control, menopausal status",3,Non-Hispanic White,Other,0.95,0.74,1.22
10.1016/j.ygyno.2020.10.033,4,Yes,Medicare - Yes,No,NA,endometrial hyperplasia symptoms,OR,NA,"age at first visit, bmi, obstetric history, medicaid, commercial insurance, family history of any female cancer, smoking/alcohol use history, diabetes, hypertension, hypothyroidism, birth control, menopausal status",1,Non-Hispanic White,Hispanic,1.19,1.01,1.4
10.1016/j.ygyno.2020.10.033,4,Yes,Medicare - Yes,No,NA,endometrial hyperplasia symptoms,OR,NA,"age at first visit, bmi, obstetric history, medicaid, commercial insurance, family history of any female cancer, smoking/alcohol use history, diabetes, hypertension, hypothyroidism, birth control, menopausal status",2,Non-Hispanic White,Non-Hispanic Black,1.72,1.51,1.97
10.1016/j.ygyno.2020.10.033,4,Yes,Medicare - Yes,No,NA,endometrial hyperplasia symptoms,OR,NA,"age at first visit, bmi, obstetric history, medicaid, commercial insurance, family history of any female cancer, smoking/alcohol use history, diabetes, hypertension, hypothyroidism, birth control, menopausal status",3,Non-Hispanic White,Other,1.6,1.07,2.37
10.1016/j.ygyno.2020.10.040,1,Yes,Whites,NA,NA,five-year hazard ratios of death associated with treatment adherence status,HR,NA,"age, year of diagnosis, residence, annual household income, educational attainment, insurance, facility type, treatment delay, charlson comorbidity score, stage, histology, grade, treatment adherence status",1,Surgery/Chemotherapy Yes/Yes,Surgery/Chemotherapy Yes/No,1.92,1.87,1.97
10.1016/j.ygyno.2020.10.040,1,Yes,Whites,NA,NA,five-year hazard ratios of death associated with treatment adherence status,HR,NA,"age, year of diagnosis, residence, annual household income, educational attainment, insurance, facility type, treatment delay, charlson comorbidity score, stage, histology, grade, treatment adherence status",2,Surgery/Chemotherapy Yes/Yes,Surgery/Chemotherapy No/Yes,1.98,1.92,2.03
10.1016/j.ygyno.2020.10.040,1,Yes,Whites,NA,NA,five-year hazard ratios of death associated with treatment adherence status,HR,NA,"age, year of diagnosis, residence, annual household income, educational attainment, insurance, facility type, treatment delay, charlson comorbidity score, stage, histology, grade, treatment adherence status",3,Surgery/Chemotherapy Yes/Yes,Surgery/Chemotherapy No/No,5.17,4.93,5.42
10.1016/j.ygyno.2020.10.040,2,Yes,Blacks,NA,NA,five-year hazard ratios of death associated with treatment adherence status,HR,NA,"age, year of diagnosis, residence, annual household income, educational attainment, insurance, facility type, treatment delay, charlson comorbidity score, stage, histology, grade, treatment adherence status",1,Surgery/Chemotherapy Yes/Yes,Surgery/Chemotherapy Yes/No,1.91,1.75,2.07
10.1016/j.ygyno.2020.10.040,2,Yes,Blacks,NA,NA,five-year hazard ratios of death associated with treatment adherence status,HR,NA,"age, year of diagnosis, residence, annual household income, educational attainment, insurance, facility type, treatment delay, charlson comorbidity score, stage, histology, grade, treatment adherence status",2,Surgery/Chemotherapy Yes/Yes,Surgery/Chemotherapy No/Yes,2.01,1.85,2.18
10.1016/j.ygyno.2020.10.040,2,Yes,Blacks,NA,NA,five-year hazard ratios of death associated with treatment adherence status,HR,NA,"age, year of diagnosis, residence, annual household income, educational attainment, insurance, facility type, treatment delay, charlson comorbidity score, stage, histology, grade, treatment adherence status",3,Surgery/Chemotherapy Yes/Yes,Surgery/Chemotherapy No/No,4.56,3.92,5.31
10.1016/j.ygyno.2020.10.040,3,Yes,Whites,NA,NA,five-year overall survival associated with treatment adherence status,Five-year overall survival rate (%),NA,"age, year of diagnosis, residence, annual household income, educational attainment, insurance, facility type, treatment delay, charlson comorbidity score, stage, histology, grade, treatment adherence status",1,Surgery/Chemotherapy Yes/Yes,Surgery/Chemotherapy Yes/No,42.8,NA,NA
10.1016/j.ygyno.2020.10.040,3,Yes,Whites,NA,NA,five-year overall survival associated with treatment adherence status,Five-year overall survival rate (%),NA,"age, year of diagnosis, residence, annual household income, educational attainment, insurance, facility type, treatment delay, charlson comorbidity score, stage, histology, grade, treatment adherence status",2,Surgery/Chemotherapy Yes/Yes,Surgery/Chemotherapy Yes/No,10.6,NA,NA
10.1016/j.ygyno.2020.10.040,3,Yes,Whites,NA,NA,five-year overall survival associated with treatment adherence status,Five-year overall survival rate (%),NA,"age, year of diagnosis, residence, annual household income, educational attainment, insurance, facility type, treatment delay, charlson comorbidity score, stage, histology, grade, treatment adherence status",3,Surgery/Chemotherapy Yes/Yes,Surgery/Chemotherapy No/No,3.9,NA,NA
10.1016/j.ygyno.2020.10.040,4,Yes,Blacks,NA,NA,five-year overall survival associated with treatment adherence status,Five-year overall survival rate (%),NA,"age, year of diagnosis, residence, annual household income, educational attainment, insurance, facility type, treatment delay, charlson comorbidity score, stage, histology, grade, treatment adherence status",1,Surgery/Chemotherapy Yes/Yes,Surgery/Chemotherapy Yes/No,40.3,NA,NA
10.1016/j.ygyno.2020.10.040,4,Yes,Blacks,NA,NA,five-year overall survival associated with treatment adherence status,Five-year overall survival rate (%),NA,"age, year of diagnosis, residence, annual household income, educational attainment, insurance, facility type, treatment delay, charlson comorbidity score, stage, histology, grade, treatment adherence status",2,Surgery/Chemotherapy Yes/Yes,Surgery/Chemotherapy No/Yes,10.1,NA,NA
10.1016/j.ygyno.2020.10.040,4,Yes,Blacks,NA,NA,five-year overall survival associated with treatment adherence status,Five-year overall survival rate (%),NA,"age, year of diagnosis, residence, annual household income, educational attainment, insurance, facility type, treatment delay, charlson comorbidity score, stage, histology, grade, treatment adherence status",3,Surgery/Chemotherapy Yes/Yes,Surgery/Chemotherapy No/No,5,NA,NA
10.1016/j.ygyno.2020.11.019,1,No,NA,No,NA,% urm,% of positions,NA,none,1,NA,Gyn Onc,26.1,-99,-99
10.1016/j.ygyno.2020.11.019,1,No,NA,No,NA,% urm,% of positions,NA,none,2,NA,Ob Gyn,35.2,-99,-99
10.1016/j.ygyno.2020.11.019,1,No,NA,No,NA,% urm,% of positions,NA,none,3,NA,All Other Surgical,33.1,-99,-99
10.1016/j.ygyno.2020.11.019,1,No,NA,No,NA,% urm,% of positions,NA,none,4,NA,All Other Medical,46.3,-99,-99
10.1016/j.ygyno.2020.11.019,2,No,NA,No,NA,% hbno,% of positions,NA,none,1,None,Gyn Onc,12.7,-99,-99
10.1016/j.ygyno.2020.11.019,2,No,NA,No,NA,% hbno,% of positions,NA,none,2,None,Ob Gyn,22.3,-99,-99
10.1016/j.ygyno.2020.11.019,2,No,NA,No,NA,% hbno,% of positions,NA,none,3,None,All Other Surgical,16.1,-99,-99
10.1016/j.ygyno.2020.11.019,2,No,NA,No,NA,% hbno,% of positions,NA,none,4,None,All Other Medical,20.6,-99,-99
10.1016/j.ygyno.2020.11.019,3,No,NA,No,NA,% asian/pi,% of positions,NA,none,1,None,Gyn Onc,13.4,-99,-99
10.1016/j.ygyno.2020.11.019,3,No,NA,No,NA,% asian/pi,% of positions,NA,none,2,None,Ob Gyn,12.9,-99,-99
10.1016/j.ygyno.2020.11.019,3,No,NA,No,NA,% asian/pi,% of positions,NA,none,3,None,All Other Surgical,17,-99,-99
10.1016/j.ygyno.2020.11.019,3,No,NA,No,NA,% asian/pi,% of positions,NA,none,4,None,All Other Medical,25.7,NA,NA
10.1016/j.ygyno.2020.11.031,1,No,NA,No,NA,utilization of palliative care among ovarian cancer patients,OR,NA,"age, follow-up time from cancer diagnosis to last contact or death (months), insurance type, median income, comorbidity score, cancer care facility type, census region, year of cancer diagnosis, cancer grade",1,Non-Hispanic White,Non-Hispanic Black,0.87,0.78,0.97
10.1016/j.ygyno.2020.11.031,1,No,NA,No,NA,utilization of palliative care among ovarian cancer patients,OR,NA,"age, follow-up time from cancer diagnosis to last contact or death (months), insurance type, median income, comorbidity score, cancer care facility type, census region, year of cancer diagnosis, cancer grade",2,Non-Hispanic White,Hispanic,0.77,0.66,0.91
10.1016/j.ygyno.2021.01.041,1,No,NA,No,NA,receipt of adjuvant radiation,OR,NA,"age, stage, grade, ln assessment, income, insurance, facility, distance, rurality",1,White,Black,0.79,0.69,0.91
10.1016/j.ygyno.2021.01.041,1,No,NA,No,NA,receipt of adjuvant radiation,OR,NA,"age, stage, grade, ln assessment, income, insurance, facility, distance, rurality",2,White,Hispanic,0.75,0.64,0.87
10.1016/j.ygyno.2021.01.041,1,No,NA,No,NA,receipt of adjuvant radiation,OR,NA,"age, stage, grade, ln assessment, income, insurance, facility, distance, rurality",3,White,Asian,0.75,0.6,0.94
10.1016/j.ygyno.2021.01.041,1,No,NA,No,NA,receipt of adjuvant radiation,OR,NA,"age, stage, grade, ln assessment, income, insurance, facility, distance, rurality",4,White,Others,0.73,0.59,0.9
10.1016/j.ygyno.2021.01.041,2,No,NA,No,NA,mortality,HR,NA,"age, stage, grade, ln assessment, rt, income, insurance, facility, distance, rurality",1,White,Black,1.28,1.12,1.45
10.1016/j.ygyno.2021.01.041,2,No,NA,No,NA,mortality,HR,NA,"age, stage, grade, ln assessment, rt, income, insurance, facility, distance, rurality",2,White,Hispanic,0.71,0.58,0.87
10.1016/j.ygyno.2021.01.041,2,No,NA,No,NA,mortality,HR,NA,"age, stage, grade, ln assessment, rt, income, insurance, facility, distance, rurality",3,White,Asian,0.86,0.64,1.16
10.1016/j.ygyno.2021.01.041,2,No,NA,No,NA,mortality,HR,NA,"age, stage, grade, ln assessment, rt, income, insurance, facility, distance, rurality",4,White,Others,0.95,0.75,1.21
10.1016/j.ygyno.2021.02.037,1,No,NA,No,NA,annual percent change in the hysterectomy- and pregnancy- corrected incidence rates of uterine cancer,Incidence,NA,age,1,N/A,White,0.4,0,0.8
10.1016/j.ygyno.2021.02.037,1,No,NA,No,NA,annual percent change in the hysterectomy- and pregnancy- corrected incidence rates of uterine cancer,Incidence,NA,age,2,N/A,Black,2.3,1.4,3.2
10.1016/j.ygyno.2021.02.037,1,No,NA,No,NA,annual percent change in the hysterectomy- and pregnancy- corrected incidence rates of uterine cancer,Incidence,NA,age,3,N/A,Hispanic,1.1,0.7,1.5
10.1016/j.ygyno.2021.02.037,1,No,NA,No,NA,annual percent change in the hysterectomy- and pregnancy- corrected incidence rates of uterine cancer,Incidence,NA,age,4,N/A,Asian/Pacific Islander,1.3,0.7,1.9
10.1016/j.ygyno.2021.02.037,1,No,NA,No,NA,annual percent change in the hysterectomy- and pregnancy- corrected incidence rates of uterine cancer,Incidence,NA,age,5,N/A,Other or unknown,1,0.2,1.9
10.1093/humrep/deaa063,1,Yes,Race - White,No,NA,implantation,RR,NA,"total serum lipid, age, bmi, year of bde/oh-bde sample collection, day 3 fsh levels, iu/l, and ivf protocol (antagonist, flare, luteal phase agonist)",1,N/A,one IQR increase in BDE47,1.07,0.95,1.19
10.1093/humrep/deaa063,2,Yes,Race - Other,No,NA,implantation,RR,NA,"total serum lipid, age, bmi, year of bde/oh-bde sample collection, day 3 fsh levels, iu/l, and ivf protocol (antagonist, flare, luteal phase agonist)",1,N/A,one IQR increase in BDE47,0.73,0.49,1.09
10.1093/humrep/deaa063,3,Yes,Race - White,No,NA,clinical pregnancy,RR,NA,"models adjusted for total serum lipid, age, bmi, year of bde/oh-bde sample collection, day 3 fsh levels, iu/l, and ivf protocol (antagonist, flare, luteal phase agonist)",1,N/A,one IQR increase in BDE47,1.04,0.91,1.18
10.1093/humrep/deaa063,4,Yes,Race - Other,No,NA,clinical pregnancy,RR,NA,"models adjusted for total serum lipid, age, bmi, year of bde/oh-bde sample collection, day 3 fsh levels, iu/l, and ivf protocol (antagonist, flare, luteal phase agonist)",1,N/A,one IQR increase in BDE47,0.63,0.41,0.96
10.1093/humrep/deaa063,5,Yes,Race - White,No,NA,live birth,RR,NA,"models adjusted for total serum lipid, age, bmi, year of bde/oh-bde sample collection, day 3 fsh levels, iu/l, and ivf protocol (antagonist, flare, luteal phase agonist)",1,N/A,one IQR increase in BDE47,1.08,0.92,1.28
10.1093/humrep/dev332,1,No,NA,Yes,"Any complication (blood transfusion, sterilization or length of stay > 2 days)",ectopic pregnancy complications,Incidence rate ratio,NA,"age, state",1,White,Black,1.47,1.43,1.53
10.1093/humrep/dev332,1,No,NA,Yes,"Any complication (blood transfusion, sterilization or length of stay > 2 days)",ectopic pregnancy complications,Incidence rate ratio,NA,"age, state",2,White,American Indian/Alaskan Native,1.34,1.16,1.55
10.1093/humrep/dev332,1,No,NA,Yes,"Any complication (blood transfusion, sterilization or length of stay > 2 days)",ectopic pregnancy complications,Incidence rate ratio,NA,"age, state",3,White,Asian,1.34,1.24,1.45
10.1093/humrep/dev332,1,No,NA,Yes,"Any complication (blood transfusion, sterilization or length of stay > 2 days)",ectopic pregnancy complications,Incidence rate ratio,NA,"age, state",4,White,Hispanic,1.16,1.12,1.21
10.1093/humrep/dev332,1,No,NA,Yes,"Any complication (blood transfusion, sterilization or length of stay > 2 days)",ectopic pregnancy complications,Incidence rate ratio,NA,"age, state",5,White,Native Hawaiian/Pacific Islander,1.61,1.39,1.87
10.1093/humrep/dev332,2,No,NA,Yes,"Any complication (blood transfusion, sterilization or length of stay>2 days)",ectopic pregnancy complications,Incidence Rate Ratio,NA,"age, state, preconception care, prenatal care",1,White,Black,1.49,1.44,1.55
10.1093/humrep/dev332,2,No,NA,Yes,"Any complication (blood transfusion, sterilization or length of stay>2 days)",ectopic pregnancy complications,Incidence Rate Ratio,NA,"age, state, preconception care, prenatal care",2,White,American Indian/Alaskan Native,1.4,1.21,1.62
10.1093/humrep/dev332,2,No,NA,Yes,"Any complication (blood transfusion, sterilization or length of stay>2 days)",ectopic pregnancy complications,Incidence Rate Ratio,NA,"age, state, preconception care, prenatal care",3,White,Asian,1.36,1.25,1.47
10.1093/humrep/dev332,2,No,NA,Yes,"Any complication (blood transfusion, sterilization or length of stay>2 days)",ectopic pregnancy complications,Incidence Rate Ratio,NA,"age, state, preconception care, prenatal care",4,White,Hispanic,1.18,1.14,1.22
10.1093/humrep/dev332,2,No,NA,Yes,"Any complication (blood transfusion, sterilization or length of stay>2 days)",ectopic pregnancy complications,Incidence Rate Ratio,NA,"age, state, preconception care, prenatal care",5,White,Native Hawaiian/Pacific Islander,1.59,1.37,1.84
10.1093/humrep/dev332,3,No,NA,No,NA,transfusion,Incidence rate ratio,NA,"age, state",1,White,Black,1.28,1.23,1.34
10.1093/humrep/dev332,3,No,NA,No,NA,transfusion,Incidence rate ratio,NA,"age, state",2,White,American Indian/Alaskan Native,1.41,1.2,1.66
10.1093/humrep/dev332,3,No,NA,No,NA,transfusion,Incidence rate ratio,NA,"age, state",3,White,Asian,1.8,1.66,1.96
10.1093/humrep/dev332,3,No,NA,No,NA,transfusion,Incidence rate ratio,NA,"age, state",4,White,Hispanic,1.18,1.13,1.23
10.1093/humrep/dev332,3,No,NA,No,NA,transfusion,Incidence rate ratio,NA,"age, state",5,White,Native Hawaiian/Pacific Islander,1.91,1.55,2.36
10.1093/humrep/dev332,4,No,NA,No,NA,transfusion,Incidence rate ratio,NA,"age, state, preconception care, prenatal care",1,White,Black,1.27,1.22,1.33
10.1093/humrep/dev332,4,No,NA,No,NA,transfusion,Incidence rate ratio,NA,"age, state, preconception care, prenatal care",2,White,American Indian/Alaskan Native,1.44,1.23,1.7
10.1093/humrep/dev332,4,No,NA,No,NA,transfusion,Incidence rate ratio,NA,"age, state, preconception care, prenatal care",3,White,Asian,1.8,1.65,1.96
10.1093/humrep/dev332,4,No,NA,No,NA,transfusion,Incidence rate ratio,NA,"age, state, preconception care, prenatal care",4,White,Hispanic,1.15,1.1,1.2
10.1093/humrep/dev332,4,No,NA,No,NA,transfusion,Incidence rate ratio,NA,"age, state, preconception care, prenatal care",5,White,Native Hawaiian/Pacific Islander,1.84,1.49,2.27
10.1093/humrep/dev332,5,No,NA,Yes,Sterilization (hysterectomy or other),ectopic pregnancy complications,Incidence rate ratio,NA,"age, state",1,White,Black,1.4,1.32,1.49
10.1093/humrep/dev332,5,No,NA,Yes,Sterilization (hysterectomy or other),ectopic pregnancy complications,Incidence rate ratio,NA,"age, state",2,White,Asian,1.78,1.58,2.01
10.1093/humrep/dev332,5,No,NA,Yes,Sterilization (hysterectomy or other),ectopic pregnancy complications,Incidence rate ratio,NA,"age, state",3,White,Hispanic,1.41,1.32,1.51
10.1097/AOG.0000000000001088,1,Yes,Uterine cancer,No,NA,"mode of hysterectomy (laparoscopic, robotic, or vaginal hysterectomy compared with abdominal hysterectomy)",OR,NA,none,1,White,Black,0.45,0.36,0.57
10.1097/AOG.0000000000001088,1,Yes,Uterine cancer,No,NA,"mode of hysterectomy (laparoscopic, robotic, or vaginal hysterectomy compared with abdominal hysterectomy)",OR,NA,none,2,White,Hispanic,0.82,0.63,1.05
10.1097/AOG.0000000000001088,1,Yes,Uterine cancer,No,NA,"mode of hysterectomy (laparoscopic, robotic, or vaginal hysterectomy compared with abdominal hysterectomy)",OR,NA,none,3,White,Asian or Pacific Islander,1.13,0.77,1.67
10.1097/AOG.0000000000001088,1,Yes,Uterine cancer,No,NA,"mode of hysterectomy (laparoscopic, robotic, or vaginal hysterectomy compared with abdominal hysterectomy)",OR,NA,none,4,White,Native American,0.96,0.29,3.12
10.1097/AOG.0000000000001088,1,Yes,Uterine cancer,No,NA,"mode of hysterectomy (laparoscopic, robotic, or vaginal hysterectomy compared with abdominal hysterectomy)",OR,NA,none,5,White,Other,0.63,0.43,0.91
10.1097/AOG.0000000000001088,1,Yes,Uterine cancer,No,NA,"mode of hysterectomy (laparoscopic, robotic, or vaginal hysterectomy compared with abdominal hysterectomy)",OR,NA,none,6,White,Missing,0.87,0.56,1.34
10.1097/AOG.0000000000001088,2,Yes,Uterine cancer,No,NA,"mode of hysterectomy (laparoscopic, robotic, or vaginal hysterectomy compared with abdominal hysterectomy)",OR,NA,"age, indication, adnexal surgery, urban-rural location, median household income national quartile for patient zip code, primary payer, region of hospital, location and teaching status",1,White,Black,0.5,0.4,0.63
10.1097/AOG.0000000000001088,2,Yes,Uterine cancer,No,NA,"mode of hysterectomy (laparoscopic, robotic, or vaginal hysterectomy compared with abdominal hysterectomy)",OR,NA,"age, indication, adnexal surgery, urban-rural location, median household income national quartile for patient zip code, primary payer, region of hospital, location and teaching status",2,White,Hispanic,0.77,0.58,1.02
10.1097/AOG.0000000000001088,2,Yes,Uterine cancer,No,NA,"mode of hysterectomy (laparoscopic, robotic, or vaginal hysterectomy compared with abdominal hysterectomy)",OR,NA,"age, indication, adnexal surgery, urban-rural location, median household income national quartile for patient zip code, primary payer, region of hospital, location and teaching status",3,White,Asian or Pacific Islander,0.76,0.5,1.14
10.1097/AOG.0000000000001088,2,Yes,Uterine cancer,No,NA,"mode of hysterectomy (laparoscopic, robotic, or vaginal hysterectomy compared with abdominal hysterectomy)",OR,NA,"age, indication, adnexal surgery, urban-rural location, median household income national quartile for patient zip code, primary payer, region of hospital, location and teaching status",4,White,Native American,0.74,0.26,2.08
10.1097/AOG.0000000000001088,2,Yes,Uterine cancer,No,NA,"mode of hysterectomy (laparoscopic, robotic, or vaginal hysterectomy compared with abdominal hysterectomy)",OR,NA,"age, indication, adnexal surgery, urban-rural location, median household income national quartile for patient zip code, primary payer, region of hospital, location and teaching status",5,White,Other,0.56,0.38,0.82
10.1097/AOG.0000000000001088,2,Yes,Uterine cancer,No,NA,"mode of hysterectomy (laparoscopic, robotic, or vaginal hysterectomy compared with abdominal hysterectomy)",OR,NA,"age, indication, adnexal surgery, urban-rural location, median household income national quartile for patient zip code, primary payer, region of hospital, location and teaching status",6,White,Missing,1.04,0.67,1.63
10.1097/AOG.0000000000001088,3,Yes,Cervical cancer,No,NA,"mode of hysterectomy (laparoscopic, robotic, or vaginal hysterectomy compared with abdominal hysterectomy)",OR,NA,none,1,White,Black,0.44,0.27,0.71
10.1097/AOG.0000000000001088,3,Yes,Cervical cancer,No,NA,"mode of hysterectomy (laparoscopic, robotic, or vaginal hysterectomy compared with abdominal hysterectomy)",OR,NA,none,2,White,Hispanic,0.85,0.55,1.32
10.1097/AOG.0000000000001088,3,Yes,Cervical cancer,No,NA,"mode of hysterectomy (laparoscopic, robotic, or vaginal hysterectomy compared with abdominal hysterectomy)",OR,NA,none,3,White,Asian or Pacific Islander,1.04,0.57,1.89
10.1097/AOG.0000000000001088,3,Yes,Cervical cancer,No,NA,"mode of hysterectomy (laparoscopic, robotic, or vaginal hysterectomy compared with abdominal hysterectomy)",OR,NA,none,4,White,Native American,3.45,0.36,33.3
10.1097/AOG.0000000000001088,3,Yes,Cervical cancer,No,NA,"mode of hysterectomy (laparoscopic, robotic, or vaginal hysterectomy compared with abdominal hysterectomy)",OR,NA,none,5,White,Other,0.67,0.34,1.34
10.1097/AOG.0000000000001088,3,Yes,Cervical cancer,No,NA,"mode of hysterectomy (laparoscopic, robotic, or vaginal hysterectomy compared with abdominal hysterectomy)",OR,NA,none,6,White,Missing,0.52,0.24,1.11
10.1097/AOG.0000000000001088,4,Yes,Cervical cancer,No,NA,"mode of hysterectomy (laparoscopic, robotic, or vaginal hysterectomy compared with abdominal hysterectomy)",OR,NA,"age, indication, adnexal surgery, urban-rural location, median household income national quartile for patient zip code, primary payer, region of hospital, location and teaching status",1,White,Black,0.56,0.33,0.96
10.1097/AOG.0000000000001088,4,Yes,Cervical cancer,No,NA,"mode of hysterectomy (laparoscopic, robotic, or vaginal hysterectomy compared with abdominal hysterectomy)",OR,NA,"age, indication, adnexal surgery, urban-rural location, median household income national quartile for patient zip code, primary payer, region of hospital, location and teaching status",2,White,Hispanic,0.84,0.52,1.36
10.1097/AOG.0000000000001088,4,Yes,Cervical cancer,No,NA,"mode of hysterectomy (laparoscopic, robotic, or vaginal hysterectomy compared with abdominal hysterectomy)",OR,NA,"age, indication, adnexal surgery, urban-rural location, median household income national quartile for patient zip code, primary payer, region of hospital, location and teaching status",3,White,Asian or Pacific Islander,0.92,0.47,1.78
10.1097/AOG.0000000000001088,4,Yes,Cervical cancer,No,NA,"mode of hysterectomy (laparoscopic, robotic, or vaginal hysterectomy compared with abdominal hysterectomy)",OR,NA,"age, indication, adnexal surgery, urban-rural location, median household income national quartile for patient zip code, primary payer, region of hospital, location and teaching status",4,White,Native American,3.95,0.5,31.5
10.1097/AOG.0000000000001088,4,Yes,Cervical cancer,No,NA,"mode of hysterectomy (laparoscopic, robotic, or vaginal hysterectomy compared with abdominal hysterectomy)",OR,NA,"age, indication, adnexal surgery, urban-rural location, median household income national quartile for patient zip code, primary payer, region of hospital, location and teaching status",5,White,Other,0.69,0.34,1.39
10.1097/AOG.0000000000001088,4,Yes,Cervical cancer,No,NA,"mode of hysterectomy (laparoscopic, robotic, or vaginal hysterectomy compared with abdominal hysterectomy)",OR,NA,"age, indication, adnexal surgery, urban-rural location, median household income national quartile for patient zip code, primary payer, region of hospital, location and teaching status",6,White,Missing,0.55,0.24,1.24
10.1097/AOG.0000000000001090,1,Yes,Vaginal Delivery,No,NA,30-day readmission,OR,NA,"age, quadratic age, facility volume, year of admission",1,White,Asian,0.96,0.69,1.35
10.1097/AOG.0000000000001090,1,Yes,Vaginal Delivery,No,NA,30-day readmission,OR,NA,"age, quadratic age, facility volume, year of admission",2,White,Black,1.83,1.57,2.13
10.1097/AOG.0000000000001090,1,Yes,Vaginal Delivery,No,NA,30-day readmission,OR,NA,"age, quadratic age, facility volume, year of admission",3,White,Hispanic,1.35,1.17,1.56
10.1097/AOG.0000000000001090,1,Yes,Vaginal Delivery,No,NA,30-day readmission,OR,NA,"age, quadratic age, facility volume, year of admission",4,White,Other race,0.79,0.63,0.99
10.1097/AOG.0000000000001090,2,Yes,Vaginal Delivery,No,NA,30-day readmission,OR,NA,"age, quadratic age, facility volume, year of admission, patient sickness, socioeconomic status, payer",1,White,Asian,0.99,0.71,1.38
10.1097/AOG.0000000000001090,2,Yes,Vaginal Delivery,No,NA,30-day readmission,OR,NA,"age, quadratic age, facility volume, year of admission, patient sickness, socioeconomic status, payer",2,White,Black,1.6,1.36,1.89
10.1097/AOG.0000000000001090,2,Yes,Vaginal Delivery,No,NA,30-day readmission,OR,NA,"age, quadratic age, facility volume, year of admission, patient sickness, socioeconomic status, payer",3,White,Hispanic,1.2,1.03,1.41
10.1097/AOG.0000000000001090,2,Yes,Vaginal Delivery,No,NA,30-day readmission,OR,NA,"age, quadratic age, facility volume, year of admission, patient sickness, socioeconomic status, payer",4,White,Other race,0.77,0.61,0.96
10.1097/AOG.0000000000001090,3,Yes,Cesarean Delivery,No,NA,30-day readmission,OR,NA,"age, quadratic age, facility volume, year of admission",1,White,Asian,0.7,0.45,1.09
10.1097/AOG.0000000000001090,3,Yes,Cesarean Delivery,No,NA,30-day readmission,OR,NA,"age, quadratic age, facility volume, year of admission",2,White,Black,2.09,1.77,2.46
10.1097/AOG.0000000000001090,3,Yes,Cesarean Delivery,No,NA,30-day readmission,OR,NA,"age, quadratic age, facility volume, year of admission",3,White,Hispanic,1.52,1.3,1.79
10.1097/AOG.0000000000001090,3,Yes,Cesarean Delivery,No,NA,30-day readmission,OR,NA,"age, quadratic age, facility volume, year of admission",4,White,Other race,0.83,0.64,1.07
10.1097/AOG.0000000000001090,4,Yes,Cesarean Delivery,No,NA,30-day readmission,OR,NA,"age, quadratic age, facility volume, year of admission, patient sickness, socioeconomic status, payer",1,White,Asian,0.7,0.45,1.1
10.1097/AOG.0000000000001090,4,Yes,Cesarean Delivery,No,NA,30-day readmission,OR,NA,"age, quadratic age, facility volume, year of admission, patient sickness, socioeconomic status, payer",2,White,Black,1.66,1.38,1.99
10.1097/AOG.0000000000001090,4,Yes,Cesarean Delivery,No,NA,30-day readmission,OR,NA,"age, quadratic age, facility volume, year of admission, patient sickness, socioeconomic status, payer",3,White,Hispanic,1.29,1.07,1.54
10.1097/AOG.0000000000001090,4,Yes,Cesarean Delivery,No,NA,30-day readmission,OR,NA,"age, quadratic age, facility volume, year of admission, patient sickness, socioeconomic status, payer",4,White,Other race,0.79,0.61,1.01
10.1097/AOG.0000000000001094,1,Yes,2012,No,NA,u.s. women's use of long-acting reversible contraception methods,OR,NA,none,1,"White, non-Hispanic","Black, non-Hispanic",0.7,0.5,1
10.1097/AOG.0000000000001094,1,Yes,2012,No,NA,u.s. women's use of long-acting reversible contraception methods,OR,NA,none,2,"White, non-Hispanic","Other or multiple races, non-Hispanic",0.9,0.5,1.7
10.1097/AOG.0000000000001094,1,Yes,2012,No,NA,u.s. women's use of long-acting reversible contraception methods,OR,NA,none,3,"White, non-Hispanic",Hispanic,1.4,0.9,2
10.1097/AOG.0000000000001094,2,Yes,2012,No,NA,u.s. women's use of long-acting reversible contraception methods,OR,NA,"income as a % of federal poverty level, age, born outside the united states, region, relationship status, education, employment, current insurance coverage, religious affiliation, no. of male sexual partners in previous year, ever experienced unwanted pregnancy, total no. of live births",1,"White, non-Hispanic","Black, non-Hispanic",0.6,0.4,0.9
10.1097/AOG.0000000000001094,2,Yes,2012,No,NA,u.s. women's use of long-acting reversible contraception methods,OR,NA,"income as a % of federal poverty level, age, born outside the united states, region, relationship status, education, employment, current insurance coverage, religious affiliation, no. of male sexual partners in previous year, ever experienced unwanted pregnancy, total no. of live births",2,"White, non-Hispanic","Other or multiple races, non-Hispanic",0.6,0.3,1.2
10.1097/AOG.0000000000001094,2,Yes,2012,No,NA,u.s. women's use of long-acting reversible contraception methods,OR,NA,"income as a % of federal poverty level, age, born outside the united states, region, relationship status, education, employment, current insurance coverage, religious affiliation, no. of male sexual partners in previous year, ever experienced unwanted pregnancy, total no. of live births",3,"White, non-Hispanic",Hispanic,0.7,0.5,1.2
10.1097/AOG.0000000000001094,3,Yes,2012,No,NA,women who have ever discontinued a long-acting reversible contraception method as a result of dissatisfaction among those women who have ever used long-acting reversible contraception by selected demographic characteristics,OR,NA,"income as a % of federal poverty level, age, born outside the united states, region, relationship status, education, employment, current insurance coverage, religious affiliation, no. of male sexual partners in previous year, ever experienced unwanted pregnancy, total no. of live births",1,"White, non-Hispanic","Black, non-Hispanic",0.7,0.4,1.2
10.1097/AOG.0000000000001094,3,Yes,2012,No,NA,women who have ever discontinued a long-acting reversible contraception method as a result of dissatisfaction among those women who have ever used long-acting reversible contraception by selected demographic characteristics,OR,NA,"income as a % of federal poverty level, age, born outside the united states, region, relationship status, education, employment, current insurance coverage, religious affiliation, no. of male sexual partners in previous year, ever experienced unwanted pregnancy, total no. of live births",2,"White, non-Hispanic","Other or multiple races, non-Hispanic",1.6,0.6,4.4
10.1097/AOG.0000000000001094,3,Yes,2012,No,NA,women who have ever discontinued a long-acting reversible contraception method as a result of dissatisfaction among those women who have ever used long-acting reversible contraception by selected demographic characteristics,OR,NA,"income as a % of federal poverty level, age, born outside the united states, region, relationship status, education, employment, current insurance coverage, religious affiliation, no. of male sexual partners in previous year, ever experienced unwanted pregnancy, total no. of live births",3,"White, non-Hispanic",Hispanic,1.2,0.8,2
10.1097/AOG.0000000000001819,1,No,NA,No,NA,nonadherence to national comprehensive cancer network treatment guidelines for locally advanced cervical cancer,OR,NA,"age, income, charlson comorbidity index, insurance status, tumor stage, tumor histology, tumor grade of disease, hospital volume, distance from place of residence to the hospital, year of diagnosis",1,Non-Hispanic white,Non-Hispanic black,0.91,0.83,0.98
10.1097/AOG.0000000000001819,1,No,NA,No,NA,nonadherence to national comprehensive cancer network treatment guidelines for locally advanced cervical cancer,OR,NA,"age, income, charlson comorbidity index, insurance status, tumor stage, tumor histology, tumor grade of disease, hospital volume, distance from place of residence to the hospital, year of diagnosis",2,Non-Hispanic white,Hispanic,0.73,0.43,0.67
10.1097/AOG.0000000000001819,1,No,NA,No,NA,nonadherence to national comprehensive cancer network treatment guidelines for locally advanced cervical cancer,OR,NA,"age, income, charlson comorbidity index, insurance status, tumor stage, tumor histology, tumor grade of disease, hospital volume, distance from place of residence to the hospital, year of diagnosis",3,Non-Hispanic white,Other,1.01,0.88,1.15
10.1097/AOG.0000000000001819,2,No,NA,No,NA,overall survival based on the cox proportional hazard model,HR,NA,"age, income, charlson comorbidity index, insurance status, tumor stage, tumor histology, tumor grade of disease, hospital volume, distance from place of residence to the hospital, year of diagnosis",1,Non-Hispanic white,Non-Hispanic black,0.98,0.92,1.04
10.1097/AOG.0000000000001819,2,No,NA,No,NA,overall survival based on the cox proportional hazard model,HR,NA,"age, income, charlson comorbidity index, insurance status, tumor stage, tumor histology, tumor grade of disease, hospital volume, distance from place of residence to the hospital, year of diagnosis",2,Non-Hispanic white,Hispanic,0.68,0.62,0.74
10.1097/AOG.0000000000001819,2,No,NA,No,NA,overall survival based on the cox proportional hazard model,HR,NA,"age, income, charlson comorbidity index, insurance status, tumor stage, tumor histology, tumor grade of disease, hospital volume, distance from place of residence to the hospital, year of diagnosis",3,Non-Hispanic white,Other,0.82,0.74,0.92
10.1097/AOG.0000000000001819,3,No,NA,Yes,Propensity-Matched Cohort,overall survival based on the cox proportional hazard model,HR,NA,"age, income, charlson comorbidity index, insurance status, tumor stage, tumor histology, tumor grade of disease, hospital volume, distance from place of residence to the hospital, year of diagnosis",1,Non-Hispanic white,Non-Hispanic black,1.04,0.94,1.14
10.1097/AOG.0000000000001819,3,No,NA,Yes,Propensity-Matched Cohort,overall survival based on the cox proportional hazard model,HR,NA,"age, income, charlson comorbidity index, insurance status, tumor stage, tumor histology, tumor grade of disease, hospital volume, distance from place of residence to the hospital, year of diagnosis",2,Non-Hispanic white,Hispanic,0.69,0.59,0.77
10.1097/AOG.0000000000001819,3,No,NA,Yes,Propensity-Matched Cohort,overall survival based on the cox proportional hazard model,HR,NA,"age, income, charlson comorbidity index, insurance status, tumor stage, tumor histology, tumor grade of disease, hospital volume, distance from place of residence to the hospital, year of diagnosis",3,Non-Hispanic white,Other,0.79,0.68,0.84
10.1097/AOG.0000000000001864,1,No,NA,No,NA,severe maternal morbidity,OR,NA,none,1,Non-Hispanic white,Hispanic,1.87,1.76,1.99
10.1097/AOG.0000000000001864,1,No,NA,No,NA,severe maternal morbidity,OR,NA,none,2,Non-Hispanic white,Puerto Rican,2.25,2.04,2.47
10.1097/AOG.0000000000001864,1,No,NA,No,NA,severe maternal morbidity,OR,NA,none,3,Non-Hispanic white,Foreign Mexican,1.87,1.7,2.05
10.1097/AOG.0000000000001864,1,No,NA,No,NA,severe maternal morbidity,OR,NA,none,4,Non-Hispanic white,Foreign Dominican,1.98,1.81,2.16
10.1097/AOG.0000000000001864,2,No,NA,No,NA,severe maternal morbidity,OR,NA,"patient characteristics (age, country of birth, clinical and obstetric
factors, clinical comorbidities), clustering of patients within hospitals",1,Non-Hispanic White,Hispanic,1.42,1.22,1.66
10.1097/AOG.0000000000001864,2,No,NA,No,NA,severe maternal morbidity,OR,NA,"patient characteristics (age, country of birth, clinical and obstetric
factors, clinical comorbidities), clustering of patients within hospitals",2,Non-Hispanic White,Puerto Rican,1.85,1.52,2.25
10.1097/AOG.0000000000001864,2,No,NA,No,NA,severe maternal morbidity,OR,NA,"patient characteristics (age, country of birth, clinical and obstetric
factors, clinical comorbidities), clustering of patients within hospitals",3,Non-Hispanic White,Foreign Mexican,1.4,1.14,1.72
10.1097/AOG.0000000000001864,2,No,NA,No,NA,severe maternal morbidity,OR,NA,"patient characteristics (age, country of birth, clinical and obstetric
factors, clinical comorbidities), clustering of patients within hospitals",4,Non-Hispanic White,Foreign Dominican,1.56,1.31,1.85
10.1097/AOG.0000000000001864,3,No,NA,No,NA,severe maternal morbidity,OR,NA,"patient characteristics (age, country of birth, clinical and obstetric
factors, clinical comorbidities), delivery hospital, clustering of patients within hospitals",1,Non-Hispanic white,Hispanic,1.26,1.18,1.42
10.1097/AOG.0000000000001864,3,No,NA,No,NA,severe maternal morbidity,OR,NA,"patient characteristics (age, country of birth, clinical and obstetric
factors, clinical comorbidities), delivery hospital, clustering of patients within hospitals",2,Non-Hispanic white,Puerto Rican,1.71,1.44,2.03
10.1097/AOG.0000000000001864,3,No,NA,No,NA,severe maternal morbidity,OR,NA,"patient characteristics (age, country of birth, clinical and obstetric
factors, clinical comorbidities), delivery hospital, clustering of patients within hospitals",3,Non-Hispanic white,Foreign Mexican,1.21,1.03,1.42
10.1097/AOG.0000000000001864,3,No,NA,No,NA,severe maternal morbidity,OR,NA,"patient characteristics (age, country of birth, clinical and obstetric
factors, clinical comorbidities), delivery hospital, clustering of patients within hospitals",4,Non-Hispanic white,Foreign Dominican,1.26,1.1,1.44
10.1097/AOG.0000000000001864,4,No,NA,No,NA,severe maternal morbidity,rate (%),NA,none,1,N/A,Non-Hispanic white,1.48,-99,-99
10.1097/AOG.0000000000001864,4,No,NA,No,NA,severe maternal morbidity,rate (%),NA,none,2,N/A,Hispanic,2.74,-99,-99
10.1097/AOG.0000000000001864,4,No,NA,No,NA,severe maternal morbidity,rate (%),NA,none,3,N/A,Foreign Dominican,2.74,-99,-99
10.1097/AOG.0000000000001864,4,No,NA,No,NA,severe maternal morbidity,rate (%),NA,none,4,N/A,Puerto Rican,2.89,-99,-99
10.1097/AOG.0000000000001864,4,No,NA,No,NA,severe maternal morbidity,rate (%),NA,none,5,N/A,Foreign mexican,3.28,-99,-99
10.1097/AOG.0000000000001864,5,No,NA,No,NA,hispanic-white disparity in severe maternal morbidity,rate (%),NA,none,1,Non-Hispanic white,Hispanic,1.26,-99,-99
10.1097/AOG.0000000000001864,5,No,NA,No,NA,hispanic-white disparity in severe maternal morbidity,rate (%),NA,none,2,Non-Hispanic white,Foreign mexican,1.8,-99,-99
10.1097/AOG.0000000000001864,5,No,NA,No,NA,hispanic-white disparity in severe maternal morbidity,rate (%),NA,none,3,Non-Hispanic white,Foreign dominican,1.26,-99,-99
10.1097/AOG.0000000000001864,5,No,NA,No,NA,hispanic-white disparity in severe maternal morbidity,rate (%),NA,none,4,Non-Hispanic white,Puerto Rican,1.41,-99,-99
10.1097/AOG.0000000000002031,1,Yes,"LBW (Less than 2,500 g)",Yes,ART singletons,"low-birth-weight among singletons conceived with assisted reproductive technology among florida, massachusetts, and michigan residents, by maternal race and ethnicity, 2000-2010",RR,NA,n/a,1,Non-Hispanic white,Non-Hispanic black,2.12,1.83,2.47
10.1097/AOG.0000000000002031,1,Yes,"LBW (Less than 2,500 g)",Yes,ART singletons,"low-birth-weight among singletons conceived with assisted reproductive technology among florida, massachusetts, and michigan residents, by maternal race and ethnicity, 2000-2010",RR,NA,n/a,2,Non-Hispanic white,Hispanic,1.33,1.16,1.52
10.1097/AOG.0000000000002031,1,Yes,"LBW (Less than 2,500 g)",Yes,ART singletons,"low-birth-weight among singletons conceived with assisted reproductive technology among florida, massachusetts, and michigan residents, by maternal race and ethnicity, 2000-2010",RR,NA,n/a,3,Non-Hispanic white,Asian or Pacific Islander,1.36,1.16,1.6
10.1097/AOG.0000000000002031,2,Yes,"LBW (less than 2,500 g)",Yes,ART singletons,low-birth-weight among singletons conceived with assisted reproductive technology,RR,NA,"state of residence, age, education, marital status, nativity, smoking during pregnancy, diabetes history (pregestational or gestational), chronic hypertension history (pregestational), gravidity, parity, initiation of prenatal care in the first
trimester, and conception with art",1,Non-Hispanic White,Non-Hispanic black,1.87,1.57,2.23
10.1097/AOG.0000000000002031,2,Yes,"LBW (less than 2,500 g)",Yes,ART singletons,low-birth-weight among singletons conceived with assisted reproductive technology,RR,NA,"state of residence, age, education, marital status, nativity, smoking during pregnancy, diabetes history (pregestational or gestational), chronic hypertension history (pregestational), gravidity, parity, initiation of prenatal care in the first
trimester, and conception with art",2,Non-Hispanic White,Hispanic,1.26,1.09,1.47
10.1097/AOG.0000000000002031,2,Yes,"LBW (less than 2,500 g)",Yes,ART singletons,low-birth-weight among singletons conceived with assisted reproductive technology,RR,NA,"state of residence, age, education, marital status, nativity, smoking during pregnancy, diabetes history (pregestational or gestational), chronic hypertension history (pregestational), gravidity, parity, initiation of prenatal care in the first
trimester, and conception with art",3,Non-Hispanic White,Asian or Pacific Islander,1.39,1.16,1.65
10.1097/AOG.0000000000002031,3,Yes,"LBW (less than 2,500 g)",Yes,Non-ART singletons,low-birth-weight among singletons conceived without assisted reproductive technology,RR,NA,n/a,1,Non-Hispanic white,Non-Hispanic black,2.27,2.25,2.29
10.1097/AOG.0000000000002031,3,Yes,"LBW (less than 2,500 g)",Yes,Non-ART singletons,low-birth-weight among singletons conceived without assisted reproductive technology,RR,NA,n/a,2,Non-Hispanic white,Hispanic,1.16,1.14,1.17
10.1097/AOG.0000000000002031,3,Yes,"LBW (less than 2,500 g)",Yes,Non-ART singletons,low-birth-weight among singletons conceived without assisted reproductive technology,RR,NA,n/a,3,Non-Hispanic white,Asian or Pacific Islander,1.31,1.29,1.34
10.1097/AOG.0000000000002031,4,Yes,"LBW (less than 2,500 g)",Yes,Non-ART singletons,low-birth-weight among singletons conceived without assistive reproductive technology,RR,NA,"state of residence, age, education, marital status, nativity, smoking during pregnancy, diabetes history (pregestational or gestational), chronic hypertension history (pregestational), gravidity, parity, initiation of prenatal care in the first
trimester, and conception with art",1,Non-Hispanic white,Non-Hispanic black,2.12,2.1,2.14
10.1097/AOG.0000000000002031,4,Yes,"LBW (less than 2,500 g)",Yes,Non-ART singletons,low-birth-weight among singletons conceived without assistive reproductive technology,RR,NA,"state of residence, age, education, marital status, nativity, smoking during pregnancy, diabetes history (pregestational or gestational), chronic hypertension history (pregestational), gravidity, parity, initiation of prenatal care in the first
trimester, and conception with art",2,Non-Hispanic white,Hispanic,1.15,1.13,1.16
10.1097/AOG.0000000000002031,4,Yes,"LBW (less than 2,500 g)",Yes,Non-ART singletons,low-birth-weight among singletons conceived without assistive reproductive technology,RR,NA,"state of residence, age, education, marital status, nativity, smoking during pregnancy, diabetes history (pregestational or gestational), chronic hypertension history (pregestational), gravidity, parity, initiation of prenatal care in the first
trimester, and conception with art",3,Non-Hispanic white,Asian or Pacific Islander,1.55,1.52,1.58
10.1097/AOG.0000000000002031,5,Yes,Preterm Birth (less than 37 week of gestation),Yes,ART singletons,preterm births among singletons conceived with assisted reproductive technology,RR,NA,n/a,1,Non-Hispanic white,Non-Hispanic black,1.81,1.59,2.07
10.1097/AOG.0000000000002031,5,Yes,Preterm Birth (less than 37 week of gestation),Yes,ART singletons,preterm births among singletons conceived with assisted reproductive technology,RR,NA,n/a,2,Non-Hispanic white,Hispanic,1.16,1.03,1.31
10.1097/AOG.0000000000002031,5,Yes,Preterm Birth (less than 37 week of gestation),Yes,ART singletons,preterm births among singletons conceived with assisted reproductive technology,RR,NA,n/a,3,Non-Hispanic white,Asian or Pacific Islander,1.07,0.92,1.24
10.1097/AOG.0000000000002114,1,Yes,< 20 years of age,No,NA,pregnancy-related mortality,"rate per 100,000 live births",NA,none,1,N/A,Non-Hispanic white,9.5,-99,-99
10.1097/AOG.0000000000002114,1,Yes,< 20 years of age,No,NA,pregnancy-related mortality,"rate per 100,000 live births",NA,none,2,N/A,Non-Hispanic black,18.6,-99,-99
10.1097/AOG.0000000000002114,1,Yes,< 20 years of age,No,NA,pregnancy-related mortality,"rate per 100,000 live births",NA,none,3,N/A,Hispanic,6.1,-99,-99
10.1097/AOG.0000000000002114,1,Yes,< 20 years of age,No,NA,pregnancy-related mortality,"rate per 100,000 live births",NA,none,4,N/A,Other,8.7,-99,-99
10.1097/AOG.0000000000002114,2,Yes,20-24 years of age,No,NA,pregnancy-related mortality,"rate per 100,000 live births",NA,none,1,N/A,Non-Hispanic white,9.9,-99,-99
10.1097/AOG.0000000000002114,2,Yes,20-24 years of age,No,NA,pregnancy-related mortality,"rate per 100,000 live births",NA,none,2,N/A,Non-Hispanic black,27.5,-99,-99
10.1097/AOG.0000000000002114,2,Yes,20-24 years of age,No,NA,pregnancy-related mortality,"rate per 100,000 live births",NA,none,3,N/A,Hispanic,7.2,-99,-99
10.1097/AOG.0000000000002114,2,Yes,20-24 years of age,No,NA,pregnancy-related mortality,"rate per 100,000 live births",NA,none,4,N/A,Other,10.1,-99,-99
10.1097/AOG.0000000000002114,3,Yes,25-29 years of age,No,NA,pregnancy-related mortality,"rate per 100,000 live births",NA,none,1,N/A,Non-Hispanic white,10.6,-99,-99
10.1097/AOG.0000000000002114,3,Yes,25-29 years of age,No,NA,pregnancy-related mortality,"rate per 100,000 live births",NA,none,2,N/A,Non-Hispanic black,39.2,-99,-99
10.1097/AOG.0000000000002114,3,Yes,25-29 years of age,No,NA,pregnancy-related mortality,"rate per 100,000 live births",NA,none,3,N/A,Hispanic,9.2,-99,-99
10.1097/AOG.0000000000002114,3,Yes,25-29 years of age,No,NA,pregnancy-related mortality,"rate per 100,000 live births",NA,none,4,N/A,Other,10.1,-99,-99
10.1097/AOG.0000000000002114,4,Yes,30-34 years of age,No,NA,pregnancy-related mortality,"rate per 100,000 live births",NA,none,1,N/A,Non-Hispanic white,10.7,-99,-99
10.1097/AOG.0000000000002114,4,Yes,30-34 years of age,No,NA,pregnancy-related mortality,"rate per 100,000 live births",NA,none,2,N/A,Non-Hispanic black,51.7,-99,-99
10.1097/AOG.0000000000002114,4,Yes,30-34 years of age,No,NA,pregnancy-related mortality,"rate per 100,000 live births",NA,none,3,N/A,Hispanic,10.5,-99,-99
10.1097/AOG.0000000000002114,4,Yes,30-34 years of age,No,NA,pregnancy-related mortality,"rate per 100,000 live births",NA,none,4,N/A,Other,13.3,-99,-99
10.1097/AOG.0000000000002114,5,Yes,>= 40 years of age,No,NA,pregnancy-related mortality,"rate per 100,000 live births",NA,none,1,N/A,Non-Hispanic white,53.9,-99,-99
10.1097/AOG.0000000000002114,5,Yes,>= 40 years of age,No,NA,pregnancy-related mortality,"rate per 100,000 live births",NA,none,2,N/A,Non-Hispanic black,191.6,-99,-99
10.1097/AOG.0000000000002114,5,Yes,>= 40 years of age,No,NA,pregnancy-related mortality,"rate per 100,000 live births",NA,none,3,N/A,Hispanic,44.1,-99,-99
10.1097/AOG.0000000000002114,5,Yes,>= 40 years of age,No,NA,pregnancy-related mortality,"rate per 100,000 live births",NA,none,4,N/A,Other,29.4,-99,-99
10.1097/AOG.0000000000002343,1,No,NA,No,NA,odds of cesarean delivery by maternal race in the nulliparous cohort,OR,NA,n/a,1,Non-Hispanic White,Non-Hispanic Black,1.19,1.12,1.26
10.1097/AOG.0000000000002343,1,No,NA,No,NA,odds of cesarean delivery by maternal race in the nulliparous cohort,OR,NA,n/a,2,Non-Hispanic White,Asian,1.21,1.1,1.32
10.1097/AOG.0000000000002343,1,No,NA,No,NA,odds of cesarean delivery by maternal race in the nulliparous cohort,OR,NA,n/a,3,Non-Hispanic White,Hispanic,0.95,0.89,1.01
10.1097/AOG.0000000000002343,2,No,NA,No,NA,odds of cesarean delivery by maternal race and ethnicity in the nulliparous cohort,OR,NA,"age, body mass index, diabetes, smoking, chorioamnionitis, gestational hypertension or
preeclampsia, gestational age at delivery, and hospital.",1,Non-Hispanic white,Non-Hispanic Black,1.47,1.36,1.59
10.1097/AOG.0000000000002343,2,No,NA,No,NA,odds of cesarean delivery by maternal race and ethnicity in the nulliparous cohort,OR,NA,"age, body mass index, diabetes, smoking, chorioamnionitis, gestational hypertension or
preeclampsia, gestational age at delivery, and hospital.",2,Non-Hispanic white,Asian,1.26,1.14,1.4
10.1097/AOG.0000000000002343,2,No,NA,No,NA,odds of cesarean delivery by maternal race and ethnicity in the nulliparous cohort,OR,NA,"age, body mass index, diabetes, smoking, chorioamnionitis, gestational hypertension or
preeclampsia, gestational age at delivery, and hospital.",3,Non-Hispanic white,Hispanic,1.17,1.07,1.27
10.1097/AOG.0000000000002343,3,No,NA,No,NA,odds of cesarean delivery by maternal race and ethnicity in the multiparous cohort,OR,NA,n/a,1,Non-Hispanic White,Non-Hispanic Black,1.78,1.61,1.97
10.1097/AOG.0000000000002343,3,No,NA,No,NA,odds of cesarean delivery by maternal race and ethnicity in the multiparous cohort,OR,NA,n/a,2,Non-Hispanic White,Asian,1.2,0.97,1.48
10.1097/AOG.0000000000002343,3,No,NA,No,NA,odds of cesarean delivery by maternal race and ethnicity in the multiparous cohort,OR,NA,n/a,3,Non-Hispanic White,Hispanic,1.24,1.12,1.37
10.1097/AOG.0000000000002343,4,No,NA,No,NA,odds of cesarean delivery by maternal race and ethnicity in the multiparous cohort,OR,NA,"age, body mass index, diabetes, smoking, chorioamnionitis, gestational hypertension or
preeclampsia, gestational age at delivery, and hospital.",1,Non-Hispanic White,Non-Hispanic Black,1.51,1.33,1.7
10.1097/AOG.0000000000002343,4,No,NA,No,NA,odds of cesarean delivery by maternal race and ethnicity in the multiparous cohort,OR,NA,"age, body mass index, diabetes, smoking, chorioamnionitis, gestational hypertension or
preeclampsia, gestational age at delivery, and hospital.",2,Non-Hispanic White,Asian,1,0.8,1.25
10.1097/AOG.0000000000002343,4,No,NA,No,NA,odds of cesarean delivery by maternal race and ethnicity in the multiparous cohort,OR,NA,"age, body mass index, diabetes, smoking, chorioamnionitis, gestational hypertension or
preeclampsia, gestational age at delivery, and hospital.",3,Non-Hispanic White,Hispanic,1.12,0.98,1.27
10.1097/AOG.0000000000002427,1,No,NA,No,NA,preterm birth,OR,NA,"maternal age categories, mother married, mother's education level, mother smoked during pregnancy, first birth, pregnancy-associated hypertension, chronic (preexisting) hypertension, diabetes (any type), male newborn, birth year",1,USBW,USBB,1.571,1.55,1.593
10.1097/AOG.0000000000002427,1,No,NA,No,NA,preterm birth,OR,NA,"maternal age categories, mother married, mother's education level, mother smoked during pregnancy, first birth, pregnancy-associated hypertension, chronic (preexisting) hypertension, diabetes (any type), male newborn, birth year",2,USBW,ABB,1.135,1.055,1.221
10.1097/AOG.0000000000002427,1,No,NA,No,NA,preterm birth,OR,NA,"maternal age categories, mother married, mother's education level, mother smoked during pregnancy, first birth, pregnancy-associated hypertension, chronic (preexisting) hypertension, diabetes (any type), male newborn, birth year",3,USBW,SB,0.772,0.697,0.855
10.1097/AOG.0000000000002427,2,No,NA,No,NA,postterm death,OR,NA,"maternal age categories, mother married, mother's education level, mother smoked during pregnancy, first birth, pregnancy-associated hypertension, chronic (preexisting) hypertension, diabetes (any type), male newborn, birth year",1,USBW,USBB,1.066,1.006,1.131
10.1097/AOG.0000000000002427,2,No,NA,No,NA,postterm death,OR,NA,"maternal age categories, mother married, mother's education level, mother smoked during pregnancy, first birth, pregnancy-associated hypertension, chronic (preexisting) hypertension, diabetes (any type), male newborn, birth year",2,USBW,ABB,1.905,1.53,2.372
10.1097/AOG.0000000000002427,2,No,NA,No,NA,postterm death,OR,NA,"maternal age categories, mother married, mother's education level, mother smoked during pregnancy, first birth, pregnancy-associated hypertension, chronic (preexisting) hypertension, diabetes (any type), male newborn, birth year",3,USBW,SB,10.323,9.24,11.533
10.1097/AOG.0000000000002427,3,No,NA,No,NA,meconium-stained amniotic fluid,Prevalence,NA,none,1,None,USBW,5.2,-99,-99
10.1097/AOG.0000000000002427,3,No,NA,No,NA,meconium-stained amniotic fluid,Prevalence,NA,none,2,None,USBB,7.5,-99,-99
10.1097/AOG.0000000000002427,3,No,NA,No,NA,meconium-stained amniotic fluid,Prevalence,NA,none,3,None,ABB,12.2,-99,-99
10.1097/AOG.0000000000002427,3,No,NA,No,NA,meconium-stained amniotic fluid,Prevalence,NA,none,4,None,SB,17.6,-99,-99
10.1097/AOG.0000000000002427,4,No,NA,NA,NA,meconium aspiration syndrome,Prevalence,NA,none,1,None,USBW,0,-99,-99
10.1097/AOG.0000000000002427,4,No,NA,NA,NA,meconium aspiration syndrome,Prevalence,NA,none,2,None,USBB,0,-99,-99
10.1097/AOG.0000000000002427,4,No,NA,NA,NA,meconium aspiration syndrome,Prevalence,NA,none,3,None,ABB,0,-99,-99
10.1097/AOG.0000000000002427,4,No,NA,NA,NA,meconium aspiration syndrome,Prevalence,NA,none,4,None,SB,0,-99,-99
10.1097/AOG.0000000000002427,5,No,NA,No,NA,apgar score at 5 min <7,Prevalence,NA,none,1,None,USBW,3.7,-99,-99
10.1097/AOG.0000000000002427,5,No,NA,No,NA,apgar score at 5 min <7,Prevalence,NA,none,2,None,USBB,6.1,-99,-99
10.1097/AOG.0000000000002427,5,No,NA,No,NA,apgar score at 5 min <7,Prevalence,NA,none,3,None,ABB,5.7,-99,-99
10.1097/AOG.0000000000002427,5,No,NA,No,NA,apgar score at 5 min <7,Prevalence,NA,none,4,None,SB,5.4,-99,-99
10.1097/AOG.0000000000002441,1,No,NA,No,NA,any preterm birth,Prevalence,NA,none,1,None,NHW,8.1,-99,-99
10.1097/AOG.0000000000002441,1,No,NA,No,NA,any preterm birth,Prevalence,NA,none,2,None,NHB,12.3,-99,-99
10.1097/AOG.0000000000002441,1,No,NA,No,NA,any preterm birth,Prevalence,NA,none,3,None,Hispanic,8.1,-99,-99
10.1097/AOG.0000000000002441,1,No,NA,No,NA,any preterm birth,Prevalence,NA,none,4,None,Asian,6.3,-99,-99
10.1097/AOG.0000000000002441,1,No,NA,No,NA,any preterm birth,Prevalence,NA,none,5,None,Other,9.9,-99,-99
10.1097/AOG.0000000000002441,2,No,NA,No,NA,medically-indicated preterm birth,Prevalence,NA,none,1,None,NHW,3.2,-99,-99
10.1097/AOG.0000000000002441,2,No,NA,No,NA,medically-indicated preterm birth,Prevalence,NA,none,2,None,NHB,5.8,-99,-99
10.1097/AOG.0000000000002441,2,No,NA,No,NA,medically-indicated preterm birth,Prevalence,NA,none,3,None,Hispanic,3.2,-99,-99
10.1097/AOG.0000000000002441,2,No,NA,No,NA,medically-indicated preterm birth,Prevalence,NA,none,4,None,Asian,2.1,-99,-99
10.1097/AOG.0000000000002441,2,No,NA,No,NA,medically-indicated preterm birth,Prevalence,NA,none,5,None,Other,3.8,-99,-99
10.1097/AOG.0000000000002441,3,No,NA,No,NA,spontaneous preterm birth,Prevalence,NA,none,1,None,NHW,4.8,-99,-99
10.1097/AOG.0000000000002441,3,No,NA,No,NA,spontaneous preterm birth,Prevalence,NA,none,2,None,NHB,6.4,-99,-99
10.1097/AOG.0000000000002441,3,No,NA,No,NA,spontaneous preterm birth,Prevalence,NA,none,3,None,Hispanic,4.7,-99,-99
10.1097/AOG.0000000000002441,3,No,NA,No,NA,spontaneous preterm birth,Prevalence,NA,none,4,None,Asian,4.2,-99,-99
10.1097/AOG.0000000000002441,3,No,NA,No,NA,spontaneous preterm birth,Prevalence,NA,none,5,None,Other,6.1,-99,-99
10.1097/AOG.0000000000002441,4,No,NA,No,NA,hypertensive disease of pregnancy,Prevalence,NA,none,1,None,NHW,13.4,-99,-99
10.1097/AOG.0000000000002441,4,No,NA,No,NA,hypertensive disease of pregnancy,Prevalence,NA,none,2,None,NHB,16.7,-99,-99
10.1097/AOG.0000000000002441,4,No,NA,No,NA,hypertensive disease of pregnancy,Prevalence,NA,none,3,None,Hispanic,10.6,-99,-99
10.1097/AOG.0000000000002441,4,No,NA,No,NA,hypertensive disease of pregnancy,Prevalence,NA,none,4,None,Asian,8.5,-99,-99
10.1097/AOG.0000000000002441,4,No,NA,No,NA,hypertensive disease of pregnancy,Prevalence,NA,none,5,None,Other,13.2,-99,-99
10.1097/AOG.0000000000002441,5,No,NA,No,NA,small-for-gestational-age birth,Prevalence,NA,none,1,None,NHW,8.6,-99,-99
10.1097/AOG.0000000000002441,5,No,NA,No,NA,small-for-gestational-age birth,Prevalence,NA,none,2,None,NHB,17.2,-99,-99
10.1097/AOG.0000000000002441,5,No,NA,No,NA,small-for-gestational-age birth,Prevalence,NA,none,3,None,Hispanic,11.7,-99,-99
10.1097/AOG.0000000000002441,5,No,NA,No,NA,small-for-gestational-age birth,Prevalence,NA,none,4,None,Asian,16.4,-99,-99
10.1097/AOG.0000000000002441,5,No,NA,No,NA,small-for-gestational-age birth,Prevalence,NA,none,5,None,Other,12,-99,-99
10.1097/AOG.0000000000002534,1,No,NA,No,NA,"correlation coefficients between state-specific maternal demographic and maternal mortality in the united states, 2005-2014",Simple Pearson's Correlation Coefficient,NA,n/a,1,N/A,% deliveries to non-Hispanic black women,0.501,NA,NA
10.1097/AOG.0000000000002534,1,No,NA,No,NA,"correlation coefficients between state-specific maternal demographic and maternal mortality in the united states, 2005-2014",Simple Pearson's Correlation Coefficient,NA,n/a,2,N/A,% deliveries to Hispanic women,-0.006,NA,NA
10.1097/AOG.0000000000002534,1,No,NA,No,NA,"correlation coefficients between state-specific maternal demographic and maternal mortality in the united states, 2005-2014",Simple Pearson's Correlation Coefficient,NA,n/a,3,N/A,% deliveries to non-Hispanic white women,-0.254,NA,NA
10.1097/AOG.0000000000002534,1,No,NA,No,NA,"correlation coefficients between state-specific maternal demographic and maternal mortality in the united states, 2005-2014",Simple Pearson's Correlation Coefficient,NA,n/a,4,N/A,% deliveries to Native American women,-0.016,NA,NA
10.1097/AOG.0000000000002534,1,No,NA,No,NA,"correlation coefficients between state-specific maternal demographic and maternal mortality in the united states, 2005-2014",Simple Pearson's Correlation Coefficient,NA,n/a,5,N/A,% deliveries to Asian women,-0.141,NA,NA
10.1097/AOG.0000000000002591,1,No,NA,No,NA,adherence to national comprehensive cancer network treatment guidelines in treatment recieved,% of adherent cases,NA,none,1,None,Non-Hispanic White,43.2,-99,-99
10.1097/AOG.0000000000002591,1,No,NA,No,NA,adherence to national comprehensive cancer network treatment guidelines in treatment recieved,% of adherent cases,NA,none,2,None,Black,4.6,-99,-99
10.1097/AOG.0000000000002591,1,No,NA,No,NA,adherence to national comprehensive cancer network treatment guidelines in treatment recieved,% of adherent cases,NA,none,3,None,Hispanic,37.1,-99,-99
10.1097/AOG.0000000000002591,1,No,NA,No,NA,adherence to national comprehensive cancer network treatment guidelines in treatment recieved,% of adherent cases,NA,none,4,None,Asian/Pacific Islander,14.1,-99,-99
10.1097/AOG.0000000000002591,1,No,NA,No,NA,adherence to national comprehensive cancer network treatment guidelines in treatment recieved,% of adherent cases,NA,none,5,None,Others/Unknown,1,-99,-99
10.1097/AOG.0000000000002591,2,No,NA,No,NA,receipt of nccn guideline-adherent care,OR,NA,none,1,Non-Hispanic white,Black,0.8,0.63,1.02
10.1097/AOG.0000000000002591,2,No,NA,No,NA,receipt of nccn guideline-adherent care,OR,NA,none,2,Non-Hispanic white,Hispanic,0.88,0.79,0.99
10.1097/AOG.0000000000002591,2,No,NA,No,NA,receipt of nccn guideline-adherent care,OR,NA,none,3,Non-Hispanic white,Asian or Pacific Islander,0.97,0.83,1.14
10.1097/AOG.0000000000002591,2,No,NA,No,NA,receipt of nccn guideline-adherent care,OR,NA,none,4,Non-Hispanic white,Others or Unknown,0.8,0.49,1.29
10.1097/AOG.0000000000002591,3,No,NA,No,NA,nccn guideline-adherent care,OR,NA,"age at diagnosis, year of diagnosis, insurance, socioeconomic status, marital status at diagnosis, charlson comorbidity score, tumor stage, grade, size, histology, hospital volume",1,Non-Hispanic White,Black,0.91,0.71,1.17
10.1097/AOG.0000000000002591,3,No,NA,No,NA,nccn guideline-adherent care,OR,NA,"age at diagnosis, year of diagnosis, insurance, socioeconomic status, marital status at diagnosis, charlson comorbidity score, tumor stage, grade, size, histology, hospital volume",2,Non-Hispanic White,Hispanic,0.99,0.87,1.13
10.1097/AOG.0000000000002591,3,No,NA,No,NA,nccn guideline-adherent care,OR,NA,"age at diagnosis, year of diagnosis, insurance, socioeconomic status, marital status at diagnosis, charlson comorbidity score, tumor stage, grade, size, histology, hospital volume",3,Non-Hispanic White,Asian or Pacific Islander,1.03,0.88,1.22
10.1097/AOG.0000000000002591,3,No,NA,No,NA,nccn guideline-adherent care,OR,NA,"age at diagnosis, year of diagnosis, insurance, socioeconomic status, marital status at diagnosis, charlson comorbidity score, tumor stage, grade, size, histology, hospital volume",4,Non-Hispanic White,Others or Unknown,0.85,0.52,1.4
10.1097/AOG.0000000000002591,4,No,NA,No,NA,cervical cancer-specific mortality,HR,NA,none,1,Non-Hispanic white,Black,1.64,1.23,2.2
10.1097/AOG.0000000000002591,4,No,NA,No,NA,cervical cancer-specific mortality,HR,NA,none,2,Non-Hispanic white,Hispanic,0.99,0.83,1.18
10.1097/AOG.0000000000002591,4,No,NA,No,NA,cervical cancer-specific mortality,HR,NA,none,3,Non-Hispanic white,Asian or Pacific Islander,0.94,0.74,1.2
10.1097/AOG.0000000000002591,4,No,NA,No,NA,cervical cancer-specific mortality,HR,NA,none,4,Non-Hispanic white,Others or Unknown,0.92,0.44,1.95
10.1097/AOG.0000000000002591,5,No,NA,No,NA,cervical cancer-specific mortality,HR,NA,"insurance, socioeconomic status, marital status at diagnosis, charlson comorbidity score, tumor grade, stage, size, histology, hospital volume, adherence",1,Non-Hispanic white,Black,1.56,1.08,2.27
10.1097/AOG.0000000000002591,5,No,NA,No,NA,cervical cancer-specific mortality,HR,NA,"insurance, socioeconomic status, marital status at diagnosis, charlson comorbidity score, tumor grade, stage, size, histology, hospital volume, adherence",2,Non-Hispanic white,Hispanic,0.95,0.76,1.2
10.1097/AOG.0000000000002591,5,No,NA,No,NA,cervical cancer-specific mortality,HR,NA,"insurance, socioeconomic status, marital status at diagnosis, charlson comorbidity score, tumor grade, stage, size, histology, hospital volume, adherence",3,Non-Hispanic white,Asian or Pacific Islander,1,0.75,1.33
10.1097/AOG.0000000000002591,5,No,NA,No,NA,cervical cancer-specific mortality,HR,NA,"insurance, socioeconomic status, marital status at diagnosis, charlson comorbidity score, tumor grade, stage, size, histology, hospital volume, adherence",4,Non-Hispanic white,Others or Unknown,1.34,0.58,3.1
10.1097/AOG.0000000000002738,1,No,NA,NA,NA,or time min; surgical morbidity after abdominal myomectomy,OR,NA,none,1,NA,Caucasian,120.1,116.1,124
10.1097/AOG.0000000000002738,1,No,NA,NA,NA,or time min; surgical morbidity after abdominal myomectomy,OR,NA,none,2,NA,African American,26,21.1,30.8
10.1097/AOG.0000000000002738,1,No,NA,NA,NA,or time min; surgical morbidity after abdominal myomectomy,OR,NA,none,3,NA,Asian American,11,3.2,18.7
10.1097/AOG.0000000000002738,1,No,NA,NA,NA,or time min; surgical morbidity after abdominal myomectomy,OR,NA,none,4,NA,Hispanic American,-5.5,-13.4,2.5
10.1097/AOG.0000000000002738,2,Yes,Surgical Morbidity after Abdominal Myomectomy,NA,NA,blood transfusion,Unclear,NA,none,1,None,Caucasian,76,NA,NA
10.1097/AOG.0000000000002738,2,Yes,Surgical Morbidity after Abdominal Myomectomy,NA,NA,blood transfusion,Unclear,NA,none,2,None,African American,383,NA,NA
10.1097/AOG.0000000000002738,2,Yes,Surgical Morbidity after Abdominal Myomectomy,NA,NA,blood transfusion,Unclear,NA,none,3,None,Asian American,44,NA,NA
10.1097/AOG.0000000000002738,2,Yes,Surgical Morbidity after Abdominal Myomectomy,NA,NA,blood transfusion,Unclear,NA,none,4,None,Hispanic American,42,NA,NA
10.1097/AOG.0000000000002738,3,Yes,Surgical Morbidity after abdominal Myomectomy,NA,NA,surgical site infection,unclear,NA,none,1,NA,Caucasian,18,NA,NA
10.1097/AOG.0000000000002738,3,Yes,Surgical Morbidity after abdominal Myomectomy,NA,NA,surgical site infection,unclear,NA,none,2,NA,African American,38,NA,NA
10.1097/AOG.0000000000002738,3,Yes,Surgical Morbidity after abdominal Myomectomy,NA,NA,surgical site infection,unclear,NA,none,3,NA,Asian American,2,NA,NA
10.1097/AOG.0000000000002738,3,Yes,Surgical Morbidity after abdominal Myomectomy,NA,NA,surgical site infection,unclear,NA,none,4,NA,Hispanic American,4,NA,NA
10.1097/AOG.0000000000002738,4,Yes,Surgical Morbidity After Abdominal Myomectomy,No,NA,wound dehiscence,unclear,NA,none,1,NA,Caucasian,1,NA,NA
10.1097/AOG.0000000000002738,4,Yes,Surgical Morbidity After Abdominal Myomectomy,No,NA,wound dehiscence,unclear,NA,none,2,NA,African American,8,NA,NA
10.1097/AOG.0000000000002738,4,Yes,Surgical Morbidity After Abdominal Myomectomy,No,NA,wound dehiscence,unclear,NA,none,3,NA,Asian American,0,NA,NA
10.1097/AOG.0000000000002738,4,Yes,Surgical Morbidity After Abdominal Myomectomy,No,NA,wound dehiscence,unclear,NA,none,4,NA,Hispanic American,0,NA,NA
10.1097/AOG.0000000000002738,5,No,NA,No,NA,composite morbidity after abdominal myomectomy,Unclear,NA,none,1,NA,Caucasian,103,NA,NA
10.1097/AOG.0000000000002738,5,No,NA,No,NA,composite morbidity after abdominal myomectomy,Unclear,NA,none,2,NA,African American,454,NA,NA
10.1097/AOG.0000000000002738,5,No,NA,No,NA,composite morbidity after abdominal myomectomy,Unclear,NA,none,3,NA,Asian American,48,NA,NA
10.1097/AOG.0000000000002738,5,No,NA,No,NA,composite morbidity after abdominal myomectomy,Unclear,NA,none,4,NA,Hispanic American,48,NA,NA
10.1097/AOG.0000000000002802,1,No,NA,No,NA,prevalence of human papillomavirus vaccine series completion,%,NA,none,1,NA,Hispanic,38.9,NA,NA
10.1097/AOG.0000000000002802,1,No,NA,No,NA,prevalence of human papillomavirus vaccine series completion,%,NA,none,2,NA,White,43,NA,NA
10.1097/AOG.0000000000002802,1,No,NA,No,NA,prevalence of human papillomavirus vaccine series completion,%,NA,none,3,NA,Asian or Pacific Islander,49.5,NA,NA
10.1097/AOG.0000000000002802,1,No,NA,No,NA,prevalence of human papillomavirus vaccine series completion,%,NA,none,4,NA,Black,28.7,NA,NA
10.1097/AOG.0000000000002802,1,No,NA,No,NA,prevalence of human papillomavirus vaccine series completion,%,NA,none,5,NA,Other or unkown,33.9,NA,NA
10.1097/AOG.0000000000002802,2,No,NA,No,NA,human papillomavirus vaccine series completion associated with race and ethnicity among females aged 11–26 years,OR,NA,age,1,White,Hispanic,0.82,0.8,0.85
10.1097/AOG.0000000000002802,2,No,NA,No,NA,human papillomavirus vaccine series completion associated with race and ethnicity among females aged 11–26 years,OR,NA,age,2,White,Asian or Pacific Islander,1.29,1.25,1.34
10.1097/AOG.0000000000002802,2,No,NA,No,NA,human papillomavirus vaccine series completion associated with race and ethnicity among females aged 11–26 years,OR,NA,age,3,White,Black,0.53,0.5,0.55
10.1097/AOG.0000000000002802,2,No,NA,No,NA,human papillomavirus vaccine series completion associated with race and ethnicity among females aged 11–26 years,OR,NA,age,4,White,Others or Unknown,0.68,0.65,0.72
10.1097/AOG.0000000000002937,1,No,NA,No,NA,"severe maternal morbidity per 10,000 delivery hospitalizations",Incidence,NA,none,1,N/A,Non-Hispanic White,136.3,133.7,139
10.1097/AOG.0000000000002937,1,No,NA,No,NA,"severe maternal morbidity per 10,000 delivery hospitalizations",Incidence,NA,none,2,N/A,Non-Hispanic Black,244.5,236.5,252.4
10.1097/AOG.0000000000002937,1,No,NA,No,NA,"severe maternal morbidity per 10,000 delivery hospitalizations",Incidence,NA,none,3,N/A,Hispanic,175.3,170.1,180.5
10.1097/AOG.0000000000002937,1,No,NA,No,NA,"severe maternal morbidity per 10,000 delivery hospitalizations",Incidence,NA,none,4,N/A,Asian/Pacific Islander,157.8,149.2,166.4
10.1097/AOG.0000000000002937,1,No,NA,No,NA,"severe maternal morbidity per 10,000 delivery hospitalizations",Incidence,NA,none,5,N/A,American Indian/Alaska Native,213.6,187.6,239.6
10.1097/AOG.0000000000002937,2,No,NA,No,NA,"severe maternal morbidity per 10,000 delivery hospitalizations",Incidence,NA,"age, income, payer, rural vs. urban residence, hospital region",1,N/A,Non-Hispanic White,139.2,136.4,142
10.1097/AOG.0000000000002937,2,No,NA,No,NA,"severe maternal morbidity per 10,000 delivery hospitalizations",Incidence,NA,"age, income, payer, rural vs. urban residence, hospital region",2,N/A,Non-Hispanic Black,231.1,223.6,238.5
10.1097/AOG.0000000000002937,2,No,NA,No,NA,"severe maternal morbidity per 10,000 delivery hospitalizations",Incidence,NA,"age, income, payer, rural vs. urban residence, hospital region",3,N/A,Hispanic,170.2,165.1,175.2
10.1097/AOG.0000000000002937,2,No,NA,No,NA,"severe maternal morbidity per 10,000 delivery hospitalizations",Incidence,NA,"age, income, payer, rural vs. urban residence, hospital region",4,N/A,Asian/Pacific Islander,162.2,153.7,170.8
10.1097/AOG.0000000000002937,2,No,NA,No,NA,"severe maternal morbidity per 10,000 delivery hospitalizations",Incidence,NA,"age, income, payer, rural vs. urban residence, hospital region",5,N/A,American Indian/Alaska Native,206,181.2,230.8
10.1097/AOG.0000000000002937,3,No,NA,No,NA,"severe maternal morbidity without blood transfusion per 10,000 delivery",Incidence,NA,none,1,N/A,Non-Hispanic White,41.1,39.8,42.5
10.1097/AOG.0000000000002937,3,No,NA,No,NA,"severe maternal morbidity without blood transfusion per 10,000 delivery",Incidence,NA,none,2,N/A,Non-Hispanic Black,48.9,46.4,51.4
10.1097/AOG.0000000000002937,3,No,NA,No,NA,"severe maternal morbidity without blood transfusion per 10,000 delivery",Incidence,NA,none,3,N/A,Hispanic,37,35.1,39
10.1097/AOG.0000000000002937,3,No,NA,No,NA,"severe maternal morbidity without blood transfusion per 10,000 delivery",Incidence,NA,none,4,N/A,Asian/Pacific Islander,36.5,32.9,40
10.1097/AOG.0000000000002937,3,No,NA,No,NA,"severe maternal morbidity without blood transfusion per 10,000 delivery",Incidence,NA,none,5,N/A,American Indian/Alaska Native,37.2,27.1,47.3
10.1097/AOG.0000000000002937,4,No,NA,No,NA,"severe maternal morbidity without blood transfusion per 10,000 delivery",Incidence,NA,"age, income, payer, rural vs. urban residence, hospital region",1,N/A,Non-Hispanic White,40.9,39.6,42.3
10.1097/AOG.0000000000002937,4,No,NA,No,NA,"severe maternal morbidity without blood transfusion per 10,000 delivery",Incidence,NA,"age, income, payer, rural vs. urban residence, hospital region",2,N/A,Non-Hispanic Black,50.2,47.6,52.9
10.1097/AOG.0000000000002937,4,No,NA,No,NA,"severe maternal morbidity without blood transfusion per 10,000 delivery",Incidence,NA,"age, income, payer, rural vs. urban residence, hospital region",3,N/A,Hispanic,37.8,35.6,39.5
10.1097/AOG.0000000000002937,4,No,NA,No,NA,"severe maternal morbidity without blood transfusion per 10,000 delivery",Incidence,NA,"age, income, payer, rural vs. urban residence, hospital region",4,N/A,Asian/Pacific Islander,34.6,31.2,38
10.1097/AOG.0000000000002937,4,No,NA,No,NA,"severe maternal morbidity without blood transfusion per 10,000 delivery",Incidence,NA,"age, income, payer, rural vs. urban residence, hospital region",5,N/A,American Indian/Alaska Native,36.7,26.7,46.6
10.1097/AOG.0000000000002937,5,Yes,No chronic conditions,No,NA,"severe maternal morbidity per 10,000 delivery hospitalizations by comorbidity and race/ethnicity",Incidence,NA,none,1,N/A,Non-Hispanic White,125,122.4,127.6
10.1097/AOG.0000000000002937,5,Yes,No chronic conditions,No,NA,"severe maternal morbidity per 10,000 delivery hospitalizations by comorbidity and race/ethnicity",Incidence,NA,none,2,N/A,Non-Hispanic Black,216.6,209.3,223.8
10.1097/AOG.0000000000002937,5,Yes,No chronic conditions,No,NA,"severe maternal morbidity per 10,000 delivery hospitalizations by comorbidity and race/ethnicity",Incidence,NA,none,3,N/A,Hispanic,163.8,158.8,168.9
10.1097/AOG.0000000000002937,5,Yes,No chronic conditions,No,NA,"severe maternal morbidity per 10,000 delivery hospitalizations by comorbidity and race/ethnicity",Incidence,NA,none,4,N/A,Asian/Pacific Islander,145.8,137.4,154.2
10.1097/AOG.0000000000002937,5,Yes,No chronic conditions,No,NA,"severe maternal morbidity per 10,000 delivery hospitalizations by comorbidity and race/ethnicity",Incidence,NA,none,5,N/A,American Indian/Alaska Native,200,171.9,227.4
10.1097/AOG.0000000000002990,1,No,NA,No,NA,open hysterectomy,OR,NA,"uterine weight, prior abdominal surgery, pelvic surgery, endometriosis, bmi, age, comorbidity",1,White,Black,2.02,1.85,2.2
10.1097/AOG.0000000000002990,2,No,NA,Yes,Uterine Weight <250g,open hysterectomy,OR,NA,"prior abdominal surgery, pelvic surgery, endometriosis, bmi, age, comorbidity",1,White,Black,1.84,1.61,2.11
10.1097/AOG.0000000000002990,3,Yes,Route of surgery: MIS Hysterectomy,No,NA,complications,OR,NA,"uterine weight, prior abdominal surgery, pelvic surgery, endometriosis, bmi, age, comorbidity, additional procedures at time of hysterectomy",1,White,Black,1.2,1.01,1.48
10.1097/AOG.0000000000002990,4,Yes,Route of surgery: MIS Hysterectomy,Yes,Major Complication,complication,OR,NA,"uterine weight, prior abdominal surgery, pelvic surgery, endometriosis, bmi, age, comorbidity, additional procedures at time of hysterectomy",1,White,Black,1.7,1.24,2.34
10.1097/AOG.0000000000002990,5,Yes,Route of surgery: MIS Hysterectomy,Yes,Minor Complication,complications,OR,NA,"uterine weight, prior abdominal surgery, pelvic surgery, endometriosis, bmi, age, comorbidity, additional procedures at time of hysterectomy",1,White,Black,1.06,0.85,1.32
10.1097/AOG.0000000000003505,1,Yes,0-24 h Postpartum,Yes,No. of pain assessments,association among race and ethnicity and number of pain assessments,Predicted mean value,NA,"maternal age, body mass index, gestational age at
delivery, nulliparity, primary vs repeat cesarean delivery, classical vs not classical hysterotomy, admission to the neonatal intensive care unit",1,NA,Non-Hispanic white,10.2,NA,NA
10.1097/AOG.0000000000003505,1,Yes,0-24 h Postpartum,Yes,No. of pain assessments,association among race and ethnicity and number of pain assessments,Predicted mean value,NA,"maternal age, body mass index, gestational age at
delivery, nulliparity, primary vs repeat cesarean delivery, classical vs not classical hysterotomy, admission to the neonatal intensive care unit",2,NA,Other,9.8,NA,NA
10.1097/AOG.0000000000003505,1,Yes,0-24 h Postpartum,Yes,No. of pain assessments,association among race and ethnicity and number of pain assessments,Predicted mean value,NA,"maternal age, body mass index, gestational age at
delivery, nulliparity, primary vs repeat cesarean delivery, classical vs not classical hysterotomy, admission to the neonatal intensive care unit",3,NA,Non-Hispanic black,9.5,NA,NA
10.1097/AOG.0000000000003505,1,Yes,0-24 h Postpartum,Yes,No. of pain assessments,association among race and ethnicity and number of pain assessments,Predicted mean value,NA,"maternal age, body mass index, gestational age at
delivery, nulliparity, primary vs repeat cesarean delivery, classical vs not classical hysterotomy, admission to the neonatal intensive care unit",4,NA,Hispanic,9.5,NA,NA
10.1097/AOG.0000000000003505,1,Yes,0-24 h Postpartum,Yes,No. of pain assessments,association among race and ethnicity and number of pain assessments,Predicted mean value,NA,"maternal age, body mass index, gestational age at
delivery, nulliparity, primary vs repeat cesarean delivery, classical vs not classical hysterotomy, admission to the neonatal intensive care unit",5,NA,Asian,8.4,NA,NA
10.1097/AOG.0000000000003505,2,Yes,25-48 h Postpartum,Yes,No. of pain assessments,association among race and ethnicity and number of pain assessments,Predicted mean value,NA,"maternal age, body mass index, gestational age at
delivery, nulliparity, primary vs repeat cesarean delivery, classical vs not classical hysterotomy, admission to the neonatal intensive care unit",1,NA,Non-Hispanic white,9.2,NA,NA
10.1097/AOG.0000000000003505,2,Yes,25-48 h Postpartum,Yes,No. of pain assessments,association among race and ethnicity and number of pain assessments,Predicted mean value,NA,"maternal age, body mass index, gestational age at
delivery, nulliparity, primary vs repeat cesarean delivery, classical vs not classical hysterotomy, admission to the neonatal intensive care unit",2,NA,Other,8.8,NA,NA
10.1097/AOG.0000000000003505,2,Yes,25-48 h Postpartum,Yes,No. of pain assessments,association among race and ethnicity and number of pain assessments,Predicted mean value,NA,"maternal age, body mass index, gestational age at
delivery, nulliparity, primary vs repeat cesarean delivery, classical vs not classical hysterotomy, admission to the neonatal intensive care unit",3,NA,Non-Hispanic black,8.1,NA,NA
10.1097/AOG.0000000000003505,2,Yes,25-48 h Postpartum,Yes,No. of pain assessments,association among race and ethnicity and number of pain assessments,Predicted mean value,NA,"maternal age, body mass index, gestational age at
delivery, nulliparity, primary vs repeat cesarean delivery, classical vs not classical hysterotomy, admission to the neonatal intensive care unit",4,NA,Hispanic,7.9,NA,NA
10.1097/AOG.0000000000003505,2,Yes,25-48 h Postpartum,Yes,No. of pain assessments,association among race and ethnicity and number of pain assessments,Predicted mean value,NA,"maternal age, body mass index, gestational age at
delivery, nulliparity, primary vs repeat cesarean delivery, classical vs not classical hysterotomy, admission to the neonatal intensive care unit",5,NA,Asian,7.8,NA,NA
10.1097/AOG.0000000000003505,3,Yes,0-24 h Postpartum,Yes,No. of OTE doses,association among race and ethnicity and receipt of oxycodone tablet equivalents,Predicted mean value for outcome,NA,"maternal age, body mass index, gestational age at
delivery, nulliparity, primary vs repeat cesarean delivery, classical vs not classical hysterotomy, admission to the neonatal intensive care unit",1,NA,Non-Hispanic white,8.3,NA,NA
10.1097/AOG.0000000000003505,3,Yes,0-24 h Postpartum,Yes,No. of OTE doses,association among race and ethnicity and receipt of oxycodone tablet equivalents,Predicted mean value for outcome,NA,"maternal age, body mass index, gestational age at
delivery, nulliparity, primary vs repeat cesarean delivery, classical vs not classical hysterotomy, admission to the neonatal intensive care unit",2,NA,Non-Hispanic black,7.5,NA,NA
10.1097/AOG.0000000000003505,3,Yes,0-24 h Postpartum,Yes,No. of OTE doses,association among race and ethnicity and receipt of oxycodone tablet equivalents,Predicted mean value for outcome,NA,"maternal age, body mass index, gestational age at
delivery, nulliparity, primary vs repeat cesarean delivery, classical vs not classical hysterotomy, admission to the neonatal intensive care unit",3,NA,Other,7,NA,NA
10.1097/AOG.0000000000003505,3,Yes,0-24 h Postpartum,Yes,No. of OTE doses,association among race and ethnicity and receipt of oxycodone tablet equivalents,Predicted mean value for outcome,NA,"maternal age, body mass index, gestational age at
delivery, nulliparity, primary vs repeat cesarean delivery, classical vs not classical hysterotomy, admission to the neonatal intensive care unit",4,NA,Hispanic,6.6,NA,NA
10.1097/AOG.0000000000003505,3,Yes,0-24 h Postpartum,Yes,No. of OTE doses,association among race and ethnicity and receipt of oxycodone tablet equivalents,Predicted mean value for outcome,NA,"maternal age, body mass index, gestational age at
delivery, nulliparity, primary vs repeat cesarean delivery, classical vs not classical hysterotomy, admission to the neonatal intensive care unit",5,NA,Asian,5.1,NA,NA
10.1097/AOG.0000000000003505,4,Yes,25-48 h Postpartum,Yes,No. of OTE doses,association among race and ethnicity and receipt of oxycodone tablet equivalents,Predicted mean value,NA,"maternal age, body mass index, gestational age at
delivery, nulliparity, primary vs repeat cesarean delivery, classical vs not classical hysterotomy, admission to the neonatal intensive care unit",1,NA,Non-Hispanic white,7.2,NA,NA
10.1097/AOG.0000000000003505,4,Yes,25-48 h Postpartum,Yes,No. of OTE doses,association among race and ethnicity and receipt of oxycodone tablet equivalents,Predicted mean value,NA,"maternal age, body mass index, gestational age at
delivery, nulliparity, primary vs repeat cesarean delivery, classical vs not classical hysterotomy, admission to the neonatal intensive care unit",2,NA,Non-Hispanic black,5.9,NA,NA
10.1097/AOG.0000000000003505,4,Yes,25-48 h Postpartum,Yes,No. of OTE doses,association among race and ethnicity and receipt of oxycodone tablet equivalents,Predicted mean value,NA,"maternal age, body mass index, gestational age at
delivery, nulliparity, primary vs repeat cesarean delivery, classical vs not classical hysterotomy, admission to the neonatal intensive care unit",3,NA,Other,6.1,NA,NA
10.1097/AOG.0000000000003505,4,Yes,25-48 h Postpartum,Yes,No. of OTE doses,association among race and ethnicity and receipt of oxycodone tablet equivalents,Predicted mean value,NA,"maternal age, body mass index, gestational age at
delivery, nulliparity, primary vs repeat cesarean delivery, classical vs not classical hysterotomy, admission to the neonatal intensive care unit",4,NA,Hispanic,5.5,NA,NA
10.1097/AOG.0000000000003505,4,Yes,25-48 h Postpartum,Yes,No. of OTE doses,association among race and ethnicity and receipt of oxycodone tablet equivalents,Predicted mean value,NA,"maternal age, body mass index, gestational age at
delivery, nulliparity, primary vs repeat cesarean delivery, classical vs not classical hysterotomy, admission to the neonatal intensive care unit",5,NA,Asian,4.6,NA,NA
10.1097/AOG.0000000000003505,5,Yes,0-24 h Postpartum,No,No. of NSAID doses,association among race and ethnicity and receipt of nonsteroidal antiinflammatory drugs,Predicted mean value,NA,"maternal age, body mass index, gestational age at
delivery, nulliparity, primary vs repeat cesarean delivery, classical vs not classical hysterotomy, admission to the neonatal intensive care unit",1,NA,Asian,3.8,NA,NA
10.1097/AOG.0000000000003505,5,Yes,0-24 h Postpartum,No,No. of NSAID doses,association among race and ethnicity and receipt of nonsteroidal antiinflammatory drugs,Predicted mean value,NA,"maternal age, body mass index, gestational age at
delivery, nulliparity, primary vs repeat cesarean delivery, classical vs not classical hysterotomy, admission to the neonatal intensive care unit",2,NA,Non-Hispanic white,3.7,NA,NA
10.1097/AOG.0000000000003505,5,Yes,0-24 h Postpartum,No,No. of NSAID doses,association among race and ethnicity and receipt of nonsteroidal antiinflammatory drugs,Predicted mean value,NA,"maternal age, body mass index, gestational age at
delivery, nulliparity, primary vs repeat cesarean delivery, classical vs not classical hysterotomy, admission to the neonatal intensive care unit",3,NA,Non-Hispanic black,3.4,NA,NA
10.1097/AOG.0000000000003505,5,Yes,0-24 h Postpartum,No,No. of NSAID doses,association among race and ethnicity and receipt of nonsteroidal antiinflammatory drugs,Predicted mean value,NA,"maternal age, body mass index, gestational age at
delivery, nulliparity, primary vs repeat cesarean delivery, classical vs not classical hysterotomy, admission to the neonatal intensive care unit",4,NA,Hispanic,3.6,NA,NA
10.1097/AOG.0000000000003505,5,Yes,0-24 h Postpartum,No,No. of NSAID doses,association among race and ethnicity and receipt of nonsteroidal antiinflammatory drugs,Predicted mean value,NA,"maternal age, body mass index, gestational age at
delivery, nulliparity, primary vs repeat cesarean delivery, classical vs not classical hysterotomy, admission to the neonatal intensive care unit",5,NA,Other,3.6,NA,NA
10.1097/AOG.0000000000003561,1,No,NA,No,NA,pain score 5 or higher,OR,NA,n/a,1,non-Hispanic white,Hispanic,1.88,1.54,2.29
10.1097/AOG.0000000000003561,1,No,NA,No,NA,pain score 5 or higher,OR,NA,n/a,2,non-Hispanic white,Non-Hispanic Black,3.12,2.52,3.88
10.1097/AOG.0000000000003561,2,No,NA,No,NA,pain score 5 or higher,OR,NA,"age, marital status, nulliparity, gestational age, body mass index, public insurance,
tobacco use, anxiety, depression, substance use, mode of delivery, prior cesarean delivery, health care provider type (attending physician, trainee physician, advanced practitioner), and clustering of patients at the health care provider level.",1,non-Hispanic white,Hispanic,1.61,1.26,2.06
10.1097/AOG.0000000000003561,2,No,NA,No,NA,pain score 5 or higher,OR,NA,"age, marital status, nulliparity, gestational age, body mass index, public insurance,
tobacco use, anxiety, depression, substance use, mode of delivery, prior cesarean delivery, health care provider type (attending physician, trainee physician, advanced practitioner), and clustering of patients at the health care provider level.",2,non-Hispanic white,non-Hispanic Black,2.18,1.63,2.91
10.1097/AOG.0000000000003561,3,No,NA,No,NA,opioid prescription at discharge,OR,NA,n/a,1,non-Hispanic white,Hispanic,0.74,0.67,0.82
10.1097/AOG.0000000000003561,3,No,NA,No,NA,opioid prescription at discharge,OR,NA,n/a,2,non-Hispanic white,non-Hispanic Black,0.99,0.87,1.12
10.1097/AOG.0000000000003561,4,No,NA,No,NA,opioid prescription at discharge,OR,NA,"age, marital status, nulliparity, gestational age, body mass index, public insurance,
tobacco use, anxiety, depression, substance use, mode of delivery, prior cesarean delivery, health care provider type (attending physician, trainee physician, advanced practitioner), and clustering of patients at the health care provider level.",1,non-Hispanic white,Hispanic,0.8,0.67,0.96
10.1097/AOG.0000000000003561,4,No,NA,No,NA,opioid prescription at discharge,OR,NA,"age, marital status, nulliparity, gestational age, body mass index, public insurance,
tobacco use, anxiety, depression, substance use, mode of delivery, prior cesarean delivery, health care provider type (attending physician, trainee physician, advanced practitioner), and clustering of patients at the health care provider level.",2,non-Hispanic white,Non-Hispanic Black,0.78,0.62,0.98
10.1097/AOG.0000000000003591,1,Yes,Committee Determination of Preventability - Preventable,No,NA,preventable pregnancy-related death,%,NA,none,1,N/A,Non-Hispanic White,9,-99,-99
10.1097/AOG.0000000000003591,1,Yes,Committee Determination of Preventability - Preventable,No,NA,preventable pregnancy-related death,%,NA,none,2,N/A,Non-Hispanic Black,59,-99,-99
10.1097/AOG.0000000000003591,1,Yes,Committee Determination of Preventability - Preventable,No,NA,preventable pregnancy-related death,%,NA,none,3,N/A,Hispanic,33,-99,-99
10.1097/AOG.0000000000003591,1,Yes,Committee Determination of Preventability - Preventable,No,NA,preventable pregnancy-related death,%,NA,none,4,N/A,Non-Hispanic other,0,-99,-99
10.1097/AOG.0000000000003591,2,Yes,Committee Determination of Preventability - Not Preventable,No,NA,preventable pregnancy-related death,%,NA,none,1,N/A,Non-Hispanic White,82,-99,-99
10.1097/AOG.0000000000003591,2,Yes,Committee Determination of Preventability - Not Preventable,No,NA,preventable pregnancy-related death,%,NA,none,2,N/A,Non-Hispanic Black,38,-99,-99
10.1097/AOG.0000000000003591,2,Yes,Committee Determination of Preventability - Not Preventable,No,NA,preventable pregnancy-related death,%,NA,none,3,N/A,Hispanic,67,-99,-99
10.1097/AOG.0000000000003591,2,Yes,Committee Determination of Preventability - Not Preventable,No,NA,preventable pregnancy-related death,%,NA,none,4,N/A,Non-Hispanic other,100,-99,-99
10.1097/AOG.0000000000003591,3,Yes,Committee Determination of Preventability - Unable to Determine,No,NA,preventable pregnancy-related death,%,NA,none,1,N/A,Non-Hispanic White,9,-99,-99
10.1097/AOG.0000000000003591,3,Yes,Committee Determination of Preventability - Unable to Determine,No,NA,preventable pregnancy-related death,%,NA,none,2,N/A,Non-Hispanic Black,3,-99,-99
10.1097/AOG.0000000000003591,3,Yes,Committee Determination of Preventability - Unable to Determine,No,NA,preventable pregnancy-related death,%,NA,none,3,N/A,Hispanic,0,-99,-99
10.1097/AOG.0000000000003591,3,Yes,Committee Determination of Preventability - Unable to Determine,No,NA,preventable pregnancy-related death,%,NA,none,4,N/A,Non-Hispanic other,0,-99,-99
10.1097/AOG.0000000000003665,1,No,NA,No,NA,disease-specific survival for sociodemographic variables,HR,NA,"insurance, ses category, marital status, cci score, tumor characteristics",1,Non-Hispanic white,Non-Hispanic black,1.28,1.18,1.38
10.1097/AOG.0000000000003665,1,No,NA,No,NA,disease-specific survival for sociodemographic variables,HR,NA,"insurance, ses category, marital status, cci score, tumor characteristics",2,Non-Hispanic white,Hispanic,0.97,0.92,1.02
10.1097/AOG.0000000000003665,1,No,NA,No,NA,disease-specific survival for sociodemographic variables,HR,NA,"insurance, ses category, marital status, cci score, tumor characteristics",3,Non-Hispanic white,Asian or Pacific Islander,0.99,0.93,1.05
10.1097/AOG.0000000000003665,1,No,NA,No,NA,disease-specific survival for sociodemographic variables,HR,NA,"insurance, ses category, marital status, cci score, tumor characteristics",4,Non-Hispanic white,Native American or unkown,0.86,0.68,1.1
10.1097/AOG.0000000000003665,2,No,NA,No,NA,access to centers with high observed/expected ratios,OR,NA,"insurance, ses category, marital status, cci score, tumor characteristics",1,Non-Hispanic white,Non-Hispanic black,0.91,0.78,1.06
10.1097/AOG.0000000000003665,2,No,NA,No,NA,access to centers with high observed/expected ratios,OR,NA,"insurance, ses category, marital status, cci score, tumor characteristics",2,Non-Hispanic white,Hispanic,0.85,0.78,0.93
10.1097/AOG.0000000000003665,2,No,NA,No,NA,access to centers with high observed/expected ratios,OR,NA,"insurance, ses category, marital status, cci score, tumor characteristics",3,Non-Hispanic white,Asian or Pacific Islander,1.21,1.11,1.33
10.1097/AOG.0000000000003665,2,No,NA,No,NA,access to centers with high observed/expected ratios,OR,NA,"insurance, ses category, marital status, cci score, tumor characteristics",4,Non-Hispanic white,Native American or unkown,0.91,0.63,1.32
10.1097/AOG.0000000000003667,1,No,NA,No,NA,severe maternal morbidity with blood transfusion cases,Prevalence,NA,none,1,None,Black,4.2,-99,-99
10.1097/AOG.0000000000003667,1,No,NA,No,NA,severe maternal morbidity with blood transfusion cases,Prevalence,NA,none,2,None,Latina,2.85,-99,-99
10.1097/AOG.0000000000003667,1,No,NA,No,NA,severe maternal morbidity with blood transfusion cases,Prevalence,NA,none,3,None,White,1.46,-99,-99
10.1097/AOG.0000000000003667,2,No,NA,No,NA,severe maternal morbidity without blood transfusion cases,Prevalence,NA,none,1,None,Black,1.35,-99,-99
10.1097/AOG.0000000000003667,2,No,NA,No,NA,severe maternal morbidity without blood transfusion cases,Prevalence,NA,none,2,None,Latina,0.84,-99,-99
10.1097/AOG.0000000000003667,2,No,NA,No,NA,severe maternal morbidity without blood transfusion cases,Prevalence,NA,none,3,None,White,0.55,-99,-99
10.1097/AOG.0000000000003667,3,Yes,Commercially insured,No,NA,severe maternal morbidity with blood transfusion cases,Prevalence,NA,none,1,None,Black,3.73,-99,-99
10.1097/AOG.0000000000003667,3,Yes,Commercially insured,No,NA,severe maternal morbidity with blood transfusion cases,Prevalence,NA,none,2,None,Latina,2.24,-99,-99
10.1097/AOG.0000000000003667,3,Yes,Commercially insured,No,NA,severe maternal morbidity with blood transfusion cases,Prevalence,NA,none,3,None,White,1.54,-99,-99
10.1097/AOG.0000000000003667,4,Yes,Commercially insured,No,NA,severe maternal morbidity without blood transfusion cases,Prevalence,NA,none,1,None,Black,1.52,-99,-99
10.1097/AOG.0000000000003667,4,Yes,Commercially insured,No,NA,severe maternal morbidity without blood transfusion cases,Prevalence,NA,none,2,None,Latina,0.83,-99,-99
10.1097/AOG.0000000000003667,4,Yes,Commercially insured,No,NA,severe maternal morbidity without blood transfusion cases,Prevalence,NA,none,3,None,White,0.61,-99,-99
10.1097/AOG.0000000000003667,5,Yes,Medicaid,No,NA,severe maternal morbidity with blood transfusion cases,Prevalence,NA,none,1,None,Black,4.35,-99,-99
10.1097/AOG.0000000000003667,5,Yes,Medicaid,No,NA,severe maternal morbidity with blood transfusion cases,Prevalence,NA,none,2,None,Latina,2.99,-99,-99
10.1097/AOG.0000000000003667,5,Yes,Medicaid,No,NA,severe maternal morbidity with blood transfusion cases,Prevalence,NA,none,3,None,White,1.31,-99,-99
10.1097/AOG.0000000000003696,1,No,NA,No,NA,multivariable logistic regression model of selected factors associated with cesarean delivery after labor induction,OR,Adjusted,"prior vaginal birth, prior cesarean birth, maternal delivery weight, maternal height, maternal age, maternal race, gestational age",1,"White, non-Hispanic","Black, non-Hispanic",1.6,1.58,1.61
10.1097/AOG.0000000000003696,1,No,NA,No,NA,multivariable logistic regression model of selected factors associated with cesarean delivery after labor induction,OR,Adjusted,"prior vaginal birth, prior cesarean birth, maternal delivery weight, maternal height, maternal age, maternal race, gestational age",2,"White, non-Hispanic",Hispanic,1.11,1.1,1.12
10.1097/AOG.0000000000003696,1,No,NA,No,NA,multivariable logistic regression model of selected factors associated with cesarean delivery after labor induction,OR,Adjusted,"prior vaginal birth, prior cesarean birth, maternal delivery weight, maternal height, maternal age, maternal race, gestational age",3,"White, non-Hispanic",Other,1.16,1.14,1.17
10.1097/AOG.0000000000003728,1,Yes,Uninsured,Yes,Preconception,insurance status by race-ethnicity,weighted proportions,NA,n/a,1,N/A,White Non-Hispanic,9.4,9,9.8
10.1097/AOG.0000000000003728,1,Yes,Uninsured,Yes,Preconception,insurance status by race-ethnicity,weighted proportions,NA,n/a,2,N/A,Black Non-Hispanic,12.8,12,13.7
10.1097/AOG.0000000000003728,1,Yes,Uninsured,Yes,Preconception,insurance status by race-ethnicity,weighted proportions,NA,n/a,3,N/A,"Hispanic, Spanish",55.1,53,57.1
10.1097/AOG.0000000000003728,1,Yes,Uninsured,Yes,Preconception,insurance status by race-ethnicity,weighted proportions,NA,n/a,4,N/A,"Hispanic, English",22.3,20.6,24.1
10.1097/AOG.0000000000003728,1,Yes,Uninsured,Yes,Preconception,insurance status by race-ethnicity,weighted proportions,NA,n/a,5,N/A,Asian/Pacific Islander,9.6,8.4,11
10.1097/AOG.0000000000003728,1,Yes,Uninsured,Yes,Preconception,insurance status by race-ethnicity,weighted proportions,NA,n/a,6,N/A,Indigenous,23.7,21.3,26.2
10.1097/AOG.0000000000003728,1,Yes,Uninsured,Yes,Preconception,insurance status by race-ethnicity,weighted proportions,NA,n/a,7,N/A,Other/Mixed/Unknown,12.9,11.6,14.4
10.1097/AOG.0000000000003728,2,Yes,Medicaid,Yes,Preconception,insurance status by race-ethnicity,weighted proportions,NA,n/a,1,N/A,White Non-Hispanic,15.9,15.5,16.4
10.1097/AOG.0000000000003728,2,Yes,Medicaid,Yes,Preconception,insurance status by race-ethnicity,weighted proportions,NA,n/a,2,N/A,Black Non-Hispanic,39.8,38.6,40.9
10.1097/AOG.0000000000003728,2,Yes,Medicaid,Yes,Preconception,insurance status by race-ethnicity,weighted proportions,NA,n/a,3,N/A,"Hispanic, Spanish",19.5,18,21.1
10.1097/AOG.0000000000003728,2,Yes,Medicaid,Yes,Preconception,insurance status by race-ethnicity,weighted proportions,NA,n/a,4,N/A,"Hispanic, English",26.8,25.3,28.3
10.1097/AOG.0000000000003728,2,Yes,Medicaid,Yes,Preconception,insurance status by race-ethnicity,weighted proportions,NA,n/a,5,N/A,Asian/Pacific Islander,14,12.9,15.2
10.1097/AOG.0000000000003728,2,Yes,Medicaid,Yes,Preconception,insurance status by race-ethnicity,weighted proportions,NA,n/a,6,N/A,Indigenous,40.8,38.9,44.8
10.1097/AOG.0000000000003728,2,Yes,Medicaid,Yes,Preconception,insurance status by race-ethnicity,weighted proportions,NA,n/a,7,N/A,Other/Mixed/Unknown,28.2,26.4,30
10.1097/AOG.0000000000003728,3,Yes,Private,Yes,Preconception,insurance status by race-ethnicity,weighted proportions,NA,n/a,1,N/A,White Non-Hispanic,74.7,74.1,75.2
10.1097/AOG.0000000000003728,3,Yes,Private,Yes,Preconception,insurance status by race-ethnicity,weighted proportions,NA,n/a,2,N/A,Black Non-Hispanic,47.4,46.2,48.6
10.1097/AOG.0000000000003728,3,Yes,Private,Yes,Preconception,insurance status by race-ethnicity,weighted proportions,NA,n/a,3,N/A,"Hispanic, Spanish",25.4,23.6,27.3
10.1097/AOG.0000000000003728,3,Yes,Private,Yes,Preconception,insurance status by race-ethnicity,weighted proportions,NA,n/a,4,N/A,"Hispanic, English",50.9,49.1,52.7
10.1097/AOG.0000000000003728,3,Yes,Private,Yes,Preconception,insurance status by race-ethnicity,weighted proportions,NA,n/a,5,N/A,Asian/Pacific Islander,76.4,74.7,77.9
10.1097/AOG.0000000000003728,3,Yes,Private,Yes,Preconception,insurance status by race-ethnicity,weighted proportions,NA,n/a,6,N/A,Indigenous,34.5,31.5,37.7
10.1097/AOG.0000000000003728,3,Yes,Private,Yes,Preconception,insurance status by race-ethnicity,weighted proportions,NA,n/a,7,N/A,Other/Mixed/Unknown,58.9,56.9,60.9
10.1097/AOG.0000000000003728,4,Yes,Uninsured,Yes,Delivery,insurance status by race-ethnicity,weighted proportions,NA,n/a,1,N/A,White Non-Hispanic,2.2,2,2.4
10.1097/AOG.0000000000003728,4,Yes,Uninsured,Yes,Delivery,insurance status by race-ethnicity,weighted proportions,NA,n/a,2,N/A,Black Non-Hispanic,2,1.7,2.5
10.1097/AOG.0000000000003728,4,Yes,Uninsured,Yes,Delivery,insurance status by race-ethnicity,weighted proportions,NA,n/a,3,N/A,"Hispanic, Spanish",13.6,12.1,15.1
10.1097/AOG.0000000000003728,4,Yes,Uninsured,Yes,Delivery,insurance status by race-ethnicity,weighted proportions,NA,n/a,4,N/A,"Hispanic, English",3.3,2.6,4.2
10.1097/AOG.0000000000003728,4,Yes,Uninsured,Yes,Delivery,insurance status by race-ethnicity,weighted proportions,NA,n/a,5,N/A,Asian/Pacific Islander,1.4,1,2
10.1097/AOG.0000000000003728,4,Yes,Uninsured,Yes,Delivery,insurance status by race-ethnicity,weighted proportions,NA,n/a,6,N/A,Indigenous,4.3,3.4,5.5
10.1097/AOG.0000000000003728,4,Yes,Uninsured,Yes,Delivery,insurance status by race-ethnicity,weighted proportions,NA,n/a,7,N/A,Other/Mixed/Unknown,2.2,1.7,3
10.1097/AOG.0000000000003728,5,Yes,Medicaid,Yes,Delivery,insurance status by race-ethnicity,weighted proportions,NA,n/a,1,N/A,White Non-Hispanic,29.9,29.3,30.4
10.1097/AOG.0000000000003728,5,Yes,Medicaid,Yes,Delivery,insurance status by race-ethnicity,weighted proportions,NA,n/a,2,N/A,Black Non-Hispanic,65.8,64.7,67
10.1097/AOG.0000000000003728,5,Yes,Medicaid,Yes,Delivery,insurance status by race-ethnicity,weighted proportions,NA,n/a,3,N/A,"Hispanic, Spanish",67.2,65.1,69.2
10.1097/AOG.0000000000003728,5,Yes,Medicaid,Yes,Delivery,insurance status by race-ethnicity,weighted proportions,NA,n/a,4,N/A,"Hispanic, English",57.2,55.4,59
10.1097/AOG.0000000000003728,5,Yes,Medicaid,Yes,Delivery,insurance status by race-ethnicity,weighted proportions,NA,n/a,5,N/A,Asian/Pacific Islander,29.8,28.1,31.6
10.1097/AOG.0000000000003728,5,Yes,Medicaid,Yes,Delivery,insurance status by race-ethnicity,weighted proportions,NA,n/a,6,N/A,Indigenous,71,67.7,74.1
10.1097/AOG.0000000000003728,5,Yes,Medicaid,Yes,Delivery,insurance status by race-ethnicity,weighted proportions,NA,n/a,7,N/A,Other/Mixed/Unknown,48,45.9,50
10.1097/AOG.0000000000003730,1,No,NA,No,NA,composite neonatal adverse outcome,"Rate/10,000 Live Births",NA,none,1,None,Non-Hispanic White,74.6,73.8,75.3
10.1097/AOG.0000000000003730,1,No,NA,No,NA,composite neonatal adverse outcome,"Rate/10,000 Live Births",NA,none,2,None,Non-Hispanic Black,86.4,84.7,88
10.1097/AOG.0000000000003730,1,No,NA,No,NA,composite neonatal adverse outcome,"Rate/10,000 Live Births",NA,none,3,None,Hispanic,52,51.1,53
10.1097/AOG.0000000000003730,1,No,NA,No,NA,composite neonatal adverse outcome,"Rate/10,000 Live Births",NA,none,4,None,Non-Hispanic Asian,50.5,48.7,52.3
10.1097/AOG.0000000000003730,2,No,NA,No,NA,composite neonatal adverse outcome,RR,NA,none,1,Non-Hispanic White,Non-Hispanic Black,1.16,1.13,1.18
10.1097/AOG.0000000000003730,2,No,NA,No,NA,composite neonatal adverse outcome,RR,NA,none,2,Non-Hispanic White,Hispanic,0.7,0.68,0.71
10.1097/AOG.0000000000003730,2,No,NA,No,NA,composite neonatal adverse outcome,RR,NA,none,3,Non-Hispanic White,Non-Hispanic Asian,0.68,0.65,0.7
10.1097/AOG.0000000000003730,3,No,NA,No,NA,composite neonatal adverse outcome,RR,NA,"maternal age, education, marital status, insurance type, nulliparity, body mass index, prenatal care, smoking, neonatal sex, year",1,Non-Hispanic White,Non-Hispanic Black,1.07,1.05,1.1
10.1097/AOG.0000000000003730,3,No,NA,No,NA,composite neonatal adverse outcome,RR,NA,"maternal age, education, marital status, insurance type, nulliparity, body mass index, prenatal care, smoking, neonatal sex, year",2,Non-Hispanic White,Hispanic,0.69,0.68,0.71
10.1097/AOG.0000000000003730,3,No,NA,No,NA,composite neonatal adverse outcome,RR,NA,"maternal age, education, marital status, insurance type, nulliparity, body mass index, prenatal care, smoking, neonatal sex, year",3,Non-Hispanic White,Non-Hispanic Asian,0.74,0.71,0.77
10.1097/AOG.0000000000003730,4,No,NA,No,NA,apgar score less than 5 at 5 min,"Rate/10,000 Live Births",NA,none,1,None,Non-Hispanic White,38.6,38.1,39.2
10.1097/AOG.0000000000003730,4,No,NA,No,NA,apgar score less than 5 at 5 min,"Rate/10,000 Live Births",NA,none,2,None,Non-Hispanic Black,55.3,54,56.6
10.1097/AOG.0000000000003730,4,No,NA,No,NA,apgar score less than 5 at 5 min,"Rate/10,000 Live Births",NA,none,3,None,Hispanic,26.8,26.1,27.5
10.1097/AOG.0000000000003730,4,No,NA,No,NA,apgar score less than 5 at 5 min,"Rate/10,000 Live Births",NA,none,4,None,Non-Hispanic Asian,25.6,24.3,26.9
10.1097/AOG.0000000000003730,5,No,NA,No,NA,apgar score less than 5 at 5 min,RR,NA,none,1,Non-Hispanic White,Non-Hispanic Black,1.43,1.39,1.47
10.1097/AOG.0000000000003730,5,No,NA,No,NA,apgar score less than 5 at 5 min,RR,NA,none,2,Non-Hispanic White,Hispanic,0.69,0.67,0.71
10.1097/AOG.0000000000003730,5,No,NA,No,NA,apgar score less than 5 at 5 min,RR,NA,none,3,Non-Hispanic White,Non-Hispanic Asian,0.66,0.63,0.7
10.1097/AOG.0000000000003747,1,Yes,Northeast,Yes,22 wk Postnatal life support,relative risks of postnatal life support,RR,NA,hospital ownership; neonatal intensive care unit level,1,White,Black,1.84,1.33,2.56
10.1097/AOG.0000000000003747,1,Yes,Northeast,Yes,22 wk Postnatal life support,relative risks of postnatal life support,RR,NA,hospital ownership; neonatal intensive care unit level,2,White,Hispanic,1.8,1.23,2.64
10.1097/AOG.0000000000003747,1,Yes,Northeast,Yes,22 wk Postnatal life support,relative risks of postnatal life support,RR,NA,hospital ownership; neonatal intensive care unit level,3,White,Asian,1.58,0.81,3.05
10.1097/AOG.0000000000003747,2,Yes,Northeast,Yes,23 wk Postnatal life support,relative risk of postnatal life support,RR,NA,hospital ownership; neonatal intensive care unit level,1,White,Black,1.14,1.08,1.2
10.1097/AOG.0000000000003747,2,Yes,Northeast,Yes,23 wk Postnatal life support,relative risk of postnatal life support,RR,NA,hospital ownership; neonatal intensive care unit level,2,White,Hispanic,1.12,1.05,1.19
10.1097/AOG.0000000000003747,2,Yes,Northeast,Yes,23 wk Postnatal life support,relative risk of postnatal life support,RR,NA,hospital ownership; neonatal intensive care unit level,3,White,Asian,0.96,0.84,1.1
10.1097/AOG.0000000000003747,3,Yes,Midwest,Yes,22 wk Postnatal life support,relative risks of postnatal life support,RR,NA,hospital ownership; neonatal intensive care unit level,1,white,Black,1.08,0.94,1.25
10.1097/AOG.0000000000003747,3,Yes,Midwest,Yes,22 wk Postnatal life support,relative risks of postnatal life support,RR,NA,hospital ownership; neonatal intensive care unit level,2,white,Hispanic,0.94,0.71,1.24
10.1097/AOG.0000000000003747,3,Yes,Midwest,Yes,22 wk Postnatal life support,relative risks of postnatal life support,RR,NA,hospital ownership; neonatal intensive care unit level,3,white,Asian,0.71,0.41,1.24
10.1097/AOG.0000000000003747,4,Yes,Midwest,Yes,23 wk postnatal life support,relative risks of postnatal life support,RR,NA,hospital ownership; neonatal intensive care unit level,1,White,Black,1.04,1.01,1.07
10.1097/AOG.0000000000003747,4,Yes,Midwest,Yes,23 wk postnatal life support,relative risks of postnatal life support,RR,NA,hospital ownership; neonatal intensive care unit level,2,White,Hispanic,1.03,0.99,1.09
10.1097/AOG.0000000000003747,4,Yes,Midwest,Yes,23 wk postnatal life support,relative risks of postnatal life support,RR,NA,hospital ownership; neonatal intensive care unit level,3,White,Asian,0.99,0.91,1.09
10.1097/AOG.0000000000003747,5,Yes,West,Yes,22 wk postnatal life support,risks of postnatal life support,RR,NA,hospital ownership; neonatal intensive care unit level,1,White,Black,1.18,0.86,1.59
10.1097/AOG.0000000000003747,5,Yes,West,Yes,22 wk postnatal life support,risks of postnatal life support,RR,NA,hospital ownership; neonatal intensive care unit level,2,White,Hispanic,1.22,0.96,1.54
10.1097/AOG.0000000000003747,5,Yes,West,Yes,22 wk postnatal life support,risks of postnatal life support,RR,NA,hospital ownership; neonatal intensive care unit level,3,White,Asian,0.73,0.47,1.13
10.1097/AOG.0000000000003887,1,No,NA,No,NA,composite maternal adverse outcome,RR,NA,none,1,Non-Hispanic white,Non-Hispanic black,1.33,1.26,1.41
10.1097/AOG.0000000000003887,1,No,NA,No,NA,composite maternal adverse outcome,RR,NA,none,2,Non-Hispanic white,Hispanic,0.7,0.65,0.75
10.1097/AOG.0000000000003887,2,No,NA,Yes,Gestational Age 24-36 wk,composite maternal adverse outcome,RR,NA,none,1,Non-Hispanic white,Non-Hispanic black,1.35,1.19,1.53
10.1097/AOG.0000000000003887,2,No,NA,Yes,Gestational Age 24-36 wk,composite maternal adverse outcome,RR,NA,none,2,Non-Hispanic white,Hispanic,0.75,0.63,0.89
10.1097/AOG.0000000000003887,3,No,NA,Yes,Gestational Age 37-40 wk,composite maternal adverse outcome,RR,NA,none,1,Non-Hispanic White,Non-Hispanic Black,1.19,1.1,1.29
10.1097/AOG.0000000000003887,3,No,NA,Yes,Gestational Age 37-40 wk,composite maternal adverse outcome,RR,NA,none,2,Non-Hispanic White,Hispanic,0.67,0.61,0.73
10.1097/AOG.0000000000003887,4,No,NA,No,NA,composite maternal adverse outcome,RR,NA,"maternal age, education, marital status, insurance status, prepregnancy bmi, nulliparous, prenatal care, smoking during pregnancy, diabetes, hypertensive disorders, neonatal sex, and year",1,Non-Hispanic white,Non-Hispanic black,1.2,1.13,1.27
10.1097/AOG.0000000000003887,4,No,NA,No,NA,composite maternal adverse outcome,RR,NA,"maternal age, education, marital status, insurance status, prepregnancy bmi, nulliparous, prenatal care, smoking during pregnancy, diabetes, hypertensive disorders, neonatal sex, and year",2,Non-Hispanic white,Hispanic,0.69,0.64,0.74
10.1097/AOG.0000000000003887,5,No,NA,Yes,Gestational Age 24-36 wk,composite maternal adverse outcome,RR,NA,"maternal age, education, marital status, insurance status, prepregnancy bmi, nulliparous, prenatal care, smoking during pregnancy, diabetes, hypertensive disorders, neonatal sex, and year",1,Non-Hispanic white,Non-Hispanic black,1.19,1.04,1.36
10.1097/AOG.0000000000003887,5,No,NA,Yes,Gestational Age 24-36 wk,composite maternal adverse outcome,RR,NA,"maternal age, education, marital status, insurance status, prepregnancy bmi, nulliparous, prenatal care, smoking during pregnancy, diabetes, hypertensive disorders, neonatal sex, and year",2,Non-Hispanic white,Hispanic,0.74,0.62,0.88
10.1097/AOG.0000000000004057,1,No,NA,Yes,Severe Maternal Morbidity,unadjusted logistic regressions for associations between patient-level and hospital-level characteristics and maternal morbidity measures,OR,NA,n/a,1,Non-Hispanic White,Non-Hispanic Black,2.2,2.1,2.3
10.1097/AOG.0000000000004057,1,No,NA,Yes,Severe Maternal Morbidity,unadjusted logistic regressions for associations between patient-level and hospital-level characteristics and maternal morbidity measures,OR,NA,n/a,2,Non-Hispanic White,Non-Hispanic Asian,1.5,1.4,1.6
10.1097/AOG.0000000000004057,1,No,NA,Yes,Severe Maternal Morbidity,unadjusted logistic regressions for associations between patient-level and hospital-level characteristics and maternal morbidity measures,OR,NA,n/a,3,Non-Hispanic White,Hispanic,1.6,1.5,1.7
10.1097/AOG.0000000000004057,1,No,NA,Yes,Severe Maternal Morbidity,unadjusted logistic regressions for associations between patient-level and hospital-level characteristics and maternal morbidity measures,OR,NA,n/a,4,Non-Hispanic White,Other or missing,1.3,1.2,1.4
10.1097/AOG.0000000000004057,2,No,NA,Yes,Severe Maternal Morbidity,adjusted logistic regressions for associations between patient-level and hospital-level characteristics and maternal morbidity measures,OR,NA,"age, race and ethnicity, primary expected payer, number of comorbidities, delivery type, median household income quartile, location of residence",1,Non-Hispanic White,Non-Hispanic Black,1.5,1.4,1.6
10.1097/AOG.0000000000004057,2,No,NA,Yes,Severe Maternal Morbidity,adjusted logistic regressions for associations between patient-level and hospital-level characteristics and maternal morbidity measures,OR,NA,"age, race and ethnicity, primary expected payer, number of comorbidities, delivery type, median household income quartile, location of residence",2,Non-Hispanic White,Non-Hispanic Asian,1.7,1.5,1.8
10.1097/AOG.0000000000004057,2,No,NA,Yes,Severe Maternal Morbidity,adjusted logistic regressions for associations between patient-level and hospital-level characteristics and maternal morbidity measures,OR,NA,"age, race and ethnicity, primary expected payer, number of comorbidities, delivery type, median household income quartile, location of residence",3,Non-Hispanic White,Hispanic,1.4,1.4,1.5
10.1097/AOG.0000000000004057,2,No,NA,Yes,Severe Maternal Morbidity,adjusted logistic regressions for associations between patient-level and hospital-level characteristics and maternal morbidity measures,OR,NA,"age, race and ethnicity, primary expected payer, number of comorbidities, delivery type, median household income quartile, location of residence",4,Non-Hispanic White,Other or missing,1.4,1.3,1.4
10.1097/AOG.0000000000004057,3,No,NA,Yes,"Severe Maternal Morbidity, Excluding Blood Transfusion Only",unadjusted logistic regressions for associations between patient-level and hospital-level characteristics and maternal morbidity measures,OR,NA,n/a,1,Non-Hispanic White,Non-Hispanic Black,2.2,2.1,2.4
10.1097/AOG.0000000000004057,3,No,NA,Yes,"Severe Maternal Morbidity, Excluding Blood Transfusion Only",unadjusted logistic regressions for associations between patient-level and hospital-level characteristics and maternal morbidity measures,OR,NA,n/a,2,Non-Hispanic White,Non-Hispanic Asian,1.5,1.4,1.7
10.1097/AOG.0000000000004057,3,No,NA,Yes,"Severe Maternal Morbidity, Excluding Blood Transfusion Only",unadjusted logistic regressions for associations between patient-level and hospital-level characteristics and maternal morbidity measures,OR,NA,n/a,3,Non-Hispanic White,Hispanic,1.4,1.3,1.5
10.1097/AOG.0000000000004057,3,No,NA,Yes,"Severe Maternal Morbidity, Excluding Blood Transfusion Only",unadjusted logistic regressions for associations between patient-level and hospital-level characteristics and maternal morbidity measures,OR,NA,n/a,4,Non-Hispanic White,Other or missing,1.2,1.1,1.4
10.1097/AOG.0000000000004057,4,No,NA,Yes,"Severe Maternal Morbidity, Excluding Blood Transfusion Only",adjusted logistic regressions for associations between patient-level and hospital-level characteristics and maternal morbidity measures,OR,NA,"age, race and ethnicity, primary expected payer, number of comorbidities, delivery type, median household income quartile, location of residence",1,Non-White Hispanic,Non-Hispanic Black,1.5,1.4,1.6
10.1097/AOG.0000000000004057,4,No,NA,Yes,"Severe Maternal Morbidity, Excluding Blood Transfusion Only",adjusted logistic regressions for associations between patient-level and hospital-level characteristics and maternal morbidity measures,OR,NA,"age, race and ethnicity, primary expected payer, number of comorbidities, delivery type, median household income quartile, location of residence",2,Non-White Hispanic,Non-Hispanic Asian,1.5,1.4,1.7
10.1097/AOG.0000000000004057,4,No,NA,Yes,"Severe Maternal Morbidity, Excluding Blood Transfusion Only",adjusted logistic regressions for associations between patient-level and hospital-level characteristics and maternal morbidity measures,OR,NA,"age, race and ethnicity, primary expected payer, number of comorbidities, delivery type, median household income quartile, location of residence",3,Non-White Hispanic,Hispanic,1.3,1.2,1.4
10.1097/AOG.0000000000004057,4,No,NA,Yes,"Severe Maternal Morbidity, Excluding Blood Transfusion Only",adjusted logistic regressions for associations between patient-level and hospital-level characteristics and maternal morbidity measures,OR,NA,"age, race and ethnicity, primary expected payer, number of comorbidities, delivery type, median household income quartile, location of residence",4,Non-White Hispanic,Other or missing,1.2,1.1,1.4
10.1097/AOG.0000000000004183,1,Yes,Hemorrhage,No,NA,severe maternal morbidity,%,NA,none,1,N/A,Non-Hispanic White,56.9,-99,-99
10.1097/AOG.0000000000004183,1,Yes,Hemorrhage,No,NA,severe maternal morbidity,%,NA,none,2,N/A,Non-Hispanic Black,31,-99,-99
10.1097/AOG.0000000000004183,1,Yes,Hemorrhage,No,NA,severe maternal morbidity,%,NA,none,3,N/A,Hispanic,47,-99,-99
10.1097/AOG.0000000000004183,2,Yes,Preeclampsia or eclampsia,No,NA,severe maternal morbidity,%,NA,none,1,N/A,Non-Hispanic White,18.1,-99,-99
10.1097/AOG.0000000000004183,2,Yes,Preeclampsia or eclampsia,No,NA,severe maternal morbidity,%,NA,none,2,N/A,Non-Hispanic Black,31,-99,-99
10.1097/AOG.0000000000004183,2,Yes,Preeclampsia or eclampsia,No,NA,severe maternal morbidity,%,NA,none,3,N/A,Hispanic,11,-99,-99
10.1097/AOG.0000000000004183,3,No,NA,No,NA,severe maternal morbidity potentially preventable,%,NA,none,1,N/A,Non-Hispanic White,23.4,-99,-99
10.1097/AOG.0000000000004183,3,No,NA,No,NA,severe maternal morbidity potentially preventable,%,NA,none,2,N/A,Non-Hispanic Black,26,-99,-99
10.1097/AOG.0000000000004183,3,No,NA,No,NA,severe maternal morbidity potentially preventable,%,NA,none,3,N/A,Hispanic,15,-99,-99
10.1097/AOG.0000000000004183,4,No,NA,No,NA,"severe maternal morbidity not preventable, improvement needed",%,NA,none,1,N/A,Non-Hispanic White,15.6,-99,-99
10.1097/AOG.0000000000004183,4,No,NA,No,NA,"severe maternal morbidity not preventable, improvement needed",%,NA,none,2,N/A,Non-Hispanic Black,28,-99,-99
10.1097/AOG.0000000000004183,4,No,NA,No,NA,"severe maternal morbidity not preventable, improvement needed",%,NA,none,3,N/A,Hispanic,18,-99,-99
10.1097/AOG.0000000000004183,5,No,NA,No,NA,severe maternal morbidity any improvement needed,%,NA,none,1,N/A,Non-Hispanic White,39,-99,-99
10.1097/AOG.0000000000004183,5,No,NA,No,NA,severe maternal morbidity any improvement needed,%,NA,none,2,N/A,Non-Hispanic Black,53,-99,-99
10.1097/AOG.0000000000004183,5,No,NA,No,NA,severe maternal morbidity any improvement needed,%,NA,none,3,N/A,Hispanic,32,-99,-99
10.1097/AOG.0000000000004212,1,No,NA,No,NA,association between race and risk for major depression 30 days after medical management of early pregnancy loss,OR,NA,none,1,Non-Black,Black,2.02,1.15,3.55
10.1097/AOG.0000000000004212,2,No,NA,No,NA,association between race and risk for major depression 30 days after medical management of early pregnancy loss,OR,NA,"parity, baseline depression, adverse childhood experience score",1,Non-Black,Black,2.48,1.28,4.81
10.1097/AOG.0000000000004212,3,No,NA,No,NA,association between race and high perceived stress 30 days after medical management of early pregnancy loss,OR,NA,none,1,Non-Black,Black,1.67,0.64,4.37
10.1097/AOG.0000000000004212,4,No,NA,No,NA,association between race and high perceived stress 30 days after medical management of early pregnancy loss,OR,NA,"baseline stress, adverse childhood experience score",1,Non-Black,Black,1.09,0.36,3.26
10.1097/AOG.0000000000004325,1,No,NA,No,NA,receiving national comprehensive cancer network guideline–adherent treatment for gynecologic cancer,%,NA,none,1,NA,Non-Hispanic White,79.1,NA,NA
10.1097/AOG.0000000000004325,1,No,NA,No,NA,receiving national comprehensive cancer network guideline–adherent treatment for gynecologic cancer,%,NA,none,2,NA,Non-Hispanic Black,69.3,NA,NA
10.1097/AOG.0000000000004325,1,No,NA,No,NA,receiving national comprehensive cancer network guideline–adherent treatment for gynecologic cancer,%,NA,none,3,NA,Asian,75.9,NA,NA
10.1097/AOG.0000000000004325,1,No,NA,No,NA,receiving national comprehensive cancer network guideline–adherent treatment for gynecologic cancer,%,NA,none,4,NA,Hispanic,80.5,NA,NA
10.1097/AOG.0000000000004325,2,No,NA,No,NA,receiving national comprehensive cancer network guideline–adherent treatment for gynecologic cancer,OR,NA,"age at diagnosis, marital status, active-duty status, military service or sponsor branch, region, comorbid conditions, diagnosis year, tumor site (model for ""gynecologic cancer"" only), tumor stage, tumor grade, tumor histology.",1,Non-Hispanic White,Non-Hispanic Black,0.73,0.53,1
10.1097/AOG.0000000000004325,2,No,NA,No,NA,receiving national comprehensive cancer network guideline–adherent treatment for gynecologic cancer,OR,NA,"age at diagnosis, marital status, active-duty status, military service or sponsor branch, region, comorbid conditions, diagnosis year, tumor site (model for ""gynecologic cancer"" only), tumor stage, tumor grade, tumor histology.",2,Non-Hispanic White,Asian,1.18,0.84,1.48
10.1097/AOG.0000000000004325,2,No,NA,No,NA,receiving national comprehensive cancer network guideline–adherent treatment for gynecologic cancer,OR,NA,"age at diagnosis, marital status, active-duty status, military service or sponsor branch, region, comorbid conditions, diagnosis year, tumor site (model for ""gynecologic cancer"" only), tumor stage, tumor grade, tumor histology.",3,Non-Hispanic White,Hispanic,1.3,0.86,1.96
10.1097/AOG.0000000000004325,3,Yes,Cervical Cancer,No,NA,receiving national comprehensive cancer network guideline–adherent treatment for gynecologic cancers,%,NA,none,1,NA,Non-Hispanic White,74.9,NA,NA
10.1097/AOG.0000000000004325,3,Yes,Cervical Cancer,No,NA,receiving national comprehensive cancer network guideline–adherent treatment for gynecologic cancers,%,NA,none,2,NA,Non-Hispanic Black,67.9,NA,NA
10.1097/AOG.0000000000004325,3,Yes,Cervical Cancer,No,NA,receiving national comprehensive cancer network guideline–adherent treatment for gynecologic cancers,%,NA,none,3,NA,Asian,66.3,NA,NA
10.1097/AOG.0000000000004325,3,Yes,Cervical Cancer,No,NA,receiving national comprehensive cancer network guideline–adherent treatment for gynecologic cancers,%,NA,none,4,NA,Hispanic,78.1,NA,NA
10.1097/AOG.0000000000004325,4,Yes,Cervical Cancer,No,NA,receiving national comprehensive cancer network guideline–adherent treatment for gynecologic cancers,OR,NA,"age at diagnosis, marital status, active-duty status, military service or sponsor branch, region, comorbid conditions, diagnosis year, tumor site (model for “gynecologic cancer” only), tumor stage, tumor grade, tumor histology",1,Non-Hispanic White,Non-Hispanic Black,1,0.47,2.11
10.1097/AOG.0000000000004325,4,Yes,Cervical Cancer,No,NA,receiving national comprehensive cancer network guideline–adherent treatment for gynecologic cancers,OR,NA,"age at diagnosis, marital status, active-duty status, military service or sponsor branch, region, comorbid conditions, diagnosis year, tumor site (model for “gynecologic cancer” only), tumor stage, tumor grade, tumor histology",2,Non-Hispanic White,Asian,1.19,0.68,2.1
10.1097/AOG.0000000000004325,4,Yes,Cervical Cancer,No,NA,receiving national comprehensive cancer network guideline–adherent treatment for gynecologic cancers,OR,NA,"age at diagnosis, marital status, active-duty status, military service or sponsor branch, region, comorbid conditions, diagnosis year, tumor site (model for “gynecologic cancer” only), tumor stage, tumor grade, tumor histology",3,Non-Hispanic White,Hispanic,2.17,0.91,5.2
10.1097/AOG.0000000000004325,5,Yes,Ovarian cancer,No,NA,receiving national comprehensive cancer network guideline–adherent treatment for gynecologic cancers,%,NA,none,1,None,Non-Hispanic White,86.7,NA,NA
10.1097/AOG.0000000000004325,5,Yes,Ovarian cancer,No,NA,receiving national comprehensive cancer network guideline–adherent treatment for gynecologic cancers,%,NA,none,2,None,Non-Hispanic Black,82.4,NA,NA
10.1097/AOG.0000000000004325,5,Yes,Ovarian cancer,No,NA,receiving national comprehensive cancer network guideline–adherent treatment for gynecologic cancers,%,NA,none,3,None,Asian,92.7,NA,NA
10.1097/AOG.0000000000004325,5,Yes,Ovarian cancer,No,NA,receiving national comprehensive cancer network guideline–adherent treatment for gynecologic cancers,%,NA,none,4,None,Hispanic,90.2,NA,NA
10.1097/AOG.0000000000004356,2,No,NA,No,NA,severe maternal morbidity,OR,NA,none,1,White,Black,3.02,2.88,3.17
10.1097/AOG.0000000000004356,2,No,NA,No,NA,severe maternal morbidity,OR,NA,none,2,White,Latina,2.01,1.9,2.12
10.1097/AOG.0000000000004356,2,No,NA,No,NA,severe maternal morbidity,OR,NA,none,3,White,Asian,1.25,1.15,1.35
10.1097/AOG.0000000000004356,2,No,NA,No,NA,severe maternal morbidity,OR,NA,none,4,White,Other,2.24,1.45,3.45
10.1097/AOG.0000000000004356,3,No,NA,No,NA,severe maternal morbidity,OR,NA,"age (continuous), medicaid insurance (yes or no), parity (primiparous, multiparous without prior cesarean delivery, multiparous with prior cesarean delivery), and education level (less than high school, high school, some college or associate degree, college degree or greater.",1,White,Black,2.9,2.72,3.09
10.1097/AOG.0000000000004356,3,No,NA,No,NA,severe maternal morbidity,OR,NA,"age (continuous), medicaid insurance (yes or no), parity (primiparous, multiparous without prior cesarean delivery, multiparous with prior cesarean delivery), and education level (less than high school, high school, some college or associate degree, college degree or greater.",2,White,Latina,1.92,1.81,2.04
10.1097/AOG.0000000000004356,3,No,NA,No,NA,severe maternal morbidity,OR,NA,"age (continuous), medicaid insurance (yes or no), parity (primiparous, multiparous without prior cesarean delivery, multiparous with prior cesarean delivery), and education level (less than high school, high school, some college or associate degree, college degree or greater.",3,White,Asian,1.2,1.11,1.29
10.1097/AOG.0000000000004356,3,No,NA,No,NA,severe maternal morbidity,OR,NA,"age (continuous), medicaid insurance (yes or no), parity (primiparous, multiparous without prior cesarean delivery, multiparous with prior cesarean delivery), and education level (less than high school, high school, some college or associate degree, college degree or greater.",4,White,Other,2.22,1.62,3.05
10.1097/AOG.0000000000004356,4,No,NA,No,NA,severe maternal morbidity,OR,NA,"age (continuous), medicaid insurance (yes or no), parity (primiparous, multiparous without prior cesarean delivery, multiparous with prior cesarean delivery), and education level (less than high school, high school, some college or associate degree, college degree or greater.",1,White,Black,2.8,2.63,3
10.1097/AOG.0000000000004356,4,No,NA,No,NA,severe maternal morbidity,OR,NA,"age (continuous), medicaid insurance (yes or no), parity (primiparous, multiparous without prior cesarean delivery, multiparous with prior cesarean delivery), and education level (less than high school, high school, some college or associate degree, college degree or greater.",2,White,Latina,1.88,1.77,1.99
10.1097/AOG.0000000000004356,4,No,NA,No,NA,severe maternal morbidity,OR,NA,"age (continuous), medicaid insurance (yes or no), parity (primiparous, multiparous without prior cesarean delivery, multiparous with prior cesarean delivery), and education level (less than high school, high school, some college or associate degree, college degree or greater.",3,White,Asian,1.21,1.12,1.3
10.1097/AOG.0000000000004356,4,No,NA,No,NA,severe maternal morbidity,OR,NA,"age (continuous), medicaid insurance (yes or no), parity (primiparous, multiparous without prior cesarean delivery, multiparous with prior cesarean delivery), and education level (less than high school, high school, some college or associate degree, college degree or greater.",4,White,Other,2.2,1.6,3.02
10.1097/AOG.0000000000004356,5,No,NA,No,NA,severe maternal morbidity,OR,NA,"age (continuous), medicaid insurance (yes or no), parity (primiparous, multiparous without prior cesarean delivery, multiparous with prior cesarean delivery), and education level (less than high school, high school, some college or associate degree, college degree or greater.",1,White,Black,1.03,1.02,1.05
10.1097/AOG.0000000000004356,5,No,NA,No,NA,severe maternal morbidity,OR,NA,"age (continuous), medicaid insurance (yes or no), parity (primiparous, multiparous without prior cesarean delivery, multiparous with prior cesarean delivery), and education level (less than high school, high school, some college or associate degree, college degree or greater.",2,White,Latina,1.02,1.01,1.03
10.1097/AOG.0000000000004356,5,No,NA,No,NA,severe maternal morbidity,OR,NA,"age (continuous), medicaid insurance (yes or no), parity (primiparous, multiparous without prior cesarean delivery, multiparous with prior cesarean delivery), and education level (less than high school, high school, some college or associate degree, college degree or greater.",3,White,Asian,0.99,0.99,1
10.1097/AOG.0000000000004356,5,No,NA,No,NA,severe maternal morbidity,OR,NA,"age (continuous), medicaid insurance (yes or no), parity (primiparous, multiparous without prior cesarean delivery, multiparous with prior cesarean delivery), and education level (less than high school, high school, some college or associate degree, college degree or greater.",4,White,Other,1.01,1.01,1.02
10.1097/AOG.0000000000004362,1,No,NA,No,NA,risk factors for failure to rescue from severe maternal morbidity,OR,NA,"age, health insurance, quartile of median household income for the patient zip code of residence, previous cesarean birth, admission mode, admission during a weekend, induction of labor, delivery mode, hospital location and teaching status, hospital bed size, hospital census region",1,White,Black,1.625,1.492,1.769
10.1097/AOG.0000000000004362,1,No,NA,No,NA,risk factors for failure to rescue from severe maternal morbidity,OR,NA,"age, health insurance, quartile of median household income for the patient zip code of residence, previous cesarean birth, admission mode, admission during a weekend, induction of labor, delivery mode, hospital location and teaching status, hospital bed size, hospital census region",2,White,Hispanic,0.953,0.865,1.05
10.1097/AOG.0000000000004362,1,No,NA,No,NA,risk factors for failure to rescue from severe maternal morbidity,OR,NA,"age, health insurance, quartile of median household income for the patient zip code of residence, previous cesarean birth, admission mode, admission during a weekend, induction of labor, delivery mode, hospital location and teaching status, hospital bed size, hospital census region",3,White,Other,1.314,1.178,1.466
10.1097/AOG.0000000000004362,1,No,NA,No,NA,risk factors for failure to rescue from severe maternal morbidity,OR,NA,"age, health insurance, quartile of median household income for the patient zip code of residence, previous cesarean birth, admission mode, admission during a weekend, induction of labor, delivery mode, hospital location and teaching status, hospital bed size, hospital census region",4,White,Missing,1.133,1.028,1.249
10.1097/AOG.0000000000004362,2,No,NA,No,NA,severe maternal morbidity,rate per 1000 delivery hospitalizations,NA,none,1,N/A,White,11.25,11.19,11.32
10.1097/AOG.0000000000004362,2,No,NA,No,NA,severe maternal morbidity,rate per 1000 delivery hospitalizations,NA,none,2,N/A,Black,22.37,22.2,22.56
10.1097/AOG.0000000000004362,2,No,NA,No,NA,severe maternal morbidity,rate per 1000 delivery hospitalizations,NA,none,3,N/A,Hispanic,15.02,14.91,15.13
10.1097/AOG.0000000000004362,2,No,NA,No,NA,severe maternal morbidity,rate per 1000 delivery hospitalizations,NA,none,4,N/A,Other,14.66,14.49,14.82
10.1097/AOG.0000000000004362,2,No,NA,No,NA,severe maternal morbidity,rate per 1000 delivery hospitalizations,NA,none,5,N/A,Missing,10.89,10.78,10.98
10.1097/AOG.0000000000004362,3,No,NA,No,NA,severe maternal morbidity,Rate Ratio (Ratio of the SMM rate in the racial and ethnic category to the SMM rate in non-Hispanic White women),NA,none,1,White,Black,1.99,1.97,2.01
10.1097/AOG.0000000000004362,3,No,NA,No,NA,severe maternal morbidity,Rate Ratio (Ratio of the SMM rate in the racial and ethnic category to the SMM rate in non-Hispanic White women),NA,none,2,White,Hispanic,1.33,1.32,1.35
10.1097/AOG.0000000000004362,3,No,NA,No,NA,severe maternal morbidity,Rate Ratio (Ratio of the SMM rate in the racial and ethnic category to the SMM rate in non-Hispanic White women),NA,none,3,White,Other,1.3,1.29,1.32
10.1097/AOG.0000000000004362,3,No,NA,No,NA,severe maternal morbidity,Rate Ratio (Ratio of the SMM rate in the racial and ethnic category to the SMM rate in non-Hispanic White women),NA,none,4,White,Missing,0.97,0.96,0.98
10.1097/AOG.0000000000004362,4,No,NA,No,NA,excess severe maternal morbidity,rate per 1000 delivery hospitalizations (Difference between the SMM rate in the racial and ethnic category and the SMM rate in non-Hispanic White women),NA,none,1,White,Black,11.12,10.93,11.31
10.1097/AOG.0000000000004362,4,No,NA,No,NA,excess severe maternal morbidity,rate per 1000 delivery hospitalizations (Difference between the SMM rate in the racial and ethnic category and the SMM rate in non-Hispanic White women),NA,none,2,White,Hispanic,3.77,3.62,3.89
10.1097/AOG.0000000000004362,4,No,NA,No,NA,excess severe maternal morbidity,rate per 1000 delivery hospitalizations (Difference between the SMM rate in the racial and ethnic category and the SMM rate in non-Hispanic White women),NA,none,3,White,Other,3.41,3.22,3.59
10.1097/AOG.0000000000004362,4,No,NA,No,NA,excess severe maternal morbidity,rate per 1000 delivery hospitalizations (Difference between the SMM rate in the racial and ethnic category and the SMM rate in non-Hispanic White women),NA,none,4,White,Missing,-0.36,-0.49,-0.24
10.1097/AOG.0000000000004362,5,No,NA,No,NA,associated number of severe maternal morbidity cases,Product of the excess SMM rate and the number of discharges in the racial and ethnic category,NA,none,1,White,Black,93344,91767,94979
10.1097/AOG.0000000000004362,5,No,NA,No,NA,associated number of severe maternal morbidity cases,Product of the excess SMM rate and the number of discharges in the racial and ethnic category,NA,none,2,White,Hispanic,51270,49370,52991
10.1097/AOG.0000000000004362,5,No,NA,No,NA,associated number of severe maternal morbidity cases,Product of the excess SMM rate and the number of discharges in the racial and ethnic category,NA,none,3,White,Other,21989,20830,23183
10.1097/AOG.0000000000004362,5,No,NA,No,NA,associated number of severe maternal morbidity cases,Product of the excess SMM rate and the number of discharges in the racial and ethnic category,NA,none,4,White,Missing,-4849,-6496,-3161
10.1097/AOG.0b013e3182113c10,1,No,NA,No,NA,decline in ectopic pregnancy mortality ratio,"% decline in deaths per 100,000 live births",NA,none,1,N/A,White,60.4,-99,-99
10.1097/AOG.0b013e3182113c10,1,No,NA,No,NA,decline in ectopic pregnancy mortality ratio,"% decline in deaths per 100,000 live births",NA,none,2,N/A,African American,50.8,-99,-99
10.1097/AOG.0b013e3182113c10,2,Yes,1980-1984,No,NA,ectopic pregnancy mortality,OR,NA,none,1,White,African American,5.5,5.3,5.8
10.1097/AOG.0b013e3182113c10,3,Yes,2003-2007,No,NA,ectopic pregnancy mortality,OR,NA,none,1,White,African American,6.8,6.5,7.3
10.1097/AOG.0b013e3182113c10,4,No,NA,No,NA,average annual decline in ectopic pregnancy mortality ratio during 1980–2007,%,NA,none,1,N/A,White,3.5,-99,-99
10.1097/AOG.0b013e3182113c10,4,No,NA,No,NA,average annual decline in ectopic pregnancy mortality ratio during 1980–2007,%,NA,none,2,N/A,African American,2.8,-99,-99
10.1097/AOG.0b013e3182113c10,5,No,NA,No,NA,overall projected decline in ectopic pregnancy mortality ratio between 2003–2007 and 2013–2017,%,NA,none,1,N/A,White,29.6,-99,-99
10.1097/AOG.0b013e3182113c10,5,No,NA,No,NA,overall projected decline in ectopic pregnancy mortality ratio between 2003–2007 and 2013–2017,%,NA,none,2,N/A,African American,24.9,-99,-99
10.1097/AOG.0b013e3182179e28,1,Yes,Gestational age - 37-38 weeks,No,NA,neonatal death,"rate per 1,000 live births",NA,none,1,N/A,Hispanic,1.1,-99,-99
10.1097/AOG.0b013e3182179e28,1,Yes,Gestational age - 37-38 weeks,No,NA,neonatal death,"rate per 1,000 live births",NA,none,2,N/A,Non-Hispanic White,1.1,-99,-99
10.1097/AOG.0b013e3182179e28,1,Yes,Gestational age - 37-38 weeks,No,NA,neonatal death,"rate per 1,000 live births",NA,none,3,N/A,Non-Hispanic Black,1.6,-99,-99
10.1097/AOG.0b013e3182179e28,2,Yes,Gestational age - 37-38 weeks,No,NA,neonatal death,RR,NA,none,1,Non-Hispanic White,Hispanic,1,0.9,1.2
10.1097/AOG.0b013e3182179e28,2,Yes,Gestational age - 37-38 weeks,No,NA,neonatal death,RR,NA,none,2,Non-Hispanic White,Non-Hispanic Black,1.4,1.2,1.6
10.1097/AOG.0b013e3182179e28,3,Yes,Gestational age - 39-41 weeks,No,NA,neonatal death,"rate per 1,000 live births",NA,none,1,N/A,Hispanic,0.7,-99,-99
10.1097/AOG.0b013e3182179e28,3,Yes,Gestational age - 39-41 weeks,No,NA,neonatal death,"rate per 1,000 live births",NA,none,2,N/A,Non-Hispanic White,0.7,-99,-99
10.1097/AOG.0b013e3182179e28,3,Yes,Gestational age - 39-41 weeks,No,NA,neonatal death,"rate per 1,000 live births",NA,none,3,N/A,Non-Hispanic Black,0.9,-99,-99
10.1097/AOG.0b013e3182179e28,4,Yes,Gestational age - 39-41 weeks,No,NA,neonatal death,RR,NA,none,1,Non-Hispanic White,Hispanic,1,0.9,1.1
10.1097/AOG.0b013e3182179e28,4,Yes,Gestational age - 39-41 weeks,No,NA,neonatal death,RR,NA,none,2,Non-Hispanic White,Non-Hispanic Black,1.4,1.2,1.6
10.1097/AOG.0b013e3182179e28,5,Yes,Gestational age - 37-38 weeks,No,NA,postneonatal death,"rate per 1,000 live births",NA,none,1,N/A,Hispanic,1.3,-99,-99
10.1097/AOG.0b013e3182179e28,5,Yes,Gestational age - 37-38 weeks,No,NA,postneonatal death,"rate per 1,000 live births",NA,none,2,N/A,Non-Hispanic White,1.7,-99,-99
10.1097/AOG.0b013e3182179e28,5,Yes,Gestational age - 37-38 weeks,No,NA,postneonatal death,"rate per 1,000 live births",NA,none,3,N/A,Non-Hispanic Black,3,-99,-99
10.1097/AOG.0b013e31825cb87a,1,Yes,White,No,NA,"pregnancy-related mortality risk ratios by race, hispanic ethnicity, and nativity in the united states, 1993-2006",RR,NA,n/a,1,U.S.-born women,Foreign-born,0.83,0.69,0.98
10.1097/AOG.0b013e31825cb87a,2,Yes,Hispanic,No,NA,"pregnancy-related mortality risk ratios by race, hispanic ethnicity, and nativity in the united states, 1993-2006",RR,NA,n/a,1,U.S.-born women,Foreign-born,1.21,1.07,1.36
10.1097/AOG.0b013e31825cb87a,3,Yes,Black,No,NA,"pregnancy-related mortality risk ratios by race, hispanic ethnicity, and nativity in the united states, 1993-2006",RR,NA,n/a,1,U.S.-born women,Foreign-born,0.92,0.82,1.03
10.1097/AOG.0b013e31825cb87a,4,Yes,Asian or Pacific Islander,No,NA,"pregnancy-related mortality risk ratios by race, hispanic ethnicity, and nativity in the united states, 1993-2006",RR,NA,n/a,1,U.S.-born women,Foreign-born,1.37,0.98,1.92
10.1097/AOG.0b013e31825cb87a,5,No,NA,No,NA,"pregnancy-related mortality risk ratios by race, hispanic ethnicity, and nativity in the united states, 1993-2006",RR,NA,n/a,1,U.S. born white women,Foreign-born white women,0.83,0.69,0.98
10.1097/AOG.0b013e31825cb87a,5,No,NA,No,NA,"pregnancy-related mortality risk ratios by race, hispanic ethnicity, and nativity in the united states, 1993-2006",RR,NA,n/a,2,U.S. born white women,U.S.-born Hispanic women,1.06,0.95,1.18
10.1097/AOG.0b013e31825cb87a,5,No,NA,No,NA,"pregnancy-related mortality risk ratios by race, hispanic ethnicity, and nativity in the united states, 1993-2006",RR,NA,n/a,3,U.S. born white women,Foreign-born Hispanic women,1.28,1.18,1.38
10.1097/AOG.0b013e31825cb87a,5,No,NA,No,NA,"pregnancy-related mortality risk ratios by race, hispanic ethnicity, and nativity in the united states, 1993-2006",RR,NA,n/a,4,U.S. born white women,U.S.-born Black women,3.87,3.67,4.08
10.1097/AOG.0b013e31825cb87a,5,No,NA,No,NA,"pregnancy-related mortality risk ratios by race, hispanic ethnicity, and nativity in the united states, 1993-2006",RR,NA,n/a,5,U.S. born white women,Foreign-born Black women,3.55,3.18,3.98
10.1097/AOG.0b013e31825cb87a,5,No,NA,No,NA,"pregnancy-related mortality risk ratios by race, hispanic ethnicity, and nativity in the united states, 1993-2006",RR,NA,n/a,6,U.S. born white women,U.S.-born Asian or Pacific Islander women,0.96,0.69,1.31
10.1097/AOG.0b013e31825cb87a,5,No,NA,No,NA,"pregnancy-related mortality risk ratios by race, hispanic ethnicity, and nativity in the united states, 1993-2006",RR,NA,n/a,7,U.S. born white women,Foreign-born Asian or Pacific Islander women,1.31,1.16,1.49
10.1097/AOG.0b013e3182932238,1,No,2000,No,NA,cesarean delivery (denominator is all deliveries),rate per 1000 deliveries,NA,"age, comorbidity, disease-related group as specified by agency for healthcare research and quality",1,N/A,Whites,197.5,-99,-99
10.1097/AOG.0b013e3182932238,1,No,2000,No,NA,cesarean delivery (denominator is all deliveries),rate per 1000 deliveries,NA,"age, comorbidity, disease-related group as specified by agency for healthcare research and quality",2,N/A,Blacks,225.1,-99,-99
10.1097/AOG.0b013e3182932238,2,Yes,2000,No,NA,primary cesarean delivery (denominator is all deliveries),rate per 1000 deliveries,NA,"age, comorbidity, disease-related group as specific by agency for healthcare research and quality",1,N/A,Whites,125.8,-99,-99
10.1097/AOG.0b013e3182932238,2,Yes,2000,No,NA,primary cesarean delivery (denominator is all deliveries),rate per 1000 deliveries,NA,"age, comorbidity, disease-related group as specific by agency for healthcare research and quality",2,N/A,Blacks,150.8,-99,-99
10.1097/AOG.0b013e3182932238,3,Yes,2000,No,NA,"vaginal birth after cesarean, uncomplicated (denominator is previous cesarean)",rate per 1000 deliveries,NA,"age, comorbidity, disease-related group as specific by agency for healthcare research and quality",1,N/A,Whites,284.4,-99,-99
10.1097/AOG.0b013e3182932238,3,Yes,2000,No,NA,"vaginal birth after cesarean, uncomplicated (denominator is previous cesarean)",rate per 1000 deliveries,NA,"age, comorbidity, disease-related group as specific by agency for healthcare research and quality",2,N/A,Blacks,286.6,-99,-99
10.1097/AOG.0b013e3182932238,4,Yes,2000,No,NA,"vaginal birth after cesarean, all (denominator is previous cesarean)",rate per 1000 deliveries,NA,"age, comorbidity, disease--related group as specific by agency for healthcare research and quality",1,N/A,Whites,271.1,-99,-99
10.1097/AOG.0b013e3182932238,4,Yes,2000,No,NA,"vaginal birth after cesarean, all (denominator is previous cesarean)",rate per 1000 deliveries,NA,"age, comorbidity, disease--related group as specific by agency for healthcare research and quality",2,N/A,Blacks,281.3,-99,-99
10.1097/AOG.0b013e3182932238,5,Yes,2009,No,NA,cesarean delivery (denominator is all deliveries),rate per 1000 deliveries,NA,"age, comorbidity, disease-related group as specific by agency for healthcare research and quality",1,N/A,Whites,303,-99,-99
10.1097/AOG.0b013e3182932238,5,Yes,2009,No,NA,cesarean delivery (denominator is all deliveries),rate per 1000 deliveries,NA,"age, comorbidity, disease-related group as specific by agency for healthcare research and quality",2,N/A,Blacks,330.8,-99,-99
10.1111/1471-0528.16512,1,No,NA,No,NA,cardiovascular severe maternal morbidity at delivery,OR,NA,"maternal age, maternal race/ethnicity, maternal education, previous live births, prior poor pregnancy outcome, prior caesarean delivery, multiple gestation, chronic hypertension, gestational hypertension, asthma, cardiac lesions or valvular heart disease, age x previous live birth, maternal education x gestational hypertension, multiple gestation x gestational hypertension",1,"Non-Hispanic, White","Non-Hispanic, Black",2.19,1.5,3.21
10.1111/1471-0528.16512,1,No,NA,No,NA,cardiovascular severe maternal morbidity at delivery,OR,NA,"maternal age, maternal race/ethnicity, maternal education, previous live births, prior poor pregnancy outcome, prior caesarean delivery, multiple gestation, chronic hypertension, gestational hypertension, asthma, cardiac lesions or valvular heart disease, age x previous live birth, maternal education x gestational hypertension, multiple gestation x gestational hypertension",2,"Non-Hispanic, White","Non-Hispanic, Asian",1.76,1.02,3.04
10.1111/1471-0528.16512,1,No,NA,No,NA,cardiovascular severe maternal morbidity at delivery,OR,NA,"maternal age, maternal race/ethnicity, maternal education, previous live births, prior poor pregnancy outcome, prior caesarean delivery, multiple gestation, chronic hypertension, gestational hypertension, asthma, cardiac lesions or valvular heart disease, age x previous live birth, maternal education x gestational hypertension, multiple gestation x gestational hypertension",3,"Non-Hispanic, White","Non-Hispanic, all others",2.01,1.28,3.17
10.1111/1471-0528.16512,1,No,NA,No,NA,cardiovascular severe maternal morbidity at delivery,OR,NA,"maternal age, maternal race/ethnicity, maternal education, previous live births, prior poor pregnancy outcome, prior caesarean delivery, multiple gestation, chronic hypertension, gestational hypertension, asthma, cardiac lesions or valvular heart disease, age x previous live birth, maternal education x gestational hypertension, multiple gestation x gestational hypertension",4,"Non-Hispanic, White",Hispanic,1.53,1.14,2.06
10.1111/1471-0528.16512,1,No,NA,No,NA,cardiovascular severe maternal morbidity at delivery,OR,NA,"maternal age, maternal race/ethnicity, maternal education, previous live births, prior poor pregnancy outcome, prior caesarean delivery, multiple gestation, chronic hypertension, gestational hypertension, asthma, cardiac lesions or valvular heart disease, age x previous live birth, maternal education x gestational hypertension, multiple gestation x gestational hypertension",5,"Non-Hispanic, White",Unknown,0.63,0.44,0.91
10.1111/1471-0528.16512,2,No,NA,No,NA,postpartum cardiovascular severe maternal morbidity,OR,NA,"maternal age, maternal race/ethnicity, gestational age, delivery mode, chronic hypertension, gestational hypertension, pre-eclampsia groups, hypothyroidism",1,"Non-Hispanic, White","Non-Hispanic, Black",4.41,2.56,7.59
10.1111/1471-0528.16512,2,No,NA,No,NA,postpartum cardiovascular severe maternal morbidity,OR,NA,"maternal age, maternal race/ethnicity, gestational age, delivery mode, chronic hypertension, gestational hypertension, pre-eclampsia groups, hypothyroidism",2,"Non-Hispanic, White","Non-Hispanic, Asian/others",0.9,0.38,2.14
10.1111/1471-0528.16512,2,No,NA,No,NA,postpartum cardiovascular severe maternal morbidity,OR,NA,"maternal age, maternal race/ethnicity, gestational age, delivery mode, chronic hypertension, gestational hypertension, pre-eclampsia groups, hypothyroidism",3,"Non-Hispanic, White",Hispanic,0.81,0.42,1.53
10.1111/1471-0528.16512,2,No,NA,No,NA,postpartum cardiovascular severe maternal morbidity,OR,NA,"maternal age, maternal race/ethnicity, gestational age, delivery mode, chronic hypertension, gestational hypertension, pre-eclampsia groups, hypothyroidism",4,"Non-Hispanic, White",Unknown,0.41,0.18,0.92
10.1016/j.ajog.2021.01.004,1,No,NA,No,NA,Maternal In-Hospital Death,Incidence,"per 100,000 live births",None,1,N/A,Black patients,11.5,-99,-99
10.1016/j.ajog.2021.01.004,1,No,NA,No,NA,Maternal In-Hospital Death,Incidence,"per 100,000 live births",None,2,N/A,White patients,4.8,-99,-99
10.1016/j.ajog.2021.01.004,2,Yes,Teaching Hospitals,No,NA,Maternal In-Hospital Death,Incidence,"per 100,000 live births",None,1,N/A,Black patients,13.2,-99,-99
10.1016/j.ajog.2021.01.004,2,Yes,Teaching Hospitals,No,NA,Maternal In-Hospital Death,Incidence,"per 100,000 live births",None,2,N/A,White patients,7.1,-99,-99
10.1016/j.ajog.2021.01.004,3,Yes,NonTeaching Hospitals,No,NA,Maternal In-Hospital Death,Incidence,"per 100,000 live births",None,1,N/A,Black patients,10.9,-99,-99
10.1016/j.ajog.2021.01.004,3,Yes,NonTeaching Hospitals,No,NA,Maternal In-Hospital Death,Incidence,"per 100,000 live births",None,2,N/A,White patients,4.5,-99,-99
10.1016/j.ajog.2021.01.004,4,Yes,Non-Black-Serving Hospitals,No,NA,Maternal In-Hospital Death,Incidence,"per 100,000 live births",None,1,N/A,Black patients,10.6,-99,-99
10.1016/j.ajog.2021.01.004,4,Yes,Non-Black-Serving Hospitals,No,NA,Maternal In-Hospital Death,Incidence,"per 100,000 live births",None,2,N/A,White patients,4.1,-99,-99
10.1016/j.ajog.2021.01.004,5,Yes,Black-Serving Hospitals,No,NA,Maternal In-Hospital Death,Incidence,"per 100,000 live births",None,1,N/A,Black patients,11.8,-99,-99
10.1016/j.ajog.2021.01.004,5,Yes,Black-Serving Hospitals,No,NA,Maternal In-Hospital Death,Incidence,"per 100,000 live births",None,2,N/A,White patients,6.7,-99,-99
10.1016/j.ajog.2021.01.004,6,No,NA,No,NA,Maternal In-Hospital Death,RR,NA,None,1,White patients,Black patients,2.38,1.89,3.02
10.1016/j.ajog.2021.01.004,7,Yes,Teaching Hospitals,No,NA,Maternal In-Hospital Death,RR,NA,None,1,White patients,Black patients,1.86,1.18,2.93
10.1016/j.ajog.2021.01.004,8,Yes,NonTeaching Hospitals,No,NA,Maternal In-Hospital Death,RR,NA,None,1,White patients,Black patients,2.44,1.84,3.23
10.1016/j.ajog.2021.01.004,9,Yes,Non-Black-Serving Hospitals,No,NA,Maternal In-Hospital Death,RR,NA,None,1,White patients,Black patients,2.56,1.61,4.09
10.1016/j.ajog.2021.01.004,10,Yes,Black-Serving Hospitals,No,NA,Maternal In-Hospital Death,RR,NA,None,1,White patients,Black patients,1.75,1.29,2.38
10.1016/j.ajog.2021.01.004,11,No,NA,No,NA,Expected Maternal In-Hospital Death,RR,NA,"maternal age, insurance, gestational age at delivery, multiple gestations, mode of delivery, rurality, year, pregnancy comorbid conditions (chronic hypertension, chronic cardiac disease, diabetes mellitus, chronic renal disease), and state of delivery (California, Missouri, and Pennsylvania",1,White patients,Black patients,1.65,1.51,1.79
10.1016/j.ajog.2021.01.004,12,Yes,Teaching Hospitals,No,NA,Expected Maternal In-Hospital Death,RR,NA,"maternal age, insurance, gestational age at delivery, multiple gestations, mode of delivery, rurality, year, pregnancy comorbid conditions (chronic hypertension, chronic cardiac disease, diabetes mellitus, chronic renal disease), and state of delivery (California, Missouri, and Pennsylvania",1,White patients,Black patients,1.31,1.2,1.45
10.1016/j.ajog.2021.01.004,13,Yes,NonTeaching Hospitals,No,NA,Expected Maternal In-Hospital Death,RR,NA,"maternal age, insurance, gestational age at delivery, multiple gestations, mode of delivery, rurality, year, pregnancy comorbid conditions (chronic hypertension, chronic cardiac disease, diabetes mellitus, chronic renal disease), and state of delivery (California, Missouri, and Pennsylvania",1,White patients,Black patients,1.72,1.57,1.87
10.1016/j.ajog.2021.01.004,14,Yes,Non-Black-Serving Hospitals,No,NA,Expected Maternal In-Hospital Death,RR,NA,"maternal age, insurance, gestational age at delivery, multiple gestations, mode of delivery, rurality, year, pregnancy comorbid conditions (chronic hypertension, chronic cardiac disease, diabetes mellitus, chronic renal disease), and state of delivery (California, Missouri, and Pennsylvania",1,White patients,Black patients,1.82,1.67,1.98
10.1016/j.ajog.2021.01.004,15,Yes,Black-Serving Hospitals,No,NA,Expected Maternal In-Hospital Death,RR,NA,"maternal age, insurance, gestational age at delivery, multiple gestations, mode of delivery, rurality, year, pregnancy comorbid conditions (chronic hypertension, chronic cardiac disease, diabetes mellitus, chronic renal disease), and state of delivery (California, Missouri, and Pennsylvania",1,White patients,Black patients,1.42,1.31,1.53
10.1016/j.ajog.2021.01.004,16,No,NA,No,NA,Maternal In-Hospital Death,Ratio of Observed RR to Expected RR,NA,"maternal age, insurance, gestational age at delivery, multiple gestations, mode of delivery, rurality, year, pregnancy comorbid conditions (chronic hypertension, chronic cardiac disease, diabetes mellitus, chronic renal disease), and state of delivery (California, Missouri, and Pennsylvania",1,White patients,Black patients,1.44,1.17,1.79
10.1016/j.ajog.2021.01.004,17,Yes,Teaching Hospitals,No,NA,Maternal In-Hospital Death,Ratio of Observed RR to Expected RR,NA,"maternal age, insurance, gestational age at delivery, multiple gestations, mode of delivery, rurality, year, pregnancy comorbid conditions (chronic hypertension, chronic cardiac disease, diabetes mellitus, chronic renal disease), and state of delivery (California, Missouri, and Pennsylvania",1,White patients,Black patients,1.42,0.9,2.15
10.1016/j.ajog.2021.01.004,18,Yes,NonTeaching Hospitals,No,NA,Maternal In-Hospital Death,Ratio of Observed RR to Expected RR,NA,"maternal age, insurance, gestational age at delivery, multiple gestations, mode of delivery, rurality, year, pregnancy comorbid conditions (chronic hypertension, chronic cardiac disease, diabetes mellitus, chronic renal disease), and state of delivery (California, Missouri, and Pennsylvania",1,White patients,Black patients,1.42,1.09,1.86
10.1016/j.ajog.2021.01.004,19,Yes,Non-Black-Serving Hospitals,No,NA,Maternal In-Hospital Death,Ratio of Observed RR to Expected RR,NA,"maternal age, insurance, gestational age at delivery, multiple gestations, mode of delivery, rurality, year, pregnancy comorbid conditions (chronic hypertension, chronic cardiac disease, diabetes mellitus, chronic renal disease), and state of delivery (California, Missouri, and Pennsylvania",1,White patients,Black patients,1.41,0.88,2.16
10.1016/j.ajog.2021.01.004,20,Yes,Black-Serving Hospitals,No,NA,Maternal In-Hospital Death,Ratio of Observed RR to Expected RR,NA,"maternal age, insurance, gestational age at delivery, multiple gestations, mode of delivery, rurality, year, pregnancy comorbid conditions (chronic hypertension, chronic cardiac disease, diabetes mellitus, chronic renal disease), and state of delivery (California, Missouri, and Pennsylvania",1,White patients,Black patients,1.23,0.95,1.69
10.1016/j.ajog.2021.01.004,21,Yes,"Teaching Hospitals, NonBlack-serving",No,NA,Maternal In-Hospital Death,Incidence,"per 100,000 live births",None,1,N/A,Black patients,22,-99,-99
10.1016/j.ajog.2021.01.004,21,Yes,"Teaching Hospitals, NonBlack-serving",No,NA,Maternal In-Hospital Death,Incidence,"per 100,000 live births",None,2,N/A,White,6.6,-99,-99
10.1016/j.ajog.2021.01.004,22,Yes,"Teaching Hospitals, Black-serving",No,NA,Maternal In-Hospital Death,Incidence,"per 100,000 live births",None,1,N/A,Black patients,12,-99,-99
10.1016/j.ajog.2021.01.004,22,Yes,"Teaching Hospitals, Black-serving",No,NA,Maternal In-Hospital Death,Incidence,"per 100,000 live births",None,2,N/A,White,7.7,-99,-99
10.1016/j.ajog.2021.01.004,23,Yes,"Nonteaching Hospitals, NonBlack-serving",No,NA,Maternal In-Hospital Death,Incidence,"per 100,000 live births",None,1,N/A,Black patients,8.6,-99,-99
10.1016/j.ajog.2021.01.004,23,Yes,"Nonteaching Hospitals, NonBlack-serving",No,NA,Maternal In-Hospital Death,Incidence,"per 100,000 live births",None,2,N/A,White,3.9,-99,-99
10.1016/j.ajog.2021.01.004,24,Yes,"Nonteaching Hospitals, Black-serving",No,NA,Maternal In-Hospital Death,Incidence,"per 100,000 live births",None,1,N/A,Black patients,11.7,-99,-99
10.1016/j.ajog.2021.01.004,24,Yes,"Nonteaching Hospitals, Black-serving",No,NA,Maternal In-Hospital Death,Incidence,"per 100,000 live births",None,2,N/A,White,6.4,-99,-99
10.1016/j.ajog.2021.01.004,25,Yes,"Teaching Hospitals, NonBlack-serving",No,NA,Maternal In-Hospital Death,RR,NA,None,1,White patients,Black patients,3.35,1.34,8.38
10.1016/j.ajog.2021.01.004,26,Yes,"Teaching Hospitals, Black-serving",No,NA,Maternal In-Hospital Death,RR,NA,None,1,White patients,Black patients,1.6,0.94,2.74
10.1016/j.ajog.2021.01.004,27,Yes,"Nonteaching Hospitals, NonBlack-serving",No,NA,Maternal In-Hospital Death,RR,NA,None,1,White patients,Black patients,2.21,1.27,3.84
10.1016/j.ajog.2021.01.004,28,Yes,"Nonteaching Hospitals, Black-serving",No,NA,Maternal In-Hospital Death,RR,NA,None,1,White patients,Black patients,1.83,1.26,2.65
10.1016/j.ajog.2021.01.004,29,Yes,"Teaching Hospitals, NonBlack-serving",No,NA,Expected Maternal In-Hospital Death,RR,NA,"maternal age, insurance, gestational age at delivery, multiple gestations, mode of delivery, rurality, year, pregnancy comorbid conditions (chronic hypertension, chronic cardiac disease, diabetes mellitus, chronic renal disease), and state of delivery (California, Missouri, and Pennsylvania",1,White patients,Black patients,1.91,1.7,2.18
10.1016/j.ajog.2021.01.004,30,Yes,"Teaching Hospitals, Black-serving",No,NA,Expected Maternal In-Hospital Death,RR,NA,"maternal age, insurance, gestational age at delivery, multiple gestations, mode of delivery, rurality, year, pregnancy comorbid conditions (chronic hypertension, chronic cardiac disease, diabetes mellitus, chronic renal disease), and state of delivery (California, Missouri, and Pennsylvania",1,White patients,Black patients,1.21,1.1,1.35
10.1016/j.ajog.2021.01.004,31,Yes,"Nonteaching Hospitals, NonBlack-serving",No,NA,Expected Maternal In-Hospital Death,RR,NA,"maternal age, insurance, gestational age at delivery, multiple gestations, mode of delivery, rurality, year, pregnancy comorbid conditions (chronic hypertension, chronic cardiac disease, diabetes mellitus, chronic renal disease), and state of delivery (California, Missouri, and Pennsylvania",1,White patients,Black patients,1.75,1.61,1.91
10.1016/j.ajog.2021.01.004,32,Yes,"Nonteaching Hospitals, Black-serving",No,NA,Expected Maternal In-Hospital Death,RR,NA,"maternal age, insurance, gestational age at delivery, multiple gestations, mode of delivery, rurality, year, pregnancy comorbid conditions (chronic hypertension, chronic cardiac disease, diabetes mellitus, chronic renal disease), and state of delivery (California, Missouri, and Pennsylvania",1,White patients,Black patients,1.53,1.41,1.63
10.1016/j.ajog.2021.01.004,33,Yes,"Teaching Hospitals, NonBlack-serving",No,NA,Maternal In-Hospital Death,Ratio of Observed RR to Expected RR,NA,"maternal age, insurance, gestational age at delivery, multiple gestations, mode of delivery, rurality, year, pregnancy comorbid conditions (chronic hypertension, chronic cardiac disease, diabetes mellitus, chronic renal disease), and state of delivery (California, Missouri, and Pennsylvania",1,White patients,Black patients,1.75,0.57,4.26
10.1016/j.ajog.2021.01.004,34,Yes,"Teaching Hospitals, Black-serving",No,NA,Maternal In-Hospital Death,Ratio of Observed RR to Expected RR,NA,"maternal age, insurance, gestational age at delivery, multiple gestations, mode of delivery, rurality, year, pregnancy comorbid conditions (chronic hypertension, chronic cardiac disease, diabetes mellitus, chronic renal disease), and state of delivery (California, Missouri, and Pennsylvania",1,White patients,Black patients,1.32,0.81,2.22
10.1016/j.ajog.2021.01.004,35,Yes,"Nonteaching Hospitals, NonBlack-serving",No,NA,Maternal In-Hospital Death,Ratio of Observed RR to Expected RR,NA,"maternal age, insurance, gestational age at delivery, multiple gestations, mode of delivery, rurality, year, pregnancy comorbid conditions (chronic hypertension, chronic cardiac disease, diabetes mellitus, chronic renal disease), and state of delivery (California, Missouri, and Pennsylvania",1,White patients,Black patients,1.26,0.69,2.06
10.1016/j.ajog.2021.01.004,36,Yes,"Nonteaching Hospitals, Black-serving",No,NA,Maternal In-Hospital Death,Ratio of Observed RR to Expected RR,NA,"maternal age, insurance, gestational age at delivery, multiple gestations, mode of delivery, rurality, year, pregnancy comorbid conditions (chronic hypertension, chronic cardiac disease, diabetes mellitus, chronic renal disease), and state of delivery (California, Missouri, and Pennsylvania",1,White patients,Black patients,1.2,0.84,1.74
10.1016/j.ajog.2021.02.015,1,No,NA,No,NA,Agreement with the statement regarding the effect of timing/age on the ability to bear children,Mean point estimate,NA,"age, parity, household income, religion, education, fertility treatment status, insurance coverage",1,N/A,White,28,26.4,29.6
10.1016/j.ajog.2021.02.015,1,No,NA,No,NA,Agreement with the statement regarding the effect of timing/age on the ability to bear children,Mean point estimate,NA,"age, parity, household income, religion, education, fertility treatment status, insurance coverage",2,N/A,Black,30.7,25.3,36.1
10.1016/j.ajog.2021.02.015,1,No,NA,No,NA,Agreement with the statement regarding the effect of timing/age on the ability to bear children,Mean point estimate,NA,"age, parity, household income, religion, education, fertility treatment status, insurance coverage",3,N/A,Latinx,27.4,21.3,33.4
10.1016/j.ajog.2021.02.015,1,No,NA,No,NA,Agreement with the statement regarding the effect of timing/age on the ability to bear children,Mean point estimate,NA,"age, parity, household income, religion, education, fertility treatment status, insurance coverage",4,N/A,Asian,24,18.8,29.1
10.1016/j.ajog.2021.02.015,1,No,NA,No,NA,Agreement with the statement regarding the effect of timing/age on the ability to bear children,Mean point estimate,NA,"age, parity, household income, religion, education, fertility treatment status, insurance coverage",5,N/A,Multiple or other,30.4,24.8,36.1
10.1016/j.ajog.2021.02.015,2,No,NA,No,NA,Agreement with the statement regarding the effect of stress on the ability to bear children,Mean point estimate,NA,"age, parity, household income, religion, education, fertility treatment status, insurance coverage",1,N/A,White,52.8,50.9,54.8
10.1016/j.ajog.2021.02.015,2,No,NA,No,NA,Agreement with the statement regarding the effect of stress on the ability to bear children,Mean point estimate,NA,"age, parity, household income, religion, education, fertility treatment status, insurance coverage",2,N/A,Black,40,33.3,46.7
10.1016/j.ajog.2021.02.015,2,No,NA,No,NA,Agreement with the statement regarding the effect of stress on the ability to bear children,Mean point estimate,NA,"age, parity, household income, religion, education, fertility treatment status, insurance coverage",3,N/A,Latinx,42,34.6,49.5
10.1016/j.ajog.2021.02.015,2,No,NA,No,NA,Agreement with the statement regarding the effect of stress on the ability to bear children,Mean point estimate,NA,"age, parity, household income, religion, education, fertility treatment status, insurance coverage",4,N/A,Asian,41.6,35.1,48.1
10.1016/j.ajog.2021.02.015,2,No,NA,No,NA,Agreement with the statement regarding the effect of stress on the ability to bear children,Mean point estimate,NA,"age, parity, household income, religion, education, fertility treatment status, insurance coverage",5,N/A,Multiple or other,46.5,39.6,53.5
10.1016/j.ajog.2021.02.015,3,No,NA,No,NA,Agreement with the statement regarding the effect of God's will on the ability to bear children,Mean point estimate,NA,"age, parity, household income, religion, education, fertility treatment status, insurance coverage",1,N/A,White,70.2,68.1,72.2
10.1016/j.ajog.2021.02.015,3,No,NA,No,NA,Agreement with the statement regarding the effect of God's will on the ability to bear children,Mean point estimate,NA,"age, parity, household income, religion, education, fertility treatment status, insurance coverage",2,N/A,Black,41.4,34.5,48.4
10.1016/j.ajog.2021.02.015,3,No,NA,No,NA,Agreement with the statement regarding the effect of God's will on the ability to bear children,Mean point estimate,NA,"age, parity, household income, religion, education, fertility treatment status, insurance coverage",3,N/A,Latinx,53.6,45.9,61.2
10.1016/j.ajog.2021.02.015,3,No,NA,No,NA,Agreement with the statement regarding the effect of God's will on the ability to bear children,Mean point estimate,NA,"age, parity, household income, religion, education, fertility treatment status, insurance coverage",4,N/A,Asian,55.6,48.3,62.1
10.1016/j.ajog.2021.02.015,3,No,NA,No,NA,Agreement with the statement regarding the effect of God's will on the ability to bear children,Mean point estimate,NA,"age, parity, household income, religion, education, fertility treatment status, insurance coverage",5,N/A,Multiple or other,66.3,59,73.6
10.1016/j.ajog.2021.02.015,4,No,NA,No,NA,Agreement with the statement regarding the effect of biology/physiology on the ability to bear children,Mean point estimate,NA,"age, parity, household income, religion, education, fertility treatment status, insurance coverage",1,N/A,White,20.8,19.4,22.2
10.1016/j.ajog.2021.02.015,4,No,NA,No,NA,Agreement with the statement regarding the effect of biology/physiology on the ability to bear children,Mean point estimate,NA,"age, parity, household income, religion, education, fertility treatment status, insurance coverage",2,N/A,Black,29.8,24.7,34.3
10.1016/j.ajog.2021.02.015,4,No,NA,No,NA,Agreement with the statement regarding the effect of biology/physiology on the ability to bear children,Mean point estimate,NA,"age, parity, household income, religion, education, fertility treatment status, insurance coverage",3,N/A,Latinx,27.7,22.6,32.8
10.1016/j.ajog.2021.02.015,4,No,NA,No,NA,Agreement with the statement regarding the effect of biology/physiology on the ability to bear children,Mean point estimate,NA,"age, parity, household income, religion, education, fertility treatment status, insurance coverage",4,N/A,Asian,19.1,14.5,23.6
10.1016/j.ajog.2021.02.015,4,No,NA,No,NA,Agreement with the statement regarding the effect of biology/physiology on the ability to bear children,Mean point estimate,NA,"age, parity, household income, religion, education, fertility treatment status, insurance coverage",5,N/A,Multiple or other,19.6,14.7,24.4
10.1016/j.ajog.2021.02.015,5,No,NA,No,NA,Agreement with the statement regarding the effect of chance on the ability to bear children,Mean point estimate,NA,"age, parity, household income, religion, education, fertility treatment status, insurance coverage",1,N/A,White,46.9,45,48.8
10.1016/j.ajog.2021.02.015,5,No,NA,No,NA,Agreement with the statement regarding the effect of chance on the ability to bear children,Mean point estimate,NA,"age, parity, household income, religion, education, fertility treatment status, insurance coverage",2,N/A,Black,48.1,41.4,54.9
10.1016/j.ajog.2021.02.015,5,No,NA,No,NA,Agreement with the statement regarding the effect of chance on the ability to bear children,Mean point estimate,NA,"age, parity, household income, religion, education, fertility treatment status, insurance coverage",3,N/A,Latinx,43.1,35.8,50.4
10.1016/j.ajog.2021.02.015,5,No,NA,No,NA,Agreement with the statement regarding the effect of chance on the ability to bear children,Mean point estimate,NA,"age, parity, household income, religion, education, fertility treatment status, insurance coverage",4,N/A,Asian,45.7,39.4,52
10.1016/j.ajog.2021.02.015,5,No,NA,No,NA,Agreement with the statement regarding the effect of chance on the ability to bear children,Mean point estimate,NA,"age, parity, household income, religion, education, fertility treatment status, insurance coverage",5,N/A,Multiple or other,41.3,34.4,48.1
10.1016/j.ajog.2021.02.017,1,No,NA,No,NA,Cervical length < 15 mm,Percent,NA,none,1,N/A,White,0.2,-99,-99
10.1016/j.ajog.2021.02.017,1,No,NA,No,NA,Cervical length < 15 mm,Percent,NA,none,2,N/A,Black,0.9,-99,-99
10.1016/j.ajog.2021.02.017,1,No,NA,No,NA,Cervical length < 15 mm,Percent,NA,none,3,N/A,Hispanic,0.5,-99,-99
10.1016/j.ajog.2021.02.017,1,No,NA,No,NA,Cervical length < 15 mm,Percent,NA,none,4,N/A,Other,0.5,-99,-99
10.1016/j.ajog.2021.02.017,2,No,NA,No,NA,Cervical length < 25 mm,Percent,NA,none,1,N/A,White,1,-99,-99
10.1016/j.ajog.2021.02.017,2,No,NA,No,NA,Cervical length < 25 mm,Percent,NA,none,2,N/A,Black,3.8,-99,-99
10.1016/j.ajog.2021.02.017,2,No,NA,No,NA,Cervical length < 25 mm,Percent,NA,none,3,N/A,Hispanic,1.7,-99,-99
10.1016/j.ajog.2021.02.017,2,No,NA,No,NA,Cervical length < 25 mm,Percent,NA,none,4,N/A,Other,1.2,-99,-99
10.1016/j.ajog.2021.02.017,3,No,NA,No,NA,Cervical length < 30 mm,Percent,NA,none,1,N/A,White,3.9,-99,-99
10.1016/j.ajog.2021.02.017,3,No,NA,No,NA,Cervical length < 30 mm,Percent,NA,none,2,N/A,Black,9,-99,-99
10.1016/j.ajog.2021.02.017,3,No,NA,No,NA,Cervical length < 30 mm,Percent,NA,none,3,N/A,Hispanic,4.5,-99,-99
10.1016/j.ajog.2021.02.017,3,No,NA,No,NA,Cervical length < 30 mm,Percent,NA,none,4,N/A,Other,4.5,-99,-99
10.1016/j.ajog.2021.02.017,4,No,NA,No,NA,Cervical funneling,Percent,NA,none,1,N/A,White,0.5,-99,-99
10.1016/j.ajog.2021.02.017,4,No,NA,No,NA,Cervical funneling,Percent,NA,none,2,N/A,Black,2.6,-99,-99
10.1016/j.ajog.2021.02.017,4,No,NA,No,NA,Cervical funneling,Percent,NA,none,3,N/A,Hispanic,1.8,-99,-99
10.1016/j.ajog.2021.02.017,4,No,NA,No,NA,Cervical funneling,Percent,NA,none,4,N/A,Other,1.9,-99,-99
10.1016/j.ajog.2021.02.017,5,No,NA,No,NA,Intraamniotic debris,Percent,NA,none,1,N/A,White,2.8,-99,-99
10.1016/j.ajog.2021.02.017,5,No,NA,No,NA,Intraamniotic debris,Percent,NA,none,2,N/A,Black,4.6,-99,-99
10.1016/j.ajog.2021.02.017,5,No,NA,No,NA,Intraamniotic debris,Percent,NA,none,3,N/A,Hispanic,6.4,-99,-99
10.1016/j.ajog.2021.02.017,5,No,NA,No,NA,Intraamniotic debris,Percent,NA,none,4,N/A,Other,2.1,-99,-99
10.1016/j.ajog.2021.03.040,1,Yes,2009-2013,No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",None,1,N/A,Non-Hispanic White,15.8,-99,-99
10.1016/j.ajog.2021.03.040,1,Yes,2009-2013,No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",None,2,N/A,Non-Hispanic Black,46.6,-99,-99
10.1016/j.ajog.2021.03.040,1,Yes,2009-2013,No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",None,3,N/A,Hispanic,12.8,-99,-99
10.1016/j.ajog.2021.03.040,2,Yes,2014-2018,No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",None,1,N/A,Non-Hispanic White,14.5,-99,-99
10.1016/j.ajog.2021.03.040,2,Yes,2014-2018,No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",None,2,N/A,Non-Hispanic Black,29.4,-99,-99
10.1016/j.ajog.2021.03.040,2,Yes,2014-2018,No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",None,3,N/A,Hispanic,7.4,-99,-99
10.1016/j.ajog.2021.04.210,1,No,NA,No,NA,Any medication to treat opioid use disorder in the year after delivery,HR,NA,None,1,White non-Hispanic,Other,1.53,1.25,1.87
10.1016/j.ajog.2021.04.210,2,No,NA,No,NA,Any medication to treat opioid use disorder in the year after delivery,HR,NA,"year of birth, MassHealth delivery, medication for opioid use disorder treatment in pregnancy, other opioid prescription (3 months before delivery), incarceration in pregnancy/postpartum, medication type for medication for opioid use disorder",1,White non-Hispanic,Other,1.48,1.21,1.81
10.1016/j.ajog.2021.04.210,3,No,NA,No,NA,Any buprenorphine to treat opioid use disorder in the year after delivery,HR,NA,None,1,White non-Hispanic,Other,1.45,1.1,1.93
10.1016/j.ajog.2021.04.210,4,No,NA,No,NA,Any buprenorphine to treat opioid use disorder in the year after delivery,HR,NA,"year of birth, maternal age, MassHealth delivery, medication for opioid use disorder treatment in pregnancy, incarceration in pregnancy/postpartum",1,White non-Hispanic,Other,1.33,1,1.77
10.1016/j.ajog.2021.04.210,5,No,NA,No,NA,Methadone only to treat opioid use disorder in the year after delivery,HR,NA,None,1,White non-Hispanic,Other,1.6,1.2,2.14
10.1016/j.ajog.2021.04.210,6,No,NA,No,NA,Methadone only to treat opioid use disorder in the year after delivery,HR,NA,"year of birth, rural residence, overdose event, medication for opioid use disorder treatment in pregnancy, other opioid prescription (3 months before delivery), incarceration in pregnancy/postpartum",1,White non-Hispanic,Other,1.8,1.34,2.41
10.1016/j.ajog.2021.05.002,1,No,NA,No,NA,Abdominal sacrocolpopexy,OR,NA,"age, comorbidities, ASA classification, and concurrent surgery",1,White,African American,1.07,0.94,1.22
10.1016/j.ajog.2021.05.002,1,No,NA,No,NA,Abdominal sacrocolpopexy,OR,NA,"age, comorbidities, ASA classification, and concurrent surgery",2,White,Latina,0.92,0.83,1.02
10.1016/j.ajog.2021.05.002,1,No,NA,No,NA,Abdominal sacrocolpopexy,OR,NA,"age, comorbidities, ASA classification, and concurrent surgery",3,White,Asian,0.82,0.68,0.99
10.1016/j.ajog.2021.05.002,1,No,NA,No,NA,Abdominal sacrocolpopexy,OR,NA,"age, comorbidities, ASA classification, and concurrent surgery",4,White,American Indian or Alaska Native,0.89,0.55,1.45
10.1016/j.ajog.2021.05.002,1,No,NA,No,NA,Abdominal sacrocolpopexy,OR,NA,"age, comorbidities, ASA classification, and concurrent surgery",5,White,native hawaiian or pacific islander,0.56,0.39,0.82
10.1016/j.ajog.2021.05.002,1,No,NA,No,NA,Abdominal sacrocolpopexy,OR,NA,"age, comorbidities, ASA classification, and concurrent surgery",6,White,Unknown,0.47,0.43,0.52
10.1016/j.ajog.2021.05.002,2,No,NA,No,NA,Laparoscopic,OR,NA,"age, comorbidities, ASA classification, and concurrent surgery",1,White,African American,0.85,0.69,1.04
10.1016/j.ajog.2021.05.002,2,No,NA,No,NA,Laparoscopic,OR,NA,"age, comorbidities, ASA classification, and concurrent surgery",2,White,Latina,0.68,0.58,0.79
10.1016/j.ajog.2021.05.002,2,No,NA,No,NA,Laparoscopic,OR,NA,"age, comorbidities, ASA classification, and concurrent surgery",3,White,Asian,0.81,0.6,1.09
10.1016/j.ajog.2021.05.002,2,No,NA,No,NA,Laparoscopic,OR,NA,"age, comorbidities, ASA classification, and concurrent surgery",4,White,American Indian or Alaska Native,0.6,0.29,1.21
10.1016/j.ajog.2021.05.002,2,No,NA,No,NA,Laparoscopic,OR,NA,"age, comorbidities, ASA classification, and concurrent surgery",5,White,native hawaiian or pacific islander,0.31,0.17,0.56
10.1016/j.ajog.2021.05.002,2,No,NA,No,NA,Laparoscopic,OR,NA,"age, comorbidities, ASA classification, and concurrent surgery",6,White,Unknown,0.44,0.38,0.52
10.1016/j.ajog.2021.05.002,3,No,NA,No,NA,Blood transfusion,OR,NA,"age, comorbidities, asa classification,
concurrent surgery, and surgical approach",1,White,African American,3.04,1.95,4.73
10.1016/j.ajog.2021.05.002,3,No,NA,No,NA,Blood transfusion,OR,NA,"age, comorbidities, asa classification,
concurrent surgery, and surgical approach",2,White,Latina,2.65,1.82,3.87
10.1016/j.ajog.2021.05.002,3,No,NA,No,NA,Blood transfusion,OR,NA,"age, comorbidities, asa classification,
concurrent surgery, and surgical approach",3,White,Asian,1.85,0.89,3.85
10.1016/j.ajog.2021.05.002,3,No,NA,No,NA,Blood transfusion,OR,NA,"age, comorbidities, asa classification,
concurrent surgery, and surgical approach",4,White,American Indian or Alaska Native,1.52,0.21,11.12
10.1016/j.ajog.2021.05.002,3,No,NA,No,NA,Blood transfusion,OR,NA,"age, comorbidities, asa classification,
concurrent surgery, and surgical approach",5,White,Unknown,1.53,0.99,2.37
10.1016/j.ajog.2021.05.002,4,No,NA,No,NA,deep venous thrombosis and pulmonary embolism,OR,NA,"age, comorbidities, asa classification,
concurrent surgery, and surgical approach",1,White,African American,2.46,1.1,5.48
10.1016/j.ajog.2021.05.002,4,No,NA,No,NA,deep venous thrombosis and pulmonary embolism,OR,NA,"age, comorbidities, asa classification,
concurrent surgery, and surgical approach",2,White,Latina,0.59,0.18,1.94
10.1016/j.ajog.2021.05.002,4,No,NA,No,NA,deep venous thrombosis and pulmonary embolism,OR,NA,"age, comorbidities, asa classification,
concurrent surgery, and surgical approach",3,White,Asian,0.81,0.11,5.95
10.1016/j.ajog.2021.05.002,5,No,NA,No,NA,urinary track infection,OR,NA,"age, comorbidities, asa classification,
concurrent surgery, and surgical approach",1,White,African American,0.68,0.49,0.96
10.1016/j.ajog.2021.05.002,5,No,NA,No,NA,urinary track infection,OR,NA,"age, comorbidities, asa classification,
concurrent surgery, and surgical approach",2,White,Latina,1.08,0.87,1.34
10.1016/j.ajog.2021.05.002,5,No,NA,No,NA,urinary track infection,OR,NA,"age, comorbidities, asa classification,
concurrent surgery, and surgical approach",3,White,Asian,1.05,0.7,1.56
10.1016/j.ajog.2021.05.002,5,No,NA,No,NA,urinary track infection,OR,NA,"age, comorbidities, asa classification,
concurrent surgery, and surgical approach",4,White,American Indian or Alaska Native,0.24,0.03,1.71
10.1016/j.ajog.2021.05.002,5,No,NA,No,NA,urinary track infection,OR,NA,"age, comorbidities, asa classification,
concurrent surgery, and surgical approach",5,White,native hawaiian or pacific islander,1.47,0.74,2.91
10.1016/j.ajog.2021.05.002,5,No,NA,No,NA,urinary track infection,OR,NA,"age, comorbidities, asa classification,
concurrent surgery, and surgical approach",6,White,Unknown,1.57,1.32,1.86
10.1016/j.ajog.2021.05.002,6,No,NA,No,NA,Clavien-Dindo complication grade II,OR,NA,"age, comorbidities, asa classification,
concurrent surgery, and surgical approach",1,White,African American,1.03,0.8,1.34
10.1016/j.ajog.2021.05.002,6,No,NA,No,NA,Clavien-Dindo complication grade II,OR,NA,"age, comorbidities, asa classification,
concurrent surgery, and surgical approach",2,White,Latina,1.25,1.04,1.51
10.1016/j.ajog.2021.05.002,6,No,NA,No,NA,Clavien-Dindo complication grade II,OR,NA,"age, comorbidities, asa classification,
concurrent surgery, and surgical approach",3,White,Asian,1.13,0.8,1.62
10.1016/j.ajog.2021.05.002,6,No,NA,No,NA,Clavien-Dindo complication grade II,OR,NA,"age, comorbidities, asa classification,
concurrent surgery, and surgical approach",4,White,American Indian or Alaska Native,0.39,0.1,1.6
10.1016/j.ajog.2021.05.002,6,No,NA,No,NA,Clavien-Dindo complication grade II,OR,NA,"age, comorbidities, asa classification,
concurrent surgery, and surgical approach",5,White,native hawaiian or pacific islander,1.21,0.61,2.39
10.1016/j.ajog.2021.05.002,6,No,NA,No,NA,Clavien-Dindo complication grade II,OR,NA,"age, comorbidities, asa classification,
concurrent surgery, and surgical approach",6,White,Unknown,1.56,1.32,1.83
10.1016/j.ajog.2021.05.045,1,No,NA,No,NA,bilateral oophorectomy alone,Incidence,"per 10,000 women",None,1,N/A,non-Hispanic Black,1.2,-99,-99
10.1016/j.ajog.2021.05.045,1,No,NA,No,NA,bilateral oophorectomy alone,Incidence,"per 10,000 women",None,2,N/A,non-Hispanic White,0.8,-99,-99
10.1016/j.ajog.2021.05.045,2,No,NA,No,NA,hysterectomy with bilateral oophorectomy,Incidence,"per 10,000 women",None,1,N/A,non-Hispanic Black,18.3,-99,-99
10.1016/j.ajog.2021.05.045,2,No,NA,No,NA,hysterectomy with bilateral oophorectomy,Incidence,"per 10,000 women",None,2,N/A,non-Hispanic White,19.1,-99,-99
10.1016/j.ajog.2021.05.045,3,No,NA,No,NA,overall bilateral oophorectomy,Incidence,"per 10,000 women",None,1,N/A,non-Hispanic Black,19.5,-99,-99
10.1016/j.ajog.2021.05.045,3,No,NA,No,NA,overall bilateral oophorectomy,Incidence,"per 10,000 women",None,2,N/A,non-Hispanic White,20,-99,-99
10.1016/j.ajog.2021.05.045,4,Yes,2011,No,NA,bilateral oophorectomy alone,Incidence,"per 10,000 women",None,1,N/A,non-Hispanic Black,1.8,-99,-99
10.1016/j.ajog.2021.05.045,4,Yes,2011,No,NA,bilateral oophorectomy alone,Incidence,"per 10,000 women",None,2,N/A,non-Hispanic White,0.8,-99,-99
10.1016/j.ajog.2021.05.045,5,Yes,2011,No,NA,hysterectomy with bilateral oophorectomy,Incidence,"per 10,000 women",None,1,N/A,non-Hispanic Black,11.4,-99,-99
10.1016/j.ajog.2021.05.045,5,Yes,2011,No,NA,hysterectomy with bilateral oophorectomy,Incidence,"per 10,000 women",None,2,N/A,non-Hispanic White,16.8,-99,-99
10.1016/j.ajog.2021.05.045,6,Yes,2011,No,NA,overall bilateral oophorectomy,Incidence,"per 10,000 women",None,1,N/A,non-Hispanic Black,13.2,-99,-99
10.1016/j.ajog.2021.05.045,6,Yes,2011,No,NA,overall bilateral oophorectomy,Incidence,"per 10,000 women",None,2,N/A,non-Hispanic White,17.7,-99,-99
10.1016/j.ajog.2021.05.045,7,Yes,2012,No,NA,bilateral oophorectomy alone,Incidence,"per 10,000 women",None,1,N/A,non-Hispanic Black,1.1,-99,-99
10.1016/j.ajog.2021.05.045,7,Yes,2012,No,NA,bilateral oophorectomy alone,Incidence,"per 10,000 women",None,2,N/A,non-Hispanic White,1,-99,-99
10.1016/j.ajog.2021.05.045,8,Yes,2012,No,NA,hysterectomy with bilateral oophorectomy,Incidence,"per 10,000 women",None,1,N/A,non-Hispanic Black,14.3,-99,-99
10.1016/j.ajog.2021.05.045,8,Yes,2012,No,NA,hysterectomy with bilateral oophorectomy,Incidence,"per 10,000 women",None,2,N/A,non-Hispanic White,17.1,-99,-99
10.1016/j.ajog.2021.05.045,9,Yes,2012,No,NA,overall bilateral oophorectomy,Incidence,"per 10,000 women",None,1,N/A,non-Hispanic Black,15.4,-99,-99
10.1016/j.ajog.2021.05.045,9,Yes,2012,No,NA,overall bilateral oophorectomy,Incidence,"per 10,000 women",None,2,N/A,non-Hispanic White,18.1,-99,-99
10.1016/j.ajog.2021.05.045,10,Yes,2013,No,NA,bilateral oophorectomy alone,Incidence,"per 10,000 women",None,1,N/A,non-Hispanic Black,1,-99,-99
10.1016/j.ajog.2021.05.045,10,Yes,2013,No,NA,bilateral oophorectomy alone,Incidence,"per 10,000 women",None,2,N/A,non-Hispanic White,0.7,-99,-99
10.1016/j.ajog.2021.05.045,11,Yes,2013,No,NA,hysterectomy with bilateral oophorectomy,Incidence,"per 10,000 women",None,1,N/A,non-Hispanic Black,19.9,-99,-99
10.1016/j.ajog.2021.05.045,11,Yes,2013,No,NA,hysterectomy with bilateral oophorectomy,Incidence,"per 10,000 women",None,2,N/A,non-Hispanic White,18.6,-99,-99
10.1016/j.ajog.2021.05.045,12,Yes,2013,No,NA,overall bilateral oophorectomy,Incidence,"per 10,000 women",None,1,N/A,non-Hispanic Black,19.4,-99,-99
10.1016/j.ajog.2021.05.045,12,Yes,2013,No,NA,overall bilateral oophorectomy,Incidence,"per 10,000 women",None,2,N/A,non-Hispanic White,19.3,-99,-99
10.1016/j.ajog.2021.05.045,13,Yes,2014,No,NA,bilateral oophorectomy alone,Incidence,"per 10,000 women",None,1,N/A,non-Hispanic Black,1.1,-99,-99
10.1016/j.ajog.2021.05.045,13,Yes,2014,No,NA,bilateral oophorectomy alone,Incidence,"per 10,000 women",None,2,N/A,non-Hispanic White,0.7,-99,-99
10.1016/j.ajog.2021.05.045,14,Yes,2014,No,NA,hysterectomy with bilateral oophorectomy,Incidence,"per 10,000 women",None,1,N/A,non-Hispanic Black,27.3,-99,-99
10.1016/j.ajog.2021.05.045,14,Yes,2014,No,NA,hysterectomy with bilateral oophorectomy,Incidence,"per 10,000 women",None,2,N/A,non-Hispanic White,24.1,-99,-99
10.1016/j.ajog.2021.05.045,15,Yes,2014,No,NA,overall bilateral oophorectomy,Incidence,"per 10,000 women",None,1,N/A,non-Hispanic Black,28.4,-99,-99
10.1016/j.ajog.2021.05.045,15,Yes,2014,No,NA,overall bilateral oophorectomy,Incidence,"per 10,000 women",None,2,N/A,non-Hispanic White,24.8,-99,-99
10.1016/j.ajog.2021.05.045,16,Yes,2011,No,NA,hysterectomy with oophorectomy,Percent,NA,None,1,N/A,non-Hispanic White,33.53,-99,-99
10.1016/j.ajog.2021.05.045,16,Yes,2011,No,NA,hysterectomy with oophorectomy,Percent,NA,None,2,N/A,non-Hispanic Black,18.39,-99,-99
10.1016/j.ajog.2021.05.045,17,Yes,2012,No,NA,hysterectomy with oophorectomy,Percent,NA,None,1,N/A,non-Hispanic White,36.38,-99,-99
10.1016/j.ajog.2021.05.045,17,Yes,2012,No,NA,hysterectomy with oophorectomy,Percent,NA,None,2,N/A,non-Hispanic Black,23.32,-99,-99
10.1016/j.ajog.2021.05.045,18,Yes,2013,No,NA,hysterectomy with oophorectomy,Percent,NA,None,1,N/A,non-Hispanic White,44.7,-99,-99
10.1016/j.ajog.2021.05.045,18,Yes,2013,No,NA,hysterectomy with oophorectomy,Percent,NA,None,2,N/A,non-Hispanic Black,33.1,-99,-99
10.1016/j.ajog.2021.05.045,19,Yes,2014,No,NA,hysterectomy with oophorectomy,Percent,NA,None,1,N/A,non-Hispanic White,57.74,-99,-99
10.1016/j.ajog.2021.05.045,19,Yes,2014,No,NA,hysterectomy with oophorectomy,Percent,NA,None,2,N/A,non-Hispanic Black,45.94,-99,-99
10.1016/j.ajog.2021.08.033,1,No,NA,No,NA,Tone of recommendation letters for medical school applicants - Analytical thinking,Least-square mean (scale 0 - 100),NA,"United States Medical Licensing Examination Step 1 score, medical school ranking, interview status, and letter writer gender",1,N/A,Applicant letters for individuals underrepresented in medicine,86.1,-99,-99
10.1016/j.ajog.2021.08.033,1,No,NA,No,NA,Tone of recommendation letters for medical school applicants - Analytical thinking,Least-square mean (scale 0 - 100),NA,"United States Medical Licensing Examination Step 1 score, medical school ranking, interview status, and letter writer gender",2,N/A,Applicant letters for White and Asian individuals,84.9,-99,-99
10.1016/j.ajog.2021.08.033,2,No,NA,No,NA,Tone of recommendation letters for medical school applicants - Clout,Least-square mean (scale 0 - 100),NA,"United States Medical Licensing Examination Step 1 score, medical school ranking, interview status, and letter writer gender",1,N/A,Applicant letters for individuals underrepresented in medicine,5.4,-99,-99
10.1016/j.ajog.2021.08.033,2,No,NA,No,NA,Tone of recommendation letters for medical school applicants - Clout,Least-square mean (scale 0 - 100),NA,"United States Medical Licensing Examination Step 1 score, medical school ranking, interview status, and letter writer gender",2,N/A,Applicant letters for White and Asian individuals,6.2,-99,-99
10.1016/j.ajog.2021.08.033,3,No,NA,No,NA,Tone of recommendation letters for medical school applicants - Authenticity,Least-square mean (scale 0 - 100),NA,"United States Medical Licensing Examination Step 1 score, medical school ranking, interview status, and letter writer gender",1,N/A,Applicant letters for individuals underrepresented in medicine,83.7,-99,-99
10.1016/j.ajog.2021.08.033,3,No,NA,No,NA,Tone of recommendation letters for medical school applicants - Authenticity,Least-square mean (scale 0 - 100),NA,"United States Medical Licensing Examination Step 1 score, medical school ranking, interview status, and letter writer gender",2,N/A,Applicant letters for White and Asian individuals,83.2,-99,-99
10.1016/j.ajog.2021.08.033,4,No,NA,No,NA,Tone of recommendation letters for medical school applicants - Emotional,Least-square mean (scale 0 - 100),NA,"United States Medical Licensing Examination Step 1 score, medical school ranking, interview status, and letter writer gender",1,N/A,Applicant letters for individuals underrepresented in medicine,92.2,-99,-99
10.1016/j.ajog.2021.08.033,4,No,NA,No,NA,Tone of recommendation letters for medical school applicants - Emotional,Least-square mean (scale 0 - 100),NA,"United States Medical Licensing Examination Step 1 score, medical school ranking, interview status, and letter writer gender",2,N/A,Applicant letters for White and Asian individuals,92.7,-99,-99
10.1016/j.ajog.2021.10.031,1,No,NA,No,NA,Intraoperative complication,Percent,NA,None,1,N/A,non-Hispanic White,9,-99,-99
10.1016/j.ajog.2021.10.031,1,No,NA,No,NA,Intraoperative complication,Percent,NA,None,2,N/A,non-Hispanic Black,8,-99,-99
10.1016/j.ajog.2021.10.031,1,No,NA,No,NA,Intraoperative complication,Percent,NA,None,3,N/A,Hispanic,10,-99,-99
10.1016/j.ajog.2021.10.031,2,No,NA,No,NA,Postoperative surgical complications,Percent,NA,None,1,N/A,non-Hispanic White,23,-99,-99
10.1016/j.ajog.2021.10.031,2,No,NA,No,NA,Postoperative surgical complications,Percent,NA,None,2,N/A,non-Hispanic Black,27,-99,-99
10.1016/j.ajog.2021.10.031,2,No,NA,No,NA,Postoperative surgical complications,Percent,NA,None,3,N/A,Hispanic,25,-99,-99
10.1016/j.ajog.2021.10.031,3,No,NA,No,NA,Postoperative complications,Percent,NA,None,1,N/A,non-Hispanic White,25,-99,-99
10.1016/j.ajog.2021.10.031,3,No,NA,No,NA,Postoperative complications,Percent,NA,None,2,N/A,non-Hispanic Black,30,-99,-99
10.1016/j.ajog.2021.10.031,3,No,NA,No,NA,Postoperative complications,Percent,NA,None,3,N/A,Hispanic,28,-99,-99
10.1016/j.ajog.2021.10.031,4,No,NA,No,NA,No complications,Percent,NA,None,1,N/A,non-Hispanic White,56,-99,-99
10.1016/j.ajog.2021.10.031,4,No,NA,No,NA,No complications,Percent,NA,None,2,N/A,non-Hispanic Black,50,-99,-99
10.1016/j.ajog.2021.10.031,4,No,NA,No,NA,No complications,Percent,NA,None,3,N/A,Hispanic,55,-99,-99
10.1016/j.ajog.2021.10.031,5,No,NA,No,NA,>=5 Complications,Percent,NA,None,1,N/A,non-Hispanic White,3,-99,-99
10.1016/j.ajog.2021.10.031,5,No,NA,No,NA,>=5 Complications,Percent,NA,None,2,N/A,non-Hispanic Black,5,-99,-99
10.1016/j.ajog.2021.10.031,5,No,NA,No,NA,>=5 Complications,Percent,NA,None,3,N/A,Hispanic,4,-99,-99
10.1016/j.ajog.2021.10.031,6,Yes,FIGO Stage I,No,NA,Adjuvant treatment received,Percent,NA,None,1,N/A,non-Hispanic White,54,-99,-99
10.1016/j.ajog.2021.10.031,6,Yes,FIGO Stage I,No,NA,Adjuvant treatment received,Percent,NA,None,2,N/A,non-Hispanic Black,60,-99,-99
10.1016/j.ajog.2021.10.031,6,Yes,FIGO Stage I,No,NA,Adjuvant treatment received,Percent,NA,None,3,N/A,Hispanic,55,-99,-99
10.1016/j.ajog.2021.10.031,7,Yes,FIGO Stage II,No,NA,Adjuvant treatment received,Percent,NA,None,1,N/A,non-Hispanic White,70,-99,-99
10.1016/j.ajog.2021.10.031,7,Yes,FIGO Stage II,No,NA,Adjuvant treatment received,Percent,NA,None,2,N/A,non-Hispanic Black,72,-99,-99
10.1016/j.ajog.2021.10.031,7,Yes,FIGO Stage II,No,NA,Adjuvant treatment received,Percent,NA,None,3,N/A,Hispanic,77,-99,-99
10.1016/j.ajog.2021.10.031,8,Yes,FIGO Stage III,No,NA,Adjuvant treatment received,Percent,NA,None,1,N/A,non-Hispanic White,72,-99,-99
10.1016/j.ajog.2021.10.031,8,Yes,FIGO Stage III,No,NA,Adjuvant treatment received,Percent,NA,None,2,N/A,non-Hispanic Black,69,-99,-99
10.1016/j.ajog.2021.10.031,8,Yes,FIGO Stage III,No,NA,Adjuvant treatment received,Percent,NA,None,3,N/A,Hispanic,69,-99,-99
10.1016/j.ajog.2021.10.031,9,Yes,FIGO Stage IV,No,NA,Adjuvant treatment received,Percent,NA,None,1,N/A,non-Hispanic White,68,-99,-99
10.1016/j.ajog.2021.10.031,9,Yes,FIGO Stage IV,No,NA,Adjuvant treatment received,Percent,NA,None,2,N/A,non-Hispanic Black,65,-99,-99
10.1016/j.ajog.2021.10.031,9,Yes,FIGO Stage IV,No,NA,Adjuvant treatment received,Percent,NA,None,3,N/A,Hispanic,54,-99,-99
10.1016/j.ajog.2021.10.031,10,No,NA,No,NA,Adjuvant treatment received,Percent,NA,None,1,N/A,non-Hispanic White,92,-99,-99
10.1016/j.ajog.2021.10.031,10,No,NA,No,NA,Adjuvant treatment received,Percent,NA,None,2,N/A,non-Hispanic Black,91,-99,-99
10.1016/j.ajog.2021.10.031,10,No,NA,No,NA,Adjuvant treatment received,Percent,NA,None,3,N/A,Hispanic,88,-99,-99
10.1016/j.ajog.2021.10.031,11,No,NA,No,NA,treatment delay of adjuvant treatment among patients who survived at least 3 months,OR,NA,"surgical complications, age group, histology, FIGO stage, marital status, comorbidity score, surgery type, lymphadenectomy, urban-rural indicator, diagnosis year",1,non-Hispanic White,non-Hispanic Black,1.02,0.78,1.33
10.1016/j.ajog.2021.10.031,11,No,NA,No,NA,treatment delay of adjuvant treatment among patients who survived at least 3 months,OR,NA,"surgical complications, age group, histology, FIGO stage, marital status, comorbidity score, surgery type, lymphadenectomy, urban-rural indicator, diagnosis year",2,non-Hispanic White,Hispanic,1.63,1.18,2.25
10.1016/j.ajog.2021.10.031,12,No,NA,No,NA,No adjuvant treatment,OR,NA,"surgical complications, age group, histology, FIGO stage, marital status, comorbidity score, surgery type, lymphadenectomy, urban-rural indicator, diagnosis year",1,non-Hispanic White,non-Hispanic Black,0.96,0.84,1.11
10.1016/j.ajog.2021.10.031,12,No,NA,No,NA,No adjuvant treatment,OR,NA,"surgical complications, age group, histology, FIGO stage, marital status, comorbidity score, surgery type, lymphadenectomy, urban-rural indicator, diagnosis year",2,non-Hispanic White,Hispanic,1.16,0.95,1.41
10.1016/j.ajog.2021.10.031,13,No,NA,Yes,FIGO stage II or higher,treatment delay,OR,NA,"surgical complications, age group, histology, FIGO stage, marital status, comorbidity score, surgery type, lymphadenectomy, urban-rural indicator, diagnosis year",1,non-Hispanic White,non-Hispanic Black,1.17,0.8,1.72
10.1016/j.ajog.2021.10.031,13,No,NA,Yes,FIGO stage II or higher,treatment delay,OR,NA,"surgical complications, age group, histology, FIGO stage, marital status, comorbidity score, surgery type, lymphadenectomy, urban-rural indicator, diagnosis year",2,non-Hispanic White,Hispanic,1.98,1.23,3.17
10.1016/j.ajog.2021.10.031,14,No,NA,Yes,FIGO stage II or higher,No adjuvant treatment,OR,NA,"surgical complications, age group, histology, FIGO stage, marital status, comorbidity score, surgery type, lymphadenectomy, urban-rural indicator, diagnosis year",1,non-Hispanic White,non-Hispanic Black,1.36,1.07,1.72
10.1016/j.ajog.2021.10.031,14,No,NA,Yes,FIGO stage II or higher,No adjuvant treatment,OR,NA,"surgical complications, age group, histology, FIGO stage, marital status, comorbidity score, surgery type, lymphadenectomy, urban-rural indicator, diagnosis year",2,non-Hispanic White,Hispanic,1.43,1.01,2.03
10.1016/j.ajog.2021.10.031,15,Yes,FIGO stage I-II,No,NA,Death > 3 months and within one year,HR,NA,"surgical complications, adjuvant therapy, age group, histology, marital status, comorbidity score, surgery type, lymphadenectomy, urban-rural indicator, diagnosis year",1,non-Hispanic White,non-Hispanic Black,1.42,1.14,1.76
10.1016/j.ajog.2021.10.031,15,Yes,FIGO stage I-II,No,NA,Death > 3 months and within one year,HR,NA,"surgical complications, adjuvant therapy, age group, histology, marital status, comorbidity score, surgery type, lymphadenectomy, urban-rural indicator, diagnosis year",2,non-Hispanic White,Hispanic,0.7,0.46,1.07
10.1016/j.ajog.2021.10.031,16,Yes,FIGO stage I-II,No,NA,Death >1 to 5 years,HR,NA,"surgical complications, adjuvant therapy, age group, histology, marital status, comorbidity score, surgery type, lymphadenectomy, urban-rural indicator, diagnosis year",1,non-Hispanic White,non-Hispanic Black,1.34,1.18,1.52
10.1016/j.ajog.2021.10.031,16,Yes,FIGO stage I-II,No,NA,Death >1 to 5 years,HR,NA,"surgical complications, adjuvant therapy, age group, histology, marital status, comorbidity score, surgery type, lymphadenectomy, urban-rural indicator, diagnosis year",2,non-Hispanic White,Hispanic,0.88,0.72,1.07
10.1016/j.ajog.2021.10.031,17,Yes,FIGO stage III-IV,No,NA,Death > 3 months and within one year,HR,NA,"surgical complications, adjuvant therapy, age group, histology, marital status, comorbidity score, surgery type, lymphadenectomy, urban-rural indicator, diagnosis year",1,non-Hispanic White,non-Hispanic Black,1.19,0.98,1.44
10.1016/j.ajog.2021.10.031,17,Yes,FIGO stage III-IV,No,NA,Death > 3 months and within one year,HR,NA,"surgical complications, adjuvant therapy, age group, histology, marital status, comorbidity score, surgery type, lymphadenectomy, urban-rural indicator, diagnosis year",2,non-Hispanic White,Hispanic,1.24,0.94,1.64
10.1016/j.ajog.2021.10.031,18,Yes,FIGO stage III-IV,No,NA,Death >1 to 5 years,HR,NA,"surgical complications, adjuvant therapy, age group, histology, marital status, comorbidity score, surgery type, lymphadenectomy, urban-rural indicator, diagnosis year",1,non-Hispanic White,non-Hispanic Black,1.27,1.07,1.5
10.1016/j.ajog.2021.10.031,18,Yes,FIGO stage III-IV,No,NA,Death >1 to 5 years,HR,NA,"surgical complications, adjuvant therapy, age group, histology, marital status, comorbidity score, surgery type, lymphadenectomy, urban-rural indicator, diagnosis year",2,non-Hispanic White,Hispanic,1.1,0.87,1.41
10.1016/j.ajog.2022.01.021,1,No,NA,No,NA,Surgical procedure for endometriosis - Laparoscopic excision or fulguration of pelvic lesions,Percent,NA,None,1,N/A,White,27.2,-99,-99
10.1016/j.ajog.2022.01.021,1,No,NA,No,NA,Surgical procedure for endometriosis - Laparoscopic excision or fulguration of pelvic lesions,Percent,NA,None,2,N/A,Hispanic,26.9,-99,-99
10.1016/j.ajog.2022.01.021,1,No,NA,No,NA,Surgical procedure for endometriosis - Laparoscopic excision or fulguration of pelvic lesions,Percent,NA,None,3,N/A,Black,25.9,-99,-99
10.1016/j.ajog.2022.01.021,1,No,NA,No,NA,Surgical procedure for endometriosis - Laparoscopic excision or fulguration of pelvic lesions,Percent,NA,None,4,N/A,Asian,43.5,-99,-99
10.1016/j.ajog.2022.01.021,1,No,NA,No,NA,Surgical procedure for endometriosis - Laparoscopic excision or fulguration of pelvic lesions,Percent,NA,None,5,N/A,Pacific Islander,41.5,-99,-99
10.1016/j.ajog.2022.01.021,1,No,NA,No,NA,Surgical procedure for endometriosis - Laparoscopic excision or fulguration of pelvic lesions,Percent,NA,None,6,N/A,Native American,19.7,-99,-99
10.1016/j.ajog.2022.01.021,1,No,NA,No,NA,Surgical procedure for endometriosis - Laparoscopic excision or fulguration of pelvic lesions,Percent,NA,None,7,N/A,Unknown,24.3,-99,-99
10.1016/j.ajog.2022.01.021,2,No,NA,No,NA,Surgical procedure for endometriosis - Ureterolysis,Percent,NA,None,1,N/A,White,1.8,-99,-99
10.1016/j.ajog.2022.01.021,2,No,NA,No,NA,Surgical procedure for endometriosis - Ureterolysis,Percent,NA,None,2,N/A,Hispanic,3.2,-99,-99
10.1016/j.ajog.2022.01.021,2,No,NA,No,NA,Surgical procedure for endometriosis - Ureterolysis,Percent,NA,None,3,N/A,Black,3.1,-99,-99
10.1016/j.ajog.2022.01.021,2,No,NA,No,NA,Surgical procedure for endometriosis - Ureterolysis,Percent,NA,None,4,N/A,Asian,1.8,-99,-99
10.1016/j.ajog.2022.01.021,2,No,NA,No,NA,Surgical procedure for endometriosis - Ureterolysis,Percent,NA,None,5,N/A,Pacific Islander,1.7,-99,-99
10.1016/j.ajog.2022.01.021,2,No,NA,No,NA,Surgical procedure for endometriosis - Ureterolysis,Percent,NA,None,6,N/A,Native American,0,-99,-99
10.1016/j.ajog.2022.01.021,2,No,NA,No,NA,Surgical procedure for endometriosis - Ureterolysis,Percent,NA,None,7,N/A,Unknown,3.3,-99,-99
10.1016/j.ajog.2022.01.021,3,No,NA,No,NA,Surgical procedure for endometriosis - Ovarian cyst drainage,Percent,NA,None,1,N/A,White,2.3,-99,-99
10.1016/j.ajog.2022.01.021,3,No,NA,No,NA,Surgical procedure for endometriosis - Ovarian cyst drainage,Percent,NA,None,2,N/A,Hispanic,2.4,-99,-99
10.1016/j.ajog.2022.01.021,3,No,NA,No,NA,Surgical procedure for endometriosis - Ovarian cyst drainage,Percent,NA,None,3,N/A,Black,3.1,-99,-99
10.1016/j.ajog.2022.01.021,3,No,NA,No,NA,Surgical procedure for endometriosis - Ovarian cyst drainage,Percent,NA,None,4,N/A,Asian,1.9,-99,-99
10.1016/j.ajog.2022.01.021,3,No,NA,No,NA,Surgical procedure for endometriosis - Ovarian cyst drainage,Percent,NA,None,5,N/A,Pacific Islander,1.7,-99,-99
10.1016/j.ajog.2022.01.021,3,No,NA,No,NA,Surgical procedure for endometriosis - Ovarian cyst drainage,Percent,NA,None,6,N/A,Native American,1.3,-99,-99
10.1016/j.ajog.2022.01.021,3,No,NA,No,NA,Surgical procedure for endometriosis - Ovarian cyst drainage,Percent,NA,None,7,N/A,Unknown,5.5,-99,-99
10.1016/j.ajog.2022.01.021,4,No,NA,No,NA,Surgical procedure for endometriosis - Ovarian cystectomy,Percent,NA,None,1,N/A,White,2.2,-99,-99
10.1016/j.ajog.2022.01.021,4,No,NA,No,NA,Surgical procedure for endometriosis - Ovarian cystectomy,Percent,NA,None,2,N/A,Hispanic,5.8,-99,-99
10.1016/j.ajog.2022.01.021,4,No,NA,No,NA,Surgical procedure for endometriosis - Ovarian cystectomy,Percent,NA,None,3,N/A,Black,3.4,-99,-99
10.1016/j.ajog.2022.01.021,4,No,NA,No,NA,Surgical procedure for endometriosis - Ovarian cystectomy,Percent,NA,None,4,N/A,Asian,9.3,-99,-99
10.1016/j.ajog.2022.01.021,4,No,NA,No,NA,Surgical procedure for endometriosis - Ovarian cystectomy,Percent,NA,None,5,N/A,Pacific Islander,10.2,-99,-99
10.1016/j.ajog.2022.01.021,4,No,NA,No,NA,Surgical procedure for endometriosis - Ovarian cystectomy,Percent,NA,None,6,N/A,Native American,3.9,-99,-99
10.1016/j.ajog.2022.01.021,4,No,NA,No,NA,Surgical procedure for endometriosis - Ovarian cystectomy,Percent,NA,None,7,N/A,Unknown,5.4,-99,-99
10.1016/j.ajog.2022.01.021,5,No,NA,No,NA,Surgical procedure for endometriosis - Oophorectomy,Percent,NA,None,1,N/A,White,3.7,-99,-99
10.1016/j.ajog.2022.01.021,5,No,NA,No,NA,Surgical procedure for endometriosis - Oophorectomy,Percent,NA,None,2,N/A,Hispanic,8.8,-99,-99
10.1016/j.ajog.2022.01.021,5,No,NA,No,NA,Surgical procedure for endometriosis - Oophorectomy,Percent,NA,None,3,N/A,Black,6.7,-99,-99
10.1016/j.ajog.2022.01.021,5,No,NA,No,NA,Surgical procedure for endometriosis - Oophorectomy,Percent,NA,None,4,N/A,Asian,4.8,-99,-99
10.1016/j.ajog.2022.01.021,5,No,NA,No,NA,Surgical procedure for endometriosis - Oophorectomy,Percent,NA,None,5,N/A,Pacific Islander,5.1,-99,-99
10.1016/j.ajog.2022.01.021,5,No,NA,No,NA,Surgical procedure for endometriosis - Oophorectomy,Percent,NA,None,6,N/A,Native American,5.3,-99,-99
10.1016/j.ajog.2022.01.021,5,No,NA,No,NA,Surgical procedure for endometriosis - Oophorectomy,Percent,NA,None,7,N/A,Unknown,7.7,-99,-99
10.1016/j.ajog.2022.01.021,6,No,NA,No,NA,Surgical procedure for endometriosis - Salpingectomy or tubal ligation,Percent,NA,None,1,N/A,White,0.9,-99,-99
10.1016/j.ajog.2022.01.021,6,No,NA,No,NA,Surgical procedure for endometriosis - Salpingectomy or tubal ligation,Percent,NA,None,2,N/A,Hispanic,1.2,-99,-99
10.1016/j.ajog.2022.01.021,6,No,NA,No,NA,Surgical procedure for endometriosis - Salpingectomy or tubal ligation,Percent,NA,None,3,N/A,Black,1.1,-99,-99
10.1016/j.ajog.2022.01.021,6,No,NA,No,NA,Surgical procedure for endometriosis - Salpingectomy or tubal ligation,Percent,NA,None,4,N/A,Asian,1.1,-99,-99
10.1016/j.ajog.2022.01.021,6,No,NA,No,NA,Surgical procedure for endometriosis - Salpingectomy or tubal ligation,Percent,NA,None,5,N/A,Pacific Islander,2.5,-99,-99
10.1016/j.ajog.2022.01.021,6,No,NA,No,NA,Surgical procedure for endometriosis - Salpingectomy or tubal ligation,Percent,NA,None,6,N/A,Native American,2.6,-99,-99
10.1016/j.ajog.2022.01.021,6,No,NA,No,NA,Surgical procedure for endometriosis - Salpingectomy or tubal ligation,Percent,NA,None,7,N/A,Unknown,1.7,-99,-99
10.1016/j.ajog.2022.01.021,7,No,NA,No,NA,Surgical procedure for endometriosis - Myomectomy,Percent,NA,None,1,N/A,White,1.8,-99,-99
10.1016/j.ajog.2022.01.021,7,No,NA,No,NA,Surgical procedure for endometriosis - Myomectomy,Percent,NA,None,2,N/A,Hispanic,3.1,-99,-99
10.1016/j.ajog.2022.01.021,7,No,NA,No,NA,Surgical procedure for endometriosis - Myomectomy,Percent,NA,None,3,N/A,Black,5.2,-99,-99
10.1016/j.ajog.2022.01.021,7,No,NA,No,NA,Surgical procedure for endometriosis - Myomectomy,Percent,NA,None,4,N/A,Asian,5,-99,-99
10.1016/j.ajog.2022.01.021,7,No,NA,No,NA,Surgical procedure for endometriosis - Myomectomy,Percent,NA,None,5,N/A,Pacific Islander,0,-99,-99
10.1016/j.ajog.2022.01.021,7,No,NA,No,NA,Surgical procedure for endometriosis - Myomectomy,Percent,NA,None,6,N/A,Native American,0,-99,-99
10.1016/j.ajog.2022.01.021,7,No,NA,No,NA,Surgical procedure for endometriosis - Myomectomy,Percent,NA,None,7,N/A,Unknown,1.2,-99,-99
10.1016/j.ajog.2022.01.021,8,No,NA,No,NA,Surgical procedure for endometriosis - Hysterectomy,Percent,NA,None,1,N/A,White,59.5,-99,-99
10.1016/j.ajog.2022.01.021,8,No,NA,No,NA,Surgical procedure for endometriosis - Hysterectomy,Percent,NA,None,2,N/A,Hispanic,49.3,-99,-99
10.1016/j.ajog.2022.01.021,8,No,NA,No,NA,Surgical procedure for endometriosis - Hysterectomy,Percent,NA,None,3,N/A,Black,48.7,-99,-99
10.1016/j.ajog.2022.01.021,8,No,NA,No,NA,Surgical procedure for endometriosis - Hysterectomy,Percent,NA,None,4,N/A,Asian,32.9,-99,-99
10.1016/j.ajog.2022.01.021,8,No,NA,No,NA,Surgical procedure for endometriosis - Hysterectomy,Percent,NA,None,5,N/A,Pacific Islander,33.1,-99,-99
10.1016/j.ajog.2022.01.021,8,No,NA,No,NA,Surgical procedure for endometriosis - Hysterectomy,Percent,NA,None,6,N/A,Native American,75,-99,-99
10.1016/j.ajog.2022.01.021,8,No,NA,No,NA,Surgical procedure for endometriosis - Hysterectomy,Percent,NA,None,7,N/A,Unknown,47.5,-99,-99
10.1016/j.ajog.2022.01.021,9,No,NA,No,NA,Laparotomy,OR,NA,None,1,White,Hispanic,1.5,1.28,1.77
10.1016/j.ajog.2022.01.021,9,No,NA,No,NA,Laparotomy,OR,NA,None,2,White,Black,1.81,1.54,2.13
10.1016/j.ajog.2022.01.021,9,No,NA,No,NA,Laparotomy,OR,NA,None,3,White,Asian,1.18,0.97,1.43
10.1016/j.ajog.2022.01.021,9,No,NA,No,NA,Laparotomy,OR,NA,None,4,White,Pacific Islander,1.82,1.18,2.83
10.1016/j.ajog.2022.01.021,9,No,NA,No,NA,Laparotomy,OR,NA,None,5,White,Native American,1.87,1.13,3.1
10.1016/j.ajog.2022.01.021,9,No,NA,No,NA,Laparotomy,OR,NA,None,6,White,Unknown,1.85,1.62,2.12
10.1016/j.ajog.2022.01.021,10,Yes,Procedure for endometriosis - Hysterectomy,No,NA,Laparotomy,OR,NA,None,1,White,Hispanic,1.7,1.39,2.06
10.1016/j.ajog.2022.01.021,10,Yes,Procedure for endometriosis - Hysterectomy,No,NA,Laparotomy,OR,NA,None,2,White,Black,1.93,1.57,2.36
10.1016/j.ajog.2022.01.021,10,Yes,Procedure for endometriosis - Hysterectomy,No,NA,Laparotomy,OR,NA,None,3,White,Asian,2.03,1.56,2.65
10.1016/j.ajog.2022.01.021,10,Yes,Procedure for endometriosis - Hysterectomy,No,NA,Laparotomy,OR,NA,None,4,White,Pacific Islander,5.16,2.67,9.95
10.1016/j.ajog.2022.01.021,10,Yes,Procedure for endometriosis - Hysterectomy,No,NA,Laparotomy,OR,NA,None,5,White,Native American,1.33,0.76,2.34
10.1016/j.ajog.2022.01.021,10,Yes,Procedure for endometriosis - Hysterectomy,No,NA,Laparotomy,OR,NA,None,6,White,Unknown,2.15,1.82,2.55
10.1016/j.ajog.2022.01.021,11,Yes,Procedure for endometriosis - Nonhysterectomy procedures,No,NA,Laparotomy,OR,NA,None,1,White,Hispanic,1.79,1.28,2.51
10.1016/j.ajog.2022.01.021,11,Yes,Procedure for endometriosis - Nonhysterectomy procedures,No,NA,Laparotomy,OR,NA,None,2,White,Black,2.93,2.18,3.94
10.1016/j.ajog.2022.01.021,11,Yes,Procedure for endometriosis - Nonhysterectomy procedures,No,NA,Laparotomy,OR,NA,None,3,White,Asian,1.44,1.01,2.05
10.1016/j.ajog.2022.01.021,11,Yes,Procedure for endometriosis - Nonhysterectomy procedures,No,NA,Laparotomy,OR,NA,None,4,White,Pacific Islander,0.72,0.22,2.31
10.1016/j.ajog.2022.01.021,11,Yes,Procedure for endometriosis - Nonhysterectomy procedures,No,NA,Laparotomy,OR,NA,None,5,White,Native American,3.09,0.87,10.93
10.1016/j.ajog.2022.01.021,11,Yes,Procedure for endometriosis - Nonhysterectomy procedures,No,NA,Laparotomy,OR,NA,None,6,White,Unknown,2.23,1.7,2.93
10.1016/j.ajog.2022.01.021,12,No,NA,No,NA,Composite perioperative complication,OR,NA,None,1,White,Hispanic,1.31,1.06,1.62
10.1016/j.ajog.2022.01.021,12,No,NA,No,NA,Composite perioperative complication,OR,NA,None,2,White,Black,1.82,1.48,2.23
10.1016/j.ajog.2022.01.021,12,No,NA,No,NA,Composite perioperative complication,OR,NA,None,3,White,Asian,0.95,0.72,1.25
10.1016/j.ajog.2022.01.021,12,No,NA,No,NA,Composite perioperative complication,OR,NA,None,4,White,Pacific Islander,2.27,1.41,3.66
10.1016/j.ajog.2022.01.021,12,No,NA,No,NA,Composite perioperative complication,OR,NA,None,5,White,Native American,2.58,1.46,4.55
10.1016/j.ajog.2022.01.021,12,No,NA,No,NA,Composite perioperative complication,OR,NA,None,6,White,Unknown,1.09,0.9,1.33
10.1016/j.ajog.2022.01.021,13,Yes,Procedure for endometriosis - Hysterectomy,No,NA,Composite perioperative complication,OR,NA,None,1,White,Hispanic,1.61,1.24,2.09
10.1016/j.ajog.2022.01.021,13,Yes,Procedure for endometriosis - Hysterectomy,No,NA,Composite perioperative complication,OR,NA,None,2,White,Black,1.97,1.52,2.56
10.1016/j.ajog.2022.01.021,13,Yes,Procedure for endometriosis - Hysterectomy,No,NA,Composite perioperative complication,OR,NA,None,3,White,Asian,1.59,1.11,2.27
10.1016/j.ajog.2022.01.021,13,Yes,Procedure for endometriosis - Hysterectomy,No,NA,Composite perioperative complication,OR,NA,None,4,White,Pacific Islander,3.78,1.9,7.51
10.1016/j.ajog.2022.01.021,13,Yes,Procedure for endometriosis - Hysterectomy,No,NA,Composite perioperative complication,OR,NA,None,5,White,Native American,2.51,1.34,4.7
10.1016/j.ajog.2022.01.021,13,Yes,Procedure for endometriosis - Hysterectomy,No,NA,Composite perioperative complication,OR,NA,None,6,White,Unknown,1.31,1.02,1.67
10.1016/j.ajog.2022.01.021,14,Yes,Procedure for endometriosis - Nonhysterectomy procedures,No,NA,Composite perioperative complication,OR,NA,None,1,White,Hispanic,1.06,0.72,1.56
10.1016/j.ajog.2022.01.021,14,Yes,Procedure for endometriosis - Nonhysterectomy procedures,No,NA,Composite perioperative complication,OR,NA,None,2,White,Black,1.91,1.37,2.65
10.1016/j.ajog.2022.01.021,14,Yes,Procedure for endometriosis - Nonhysterectomy procedures,No,NA,Composite perioperative complication,OR,NA,None,3,White,Asian,0.76,0.49,1.18
10.1016/j.ajog.2022.01.021,14,Yes,Procedure for endometriosis - Nonhysterectomy procedures,No,NA,Composite perioperative complication,OR,NA,None,4,White,Pacific Islander,1.99,0.98,4.04
10.1016/j.ajog.2022.01.021,14,Yes,Procedure for endometriosis - Nonhysterectomy procedures,No,NA,Composite perioperative complication,OR,NA,None,5,White,Native American,1.82,0.42,7.94
10.1016/j.ajog.2022.01.021,14,Yes,Procedure for endometriosis - Nonhysterectomy procedures,No,NA,Composite perioperative complication,OR,NA,None,6,White,Unknown,0.98,0.7,1.38
10.1016/j.ajog.2022.01.021,15,No,NA,No,NA,Composite perioperative complication,OR,NA,"Age, Body mass index, ASA classification 3 or 4, Tobacco use, Diabetes mellitus, hypertension requiring medication, Chronic obstructive pulmonary disease, Emergency surgical case",1,White,Hispanic,1.32,1.06,1.64
10.1016/j.ajog.2022.01.021,15,No,NA,No,NA,Composite perioperative complication,OR,NA,"Age, Body mass index, ASA classification 3 or 4, Tobacco use, Diabetes mellitus, hypertension requiring medication, Chronic obstructive pulmonary disease, Emergency surgical case",2,White,Black,1.71,1.39,2.1
10.1016/j.ajog.2022.01.021,15,No,NA,No,NA,Composite perioperative complication,OR,NA,"Age, Body mass index, ASA classification 3 or 4, Tobacco use, Diabetes mellitus, hypertension requiring medication, Chronic obstructive pulmonary disease, Emergency surgical case",3,White,Asian,0.97,0.74,1.28
10.1016/j.ajog.2022.01.021,15,No,NA,No,NA,Composite perioperative complication,OR,NA,"Age, Body mass index, ASA classification 3 or 4, Tobacco use, Diabetes mellitus, hypertension requiring medication, Chronic obstructive pulmonary disease, Emergency surgical case",4,White,Pacific Islander,2.08,1.28,3.37
10.1016/j.ajog.2022.01.021,15,No,NA,No,NA,Composite perioperative complication,OR,NA,"Age, Body mass index, ASA classification 3 or 4, Tobacco use, Diabetes mellitus, hypertension requiring medication, Chronic obstructive pulmonary disease, Emergency surgical case",5,White,Native American,2.34,1.32,4.17
10.1016/j.ajog.2022.01.021,15,No,NA,No,NA,Composite perioperative complication,OR,NA,"Age, Body mass index, ASA classification 3 or 4, Tobacco use, Diabetes mellitus, hypertension requiring medication, Chronic obstructive pulmonary disease, Emergency surgical case",6,White,Unknown,1.11,0.91,1.35
10.1016/j.ajog.2022.01.021,16,Yes,Procedure for endometriosis - Hysterectomy,No,NA,Laparotomy,OR,NA,"Age, Body mass index, ASA classification 3 or 4, Tobacco use, Diabetes mellitus, hypertension requiring medication, Chronic obstructive pulmonary disease, Emergency surgical case",1,White,Hispanic,1.68,1.38,2.06
10.1016/j.ajog.2022.01.021,16,Yes,Procedure for endometriosis - Hysterectomy,No,NA,Laparotomy,OR,NA,"Age, Body mass index, ASA classification 3 or 4, Tobacco use, Diabetes mellitus, hypertension requiring medication, Chronic obstructive pulmonary disease, Emergency surgical case",2,White,Black,1.77,1.43,2.18
10.1016/j.ajog.2022.01.021,16,Yes,Procedure for endometriosis - Hysterectomy,No,NA,Laparotomy,OR,NA,"Age, Body mass index, ASA classification 3 or 4, Tobacco use, Diabetes mellitus, hypertension requiring medication, Chronic obstructive pulmonary disease, Emergency surgical case",3,White,Asian,1.87,1.43,2.46
10.1016/j.ajog.2022.01.021,16,Yes,Procedure for endometriosis - Hysterectomy,No,NA,Laparotomy,OR,NA,"Age, Body mass index, ASA classification 3 or 4, Tobacco use, Diabetes mellitus, hypertension requiring medication, Chronic obstructive pulmonary disease, Emergency surgical case",4,White,Pacific Islander,4.16,2.14,8.1
10.1016/j.ajog.2022.01.021,16,Yes,Procedure for endometriosis - Hysterectomy,No,NA,Laparotomy,OR,NA,"Age, Body mass index, ASA classification 3 or 4, Tobacco use, Diabetes mellitus, hypertension requiring medication, Chronic obstructive pulmonary disease, Emergency surgical case",5,White,Native American,1.21,0.69,2.15
10.1016/j.ajog.2022.01.021,16,Yes,Procedure for endometriosis - Hysterectomy,No,NA,Laparotomy,OR,NA,"Age, Body mass index, ASA classification 3 or 4, Tobacco use, Diabetes mellitus, hypertension requiring medication, Chronic obstructive pulmonary disease, Emergency surgical case",6,White,Unknown,2.07,1.75,2.47
10.1016/j.ajog.2022.01.021,17,Yes,Procedure for endometriosis - Nonhysterectomy procedures,No,NA,Laparotomy,OR,NA,"Age, Body mass index, ASA classification 3 or 4, Tobacco use, Diabetes mellitus, hypertension requiring medication, Chronic obstructive pulmonary disease, Emergency surgical case",1,White,Hispanic,1.64,1.16,2.3
10.1016/j.ajog.2022.01.021,17,Yes,Procedure for endometriosis - Nonhysterectomy procedures,No,NA,Laparotomy,OR,NA,"Age, Body mass index, ASA classification 3 or 4, Tobacco use, Diabetes mellitus, hypertension requiring medication, Chronic obstructive pulmonary disease, Emergency surgical case",2,White,Black,2.64,1.95,3.58
10.1016/j.ajog.2022.01.021,17,Yes,Procedure for endometriosis - Nonhysterectomy procedures,No,NA,Laparotomy,OR,NA,"Age, Body mass index, ASA classification 3 or 4, Tobacco use, Diabetes mellitus, hypertension requiring medication, Chronic obstructive pulmonary disease, Emergency surgical case",3,White,Asian,1.42,0.99,2.05
10.1016/j.ajog.2022.01.021,17,Yes,Procedure for endometriosis - Nonhysterectomy procedures,No,NA,Laparotomy,OR,NA,"Age, Body mass index, ASA classification 3 or 4, Tobacco use, Diabetes mellitus, hypertension requiring medication, Chronic obstructive pulmonary disease, Emergency surgical case",4,White,Pacific Islander,0.59,0.18,1.92
10.1016/j.ajog.2022.01.021,17,Yes,Procedure for endometriosis - Nonhysterectomy procedures,No,NA,Laparotomy,OR,NA,"Age, Body mass index, ASA classification 3 or 4, Tobacco use, Diabetes mellitus, hypertension requiring medication, Chronic obstructive pulmonary disease, Emergency surgical case",5,White,Native American,3.02,0.83,11.05
10.1016/j.ajog.2022.01.021,17,Yes,Procedure for endometriosis - Nonhysterectomy procedures,No,NA,Laparotomy,OR,NA,"Age, Body mass index, ASA classification 3 or 4, Tobacco use, Diabetes mellitus, hypertension requiring medication, Chronic obstructive pulmonary disease, Emergency surgical case",6,White,Unknown,2.21,1.68,2.92
10.1016/j.ajog.2022.01.021,18,No,NA,No,NA,Oophorectomy performed during endometriosis surgery,OR,NA,"Age, Body mass index, ASA classification 3 or 4, Tobacco use, Diabetes mellitus, hypertension requiring medication, Chronic obstructive pulmonary disease, Emergency surgical case",1,White,Hispanic,2.57,1.96,3.37
10.1016/j.ajog.2022.01.021,18,No,NA,No,NA,Oophorectomy performed during endometriosis surgery,OR,NA,"Age, Body mass index, ASA classification 3 or 4, Tobacco use, Diabetes mellitus, hypertension requiring medication, Chronic obstructive pulmonary disease, Emergency surgical case",2,White,Black,2.06,1.51,2.8
10.1016/j.ajog.2022.01.021,18,No,NA,No,NA,Oophorectomy performed during endometriosis surgery,OR,NA,"Age, Body mass index, ASA classification 3 or 4, Tobacco use, Diabetes mellitus, hypertension requiring medication, Chronic obstructive pulmonary disease, Emergency surgical case",3,White,Asian,1.25,0.84,1.86
10.1016/j.ajog.2022.01.021,18,No,NA,No,NA,Oophorectomy performed during endometriosis surgery,OR,NA,"Age, Body mass index, ASA classification 3 or 4, Tobacco use, Diabetes mellitus, hypertension requiring medication, Chronic obstructive pulmonary disease, Emergency surgical case",4,White,Pacific Islander,1.53,0.66,3.53
10.1016/j.ajog.2022.01.021,18,No,NA,No,NA,Oophorectomy performed during endometriosis surgery,OR,NA,"Age, Body mass index, ASA classification 3 or 4, Tobacco use, Diabetes mellitus, hypertension requiring medication, Chronic obstructive pulmonary disease, Emergency surgical case",5,White,Native American,1.65,0.59,4.58
10.1016/j.ajog.2022.01.021,18,No,NA,No,NA,Oophorectomy performed during endometriosis surgery,OR,NA,"Age, Body mass index, ASA classification 3 or 4, Tobacco use, Diabetes mellitus, hypertension requiring medication, Chronic obstructive pulmonary disease, Emergency surgical case",6,White,Unknown,2.39,1.87,3.04
10.1016/j.ajog.2022.01.022,1,No,NA,No,NA,Minimally Invasive Myomectomy for Uterine Leiomyomas,Annual relative increase in percentage between 2009 and 2017,NA,None,1,N/A,Black,1.16,1.08,1.26
10.1016/j.ajog.2022.01.022,1,No,NA,No,NA,Minimally Invasive Myomectomy for Uterine Leiomyomas,Annual relative increase in percentage between 2009 and 2017,NA,None,2,N/A,Non-Black,1.14,1.09,1.19
10.1016/j.ajog.2022.01.022,2,Yes,Fibroid weight of <=500 g,No,NA,Minimally Invasive Myomectomy for Uterine Leiomyomas,Annual relative increase in percentage between 2009 and 2017,NA,None,1,N/A,Black,1.15,1.07,1.23
10.1016/j.ajog.2022.01.022,2,Yes,Fibroid weight of <=500 g,No,NA,Minimally Invasive Myomectomy for Uterine Leiomyomas,Annual relative increase in percentage between 2009 and 2017,NA,None,2,N/A,Non-Black,1.13,1.08,1.17
10.1016/j.ajog.2022.01.022,3,Yes,Fibroid weight of >500 g,No,NA,Minimally Invasive Myomectomy for Uterine Leiomyomas,Annual relative increase in percentage between 2009 and 2017,NA,None,1,N/A,Black,1.2,1.1,1.32
10.1016/j.ajog.2022.01.022,3,Yes,Fibroid weight of >500 g,No,NA,Minimally Invasive Myomectomy for Uterine Leiomyomas,Annual relative increase in percentage between 2009 and 2017,NA,None,2,N/A,Non-Black,1.19,1.13,1.26
10.1016/j.ajog.2022.01.022,4,No,NA,No,NA,Minimally Invasive Myomectomy for Uterine Leiomyomas,RR,primary exposure,None,1,Non-Black,Black,0.65,0.56,0.75
10.1016/j.ajog.2022.01.022,5,No,NA,No,NA,Minimally Invasive Myomectomy for Uterine Leiomyomas,RR,race x fibroid weight interaction,"fibroid weight, age group, lowincome residence, patient clinical characteristics, parity, body mass index, charlson comorbidity index score, previous pelvic surgery, surgeon volume, year of myomectomy",1,nonBlack x fibroid weight of <= 500 g,Non-Black x Fibroid Weight of > 500 g,0.45,0.35,0.58
10.1016/j.ajog.2022.01.022,5,No,NA,No,NA,Minimally Invasive Myomectomy for Uterine Leiomyomas,RR,race x fibroid weight interaction,"fibroid weight, age group, lowincome residence, patient clinical characteristics, parity, body mass index, charlson comorbidity index score, previous pelvic surgery, surgeon volume, year of myomectomy",2,nonBlack x fibroid weight of <= 500 g,Black x Fibroid Weight of <= 500 g,0.74,0.58,0.95
10.1016/j.ajog.2022.01.022,5,No,NA,No,NA,Minimally Invasive Myomectomy for Uterine Leiomyomas,RR,race x fibroid weight interaction,"fibroid weight, age group, lowincome residence, patient clinical characteristics, parity, body mass index, charlson comorbidity index score, previous pelvic surgery, surgeon volume, year of myomectomy",3,nonBlack x fibroid weight of <= 500 g,Black x Fibroid Weight of > 500 g,0.26,0.18,0.36
10.1016/j.ajog.2022.03.004,1,No,NA,No,NA,Refusal of adjuvant radiation,OR,NA,"race (White, Black), age ( 50, 50e69, 70), Charlson Comorbidity score (0, 1, 2), insurance (none, private, Medicaid, Medicare, other government, unknown), income (<$48,000, $48,000), education ( 21%, 13%e20.9%, 7%e12.9%, <7%), facility type (community cancer program, comprehensive community cancer program, academic/research program, integrated network cancer program), facility location (Northeast, South, Midwest, Mountain, Pacific Coast), histology (low-grade endometrioid, high-grade endometrioid, serous, carcinosarcoma, mixed epithelial, clear-cell), stage (I, II, III, IV), chemotherapy (no, yes, unknown)",1,White,Black,1,0.91,1.11
10.1016/j.ajog.2022.03.004,2,No,NA,No,NA,Refusal of chemotherapy,OR,NA,"race (White, Black), age ( 50, 50e69, 70), Charlson Comorbidity score (0, 1, 2), insurance (none, private, Medicaid, Medicare, other government, unknown), income (<$48,000, $48,000), education ( 21%, 13%e20.9%, 7%e12.9%, <7%), facility type (community cancer program, comprehensive community cancer program, academic/research program, integrated network cancer program), facility location (Northeast, South, Midwest, Mountain, Pacific Coast), histology (low-grade endometrioid, high-grade endometrioid, serous, carcinosarcoma, mixed epithelial, clear-cell), stage (I, II, III, IV), radiation (no, yes, unknown)",1,White,Black,1.26,1.15,1.37
10.1016/j.ajog.2022.03.018,1,No,NA,No,NA,preterm birth,OR,NA,"recieved intensive care management, prenatal visits, and number of risk factors",1,White,Black,1.54,1.3,1.83
10.1016/j.ajog.2022.03.018,2,No,NA,No,NA,low birthweight,OR,NA,"recieved intensive care management, prenatal visits, and number of risk factors",1,White,Black,1.65,1.39,1.97
10.1016/j.ajog.2022.03.018,3,No,NA,No,NA,preterm birth,OR,NA,"implementation of Maternal-Infant Impactibility score, prenatal visits, and number of risk factors",1,White,Black,1.53,1.29,1.82
10.1016/j.ajog.2022.03.018,4,No,NA,No,NA,low birthweight,OR,NA,"implementation of Maternal-Infant Impactibility score, prenatal visits, and number of risk factors",1,White,Black,1.64,1.38,1.96
10.1016/j.ajog.2022.03.047,1,No,NA,No,NA,Willingness to share maternal genetic data with academic researchers for non-clinical purposes,mean,NA,none,1,N/A,White,2.88,-99,-99
10.1016/j.ajog.2022.03.047,1,No,NA,No,NA,Willingness to share maternal genetic data with academic researchers for non-clinical purposes,mean,NA,none,2,N/A,Other,2.15,-99,-99
10.1016/j.ajog.2022.03.047,2,No,NA,No,NA,Willingness to share maternal genetic data with a government-funded medical research database for non-clinical purposes,mean,NA,none,1,N/A,White,2.16,-99,-99
10.1016/j.ajog.2022.03.047,2,No,NA,No,NA,Willingness to share maternal genetic data with a government-funded medical research database for non-clinical purposes,mean,NA,none,2,N/A,Other,1.83,-99,-99
10.1016/j.ajog.2022.03.047,3,No,NA,No,NA,Willingness to share maternal genetic data with other companies for non-clinical purposes,mean,NA,none,1,N/A,White,1.93,-99,-99
10.1016/j.ajog.2022.03.047,3,No,NA,No,NA,Willingness to share maternal genetic data with other companies for non-clinical purposes,mean,NA,none,2,N/A,Other,1.63,-99,-99
10.1016/j.ajog.2022.04.036,1,Yes,All Years (2011-2019),No,NA,Opportunistic Salpingectomy by Adoption: Hysterectomy Procedures,RR,NA,"Age at surgery, year of surgery, marital status, insurance type, comorbidities, hysterectomy route, indications for hysterectomy, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients,  and provider specialty; b Adjusted for age at surgery, year of surgery, marital status, insurance type, comorbidities, type of sterilization, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients, and provider specialty.",1,Non-Hispanic White,Non-Hispanic Black,0.94,0.92,0.97
10.1016/j.ajog.2022.04.036,1,Yes,All Years (2011-2019),No,NA,Opportunistic Salpingectomy by Adoption: Hysterectomy Procedures,RR,NA,"Age at surgery, year of surgery, marital status, insurance type, comorbidities, hysterectomy route, indications for hysterectomy, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients,  and provider specialty; b Adjusted for age at surgery, year of surgery, marital status, insurance type, comorbidities, type of sterilization, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients, and provider specialty.",2,Non-Hispanic White,Hispanic,0.98,0.95,1
10.1016/j.ajog.2022.04.036,1,Yes,All Years (2011-2019),No,NA,Opportunistic Salpingectomy by Adoption: Hysterectomy Procedures,RR,NA,"Age at surgery, year of surgery, marital status, insurance type, comorbidities, hysterectomy route, indications for hysterectomy, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients,  and provider specialty; b Adjusted for age at surgery, year of surgery, marital status, insurance type, comorbidities, type of sterilization, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients, and provider specialty.",3,Non-Hispanic White,Non-Hispanic other race,0.93,0.9,0.96
10.1016/j.ajog.2022.04.036,2,Yes,Before Guideline (2011 - 2013),No,NA,Opportunistic Salpingectomy by Adoption: Hysterectomy Procedures,RR,NA,"Age at surgery, year of surgery, marital status, insurance type, comorbidities, hysterectomy route, indications for hysterectomy, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients,  and provider specialty; b Adjusted for age at surgery, year of surgery, marital status, insurance type, comorbidities, type of sterilization, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients, and provider specialty.",1,Non-Hispanic White,Non-Hispanic Black,0.8,0.73,0.88
10.1016/j.ajog.2022.04.036,2,Yes,Before Guideline (2011 - 2013),No,NA,Opportunistic Salpingectomy by Adoption: Hysterectomy Procedures,RR,NA,"Age at surgery, year of surgery, marital status, insurance type, comorbidities, hysterectomy route, indications for hysterectomy, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients,  and provider specialty; b Adjusted for age at surgery, year of surgery, marital status, insurance type, comorbidities, type of sterilization, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients, and provider specialty.",2,Non-Hispanic White,Hispanic,0.99,0.89,1.11
10.1016/j.ajog.2022.04.036,2,Yes,Before Guideline (2011 - 2013),No,NA,Opportunistic Salpingectomy by Adoption: Hysterectomy Procedures,RR,NA,"Age at surgery, year of surgery, marital status, insurance type, comorbidities, hysterectomy route, indications for hysterectomy, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients,  and provider specialty; b Adjusted for age at surgery, year of surgery, marital status, insurance type, comorbidities, type of sterilization, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients, and provider specialty.",3,Non-Hispanic White,Non-Hispanic other race,0.92,0.81,1.05
10.1016/j.ajog.2022.04.036,3,Yes,After Guideline (2014-2018),No,NA,Opportunistic Salpingectomy by Adoption: Hysterectomy Procedures,RR,NA,"Age at surgery, year of surgery, marital status, insurance type, comorbidities, hysterectomy route, indications for hysterectomy, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients,  and provider specialty; b Adjusted for age at surgery, year of surgery, marital status, insurance type, comorbidities, type of sterilization, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients, and provider specialty.",1,Non-Hispanic White,Non-Hispanic Black,0.98,0.95,1.01
10.1016/j.ajog.2022.04.036,3,Yes,After Guideline (2014-2018),No,NA,Opportunistic Salpingectomy by Adoption: Hysterectomy Procedures,RR,NA,"Age at surgery, year of surgery, marital status, insurance type, comorbidities, hysterectomy route, indications for hysterectomy, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients,  and provider specialty; b Adjusted for age at surgery, year of surgery, marital status, insurance type, comorbidities, type of sterilization, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients, and provider specialty.",2,Non-Hispanic White,Hispanic,0.97,0.94,1.01
10.1016/j.ajog.2022.04.036,3,Yes,After Guideline (2014-2018),No,NA,Opportunistic Salpingectomy by Adoption: Hysterectomy Procedures,RR,NA,"Age at surgery, year of surgery, marital status, insurance type, comorbidities, hysterectomy route, indications for hysterectomy, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients,  and provider specialty; b Adjusted for age at surgery, year of surgery, marital status, insurance type, comorbidities, type of sterilization, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients, and provider specialty.",3,Non-Hispanic White,Non-Hispanic other race,0.93,0.89,0.97
10.1016/j.ajog.2022.04.036,4,Yes,All Years (2011-2019),No,NA,Opportunistic Salpingectomy by Adoption: Sterilization Procedures,RR,NA,"Age at surgery, year of surgery, marital status, insurance type, comorbidities, hysterectomy route, indications for hysterectomy, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients,  and provider specialty; b Adjusted for age at surgery, year of surgery, marital status, insurance type, comorbidities, type of sterilization, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients, and provider specialty.",1,Non-Hispanic White,Non-Hispanic Black,0.91,0.88,0.95
10.1016/j.ajog.2022.04.036,4,Yes,All Years (2011-2019),No,NA,Opportunistic Salpingectomy by Adoption: Sterilization Procedures,RR,NA,"Age at surgery, year of surgery, marital status, insurance type, comorbidities, hysterectomy route, indications for hysterectomy, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients,  and provider specialty; b Adjusted for age at surgery, year of surgery, marital status, insurance type, comorbidities, type of sterilization, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients, and provider specialty.",2,Non-Hispanic White,Hispanic,1,0.94,1.06
10.1016/j.ajog.2022.04.036,4,Yes,All Years (2011-2019),No,NA,Opportunistic Salpingectomy by Adoption: Sterilization Procedures,RR,NA,"Age at surgery, year of surgery, marital status, insurance type, comorbidities, hysterectomy route, indications for hysterectomy, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients,  and provider specialty; b Adjusted for age at surgery, year of surgery, marital status, insurance type, comorbidities, type of sterilization, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients, and provider specialty.",3,Non-Hispanic White,Non-Hispanic other race,0.99,0.85,1.15
10.1016/j.ajog.2022.04.036,5,Yes,Before Guideline (2011 - 2013),No,NA,Opportunistic Salpingectomy by Adoption: Sterilization Procedures,RR,NA,"Age at surgery, year of surgery, marital status, insurance type, comorbidities, hysterectomy route, indications for hysterectomy, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients,  and provider specialty; b Adjusted for age at surgery, year of surgery, marital status, insurance type, comorbidities, type of sterilization, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients, and provider specialty.",1,Non-Hispanic White,Non-Hispanic Black,0.92,0.68,1.25
10.1016/j.ajog.2022.04.036,5,Yes,Before Guideline (2011 - 2013),No,NA,Opportunistic Salpingectomy by Adoption: Sterilization Procedures,RR,NA,"Age at surgery, year of surgery, marital status, insurance type, comorbidities, hysterectomy route, indications for hysterectomy, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients,  and provider specialty; b Adjusted for age at surgery, year of surgery, marital status, insurance type, comorbidities, type of sterilization, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients, and provider specialty.",2,Non-Hispanic White,Hispanic,1,0.73,1.38
10.1016/j.ajog.2022.04.036,5,Yes,Before Guideline (2011 - 2013),No,NA,Opportunistic Salpingectomy by Adoption: Sterilization Procedures,RR,NA,"Age at surgery, year of surgery, marital status, insurance type, comorbidities, hysterectomy route, indications for hysterectomy, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients,  and provider specialty; b Adjusted for age at surgery, year of surgery, marital status, insurance type, comorbidities, type of sterilization, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients, and provider specialty.",3,Non-Hispanic White,Non-Hispanic other race,0.87,0.57,1.31
10.1016/j.ajog.2022.04.036,6,Yes,After Guideline (2014-2018),No,NA,Opportunistic Salpingectomy by Adoption: Sterilization Procedures,RR,NA,"Age at surgery, year of surgery, marital status, insurance type, comorbidities, hysterectomy route, indications for hysterectomy, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients,  and provider specialty; b Adjusted for age at surgery, year of surgery, marital status, insurance type, comorbidities, type of sterilization, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients, and provider specialty.",1,Non-Hispanic White,Non-Hispanic Black,0.91,0.87,0.95
10.1016/j.ajog.2022.04.036,6,Yes,After Guideline (2014-2018),No,NA,Opportunistic Salpingectomy by Adoption: Sterilization Procedures,RR,NA,"Age at surgery, year of surgery, marital status, insurance type, comorbidities, hysterectomy route, indications for hysterectomy, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients,  and provider specialty; b Adjusted for age at surgery, year of surgery, marital status, insurance type, comorbidities, type of sterilization, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients, and provider specialty.",2,Non-Hispanic White,Hispanic,1,0.94,1.07
10.1016/j.ajog.2022.04.036,6,Yes,After Guideline (2014-2018),No,NA,Opportunistic Salpingectomy by Adoption: Sterilization Procedures,RR,NA,"Age at surgery, year of surgery, marital status, insurance type, comorbidities, hysterectomy route, indications for hysterectomy, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients,  and provider specialty; b Adjusted for age at surgery, year of surgery, marital status, insurance type, comorbidities, type of sterilization, location, region, teaching status, bed size, place of service, hospital volume, proportion of Medicaid and uninsured patients, and provider specialty.",3,Non-Hispanic White,Non-Hispanic other race,1,0.85,1.18
10.1016/j.ajog.2022.04.045,1,Yes,Nonexpansion states Black Race,No,NA,2 year survival combined cancer sites,HR,NA,none,1,pre 2014,post 2014,0.89,0.83,0.97
10.1016/j.ajog.2022.04.045,2,Yes,Nonexpansion states White Race,No,NA,2 year survival combined cancer sites,HR,NA,none,1,pre 2014,post 2014,0.97,0.93,1.01
10.1016/j.ajog.2022.04.045,3,Yes,Nonexpansion states Hispanic Ethnicity,No,NA,2 year survival combined cancer sites,HR,NA,none,1,pre 2014,post 2014,0.8,0.7,0.92
10.1016/j.ajog.2022.04.045,4,Yes,Nonexpansion states Non-Hispanic Ethnicity,No,NA,2 year survival combined cancer sites,HR,NA,none,1,pre 2014,post 2014,0.98,0.94,1.02
10.1016/j.ajog.2022.04.045,5,Yes,January 2014 expansion states Black Race,No,NA,2 year survival combined cancer sites,HR,NA,none,1,pre 2014,post 2014,0.94,0.84,1.05
10.1016/j.ajog.2022.04.045,6,Yes,January 2014 expansion states White Race,No,NA,2 year survival combined cancer sites,HR,NA,none,1,pre 2014,post 2014,0.94,0.9,0.99
10.1016/j.ajog.2022.04.045,7,Yes,January 2014 expansion states Hispanic Ethnicity,No,NA,2 year survival combined cancer sites,HR,NA,none,1,pre 2014,post 2014,0.85,0.7,1.03
10.1016/j.ajog.2022.04.045,8,Yes,January 2014 expansion states Non-Hispanic Ethnicity,No,NA,2 year survival combined cancer sites,HR,NA,none,1,pre 2014,post 2014,0.94,0.9,0.98
10.1016/j.ajog.2022.04.045,9,Yes,Nonexpansion states Black Race,No,NA,2 year survival endometrial cancer,HR,NA,none,1,pre 2014,post 2014,0.9,0.78,1.03
10.1016/j.ajog.2022.04.045,10,Yes,Nonexpansion states White Race,No,NA,2 year survival endometrial cancer,HR,NA,none,1,pre 2014,post 2014,1.05,0.97,1.13
10.1016/j.ajog.2022.04.045,11,Yes,Nonexpansion states Hispanic Ethnicity,No,NA,2 year survival endometrial cancer,HR,NA,none,1,pre 2014,post 2014,0.88,0.67,1.15
10.1016/j.ajog.2022.04.045,12,Yes,Nonexpansion states Non-Hispanic Ethnicity,No,NA,2 year survival endometrial cancer,HR,NA,none,1,pre 2014,post 2014,1.06,0.98,1.13
10.1016/j.ajog.2022.04.045,13,Yes,January 2014 expansion states Black Race,No,NA,2 year survival endometrial cancer,HR,NA,none,1,pre 2014,post 2014,0.91,0.76,1.09
10.1016/j.ajog.2022.04.045,14,Yes,January 2014 expansion states White Race,No,NA,2 year survival endometrial cancer,HR,NA,none,1,pre 2014,post 2014,1.03,0.94,1.13
10.1016/j.ajog.2022.04.045,15,Yes,January 2014 expansion states Hispanic Ethnicity,No,NA,2 year survival endometrial cancer,HR,NA,none,1,pre 2014,post 2014,1.28,0.9,1.8
10.1016/j.ajog.2022.04.045,16,Yes,January 2014 expansion states Non-Hispanic Ethnicity,No,NA,2 year survival endometrial cancer,HR,NA,none,1,pre 2014,post 2014,1.01,0.93,1.09
10.1016/j.ajog.2022.04.045,17,Yes,Nonexpansion states Black Race,No,NA,2 year survival ovarian cancer,HR,NA,none,1,pre 2014,post 2014,0.93,0.81,1.07
10.1016/j.ajog.2022.04.045,18,Yes,Nonexpansion states White Race,No,NA,2 year survival ovarian cancer,HR,NA,none,1,pre 2014,post 2014,0.98,0.91,1.04
10.1016/j.ajog.2022.04.045,19,Yes,Nonexpansion states Hispanic Ethnicity,No,NA,2 year survival ovarian cancer,HR,NA,none,1,pre 2014,post 2014,0.82,0.65,1.03
10.1016/j.ajog.2022.04.045,20,Yes,Nonexpansion states Non-Hispanic Ethnicity,No,NA,2 year survival ovarian cancer,HR,NA,none,1,pre 2014,post 2014,0.98,0.92,1.04
10.1016/j.ajog.2022.04.045,21,Yes,January 2014 expansion states Black Race,No,NA,2 year survival ovarian cancer,HR,NA,none,1,pre 2014,post 2014,0.87,0.71,1.08
10.1016/j.ajog.2022.04.045,22,Yes,January 2014 expansion states White Race,No,NA,2 year survival ovarian cancer,HR,NA,none,1,pre 2014,post 2014,0.9,0.83,0.96
10.1016/j.ajog.2022.04.045,23,Yes,January 2014 expansion states Hispanic Ethnicity,No,NA,2 year survival ovarian cancer,HR,NA,none,1,pre 2014,post 2014,0.77,0.55,1.08
10.1016/j.ajog.2022.04.045,24,Yes,January 2014 expansion states Non-Hispanic Ethnicity,No,NA,2 year survival ovarian cancer,HR,NA,none,1,pre 2014,post 2014,0.9,0.83,0.95
10.1016/j.ajog.2022.04.045,25,Yes,Nonexpansion states Black Race,No,NA,2 year survival cervical cancer,HR,NA,none,1,pre 2014,post 2014,0.95,0.82,1.09
10.1016/j.ajog.2022.04.045,26,Yes,Nonexpansion states White Race,No,NA,2 year survival cervical cancer,HR,NA,none,1,pre 2014,post 2014,0.91,0.84,1.09
10.1016/j.ajog.2022.04.045,27,Yes,Nonexpansion states Hispanic Ethnicity,No,NA,2 year survival cervical cancer,HR,NA,none,1,pre 2014,post 2014,0.73,0.58,0.92
10.1016/j.ajog.2022.04.045,28,Yes,Nonexpansion states Non-Hispanic Ethnicity,No,NA,2 year survival cervical cancer,HR,NA,none,1,pre 2014,post 2014,0.94,0.87,1.01
10.1016/j.ajog.2022.04.045,29,Yes,January 2014 expansion states Black Race,No,NA,2 year survival cervical cancer,HR,NA,none,1,pre 2014,post 2014,1.11,0.9,1.37
10.1016/j.ajog.2022.04.045,30,Yes,January 2014 expansion states White Race,No,NA,2 year survival cervical cancer,HR,NA,none,1,pre 2014,post 2014,0.9,0.81,0.98
10.1016/j.ajog.2022.04.045,31,Yes,January 2014 expansion states Hispanic Ethnicity,No,NA,2 year survival cervical cancer,HR,NA,none,1,pre 2014,post 2014,0.7,0.49,1.01
10.1016/j.ajog.2022.04.045,32,Yes,January 2014 expansion states Non-Hispanic Ethnicity,No,NA,2 year survival cervical cancer,HR,NA,none,1,pre 2014,post 2014,0.91,0.83,1
10.1016/j.ajog.2022.04.045,33,Yes,Nonexpansion states Black Race,No,NA,2 year survival vulvar cancer,HR,NA,none,1,pre 2014,post 2014,0.89,0.53,1.48
10.1016/j.ajog.2022.04.045,34,Yes,Nonexpansion states White Race,No,NA,2 year survival vulvar cancer,HR,NA,none,1,pre 2014,post 2014,1.18,0.98,1.42
10.1016/j.ajog.2022.04.045,35,Yes,Nonexpansion states Hispanic Ethnicity,No,NA,2 year survival vulvar cancer,HR,NA,none,1,pre 2014,post 2014,1.19,0.47,3.01
10.1016/j.ajog.2022.04.045,36,Yes,Nonexpansion states Non-Hispanic Ethnicity,No,NA,2 year survival vulvar cancer,HR,NA,none,1,pre 2014,post 2014,1.12,0.94,1.34
10.1016/j.ajog.2022.04.045,37,Yes,January 2014 expansion states Black Race,No,NA,2 year survival vulvar cancer,HR,NA,none,1,pre 2014,post 2014,0.96,0.5,1.87
10.1016/j.ajog.2022.04.045,38,Yes,January 2014 expansion states White Race,No,NA,2 year survival vulvar cancer,HR,NA,none,1,pre 2014,post 2014,1.19,0.96,1.49
10.1016/j.ajog.2022.04.045,39,Yes,January 2014 expansion states Hispanic Ethnicity,No,NA,2 year survival vulvar cancer,HR,NA,none,1,pre 2014,post 2014,0.74,0.13,4.03
10.1016/j.ajog.2022.04.045,40,Yes,January 2014 expansion states Non-Hispanic Ethnicity,No,NA,2 year survival vulvar cancer,HR,NA,none,1,pre 2014,post 2014,1.17,0.94,1.44
10.1016/j.ajog.2022.04.045,41,Yes,Nonexpansion states Black Race,No,NA,2 year survival vaginal cancer,HR,NA,none,1,pre 2014,post 2014,0.87,0.52,1.45
10.1016/j.ajog.2022.04.045,42,Yes,Nonexpansion states White Race,No,NA,2 year survival vaginal cancer,HR,NA,none,1,pre 2014,post 2014,0.88,0.65,1.2
10.1016/j.ajog.2022.04.045,43,Yes,Nonexpansion states Hispanic Ethnicity,No,NA,2 year survival vaginal cancer,HR,NA,none,1,pre 2014,post 2014,2.51,0.65,9.73
10.1016/j.ajog.2022.04.045,44,Yes,Nonexpansion states Non-Hispanic Ethnicity,No,NA,2 year survival vaginal cancer,HR,NA,none,1,pre 2014,post 2014,0.86,0.66,1.12
10.1016/j.ajog.2022.04.045,45,Yes,January 2014 expansion states Black Race,No,NA,2 year survival vaginal cancer,HR,NA,none,1,pre 2014,post 2014,1.66,0.77,3.58
10.1016/j.ajog.2022.04.045,46,Yes,January 2014 expansion states White Race,No,NA,2 year survival vaginal cancer,HR,NA,none,1,pre 2014,post 2014,1.03,0.72,1.46
10.1016/j.ajog.2022.04.045,47,Yes,January 2014 expansion states Hispanic Ethnicity,No,NA,2 year survival vaginal cancer,HR,NA,none,1,pre 2014,post 2014,0.33,0.04,2.8
10.1016/j.ajog.2022.04.045,48,Yes,January 2014 expansion states Non-Hispanic Ethnicity,No,NA,2 year survival vaginal cancer,HR,NA,none,1,pre 2014,post 2014,1.09,0.79,1.5
10.1016/j.ajog.2022.06.066,1,Yes,Race and Ethnicity- Black,No,NA,preterm birth,OR,NA,None,1,individual prenatal care,group prenatal care,1.14,0.75,1.73
10.1016/j.ajog.2022.06.066,2,Yes,Race and Ethnicity- White,No,NA,preterm birth,OR,NA,None,1,individual prenatal care,group prenatal care,1.45,0.9,2.34
10.1016/j.ajog.2022.06.066,3,Yes,Race and Ethnicity- Hispanic,No,NA,preterm birth,OR,NA,None,1,individual prenatal care,group prenatal care,1.06,0.55,2.05
10.1016/j.ajog.2022.06.066,4,Yes,Race and Ethnicity- Black,No,NA,low birthweight,OR,NA,None,1,individual prenatal care,group prenatal care,0.98,0.65,1.48
10.1016/j.ajog.2022.06.066,5,Yes,Race and Ethnicity- White,No,NA,low birthweight,OR,NA,None,1,individual prenatal care,group prenatal care,1.43,0.84,2.46
10.1016/j.ajog.2022.06.066,6,Yes,Race and Ethnicity- Hispanic,No,NA,low birthweight,OR,NA,None,1,individual prenatal care,group prenatal care,0.86,0.41,1.8
10.1016/j.ajog.2022.06.066,7,Yes,group prenatal care,Yes,intent to treat,preterm birth,OR,NA,None,1,White,Black,1.07,0.7,1.65
10.1016/j.ajog.2022.06.066,8,Yes,group prenatal care,Yes,modified intent to treat,preterm birth,OR,NA,smoking in the three months prior to pregnancy,1,White,Black,1.05,0.62,1.79
10.1016/j.ajog.2022.06.066,9,Yes,group prenatal care,Yes,per compliance,preterm birth,OR,NA,smoking during pregnancy and in the three months prior to pregnancy,1,White,Black,0.92,0.46,1.82
10.1016/j.ajog.2022.06.066,10,Yes,individual prenatal care,Yes,intent to treat,preterm birth,OR,NA,None,1,White,Black,1.37,0.85,2.19
10.1016/j.ajog.2022.06.066,11,Yes,individual prenatal care,Yes,modified intent to treat,preterm birth,OR,NA,smoking in the three months prior to pregnancy,1,White,Black,1.37,0.84,2.26
10.1016/j.ajog.2022.06.066,12,Yes,individual prenatal care,Yes,per compliance,preterm birth,OR,NA,smoking during pregnancy and in the three months prior to pregnancy,1,White,Black,1.31,0.74,2.31
10.1016/j.ajog.2022.06.066,13,Yes,group prenatal care,Yes,intent to treat,low birthweight,OR,NA,None,1,White,Black,1.45,0.91,2.3
10.1016/j.ajog.2022.06.066,14,Yes,group prenatal care,Yes,modified intent to treat,low birthweight,OR,NA,smoking in the three months prior to pregnancy,1,White,Black,1.74,0.97,3.13
10.1016/j.ajog.2022.06.066,15,Yes,group prenatal care,Yes,per compliance,low birthweight,OR,NA,smoking during pregnancy and in the three months prior to pregnancy,1,White,Black,1.58,0.74,3.34
10.1016/j.ajog.2022.06.066,16,Yes,individual prenatal care,Yes,intent to treat,low birthweight,OR,NA,None,1,White,Black,2.13,1.29,3.5
10.1016/j.ajog.2022.06.066,17,Yes,individual prenatal care,Yes,modified intent to treat,low birthweight,OR,NA,smoking in the three months prior to pregnancy,1,White,Black,2.04,1.23,3.41
10.1016/j.ajog.2022.06.066,18,Yes,individual prenatal care,Yes,per compliance,low birthweight,OR,NA,smoking during pregnancy and in the three months prior to pregnancy,1,White,Black,2,1.14,3.5
10.1016/j.ajog.2022.07.055,1,No,NA,No,NA,1-minute Apgar score,OR,NA,None,1,non-Black,Black,0.63,0.5,0.8
10.1016/j.ajog.2022.07.055,2,No,NA,No,NA,1-minute Apgar score,OR,NA,"gestational age, umbilical artery pH, and umbilical artery base deficit",1,non-Black,Black,0.62,0.49,0.79
10.1016/j.ajog.2022.07.055,3,No,NA,No,NA,1-minute Apgar score,OR,NA,"gestational age, umbilical artery pH, umbilical artery base deficit, maternal hypertension, fetal growth restriction, insulin, magnesium, and maternal diabetes mellitus",1,non-Black,Black,0.63,0.5,0.81
10.1016/j.ajog.2022.07.055,4,No,NA,No,NA,5-minute Apgar score,OR,NA,None,1,non-Black,Black,0.65,0.49,0.87
10.1016/j.ajog.2022.07.055,5,No,NA,No,NA,5-minute Apgar score,OR,NA,"gestational age, umbilical artery pH, and umbilical artery base deficit",1,non-Black,Black,0.64,0.47,0.87
10.1016/j.ajog.2022.07.055,6,No,NA,No,NA,5-minute Apgar score,OR,NA,"gestational age, umbilical artery pH, umbilical artery base deficit, maternal hypertension, fetal growth restriction, insulin, magnesium, and maternal diabetes mellitus",1,non-Black,Black,0.64,0.47,0.87
10.1016/j.ajog.2022.07.055,7,No,NA,No,NA,Color Apgar at 1 minute,OR,NA,None,1,non-Black,Black,0.52,0.4,0.67
10.1016/j.ajog.2022.07.055,8,No,NA,No,NA,Color Apgar at 1 minute,OR,NA,"gestational age, umbilical artery pH, and umbilical artery base deficit",1,non-Black,Black,0.52,0.39,0.67
10.1016/j.ajog.2022.07.055,9,No,NA,No,NA,Color Apgar at 1 minute,OR,NA,"gestational age, umbilical artery pH, umbilical artery base deficit, maternal hypertension, fetal growth restriction, insulin, magnesium, and maternal diabetes mellitus",1,non-Black,Black,0.52,0.39,0.68
10.1016/j.ajog.2022.07.055,10,No,NA,No,NA,Neonatal intensive care unit admission for full-term neonates,OR,NA,None,1,non-Black,Black,1.35,1.03,1.77
10.1016/j.ajog.2022.07.055,11,No,NA,No,NA,Neonatal intensive care unit admission for full-term neonates,OR,NA,"gestational age, umbilical artery pH, and umbilical artery base deficit",1,non-Black,Black,1.29,0.95,1.74
10.1016/j.ajog.2022.07.055,12,No,NA,No,NA,Neonatal intensive care unit admission for full-term neonates,OR,NA,"gestational age, umbilical artery pH, umbilical artery base deficit, maternal hypertension, fetal growth restriction, insulin, magnesium, and maternal diabetes mellitus",1,non-Black,Black,1.29,0.94,1.77
10.1016/j.ajog.2022.08.043,1,No,NA,No,NA,likelihood of ever testing for biomarkers in epithelial ovarian cancer,RR,NA,"age, ethnicity, insurance at diagnosis, stage at diagnosis, histology, BMI, Eastern Cooperative Oncology Group, years of diagnosis",1,White,Asian,1.11,0.93,1.34
10.1016/j.ajog.2022.08.043,1,No,NA,No,NA,likelihood of ever testing for biomarkers in epithelial ovarian cancer,RR,NA,"age, ethnicity, insurance at diagnosis, stage at diagnosis, histology, BMI, Eastern Cooperative Oncology Group, years of diagnosis",2,White,Black or African American,0.93,0.82,1.06
10.1016/j.ajog.2022.08.043,1,No,NA,No,NA,likelihood of ever testing for biomarkers in epithelial ovarian cancer,RR,NA,"age, ethnicity, insurance at diagnosis, stage at diagnosis, histology, BMI, Eastern Cooperative Oncology Group, years of diagnosis",3,White,Other Race,1.01,0.92,1.1
10.1016/j.ajog.2022.08.043,1,No,NA,No,NA,likelihood of ever testing for biomarkers in epithelial ovarian cancer,RR,NA,"age, ethnicity, insurance at diagnosis, stage at diagnosis, histology, BMI, Eastern Cooperative Oncology Group, years of diagnosis",4,White,Unknown,0.9,0.81,0.99
10.1016/j.ajog.2022.08.043,2,No,NA,No,NA,likelihood of ever testing for biomarkers in epithelial ovarian cancer,RR,NA,"age, race, insurance at diagnosis, stage at diagnosis, histology, BMI, Eastern Cooperative Oncology Group, years of diagnosis",1,Not Hispanic or Latino,Hispanic or Latino,0.97,0.86,1.1
10.1016/j.ajog.2022.10.043,1,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Cumulative Live Birth",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",1,Non-Hispanic White,Non-Hispanic Black/African American,0.84,0.8,0.88
10.1016/j.ajog.2022.10.043,1,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Cumulative Live Birth",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",2,Non-Hispanic White,Non-Hispanic Asian,0.86,0.82,0.89
10.1016/j.ajog.2022.10.043,1,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Cumulative Live Birth",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",3,Non-Hispanic White,Other,0.86,0.77,0.96
10.1016/j.ajog.2022.10.043,1,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Cumulative Live Birth",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",4,Non-Hispanic White,Multiple Races,0.88,0.79,0.97
10.1016/j.ajog.2022.10.043,1,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Cumulative Live Birth",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",5,Non-Hispanic White,Hispanic/Latinx,0.93,0.9,0.96
10.1016/j.ajog.2022.10.043,2,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Cumulative Live Birth",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",1,Non-Hispanic White,Non-Hispanic Black/African American,0.81,0.77,0.84
10.1016/j.ajog.2022.10.043,2,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Cumulative Live Birth",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",2,Non-Hispanic White,Non-Hispanic Asian,0.86,0.83,0.9
10.1016/j.ajog.2022.10.043,2,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Cumulative Live Birth",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",3,Non-Hispanic White,Other,0.86,0.74,0.99
10.1016/j.ajog.2022.10.043,2,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Cumulative Live Birth",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",4,Non-Hispanic White,Multiple Races,0.93,0.83,1.05
10.1016/j.ajog.2022.10.043,2,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Cumulative Live Birth",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",5,Non-Hispanic White,Hispanic/Latinx,0.91,0.89,0.94
10.1016/j.ajog.2022.10.043,3,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Live Birth Among Cycle Starts",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",1,Non-Hispanic White,Non-Hispanic Black/African American,0.86,0.83,0.91
10.1016/j.ajog.2022.10.043,3,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Live Birth Among Cycle Starts",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",2,Non-Hispanic White,Non-Hispanic Asian,0.91,0.88,0.94
10.1016/j.ajog.2022.10.043,3,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Live Birth Among Cycle Starts",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",3,Non-Hispanic White,Other,0.91,0.82,1.01
10.1016/j.ajog.2022.10.043,3,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Live Birth Among Cycle Starts",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",4,Non-Hispanic White,Multiple Races,0.88,0.8,0.98
10.1016/j.ajog.2022.10.043,3,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Live Birth Among Cycle Starts",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",5,Non-Hispanic White,Hispanic/Latinx,0.97,0.95,1
10.1016/j.ajog.2022.10.043,4,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Live Birth Among Cycle Starts",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",1,Non-Hispanic White,Non-Hispanic Black/African American,0.85,0.81,0.88
10.1016/j.ajog.2022.10.043,4,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Live Birth Among Cycle Starts",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",2,Non-Hispanic White,Non-Hispanic Asian,0.88,0.85,0.91
10.1016/j.ajog.2022.10.043,4,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Live Birth Among Cycle Starts",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",3,Non-Hispanic White,Other,0.96,0.86,1.07
10.1016/j.ajog.2022.10.043,4,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Live Birth Among Cycle Starts",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",4,Non-Hispanic White,Multiple Races,1.01,0.91,1.12
10.1016/j.ajog.2022.10.043,4,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Live Birth Among Cycle Starts",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",5,Non-Hispanic White,Hispanic/Latinx,0.96,0.92,0.99
10.1016/j.ajog.2022.10.043,5,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Live Birth Among Embryo Transfers",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",1,Non-Hispanic White,Non-Hispanic Black/African American,0.87,0.83,0.91
10.1016/j.ajog.2022.10.043,5,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Live Birth Among Embryo Transfers",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",2,Non-Hispanic White,Non-Hispanic Asian,0.92,0.89,0.95
10.1016/j.ajog.2022.10.043,5,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Live Birth Among Embryo Transfers",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",3,Non-Hispanic White,Other,0.91,0.82,1.01
10.1016/j.ajog.2022.10.043,5,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Live Birth Among Embryo Transfers",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",4,Non-Hispanic White,Multiple Races,0.88,0.77,1.01
10.1016/j.ajog.2022.10.043,5,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Live Birth Among Embryo Transfers",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",5,Non-Hispanic White,Hispanic/Latinx,0.94,0.91,0.98
10.1016/j.ajog.2022.10.043,6,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Live Birth among Embryo Transfers",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",1,Non-Hispanic White,Non-Hispanic Black/African American,0.85,0.82,0.88
10.1016/j.ajog.2022.10.043,6,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Live Birth among Embryo Transfers",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",2,Non-Hispanic White,Non-Hispanic Asian,0.89,0.86,0.93
10.1016/j.ajog.2022.10.043,6,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Live Birth among Embryo Transfers",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",3,Non-Hispanic White,Other,0.95,0.85,1.07
10.1016/j.ajog.2022.10.043,6,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Live Birth among Embryo Transfers",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",4,Non-Hispanic White,Multiple Races,1,0.9,1.11
10.1016/j.ajog.2022.10.043,6,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Live Birth among Embryo Transfers",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",5,Non-Hispanic White,Hispanic/Latinx,0.95,0.91,0.98
10.1016/j.ajog.2022.10.043,7,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Clinical Pregnancy among Cycle Starts",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",1,Non-Hispanic White,Non-Hispanic Black/African American,0.9,0.87,0.94
10.1016/j.ajog.2022.10.043,7,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Clinical Pregnancy among Cycle Starts",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",2,Non-Hispanic White,Non-Hispanic Asian,0.92,0.9,0.94
10.1016/j.ajog.2022.10.043,7,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Clinical Pregnancy among Cycle Starts",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",3,Non-Hispanic White,Other,0.91,0.84,0.99
10.1016/j.ajog.2022.10.043,7,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Clinical Pregnancy among Cycle Starts",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",4,Non-Hispanic White,Multiple Races,0.91,0.8,1.02
10.1016/j.ajog.2022.10.043,7,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Clinical Pregnancy among Cycle Starts",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",5,Non-Hispanic White,Hispanic/Latinx,1,0.97,1.04
10.1016/j.ajog.2022.10.043,8,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Clinical Pregnancy among Cycle Starts",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",1,Non-Hispanic White,Non-Hispanic Black/African American,0.89,0.86,0.92
10.1016/j.ajog.2022.10.043,8,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Clinical Pregnancy among Cycle Starts",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",2,Non-Hispanic White,Non-Hispanic Asian,0.89,0.86,0.92
10.1016/j.ajog.2022.10.043,8,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Clinical Pregnancy among Cycle Starts",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",3,Non-Hispanic White,Other,0.91,0.79,1.03
10.1016/j.ajog.2022.10.043,8,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Clinical Pregnancy among Cycle Starts",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",4,Non-Hispanic White,Multiple Races,1.09,1,1.19
10.1016/j.ajog.2022.10.043,8,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Clinical Pregnancy among Cycle Starts",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",5,Non-Hispanic White,Hispanic/Latinx,0.98,0.93,1.03
10.1016/j.ajog.2022.10.043,9,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Clinical Pregnancy among Embryo Transfers",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",1,Non-Hispanic White,Non-Hispanic Black/African American,0.92,0.89,0.95
10.1016/j.ajog.2022.10.043,9,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Clinical Pregnancy among Embryo Transfers",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",2,Non-Hispanic White,Non-Hispanic Asian,0.93,0.91,0.96
10.1016/j.ajog.2022.10.043,9,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Clinical Pregnancy among Embryo Transfers",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",3,Non-Hispanic White,Other,0.91,0.84,1
10.1016/j.ajog.2022.10.043,9,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Clinical Pregnancy among Embryo Transfers",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",4,Non-Hispanic White,Multiple Races,0.91,0.78,1.07
10.1016/j.ajog.2022.10.043,9,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Clinical Pregnancy among Embryo Transfers",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",5,Non-Hispanic White,Hispanic/Latinx,0.98,0.94,1.01
10.1016/j.ajog.2022.10.043,10,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Clinical Pregnancy among Embryo Transfers",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",1,Non-Hispanic White,Non-Hispanic Black/African American,0.88,0.86,0.91
10.1016/j.ajog.2022.10.043,10,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Clinical Pregnancy among Embryo Transfers",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",2,Non-Hispanic White,Non-Hispanic Asian,0.91,0.88,0.94
10.1016/j.ajog.2022.10.043,10,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Clinical Pregnancy among Embryo Transfers",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",3,Non-Hispanic White,Other,0.89,0.77,1.02
10.1016/j.ajog.2022.10.043,10,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Clinical Pregnancy among Embryo Transfers",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",4,Non-Hispanic White,Multiple Races,1.09,0.99,1.21
10.1016/j.ajog.2022.10.043,10,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Clinical Pregnancy among Embryo Transfers",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",5,Non-Hispanic White,Hispanic/Latinx,0.97,0.92,1.02
10.1016/j.ajog.2022.10.043,11,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Spontaneous Abortion",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",1,Non-Hispanic White,Non-Hispanic Black/African American,1.19,1.1,1.28
10.1016/j.ajog.2022.10.043,11,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Spontaneous Abortion",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",2,Non-Hispanic White,Non-Hispanic Asian,1.07,1.01,1.13
10.1016/j.ajog.2022.10.043,11,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Spontaneous Abortion",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",3,Non-Hispanic White,Other,1.04,0.84,1.28
10.1016/j.ajog.2022.10.043,11,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Spontaneous Abortion",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",4,Non-Hispanic White,Multiple Races,1.13,0.99,1.3
10.1016/j.ajog.2022.10.043,11,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Spontaneous Abortion",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",5,Non-Hispanic White,Hispanic/Latinx,1.09,1.04,1.15
10.1016/j.ajog.2022.10.043,12,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Spontaneous Abortion",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",1,Non-Hispanic White,Non-Hispanic Black/African American,1.17,1.1,1.24
10.1016/j.ajog.2022.10.043,12,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Spontaneous Abortion",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",2,Non-Hispanic White,Non-Hispanic Asian,1.11,1.06,1.18
10.1016/j.ajog.2022.10.043,12,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Spontaneous Abortion",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",3,Non-Hispanic White,Other,0.8,0.6,1.08
10.1016/j.ajog.2022.10.043,12,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Spontaneous Abortion",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",4,Non-Hispanic White,Multiple Races,1.2,0.97,1.49
10.1016/j.ajog.2022.10.043,12,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Spontaneous Abortion",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",5,Non-Hispanic White,Hispanic/Latinx,1.07,1,1.15
10.1016/j.ajog.2022.10.043,13,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Cycle Cancellation",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",1,Non-Hispanic White,Non-Hispanic Black/African American,1.15,1.07,1.22
10.1016/j.ajog.2022.10.043,13,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Cycle Cancellation",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",2,Non-Hispanic White,Non-Hispanic Asian,0.87,0.77,0.98
10.1016/j.ajog.2022.10.043,13,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Cycle Cancellation",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",3,Non-Hispanic White,Other,1.18,0.99,1.41
10.1016/j.ajog.2022.10.043,13,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Cycle Cancellation",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",4,Non-Hispanic White,Multiple Races,1.06,0.94,1.2
10.1016/j.ajog.2022.10.043,13,Yes,No state insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Cycle Cancellation",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",5,Non-Hispanic White,Hispanic/Latinx,1.02,0.98,1.06
10.1016/j.ajog.2022.10.043,14,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Cycle Cancellation",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",1,Non-Hispanic White,Non-Hispanic Black/African American,1.25,1.17,1.33
10.1016/j.ajog.2022.10.043,14,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Cycle Cancellation",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",2,Non-Hispanic White,Non-Hispanic Asian,1.02,0.94,1.1
10.1016/j.ajog.2022.10.043,14,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Cycle Cancellation",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",3,Non-Hispanic White,Other,1.05,0.77,1.43
10.1016/j.ajog.2022.10.043,14,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Cycle Cancellation",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",4,Non-Hispanic White,Multiple Races,1.04,0.84,1.28
10.1016/j.ajog.2022.10.043,14,Yes,State insurance mandate for IVF coverage,No,NA,"Clinical in vitro fertilization outcomes within state insurance mandate status group, 2014-2019: Cycle Cancellation",OR,NA,"Patient age, body mass index (<18.5, 18.5-24.9, 25-29.9, 30+, missing), follicle-stimulating hormone <10, anti-Mullerian hormone (<1, 1-4, >4), any previous spontaneous abortion, parous, and reason for assisted reproductive technology, including any male factor infertility, endometriosis, any tubal factor infertility, uterine factor infertility, ovulatory factor infertility, diminished ovarian reserve, and unexplained infertility.",5,Non-Hispanic White,Hispanic/Latinx,1.09,1,1.19
10.1016/j.ajog.2023.01.002,1,Yes,Race- White,No,NA,all-cause 30-day rehospitalization,IRR,NA,"age, race, ethnicity, conditions at time of delivery including diabetes mellitus, hypertension, infection, preterm delivery, venous thromboembolism, behavioral health condition, and covid19; count of aforementioned conditions; and lace readmission risk score (length of stay, acuity of admission, comorbidity of patient measured using the charlson comorbidity score, emergency department use measured as number of admissions 6 months before delivery discharge)",1,not enrolled in transitional care management program,enrolled in transitional management program,1.12,0.81,1.55
10.1016/j.ajog.2023.01.002,2,Yes,Race- Black,No,NA,all-cause 30-day rehospitalization,IRR,NA,"age, race, ethnicity, conditions at time of delivery including diabetes mellitus, hypertension, infection, preterm delivery, venous thromboembolism, behavioral health condition, and covid19; count of aforementioned conditions; and lace readmission risk score (length of stay, acuity of admission, comorbidity of patient measured using the charlson comorbidity score, emergency department use measured as number of admissions 6 months before delivery discharge)",1,not enrolled in transitional care management program,enrolled in transitional management program,0.57,0.42,0.8
10.1016/j.ajog.2023.01.002,3,Yes,Race- Multiracial,No,NA,all-cause 30-day rehospitalization,IRR,NA,"age, race, ethnicity, conditions at time of delivery including diabetes mellitus, hypertension, infection, preterm delivery, venous thromboembolism, behavioral health condition, and covid19; count of aforementioned conditions; and lace readmission risk score (length of stay, acuity of admission, comorbidity of patient measured using the charlson comorbidity score, emergency department use measured as number of admissions 6 months before delivery discharge)",1,not enrolled in transitional care management program,enrolled in transitional management program,0.99,0.66,1.49
10.1016/j.ajog.2023.01.002,4,Yes,Race- Asian or Pacific Islander,No,NA,all-cause 30-day rehospitalization,IRR,NA,"age, race, ethnicity, conditions at time of delivery including diabetes mellitus, hypertension, infection, preterm delivery, venous thromboembolism, behavioral health condition, and covid19; count of aforementioned conditions; and lace readmission risk score (length of stay, acuity of admission, comorbidity of patient measured using the charlson comorbidity score, emergency department use measured as number of admissions 6 months before delivery discharge)",1,not enrolled in transitional care management program,enrolled in transitional management program,0.58,0.38,0.9
10.1016/j.ajog.2023.01.002,5,Yes,Race- American Indian or Alaska Native,No,NA,all-cause 30-day rehospitalization,IRR,NA,"age, race, ethnicity, conditions at time of delivery including diabetes mellitus, hypertension, infection, preterm delivery, venous thromboembolism, behavioral health condition, and covid19; count of aforementioned conditions; and lace readmission risk score (length of stay, acuity of admission, comorbidity of patient measured using the charlson comorbidity score, emergency department use measured as number of admissions 6 months before delivery discharge)",1,not enrolled in transitional care management program,enrolled in transitional management program,2.24,0.09,5.66
10.1016/j.ajog.2023.01.002,6,Yes,Race- Unknown,No,NA,all-cause 30-day rehospitalization,IRR,NA,"age, race, ethnicity, conditions at time of delivery including diabetes mellitus, hypertension, infection, preterm delivery, venous thromboembolism, behavioral health condition, and covid19; count of aforementioned conditions; and lace readmission risk score (length of stay, acuity of admission, comorbidity of patient measured using the charlson comorbidity score, emergency department use measured as number of admissions 6 months before delivery discharge)",1,not enrolled in transitional care management program,enrolled in transitional management program,1.12,0.35,3.52
10.1016/j.ajog.2023.06.027,1,Yes,OBGYN Specialty - Benign subspecialty gynecology,No,NA,RN pain reassessment non-compliance proportions,OR,NA,"Age, BMI category, pre vs post-March 2020, hysterectomy vs. non-hysterectomy, number of nurses attending to patient",1,White,Black,1.37,0.98,1.93
10.1016/j.ajog.2023.06.027,2,Yes,OBGYN Specialty -  Gynecologic oncology,No,NA,RN pain reassessment non-compliance proportions,OR,NA,"Age, BMI category, pre vs post-March 2020, hysterectomy vs. non-hysterectomy, number of nurses attending to patient",1,White,Black,0.54,0.4,0.74
10.1016/j.ajog.2023.06.027,3,Yes,OBGYN Specialty -  Generalist OBGYN,No,NA,RN pain reassessment non-compliance proportions,OR,NA,"Age, BMI category, pre vs post-March 2020, hysterectomy vs. non-hysterectomy, number of nurses attending to patient",1,White,Black,1.05,0.94,1.18
10.1016/j.ajog.2023.06.027,4,Yes,OBGYN Specialty -  Maternal fetal medicine,No,NA,RN pain reassessment non-compliance proportions,OR,NA,"Age, BMI category, pre vs post-March 2020, hysterectomy vs. non-hysterectomy, number of nurses attending to patient",1,White,Black,1.17,1.01,1.36
10.1016/j.ajog.2023.06.027,5,Yes,OBGYN Specialty -  Midwifery,No,NA,RN pain reassessment non-compliance proportions,OR,NA,"Age, BMI category, pre vs post-March 2020, hysterectomy vs. non-hysterectomy, number of nurses attending to patient",1,White,Black,0.94,0.85,1.04
10.1016/j.ajog.2023.06.027,6,Yes,OBGYN Specialty - Benign subspecialty gynecology,No,NA,RN pain reassessment non-compliance proportions,OR,NA,"Age, BMI category, pre vs post-March 2020, hysterectomy vs. non-hysterectomy, number of nurses attending to patient",1,Other race,Black,1.29,0.48,3.43
10.1016/j.ajog.2023.06.027,7,Yes,OBGYN Specialty -  Gynecologic oncology,No,NA,RN pain reassessment non-compliance proportions,OR,NA,"Age, BMI category, pre vs post-March 2020, hysterectomy vs. non-hysterectomy, number of nurses attending to patient",1,Other race,Black,0.52,0.26,1.03
10.1016/j.ajog.2023.06.027,8,Yes,OBGYN Specialty -  Generalist OBGYN,No,NA,RN pain reassessment non-compliance proportions,OR,NA,"Age, BMI category, pre vs post-March 2020, hysterectomy vs. non-hysterectomy, number of nurses attending to patient",1,Other race,Black,1,0.85,1.16
10.1016/j.ajog.2023.06.027,9,Yes,OBGYN Specialty -  Maternal fetal medicine,No,NA,RN pain reassessment non-compliance proportions,OR,NA,"Age, BMI category, pre vs post-March 2020, hysterectomy vs. non-hysterectomy, number of nurses attending to patient",1,Other race,Black,1.07,0.82,1.39
10.1016/j.ajog.2023.06.027,10,Yes,OBGYN Specialty -  Midwifery,No,NA,RN pain reassessment non-compliance proportions,OR,NA,"Age, BMI category, pre vs post-March 2020, hysterectomy vs. non-hysterectomy, number of nurses attending to patient",1,Other race,Black,0.94,0.82,1.08
10.1016/j.ajog.2023.06.027,11,Yes,OBGYN Specialty - Benign subspecialty gynecology,No,NA,RN pain reassessment non-compliance proportions,OR,NA,"Age, BMI category, pre vs post-March 2020, hysterectomy vs. non-hysterectomy, number of nurses attending to patient",1,White,Other race,1.07,0.41,2.78
10.1016/j.ajog.2023.06.027,12,Yes,OBGYN Specialty -  Gynecologic oncology,No,NA,RN pain reassessment non-compliance proportions,OR,NA,"Age, BMI category, pre vs post-March 2020, hysterectomy vs. non-hysterectomy, number of nurses attending to patient",1,White,Other race,1.05,0.55,1.99
10.1016/j.ajog.2023.06.027,13,Yes,OBGYN Specialty -  Generalist OBGYN,No,NA,RN pain reassessment non-compliance proportions,OR,NA,"Age, BMI category, pre vs post-March 2020, hysterectomy vs. non-hysterectomy, number of nurses attending to patient",1,White,Other race,1.06,0.93,1.2
10.1016/j.ajog.2023.06.027,14,Yes,OBGYN Specialty -  Maternal fetal medicine,No,NA,RN pain reassessment non-compliance proportions,OR,NA,"Age, BMI category, pre vs post-March 2020, hysterectomy vs. non-hysterectomy, number of nurses attending to patient",1,White,Other race,1.1,0.86,1.4
10.1016/j.ajog.2023.06.027,15,Yes,OBGYN Specialty -  Midwifery,No,NA,RN pain reassessment non-compliance proportions,OR,NA,"Age, BMI category, pre vs post-March 2020, hysterectomy vs. non-hysterectomy, number of nurses attending to patient",1,White,Other race,1,0.89,1.12
10.1016/j.ajog.2023.06.027,16,Yes,White,No,NA,RN pain reassessment non-compliance proportions,OR,NA,"Age, BMI category, pre vs post-March 2020, hysterectomy vs. non-hysterectomy, number of nurses attending to patient",1,OBGYN Specialty -  Gynecologic oncology,OBGYN Specialty -  Benign subspecialty gynecology,1.09,0.87,1.36
10.1016/j.ajog.2023.06.027,17,Yes,Black,No,NA,RN pain reassessment non-compliance proportions,OR,NA,"Age, BMI category, pre vs post-March 2020, hysterectomy vs. non-hysterectomy, number of nurses attending to patient",1,OBGYN Specialty -  Gynecologic oncology,OBGYN Specialty -  Benign subspecialty gynecology,2.78,1.83,4.21
10.1016/j.ajog.2023.06.027,18,Yes,Other race,No,NA,RN pain reassessment non-compliance proportions,OR,NA,"Age, BMI category, pre vs post-March 2020, hysterectomy vs. non-hysterectomy, number of nurses attending to patient",1,OBGYN Specialty -  Gynecologic oncology,OBGYN Specialty -  Benign subspecialty gynecology,1.11,0.36,3.45
10.1016/j.ajog.2023.06.027,19,Yes,White,No,NA,RN pain reassessment non-compliance proportions,OR,NA,"Age, BMI category, pre vs post-March 2020, hysterectomy vs. non-hysterectomy, number of nurses attending to patient",1,OBGYN Specialty -  Generalist OBGYN,OBGYN Specialty -  Benign subspecialty gynecology,1.3,1.06,1.59
10.1016/j.ajog.2023.06.027,20,Yes,Black,No,NA,RN pain reassessment non-compliance proportions,OR,NA,"Age, BMI category, pre vs post-March 2020, hysterectomy vs. non-hysterectomy, number of nurses attending to patient",1,OBGYN Specialty -  Generalist OBGYN,OBGYN Specialty -  Benign subspecialty gynecology,1.69,1.23,2.33
10.1016/j.ajog.2023.06.027,21,Yes,Other race,No,NA,RN pain reassessment non-compliance proportions,OR,NA,"Age, BMI category, pre vs post-March 2020, hysterectomy vs. non-hysterectomy, number of nurses attending to patient",1,OBGYN Specialty -  Generalist OBGYN,OBGYN Specialty -  Benign subspecialty gynecology,1.31,0.51,3.4
10.1016/j.ajog.2023.06.027,22,Yes,White,No,NA,RN pain reassessment non-compliance proportions,OR,NA,"Age, BMI category, pre vs post-March 2020, hysterectomy vs. non-hysterectomy, number of nurses attending to patient",1,OBGYN Specialty -  Generalist OBGYN,OBGYN Specialty -  Gynecologic oncology,1.19,0.99,1.43
10.1016/j.ajog.2023.06.027,23,Yes,Black,No,NA,RN pain reassessment non-compliance proportions,OR,NA,"Age, BMI category, pre vs post-March 2020, hysterectomy vs. non-hysterectomy, number of nurses attending to patient",1,OBGYN Specialty -  Generalist OBGYN,OBGYN Specialty -  Gynecologic oncology,0.61,0.44,0.84
10.1016/j.ajog.2023.06.027,24,Yes,Other race,No,NA,RN pain reassessment non-compliance proportions,OR,NA,"Age, BMI category, pre vs post-March 2020, hysterectomy vs. non-hysterectomy, number of nurses attending to patient",1,OBGYN Specialty -  Generalist OBGYN,OBGYN Specialty -  Gynecologic oncology,1.18,0.62,2.24
10.1016/j.ajog.2023.06.045,1,No,NA,Yes,Pregnant,trichomonas vaginalis positivity,OR,NA,None,1,Non-Hispanic White,Hispanic,0.68,0.5,0.93
10.1016/j.ajog.2023.06.045,1,No,NA,Yes,Pregnant,trichomonas vaginalis positivity,OR,NA,None,2,Non-Hispanic White,Non-Hispanic Black,3.46,2.65,4.52
10.1016/j.ajog.2023.06.045,2,No,NA,Yes,Pregnant,trichomonas vaginalis positivity,OR,NA,None,1,Non-Hispanic White,Hispanic,0.32,0.2,0.53
10.1016/j.ajog.2023.06.045,2,No,NA,Yes,Pregnant,trichomonas vaginalis positivity,OR,NA,None,2,Non-Hispanic White,Non-Hispanic Black,1.94,1.27,2.96
10.1016/j.ajog.2023.06.045,3,No,NA,Yes,Pregnant,trichomonas vaginalis positivity,OR,NA,"preferred language, marital status, multigravid, current or former smoker",1,Non-Hispanic White,Hispanic,1.16,0.82,1.63
10.1016/j.ajog.2023.06.045,3,No,NA,Yes,Pregnant,trichomonas vaginalis positivity,OR,NA,"preferred language, marital status, multigravid, current or former smoker",2,Non-Hispanic White,Non-Hispanic Black,3.69,2.75,4.95
10.1016/j.ajog.2023.06.045,4,No,NA,Yes,Pregnant,trichomonas vaginalis positivity,OR,NA,"preferred language, marital status, multigravid, current or former smoker",1,Non-Hispanic White,Hispanic,0.63,0.35,1.011
10.1016/j.ajog.2023.06.045,4,No,NA,Yes,Pregnant,trichomonas vaginalis positivity,OR,NA,"preferred language, marital status, multigravid, current or former smoker",2,Non-Hispanic White,non-Hispanic Black,1.82,1.15,2.687
10.1016/j.ajog.2023.06.045,5,No,NA,Yes,Pregnant,women who were re-tested within 90 days after a positive index test,OR,NA,None,1,Non-Hispanic White,Hispanic,0.88,0.47,1.65
10.1016/j.ajog.2023.06.045,5,No,NA,Yes,Pregnant,women who were re-tested within 90 days after a positive index test,OR,NA,None,2,Non-Hispanic White,Non-Hispanic Black,0.54,0.31,0.93
10.1016/j.ajog.2023.06.045,6,No,NA,Yes,Pregnant,women who were re-tested within 90 days after a positive index test,OR,NA,None,1,Non-Hispanic White,Hispanic,0.96,0.36,2.55
10.1016/j.ajog.2023.06.045,6,No,NA,Yes,Pregnant,women who were re-tested within 90 days after a positive index test,OR,NA,None,2,Non-Hispanic White,Non-Hispanic Black,0.72,0.32,1.62
10.1016/j.ajog.2023.06.045,7,No,NA,Yes,Pregnant,women who were re-tested within 90 days after a positive index test,OR,NA,"preferred language, marital status, multigravid, current or former smoker, hivpositive",1,Non-Hispanic White,Hispanic,0.78,0.41,1.49
10.1016/j.ajog.2023.06.045,7,No,NA,Yes,Pregnant,women who were re-tested within 90 days after a positive index test,OR,NA,"preferred language, marital status, multigravid, current or former smoker, hivpositive",2,Non-Hispanic White,Non-Hispanic Black,0.54,0.31,0.92
10.1016/j.fertnstert.2021.02.032,1,No,NA,No,NA,Indication for oocyte cryopreservation - Fertility preservation (not otherwise specified) or no reason given,Percent,NA,none,1,N/A,Non-Hispanic White,27.3,-99,-99
10.1016/j.fertnstert.2021.02.032,1,No,NA,No,NA,Indication for oocyte cryopreservation - Fertility preservation (not otherwise specified) or no reason given,Percent,NA,none,2,N/A,Non-Hispanic Black,20,-99,-99
10.1016/j.fertnstert.2021.02.032,1,No,NA,No,NA,Indication for oocyte cryopreservation - Fertility preservation (not otherwise specified) or no reason given,Percent,NA,none,3,N/A,Asian/Pacific Islander,26.2,-99,-99
10.1016/j.fertnstert.2021.02.032,1,No,NA,No,NA,Indication for oocyte cryopreservation - Fertility preservation (not otherwise specified) or no reason given,Percent,NA,none,4,N/A,Hispanic,24.3,-99,-99
10.1016/j.fertnstert.2021.02.032,1,No,NA,No,NA,Indication for oocyte cryopreservation - Fertility preservation (not otherwise specified) or no reason given,Percent,NA,none,5,N/A,"American Indian, Alaskan native, or mixed race including 2+ selected races",26.2,-99,-99
10.1016/j.fertnstert.2021.02.032,2,No,NA,No,NA,Indication for oocyte cryopreservation - diminished ovarian reserve,Percent,NA,none,1,N/A,Non-Hispanic White,21.5,-99,-99
10.1016/j.fertnstert.2021.02.032,2,No,NA,No,NA,Indication for oocyte cryopreservation - diminished ovarian reserve,Percent,NA,none,2,N/A,Non-Hispanic Black,24.6,-99,-99
10.1016/j.fertnstert.2021.02.032,2,No,NA,No,NA,Indication for oocyte cryopreservation - diminished ovarian reserve,Percent,NA,none,3,N/A,Asian/Pacific Islander,28.7,-99,-99
10.1016/j.fertnstert.2021.02.032,2,No,NA,No,NA,Indication for oocyte cryopreservation - diminished ovarian reserve,Percent,NA,none,4,N/A,Hispanic,27,-99,-99
10.1016/j.fertnstert.2021.02.032,2,No,NA,No,NA,Indication for oocyte cryopreservation - diminished ovarian reserve,Percent,NA,none,5,N/A,"American Indian, Alaskan native, or mixed race including 2+ selected races",21.4,-99,-99
10.1016/j.fertnstert.2021.02.032,3,No,NA,No,NA,Indication for oocyte cryopreservation - infertility diagnosis,Percent,NA,none,1,N/A,Non-Hispanic White,13.9,-99,-99
10.1016/j.fertnstert.2021.02.032,3,No,NA,No,NA,Indication for oocyte cryopreservation - infertility diagnosis,Percent,NA,none,2,N/A,Non-Hispanic Black,21.6,-99,-99
10.1016/j.fertnstert.2021.02.032,3,No,NA,No,NA,Indication for oocyte cryopreservation - infertility diagnosis,Percent,NA,none,3,N/A,Asian/Pacific Islander,16.3,-99,-99
10.1016/j.fertnstert.2021.02.032,3,No,NA,No,NA,Indication for oocyte cryopreservation - infertility diagnosis,Percent,NA,none,4,N/A,Hispanic,19.8,-99,-99
10.1016/j.fertnstert.2021.02.032,3,No,NA,No,NA,Indication for oocyte cryopreservation - infertility diagnosis,Percent,NA,none,5,N/A,"American Indian, Alaskan native, or mixed race including 2+ selected races",12,-99,-99
10.1016/j.fertnstert.2021.02.032,4,No,NA,No,NA,Indication for oocyte cryopreservation - gonadotoxic therapy,Percent,NA,none,1,N/A,Non-Hispanic White,7.7,-99,-99
10.1016/j.fertnstert.2021.02.032,4,No,NA,No,NA,Indication for oocyte cryopreservation - gonadotoxic therapy,Percent,NA,none,2,N/A,Non-Hispanic Black,8.8,-99,-99
10.1016/j.fertnstert.2021.02.032,4,No,NA,No,NA,Indication for oocyte cryopreservation - gonadotoxic therapy,Percent,NA,none,3,N/A,Asian/Pacific Islander,3.4,-99,-99
10.1016/j.fertnstert.2021.02.032,4,No,NA,No,NA,Indication for oocyte cryopreservation - gonadotoxic therapy,Percent,NA,none,4,N/A,Hispanic,10.7,-99,-99
10.1016/j.fertnstert.2021.02.032,4,No,NA,No,NA,Indication for oocyte cryopreservation - gonadotoxic therapy,Percent,NA,none,5,N/A,"American Indian, Alaskan native, or mixed race including 2+ selected races",4.6,-99,-99
10.1016/j.fertnstert.2021.02.032,5,No,NA,No,NA,"Indication for oocyte cryopreservation - Fertility perservation, medical reason",Percent,NA,none,1,N/A,Non-Hispanic White,0.9,-99,-99
10.1016/j.fertnstert.2021.02.032,5,No,NA,No,NA,"Indication for oocyte cryopreservation - Fertility perservation, medical reason",Percent,NA,none,2,N/A,Non-Hispanic Black,0.7,-99,-99
10.1016/j.fertnstert.2021.02.032,5,No,NA,No,NA,"Indication for oocyte cryopreservation - Fertility perservation, medical reason",Percent,NA,none,3,N/A,Asian/Pacific Islander,0.9,-99,-99
10.1016/j.fertnstert.2021.02.032,5,No,NA,No,NA,"Indication for oocyte cryopreservation - Fertility perservation, medical reason",Percent,NA,none,4,N/A,Hispanic,1,-99,-99
10.1016/j.fertnstert.2021.02.032,5,No,NA,No,NA,"Indication for oocyte cryopreservation - Fertility perservation, medical reason",Percent,NA,none,5,N/A,"American Indian, Alaskan native, or mixed race including 2+ selected races",0.9,-99,-99
10.1016/j.fertnstert.2021.02.032,6,No,NA,No,NA,Indication for oocyte cryopreservation - Other,Percent,NA,none,1,N/A,Non-Hispanic White,0.9,-99,-99
10.1016/j.fertnstert.2021.02.032,6,No,NA,No,NA,Indication for oocyte cryopreservation - Other,Percent,NA,none,2,N/A,Non-Hispanic Black,1.3,-99,-99
10.1016/j.fertnstert.2021.02.032,6,No,NA,No,NA,Indication for oocyte cryopreservation - Other,Percent,NA,none,3,N/A,Asian/Pacific Islander,1.3,-99,-99
10.1016/j.fertnstert.2021.02.032,6,No,NA,No,NA,Indication for oocyte cryopreservation - Other,Percent,NA,none,4,N/A,Hispanic,1,-99,-99
10.1016/j.fertnstert.2021.02.032,6,No,NA,No,NA,Indication for oocyte cryopreservation - Other,Percent,NA,none,5,N/A,"American Indian, Alaskan native, or mixed race including 2+ selected races",2,-99,-99
10.1016/j.fertnstert.2021.02.032,7,No,NA,No,NA,Gonadotropin dose > 4000 IU,RR,NA,none,1,Non-Hispanic White,Non-Hispanic black,1.01,0.91,1.13
10.1016/j.fertnstert.2021.02.032,7,No,NA,No,NA,Gonadotropin dose > 4000 IU,RR,NA,none,2,Non-Hispanic White,Asian/Pacific islander,0.87,0.77,0.97
10.1016/j.fertnstert.2021.02.032,7,No,NA,No,NA,Gonadotropin dose > 4000 IU,RR,NA,none,3,Non-Hispanic White,Hispanic,0.95,0.86,1.03
10.1016/j.fertnstert.2021.02.032,7,No,NA,No,NA,Gonadotropin dose > 4000 IU,RR,NA,none,4,Non-Hispanic White,"American Indian, Alaskan native, or mixed race including 2+ selected races",0.92,0.8,1.05
10.1016/j.fertnstert.2021.02.032,8,No,NA,No,NA,Cycle cancellation,RR,NA,none,1,Non-Hispanic White,Non-Hispanic black,1.05,0.89,1.25
10.1016/j.fertnstert.2021.02.032,8,No,NA,No,NA,Cycle cancellation,RR,NA,none,2,Non-Hispanic White,Asian/Pacific islander,0.88,0.78,1
10.1016/j.fertnstert.2021.02.032,8,No,NA,No,NA,Cycle cancellation,RR,NA,none,3,Non-Hispanic White,Hispanic,0.96,0.76,1.21
10.1016/j.fertnstert.2021.02.032,8,No,NA,No,NA,Cycle cancellation,RR,NA,none,4,Non-Hispanic White,"American Indian, Alaskan native, or mixed race including 2+ selected races",0.87,0.62,1.22
10.1016/j.fertnstert.2021.02.032,9,No,NA,No,NA,Hyperstimulation,RR,NA,none,1,Non-Hispanic White,Non-Hispanic black,1.67,0.82,3.41
10.1016/j.fertnstert.2021.02.032,9,No,NA,No,NA,Hyperstimulation,RR,NA,none,2,Non-Hispanic White,Asian/Pacific islander,0.61,0.28,1.32
10.1016/j.fertnstert.2021.02.032,9,No,NA,No,NA,Hyperstimulation,RR,NA,none,3,Non-Hispanic White,Hispanic,1.09,0.3,4.05
10.1016/j.fertnstert.2021.02.032,9,No,NA,No,NA,Hyperstimulation,RR,NA,none,4,Non-Hispanic White,"American Indian, Alaskan native, or mixed race including 2+ selected races",0.86,0.11,6.6
10.1016/j.fertnstert.2021.02.032,10,No,NA,No,NA,number of oocytes retrieved,log risk,NA,none,1,Non-Hispanic White,Non-Hispanic black,-0.01,-0.05,0.03
10.1016/j.fertnstert.2021.02.032,10,No,NA,No,NA,number of oocytes retrieved,log risk,NA,none,2,Non-Hispanic White,Asian/Pacific islander,-0.13,-0.15,-0.1
10.1016/j.fertnstert.2021.02.032,10,No,NA,No,NA,number of oocytes retrieved,log risk,NA,none,3,Non-Hispanic White,Hispanic,-0.06,-0.1,-0.02
10.1016/j.fertnstert.2021.02.032,10,No,NA,No,NA,number of oocytes retrieved,log risk,NA,none,4,Non-Hispanic White,"American Indian, Alaskan native, or mixed race including 2+ selected races",0.01,-0.04,0.06
10.1016/j.fertnstert.2021.02.032,11,No,NA,No,NA,mature oocytes,predicted percentage,NA,none,1,N/A,Non-Hispanic white,79.1,77.2,81
10.1016/j.fertnstert.2021.02.032,11,No,NA,No,NA,mature oocytes,predicted percentage,NA,none,2,N/A,Non-Hispanic black,80,78.2,81.8
10.1016/j.fertnstert.2021.02.032,11,No,NA,No,NA,mature oocytes,predicted percentage,NA,none,3,N/A,Asian/Pacific Islander,78.9,77.1,80.8
10.1016/j.fertnstert.2021.02.032,11,No,NA,No,NA,mature oocytes,predicted percentage,NA,none,4,N/A,Hispanic,78.9,77.2,80.6
10.1016/j.fertnstert.2021.02.032,11,No,NA,No,NA,mature oocytes,predicted percentage,NA,none,5,N/A,"American Indian, Alaskan native, or mixed race including 2+ selected races",79.7,78.2,81.2
10.1016/j.fertnstert.2021.02.032,12,No,NA,No,NA,Gonadotropin dose > 4000 IU,RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",1,Non-Hispanic White,Non-Hispanic Black,1,0.9,1.12
10.1016/j.fertnstert.2021.02.032,12,No,NA,No,NA,Gonadotropin dose > 4000 IU,RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",2,Non-Hispanic White,Asian/Pacific islander,0.87,0.79,0.96
10.1016/j.fertnstert.2021.02.032,12,No,NA,No,NA,Gonadotropin dose > 4000 IU,RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",3,Non-Hispanic White,Hispanic,0.95,0.88,1.04
10.1016/j.fertnstert.2021.02.032,12,No,NA,No,NA,Gonadotropin dose > 4000 IU,RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",4,Non-Hispanic White,"American Indian, Alaskan native, or mixed race including 2+ selected races",0.91,0.79,1.05
10.1016/j.fertnstert.2021.02.032,13,No,NA,No,NA,Cycle cancellation,RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",1,Non-Hispanic White,Non-Hispanic Black,1.03,0.87,1.23
10.1016/j.fertnstert.2021.02.032,13,No,NA,No,NA,Cycle cancellation,RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",2,Non-Hispanic White,Asian/Pacific islander,0.83,0.74,0.94
10.1016/j.fertnstert.2021.02.032,13,No,NA,No,NA,Cycle cancellation,RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",3,Non-Hispanic White,Hispanic,0.94,0.74,1.19
10.1016/j.fertnstert.2021.02.032,13,No,NA,No,NA,Cycle cancellation,RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",4,Non-Hispanic White,"American Indian, Alaskan native, or mixed race including 2+ selected races",0.87,0.62,1.21
10.1016/j.fertnstert.2021.02.032,14,No,NA,No,NA,Hyperstimulation,RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",1,Non-Hispanic White,Non-Hispanic Black,1.78,0.88,3.6
10.1016/j.fertnstert.2021.02.032,14,No,NA,No,NA,Hyperstimulation,RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",2,Non-Hispanic White,Asian/Pacific islander,0.73,0.34,1.58
10.1016/j.fertnstert.2021.02.032,14,No,NA,No,NA,Hyperstimulation,RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",3,Non-Hispanic White,Hispanic,1.15,0.31,4.29
10.1016/j.fertnstert.2021.02.032,14,No,NA,No,NA,Hyperstimulation,RR,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",4,Non-Hispanic White,"American Indian, Alaskan native, or mixed race including 2+ selected races",0.89,0.12,6.77
10.1016/j.fertnstert.2021.02.032,15,No,NA,No,NA,number of oocytes retrieved,log risk,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",1,Non-Hispanic White,Non-Hispanic Black,0.04,0.01,0.06
10.1016/j.fertnstert.2021.02.032,15,No,NA,No,NA,number of oocytes retrieved,log risk,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",2,Non-Hispanic White,Asian/Pacific islander,-0.05,-0.07,-0.04
10.1016/j.fertnstert.2021.02.032,15,No,NA,No,NA,number of oocytes retrieved,log risk,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",3,Non-Hispanic White,Hispanic,-0.03,-0.07,0.01
10.1016/j.fertnstert.2021.02.032,15,No,NA,No,NA,number of oocytes retrieved,log risk,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",4,Non-Hispanic White,"American Indian, Alaskan native, or mixed race including 2+ selected races",0.02,-0.03,0.07
10.1016/j.fertnstert.2021.02.032,16,No,NA,No,NA,mature oocytes,predicted percentage,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",1,N/A,Non-Hispanic White,78.3,77.1,80.8
10.1016/j.fertnstert.2021.02.032,16,No,NA,No,NA,mature oocytes,predicted percentage,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",2,N/A,Non-Hispanic black,80,78.2,81.8
10.1016/j.fertnstert.2021.02.032,16,No,NA,No,NA,mature oocytes,predicted percentage,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",3,N/A,Asian/Pacific Islander,78.8,77,80.7
10.1016/j.fertnstert.2021.02.032,16,No,NA,No,NA,mature oocytes,predicted percentage,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",4,N/A,Hispanic,79.2,77.6,80.9
10.1016/j.fertnstert.2021.02.032,16,No,NA,No,NA,mature oocytes,predicted percentage,NA,"age, body mass index, stimulation protocol, diminished ovarian reserve",5,N/A,"American Indian, Alaskan native, or mixed race including 2+ selected races",79,77.5,80.5
10.1016/j.fertnstert.2021.05.092,1,No,NA,No,NA,Fertility preferences have changed due to the pandemic,OR,NA,"Age, sexual orientation, marital status, annual household income",1,White,Black or African American,3.51,1.23,10.03
10.1016/j.fertnstert.2021.05.092,1,No,NA,No,NA,Fertility preferences have changed due to the pandemic,OR,NA,"Age, sexual orientation, marital status, annual household income",2,White,"Asian, Native Hawaiian, or Pacific Islander",1.08,0.52,2.22
10.1016/j.fertnstert.2021.05.092,1,No,NA,No,NA,Fertility preferences have changed due to the pandemic,OR,NA,"Age, sexual orientation, marital status, annual household income",3,White,"American Indian, Alaska Native, or Other",1.85,0.61,5.59
10.1016/j.fertnstert.2021.05.092,2,No,NA,No,NA,Fertility preferences have changed due to the pandemic,OR,NA,"Age, sexual orientation, marital status, annual household income, health insurance",1,White,Black or African American,3.59,1.25,10.26
10.1016/j.fertnstert.2021.05.092,2,No,NA,No,NA,Fertility preferences have changed due to the pandemic,OR,NA,"Age, sexual orientation, marital status, annual household income, health insurance",2,White,"Asian, Native Hawaiian, or Pacific Islander",1.1,0.53,2.27
10.1016/j.fertnstert.2021.05.092,2,No,NA,No,NA,Fertility preferences have changed due to the pandemic,OR,NA,"Age, sexual orientation, marital status, annual household income, health insurance",3,White,"American Indian, Alaska Native, or Other",2.18,0.7,6.78
10.1016/j.fertnstert.2021.05.092,3,No,NA,No,NA,Fertility preferences have changed due to the pandemic,OR,NA,"Age, sexual orientation, marital status, annual household income, health insurance, physical health, COVID-19-related experiences",1,White,Black or African American,4.76,1.4,16.19
10.1016/j.fertnstert.2021.05.092,3,No,NA,No,NA,Fertility preferences have changed due to the pandemic,OR,NA,"Age, sexual orientation, marital status, annual household income, health insurance, physical health, COVID-19-related experiences",2,White,"Asian, Native Hawaiian, or Pacific Islander",1.21,0.56,2.62
10.1016/j.fertnstert.2021.05.092,3,No,NA,No,NA,Fertility preferences have changed due to the pandemic,OR,NA,"Age, sexual orientation, marital status, annual household income, health insurance, physical health, COVID-19-related experiences",3,White,"American Indian, Alaska Native, or Other",2.73,0.82,9.07
10.1016/j.fertnstert.2021.05.092,4,No,NA,No,NA,Fertility preferences have changed due to the pandemic,OR,NA,"Age, sexual orientation, marital status, annual household income, health insurance, physical health, COVID-19-related experiences, reproductive health - trying to conceive",1,White,Black or African American,5.45,1.5,19.9
10.1016/j.fertnstert.2021.05.092,4,No,NA,No,NA,Fertility preferences have changed due to the pandemic,OR,NA,"Age, sexual orientation, marital status, annual household income, health insurance, physical health, COVID-19-related experiences, reproductive health - trying to conceive",2,White,"Asian, Native Hawaiian, or Pacific Islander",1.27,0.57,2.82
10.1016/j.fertnstert.2021.05.092,4,No,NA,No,NA,Fertility preferences have changed due to the pandemic,OR,NA,"Age, sexual orientation, marital status, annual household income, health insurance, physical health, COVID-19-related experiences, reproductive health - trying to conceive",3,White,"American Indian, Alaska Native, or Other",2.88,0.86,9.69
10.1016/j.fertnstert.2021.05.092,5,No,NA,No,NA,Trying to conceive later,OR,NA,"Age, sexual orientation, annual household income",1,White,Black or African American,0.65,0.12,3.52
10.1016/j.fertnstert.2021.05.092,5,No,NA,No,NA,Trying to conceive later,OR,NA,"Age, sexual orientation, annual household income",2,White,"Asian, Native Hawaiian, or Pacific Islander",4.14,0.44,38.59
10.1016/j.fertnstert.2021.05.092,5,No,NA,No,NA,Trying to conceive later,OR,NA,"Age, sexual orientation, annual household income",3,White,"American Indian, Alaska Native, or Other",2.41,0.21,28.27
10.1016/j.fertnstert.2021.05.092,6,No,NA,No,NA,Trying to conceive later,OR,NA,"Age, sexual orientation, annual household income, reproductive health - trying to conceive",1,White,Black or African American,0.77,0.11,5.44
10.1016/j.fertnstert.2021.05.092,6,No,NA,No,NA,Trying to conceive later,OR,NA,"Age, sexual orientation, annual household income, reproductive health - trying to conceive",2,White,"Asian, Native Hawaiian, or Pacific Islander",3.5,0.31,38.91
10.1016/j.fertnstert.2021.05.092,6,No,NA,No,NA,Trying to conceive later,OR,NA,"Age, sexual orientation, annual household income, reproductive health - trying to conceive",3,White,"American Indian, Alaska Native, or Other",2.93,0.23,36.92
10.1016/j.fertnstert.2021.05.092,7,No,NA,No,NA,Trying to conceive later,OR,NA,"Age, sexual orientation, annual household income, reproductive health - trying to conceive, mental health - trait anxiety",1,White,Black or African American,0.51,0.06,4.46
10.1016/j.fertnstert.2021.05.092,7,No,NA,No,NA,Trying to conceive later,OR,NA,"Age, sexual orientation, annual household income, reproductive health - trying to conceive, mental health - trait anxiety",2,White,"Asian, Native Hawaiian, or Pacific Islander",1.98,0.17,23.23
10.1016/j.fertnstert.2021.05.092,7,No,NA,No,NA,Trying to conceive later,OR,NA,"Age, sexual orientation, annual household income, reproductive health - trying to conceive, mental health - trait anxiety",3,White,"American Indian, Alaska Native, or Other",2.06,0.16,26.38
10.1016/j.fertnstert.2021.05.092,8,No,NA,No,NA,Trying to conceive later,OR,NA,"Age, sexual orientation, annual household income, reproductive health - trying to conceive, mental health - depressive symptoms",1,White,Black or African American,0.62,0.07,5.77
10.1016/j.fertnstert.2021.05.092,8,No,NA,No,NA,Trying to conceive later,OR,NA,"Age, sexual orientation, annual household income, reproductive health - trying to conceive, mental health - depressive symptoms",2,White,"Asian, Native Hawaiian, or Pacific Islander",1.33,0.1,18.06
10.1016/j.fertnstert.2021.05.092,8,No,NA,No,NA,Trying to conceive later,OR,NA,"Age, sexual orientation, annual household income, reproductive health - trying to conceive, mental health - depressive symptoms",3,White,"American Indian, Alaska Native, or Other",2.65,0.2,35.71
10.1016/j.fertnstert.2021.05.092,9,No,NA,No,NA,Trying to conceive later,OR,NA,"Age, sexual orientation, annual household income, reproductive health - trying to conceive, mental health - social support",1,White,Black or African American,0.59,0.07,4.95
10.1016/j.fertnstert.2021.05.092,9,No,NA,No,NA,Trying to conceive later,OR,NA,"Age, sexual orientation, annual household income, reproductive health - trying to conceive, mental health - social support",2,White,"Asian, Native Hawaiian, or Pacific Islander",3.3,0.29,37.02
10.1016/j.fertnstert.2021.05.092,9,No,NA,No,NA,Trying to conceive later,OR,NA,"Age, sexual orientation, annual household income, reproductive health - trying to conceive, mental health - social support",3,White,"American Indian, Alaska Native, or Other",3.78,0.28,50.94
10.1016/j.fertnstert.2021.11.019,1,No,NA,No,NA,clinical pregnancy,RR,NA,None,1,White,Black,0.94,0.85,1.02
10.1016/j.fertnstert.2021.11.019,1,No,NA,No,NA,clinical pregnancy,RR,NA,None,2,White,Asian,1,0.93,1.06
10.1016/j.fertnstert.2021.11.019,1,No,NA,No,NA,clinical pregnancy,RR,NA,None,3,White,Hispanic,0.95,0.86,1.05
10.1016/j.fertnstert.2021.11.019,2,No,NA,No,NA,clinical pregnancy,RR,NA,"age, body mass index, parity, smoking status, uterine or tubal factor diagnosis and history of prior fresh or frozen embryo transfer",1,White,Black,0.94,0.85,1.04
10.1016/j.fertnstert.2021.11.019,2,No,NA,No,NA,clinical pregnancy,RR,NA,"age, body mass index, parity, smoking status, uterine or tubal factor diagnosis and history of prior fresh or frozen embryo transfer",2,White,Asian,1.02,0.95,1.1
10.1016/j.fertnstert.2021.11.019,2,No,NA,No,NA,clinical pregnancy,RR,NA,"age, body mass index, parity, smoking status, uterine or tubal factor diagnosis and history of prior fresh or frozen embryo transfer",3,White,Hispanic,0.93,0.83,1.04
10.1016/j.fertnstert.2021.11.019,3,No,NA,No,NA,clinical loss,RR,NA,None,1,White,Black,1.59,1.28,1.99
10.1016/j.fertnstert.2021.11.019,3,No,NA,No,NA,clinical loss,RR,NA,None,2,White,Asian,1.1,0.92,1.34
10.1016/j.fertnstert.2021.11.019,3,No,NA,No,NA,clinical loss,RR,NA,None,3,White,Hispanic,1.03,0.77,1.38
10.1016/j.fertnstert.2021.11.019,4,No,NA,No,NA,clinical loss,RR,NA,"age, body mass index, parity, smoking status, uterine or tubal factor diagnosis and history of prior fresh or frozen embryo transfer",1,White,Black,1.65,1.28,2.13
10.1016/j.fertnstert.2021.11.019,4,No,NA,No,NA,clinical loss,RR,NA,"age, body mass index, parity, smoking status, uterine or tubal factor diagnosis and history of prior fresh or frozen embryo transfer",2,White,Asian,1.17,0.94,1.45
10.1016/j.fertnstert.2021.11.019,4,No,NA,No,NA,clinical loss,RR,NA,"age, body mass index, parity, smoking status, uterine or tubal factor diagnosis and history of prior fresh or frozen embryo transfer",3,White,Hispanic,0.74,0.49,1.12
10.1016/j.fertnstert.2021.11.019,5,No,NA,No,NA,multiple pregnancy,RR,NA,None,1,White,Black,1.11,0.82,1.52
10.1016/j.fertnstert.2021.11.019,5,No,NA,No,NA,multiple pregnancy,RR,NA,None,2,White,Asian,0.85,0.66,1.09
10.1016/j.fertnstert.2021.11.019,5,No,NA,No,NA,multiple pregnancy,RR,NA,None,3,White,Hispanic,1.28,0.96,1.72
10.1016/j.fertnstert.2021.11.019,6,No,NA,No,NA,multiple pregnancy,RR,NA,"age, body mass index, parity, smoking status, uterine or tubal factor diagnosis and history of prior fresh or frozen embryo transfer",1,White,Black,0.98,0.68,1.41
10.1016/j.fertnstert.2021.11.019,6,No,NA,No,NA,multiple pregnancy,RR,NA,"age, body mass index, parity, smoking status, uterine or tubal factor diagnosis and history of prior fresh or frozen embryo transfer",2,White,Asian,0.88,0.67,1.17
10.1016/j.fertnstert.2021.11.019,6,No,NA,No,NA,multiple pregnancy,RR,NA,"age, body mass index, parity, smoking status, uterine or tubal factor diagnosis and history of prior fresh or frozen embryo transfer",3,White,Hispanic,1.24,0.88,1.98
10.1016/j.fertnstert.2021.11.019,7,No,NA,No,NA,live birth,RR,NA,None,1,White,Black,0.82,0.73,0.92
10.1016/j.fertnstert.2021.11.019,7,No,NA,No,NA,live birth,RR,NA,None,2,White,Asian,0.97,0.9,1.05
10.1016/j.fertnstert.2021.11.019,7,No,NA,No,NA,live birth,RR,NA,None,3,White,Hispanic,0.94,0.84,1.06
10.1016/j.fertnstert.2021.11.019,8,No,NA,No,NA,live birth,RR,NA,"age, body mass index, parity, smoking status, uterine or tubal factor diagnosis and history of prior fresh or frozen embryo transfer",1,White,Black,0.8,0.7,0.92
10.1016/j.fertnstert.2021.11.019,8,No,NA,No,NA,live birth,RR,NA,"age, body mass index, parity, smoking status, uterine or tubal factor diagnosis and history of prior fresh or frozen embryo transfer",2,White,Asian,0.98,0.9,1.07
10.1016/j.fertnstert.2021.11.019,8,No,NA,No,NA,live birth,RR,NA,"age, body mass index, parity, smoking status, uterine or tubal factor diagnosis and history of prior fresh or frozen embryo transfer",3,White,Hispanic,0.99,0.87,1.11
10.1016/j.fertnstert.2021.11.019,9,No,NA,Yes,embryos tested with preimplantation genetic testing,clinical pregnancy,RR,NA,None,1,White,Black,0.84,0.67,1.05
10.1016/j.fertnstert.2021.11.019,9,No,NA,Yes,embryos tested with preimplantation genetic testing,clinical pregnancy,RR,NA,None,2,White,Asian,1.03,0.94,1.14
10.1016/j.fertnstert.2021.11.019,9,No,NA,Yes,embryos tested with preimplantation genetic testing,clinical pregnancy,RR,NA,None,3,White,Hispanic,1.01,0.84,1.2
10.1016/j.fertnstert.2021.11.019,10,No,NA,Yes,embryos tested with preimplantation genetic testing,clinical pregnancy,RR,NA,"age, body mass index, parity, smoking status, history of prior fresh or frozen embryo transfer, and uterine or tubal factor diagnosis",1,White,Black,0.86,0.67,1.11
10.1016/j.fertnstert.2021.11.019,10,No,NA,Yes,embryos tested with preimplantation genetic testing,clinical pregnancy,RR,NA,"age, body mass index, parity, smoking status, history of prior fresh or frozen embryo transfer, and uterine or tubal factor diagnosis",2,White,Asian,1.05,0.95,1.16
10.1016/j.fertnstert.2021.11.019,10,No,NA,Yes,embryos tested with preimplantation genetic testing,clinical pregnancy,RR,NA,"age, body mass index, parity, smoking status, history of prior fresh or frozen embryo transfer, and uterine or tubal factor diagnosis",3,White,Hispanic,0.99,0.81,1.2
10.1016/j.fertnstert.2021.11.019,11,No,NA,Yes,embryos tested with preimplantation genetic testing,clinical loss,RR,NA,None,1,White,Black,1.76,1,3.07
10.1016/j.fertnstert.2021.11.019,11,No,NA,Yes,embryos tested with preimplantation genetic testing,clinical loss,RR,NA,None,2,White,Asian,0.91,0.62,1.34
10.1016/j.fertnstert.2021.11.019,11,No,NA,Yes,embryos tested with preimplantation genetic testing,clinical loss,RR,NA,None,3,White,Hispanic,1.35,0.75,2.43
10.1016/j.fertnstert.2021.11.019,12,No,NA,Yes,embryos tested with preimplantation genetic testing,clinical loss,RR,NA,"age, body mass index, parity, smoking status, history of prior fresh or frozen embryo transfer, and uterine or tubal factor diagnosis",1,White,Black,1.61,0.82,3.17
10.1016/j.fertnstert.2021.11.019,12,No,NA,Yes,embryos tested with preimplantation genetic testing,clinical loss,RR,NA,"age, body mass index, parity, smoking status, history of prior fresh or frozen embryo transfer, and uterine or tubal factor diagnosis",2,White,Asian,0.98,0.64,1.31
10.1016/j.fertnstert.2021.11.019,12,No,NA,Yes,embryos tested with preimplantation genetic testing,clinical loss,RR,NA,"age, body mass index, parity, smoking status, history of prior fresh or frozen embryo transfer, and uterine or tubal factor diagnosis",3,White,Hispanic,0.9,0.41,1.98
10.1016/j.fertnstert.2021.11.019,13,No,NA,Yes,embryos tested with preimplantation genetic testing,multiple pregnancy,RR,NA,None,1,White,Black,0.52,0.13,2.07
10.1016/j.fertnstert.2021.11.019,13,No,NA,Yes,embryos tested with preimplantation genetic testing,multiple pregnancy,RR,NA,None,2,White,Asian,0.93,0.57,1.52
10.1016/j.fertnstert.2021.11.019,13,No,NA,Yes,embryos tested with preimplantation genetic testing,multiple pregnancy,RR,NA,None,3,White,Hispanic,1.88,1.04,3.38
10.1016/j.fertnstert.2021.11.019,14,No,NA,Yes,embryos tested with preimplantation genetic testing,multiple pregnancy,RR,NA,"age, body mass index, parity, smoking status, history of prior fresh or frozen embryo transfer, and uterine or tubal factor diagnosis",1,White,Black,0.64,0.17,2.46
10.1016/j.fertnstert.2021.11.019,14,No,NA,Yes,embryos tested with preimplantation genetic testing,multiple pregnancy,RR,NA,"age, body mass index, parity, smoking status, history of prior fresh or frozen embryo transfer, and uterine or tubal factor diagnosis",2,White,Asian,0.94,0.57,1.55
10.1016/j.fertnstert.2021.11.019,14,No,NA,Yes,embryos tested with preimplantation genetic testing,multiple pregnancy,RR,NA,"age, body mass index, parity, smoking status, history of prior fresh or frozen embryo transfer, and uterine or tubal factor diagnosis",3,White,Hispanic,1.9,1.04,3.46
10.1016/j.fertnstert.2021.11.019,15,No,NA,Yes,embryos tested with preimplantation genetic testing,live birth,RR,NA,None,1,White,Black,0.73,0.53,1
10.1016/j.fertnstert.2021.11.019,15,No,NA,Yes,embryos tested with preimplantation genetic testing,live birth,RR,NA,None,2,White,Asian,1.05,0.94,1.17
10.1016/j.fertnstert.2021.11.019,15,No,NA,Yes,embryos tested with preimplantation genetic testing,live birth,RR,NA,None,3,White,Hispanic,0.95,0.76,1.17
10.1016/j.fertnstert.2021.11.019,16,No,NA,Yes,embryos tested with preimplantation genetic testing,live birth,RR,NA,"age, body mass index, parity, smoking status, history of prior fresh or frozen embryo transfer, and uterine or tubal factor diagnosis",1,White,Black,0.77,0.54,1.08
10.1016/j.fertnstert.2021.11.019,16,No,NA,Yes,embryos tested with preimplantation genetic testing,live birth,RR,NA,"age, body mass index, parity, smoking status, history of prior fresh or frozen embryo transfer, and uterine or tubal factor diagnosis",2,White,Asian,1.05,0.93,1.19
10.1016/j.fertnstert.2021.11.019,16,No,NA,Yes,embryos tested with preimplantation genetic testing,live birth,RR,NA,"age, body mass index, parity, smoking status, history of prior fresh or frozen embryo transfer, and uterine or tubal factor diagnosis",3,White,Hispanic,1.01,0.81,1.26
10.1016/j.fertnstert.2023.02.037,1,No,NA,No,NA,Live birth,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, nulliparity, history of recurrent pregnancy loss, diminished ovarian reserve, tubal factor infertility, uterine factor infertility, prior assisted reproductive technology treatment, use of preimplantation genetic testing, total number of embryos transferred, ever underwent blastocyst transfer, ever had a thawed embryo transfer""",1,White in nonmandate states,White in mandate states/global effect of state mandate,1.1,1.06,1.17
10.1016/j.fertnstert.2023.02.037,1,No,NA,No,NA,Live birth,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, nulliparity, history of recurrent pregnancy loss, diminished ovarian reserve, tubal factor infertility, uterine factor infertility, prior assisted reproductive technology treatment, use of preimplantation genetic testing, total number of embryos transferred, ever underwent blastocyst transfer, ever had a thawed embryo transfer""",2,White in nonmandate states,Black in nonmandate states,0.82,0.77,0.87
10.1016/j.fertnstert.2023.02.037,1,No,NA,No,NA,Live birth,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, nulliparity, history of recurrent pregnancy loss, diminished ovarian reserve, tubal factor infertility, uterine factor infertility, prior assisted reproductive technology treatment, use of preimplantation genetic testing, total number of embryos transferred, ever underwent blastocyst transfer, ever had a thawed embryo transfer""",3,White in nonmandate states,Black in mandate states,0.91,0.74,1.13
10.1016/j.fertnstert.2023.02.037,1,No,NA,No,NA,Live birth,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, nulliparity, history of recurrent pregnancy loss, diminished ovarian reserve, tubal factor infertility, uterine factor infertility, prior assisted reproductive technology treatment, use of preimplantation genetic testing, total number of embryos transferred, ever underwent blastocyst transfer, ever had a thawed embryo transfer""",4,White in nonmandate states,Hispanic in nonmandate states,0.93,0.89,0.99
10.1016/j.fertnstert.2023.02.037,1,No,NA,No,NA,Live birth,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, nulliparity, history of recurrent pregnancy loss, diminished ovarian reserve, tubal factor infertility, uterine factor infertility, prior assisted reproductive technology treatment, use of preimplantation genetic testing, total number of embryos transferred, ever underwent blastocyst transfer, ever had a thawed embryo transfer""",5,White in nonmandate states,Hispanic in mandate states,1.13,0.98,1.31
10.1016/j.fertnstert.2023.02.037,1,No,NA,No,NA,Live birth,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, nulliparity, history of recurrent pregnancy loss, diminished ovarian reserve, tubal factor infertility, uterine factor infertility, prior assisted reproductive technology treatment, use of preimplantation genetic testing, total number of embryos transferred, ever underwent blastocyst transfer, ever had a thawed embryo transfer""",6,White in nonmandate states,Asian and others in nonmandate states,0.96,0.93,0.99
10.1016/j.fertnstert.2023.02.037,1,No,NA,No,NA,Live birth,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, nulliparity, history of recurrent pregnancy loss, diminished ovarian reserve, tubal factor infertility, uterine factor infertility, prior assisted reproductive technology treatment, use of preimplantation genetic testing, total number of embryos transferred, ever underwent blastocyst transfer, ever had a thawed embryo transfer""",7,White in nonmandate states,Asian and others in mandate states,1.04,0.92,1.17
10.1016/j.fertnstert.2023.02.037,2,No,NA,No,NA,Live birth,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, nulliparity, history of recurrent pregnancy loss, diminished ovarian reserve, tubal factor infertility, uterine factor infertility, prior assisted reproductive technology treatment, use of preimplantation genetic testing, total number of embryos transferred, ever underwent blastocyst transfer, ever had a thawed embryo transfer""",1,White in nonmandate states,White in mandate states/global effect of state mandate,1.05,1.01,1.1
10.1016/j.fertnstert.2023.02.037,2,No,NA,No,NA,Live birth,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, nulliparity, history of recurrent pregnancy loss, diminished ovarian reserve, tubal factor infertility, uterine factor infertility, prior assisted reproductive technology treatment, use of preimplantation genetic testing, total number of embryos transferred, ever underwent blastocyst transfer, ever had a thawed embryo transfer""",2,White in nonmandate states,Black in nonmandate states,0.81,0.77,0.86
10.1016/j.fertnstert.2023.02.037,2,No,NA,No,NA,Live birth,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, nulliparity, history of recurrent pregnancy loss, diminished ovarian reserve, tubal factor infertility, uterine factor infertility, prior assisted reproductive technology treatment, use of preimplantation genetic testing, total number of embryos transferred, ever underwent blastocyst transfer, ever had a thawed embryo transfer""",3,White in nonmandate states,Black in mandate states,0.81,0.67,0.99
10.1016/j.fertnstert.2023.02.037,2,No,NA,No,NA,Live birth,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, nulliparity, history of recurrent pregnancy loss, diminished ovarian reserve, tubal factor infertility, uterine factor infertility, prior assisted reproductive technology treatment, use of preimplantation genetic testing, total number of embryos transferred, ever underwent blastocyst transfer, ever had a thawed embryo transfer""",4,White in nonmandate states,Hispanic in nonmandate states,0.95,0.9,0.996
10.1016/j.fertnstert.2023.02.037,2,No,NA,No,NA,Live birth,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, nulliparity, history of recurrent pregnancy loss, diminished ovarian reserve, tubal factor infertility, uterine factor infertility, prior assisted reproductive technology treatment, use of preimplantation genetic testing, total number of embryos transferred, ever underwent blastocyst transfer, ever had a thawed embryo transfer""",5,White in nonmandate states,Hispanic in mandate states,1.05,0.91,1.21
10.1016/j.fertnstert.2023.02.037,2,No,NA,No,NA,Live birth,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, nulliparity, history of recurrent pregnancy loss, diminished ovarian reserve, tubal factor infertility, uterine factor infertility, prior assisted reproductive technology treatment, use of preimplantation genetic testing, total number of embryos transferred, ever underwent blastocyst transfer, ever had a thawed embryo transfer""",6,White in nonmandate states,Asian and others in nonmandate states,0.98,0.95,1.01
10.1016/j.fertnstert.2023.02.037,2,No,NA,No,NA,Live birth,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, nulliparity, history of recurrent pregnancy loss, diminished ovarian reserve, tubal factor infertility, uterine factor infertility, prior assisted reproductive technology treatment, use of preimplantation genetic testing, total number of embryos transferred, ever underwent blastocyst transfer, ever had a thawed embryo transfer""",7,White in nonmandate states,Asian and others in mandate states,0.97,0.87,1.08
10.1016/j.fertnstert.2023.02.037,3,No,NA,No,NA,Clinical pregnancy,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, history of recurrent pregnancy loss, tubal factor infertility, uterine factor infertility, endometriosis, use of preimplantation genetic testing, ever underwent blastocyst transfer, ever had a thawed embryo transfer",1,White in nonmandate states,White in mandate states/global effect of state mandate,1.08,1.04,1.13
10.1016/j.fertnstert.2023.02.037,3,No,NA,No,NA,Clinical pregnancy,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, history of recurrent pregnancy loss, tubal factor infertility, uterine factor infertility, endometriosis, use of preimplantation genetic testing, ever underwent blastocyst transfer, ever had a thawed embryo transfer",2,White in nonmandate states,Black in nonmandate states,0.84,0.8,0.88
10.1016/j.fertnstert.2023.02.037,3,No,NA,No,NA,Clinical pregnancy,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, history of recurrent pregnancy loss, tubal factor infertility, uterine factor infertility, endometriosis, use of preimplantation genetic testing, ever underwent blastocyst transfer, ever had a thawed embryo transfer",3,White in nonmandate states,Black in mandate states,0.84,0.69,1.02
10.1016/j.fertnstert.2023.02.037,3,No,NA,No,NA,Clinical pregnancy,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, history of recurrent pregnancy loss, tubal factor infertility, uterine factor infertility, endometriosis, use of preimplantation genetic testing, ever underwent blastocyst transfer, ever had a thawed embryo transfer",4,White in nonmandate states,Hispanic in nonmandate states,0.95,0.91,0.99
10.1016/j.fertnstert.2023.02.037,3,No,NA,No,NA,Clinical pregnancy,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, history of recurrent pregnancy loss, tubal factor infertility, uterine factor infertility, endometriosis, use of preimplantation genetic testing, ever underwent blastocyst transfer, ever had a thawed embryo transfer",5,White in nonmandate states,Hispanic in mandate states,1.08,0.96,1.22
10.1016/j.fertnstert.2023.02.037,3,No,NA,No,NA,Clinical pregnancy,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, history of recurrent pregnancy loss, tubal factor infertility, uterine factor infertility, endometriosis, use of preimplantation genetic testing, ever underwent blastocyst transfer, ever had a thawed embryo transfer",6,White in nonmandate states,Asian and others in nonmandate states,0.97,0.94,0.99
10.1016/j.fertnstert.2023.02.037,3,No,NA,No,NA,Clinical pregnancy,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, history of recurrent pregnancy loss, tubal factor infertility, uterine factor infertility, endometriosis, use of preimplantation genetic testing, ever underwent blastocyst transfer, ever had a thawed embryo transfer",7,White in nonmandate states,Asian and others in mandate states,1.03,0.93,1.13
10.1016/j.fertnstert.2023.02.037,4,No,NA,No,NA,Clinical pregnancy,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, history of recurrent pregnancy loss, tubal factor infertility, uterine factor infertility, endometriosis, use of preimplantation genetic testing, ever underwent blastocyst transfer, ever had a thawed embryo transfer",1,White in nonmandate states,White in mandate states/global effect of state mandate,1.05,1.02,1.09
10.1016/j.fertnstert.2023.02.037,4,No,NA,No,NA,Clinical pregnancy,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, history of recurrent pregnancy loss, tubal factor infertility, uterine factor infertility, endometriosis, use of preimplantation genetic testing, ever underwent blastocyst transfer, ever had a thawed embryo transfer",2,White in nonmandate states,Black in nonmandate states,0.84,0.8,0.88
10.1016/j.fertnstert.2023.02.037,4,No,NA,No,NA,Clinical pregnancy,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, history of recurrent pregnancy loss, tubal factor infertility, uterine factor infertility, endometriosis, use of preimplantation genetic testing, ever underwent blastocyst transfer, ever had a thawed embryo transfer",3,White in nonmandate states,Black in mandate states,0.81,0.69,0.95
10.1016/j.fertnstert.2023.02.037,4,No,NA,No,NA,Clinical pregnancy,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, history of recurrent pregnancy loss, tubal factor infertility, uterine factor infertility, endometriosis, use of preimplantation genetic testing, ever underwent blastocyst transfer, ever had a thawed embryo transfer",4,White in nonmandate states,Hispanic in nonmandate states,0.96,0.92,0.999
10.1016/j.fertnstert.2023.02.037,4,No,NA,No,NA,Clinical pregnancy,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, history of recurrent pregnancy loss, tubal factor infertility, uterine factor infertility, endometriosis, use of preimplantation genetic testing, ever underwent blastocyst transfer, ever had a thawed embryo transfer",5,White in nonmandate states,Hispanic in mandate states,1.04,0.93,1.16
10.1016/j.fertnstert.2023.02.037,4,No,NA,No,NA,Clinical pregnancy,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, history of recurrent pregnancy loss, tubal factor infertility, uterine factor infertility, endometriosis, use of preimplantation genetic testing, ever underwent blastocyst transfer, ever had a thawed embryo transfer",6,White in nonmandate states,Asian and others in nonmandate states,0.98,0.96,1
10.1016/j.fertnstert.2023.02.037,4,No,NA,No,NA,Clinical pregnancy,RR,NA,"recipient's age when initiating treatment, mean age of the donors at the time when they contributed the oocytes used in the recipient's assisted reproductive technology cycle, body mass index, history of recurrent pregnancy loss, tubal factor infertility, uterine factor infertility, endometriosis, use of preimplantation genetic testing, ever underwent blastocyst transfer, ever had a thawed embryo transfer",7,White in nonmandate states,Asian and others in mandate states,0.97,0.88,1.06
10.1016/j.fertnstert.2023.02.037,5,Yes,Nonmandate states,No,NA,Live birth,RR,NA,None,1,White,Black,0.75,0.71,0.8
10.1016/j.fertnstert.2023.02.037,5,Yes,Nonmandate states,No,NA,Live birth,RR,NA,None,2,White,Hispanic,0.94,0.89,0.98
10.1016/j.fertnstert.2023.02.037,5,Yes,Nonmandate states,No,NA,Live birth,RR,NA,None,3,White,Asian and others,0.98,0.95,1.01
10.1016/j.fertnstert.2023.02.037,6,Yes,Nonmandate states,No,NA,Live birth,RR,NA,Adjusted for unknown covariates,1,White,Black,0.82,0.77,0.87
10.1016/j.fertnstert.2023.02.037,6,Yes,Nonmandate states,No,NA,Live birth,RR,NA,Adjusted for unknown covariates,2,White,Hispanic,0.93,0.89,0.99
10.1016/j.fertnstert.2023.02.037,6,Yes,Nonmandate states,No,NA,Live birth,RR,NA,Adjusted for unknown covariates,3,White,Asian and others,0.96,0.93,0.99
10.1016/j.fertnstert.2023.02.037,7,Yes,Mandate states,No,NA,Live birth,RR,NA,None,1,White,Black,0.7,0.56,0.86
10.1016/j.fertnstert.2023.02.037,7,Yes,Mandate states,No,NA,Live birth,RR,NA,None,2,White,Hispanic,0.99,0.86,1.13
10.1016/j.fertnstert.2023.02.037,7,Yes,Mandate states,No,NA,Live birth,RR,NA,None,3,White,Asian and others,0.94,0.84,1.05
10.1016/j.fertnstert.2023.02.037,8,Yes,Mandate states,No,NA,Live birth,RR,NA,Adjusted for unknown covariates,1,White,Black,0.85,0.68,1.05
10.1016/j.fertnstert.2023.02.037,8,Yes,Mandate states,No,NA,Live birth,RR,NA,Adjusted for unknown covariates,2,White,Hispanic,1.02,0.87,1.19
10.1016/j.fertnstert.2023.02.037,8,Yes,Mandate states,No,NA,Live birth,RR,NA,Adjusted for unknown covariates,3,White,Asian and others,0.93,0.82,1.06
10.1016/j.fertnstert.2023.02.037,9,Yes,Nonmandate states,No,NA,Clinical pregnancy,RR,NA,None,1,White,Black,0.8,0.76,0.83
10.1016/j.fertnstert.2023.02.037,9,Yes,Nonmandate states,No,NA,Clinical pregnancy,RR,NA,None,2,White,Hispanic,0.95,0.91,0.98
10.1016/j.fertnstert.2023.02.037,9,Yes,Nonmandate states,No,NA,Clinical pregnancy,RR,NA,None,3,White,Asian and others,0.98,0.95,1.002
10.1016/j.fertnstert.2023.02.037,10,Yes,Nonmandate states,No,NA,Clinical pregnancy,RR,NA,Adjusted for unknown covariates,1,White,Black,0.84,0.8,0.89
10.1016/j.fertnstert.2023.02.037,10,Yes,Nonmandate states,No,NA,Clinical pregnancy,RR,NA,Adjusted for unknown covariates,2,White,Hispanic,0.95,0.91,0.99
10.1016/j.fertnstert.2023.02.037,10,Yes,Nonmandate states,No,NA,Clinical pregnancy,RR,NA,Adjusted for unknown covariates,3,White,Asian and others,0.97,0.94,0.99
10.1016/j.fertnstert.2023.02.037,11,Yes,Mandate states,No,NA,Clinical pregnancy,RR,NA,None,1,White,Black,0.71,0.59,0.85
10.1016/j.fertnstert.2023.02.037,11,Yes,Mandate states,No,NA,Clinical pregnancy,RR,NA,None,2,White,Hispanic,0.97,0.87,1.09
10.1016/j.fertnstert.2023.02.037,11,Yes,Mandate states,No,NA,Clinical pregnancy,RR,NA,None,3,White,Asian and others,0.94,0.86,1.03
10.1016/j.fertnstert.2023.02.037,12,Yes,Mandate states,No,NA,Clinical pregnancy,RR,NA,Adjusted for unknown covariates,1,White,Black,0.8,0.66,0.97
10.1016/j.fertnstert.2023.02.037,12,Yes,Mandate states,No,NA,Clinical pregnancy,RR,NA,Adjusted for unknown covariates,2,White,Hispanic,1,0.88,1.14
10.1016/j.fertnstert.2023.02.037,12,Yes,Mandate states,No,NA,Clinical pregnancy,RR,NA,Adjusted for unknown covariates,3,White,Asian and others,0.94,0.85,1.05
10.1016/j.fertnstert.2023.05.159,1,No,NA,No,NA,initial infertility consultation vs. no-showed and cancelled,OR,NA,"timing relative to the onset of the pandemic, insurance status, and type of visit",1,all other races,African American race,0.37,0.28,0.5
10.1016/j.ygyno.2021.07.011,1,No,NA,No,NA,Black race,OR,NA,"high school degree, median household income, insurance type, tumor stage, tumor grade, tumor histology, facility type",1,Non-adherent to NCCN guidelines for treatment,Adherent to NCCN guidelines for treatment,1,0.89,1.13
10.1016/j.ygyno.2021.07.011,2,Yes,Care adherent to NCCN guidelines for treatment,No,NA,Survival time in months,Median,NA,None,1,N/A,White,63.4,-99,-99
10.1016/j.ygyno.2021.07.011,2,Yes,Care adherent to NCCN guidelines for treatment,No,NA,Survival time in months,Median,NA,None,2,N/A,Black,51.4,-99,-99
10.1016/j.ygyno.2021.07.011,3,Yes,Care non-adherent to NCCN guidelines for treatment,No,NA,Survival time in months,Median,NA,None,1,N/A,White,60.5,-99,-99
10.1016/j.ygyno.2021.07.011,3,Yes,Care non-adherent to NCCN guidelines for treatment,No,NA,Survival time in months,Median,NA,None,2,N/A,Black,47.2,-99,-99
10.1016/j.ygyno.2021.07.011,4,No,NA,No,NA,Survival time in months,Median,NA,None,1,N/A,White,61.1,-99,-99
10.1016/j.ygyno.2021.07.011,4,No,NA,No,NA,Survival time in months,Median,NA,None,2,N/A,Black,49.3,-99,-99
10.1016/j.ygyno.2021.07.022,1,No,NA,No,NA,all-cause death,HR,NA,"age at diagnosis, diagnosis period, tumor stage, histology, receipt of adjuvant treatment",1,non-Hispanic White,non-Hispanic black,1.64,1.19,2.27
10.1016/j.ygyno.2021.07.022,2,Yes,age at diagnosis <65,No,NA,all-cause death,HR,NA,"diagnosis period, tumor stage, histology, receipt of adjuvant treatment",1,non-Hispanic White,non-Hispanic black,1.3,0.81,2.07
10.1016/j.ygyno.2021.07.022,3,Yes,age at diagnosis 65+,No,NA,all-cause death,HR,NA,"diagnosis period, tumor stage, histology, receipt of adjuvant treatment",1,non-Hispanic White,non-Hispanic black,1.36,0.86,2.15
10.1016/j.ygyno.2021.07.022,4,Yes,Diagnosis period 1988-1994,No,NA,all-cause death,HR,NA,"age at diagnosis, tumor stage, histology, receipt of adjuvant treatment",1,non-Hispanic White,non-Hispanic black,1.04,0.41,2.62
10.1016/j.ygyno.2021.07.022,5,Yes,Diagnosis period 1995-2004,No,NA,all-cause death,HR,NA,"age at diagnosis, tumor stage, histology, receipt of adjuvant treatment",1,non-Hispanic White,non-Hispanic black,1.68,1.07,2.65
10.1016/j.ygyno.2021.07.022,6,Yes,Diagnosis period 2005-2013,No,NA,all-cause death,HR,NA,"age at diagnosis, tumor stage, histology, receipt of adjuvant treatment",1,non-Hispanic White,non-Hispanic black,1.41,0.75,2.68
10.1016/j.ygyno.2021.07.022,7,Yes,Stage I/II,No,NA,all-cause death,HR,NA,"age at diagnosis, diagnosis period, histology, receipt of adjuvant treatment",1,non-Hispanic White,non-Hispanic black,1.81,1.17,2.79
10.1016/j.ygyno.2021.07.022,8,Yes,Stage III/IV,No,NA,all-cause death,HR,NA,"age at diagnosis, diagnosis period, histology, receipt of adjuvant treatment",1,non-Hispanic White,non-Hispanic black,1.05,0.59,1.86
10.1016/j.ygyno.2021.07.022,9,Yes,Stage Unknown,No,NA,all-cause death,HR,NA,"age at diagnosis, diagnosis period, histology, receipt of adjuvant treatment",1,non-Hispanic White,non-Hispanic black,0.88,0.22,3.52
10.1016/j.ygyno.2021.07.022,10,Yes,Histology Endometrioid low grade,No,NA,all-cause death,HR,NA,"age at diagnosis, diagnosis period, tumor stage, receipt of adjuvant treatment",1,non-Hispanic White,non-Hispanic black,2.47,1.55,3.95
10.1016/j.ygyno.2021.07.022,11,Yes,Histology Endometrioid high grade,No,NA,all-cause death,HR,NA,"age at diagnosis, diagnosis period, tumor stage, receipt of adjuvant treatment",1,non-Hispanic White,non-Hispanic black,0.45,0.21,0.97
10.1016/j.ygyno.2021.07.022,12,Yes,Histology Endometrioid ungraded,No,NA,all-cause death,HR,NA,"age at diagnosis, diagnosis period, tumor stage, receipt of adjuvant treatment",1,non-Hispanic White,non-Hispanic black,1.03,0.12,8.6
10.1016/j.ygyno.2021.07.022,13,Yes,Histology Non-endometrioid,No,NA,all-cause death,HR,NA,"age at diagnosis, diagnosis period, tumor stage, receipt of adjuvant treatment",1,non-Hispanic White,non-Hispanic black,2.05,1.08,3.9
10.1016/j.ygyno.2021.07.022,14,Yes,adjuvant treatment None,No,NA,all-cause death,HR,NA,"age at diagnosis, diagnosis period, tumor stage, histology",1,non-Hispanic White,non-Hispanic black,2.15,1.31,3.53
10.1016/j.ygyno.2021.07.022,15,Yes,adjuvant treatment radiation alone,No,NA,all-cause death,HR,NA,"age at diagnosis, diagnosis period, tumor stage, histology",1,non-Hispanic White,non-Hispanic black,1.4,0.76,2.59
10.1016/j.ygyno.2021.07.022,16,Yes,adjuvant treatment Chemotherapy alone,No,NA,all-cause death,HR,NA,"age at diagnosis, diagnosis period, tumor stage, histology",1,non-Hispanic White,non-Hispanic black,0.83,0.36,1.93
10.1016/j.ygyno.2021.07.022,17,Yes,adjuvant treatment Chemotherapy and radiation,No,NA,all-cause death,HR,NA,"age at diagnosis, diagnosis period, tumor stage, histology",1,non-Hispanic White,non-Hispanic black,0.68,0.13,3.62
10.1016/j.ygyno.2021.07.022,18,Yes,adjuvant treatment Unknown,No,NA,all-cause death,HR,NA,"age at diagnosis, diagnosis period, tumor stage, histology",1,non-Hispanic White,non-Hispanic black,1.14,0.12,10.1
10.1016/j.ygyno.2021.07.036,1,Yes,Race/Ethnicity - White,No,NA,ovarian cancer-specific death,HR,NA,"age at diagnosis, insurance status, marital status, stage at diagnosis, tumor size, tumor grade, histology, treatment adherence, Charlson-Comorbidity Score, year of diagnosis, ozone, and distance to major roadway",1,average exposure < 20 parts per billion of nitrogen dioxide,average exposure 20 - 30 parts per billion of nitrogen dioxide,1.34,1.27,1.42
10.1016/j.ygyno.2021.07.036,2,Yes,Race/Ethnicity - White,No,NA,ovarian cancer-specific death,HR,NA,"age at diagnosis, insurance status, marital status, stage at diagnosis, tumor size, tumor grade, histology, treatment adherence, Charlson-Comorbidity Score, year of diagnosis, ozone, and distance to major roadway",1,average exposure < 20 parts per billion of nitrogen dioxide,average exposure >30 parts per billion of nitrogen dioxide,2.31,2.12,2.53
10.1016/j.ygyno.2021.07.036,3,Yes,Race/Ethnicity - White,No,NA,ovarian cancer-specific death,HR,NA,"age at diagnosis, insurance status, marital status, stage at diagnosis, tumor size, tumor grade, histology, treatment adherence, Charlson-Comorbidity Score, year of diagnosis, NO2, and distance to major roadway",1,average exposure to Ozone equivalent to an interquartile range lower,average exposure to Ozone  equivalent to an interquartile range higher,1.01,0.99,1.04
10.1016/j.ygyno.2021.07.036,4,Yes,Race/Ethnicity - White,No,NA,ovarian cancer-specific death,HR,NA,"age at diagnosis, insurance status, marital status, stage at diagnosis, tumor size, tumor grade, histology, treatment adherence, Charlson-Comorbidity Score, year of diagnosis, ozone, and distance to major roadway",1,average exposure to PM2.5 equivalent to an interquartile range lower,average exposure to PM2.5 equivalent to an interquartile range higher,1.45,1.41,1.5
10.1016/j.ygyno.2021.07.036,5,Yes,Race/Ethnicity - White,No,NA,ovarian cancer-specific death,HR,NA,"age at diagnosis, insurance status, marital status, stage at diagnosis, tumor size, tumor grade, histology, treatment adherence, Charlson-Comorbidity Score, year of diagnosis, ozone, and distance to major roadway",1,average exposure to Ozone equivalent to an interquartile range lower,average exposure to Ozone  equivalent to an interquartile range higher,1.03,1,1.06
10.1016/j.ygyno.2021.07.036,6,Yes,Race/Ethnicity - Black,No,NA,ovarian cancer-specific death,HR,NA,"age at diagnosis, insurance status, marital status, stage at diagnosis, tumor size, tumor grade, histology, treatment adherence, Charlson-Comorbidity Score, year of diagnosis, ozone, and distance to major roadway",1,average exposure < 20 parts per billion of nitrogen dioxide,average exposure 20 - 30 parts per billion of nitrogen dioxide,1.14,0.95,1.37
10.1016/j.ygyno.2021.07.036,7,Yes,Race/Ethnicity - Black,No,NA,ovarian cancer-specific death,HR,NA,"age at diagnosis, insurance status, marital status, stage at diagnosis, tumor size, tumor grade, histology, treatment adherence, Charlson-Comorbidity Score, year of diagnosis, ozone, and distance to major roadway",1,average exposure < 20 parts per billion of nitrogen dioxide,average exposure >30 parts per billion of nitrogen dioxide,2.56,1.93,3.4
10.1016/j.ygyno.2021.07.036,8,Yes,Race/Ethnicity - Black,No,NA,ovarian cancer-specific death,HR,NA,"age at diagnosis, insurance status, marital status, stage at diagnosis, tumor size, tumor grade, histology, treatment adherence, Charlson-Comorbidity Score, year of diagnosis, NO2, and distance to major roadway",1,average exposure to Ozone equivalent to an interquartile range lower,average exposure to Ozone  equivalent to an interquartile range higher,1.07,0.97,1.17
10.1016/j.ygyno.2021.07.036,9,Yes,Race/Ethnicity - Black,No,NA,ovarian cancer-specific death,HR,NA,"age at diagnosis, insurance status, marital status, stage at diagnosis, tumor size, tumor grade, histology, treatment adherence, Charlson-Comorbidity Score, year of diagnosis, ozone, and distance to major roadway",1,average exposure to PM2.5 equivalent to an interquartile range lower,average exposure to PM2.5 equivalent to an interquartile range higher,1.21,1.07,1.37
10.1016/j.ygyno.2021.07.036,10,Yes,Race/Ethnicity - Black,No,NA,ovarian cancer-specific death,HR,NA,"age at diagnosis, insurance status, marital status, stage at diagnosis, tumor size, tumor grade, histology, treatment adherence, Charlson-Comorbidity Score, year of diagnosis, ozone, and distance to major roadway",1,average exposure to Ozone equivalent to an interquartile range lower,average exposure to Ozone  equivalent to an interquartile range higher,1.05,0.96,1.16
10.1016/j.ygyno.2021.07.036,11,Yes,Race/Ethnicity - Hispanic,No,NA,ovarian cancer-specific death,HR,NA,"age at diagnosis, insurance status, marital status, stage at diagnosis, tumor size, tumor grade, histology, treatment adherence, Charlson-Comorbidity Score, year of diagnosis, ozone, and distance to major roadway",1,average exposure < 20 parts per billion of nitrogen dioxide,average exposure 20 - 30 parts per billion of nitrogen dioxide,1.37,1.24,1.52
10.1016/j.ygyno.2021.07.036,12,Yes,Race/Ethnicity - Hispanic,No,NA,ovarian cancer-specific death,HR,NA,"age at diagnosis, insurance status, marital status, stage at diagnosis, tumor size, tumor grade, histology, treatment adherence, Charlson-Comorbidity Score, year of diagnosis, ozone, and distance to major roadway",1,average exposure < 20 parts per billion of nitrogen dioxide,average exposure >30 parts per billion of nitrogen dioxide,3.36,2.84,3.97
10.1016/j.ygyno.2021.07.036,13,Yes,Race/Ethnicity - Hispanic,No,NA,ovarian cancer-specific death,HR,NA,"age at diagnosis, insurance status, marital status, stage at diagnosis, tumor size, tumor grade, histology, treatment adherence, Charlson-Comorbidity Score, year of diagnosis, NO2, and distance to major roadway",1,average exposure to Ozone equivalent to an interquartile range lower,average exposure to Ozone  equivalent to an interquartile range higher,1.03,0.98,1.08
10.1016/j.ygyno.2021.07.036,14,Yes,Race/Ethnicity - Hispanic,No,NA,ovarian cancer-specific death,HR,NA,"age at diagnosis, insurance status, marital status, stage at diagnosis, tumor size, tumor grade, histology, treatment adherence, Charlson-Comorbidity Score, year of diagnosis, ozone, and distance to major roadway",1,average exposure to PM2.5 equivalent to an interquartile range lower,average exposure to PM2.5 equivalent to an interquartile range higher,1.52,1.43,1.62
10.1016/j.ygyno.2021.07.036,15,Yes,Race/Ethnicity - Hispanic,No,NA,ovarian cancer-specific death,HR,NA,"age at diagnosis, insurance status, marital status, stage at diagnosis, tumor size, tumor grade, histology, treatment adherence, Charlson-Comorbidity Score, year of diagnosis, ozone, and distance to major roadway",1,average exposure to Ozone equivalent to an interquartile range lower,average exposure to Ozone  equivalent to an interquartile range higher,1.05,0.96,1.14
10.1016/j.ygyno.2021.07.036,16,Yes,Race/Ethnicity - Asian/Pacific Islander,No,NA,ovarian cancer-specific death,HR,NA,"age at diagnosis, insurance status, marital status, stage at diagnosis, tumor size, tumor grade, histology, treatment adherence, Charlson-Comorbidity Score, year of diagnosis, ozone, and distance to major roadway",1,average exposure < 20 parts per billion of nitrogen dioxide,average exposure 20 - 30 parts per billion of nitrogen dioxide,1.26,1.1,1.45
10.1016/j.ygyno.2021.07.036,17,Yes,Race/Ethnicity - Asian/Pacific Islander,No,NA,ovarian cancer-specific death,HR,NA,"age at diagnosis, insurance status, marital status, stage at diagnosis, tumor size, tumor grade, histology, treatment adherence, Charlson-Comorbidity Score, year of diagnosis, ozone, and distance to major roadway",1,average exposure < 20 parts per billion of nitrogen dioxide,average exposure >30 parts per billion of nitrogen dioxide,3.22,2.54,4.08
10.1016/j.ygyno.2021.07.036,18,Yes,Race/Ethnicity - Asian/Pacific Islander,No,NA,ovarian cancer-specific death,HR,NA,"age at diagnosis, insurance status, marital status, stage at diagnosis, tumor size, tumor grade, histology, treatment adherence, Charlson-Comorbidity Score, year of diagnosis, NO2, and distance to major roadway",1,average exposure to Ozone equivalent to an interquartile range lower,average exposure to Ozone  equivalent to an interquartile range higher,1.26,1.1,1.45
10.1016/j.ygyno.2021.07.036,19,Yes,Race/Ethnicity - Asian/Pacific Islander,No,NA,ovarian cancer-specific death,HR,NA,"age at diagnosis, insurance status, marital status, stage at diagnosis, tumor size, tumor grade, histology, treatment adherence, Charlson-Comorbidity Score, year of diagnosis, ozone, and distance to major roadway",1,average exposure to PM2.5 equivalent to an interquartile range lower,average exposure to PM2.5 equivalent to an interquartile range higher,1.41,1.32,1.51
10.1016/j.ygyno.2021.07.036,20,Yes,Race/Ethnicity - Asian/Pacific Islander,No,NA,ovarian cancer-specific death,HR,NA,"age at diagnosis, insurance status, marital status, stage at diagnosis, tumor size, tumor grade, histology, treatment adherence, Charlson-Comorbidity Score, year of diagnosis, ozone, and distance to major roadway",1,average exposure to Ozone equivalent to an interquartile range lower,average exposure to Ozone  equivalent to an interquartile range higher,0.94,0.88,1.01
10.1016/j.ygyno.2021.07.036,21,Yes,Race/Ethnicity - Other,No,NA,ovarian cancer-specific death,HR,NA,"age at diagnosis, insurance status, marital status, stage at diagnosis, tumor size, tumor grade, histology, treatment adherence, Charlson-Comorbidity Score, year of diagnosis, ozone, and distance to major roadway",1,average exposure < 20 parts per billion of nitrogen dioxide,average exposure 20 - 30 parts per billion of nitrogen dioxide,1.66,0.52,5.24
10.1016/j.ygyno.2021.07.036,22,Yes,Race/Ethnicity - Other,No,NA,ovarian cancer-specific death,HR,NA,"age at diagnosis, insurance status, marital status, stage at diagnosis, tumor size, tumor grade, histology, treatment adherence, Charlson-Comorbidity Score, year of diagnosis, ozone, and distance to major roadway",1,average exposure < 20 parts per billion of nitrogen dioxide,average exposure >30 parts per billion of nitrogen dioxide,0.96,0.2,4.63
10.1016/j.ygyno.2021.07.036,23,Yes,Race/Ethnicity - Other,No,NA,ovarian cancer-specific death,HR,NA,"age at diagnosis, insurance status, marital status, stage at diagnosis, tumor size, tumor grade, histology, treatment adherence, Charlson-Comorbidity Score, year of diagnosis, NO2, and distance to major roadway",1,average exposure to Ozone equivalent to an interquartile range lower,average exposure to Ozone  equivalent to an interquartile range higher,1.66,0.52,5.24
10.1016/j.ygyno.2021.07.036,24,Yes,Race/Ethnicity - Other,No,NA,ovarian cancer-specific death,HR,NA,"age at diagnosis, insurance status, marital status, stage at diagnosis, tumor size, tumor grade, histology, treatment adherence, Charlson-Comorbidity Score, year of diagnosis, ozone, and distance to major roadway",1,average exposure to PM2.5 equivalent to an interquartile range lower,average exposure to PM2.5 equivalent to an interquartile range higher,1.88,1.24,2.85
10.1016/j.ygyno.2021.07.036,25,Yes,Race/Ethnicity - Other,No,NA,ovarian cancer-specific death,HR,NA,"age at diagnosis, insurance status, marital status, stage at diagnosis, tumor size, tumor grade, histology, treatment adherence, Charlson-Comorbidity Score, year of diagnosis, ozone, and distance to major roadway",1,average exposure to Ozone equivalent to an interquartile range lower,average exposure to Ozone  equivalent to an interquartile range higher,1.49,1.12,1.97
10.1016/j.ygyno.2021.08.013,1,Yes,Race - White,No,NA,Census demographics,Percent,NA,None,1,N/A,"counties with county-level gynecological cancer rate < 16 cases/100,000 (1st and 2nd quintile)",85.19,-99,-99
10.1016/j.ygyno.2021.08.013,1,Yes,Race - White,No,NA,Census demographics,Percent,NA,None,2,N/A,"counties with  county-level gynecological cancer rate 16-42 cases/100,000 (3rd quintile)",82.58,-99,-99
10.1016/j.ygyno.2021.08.013,1,Yes,Race - White,No,NA,Census demographics,Percent,NA,None,3,N/A,"counties with county-level gynecological cancer rate 42.1-54.7 cases/100,000 (4th quintile)",83.21,-99,-99
10.1016/j.ygyno.2021.08.013,1,Yes,Race - White,No,NA,Census demographics,Percent,NA,None,4,N/A,"counties with  county-level gynecological cancer rate 54.8-111.5 cases/100,000 (5th quintile)",86.74,-99,-99
10.1016/j.ygyno.2021.08.013,2,Yes,Race - Black/African-American,No,NA,Census demographics,Percent,NA,None,1,N/A,"counties with county-level gynecological cancer rate < 16 cases/100,000 (1st and 2nd quintile)",7.86,-99,-99
10.1016/j.ygyno.2021.08.013,2,Yes,Race - Black/African-American,No,NA,Census demographics,Percent,NA,None,2,N/A,"counties with  county-level gynecological cancer rate 16-42 cases/100,000 (3rd quintile)",11.65,-99,-99
10.1016/j.ygyno.2021.08.013,2,Yes,Race - Black/African-American,No,NA,Census demographics,Percent,NA,None,3,N/A,"counties with county-level gynecological cancer rate 42.1-54.7 cases/100,000 (4th quintile)",10.33,-99,-99
10.1016/j.ygyno.2021.08.013,2,Yes,Race - Black/African-American,No,NA,Census demographics,Percent,NA,None,4,N/A,"counties with  county-level gynecological cancer rate 54.8-111.5 cases/100,000 (5th quintile)",7.48,-99,-99
10.1016/j.ygyno.2021.08.013,3,Yes,Race - Asian American,No,NA,Census demographics,Percent,NA,None,1,N/A,"counties with county-level gynecological cancer rate < 16 cases/100,000 (1st and 2nd quintile)",0.89,-99,-99
10.1016/j.ygyno.2021.08.013,3,Yes,Race - Asian American,No,NA,Census demographics,Percent,NA,None,2,N/A,"counties with  county-level gynecological cancer rate 16-42 cases/100,000 (3rd quintile)",1.51,-99,-99
10.1016/j.ygyno.2021.08.013,3,Yes,Race - Asian American,No,NA,Census demographics,Percent,NA,None,3,N/A,"counties with county-level gynecological cancer rate 42.1-54.7 cases/100,000 (4th quintile)",2.49,-99,-99
10.1016/j.ygyno.2021.08.013,3,Yes,Race - Asian American,No,NA,Census demographics,Percent,NA,None,4,N/A,"counties with  county-level gynecological cancer rate 54.8-111.5 cases/100,000 (5th quintile)",2.27,-99,-99
10.1016/j.ygyno.2021.08.013,4,Yes,Race - Indian or Alaskan American,No,NA,Census demographics,Percent,NA,None,1,N/A,"counties with county-level gynecological cancer rate < 16 cases/100,000 (1st and 2nd quintile)",3.83,-99,-99
10.1016/j.ygyno.2021.08.013,4,Yes,Race - Indian or Alaskan American,No,NA,Census demographics,Percent,NA,None,2,N/A,"counties with  county-level gynecological cancer rate 16-42 cases/100,000 (3rd quintile)",2.02,-99,-99
10.1016/j.ygyno.2021.08.013,4,Yes,Race - Indian or Alaskan American,No,NA,Census demographics,Percent,NA,None,3,N/A,"counties with county-level gynecological cancer rate 42.1-54.7 cases/100,000 (4th quintile)",1.58,-99,-99
10.1016/j.ygyno.2021.08.013,4,Yes,Race - Indian or Alaskan American,No,NA,Census demographics,Percent,NA,None,4,N/A,"counties with  county-level gynecological cancer rate 54.8-111.5 cases/100,000 (5th quintile)",1.03,-99,-99
10.1016/j.ygyno.2021.08.013,5,Yes,Race - Hawaiian,No,NA,Census demographics,Percent,NA,None,1,N/A,"counties with county-level gynecological cancer rate < 16 cases/100,000 (1st and 2nd quintile)",0.14,-99,-99
10.1016/j.ygyno.2021.08.013,5,Yes,Race - Hawaiian,No,NA,Census demographics,Percent,NA,None,2,N/A,"counties with  county-level gynecological cancer rate 16-42 cases/100,000 (3rd quintile)",0.13,-99,-99
10.1016/j.ygyno.2021.08.013,5,Yes,Race - Hawaiian,No,NA,Census demographics,Percent,NA,None,3,N/A,"counties with county-level gynecological cancer rate 42.1-54.7 cases/100,000 (4th quintile)",0.15,-99,-99
10.1016/j.ygyno.2021.08.013,5,Yes,Race - Hawaiian,No,NA,Census demographics,Percent,NA,None,4,N/A,"counties with  county-level gynecological cancer rate 54.8-111.5 cases/100,000 (5th quintile)",0.16,-99,-99
10.1016/j.ygyno.2021.08.013,6,Yes,Race - Two or more races,No,NA,Census demographics,Percent,NA,None,1,N/A,"counties with county-level gynecological cancer rate < 16 cases/100,000 (1st and 2nd quintile)",2.08,-99,-99
10.1016/j.ygyno.2021.08.013,6,Yes,Race - Two or more races,No,NA,Census demographics,Percent,NA,None,2,N/A,"counties with  county-level gynecological cancer rate 16-42 cases/100,000 (3rd quintile)",2.11,-99,-99
10.1016/j.ygyno.2021.08.013,6,Yes,Race - Two or more races,No,NA,Census demographics,Percent,NA,None,3,N/A,"counties with county-level gynecological cancer rate 42.1-54.7 cases/100,000 (4th quintile)",2.24,-99,-99
10.1016/j.ygyno.2021.08.013,6,Yes,Race - Two or more races,No,NA,Census demographics,Percent,NA,None,4,N/A,"counties with  county-level gynecological cancer rate 54.8-111.5 cases/100,000 (5th quintile)",2.32,-99,-99
10.1016/j.ygyno.2021.08.013,7,Yes,Ethnicity - Hispanic,No,NA,Census demographics,Percent,NA,None,1,N/A,"counties with county-level gynecological cancer rate < 16 cases/100,000 (1st and 2nd quintile)",9.87,-99,-99
10.1016/j.ygyno.2021.08.013,7,Yes,Ethnicity - Hispanic,No,NA,Census demographics,Percent,NA,None,2,N/A,"counties with  county-level gynecological cancer rate 16-42 cases/100,000 (3rd quintile)",10.33,-99,-99
10.1016/j.ygyno.2021.08.013,7,Yes,Ethnicity - Hispanic,No,NA,Census demographics,Percent,NA,None,3,N/A,"counties with county-level gynecological cancer rate 42.1-54.7 cases/100,000 (4th quintile)",10.03,-99,-99
10.1016/j.ygyno.2021.08.013,7,Yes,Ethnicity - Hispanic,No,NA,Census demographics,Percent,NA,None,4,N/A,"counties with  county-level gynecological cancer rate 54.8-111.5 cases/100,000 (5th quintile)",7.42,-99,-99
10.1016/j.ygyno.2021.08.013,8,Yes,Race - White,Yes,Counties with the highest quintile of Gynecologic cancer rates,Census demographics,Percent,NA,None,1,N/A,No gynecologic oncologist available in local/adjacent county,89.15,-99,-99
10.1016/j.ygyno.2021.08.013,8,Yes,Race - White,Yes,Counties with the highest quintile of Gynecologic cancer rates,Census demographics,Percent,NA,None,2,N/A,Gynecologic oncologist in local/adjacent county,85.31,-99,-99
10.1016/j.ygyno.2021.08.013,9,Yes,Race - Black/African-American,Yes,Counties with the highest quintile of Gynecologic cancer rates,Census demographics,Percent,NA,None,1,N/A,No gynecologic oncologist available in local/adjacent county,5.49,-99,-99
10.1016/j.ygyno.2021.08.013,9,Yes,Race - Black/African-American,Yes,Counties with the highest quintile of Gynecologic cancer rates,Census demographics,Percent,NA,None,2,N/A,Gynecologic oncologist in local/adjacent county,8.66,-99,-99
10.1016/j.ygyno.2021.08.013,10,Yes,Race - Asian American,Yes,Counties with the highest quintile of Gynecologic cancer rates,Census demographics,Percent,NA,None,1,N/A,No gynecologic oncologist available in local/adjacent county,1.5,-99,-99
10.1016/j.ygyno.2021.08.013,10,Yes,Race - Asian American,Yes,Counties with the highest quintile of Gynecologic cancer rates,Census demographics,Percent,NA,None,2,N/A,Gynecologic oncologist in local/adjacent county,2.72,-99,-99
10.1016/j.ygyno.2021.08.013,11,Yes,Race - Indian or Alaskan American,Yes,Counties with the highest quintile of Gynecologic cancer rates,Census demographics,Percent,NA,None,1,N/A,No gynecologic oncologist available in local/adjacent county,1.26,-99,-99
10.1016/j.ygyno.2021.08.013,11,Yes,Race - Indian or Alaskan American,Yes,Counties with the highest quintile of Gynecologic cancer rates,Census demographics,Percent,NA,None,2,N/A,Gynecologic oncologist in local/adjacent county,0.9,-99,-99
10.1016/j.ygyno.2021.08.013,12,Yes,Race - Hawaiian,Yes,Counties with the highest quintile of Gynecologic cancer rates,Census demographics,Percent,NA,None,1,N/A,No gynecologic oncologist available in local/adjacent county,0.23,-99,-99
10.1016/j.ygyno.2021.08.013,12,Yes,Race - Hawaiian,Yes,Counties with the highest quintile of Gynecologic cancer rates,Census demographics,Percent,NA,None,2,N/A,Gynecologic oncologist in local/adjacent county,0.12,-99,-99
10.1016/j.ygyno.2021.08.013,13,Yes,Race - Two or more races,Yes,Counties with the highest quintile of Gynecologic cancer rates,Census demographics,Percent,NA,None,1,N/A,No gynecologic oncologist available in local/adjacent county,2.37,-99,-99
10.1016/j.ygyno.2021.08.013,13,Yes,Race - Two or more races,Yes,Counties with the highest quintile of Gynecologic cancer rates,Census demographics,Percent,NA,None,2,N/A,Gynecologic oncologist in local/adjacent county,2.29,-99,-99
10.1016/j.ygyno.2021.08.013,14,Yes,Ethnicity - Hispanic,Yes,Counties with the highest quintile of Gynecologic cancer rates,Census demographics,Percent,NA,None,1,N/A,No gynecologic oncologist available in local/adjacent county,5.99,-99,-99
10.1016/j.ygyno.2021.08.013,14,Yes,Ethnicity - Hispanic,Yes,Counties with the highest quintile of Gynecologic cancer rates,Census demographics,Percent,NA,None,2,N/A,Gynecologic oncologist in local/adjacent county,8.28,-99,-99
10.1016/j.ygyno.2021.08.015,1,Yes,2001-2003,No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",1,N/A,White,64.7,63.9,65.4
10.1016/j.ygyno.2021.08.015,1,Yes,2001-2003,No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",2,N/A,Black,56.7,55.1,58.3
10.1016/j.ygyno.2021.08.015,2,Yes,2004-2008,No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",1,N/A,White,63.6,63,64.2
10.1016/j.ygyno.2021.08.015,2,Yes,2004-2008,No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",2,N/A,Black,55.5,54.2,56.8
10.1016/j.ygyno.2021.08.015,3,Yes,2009-2014,No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",1,N/A,White,63,62.2,63.7
10.1016/j.ygyno.2021.08.015,3,Yes,2009-2014,No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",2,N/A,Black,55.8,54.3,57.4
10.1016/j.ygyno.2021.08.015,4,Yes,"Year 2001-2003, Localized cancer",No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",1,N/A,White,85.4,84.2,86.5
10.1016/j.ygyno.2021.08.015,4,Yes,"Year 2001-2003, Localized cancer",No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",2,N/A,Black,78.6,76,81.1
10.1016/j.ygyno.2021.08.015,5,Yes,"Year 2004-2008, Localized cancer",No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",1,N/A,White,86.6,85.7,87.6
10.1016/j.ygyno.2021.08.015,5,Yes,"Year 2004-2008, Localized cancer",No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",2,N/A,Black,79.3,77.2,81.4
10.1016/j.ygyno.2021.08.015,6,Yes,"Year 2009-2014, Localized cancer",No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",1,N/A,White,86.9,85.4,88.5
10.1016/j.ygyno.2021.08.015,6,Yes,"Year 2009-2014, Localized cancer",No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",2,N/A,Black,83.6,80.8,86.5
10.1016/j.ygyno.2021.08.015,7,Yes,"Year 2001-2003, Regional cancer",No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",1,N/A,White,53.6,52.3,54.8
10.1016/j.ygyno.2021.08.015,7,Yes,"Year 2001-2003, Regional cancer",No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",2,N/A,Black,46.8,44.2,49.3
10.1016/j.ygyno.2021.08.015,8,Yes,"Year 2004-2008, Regional cancer",No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",1,N/A,White,56.5,55.5,57.4
10.1016/j.ygyno.2021.08.015,8,Yes,"Year 2004-2008, Regional cancer",No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",2,N/A,Black,50.1,48.1,52.1
10.1016/j.ygyno.2021.08.015,9,Yes,"Year 2009-2014, Regional cancer",No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",1,N/A,White,56.7,55.4,58
10.1016/j.ygyno.2021.08.015,9,Yes,"Year 2009-2014, Regional cancer",No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",2,N/A,Black,51.7,49.2,54.2
10.1016/j.ygyno.2021.08.015,10,Yes,"Year 2001-2003, Distant cancer",No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",1,N/A,White,17.4,15.8,19
10.1016/j.ygyno.2021.08.015,10,Yes,"Year 2001-2003, Distant cancer",No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",2,N/A,Black,13.8,10.8,16.8
10.1016/j.ygyno.2021.08.015,11,Yes,"Year 2004-2008, Distant cancer",No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",1,N/A,White,16.7,15.5,17.8
10.1016/j.ygyno.2021.08.015,11,Yes,"Year 2004-2008, Distant cancer",No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",2,N/A,Black,14,11.8,16.1
10.1016/j.ygyno.2021.08.015,12,Yes,"Year 2009-2014, Distant cancer",No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",1,N/A,White,19.3,17.9,20.8
10.1016/j.ygyno.2021.08.015,12,Yes,"Year 2009-2014, Distant cancer",No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",2,N/A,Black,13.7,11.2,16.2
10.1016/j.ygyno.2021.08.015,13,Yes,"Year 2001-2003, Unknown cancer",No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",1,N/A,White,58.7,56.3,61.1
10.1016/j.ygyno.2021.08.015,13,Yes,"Year 2001-2003, Unknown cancer",No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",2,N/A,Black,50.1,45,55.2
10.1016/j.ygyno.2021.08.015,14,Yes,"Year 2004-2008, Unknown cancer",No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",1,N/A,White,54.3,52.1,56.5
10.1016/j.ygyno.2021.08.015,14,Yes,"Year 2004-2008, Unknown cancer",No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",2,N/A,Black,48.1,43.6,52.6
10.1016/j.ygyno.2021.08.015,15,Yes,"Year 2009-2014, Unknown cancer",No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",1,N/A,White,53.6,50.9,56.4
10.1016/j.ygyno.2021.08.015,15,Yes,"Year 2009-2014, Unknown cancer",No,NA,age-standardized five-year net survival,Percent,NA,"background mortality defined within county, age, sex, calendar year, socioeconomic status, and race",2,N/A,Black,51,46.1,55.9
10.1016/j.ygyno.2021.08.015,16,Yes,localized cervical cancer,No,NA,cancer-directed surgery,Percent,NA,None,1,N/A,White,84.2,-99,-99
10.1016/j.ygyno.2021.08.015,16,Yes,localized cervical cancer,No,NA,cancer-directed surgery,Percent,NA,None,2,N/A,Black,74.3,-99,-99
10.1016/j.ygyno.2021.08.015,17,Yes,regional cervical cancer,No,NA,cancer-directed surgery,Percent,NA,None,1,N/A,White,36,-99,-99
10.1016/j.ygyno.2021.08.015,17,Yes,regional cervical cancer,No,NA,cancer-directed surgery,Percent,NA,None,2,N/A,Black,26.8,-99,-99
10.1016/j.ygyno.2021.08.015,18,Yes,distant cervical cancer,No,NA,cancer-directed surgery,Percent,NA,None,1,N/A,White,19.1,-99,-99
10.1016/j.ygyno.2021.08.015,18,Yes,distant cervical cancer,No,NA,cancer-directed surgery,Percent,NA,None,2,N/A,Black,15.1,-99,-99
10.1016/j.ygyno.2021.08.015,19,Yes,localized cervical cancer,No,NA,radiotherapy,Percent,NA,None,1,N/A,White,23,-99,-99
10.1016/j.ygyno.2021.08.015,19,Yes,localized cervical cancer,No,NA,radiotherapy,Percent,NA,None,2,N/A,Black,32.4,-99,-99
10.1016/j.ygyno.2021.08.015,20,Yes,regional cervical cancer,No,NA,radiotherapy,Percent,NA,None,1,N/A,White,74.7,-99,-99
10.1016/j.ygyno.2021.08.015,20,Yes,regional cervical cancer,No,NA,radiotherapy,Percent,NA,None,2,N/A,Black,76.6,-99,-99
10.1016/j.ygyno.2021.08.015,21,Yes,distant cervical cancer,No,NA,radiotherapy,Percent,NA,None,1,N/A,White,57.6,-99,-99
10.1016/j.ygyno.2021.08.015,21,Yes,distant cervical cancer,No,NA,radiotherapy,Percent,NA,None,2,N/A,Black,57.5,-99,-99
10.1016/j.ygyno.2021.08.015,22,Yes,localized cervical cancer,No,NA,systemic therapy,Percent,NA,None,1,N/A,White,17.3,-99,-99
10.1016/j.ygyno.2021.08.015,22,Yes,localized cervical cancer,No,NA,systemic therapy,Percent,NA,None,2,N/A,Black,23.3,-99,-99
10.1016/j.ygyno.2021.08.015,23,Yes,regional cervical cancer,No,NA,systemic therapy,Percent,NA,None,1,N/A,White,71.8,-99,-99
10.1016/j.ygyno.2021.08.015,23,Yes,regional cervical cancer,No,NA,systemic therapy,Percent,NA,None,2,N/A,Black,68.9,-99,-99
10.1016/j.ygyno.2021.08.015,24,Yes,distant cervical cancer,No,NA,systemic therapy,Percent,NA,None,1,N/A,White,64.6,-99,-99
10.1016/j.ygyno.2021.08.015,24,Yes,distant cervical cancer,No,NA,systemic therapy,Percent,NA,None,2,N/A,Black,57.7,-99,-99
10.1016/j.ygyno.2021.10.090,1,No,NA,No,NA,not getting chemotherapy recommendations,OR,NA,none,1,White,Black,2,1.53,2.61
10.1016/j.ygyno.2021.10.090,1,No,NA,No,NA,not getting chemotherapy recommendations,OR,NA,none,2,White,Other,0.86,0.55,1.34
10.1016/j.ygyno.2021.10.090,2,No,NA,No,NA,not getting chemotherapy recommendations,OR,NA,"age, insurance status, facility type, Charlson-Deyo score",1,White,Black,2.12,1.61,2.78
10.1016/j.ygyno.2021.10.090,2,No,NA,No,NA,not getting chemotherapy recommendations,OR,NA,"age, insurance status, facility type, Charlson-Deyo score",2,White,Other,1.08,0.68,1.7
10.1016/j.ygyno.2021.10.090,3,No,NA,No,NA,not getting chemotherapy recommendations,OR,NA,"age, insurance status, facility type, Charlson-Deyo score",1,White,Black,2.14,1.63,2.82
10.1016/j.ygyno.2021.10.090,3,No,NA,No,NA,not getting chemotherapy recommendations,OR,NA,"age, insurance status, facility type, Charlson-Deyo score",2,White,Other,1.1,0.7,1.73
10.1016/j.ygyno.2021.10.090,4,No,NA,No,NA,not getting chemotherapy recommendations,OR,NA,"age, insurance status, facility type, Charlson-Deyo score, stage",1,White,Black,2.11,1.61,2.78
10.1016/j.ygyno.2021.10.090,4,No,NA,No,NA,not getting chemotherapy recommendations,OR,NA,"age, insurance status, facility type, Charlson-Deyo score, stage",2,White,Other,1.07,0.68,1.68
10.1016/j.ygyno.2021.10.090,5,No,NA,No,NA,not getting chemotherapy recommendations,OR,NA,"age, insurance status, facility type, Charlson-Deyo score, postoperative readmission, stage",1,White,Black,2.14,1.62,2.81
10.1016/j.ygyno.2021.10.090,5,No,NA,No,NA,not getting chemotherapy recommendations,OR,NA,"age, insurance status, facility type, Charlson-Deyo score, postoperative readmission, stage",2,White,Other,1.09,0.69,1.72
10.1016/j.ygyno.2021.11.015,1,No,NA,No,NA,overall survival,HR,NA,none,1,Non-Hispanic white,Non-Hispanic black,1,0.92,1.08
10.1016/j.ygyno.2021.11.015,1,No,NA,No,NA,overall survival,HR,NA,none,2,Non-Hispanic white,Hispanic,0.66,0.59,0.73
10.1016/j.ygyno.2021.11.015,1,No,NA,No,NA,overall survival,HR,NA,none,3,Non-Hispanic white,Asian/Pacific Islander,0.69,0.59,0.82
10.1016/j.ygyno.2021.11.015,1,No,NA,No,NA,overall survival,HR,NA,none,4,Non-Hispanic white,Others or unknown,0.97,0.78,1.21
10.1016/j.ygyno.2021.11.015,2,No,NA,No,NA,overall survival,HR,NA,"Age at diagnosis, year of diagnosis, insurance, Charlson-Deyo Comorbidity Score, Neighborhood median household income, Reporting facility type, Cancer stage, histology, tumor size, treatment",1,Non-Hispanic white,Non-Hispanic black,0.93,0.85,1.01
10.1016/j.ygyno.2021.11.015,2,No,NA,No,NA,overall survival,HR,NA,"Age at diagnosis, year of diagnosis, insurance, Charlson-Deyo Comorbidity Score, Neighborhood median household income, Reporting facility type, Cancer stage, histology, tumor size, treatment",2,Non-Hispanic white,Hispanic,0.68,0.61,0.76
10.1016/j.ygyno.2021.11.015,2,No,NA,No,NA,overall survival,HR,NA,"Age at diagnosis, year of diagnosis, insurance, Charlson-Deyo Comorbidity Score, Neighborhood median household income, Reporting facility type, Cancer stage, histology, tumor size, treatment",3,Non-Hispanic white,Asian/Pacific Islander,0.77,0.65,0.91
10.1016/j.ygyno.2021.11.015,2,No,NA,No,NA,overall survival,HR,NA,"Age at diagnosis, year of diagnosis, insurance, Charlson-Deyo Comorbidity Score, Neighborhood median household income, Reporting facility type, Cancer stage, histology, tumor size, treatment",4,Non-Hispanic white,Others or unknown,1,0.8,1.24
10.1016/j.ygyno.2021.11.015,3,No,NA,No,NA,receiving standard of care treatment,OR,NA,none,1,Non-Hispanic white,Non-Hispanic black,0.75,0.67,0.85
10.1016/j.ygyno.2021.11.015,3,No,NA,No,NA,receiving standard of care treatment,OR,NA,none,2,Non-Hispanic white,Hispanic,0.95,0.83,1.08
10.1016/j.ygyno.2021.11.015,3,No,NA,No,NA,receiving standard of care treatment,OR,NA,none,3,Non-Hispanic white,Asian/Pacific Islander,1.24,1.01,1.52
10.1016/j.ygyno.2021.11.015,3,No,NA,No,NA,receiving standard of care treatment,OR,NA,none,4,Non-Hispanic white,Others or unknown,1.06,0.79,1.43
10.1016/j.ygyno.2021.11.015,4,No,NA,No,NA,receiving standard of care treatment,OR,NA,"Age at diagnosis, year of diagnosis, insurance, Charlson-Deyo Comorbidity Score, Neighborhood percent of less than high school level of education, Area of residence when diagnosis, Reporting facility type, Cancer stage, histology, tumor size, treatment",1,Non-Hispanic white,Non-Hispanic black,0.82,0.72,0.93
10.1016/j.ygyno.2021.11.015,4,No,NA,No,NA,receiving standard of care treatment,OR,NA,"Age at diagnosis, year of diagnosis, insurance, Charlson-Deyo Comorbidity Score, Neighborhood percent of less than high school level of education, Area of residence when diagnosis, Reporting facility type, Cancer stage, histology, tumor size, treatment",2,Non-Hispanic white,Hispanic,0.97,0.84,1.12
10.1016/j.ygyno.2021.11.015,4,No,NA,No,NA,receiving standard of care treatment,OR,NA,"Age at diagnosis, year of diagnosis, insurance, Charlson-Deyo Comorbidity Score, Neighborhood percent of less than high school level of education, Area of residence when diagnosis, Reporting facility type, Cancer stage, histology, tumor size, treatment",3,Non-Hispanic white,Asian/Pacific Islander,1.15,0.94,1.42
10.1016/j.ygyno.2021.11.015,4,No,NA,No,NA,receiving standard of care treatment,OR,NA,"Age at diagnosis, year of diagnosis, insurance, Charlson-Deyo Comorbidity Score, Neighborhood percent of less than high school level of education, Area of residence when diagnosis, Reporting facility type, Cancer stage, histology, tumor size, treatment",4,Non-Hispanic white,Others or unknown,1.01,0.75,1.37
10.1016/j.ygyno.2022.01.001,1,No,NA,No,NA,initial National Comprehensive Cancer Network distress score,Median,NA,None,1,N/A,Non-Hispanic Black,2,-99,-99
10.1016/j.ygyno.2022.01.001,1,No,NA,No,NA,initial National Comprehensive Cancer Network distress score,Median,NA,None,2,N/A,Non-Hispanic White,4,-99,-99
10.1016/j.ygyno.2022.01.001,2,No,NA,No,NA,initial National Comprehensive Cancer Network distress score = 0,Percent,NA,None,1,N/A,Non-Hispanic Black,32.8,-99,-99
10.1016/j.ygyno.2022.01.001,2,No,NA,No,NA,initial National Comprehensive Cancer Network distress score = 0,Percent,NA,None,2,N/A,Non-Hispanic White,19.1,-99,-99
10.1016/j.ygyno.2022.01.001,3,No,NA,No,NA,reached referral threshold (initial National Comprehensive Cancer Network distress score >= 4),Percent,NA,None,1,N/A,Non-Hispanic Black,39.6,-99,-99
10.1016/j.ygyno.2022.01.001,3,No,NA,No,NA,reached referral threshold (initial National Comprehensive Cancer Network distress score >= 4),Percent,NA,None,2,N/A,Non-Hispanic White,50.6,-99,-99
10.1016/j.ygyno.2022.01.001,4,No,NA,No,NA,declined resources at initial encounter,Percent,NA,None,1,N/A,Non-Hispanic Black,50.7,-99,-99
10.1016/j.ygyno.2022.01.001,4,No,NA,No,NA,declined resources at initial encounter,Percent,NA,None,2,N/A,Non-Hispanic White,46.6,-99,-99
10.1016/j.ygyno.2022.01.001,5,No,NA,No,NA,number of National Comprehensive Cancer Network problem list problems checked (total),Median,NA,None,1,N/A,Non-Hispanic Black,3,-99,-99
10.1016/j.ygyno.2022.01.001,5,No,NA,No,NA,number of National Comprehensive Cancer Network problem list problems checked (total),Median,NA,None,2,N/A,Non-Hispanic White,4,-99,-99
10.1016/j.ygyno.2022.01.001,6,No,NA,No,NA,number of National Comprehensive Cancer Network problem list problems checked (practical),Median,NA,None,1,N/A,Non-Hispanic Black,0,-99,-99
10.1016/j.ygyno.2022.01.001,6,No,NA,No,NA,number of National Comprehensive Cancer Network problem list problems checked (practical),Median,NA,None,2,N/A,Non-Hispanic White,0,-99,-99
10.1016/j.ygyno.2022.01.001,7,No,NA,No,NA,number of National Comprehensive Cancer Network problem list problems checked (family),Median,NA,None,1,N/A,Non-Hispanic Black,0,-99,-99
10.1016/j.ygyno.2022.01.001,7,No,NA,No,NA,number of National Comprehensive Cancer Network problem list problems checked (family),Median,NA,None,2,N/A,Non-Hispanic White,0,-99,-99
10.1016/j.ygyno.2022.01.001,8,No,NA,No,NA,number of National Comprehensive Cancer Network problem list problems checked (emotional),Median,NA,None,1,N/A,Non-Hispanic Black,1,-99,-99
10.1016/j.ygyno.2022.01.001,8,No,NA,No,NA,number of National Comprehensive Cancer Network problem list problems checked (emotional),Median,NA,None,2,N/A,Non-Hispanic White,2,-99,-99
10.1016/j.ygyno.2022.01.001,9,No,NA,No,NA,number of National Comprehensive Cancer Network problem list problems checked (spiritual),Median,NA,None,1,N/A,Non-Hispanic Black,0,-99,-99
10.1016/j.ygyno.2022.01.001,9,No,NA,No,NA,number of National Comprehensive Cancer Network problem list problems checked (spiritual),Median,NA,None,2,N/A,Non-Hispanic White,0,-99,-99
10.1016/j.ygyno.2022.01.001,10,No,NA,No,NA,number of National Comprehensive Cancer Network problem list problems checked (physical),Median,NA,None,1,N/A,Non-Hispanic Black,1,-99,-99
10.1016/j.ygyno.2022.01.001,10,No,NA,No,NA,number of National Comprehensive Cancer Network problem list problems checked (physical),Median,NA,None,2,N/A,Non-Hispanic White,2,-99,-99
10.1016/j.ygyno.2022.01.032,1,No,NA,No,NA,Enrollment in poly(ADP-ribose) polymerase inhibitor clinical trials,OR,NA,none,1,Non-Hispanic White,Non-Hispanic Black,0.23,0.18,0.29
10.1016/j.ygyno.2022.01.032,1,No,NA,No,NA,Enrollment in poly(ADP-ribose) polymerase inhibitor clinical trials,OR,NA,none,2,Non-Hispanic White,Hispanic,0.3,0.25,0.38
10.1016/j.ygyno.2022.01.032,1,No,NA,No,NA,Enrollment in poly(ADP-ribose) polymerase inhibitor clinical trials,OR,NA,none,3,Non-Hispanic White,Asian/Pacific Islander,1.57,1.36,1.8
10.1016/j.ygyno.2022.02.021,1,No,NA,No,NA,Microbiota in endometrial tumors - Actinobacteria phylum,Percent,NA,None,1,N/A,Obese black,33.36,-99,-99
10.1016/j.ygyno.2022.02.021,1,No,NA,No,NA,Microbiota in endometrial tumors - Actinobacteria phylum,Percent,NA,None,2,N/A,Obese white,69.94,-99,-99
10.1016/j.ygyno.2022.02.021,2,No,NA,No,NA,Microbiota in endometrial tumors - Bacteroidetes phylum,Percent,NA,None,1,N/A,Obese black,22.38,-99,-99
10.1016/j.ygyno.2022.02.021,2,No,NA,No,NA,Microbiota in endometrial tumors - Bacteroidetes phylum,Percent,NA,None,2,N/A,Obese white,3.09,-99,-99
10.1016/j.ygyno.2022.02.021,3,No,NA,No,NA,Microbiota in endometrial tumors - Cyanobacteria phylum,Percent,NA,None,1,N/A,Obese black,1.9,-99,-99
10.1016/j.ygyno.2022.02.021,3,No,NA,No,NA,Microbiota in endometrial tumors - Cyanobacteria phylum,Percent,NA,None,2,N/A,Obese white,0.32,-99,-99
10.1016/j.ygyno.2022.02.021,4,No,NA,No,NA,Microbiota in endometrial tumors - Firmicutes phylum,Percent,NA,None,1,N/A,Obese black,8.92,-99,-99
10.1016/j.ygyno.2022.02.021,4,No,NA,No,NA,Microbiota in endometrial tumors - Firmicutes phylum,Percent,NA,None,2,N/A,Obese white,0.44,-99,-99
10.1016/j.ygyno.2022.02.021,5,No,NA,No,NA,Microbiota in endometrial tumors - OD1 phylum,Percent,NA,None,1,N/A,Obese black,14.78,-99,-99
10.1016/j.ygyno.2022.02.021,5,No,NA,No,NA,Microbiota in endometrial tumors - OD1 phylum,Percent,NA,None,2,N/A,Obese white,3,-99,-99
10.1016/j.ygyno.2022.02.021,6,No,NA,No,NA,Microbiota in endometrial tumors - Proteobacteria phylum,Percent,NA,None,1,N/A,Obese black,18.66,-99,-99
10.1016/j.ygyno.2022.02.021,6,No,NA,No,NA,Microbiota in endometrial tumors - Proteobacteria phylum,Percent,NA,None,2,N/A,Obese white,23.2,-99,-99
10.1016/j.ygyno.2022.02.021,7,No,NA,No,NA,Microbiota in endometrial tumors - Acidovorax genus,Percent,NA,None,1,N/A,Obese black,3.22,-99,-99
10.1016/j.ygyno.2022.02.021,7,No,NA,No,NA,Microbiota in endometrial tumors - Acidovorax genus,Percent,NA,None,2,N/A,Obese white,3.82,-99,-99
10.1016/j.ygyno.2022.02.021,8,No,NA,No,NA,Microbiota in endometrial tumors - Acinetobacter genus,Percent,NA,None,1,N/A,Obese black,0.04,-99,-99
10.1016/j.ygyno.2022.02.021,8,No,NA,No,NA,Microbiota in endometrial tumors - Acinetobacter genus,Percent,NA,None,2,N/A,Obese white,1.83,-99,-99
10.1016/j.ygyno.2022.02.021,9,No,NA,No,NA,Microbiota in endometrial tumors - Brachybacterium genus,Percent,NA,None,1,N/A,Obese black,9.67,-99,-99
10.1016/j.ygyno.2022.02.021,9,No,NA,No,NA,Microbiota in endometrial tumors - Brachybacterium genus,Percent,NA,None,2,N/A,Obese white,8.99,-99,-99
10.1016/j.ygyno.2022.02.021,10,No,NA,No,NA,Microbiota in endometrial tumors - Bradyrhizobium genus,Percent,NA,None,1,N/A,Obese black,0.02,-99,-99
10.1016/j.ygyno.2022.02.021,10,No,NA,No,NA,Microbiota in endometrial tumors - Bradyrhizobium genus,Percent,NA,None,2,N/A,Obese white,0.35,-99,-99
10.1016/j.ygyno.2022.02.021,11,No,NA,No,NA,Microbiota in endometrial tumors - Brevibacterium genus,Percent,NA,None,1,N/A,Obese black,12.18,-99,-99
10.1016/j.ygyno.2022.02.021,11,No,NA,No,NA,Microbiota in endometrial tumors - Brevibacterium genus,Percent,NA,None,2,N/A,Obese white,61.36,-99,-99
10.1016/j.ygyno.2022.02.021,12,No,NA,No,NA,Microbiota in endometrial tumors - Brevundimonas genus,Percent,NA,None,1,N/A,Obese black,0.08,-99,-99
10.1016/j.ygyno.2022.02.021,12,No,NA,No,NA,Microbiota in endometrial tumors - Brevundimonas genus,Percent,NA,None,2,N/A,Obese white,4.72,-99,-99
10.1016/j.ygyno.2022.02.021,13,No,NA,No,NA,Microbiota in endometrial tumors - Candidatus Rhodoluna genus,Percent,NA,None,1,N/A,Obese black,6.53,-99,-99
10.1016/j.ygyno.2022.02.021,13,No,NA,No,NA,Microbiota in endometrial tumors - Candidatus Rhodoluna genus,Percent,NA,None,2,N/A,Obese white,0.01,-99,-99
10.1016/j.ygyno.2022.02.021,14,No,NA,No,NA,Microbiota in endometrial tumors - Corynebacterium genus,Percent,NA,None,1,N/A,Obese black,0.04,-99,-99
10.1016/j.ygyno.2022.02.021,14,No,NA,No,NA,Microbiota in endometrial tumors - Corynebacterium genus,Percent,NA,None,2,N/A,Obese white,0.03,-99,-99
10.1016/j.ygyno.2022.02.021,15,No,NA,No,NA,Microbiota in endometrial tumors - Delftia genus,Percent,NA,None,1,N/A,Obese black,4.3,-99,-99
10.1016/j.ygyno.2022.02.021,15,No,NA,No,NA,Microbiota in endometrial tumors - Delftia genus,Percent,NA,None,2,N/A,Obese white,2.74,-99,-99
10.1016/j.ygyno.2022.02.021,16,No,NA,No,NA,Microbiota in endometrial tumors - Dietzia genus,Percent,NA,None,1,N/A,Obese black,0.78,-99,-99
10.1016/j.ygyno.2022.02.021,16,No,NA,No,NA,Microbiota in endometrial tumors - Dietzia genus,Percent,NA,None,2,N/A,Obese white,6.59,-99,-99
10.1016/j.ygyno.2022.02.021,17,No,NA,No,NA,Microbiota in endometrial tumors - Flavobacterium genus,Percent,NA,None,1,N/A,Obese black,41.3,-99,-99
10.1016/j.ygyno.2022.02.021,17,No,NA,No,NA,Microbiota in endometrial tumors - Flavobacterium genus,Percent,NA,None,2,N/A,Obese white,2.19,-99,-99
10.1016/j.ygyno.2022.02.021,18,No,NA,No,NA,Microbiota in endometrial tumors - Geobacillus genus,Percent,NA,None,1,N/A,Obese black,0.03,-99,-99
10.1016/j.ygyno.2022.02.021,18,No,NA,No,NA,Microbiota in endometrial tumors - Geobacillus genus,Percent,NA,None,2,N/A,Obese white,0.06,-99,-99
10.1016/j.ygyno.2022.02.021,19,No,NA,No,NA,Microbiota in endometrial tumors - Hyphomicrobium genus,Percent,NA,None,1,N/A,Obese black,0,-99,-99
10.1016/j.ygyno.2022.02.021,19,No,NA,No,NA,Microbiota in endometrial tumors - Hyphomicrobium genus,Percent,NA,None,2,N/A,Obese white,0.57,-99,-99
10.1016/j.ygyno.2022.02.021,20,No,NA,No,NA,Microbiota in endometrial tumors - Methylobacterium genus,Percent,NA,None,1,N/A,Obese black,0.36,-99,-99
10.1016/j.ygyno.2022.02.021,20,No,NA,No,NA,Microbiota in endometrial tumors - Methylobacterium genus,Percent,NA,None,2,N/A,Obese white,0.24,-99,-99
10.1016/j.ygyno.2022.02.021,21,No,NA,No,NA,Microbiota in endometrial tumors - Paenibacillus genus,Percent,NA,None,1,N/A,Obese black,2.24,-99,-99
10.1016/j.ygyno.2022.02.021,21,No,NA,No,NA,Microbiota in endometrial tumors - Paenibacillus genus,Percent,NA,None,2,N/A,Obese white,0,-99,-99
10.1016/j.ygyno.2022.02.021,22,No,NA,No,NA,Microbiota in endometrial tumors - Pelomonas genus,Percent,NA,None,1,N/A,Obese black,3.24,-99,-99
10.1016/j.ygyno.2022.02.021,22,No,NA,No,NA,Microbiota in endometrial tumors - Pelomonas genus,Percent,NA,None,2,N/A,Obese white,1.21,-99,-99
10.1016/j.ygyno.2022.02.021,23,No,NA,No,NA,Microbiota in endometrial tumors - Prevotella genus,Percent,NA,None,1,N/A,Obese black,3.25,-99,-99
10.1016/j.ygyno.2022.02.021,23,No,NA,No,NA,Microbiota in endometrial tumors - Prevotella genus,Percent,NA,None,2,N/A,Obese white,0.16,-99,-99
10.1016/j.ygyno.2022.02.021,24,No,NA,No,NA,Microbiota in endometrial tumors - Propionibacterium genus,Percent,NA,None,1,N/A,Obese black,4.43,-99,-99
10.1016/j.ygyno.2022.02.021,24,No,NA,No,NA,Microbiota in endometrial tumors - Propionibacterium genus,Percent,NA,None,2,N/A,Obese white,0.04,-99,-99
10.1016/j.ygyno.2022.02.021,25,No,NA,No,NA,Microbiota in endometrial tumors - Pseudomonas genus,Percent,NA,None,1,N/A,Obese black,0.25,-99,-99
10.1016/j.ygyno.2022.02.021,25,No,NA,No,NA,Microbiota in endometrial tumors - Pseudomonas genus,Percent,NA,None,2,N/A,Obese white,3.26,-99,-99
10.1016/j.ygyno.2022.02.021,26,No,NA,No,NA,Microbiota in endometrial tumors - Ralstonia genus,Percent,NA,None,1,N/A,Obese black,1.2,-99,-99
10.1016/j.ygyno.2022.02.021,26,No,NA,No,NA,Microbiota in endometrial tumors - Ralstonia genus,Percent,NA,None,2,N/A,Obese white,0.27,-99,-99
10.1016/j.ygyno.2022.02.021,27,No,NA,No,NA,Microbiota in endometrial tumors - Rhodobacter genus,Percent,NA,None,1,N/A,Obese black,0,-99,-99
10.1016/j.ygyno.2022.02.021,27,No,NA,No,NA,Microbiota in endometrial tumors - Rhodobacter genus,Percent,NA,None,2,N/A,Obese white,0.34,-99,-99
10.1016/j.ygyno.2022.02.021,28,No,NA,No,NA,Microbiota in endometrial tumors - Sediminibacterium genus,Percent,NA,None,1,N/A,Obese black,0.02,-99,-99
10.1016/j.ygyno.2022.02.021,28,No,NA,No,NA,Microbiota in endometrial tumors - Sediminibacterium genus,Percent,NA,None,2,N/A,Obese white,0.11,-99,-99
10.1016/j.ygyno.2022.02.021,29,No,NA,No,NA,Microbiota in endometrial tumors - Staphylococcus genus,Percent,NA,None,1,N/A,Obese black,0.05,-99,-99
10.1016/j.ygyno.2022.02.021,29,No,NA,No,NA,Microbiota in endometrial tumors - Staphylococcus genus,Percent,NA,None,2,N/A,Obese white,0.03,-99,-99
10.1016/j.ygyno.2022.02.021,30,No,NA,No,NA,Microbiota in endometrial tumors - Stenotrophomonas genus,Percent,NA,None,1,N/A,Obese black,2.14,-99,-99
10.1016/j.ygyno.2022.02.021,30,No,NA,No,NA,Microbiota in endometrial tumors - Stenotrophomonas genus,Percent,NA,None,2,N/A,Obese white,0.87,-99,-99
10.1016/j.ygyno.2022.02.021,31,No,NA,No,NA,Microbiota in endometrial tumors - Streptococcus genus,Percent,NA,None,1,N/A,Obese black,3.74,-99,-99
10.1016/j.ygyno.2022.02.021,31,No,NA,No,NA,Microbiota in endometrial tumors - Streptococcus genus,Percent,NA,None,2,N/A,Obese white,0.15,-99,-99
10.1016/j.ygyno.2022.02.021,32,No,NA,No,NA,Microbiota in endometrial tumors - Tepidimonas genus,Percent,NA,None,1,N/A,Obese black,0.9,-99,-99
10.1016/j.ygyno.2022.02.021,32,No,NA,No,NA,Microbiota in endometrial tumors - Tepidimonas genus,Percent,NA,None,2,N/A,Obese white,0.07,-99,-99
10.1016/j.ygyno.2022.07.014,1,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, Charleson-Deyo score, insurance status, income, education, facility location, facility type, year of diagnosis, histology, tumor status, surgery type, surgical approach",1,White,Black,1.2,1.13,1.28
10.1016/j.ygyno.2022.07.014,1,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, Charleson-Deyo score, insurance status, income, education, facility location, facility type, year of diagnosis, histology, tumor status, surgery type, surgical approach",2,White,Hispanic,0.98,0.9,1.08
10.1016/j.ygyno.2022.07.014,1,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, Charleson-Deyo score, insurance status, income, education, facility location, facility type, year of diagnosis, histology, tumor status, surgery type, surgical approach",3,White,Asian,1.07,0.94,1.22
10.1016/j.ygyno.2022.07.014,1,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, Charleson-Deyo score, insurance status, income, education, facility location, facility type, year of diagnosis, histology, tumor status, surgery type, surgical approach",4,White,American Indian/Alaskan Native,0.75,0.5,1.13
10.1016/j.ygyno.2022.07.014,1,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, Charleson-Deyo score, insurance status, income, education, facility location, facility type, year of diagnosis, histology, tumor status, surgery type, surgical approach",5,White,Native Hawaiian/Pacific Islander,1.54,1.09,2.18
10.1016/j.ygyno.2022.07.014,2,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index",1,White,Black,1.64,1.55,1.73
10.1016/j.ygyno.2022.07.014,2,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index",2,White,Hispanic,1.09,1,1.18
10.1016/j.ygyno.2022.07.014,2,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index",3,White,Asian,0.91,0.8,1.04
10.1016/j.ygyno.2022.07.014,2,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index",4,White,American Indian/Alaskan Native,0.81,0.54,1.21
10.1016/j.ygyno.2022.07.014,2,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index",5,White,Native Hawaiian/Pacific Islander,1.18,0.84,1.67
10.1016/j.ygyno.2022.07.014,3,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status",1,White,Black,1.6,1.51,1.69
10.1016/j.ygyno.2022.07.014,3,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status",2,White,Hispanic,1.08,0.99,1.17
10.1016/j.ygyno.2022.07.014,3,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status",3,White,Asian,0.93,0.81,1.06
10.1016/j.ygyno.2022.07.014,3,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status",4,White,American Indian/Alaskan Native,0.78,0.52,1.17
10.1016/j.ygyno.2022.07.014,3,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status",5,White,Native Hawaiian/Pacific Islander,1.13,0.8,1.6
10.1016/j.ygyno.2022.07.014,4,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location",1,White,Black,1.47,1.39,1.56
10.1016/j.ygyno.2022.07.014,4,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location",2,White,Hispanic,0.95,0.87,1.04
10.1016/j.ygyno.2022.07.014,4,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location",3,White,Asian,0.91,0.8,1.04
10.1016/j.ygyno.2022.07.014,4,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location",4,White,American Indian/Alaskan Native,0.73,0.49,1.1
10.1016/j.ygyno.2022.07.014,4,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location",5,White,Native Hawaiian/Pacific Islander,1.09,0.77,1.54
10.1016/j.ygyno.2022.07.014,5,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location, histology, stage",1,White,Black,1.41,1.32,1.49
10.1016/j.ygyno.2022.07.014,5,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location, histology, stage",2,White,Hispanic,1.02,0.94,1.12
10.1016/j.ygyno.2022.07.014,5,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location, histology, stage",3,White,Asian,1.12,0.98,1.28
10.1016/j.ygyno.2022.07.014,5,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location, histology, stage",4,White,American Indian/Alaskan Native,0.8,0.53,1.2
10.1016/j.ygyno.2022.07.014,5,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location, histology, stage",5,White,Native Hawaiian/Pacific Islander,1.65,1.17,2.33
10.1016/j.ygyno.2022.07.014,6,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location, histology, stage, surgery, surgical approach",1,White,Black,1.25,1.17,1.33
10.1016/j.ygyno.2022.07.014,6,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location, histology, stage, surgery, surgical approach",2,White,Hispanic,1,0.92,1.1
10.1016/j.ygyno.2022.07.014,6,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location, histology, stage, surgery, surgical approach",3,White,Asian,1.09,0.96,1.25
10.1016/j.ygyno.2022.07.014,6,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location, histology, stage, surgery, surgical approach",4,White,American Indian/Alaskan Native,0.76,0.5,1.14
10.1016/j.ygyno.2022.07.014,6,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location, histology, stage, surgery, surgical approach",5,White,Native Hawaiian/Pacific Islander,1.58,1.11,2.23
10.1016/j.ygyno.2022.07.014,7,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location, histology, stage, surgery, surgical approach",1,White,Black,1.2,1.13,1.28
10.1016/j.ygyno.2022.07.014,7,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location, histology, stage, surgery, surgical approach",2,White,Hispanic,0.98,0.9,1.08
10.1016/j.ygyno.2022.07.014,7,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location, histology, stage, surgery, surgical approach",3,White,Asian,1.07,0.94,1.22
10.1016/j.ygyno.2022.07.014,7,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location, histology, stage, surgery, surgical approach",4,White,American Indian/Alaskan Native,0.75,0.5,1.13
10.1016/j.ygyno.2022.07.014,7,No,NA,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location, histology, stage, surgery, surgical approach",5,White,Native Hawaiian/Pacific Islander,1.54,1.09,2.18
10.1016/j.ygyno.2022.07.014,8,Yes,surgical approach - minimally invasive,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location, histology, stage, surgery",1,White,Black,1.21,1.07,1.37
10.1016/j.ygyno.2022.07.014,8,Yes,surgical approach - minimally invasive,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location, histology, stage, surgery",2,White,Hispanic,1.03,0.87,1.21
10.1016/j.ygyno.2022.07.014,8,Yes,surgical approach - minimally invasive,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location, histology, stage, surgery",3,White,Asian,0.96,0.75,1.23
10.1016/j.ygyno.2022.07.014,8,Yes,surgical approach - minimally invasive,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location, histology, stage, surgery",4,White,American Indian/Alaskan Native,1.04,0.57,1.9
10.1016/j.ygyno.2022.07.014,8,Yes,surgical approach - minimally invasive,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location, histology, stage, surgery",5,White,Native Hawaiian/Pacific Islander,1.82,1.06,3.13
10.1016/j.ygyno.2022.07.014,9,Yes,surgical approach - laparotomy,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location, histology, stage, surgery",1,White,Black,1.26,1.14,1.4
10.1016/j.ygyno.2022.07.014,9,Yes,surgical approach - laparotomy,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location, histology, stage, surgery",2,White,Hispanic,1.17,1,1.37
10.1016/j.ygyno.2022.07.014,9,Yes,surgical approach - laparotomy,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location, histology, stage, surgery",3,White,Asian,1.25,1,1.56
10.1016/j.ygyno.2022.07.014,9,Yes,surgical approach - laparotomy,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location, histology, stage, surgery",4,White,American Indian/Alaskan Native,0.53,0.22,1.29
10.1016/j.ygyno.2022.07.014,9,Yes,surgical approach - laparotomy,No,NA,readmission risk among women with endometrial cancer,OR,NA,"age, year of diagnosis, Charlson comorbidity index, income, education, insurance status, facility type, facility location, histology, stage, surgery",5,White,Native Hawaiian/Pacific Islander,1.58,0.82,3.02
10.1016/j.ygyno.2022.09.017,1,No,NA,No,NA,hospitalization for COVID-19,OR,NA,None,1,White,Non-white,1.95,1.19,3.18
10.1016/j.ygyno.2022.09.017,2,No,NA,No,NA,hospitalization for COVID-19,OR,NA,None,1,Not Hispanic or Latino,Hispanic or Latino,0.67,0.26,1.7
10.1016/j.ygyno.2022.09.017,2,No,NA,No,NA,hospitalization for COVID-19,OR,NA,None,2,Not Hispanic or Latino,Unknown/not reported,1.57,0.66,3.76
10.1016/j.ygyno.2022.09.017,3,No,NA,No,NA,hospitalization for COVID-19,OR,NA,"age at COVID-19 diagnosis, asthma, diabetes mellitus, pulmonary embolism, symptoms at initial COVID-19 diagnosis, active malignancy",1,White,Non-white,2.95,1.53,5.71
10.1016/j.ygyno.2022.09.017,4,No,NA,No,NA,death within 30 days after COVID-19 diagnosis,OR,NA,None,1,White,Non-white,1.72,0.64,4.66
10.1016/j.ygyno.2022.09.017,5,No,NA,No,NA,death within 30 days after COVID-19 diagnosis,OR,NA,None,1,Not Hispanic or Latino,Hispanic or Latino,0.32,0.02,5.72
10.1016/j.ygyno.2022.09.017,5,No,NA,No,NA,death within 30 days after COVID-19 diagnosis,OR,NA,None,2,Not Hispanic or Latino,Unknown/not reported,2.1,0.5,8.82
10.1016/j.ygyno.2022.11.007,1,Yes,2011,No,NA,Up-to-date cervical cancer screening rates among American Indian/Alaska Native women in the Pacific Northwest,Percent,NA,None,1,N/A,Washington,61.6,-99,-99
10.1016/j.ygyno.2022.11.007,1,Yes,2011,No,NA,Up-to-date cervical cancer screening rates among American Indian/Alaska Native women in the Pacific Northwest,Percent,NA,None,2,N/A,Oregon,59.6,-99,-99
10.1016/j.ygyno.2022.11.007,1,Yes,2011,No,NA,Up-to-date cervical cancer screening rates among American Indian/Alaska Native women in the Pacific Northwest,Percent,NA,None,3,N/A,Idaho,57.1,-99,-99
10.1016/j.ygyno.2022.11.007,2,Yes,2019,No,NA,Up-to-date cervical cancer screening rates among American Indian/Alaska Native women in the Pacific Northwest,Percent,NA,None,1,N/A,2019 National Average,73.5,-99,-99
10.1016/j.ygyno.2022.11.007,2,Yes,2019,No,NA,Up-to-date cervical cancer screening rates among American Indian/Alaska Native women in the Pacific Northwest,Percent,NA,None,2,N/A,Washington,65,-99,-99
10.1016/j.ygyno.2022.11.007,2,Yes,2019,No,NA,Up-to-date cervical cancer screening rates among American Indian/Alaska Native women in the Pacific Northwest,Percent,NA,None,3,N/A,Oregon,63,-99,-99
10.1016/j.ygyno.2022.11.007,2,Yes,2019,No,NA,Up-to-date cervical cancer screening rates among American Indian/Alaska Native women in the Pacific Northwest,Percent,NA,None,4,N/A,Idaho,59.7,-99,-99
10.1016/j.ygyno.2022.11.007,3,No,NA,No,NA,"Rates of HPV vaccination initiation among American Indian/Alaska Native Youth in the Pacific Northwest, 2019",Percent,NA,None,1,N/A,2020 National Average (13-17),75.1,-99,-99
10.1016/j.ygyno.2022.11.007,3,No,NA,No,NA,"Rates of HPV vaccination initiation among American Indian/Alaska Native Youth in the Pacific Northwest, 2019",Percent,NA,None,2,N/A,Female (9-12),64.1,-99,-99
10.1016/j.ygyno.2022.11.007,3,No,NA,No,NA,"Rates of HPV vaccination initiation among American Indian/Alaska Native Youth in the Pacific Northwest, 2019",Percent,NA,None,3,N/A,Female (13-18),83.1,-99,-99
10.1016/j.ygyno.2022.11.007,3,No,NA,No,NA,"Rates of HPV vaccination initiation among American Indian/Alaska Native Youth in the Pacific Northwest, 2019",Percent,NA,None,4,N/A,Female (19-26),54.9,-99,-99
10.1016/j.ygyno.2022.11.007,3,No,NA,No,NA,"Rates of HPV vaccination initiation among American Indian/Alaska Native Youth in the Pacific Northwest, 2019",Percent,NA,None,5,N/A,Male (9-12),30.9,-99,-99
10.1016/j.ygyno.2022.11.007,3,No,NA,No,NA,"Rates of HPV vaccination initiation among American Indian/Alaska Native Youth in the Pacific Northwest, 2019",Percent,NA,None,6,N/A,Male (13-18),48.8,-99,-99
10.1016/j.ygyno.2022.11.007,3,No,NA,No,NA,"Rates of HPV vaccination initiation among American Indian/Alaska Native Youth in the Pacific Northwest, 2019",Percent,NA,None,7,N/A,Male (19-26),39.8,-99,-99
10.1016/j.ygyno.2022.11.007,4,No,NA,No,NA,"Rates of completed HPV vaccination series among American Indian/Alaska Native Youth in the Pacific Northwest, 2019",Percent,NA,None,1,N/A,2020 National Estimate (13-17),58.6,-99,-99
10.1016/j.ygyno.2022.11.007,4,No,NA,No,NA,"Rates of completed HPV vaccination series among American Indian/Alaska Native Youth in the Pacific Northwest, 2019",Percent,NA,None,2,N/A,Female (9-12),42.3,-99,-99
10.1016/j.ygyno.2022.11.007,4,No,NA,No,NA,"Rates of completed HPV vaccination series among American Indian/Alaska Native Youth in the Pacific Northwest, 2019",Percent,NA,None,3,N/A,Female (13-18),71.1,-99,-99
10.1016/j.ygyno.2022.11.007,4,No,NA,No,NA,"Rates of completed HPV vaccination series among American Indian/Alaska Native Youth in the Pacific Northwest, 2019",Percent,NA,None,4,N/A,Female (19-26),48.2,-99,-99
10.1016/j.ygyno.2022.11.007,4,No,NA,No,NA,"Rates of completed HPV vaccination series among American Indian/Alaska Native Youth in the Pacific Northwest, 2019",Percent,NA,None,5,N/A,Male (9-12),25.3,-99,-99
10.1016/j.ygyno.2022.11.007,4,No,NA,No,NA,"Rates of completed HPV vaccination series among American Indian/Alaska Native Youth in the Pacific Northwest, 2019",Percent,NA,None,6,N/A,Male (13-18),41,-99,-99
10.1016/j.ygyno.2022.11.007,4,No,NA,No,NA,"Rates of completed HPV vaccination series among American Indian/Alaska Native Youth in the Pacific Northwest, 2019",Percent,NA,None,7,N/A,Male (19-26),28.1,-99,-99
10.1016/j.ygyno.2022.11.015,1,No,NA,No,NA,endometrial cancer mortality,Incidence,cumulative 5-year rate (proportion),None,1,N/A,non-Hispanic White,0.317,0.306,0.328
10.1016/j.ygyno.2022.11.015,1,No,NA,No,NA,endometrial cancer mortality,Incidence,cumulative 5-year rate (proportion),None,2,N/A,non-Hispanic Black,0.406,0.383,0.428
10.1016/j.ygyno.2022.11.015,1,No,NA,No,NA,endometrial cancer mortality,Incidence,cumulative 5-year rate (proportion),None,3,N/A,Hispanic,0.324,0.297,0.35
10.1016/j.ygyno.2022.11.015,1,No,NA,No,NA,endometrial cancer mortality,Incidence,cumulative 5-year rate (proportion),None,4,N/A,non-Hispanic Asian/Pacific Islander,0.301,0.282,0.34
10.1016/j.ygyno.2022.11.015,2,No,NA,No,NA,overall mortality,Incidence,cumulative 5-year rate (proportion),None,1,N/A,non-Hispanic White,0.411,0.399,0.423
10.1016/j.ygyno.2022.11.015,2,No,NA,No,NA,overall mortality,Incidence,cumulative 5-year rate (proportion),None,2,N/A,non-Hispanic Black,0.537,0.513,0.562
10.1016/j.ygyno.2022.11.015,2,No,NA,No,NA,overall mortality,Incidence,cumulative 5-year rate (proportion),None,3,N/A,Hispanic,0.429,0.399,0.459
10.1016/j.ygyno.2022.11.015,2,No,NA,No,NA,overall mortality,Incidence,cumulative 5-year rate (proportion),None,4,N/A,non-Hispanic Asian/Pacific Islander,0.397,0.366,0.431
10.1016/j.ygyno.2022.11.015,3,No,NA,Yes,women with high-grade endometrioid carcinoma,endometrial cancer mortality,Incidence,cumulative 5-year rate (proportion),None,1,N/A,non-Hispanic White,0.248,0.235,0.262
10.1016/j.ygyno.2022.11.015,3,No,NA,Yes,women with high-grade endometrioid carcinoma,endometrial cancer mortality,Incidence,cumulative 5-year rate (proportion),None,2,N/A,non-Hispanic Black,0.33,0.295,0.365
10.1016/j.ygyno.2022.11.015,3,No,NA,Yes,women with high-grade endometrioid carcinoma,endometrial cancer mortality,Incidence,cumulative 5-year rate (proportion),None,3,N/A,Hispanic,0.246,0.212,0.28
10.1016/j.ygyno.2022.11.015,3,No,NA,Yes,women with high-grade endometrioid carcinoma,endometrial cancer mortality,Incidence,cumulative 5-year rate (proportion),None,4,N/A,non-Hispanic Asian/Pacific Islander,0.249,0.213,0.286
10.1016/j.ygyno.2022.11.015,4,No,NA,Yes,women with high-grade endometrioid carcinoma,overall mortality,Incidence,cumulative 5-year rate (proportion),None,1,N/A,non-Hispanic White,0.355,0.341,0.371
10.1016/j.ygyno.2022.11.015,4,No,NA,Yes,women with high-grade endometrioid carcinoma,overall mortality,Incidence,cumulative 5-year rate (proportion),None,2,N/A,non-Hispanic Black,0.457,0.42,0.495
10.1016/j.ygyno.2022.11.015,4,No,NA,Yes,women with high-grade endometrioid carcinoma,overall mortality,Incidence,cumulative 5-year rate (proportion),None,3,N/A,Hispanic,0.355,0.318,0.396
10.1016/j.ygyno.2022.11.015,4,No,NA,Yes,women with high-grade endometrioid carcinoma,overall mortality,Incidence,cumulative 5-year rate (proportion),None,4,N/A,non-Hispanic Asian/Pacific Islander,0.33,0.291,0.372
10.1016/j.ygyno.2022.11.015,5,No,NA,Yes,women with nonendometrioid carcinoma,endometrial cancer mortality,Incidence,cumulative 5-year rate (proportion),None,1,N/A,non-Hispanic White,0.407,0.39,0.425
10.1016/j.ygyno.2022.11.015,5,No,NA,Yes,women with nonendometrioid carcinoma,endometrial cancer mortality,Incidence,cumulative 5-year rate (proportion),None,2,N/A,non-Hispanic Black,0.471,0.442,0.496
10.1016/j.ygyno.2022.11.015,5,No,NA,Yes,women with nonendometrioid carcinoma,endometrial cancer mortality,Incidence,cumulative 5-year rate (proportion),None,3,N/A,Hispanic,0.405,0.364,0.446
10.1016/j.ygyno.2022.11.015,5,No,NA,Yes,women with nonendometrioid carcinoma,endometrial cancer mortality,Incidence,cumulative 5-year rate (proportion),None,4,N/A,non-Hispanic Asian/Pacific Islander,0.388,0.341,0.436
10.1016/j.ygyno.2022.11.015,6,No,NA,Yes,women with nonendometrioid carcinoma,overall mortality,Incidence,cumulative 5-year rate (proportion),None,1,N/A,non-Hispanic White,0.536,0.518,0.555
10.1016/j.ygyno.2022.11.015,6,No,NA,Yes,women with nonendometrioid carcinoma,overall mortality,Incidence,cumulative 5-year rate (proportion),None,2,N/A,non-Hispanic Black,0.63,0.6,0.659
10.1016/j.ygyno.2022.11.015,6,No,NA,Yes,women with nonendometrioid carcinoma,overall mortality,Incidence,cumulative 5-year rate (proportion),None,3,N/A,Hispanic,0.548,0.505,0.592
10.1016/j.ygyno.2022.11.015,6,No,NA,Yes,women with nonendometrioid carcinoma,overall mortality,Incidence,cumulative 5-year rate (proportion),None,4,N/A,non-Hispanic Asian/Pacific Islander,0.529,0.48,0.58
10.1016/j.ygyno.2022.11.015,7,No,NA,No,NA,endometrial cancer mortality: all histologic subtypes,HR,NA,age,1,non-Hispanic White,non-Hispanic Black,1.4,1.3,1.52
10.1016/j.ygyno.2022.11.015,7,No,NA,No,NA,endometrial cancer mortality: all histologic subtypes,HR,NA,age,2,non-Hispanic White,Hispanic,1.05,0.95,1.17
10.1016/j.ygyno.2022.11.015,7,No,NA,No,NA,endometrial cancer mortality: all histologic subtypes,HR,NA,age,3,non-Hispanic White,non-Hispanic Asian/Pacific Islander,1.01,0.9,1.13
10.1016/j.ygyno.2022.11.015,8,No,NA,No,NA,endometrial cancer mortality: all histologic subtypes,HR,NA,"age, type of insurance, geographic region, geographic location, and neighborhood socioeconomic status",1,non-Hispanic White,non-Hispanic Black,1.36,1.25,1.47
10.1016/j.ygyno.2022.11.015,8,No,NA,No,NA,endometrial cancer mortality: all histologic subtypes,HR,NA,"age, type of insurance, geographic region, geographic location, and neighborhood socioeconomic status",2,non-Hispanic White,Hispanic,0.96,0.86,1.07
10.1016/j.ygyno.2022.11.015,8,No,NA,No,NA,endometrial cancer mortality: all histologic subtypes,HR,NA,"age, type of insurance, geographic region, geographic location, and neighborhood socioeconomic status",3,non-Hispanic White,non-Hispanic Asian/Pacific Islander,0.94,0.83,1.05
10.1016/j.ygyno.2022.11.015,9,No,NA,No,NA,endometrial cancer mortality: all histologic subtypes,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, cancer grade, and histologic subtype",1,non-Hispanic White,non-Hispanic Black,1.22,1.12,1.33
10.1016/j.ygyno.2022.11.015,9,No,NA,No,NA,endometrial cancer mortality: all histologic subtypes,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, cancer grade, and histologic subtype",2,non-Hispanic White,Hispanic,0.91,0.81,1.01
10.1016/j.ygyno.2022.11.015,9,No,NA,No,NA,endometrial cancer mortality: all histologic subtypes,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, cancer grade, and histologic subtype",3,non-Hispanic White,non-Hispanic Asian/Pacific Islander,0.88,0.78,0.99
10.1016/j.ygyno.2022.11.015,10,No,NA,No,NA,endometrial cancer mortality: all histologic subtypes,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, cancer grade, histologic subtype, lymphadenectomy, and type of treatment",1,non-Hispanic White,non-Hispanic Black,1.22,1.12,1.33
10.1016/j.ygyno.2022.11.015,10,No,NA,No,NA,endometrial cancer mortality: all histologic subtypes,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, cancer grade, histologic subtype, lymphadenectomy, and type of treatment",2,non-Hispanic White,Hispanic,0.91,0.81,1.01
10.1016/j.ygyno.2022.11.015,10,No,NA,No,NA,endometrial cancer mortality: all histologic subtypes,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, cancer grade, histologic subtype, lymphadenectomy, and type of treatment",3,non-Hispanic White,non-Hispanic Asian/Pacific Islander,0.88,0.78,0.99
10.1016/j.ygyno.2022.11.015,11,No,NA,No,NA,endometrial cancer mortality: high-grade endometrioid carcinoma,HR,NA,age,1,non-Hispanic White,non-Hispanic Black,1.43,1.25,1.63
10.1016/j.ygyno.2022.11.015,11,No,NA,No,NA,endometrial cancer mortality: high-grade endometrioid carcinoma,HR,NA,age,2,non-Hispanic White,Hispanic,1.03,0.87,1.22
10.1016/j.ygyno.2022.11.015,11,No,NA,No,NA,endometrial cancer mortality: high-grade endometrioid carcinoma,HR,NA,age,3,non-Hispanic White,non-Hispanic Asian/Pacific Islander,1.08,0.91,1.28
10.1016/j.ygyno.2022.11.015,12,No,NA,No,NA,endometrial cancer mortality: high-grade endometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, and neighborhood socioeconomic status",1,non-Hispanic White,non-Hispanic Black,1.33,1.15,1.53
10.1016/j.ygyno.2022.11.015,12,No,NA,No,NA,endometrial cancer mortality: high-grade endometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, and neighborhood socioeconomic status",2,non-Hispanic White,Hispanic,0.92,0.77,1.1
10.1016/j.ygyno.2022.11.015,12,No,NA,No,NA,endometrial cancer mortality: high-grade endometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, and neighborhood socioeconomic status",3,non-Hispanic White,non-Hispanic Asian/Pacific Islander,1.02,0.86,1.22
10.1016/j.ygyno.2022.11.015,13,No,NA,No,NA,endometrial cancer mortality: high-grade endometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, and cancer grade",1,non-Hispanic White,non-Hispanic Black,1.25,1.08,1.45
10.1016/j.ygyno.2022.11.015,13,No,NA,No,NA,endometrial cancer mortality: high-grade endometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, and cancer grade",2,non-Hispanic White,Hispanic,0.83,0.69,1
10.1016/j.ygyno.2022.11.015,13,No,NA,No,NA,endometrial cancer mortality: high-grade endometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, and cancer grade",3,non-Hispanic White,non-Hispanic Asian/Pacific Islander,0.99,0.82,1.19
10.1016/j.ygyno.2022.11.015,14,No,NA,No,NA,endometrial cancer mortality: high-grade endometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, cancer grade, lymphadenectomy, and type of treatment",1,non-Hispanic White,non-Hispanic Black,1.25,1.08,1.45
10.1016/j.ygyno.2022.11.015,14,No,NA,No,NA,endometrial cancer mortality: high-grade endometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, cancer grade, lymphadenectomy, and type of treatment",2,non-Hispanic White,Hispanic,0.83,0.69,1.01
10.1016/j.ygyno.2022.11.015,14,No,NA,No,NA,endometrial cancer mortality: high-grade endometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, cancer grade, lymphadenectomy, and type of treatment",3,non-Hispanic White,non-Hispanic Asian/Pacific Islander,0.98,0.81,1.18
10.1016/j.ygyno.2022.11.015,15,No,NA,No,NA,endometrial cancer mortality: nonendometrioid carcinoma,HR,NA,age,1,non-Hispanic White,non-Hispanic Black,1.22,1.1,1.34
10.1016/j.ygyno.2022.11.015,15,No,NA,No,NA,endometrial cancer mortality: nonendometrioid carcinoma,HR,NA,age,2,non-Hispanic White,Hispanic,0.99,0.87,1.13
10.1016/j.ygyno.2022.11.015,15,No,NA,No,NA,endometrial cancer mortality: nonendometrioid carcinoma,HR,NA,age,3,non-Hispanic White,non-Hispanic Asian/Pacific Islander,0.91,0.78,1.06
10.1016/j.ygyno.2022.11.015,16,No,NA,No,NA,endometrial cancer mortality: nonendometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, and neighborhood socioeconomic status",1,non-Hispanic White,non-Hispanic Black,1.2,1.08,1.33
10.1016/j.ygyno.2022.11.015,16,No,NA,No,NA,endometrial cancer mortality: nonendometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, and neighborhood socioeconomic status",2,non-Hispanic White,Hispanic,0.92,0.81,1.06
10.1016/j.ygyno.2022.11.015,16,No,NA,No,NA,endometrial cancer mortality: nonendometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, and neighborhood socioeconomic status",3,non-Hispanic White,non-Hispanic Asian/Pacific Islander,0.85,0.73,0.99
10.1016/j.ygyno.2022.11.015,17,No,NA,No,NA,endometrial cancer mortality: nonendometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, and cancer grade",1,non-Hispanic White,non-Hispanic Black,1.2,1.08,1.34
10.1016/j.ygyno.2022.11.015,17,No,NA,No,NA,endometrial cancer mortality: nonendometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, and cancer grade",2,non-Hispanic White,Hispanic,0.95,0.83,1.09
10.1016/j.ygyno.2022.11.015,17,No,NA,No,NA,endometrial cancer mortality: nonendometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, and cancer grade",3,non-Hispanic White,non-Hispanic Asian/Pacific Islander,0.8,0.68,0.94
10.1016/j.ygyno.2022.11.015,18,No,NA,No,NA,endometrial cancer mortality: nonendometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, cancer grade, lymphadenectomy, and type of treatment",1,non-Hispanic White,non-Hispanic Black,1.2,1.08,1.34
10.1016/j.ygyno.2022.11.015,18,No,NA,No,NA,endometrial cancer mortality: nonendometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, cancer grade, lymphadenectomy, and type of treatment",2,non-Hispanic White,Hispanic,0.95,0.83,1.09
10.1016/j.ygyno.2022.11.015,18,No,NA,No,NA,endometrial cancer mortality: nonendometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, cancer grade, lymphadenectomy, and type of treatment",3,non-Hispanic White,non-Hispanic Asian/Pacific Islander,0.8,0.68,0.94
10.1016/j.ygyno.2022.11.015,19,No,NA,No,NA,overall mortality: all histologic subtypes,HR,NA,age,1,non-Hispanic White,non-Hispanic Black,1.51,1.41,1.61
10.1016/j.ygyno.2022.11.015,19,No,NA,No,NA,overall mortality: all histologic subtypes,HR,NA,age,2,non-Hispanic White,Hispanic,1.13,1.03,1.23
10.1016/j.ygyno.2022.11.015,19,No,NA,No,NA,overall mortality: all histologic subtypes,HR,NA,age,3,non-Hispanic White,non-Hispanic Asian/Pacific Islander,1.03,0.93,1.14
10.1016/j.ygyno.2022.11.015,20,No,NA,No,NA,overall mortality: all histologic subtypes,HR,NA,"age, type of insurance, geographic region, geographic location, and neighborhood socioeconomic status",1,non-Hispanic White,non-Hispanic Black,1.41,1.31,1.51
10.1016/j.ygyno.2022.11.015,20,No,NA,No,NA,overall mortality: all histologic subtypes,HR,NA,"age, type of insurance, geographic region, geographic location, and neighborhood socioeconomic status",2,non-Hispanic White,Hispanic,1.01,0.92,1.1
10.1016/j.ygyno.2022.11.015,20,No,NA,No,NA,overall mortality: all histologic subtypes,HR,NA,"age, type of insurance, geographic region, geographic location, and neighborhood socioeconomic status",3,non-Hispanic White,non-Hispanic Asian/Pacific Islander,0.97,0.87,1.07
10.1016/j.ygyno.2022.11.015,21,No,NA,No,NA,overall mortality: all histologic subtypes,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, and cancer grade",1,non-Hispanic White,non-Hispanic Black,1.34,1.25,1.44
10.1016/j.ygyno.2022.11.015,21,No,NA,No,NA,overall mortality: all histologic subtypes,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, and cancer grade",2,non-Hispanic White,Hispanic,0.97,0.89,1.07
10.1016/j.ygyno.2022.11.015,21,No,NA,No,NA,overall mortality: all histologic subtypes,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, and cancer grade",3,non-Hispanic White,non-Hispanic Asian/Pacific Islander,0.91,0.82,1.01
10.1016/j.ygyno.2022.11.015,22,No,NA,No,NA,overall mortality: all histologic subtypes,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, cancer grade, lymphadenectomy, and type of treatment",1,non-Hispanic White,non-Hispanic Black,1.34,1.24,1.44
10.1016/j.ygyno.2022.11.015,22,No,NA,No,NA,overall mortality: all histologic subtypes,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, cancer grade, lymphadenectomy, and type of treatment",2,non-Hispanic White,Hispanic,0.97,0.89,1.07
10.1016/j.ygyno.2022.11.015,22,No,NA,No,NA,overall mortality: all histologic subtypes,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, cancer grade, lymphadenectomy, and type of treatment",3,non-Hispanic White,non-Hispanic Asian/Pacific Islander,0.91,0.82,1.01
10.1016/j.ygyno.2022.11.015,23,No,NA,No,NA,overall mortality: high-grade endometrioid carcinoma,HR,NA,age,1,non-Hispanic White,non-Hispanic Black,1.41,1.25,1.58
10.1016/j.ygyno.2022.11.015,23,No,NA,No,NA,overall mortality: high-grade endometrioid carcinoma,HR,NA,age,2,non-Hispanic White,Hispanic,1.11,0.97,1.28
10.1016/j.ygyno.2022.11.015,23,No,NA,No,NA,overall mortality: high-grade endometrioid carcinoma,HR,NA,age,3,non-Hispanic White,non-Hispanic Asian/Pacific Islander,1.03,0.89,1.19
10.1016/j.ygyno.2022.11.015,24,No,NA,No,NA,overall mortality: high-grade endometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, and neighborhood socioeconomic status",1,non-Hispanic White,non-Hispanic Black,1.27,1.12,1.44
10.1016/j.ygyno.2022.11.015,24,No,NA,No,NA,overall mortality: high-grade endometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, and neighborhood socioeconomic status",2,non-Hispanic White,Hispanic,0.97,0.84,1.12
10.1016/j.ygyno.2022.11.015,24,No,NA,No,NA,overall mortality: high-grade endometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, and neighborhood socioeconomic status",3,non-Hispanic White,non-Hispanic Asian/Pacific Islander,0.97,0.83,1.13
10.1016/j.ygyno.2022.11.015,25,No,NA,No,NA,overall mortality: high-grade endometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, and cancer grade",1,non-Hispanic White,non-Hispanic Black,1.24,1.1,1.4
10.1016/j.ygyno.2022.11.015,25,No,NA,No,NA,overall mortality: high-grade endometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, and cancer grade",2,non-Hispanic White,Hispanic,0.91,0.79,1.05
10.1016/j.ygyno.2022.11.015,25,No,NA,No,NA,overall mortality: high-grade endometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, and cancer grade",3,non-Hispanic White,non-Hispanic Asian/Pacific Islander,0.96,0.82,1.12
10.1016/j.ygyno.2022.11.015,26,No,NA,No,NA,overall mortality: high-grade endometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, cancer grade, lymphadenectomy, and type of treatment",1,non-Hispanic White,non-Hispanic Black,1.23,1.09,1.39
10.1016/j.ygyno.2022.11.015,26,No,NA,No,NA,overall mortality: high-grade endometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, cancer grade, lymphadenectomy, and type of treatment",2,non-Hispanic White,Hispanic,0.9,0.78,1.04
10.1016/j.ygyno.2022.11.015,26,No,NA,No,NA,overall mortality: high-grade endometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, cancer grade, lymphadenectomy, and type of treatment",3,non-Hispanic White,non-Hispanic Asian/Pacific Islander,0.96,0.82,1.11
10.1016/j.ygyno.2022.11.015,27,No,NA,No,NA,overall mortality: nonendometrioid carcinoma,HR,NA,age,1,non-Hispanic White,non-Hispanic Black,1.39,1.28,1.51
10.1016/j.ygyno.2022.11.015,27,No,NA,No,NA,overall mortality: nonendometrioid carcinoma,HR,NA,age,2,non-Hispanic White,Hispanic,1.07,0.95,1.2
10.1016/j.ygyno.2022.11.015,27,No,NA,No,NA,overall mortality: nonendometrioid carcinoma,HR,NA,age,3,non-Hispanic White,non-Hispanic Asian/Pacific Islander,1,0.87,1.14
10.1016/j.ygyno.2022.11.015,28,No,NA,No,NA,overall mortality: nonendometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, and neighborhood socioeconomic status",1,non-Hispanic White,non-Hispanic Black,1.31,1.2,1.44
10.1016/j.ygyno.2022.11.015,28,No,NA,No,NA,overall mortality: nonendometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, and neighborhood socioeconomic status",2,non-Hispanic White,Hispanic,0.98,0.87,1.11
10.1016/j.ygyno.2022.11.015,28,No,NA,No,NA,overall mortality: nonendometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, and neighborhood socioeconomic status",3,non-Hispanic White,non-Hispanic Asian/Pacific Islander,0.94,0.82,1.08
10.1016/j.ygyno.2022.11.015,29,No,NA,No,NA,overall mortality: nonendometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, and cancer grade",1,non-Hispanic White,non-Hispanic Black,1.38,1.26,1.51
10.1016/j.ygyno.2022.11.015,29,No,NA,No,NA,overall mortality: nonendometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, and cancer grade",2,non-Hispanic White,Hispanic,1.03,0.91,1.16
10.1016/j.ygyno.2022.11.015,29,No,NA,No,NA,overall mortality: nonendometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, and cancer grade",3,non-Hispanic White,non-Hispanic Asian/Pacific Islander,0.88,0.77,1.01
10.1016/j.ygyno.2022.11.015,30,No,NA,No,NA,overall mortality: nonendometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, cancer grade, lymphadenectomy, and type of treatment",1,non-Hispanic White,non-Hispanic Black,1.39,1.27,1.51
10.1016/j.ygyno.2022.11.015,30,No,NA,No,NA,overall mortality: nonendometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, cancer grade, lymphadenectomy, and type of treatment",2,non-Hispanic White,Hispanic,1.03,0.91,1.16
10.1016/j.ygyno.2022.11.015,30,No,NA,No,NA,overall mortality: nonendometrioid carcinoma,HR,NA,"age, type of insurance, geographic region, geographic location, neighborhood socioeconomic status, cancer stage, cancer grade, lymphadenectomy, and type of treatment",3,non-Hispanic White,non-Hispanic Asian/Pacific Islander,0.87,0.76,1
10.1016/j.ygyno.2022.11.026,1,No,NA,No,NA,Sentinel lymph node biopsy for early-stage vulvar cancer,OR,NA,"Age and year at diagnosis, ethnicity, comorbidities, insurance type, tumor size, grade, facility region, facility type, Medicaid proportion",1,White,Black,0.98,0.59,1.63
10.1016/j.ygyno.2022.11.026,1,No,NA,No,NA,Sentinel lymph node biopsy for early-stage vulvar cancer,OR,NA,"Age and year at diagnosis, ethnicity, comorbidities, insurance type, tumor size, grade, facility region, facility type, Medicaid proportion",2,White,Other,0.47,0.17,1.29
10.1016/j.ygyno.2022.11.026,2,No,NA,No,NA,Sentinel lymph node biopsy for early-stage vulvar cancer,OR,NA,"Age and year at diagnosis, race, comorbidities, insurance type, tumor size, grade, facility region, facility type, Medicaid proportion",1,Non-Hispanic,Hispanic,0.83,0.4,1.71
10.1016/j.ygyno.2023.01.032,1,Yes,gynecological cancer tumor site- Cervix,No,NA,Total cases 1975-2017,count,NA,none,1,N/A,Non-Hispanic White,31467,-99,-99
10.1016/j.ygyno.2023.01.032,1,Yes,gynecological cancer tumor site- Cervix,No,NA,Total cases 1975-2017,count,NA,none,2,N/A,Non-Hispanic Black,7221,-99,-99
10.1016/j.ygyno.2023.01.032,1,Yes,gynecological cancer tumor site- Cervix,No,NA,Total cases 1975-2017,count,NA,none,3,N/A,Non-Hispanic American Indian/Alaska Native,576,-99,-99
10.1016/j.ygyno.2023.01.032,1,Yes,gynecological cancer tumor site- Cervix,No,NA,Total cases 1975-2017,count,NA,none,4,N/A,Non-Hispanic Asian or Pacific Islander,4098,-99,-99
10.1016/j.ygyno.2023.01.032,1,Yes,gynecological cancer tumor site- Cervix,No,NA,Total cases 1975-2017,count,NA,none,5,N/A,Hispanic (All races),4868,-99,-99
10.1016/j.ygyno.2023.01.032,2,Yes,gynecological cancer tumor site- Cervix,No,NA,age of diagnosis,median,NA,none,1,N/A,Non-Hispanic White,49,-99,-99
10.1016/j.ygyno.2023.01.032,2,Yes,gynecological cancer tumor site- Cervix,No,NA,age of diagnosis,median,NA,none,2,N/A,Non-Hispanic Black,50,-99,-99
10.1016/j.ygyno.2023.01.032,2,Yes,gynecological cancer tumor site- Cervix,No,NA,age of diagnosis,median,NA,none,3,N/A,Non-Hispanic American Indian/Alaska Native,46,-99,-99
10.1016/j.ygyno.2023.01.032,2,Yes,gynecological cancer tumor site- Cervix,No,NA,age of diagnosis,median,NA,none,4,N/A,Non-Hispanic Asian or Pacific Islander,50,-99,-99
10.1016/j.ygyno.2023.01.032,2,Yes,gynecological cancer tumor site- Cervix,No,NA,age of diagnosis,median,NA,none,5,N/A,Hispanic (All races),45,-99,-99
10.1016/j.ygyno.2023.01.032,3,Yes,gynecological cancer tumor site- Cervix,No,NA,survival,median years,NA,none,1,N/A,Non-Hispanic White,8.25,-99,-99
10.1016/j.ygyno.2023.01.032,3,Yes,gynecological cancer tumor site- Cervix,No,NA,survival,median years,NA,none,2,N/A,Non-Hispanic Black,4.92,-99,-99
10.1016/j.ygyno.2023.01.032,3,Yes,gynecological cancer tumor site- Cervix,No,NA,survival,median years,NA,none,3,N/A,Non-Hispanic American Indian/Alaska Native,5.96,-99,-99
10.1016/j.ygyno.2023.01.032,3,Yes,gynecological cancer tumor site- Cervix,No,NA,survival,median years,NA,none,4,N/A,Non-Hispanic Asian or Pacific Islander,7.08,-99,-99
10.1016/j.ygyno.2023.01.032,3,Yes,gynecological cancer tumor site- Cervix,No,NA,survival,median years,NA,none,5,N/A,Hispanic (All races),5.92,-99,-99
10.1016/j.ygyno.2023.01.032,4,Yes,gynecological cancer tumor site- Cervix,No,NA,Total Potential Years of Life Lost,count,NA,none,1,N/A,Non-Hispanic White,379044.1,-99,-99
10.1016/j.ygyno.2023.01.032,4,Yes,gynecological cancer tumor site- Cervix,No,NA,Total Potential Years of Life Lost,count,NA,none,2,N/A,Non-Hispanic Black,94339.05,-99,-99
10.1016/j.ygyno.2023.01.032,4,Yes,gynecological cancer tumor site- Cervix,No,NA,Total Potential Years of Life Lost,count,NA,none,3,N/A,Non-Hispanic American Indian/Alaska Native,8903.65,-99,-99
10.1016/j.ygyno.2023.01.032,4,Yes,gynecological cancer tumor site- Cervix,No,NA,Total Potential Years of Life Lost,count,NA,none,4,N/A,Non-Hispanic Asian or Pacific Islander,49541.81,-99,-99
10.1016/j.ygyno.2023.01.032,4,Yes,gynecological cancer tumor site- Cervix,No,NA,Total Potential Years of Life Lost,count,NA,none,5,N/A,Hispanic (All races),85699.66,-99,-99
10.1016/j.ygyno.2023.01.032,5,Yes,gynecological cancer tumor site- Cervix,No,NA,Potential Years of Life Lost,median,NA,none,1,N/A,Non-Hispanic White,11.75,-99,-99
10.1016/j.ygyno.2023.01.032,5,Yes,gynecological cancer tumor site- Cervix,No,NA,Potential Years of Life Lost,median,NA,none,2,N/A,Non-Hispanic Black,12.92,-99,-99
10.1016/j.ygyno.2023.01.032,5,Yes,gynecological cancer tumor site- Cervix,No,NA,Potential Years of Life Lost,median,NA,none,3,N/A,Non-Hispanic American Indian/Alaska Native,16.29,-99,-99
10.1016/j.ygyno.2023.01.032,5,Yes,gynecological cancer tumor site- Cervix,No,NA,Potential Years of Life Lost,median,NA,none,4,N/A,Non-Hispanic Asian or Pacific Islander,12.08,-99,-99
10.1016/j.ygyno.2023.01.032,5,Yes,gynecological cancer tumor site- Cervix,No,NA,Potential Years of Life Lost,median,NA,none,5,N/A,Hispanic (All races),18.88,-99,-99
10.1016/j.ygyno.2023.01.032,6,Yes,gynecological cancer tumor site- Uterus,No,NA,Total cases 1975-2017,count,NA,none,1,N/A,Non-Hispanic White,124080,-99,-99
10.1016/j.ygyno.2023.01.032,6,Yes,gynecological cancer tumor site- Uterus,No,NA,Total cases 1975-2017,count,NA,none,2,N/A,Non-Hispanic Black,11266,-99,-99
10.1016/j.ygyno.2023.01.032,6,Yes,gynecological cancer tumor site- Uterus,No,NA,Total cases 1975-2017,count,NA,none,3,N/A,Non-Hispanic American Indian/Alaska Native,903,-99,-99
10.1016/j.ygyno.2023.01.032,6,Yes,gynecological cancer tumor site- Uterus,No,NA,Total cases 1975-2017,count,NA,none,4,N/A,Non-Hispanic Asian or Pacific Islander,10548,-99,-99
10.1016/j.ygyno.2023.01.032,6,Yes,gynecological cancer tumor site- Uterus,No,NA,Total cases 1975-2017,count,NA,none,5,N/A,Hispanic (All races),7265,-99,-99
10.1016/j.ygyno.2023.01.032,7,Yes,gynecological cancer tumor site- Uterus,No,NA,age of diagnosis,median,NA,none,1,N/A,Non-Hispanic White,64,-99,-99
10.1016/j.ygyno.2023.01.032,7,Yes,gynecological cancer tumor site- Uterus,No,NA,age of diagnosis,median,NA,none,2,N/A,Non-Hispanic Black,63,-99,-99
10.1016/j.ygyno.2023.01.032,7,Yes,gynecological cancer tumor site- Uterus,No,NA,age of diagnosis,median,NA,none,3,N/A,Non-Hispanic American Indian/Alaska Native,56,-99,-99
10.1016/j.ygyno.2023.01.032,7,Yes,gynecological cancer tumor site- Uterus,No,NA,age of diagnosis,median,NA,none,4,N/A,Non-Hispanic Asian or Pacific Islander,58,-99,-99
10.1016/j.ygyno.2023.01.032,7,Yes,gynecological cancer tumor site- Uterus,No,NA,age of diagnosis,median,NA,none,5,N/A,Hispanic (All races),59,-99,-99
10.1016/j.ygyno.2023.01.032,8,Yes,gynecological cancer tumor site- Uterus,No,NA,survival,median years,NA,none,1,N/A,Non-Hispanic White,8.42,-99,-99
10.1016/j.ygyno.2023.01.032,8,Yes,gynecological cancer tumor site- Uterus,No,NA,survival,median years,NA,none,2,N/A,Non-Hispanic Black,3.17,-99,-99
10.1016/j.ygyno.2023.01.032,8,Yes,gynecological cancer tumor site- Uterus,No,NA,survival,median years,NA,none,3,N/A,Non-Hispanic American Indian/Alaska Native,5.75,-99,-99
10.1016/j.ygyno.2023.01.032,8,Yes,gynecological cancer tumor site- Uterus,No,NA,survival,median years,NA,none,4,N/A,Non-Hispanic Asian or Pacific Islander,6.42,-99,-99
10.1016/j.ygyno.2023.01.032,8,Yes,gynecological cancer tumor site- Uterus,No,NA,survival,median years,NA,none,5,N/A,Hispanic (All races),5.5,-99,-99
10.1016/j.ygyno.2023.01.032,9,Yes,gynecological cancer tumor site- Uterus,No,NA,Total Potential Years of Life Lost,count,NA,none,1,N/A,Non-Hispanic White,4545.75,-99,-99
10.1016/j.ygyno.2023.01.032,9,Yes,gynecological cancer tumor site- Uterus,No,NA,Total Potential Years of Life Lost,count,NA,none,2,N/A,Non-Hispanic Black,69638.75,-99,-99
10.1016/j.ygyno.2023.01.032,9,Yes,gynecological cancer tumor site- Uterus,No,NA,Total Potential Years of Life Lost,count,NA,none,3,N/A,Non-Hispanic American Indian/Alaska Native,10056.333,-99,-99
10.1016/j.ygyno.2023.01.032,9,Yes,gynecological cancer tumor site- Uterus,No,NA,Total Potential Years of Life Lost,count,NA,none,4,N/A,Non-Hispanic Asian or Pacific Islander,82541,-99,-99
10.1016/j.ygyno.2023.01.032,9,Yes,gynecological cancer tumor site- Uterus,No,NA,Total Potential Years of Life Lost,count,NA,none,5,N/A,Hispanic (All races),57402.58,-99,-99
10.1016/j.ygyno.2023.01.032,10,Yes,gynecological cancer tumor site- Uterus,No,NA,Potential Years of Life Lost,median,NA,none,1,N/A,Non-Hispanic White,-0.75,-99,-99
10.1016/j.ygyno.2023.01.032,10,Yes,gynecological cancer tumor site- Uterus,No,NA,Potential Years of Life Lost,median,NA,none,2,N/A,Non-Hispanic Black,6,-99,-99
10.1016/j.ygyno.2023.01.032,10,Yes,gynecological cancer tumor site- Uterus,No,NA,Potential Years of Life Lost,median,NA,none,3,N/A,Non-Hispanic American Indian/Alaska Native,10.67,-99,-99
10.1016/j.ygyno.2023.01.032,10,Yes,gynecological cancer tumor site- Uterus,No,NA,Potential Years of Life Lost,median,NA,none,4,N/A,Non-Hispanic Asian or Pacific Islander,8.08,-99,-99
10.1016/j.ygyno.2023.01.032,10,Yes,gynecological cancer tumor site- Uterus,No,NA,Potential Years of Life Lost,median,NA,none,5,N/A,Hispanic (All races),7.67,-99,-99
10.1016/j.ygyno.2023.01.032,11,Yes,gynecological cancer tumor site- Ovary,No,NA,Total Cases 1975-2017,count,NA,none,1,N/A,Non-Hispanic White,64001,-99,-99
10.1016/j.ygyno.2023.01.032,11,Yes,gynecological cancer tumor site- Ovary,No,NA,Total Cases 1975-2017,count,NA,none,2,N/A,Non-Hispanic Black,5528,-99,-99
10.1016/j.ygyno.2023.01.032,11,Yes,gynecological cancer tumor site- Ovary,No,NA,Total Cases 1975-2017,count,NA,none,3,N/A,Non-Hispanic American Indian/Alaska Native,571,-99,-99
10.1016/j.ygyno.2023.01.032,11,Yes,gynecological cancer tumor site- Ovary,No,NA,Total Cases 1975-2017,count,NA,none,4,N/A,Non-Hispanic Asian or Pacific Islander,4940,-99,-99
10.1016/j.ygyno.2023.01.032,11,Yes,gynecological cancer tumor site- Ovary,No,NA,Total Cases 1975-2017,count,NA,none,5,N/A,Hispanic (All races),4120,-99,-99
10.1016/j.ygyno.2023.01.032,12,Yes,gynecological cancer tumor site- Ovary,No,NA,age of diagnosis,median,NA,none,1,N/A,Non-Hispanic White,64,-99,-99
10.1016/j.ygyno.2023.01.032,12,Yes,gynecological cancer tumor site- Ovary,No,NA,age of diagnosis,median,NA,none,2,N/A,Non-Hispanic Black,61,-99,-99
10.1016/j.ygyno.2023.01.032,12,Yes,gynecological cancer tumor site- Ovary,No,NA,age of diagnosis,median,NA,none,3,N/A,Non-Hispanic American Indian/Alaska Native,57,-99,-99
10.1016/j.ygyno.2023.01.032,12,Yes,gynecological cancer tumor site- Ovary,No,NA,age of diagnosis,median,NA,none,4,N/A,Non-Hispanic Asian or Pacific Islander,56,-99,-99
10.1016/j.ygyno.2023.01.032,12,Yes,gynecological cancer tumor site- Ovary,No,NA,age of diagnosis,median,NA,none,5,N/A,Hispanic (All races),57,-99,-99
10.1016/j.ygyno.2023.01.032,13,Yes,gynecological cancer tumor site- Ovary,No,NA,survival,median years,NA,none,1,N/A,Non-Hispanic White,2.41,-99,-99
10.1016/j.ygyno.2023.01.032,13,Yes,gynecological cancer tumor site- Ovary,No,NA,survival,median years,NA,none,2,N/A,Non-Hispanic Black,1.75,-99,-99
10.1016/j.ygyno.2023.01.032,13,Yes,gynecological cancer tumor site- Ovary,No,NA,survival,median years,NA,none,3,N/A,Non-Hispanic American Indian/Alaska Native,2.67,-99,-99
10.1016/j.ygyno.2023.01.032,13,Yes,gynecological cancer tumor site- Ovary,No,NA,survival,median years,NA,none,4,N/A,Non-Hispanic Asian or Pacific Islander,3.25,-99,-99
10.1016/j.ygyno.2023.01.032,13,Yes,gynecological cancer tumor site- Ovary,No,NA,survival,median years,NA,none,5,N/A,Hispanic (All races),2.58,-99,-99
10.1016/j.ygyno.2023.01.032,14,Yes,gynecological cancer tumor site- Ovary,No,NA,Total Potential Years of Life Lost,count,NA,none,1,N/A,Non-Hispanic White,391531.83,-99,-99
10.1016/j.ygyno.2023.01.032,14,Yes,gynecological cancer tumor site- Ovary,No,NA,Total Potential Years of Life Lost,count,NA,none,2,N/A,Non-Hispanic Black,59282.17,-99,-99
10.1016/j.ygyno.2023.01.032,14,Yes,gynecological cancer tumor site- Ovary,No,NA,Total Potential Years of Life Lost,count,NA,none,3,N/A,Non-Hispanic American Indian/Alaska Native,6650.5,-99,-99
10.1016/j.ygyno.2023.01.032,14,Yes,gynecological cancer tumor site- Ovary,No,NA,Total Potential Years of Life Lost,count,NA,none,4,N/A,Non-Hispanic Asian or Pacific Islander,59064.75,-99,-99
10.1016/j.ygyno.2023.01.032,14,Yes,gynecological cancer tumor site- Ovary,No,NA,Total Potential Years of Life Lost,count,NA,none,5,N/A,Hispanic (All races),52366,-99,-99
10.1016/j.ygyno.2023.01.032,15,Yes,gynecological cancer tumor site- Ovary,No,NA,Potential Years of Life Lost,median,NA,none,1,N/A,Non-Hispanic White,5,-99,-99
10.1016/j.ygyno.2023.01.032,15,Yes,gynecological cancer tumor site- Ovary,No,NA,Potential Years of Life Lost,median,NA,none,2,N/A,Non-Hispanic Black,9.83,-99,-99
10.1016/j.ygyno.2023.01.032,15,Yes,gynecological cancer tumor site- Ovary,No,NA,Potential Years of Life Lost,median,NA,none,3,N/A,Non-Hispanic American Indian/Alaska Native,10.75,-99,-99
10.1016/j.ygyno.2023.01.032,15,Yes,gynecological cancer tumor site- Ovary,No,NA,Potential Years of Life Lost,median,NA,none,4,N/A,Non-Hispanic Asian or Pacific Islander,11.83,-99,-99
10.1016/j.ygyno.2023.01.032,15,Yes,gynecological cancer tumor site- Ovary,No,NA,Potential Years of Life Lost,median,NA,none,5,N/A,Hispanic (All races),11.58,-99,-99
10.1016/j.ygyno.2023.01.032,16,Yes,gynecological cancer tumor site- Vagina,No,NA,Total Cases 1975-2017,count,NA,none,1,N/A,Non-Hispanic White,3092,-99,-99
10.1016/j.ygyno.2023.01.032,16,Yes,gynecological cancer tumor site- Vagina,No,NA,Total Cases 1975-2017,count,NA,none,2,N/A,Non-Hispanic Black,607,-99,-99
10.1016/j.ygyno.2023.01.032,16,Yes,gynecological cancer tumor site- Vagina,No,NA,Total Cases 1975-2017,count,NA,none,3,N/A,Non-Hispanic American Indian/Alaska Native,31,-99,-99
10.1016/j.ygyno.2023.01.032,16,Yes,gynecological cancer tumor site- Vagina,No,NA,Total Cases 1975-2017,count,NA,none,4,N/A,Non-Hispanic Asian or Pacific Islander,223,-99,-99
10.1016/j.ygyno.2023.01.032,16,Yes,gynecological cancer tumor site- Vagina,No,NA,Total Cases 1975-2017,count,NA,none,5,N/A,Hispanic (All races),285,-99,-99
10.1016/j.ygyno.2023.01.032,17,Yes,gynecological cancer tumor site- Vagina,No,NA,age of diagnosis,median,NA,none,1,N/A,Non-Hispanic White,69,-99,-99
10.1016/j.ygyno.2023.01.032,17,Yes,gynecological cancer tumor site- Vagina,No,NA,age of diagnosis,median,NA,none,2,N/A,Non-Hispanic Black,64,-99,-99
10.1016/j.ygyno.2023.01.032,17,Yes,gynecological cancer tumor site- Vagina,No,NA,age of diagnosis,median,NA,none,3,N/A,Non-Hispanic American Indian/Alaska Native,67,-99,-99
10.1016/j.ygyno.2023.01.032,17,Yes,gynecological cancer tumor site- Vagina,No,NA,age of diagnosis,median,NA,none,4,N/A,Non-Hispanic Asian or Pacific Islander,66,-99,-99
10.1016/j.ygyno.2023.01.032,17,Yes,gynecological cancer tumor site- Vagina,No,NA,age of diagnosis,median,NA,none,5,N/A,Hispanic (All races),64,-99,-99
10.1016/j.ygyno.2023.01.032,18,Yes,gynecological cancer tumor site- Vagina,No,NA,survival,median years,NA,none,1,N/A,Non-Hispanic White,2.33,-99,-99
10.1016/j.ygyno.2023.01.032,18,Yes,gynecological cancer tumor site- Vagina,No,NA,survival,median years,NA,none,2,N/A,Non-Hispanic Black,2.17,-99,-99
10.1016/j.ygyno.2023.01.032,18,Yes,gynecological cancer tumor site- Vagina,No,NA,survival,median years,NA,none,3,N/A,Non-Hispanic American Indian/Alaska Native,1.83,-99,-99
10.1016/j.ygyno.2023.01.032,18,Yes,gynecological cancer tumor site- Vagina,No,NA,survival,median years,NA,none,4,N/A,Non-Hispanic Asian or Pacific Islander,2.75,-99,-99
10.1016/j.ygyno.2023.01.032,18,Yes,gynecological cancer tumor site- Vagina,No,NA,survival,median years,NA,none,5,N/A,Hispanic (All races),2.33,-99,-99
10.1016/j.ygyno.2023.01.032,19,Yes,gynecological cancer tumor site- Vagina,No,NA,Total Potential Years of Life Lost,count,NA,none,1,N/A,Non-Hispanic White,6698.17,-99,-99
10.1016/j.ygyno.2023.01.032,19,Yes,gynecological cancer tumor site- Vagina,No,NA,Total Potential Years of Life Lost,count,NA,none,2,N/A,Non-Hispanic Black,3802.58,-99,-99
10.1016/j.ygyno.2023.01.032,19,Yes,gynecological cancer tumor site- Vagina,No,NA,Total Potential Years of Life Lost,count,NA,none,3,N/A,Non-Hispanic American Indian/Alaska Native,42.58,-99,-99
10.1016/j.ygyno.2023.01.032,19,Yes,gynecological cancer tumor site- Vagina,No,NA,Total Potential Years of Life Lost,count,NA,none,4,N/A,Non-Hispanic Asian or Pacific Islander,1169.08,-99,-99
10.1016/j.ygyno.2023.01.032,19,Yes,gynecological cancer tumor site- Vagina,No,NA,Total Potential Years of Life Lost,count,NA,none,5,N/A,Hispanic (All races),1939.42,-99,-99
10.1016/j.ygyno.2023.01.032,20,Yes,gynecological cancer tumor site- Vagina,No,NA,Potential Years of Life Lost,median,NA,none,1,N/A,Non-Hispanic White,-0.67,-99,-99
10.1016/j.ygyno.2023.01.032,20,Yes,gynecological cancer tumor site- Vagina,No,NA,Potential Years of Life Lost,median,NA,none,2,N/A,Non-Hispanic Black,5.33,-99,-99
10.1016/j.ygyno.2023.01.032,20,Yes,gynecological cancer tumor site- Vagina,No,NA,Potential Years of Life Lost,median,NA,none,3,N/A,Non-Hispanic American Indian/Alaska Native,-2.75,-99,-99
10.1016/j.ygyno.2023.01.032,20,Yes,gynecological cancer tumor site- Vagina,No,NA,Potential Years of Life Lost,median,NA,none,4,N/A,Non-Hispanic Asian or Pacific Islander,2.5,-99,-99
10.1016/j.ygyno.2023.01.032,20,Yes,gynecological cancer tumor site- Vagina,No,NA,Potential Years of Life Lost,median,NA,none,5,N/A,Hispanic (All races),5.67,-99,-99
10.1016/j.ygyno.2023.01.032,21,Yes,gynecological cancer tumor site- Vulva,No,NA,Total Cases 1975-2017,count,NA,none,1,N/A,Non-Hispanic White,11465,-99,-99
10.1016/j.ygyno.2023.01.032,21,Yes,gynecological cancer tumor site- Vulva,No,NA,Total Cases 1975-2017,count,NA,none,2,N/A,Non-Hispanic Black,994,-99,-99
10.1016/j.ygyno.2023.01.032,21,Yes,gynecological cancer tumor site- Vulva,No,NA,Total Cases 1975-2017,count,NA,none,3,N/A,Non-Hispanic American Indian/Alaska Native,76,-99,-99
10.1016/j.ygyno.2023.01.032,21,Yes,gynecological cancer tumor site- Vulva,No,NA,Total Cases 1975-2017,count,NA,none,4,N/A,Non-Hispanic Asian or Pacific Islander,473,-99,-99
10.1016/j.ygyno.2023.01.032,21,Yes,gynecological cancer tumor site- Vulva,No,NA,Total Cases 1975-2017,count,NA,none,5,N/A,Hispanic (All races),571,-99,-99
10.1016/j.ygyno.2023.01.032,22,Yes,gynecological cancer tumor site- Vulva,No,NA,age of diagnosis,median,NA,none,1,N/A,Non-Hispanic White,71,-99,-99
10.1016/j.ygyno.2023.01.032,22,Yes,gynecological cancer tumor site- Vulva,No,NA,age of diagnosis,median,NA,none,2,N/A,Non-Hispanic Black,58,-99,-99
10.1016/j.ygyno.2023.01.032,22,Yes,gynecological cancer tumor site- Vulva,No,NA,age of diagnosis,median,NA,none,3,N/A,Non-Hispanic American Indian/Alaska Native,59,-99,-99
10.1016/j.ygyno.2023.01.032,22,Yes,gynecological cancer tumor site- Vulva,No,NA,age of diagnosis,median,NA,none,4,N/A,Non-Hispanic Asian or Pacific Islander,70,-99,-99
10.1016/j.ygyno.2023.01.032,22,Yes,gynecological cancer tumor site- Vulva,No,NA,age of diagnosis,median,NA,none,5,N/A,Hispanic (All races),64,-99,-99
10.1016/j.ygyno.2023.01.032,23,Yes,gynecological cancer tumor site- Vulva,No,NA,survival,median years,NA,none,1,N/A,Non-Hispanic White,5.08,-99,-99
10.1016/j.ygyno.2023.01.032,23,Yes,gynecological cancer tumor site- Vulva,No,NA,survival,median years,NA,none,2,N/A,Non-Hispanic Black,5.5,-99,-99
10.1016/j.ygyno.2023.01.032,23,Yes,gynecological cancer tumor site- Vulva,No,NA,survival,median years,NA,none,3,N/A,Non-Hispanic American Indian/Alaska Native,4.75,-99,-99
10.1016/j.ygyno.2023.01.032,23,Yes,gynecological cancer tumor site- Vulva,No,NA,survival,median years,NA,none,4,N/A,Non-Hispanic Asian or Pacific Islander,5.08,-99,-99
10.1016/j.ygyno.2023.01.032,23,Yes,gynecological cancer tumor site- Vulva,No,NA,survival,median years,NA,none,5,N/A,Hispanic (All races),3.42,-99,-99
10.1016/j.ygyno.2023.01.032,24,Yes,gynecological cancer tumor site- Vulva,No,NA,Total Potential Years of Life Lost,count,NA,none,1,N/A,Non-Hispanic White,-6639.58,-99,-99
10.1016/j.ygyno.2023.01.032,24,Yes,gynecological cancer tumor site- Vulva,No,NA,Total Potential Years of Life Lost,count,NA,none,2,N/A,Non-Hispanic Black,8628.67,-99,-99
10.1016/j.ygyno.2023.01.032,24,Yes,gynecological cancer tumor site- Vulva,No,NA,Total Potential Years of Life Lost,count,NA,none,3,N/A,Non-Hispanic American Indian/Alaska Native,600.25,-99,-99
10.1016/j.ygyno.2023.01.032,24,Yes,gynecological cancer tumor site- Vulva,No,NA,Total Potential Years of Life Lost,count,NA,none,4,N/A,Non-Hispanic Asian or Pacific Islander,-330.5,-99,-99
10.1016/j.ygyno.2023.01.032,24,Yes,gynecological cancer tumor site- Vulva,No,NA,Total Potential Years of Life Lost,count,NA,none,5,N/A,Hispanic (All races),2718.75,-99,-99
10.1016/j.ygyno.2023.01.032,25,Yes,gynecological cancer tumor site- Vulva,No,NA,Potential Years of Life Lost,median,NA,none,1,N/A,Non-Hispanic White,-3.58,-99,-99
10.1016/j.ygyno.2023.01.032,25,Yes,gynecological cancer tumor site- Vulva,No,NA,Potential Years of Life Lost,median,NA,none,2,N/A,Non-Hispanic Black,8.75,-99,-99
10.1016/j.ygyno.2023.01.032,25,Yes,gynecological cancer tumor site- Vulva,No,NA,Potential Years of Life Lost,median,NA,none,3,N/A,Non-Hispanic American Indian/Alaska Native,8.96,-99,-99
10.1016/j.ygyno.2023.01.032,25,Yes,gynecological cancer tumor site- Vulva,No,NA,Potential Years of Life Lost,median,NA,none,4,N/A,Non-Hispanic Asian or Pacific Islander,-3.83,-99,-99
10.1016/j.ygyno.2023.01.032,25,Yes,gynecological cancer tumor site- Vulva,No,NA,Potential Years of Life Lost,median,NA,none,5,N/A,Hispanic (All races),2.92,-99,-99
10.1016/j.ygyno.2023.02.005,1,No,NA,No,NA,Complications at all during primary stay,OR,NA,patient diagnosis,1,White,Non-White,1.37,0.99,1.91
10.1016/j.ygyno.2023.02.005,2,No,NA,No,NA,Grade ≥ 3 complications during primary stay,OR,NA,patient diagnosis,1,White,Non-White,1.2,0.7,2.08
10.1016/j.ygyno.2023.02.005,3,No,NA,No,NA,Complications at all after primary stay (within 30 days),OR,NA,patient diagnosis,1,White,Non-White,0.94,0.7,1.39
10.1016/j.ygyno.2023.02.005,4,No,NA,No,NA,Grade ≥ 3 complications after primary stay,OR,NA,patient diagnosis,1,White,Non-White,0.54,0.19,1.55
10.1016/j.ygyno.2023.02.005,5,No,NA,No,NA,30-day mortality after surgery,OR,NA,patient diagnosis,1,White,Non-White,9.71,1.72,54.76
10.1016/j.ygyno.2023.02.005,6,No,NA,No,NA,Reoperation (during primary stay or within 30 days),OR,NA,patient diagnosis,1,White,Non-White,0.59,0.13,2.64
10.1016/j.ygyno.2023.02.005,7,No,NA,No,NA,ICU Transfer (during primary stay or within 30 days),OR,NA,patient diagnosis,1,White,Non-White,2.17,0.97,4.89
10.1016/j.ygyno.2023.02.005,8,No,NA,No,NA,Readmission within 30 days,OR,NA,patient diagnosis,1,White,Non-White,0.97,0.55,1.71
10.1016/j.ygyno.2023.04.017,1,No,NA,No,NA,surgery refusal,OR,NA,none,1,White,Black,2.21,2.07,2.36
10.1016/j.ygyno.2023.04.017,1,No,NA,No,NA,surgery refusal,OR,NA,none,2,White,Asian,0.91,0.75,1.1
10.1016/j.ygyno.2023.04.017,1,No,NA,No,NA,surgery refusal,OR,NA,none,3,White,Pacific Islander/Hawaiian,0.75,0.24,2.33
10.1016/j.ygyno.2023.04.017,1,No,NA,No,NA,surgery refusal,OR,NA,none,4,White,Native American,1.08,0.69,1.67
10.1016/j.ygyno.2023.04.017,1,No,NA,No,NA,surgery refusal,OR,NA,none,5,White,Other,1.06,0.87,1.29
10.1016/j.ygyno.2023.04.017,1,No,NA,No,NA,surgery refusal,OR,NA,none,6,White,Unknown,1.14,0.9,1.45
10.1016/j.ygyno.2023.04.017,2,No,NA,No,NA,surgery refusal,OR,NA,none,1,Non-Hispanic,Hispanic,0.76,0.68,0.86
10.1016/j.ygyno.2023.04.017,3,No,NA,No,NA,surgery refusal,OR,NA,none,1,Non-Hispanic White,Non-Hispanic Black,2.2,2.06,2.35
10.1016/j.ygyno.2023.04.017,3,No,NA,No,NA,surgery refusal,OR,NA,none,2,Non-Hispanic White,Hispanic,0.87,0.77,0.98
10.1016/j.ygyno.2023.04.017,3,No,NA,No,NA,surgery refusal,OR,NA,none,3,Non-Hispanic White,Asian/Pacific Islander,0.99,0.85,1.15
10.1016/j.ygyno.2023.04.017,3,No,NA,No,NA,surgery refusal,OR,NA,none,4,Non-Hispanic White,Other,0.89,0.66,1.2
10.1016/j.ygyno.2023.04.017,3,No,NA,No,NA,surgery refusal,OR,NA,none,5,Non-Hispanic White,Unknown,1.13,0.89,1.44
10.1016/j.ygyno.2023.04.017,4,No,NA,No,NA,surgery refusal,OR,NA,"age, ethnicity, race/ethnicity, patient residence, regional household income, regional high school graduation, insurance, medicaid expansion, treatment center type, treatment region, distance to treatment center (miles), charlson cormorbidity index, primary site, stage, chemotherapy, radiation therapy",1,White,Black,1.77,1.62,1.92
10.1016/j.ygyno.2023.04.017,4,No,NA,No,NA,surgery refusal,OR,NA,"age, ethnicity, race/ethnicity, patient residence, regional household income, regional high school graduation, insurance, medicaid expansion, treatment center type, treatment region, distance to treatment center (miles), charlson cormorbidity index, primary site, stage, chemotherapy, radiation therapy",2,White,Asian,1.02,0.82,1.27
10.1016/j.ygyno.2023.04.017,4,No,NA,No,NA,surgery refusal,OR,NA,"age, ethnicity, race/ethnicity, patient residence, regional household income, regional high school graduation, insurance, medicaid expansion, treatment center type, treatment region, distance to treatment center (miles), charlson cormorbidity index, primary site, stage, chemotherapy, radiation therapy",3,White,Pacific Islander/Hawaiian,-99,-99,-99
10.1016/j.ygyno.2023.04.017,4,No,NA,No,NA,surgery refusal,OR,NA,"age, ethnicity, race/ethnicity, patient residence, regional household income, regional high school graduation, insurance, medicaid expansion, treatment center type, treatment region, distance to treatment center (miles), charlson cormorbidity index, primary site, stage, chemotherapy, radiation therapy",4,White,Native American,1.43,0.84,2.44
10.1016/j.ygyno.2023.04.017,4,No,NA,No,NA,surgery refusal,OR,NA,"age, ethnicity, race/ethnicity, patient residence, regional household income, regional high school graduation, insurance, medicaid expansion, treatment center type, treatment region, distance to treatment center (miles), charlson cormorbidity index, primary site, stage, chemotherapy, radiation therapy",5,White,Other,1.22,0.96,1.55
10.1016/j.ygyno.2023.04.017,4,No,NA,No,NA,surgery refusal,OR,NA,"age, ethnicity, race/ethnicity, patient residence, regional household income, regional high school graduation, insurance, medicaid expansion, treatment center type, treatment region, distance to treatment center (miles), charlson cormorbidity index, primary site, stage, chemotherapy, radiation therapy",6,White,Unknown,-99,-99,-99
10.1016/j.ygyno.2023.04.017,5,No,NA,No,NA,surgery refusal,OR,NA,"age, race, race/ethnicity, patient residence, regional household income, regional high school graduation, insurance, medicaid expansion, treatment center type, treatment region, distance to treatment center (miles), charlson cormorbidity index, primary site, stage, chemotherapy, radiation therapy",1,Non-Hispanic,Hispanic,0.76,0.65,0.89
10.1016/j.ygyno.2023.04.017,6,No,NA,No,NA,surgery refusal,OR,NA,"age, race, ethnicity, patient residence, regional household income, regional high school graduation, insurance, medicaid expansion, treatment center type, treatment region, distance to treatment center (miles), charlson cormorbidity index, primary site, stage, chemotherapy, radiation therapy",1,Non-Hispanic White,Non-Hispanic Black,1.78,1.64,1.94
10.1016/j.ygyno.2023.04.017,6,No,NA,No,NA,surgery refusal,OR,NA,"age, race, ethnicity, patient residence, regional household income, regional high school graduation, insurance, medicaid expansion, treatment center type, treatment region, distance to treatment center (miles), charlson cormorbidity index, primary site, stage, chemotherapy, radiation therapy",2,Non-Hispanic White,Hispanic,0.81,0.69,0.95
10.1016/j.ygyno.2023.04.017,6,No,NA,No,NA,surgery refusal,OR,NA,"age, race, ethnicity, patient residence, regional household income, regional high school graduation, insurance, medicaid expansion, treatment center type, treatment region, distance to treatment center (miles), charlson cormorbidity index, primary site, stage, chemotherapy, radiation therapy",3,Non-Hispanic White,Asian/Pacific Islander,1.16,0.97,1.38
10.1016/j.ygyno.2023.04.017,6,No,NA,No,NA,surgery refusal,OR,NA,"age, race, ethnicity, patient residence, regional household income, regional high school graduation, insurance, medicaid expansion, treatment center type, treatment region, distance to treatment center (miles), charlson cormorbidity index, primary site, stage, chemotherapy, radiation therapy",4,Non-Hispanic White,Other,0.9,0.63,1.28
10.1016/j.ygyno.2023.04.017,6,No,NA,No,NA,surgery refusal,OR,NA,"age, race, ethnicity, patient residence, regional household income, regional high school graduation, insurance, medicaid expansion, treatment center type, treatment region, distance to treatment center (miles), charlson cormorbidity index, primary site, stage, chemotherapy, radiation therapy",5,Non-Hispanic White,Unknown,-99,-99,-99
10.1016/j.ygyno.2023.05.066,1,No,NA,No,NA,Clinical Trial Participation in Ovarian Cancer,RR,NA,None,1,White,Black or African American,0.7773,0.4935,1.2242
10.1016/j.ygyno.2023.05.066,1,No,NA,No,NA,Clinical Trial Participation in Ovarian Cancer,RR,NA,None,2,White,Other or Unknown,0.6828,0.5237,0.8902
10.1016/j.ygyno.2023.05.066,2,No,NA,No,NA,Clinical Trial Participation in Ovarian Cancer,RR,NA,None,1,Not Hispanic or Latino,Hispanic or Latino,0.286,0.1345,0.608
10.1016/j.ygyno.2023.05.066,3,Yes,Community Center,No,NA,Clinical Trial Participation in Ovarian Cancer,RR,NA,None,1,White,Black or African American,0.7184,0.4239,1.2176
10.1016/j.ygyno.2023.05.066,3,Yes,Community Center,No,NA,Clinical Trial Participation in Ovarian Cancer,RR,NA,None,2,White,Other or Unknown,0.7774,0.5761,1.0491
10.1016/j.ygyno.2023.05.066,4,Yes,Community Center,No,NA,Clinical Trial Participation in Ovarian Cancer,RR,NA,None,1,Not Hispanic or Latino,Hispanic or Latino,0.1545,0.0381,0.6263
10.1016/j.ygyno.2023.05.066,5,Yes,Academic Center,No,NA,Clinical Trial Participation in Ovarian Cancer,RR,NA,None,1,White,Black or African American,0.9541,0.38,2.3955
10.1016/j.ygyno.2023.05.066,5,Yes,Academic Center,No,NA,Clinical Trial Participation in Ovarian Cancer,RR,NA,None,2,White,Other or Unknown,1.1261,0.5758,2.2023
10.1016/j.ygyno.2023.05.066,6,Yes,Academic Center,No,NA,Clinical Trial Participation in Ovarian Cancer,RR,NA,None,1,Not Hispanic or Latino,Hispanic or Latino,0.8875,0.3252,2.422
10.1016/j.ygyno.2023.06.004,1,No,NA,No,NA,Educational Themed Content,Percent,NA,none,1,N/A,White,20.4,-99,-99
10.1016/j.ygyno.2023.06.004,1,No,NA,No,NA,Educational Themed Content,Percent,NA,none,2,N/A,Black,55.6,-99,-99
10.1016/j.ygyno.2023.06.004,1,No,NA,No,NA,Educational Themed Content,Percent,NA,none,3,N/A,Asian/Pacific Islander,35,-99,-99
10.1016/j.ygyno.2023.06.004,1,No,NA,No,NA,Educational Themed Content,Percent,NA,none,4,N/A,South Asian,90,-99,-99
10.1016/j.ygyno.2023.06.004,1,No,NA,No,NA,Educational Themed Content,Percent,NA,none,5,N/A,Hispanic/Latino/a,10,-99,-99
10.1016/j.ygyno.2023.06.004,1,No,NA,No,NA,Educational Themed Content,Percent,NA,none,6,N/A,unable to determine,70.8,-99,-99
10.1016/j.ygyno.2023.06.004,2,No,NA,No,NA,DISCERN Scale,median,NA,none,1,N/A,White,1,-99,-99
10.1016/j.ygyno.2023.06.004,2,No,NA,No,NA,DISCERN Scale,median,NA,none,2,N/A,Black,2,-99,-99
10.1016/j.ygyno.2023.06.004,2,No,NA,No,NA,DISCERN Scale,median,NA,none,3,N/A,Asian/Pacific Islander,3,-99,-99
10.1016/j.ygyno.2023.06.004,2,No,NA,No,NA,DISCERN Scale,median,NA,none,4,N/A,South Asian,3,-99,-99
10.1016/j.ygyno.2023.06.004,2,No,NA,No,NA,DISCERN Scale,median,NA,none,5,N/A,Hispanic/Latino/a,2,-99,-99
10.1016/j.ygyno.2023.06.004,2,No,NA,No,NA,DISCERN Scale,median,NA,none,6,N/A,unable to determine,1,-99,-99
10.1093/humrep/dead020,1,No,NA,No,NA,MED12 mutations in leiomyoma,Percent,NA,none,1,N/A,Black,79,-99,-99
10.1093/humrep/dead020,1,No,NA,No,NA,MED12 mutations in leiomyoma,Percent,NA,none,2,N/A,White,68.5,-99,-99
10.1093/humrep/dead020,1,No,NA,No,NA,MED12 mutations in leiomyoma,Percent,NA,none,3,N/A,Other,75.5,-99,-99
10.1093/humrep/dead020,2,No,NA,No,NA,non-MED12 mutations in leiomyoma,Percent,NA,none,1,N/A,Black,21,-99,-99
10.1093/humrep/dead020,2,No,NA,No,NA,non-MED12 mutations in leiomyoma,Percent,NA,none,2,N/A,White,31.5,-99,-99
10.1093/humrep/dead020,2,No,NA,No,NA,non-MED12 mutations in leiomyoma,Percent,NA,none,3,N/A,Other,25.5,-99,-99
10.1093/humrep/dead020,3,No,NA,No,NA,c.130-c.131 missense mutations G>T,Percent,NA,none,1,N/A,Black,24.6,-99,-99
10.1093/humrep/dead020,3,No,NA,No,NA,c.130-c.131 missense mutations G>T,Percent,NA,none,2,N/A,White,18.8,-99,-99
10.1093/humrep/dead020,4,No,NA,No,NA,c.130-c.131 missense mutations G>C,Percent,NA,none,1,N/A,Black,19.2,-99,-99
10.1093/humrep/dead020,4,No,NA,No,NA,c.130-c.131 missense mutations G>C,Percent,NA,none,2,N/A,White,18.8,-99,-99
10.1093/humrep/dead020,5,No,NA,No,NA,c.130-c.131 missense mutations G>A,Percent,NA,none,1,N/A,Black,56.3,-99,-99
10.1093/humrep/dead020,5,No,NA,No,NA,c.130-c.131 missense mutations G>A,Percent,NA,none,2,N/A,White,62.4,-99,-99
10.1097/AOG.0000000000004424,1,No,NA,No,NA,Adherence to national comprehensive cancer network treatment guidelines,OR,NA,None,1,White,Black,0.88,0.83,0.92
10.1097/AOG.0000000000004424,1,No,NA,No,NA,Adherence to national comprehensive cancer network treatment guidelines,OR,NA,None,2,White,Latina,0.79,0.75,0.82
10.1097/AOG.0000000000004424,1,No,NA,No,NA,Adherence to national comprehensive cancer network treatment guidelines,OR,NA,None,3,White,Asian,1.08,1.03,1.15
10.1097/AOG.0000000000004424,1,No,NA,No,NA,Adherence to national comprehensive cancer network treatment guidelines,OR,NA,None,4,White,Native Hawaiian or Pacific Islander,1.01,0.89,1.15
10.1097/AOG.0000000000004424,1,No,NA,No,NA,Adherence to national comprehensive cancer network treatment guidelines,OR,NA,None,5,White,American Indian or Alaska Native,0.73,0.62,0.87
10.1097/AOG.0000000000004424,2,No,NA,No,NA,Adherence to national comprehensive cancer network treatment guidelines,OR,NA,"Neighborhood ses, age at diagnosis, stage at diagnosis, histology, grade, year of diagnosis",1,White,Black,0.89,0.84,0.94
10.1097/AOG.0000000000004424,2,No,NA,No,NA,Adherence to national comprehensive cancer network treatment guidelines,OR,NA,"Neighborhood ses, age at diagnosis, stage at diagnosis, histology, grade, year of diagnosis",2,White,Latina,0.92,0.88,0.96
10.1097/AOG.0000000000004424,2,No,NA,No,NA,Adherence to national comprehensive cancer network treatment guidelines,OR,NA,"Neighborhood ses, age at diagnosis, stage at diagnosis, histology, grade, year of diagnosis",3,White,Asian,1.14,1.08,1.21
10.1097/AOG.0000000000004424,2,No,NA,No,NA,Adherence to national comprehensive cancer network treatment guidelines,OR,NA,"Neighborhood ses, age at diagnosis, stage at diagnosis, histology, grade, year of diagnosis",4,White,Native Hawaiian or Pacific Islander,1.19,1.04,1.35
10.1097/AOG.0000000000004424,2,No,NA,No,NA,Adherence to national comprehensive cancer network treatment guidelines,OR,NA,"Neighborhood ses, age at diagnosis, stage at diagnosis, histology, grade, year of diagnosis",5,White,American Indian or Alaska Native,0.82,0.69,0.98
10.1097/AOG.0000000000004454,1,No,NA,No,NA,30-Day Major Postoperative Complications,RR,NA,none,1,Non-Hispanic White,Non-Hispanic Black,1.61,1.16,2.27
10.1097/AOG.0000000000004454,1,No,NA,No,NA,30-Day Major Postoperative Complications,RR,NA,none,2,Non-Hispanic White,Hispanic,0.71,0.47,1.09
10.1097/AOG.0000000000004454,2,No,NA,No,NA,30-Day Major Postoperative Complications,RR,NA,"maternal age, body mass index, tobacco use in previous 12 months, case urgency, inpatient status, operative time, work relative value unit, and procedure year; and, in the overall model, American Society of Anesthesiologists (ASA) physical status classification",1,Non-Hispanic White,Non-Hispanic Black,1.41,1.11,1.99
10.1097/AOG.0000000000004454,2,No,NA,No,NA,30-Day Major Postoperative Complications,RR,NA,"maternal age, body mass index, tobacco use in previous 12 months, case urgency, inpatient status, operative time, work relative value unit, and procedure year; and, in the overall model, American Society of Anesthesiologists (ASA) physical status classification",2,Non-Hispanic White,Hispanic,0.77,0.42,1.19
10.1097/AOG.0000000000004454,3,No,NA,Yes,Healthy sample,30-Day Major Postoperative Complications,RR,NA,None,1,Non-Hispanic White,Non-Hispanic Black,1.78,1.17,2.69
10.1097/AOG.0000000000004454,3,No,NA,Yes,Healthy sample,30-Day Major Postoperative Complications,RR,NA,None,2,Non-Hispanic White,Hispanic,0.71,0.42,1.2
10.1097/AOG.0000000000004454,4,No,NA,Yes,Healthy sample,30-Day Major Postoperative Complications,RR,NA,"maternal age, body mass index, tobacco use in previous 12 months, case urgency, inpatient status, operative time, work relative value unit, procedure year",1,Non-Hispanic White,Non-Hispanic Black,1.64,1.08,2.5
10.1097/AOG.0000000000004454,4,No,NA,Yes,Healthy sample,30-Day Major Postoperative Complications,RR,NA,"maternal age, body mass index, tobacco use in previous 12 months, case urgency, inpatient status, operative time, work relative value unit, procedure year",2,Non-Hispanic White,Hispanic,0.72,0.42,1.22
10.1097/AOG.0000000000004581,1,No,NA,No,NA,laparoscopic myomectomy approach,Percent,NA,None,1,N/A,White,4.8,-99,-99
10.1097/AOG.0000000000004581,1,No,NA,No,NA,laparoscopic myomectomy approach,Percent,NA,None,2,N/A,Black,1.3,-99,-99
10.1097/AOG.0000000000004581,1,No,NA,No,NA,laparoscopic myomectomy approach,Percent,NA,None,3,N/A,Hispanic,3,-99,-99
10.1097/AOG.0000000000004581,1,No,NA,No,NA,laparoscopic myomectomy approach,Percent,NA,None,4,N/A,Asian,3.6,-99,-99
10.1097/AOG.0000000000004581,1,No,NA,No,NA,laparoscopic myomectomy approach,Percent,NA,None,5,N/A,Other,4.5,-99,-99
10.1097/AOG.0000000000004581,2,No,NA,No,NA,complication occurrence,OR,proportion of patients in category who experienced a complication,None,1,N/A,White,6.7,-99,-99
10.1097/AOG.0000000000004581,2,No,NA,No,NA,complication occurrence,OR,proportion of patients in category who experienced a complication,None,2,N/A,Black,9,-99,-99
10.1097/AOG.0000000000004581,2,No,NA,No,NA,complication occurrence,OR,proportion of patients in category who experienced a complication,None,3,N/A,Hispanic,7.9,-99,-99
10.1097/AOG.0000000000004581,2,No,NA,No,NA,complication occurrence,OR,proportion of patients in category who experienced a complication,None,4,N/A,Asian,7.5,-99,-99
10.1097/AOG.0000000000004581,2,No,NA,No,NA,complication occurrence,OR,proportion of patients in category who experienced a complication,None,5,N/A,Other,6.4,-99,-99
10.1097/AOG.0000000000004581,3,No,NA,No,NA,complication occurrence,OR,NA,"surgical approach, payer status, comorbidities, age, and obesity",1,White,Black,1.37,1.22,1.54
10.1097/AOG.0000000000004581,3,No,NA,No,NA,complication occurrence,OR,NA,"surgical approach, payer status, comorbidities, age, and obesity",2,White,Hispanic,1.11,0.99,1.25
10.1097/AOG.0000000000004581,3,No,NA,No,NA,complication occurrence,OR,NA,"surgical approach, payer status, comorbidities, age, and obesity",3,White,Asian,1.28,1.13,1.46
10.1097/AOG.0000000000004581,3,No,NA,No,NA,complication occurrence,OR,NA,"surgical approach, payer status, comorbidities, age, and obesity",4,White,Other,0.99,0.82,1.21
10.1097/AOG.0000000000004581,4,No,NA,No,NA,complication occurrence - serious complication,OR,proportion of patients in category who experienced a complication,None,1,N/A,White,1.2,-99,-99
10.1097/AOG.0000000000004581,4,No,NA,No,NA,complication occurrence - serious complication,OR,proportion of patients in category who experienced a complication,None,2,N/A,Black,1.1,-99,-99
10.1097/AOG.0000000000004581,4,No,NA,No,NA,complication occurrence - serious complication,OR,proportion of patients in category who experienced a complication,None,3,N/A,Hispanic,1,-99,-99
10.1097/AOG.0000000000004581,4,No,NA,No,NA,complication occurrence - serious complication,OR,proportion of patients in category who experienced a complication,None,4,N/A,Asian,7.5,-99,-99
10.1097/AOG.0000000000004581,4,No,NA,No,NA,complication occurrence - serious complication,OR,proportion of patients in category who experienced a complication,None,5,N/A,Other,0.7,-99,-99
10.1097/AOG.0000000000004581,5,No,NA,No,NA,complication occurrence - serious complication,OR,NA,"surgical approach, payer status, comorbidities, age, and obesity",1,White,Black,0.98,0.73,1.31
10.1097/AOG.0000000000004581,5,No,NA,No,NA,complication occurrence - serious complication,OR,NA,"surgical approach, payer status, comorbidities, age, and obesity",2,White,Hispanic,0.85,0.62,1.15
10.1097/AOG.0000000000004581,5,No,NA,No,NA,complication occurrence - serious complication,OR,NA,"surgical approach, payer status, comorbidities, age, and obesity",3,White,Asian,0.79,0.55,1.11
10.1097/AOG.0000000000004581,5,No,NA,No,NA,complication occurrence - serious complication,OR,NA,"surgical approach, payer status, comorbidities, age, and obesity",4,White,Other,0.65,0.35,1.11
10.1097/AOG.0000000000004581,5,No,NA,No,NA,complication occurrence - serious complication,OR,NA,"surgical approach, payer status, comorbidities, age, and obesity",5,White,Other,0.65,0.35,1.11
10.1097/AOG.0000000000004581,7,No,NA,No,NA,individual complication occurrence - transfusion,Percent,proportion of patients in category who experienced a complication,None,1,N/A,White,4.5,-99,-99
10.1097/AOG.0000000000004581,7,No,NA,No,NA,individual complication occurrence - transfusion,Percent,proportion of patients in category who experienced a complication,None,2,N/A,Black,6.7,-99,-99
10.1097/AOG.0000000000004581,7,No,NA,No,NA,individual complication occurrence - transfusion,Percent,proportion of patients in category who experienced a complication,None,3,N/A,Hispanic,5.5,-99,-99
10.1097/AOG.0000000000004581,7,No,NA,No,NA,individual complication occurrence - transfusion,Percent,proportion of patients in category who experienced a complication,None,4,N/A,Asian,5.8,-99,-99
10.1097/AOG.0000000000004581,7,No,NA,No,NA,individual complication occurrence - transfusion,Percent,proportion of patients in category who experienced a complication,None,5,N/A,Other,4.7,-99,-99
10.1097/AOG.0000000000004581,8,No,NA,No,NA,individual complication occurrence - wound infection,Percent,proportion of patients in category who experienced a complication,None,1,N/A,White,0.8,-99,-99
10.1097/AOG.0000000000004581,8,No,NA,No,NA,individual complication occurrence - wound infection,Percent,proportion of patients in category who experienced a complication,None,2,N/A,Black,0.8,-99,-99
10.1097/AOG.0000000000004581,8,No,NA,No,NA,individual complication occurrence - wound infection,Percent,proportion of patients in category who experienced a complication,None,3,N/A,Hispanic,0.6,-99,-99
10.1097/AOG.0000000000004581,8,No,NA,No,NA,individual complication occurrence - wound infection,Percent,proportion of patients in category who experienced a complication,None,4,N/A,Asian,0.6,-99,-99
10.1097/AOG.0000000000004581,8,No,NA,No,NA,individual complication occurrence - wound infection,Percent,proportion of patients in category who experienced a complication,None,5,N/A,Other,0.5,-99,-99
10.1097/AOG.0000000000004581,9,No,NA,No,NA,individual complication occurrence - UTI,Percent,proportion of patients in category who experienced a complication,None,1,N/A,White,0.17,-99,-99
10.1097/AOG.0000000000004581,9,No,NA,No,NA,individual complication occurrence - UTI,Percent,proportion of patients in category who experienced a complication,None,2,N/A,Black,0.22,-99,-99
10.1097/AOG.0000000000004581,9,No,NA,No,NA,individual complication occurrence - UTI,Percent,proportion of patients in category who experienced a complication,None,3,N/A,Hispanic,0.22,-99,-99
10.1097/AOG.0000000000004581,9,No,NA,No,NA,individual complication occurrence - UTI,Percent,proportion of patients in category who experienced a complication,None,4,N/A,Asian,0.03,-99,-99
10.1097/AOG.0000000000004581,9,No,NA,No,NA,individual complication occurrence - UTI,Percent,proportion of patients in category who experienced a complication,None,5,N/A,Other,0.05,-99,-99
10.1097/AOG.0000000000004581,10,No,NA,No,NA,individual complication occurrence - any infection,Percent,proportion of patients in category who experienced a complication,None,1,N/A,White,1.8,-99,-99
10.1097/AOG.0000000000004581,10,No,NA,No,NA,individual complication occurrence - any infection,Percent,proportion of patients in category who experienced a complication,None,2,N/A,Black,1.8,-99,-99
10.1097/AOG.0000000000004581,10,No,NA,No,NA,individual complication occurrence - any infection,Percent,proportion of patients in category who experienced a complication,None,3,N/A,Hispanic,1.6,-99,-99
10.1097/AOG.0000000000004581,10,No,NA,No,NA,individual complication occurrence - any infection,Percent,proportion of patients in category who experienced a complication,None,4,N/A,Asian,1.1,-99,-99
10.1097/AOG.0000000000004581,10,No,NA,No,NA,individual complication occurrence - any infection,Percent,proportion of patients in category who experienced a complication,None,5,N/A,Other,1.1,-99,-99
10.1097/AOG.0000000000004581,11,No,NA,No,NA,individual complication occurrence - reoperation,Percent,proportion of patients in category who experienced a complication,None,1,N/A,White,0.6,-99,-99
10.1097/AOG.0000000000004581,11,No,NA,No,NA,individual complication occurrence - reoperation,Percent,proportion of patients in category who experienced a complication,None,2,N/A,Black,0.4,-99,-99
10.1097/AOG.0000000000004581,11,No,NA,No,NA,individual complication occurrence - reoperation,Percent,proportion of patients in category who experienced a complication,None,3,N/A,Hispanic,0.4,-99,-99
10.1097/AOG.0000000000004581,11,No,NA,No,NA,individual complication occurrence - reoperation,Percent,proportion of patients in category who experienced a complication,None,4,N/A,Asian,0.5,-99,-99
10.1097/AOG.0000000000004581,11,No,NA,No,NA,individual complication occurrence - reoperation,Percent,proportion of patients in category who experienced a complication,None,5,N/A,Other,0.5,-99,-99
10.1097/AOG.0000000000004581,12,No,NA,No,NA,individual complication occurrence - sepsis,Percent,proportion of patients in category who experienced a complication,None,1,N/A,White,0.2,-99,-99
10.1097/AOG.0000000000004581,12,No,NA,No,NA,individual complication occurrence - sepsis,Percent,proportion of patients in category who experienced a complication,None,2,N/A,Black,0.1,-99,-99
10.1097/AOG.0000000000004581,12,No,NA,No,NA,individual complication occurrence - sepsis,Percent,proportion of patients in category who experienced a complication,None,3,N/A,Hispanic,0.1,-99,-99
10.1097/AOG.0000000000004581,12,No,NA,No,NA,individual complication occurrence - sepsis,Percent,proportion of patients in category who experienced a complication,None,4,N/A,Asian,0,-99,-99
10.1097/AOG.0000000000004581,12,No,NA,No,NA,individual complication occurrence - sepsis,Percent,proportion of patients in category who experienced a complication,None,5,N/A,Other,0,-99,-99
10.1097/AOG.0000000000004581,13,No,NA,No,NA,individual complication occurrence - sepsis-shock,Percent,proportion of patients in category who experienced a complication,None,1,N/A,White,0.2,-99,-99
10.1097/AOG.0000000000004581,13,No,NA,No,NA,individual complication occurrence - sepsis-shock,Percent,proportion of patients in category who experienced a complication,None,2,N/A,Black,0.2,-99,-99
10.1097/AOG.0000000000004581,13,No,NA,No,NA,individual complication occurrence - sepsis-shock,Percent,proportion of patients in category who experienced a complication,None,3,N/A,Hispanic,0.2,-99,-99
10.1097/AOG.0000000000004581,13,No,NA,No,NA,individual complication occurrence - sepsis-shock,Percent,proportion of patients in category who experienced a complication,None,4,N/A,Asian,0.1,-99,-99
10.1097/AOG.0000000000004581,13,No,NA,No,NA,individual complication occurrence - sepsis-shock,Percent,proportion of patients in category who experienced a complication,None,5,N/A,Other,0,-99,-99
10.1097/AOG.0000000000004620,1,No,NA,No,NA,Cesarean birth (any indication),Percent,NA,None,1,N/A,Non-Hispanic Black,22.8,-99,-99
10.1097/AOG.0000000000004620,1,No,NA,No,NA,Cesarean birth (any indication),Percent,NA,None,2,N/A,Hispanic,21.9,-99,-99
10.1097/AOG.0000000000004620,1,No,NA,No,NA,Cesarean birth (any indication),Percent,NA,None,3,N/A,Non-Hispanic White,17.6,-99,-99
10.1097/AOG.0000000000004620,2,No,NA,No,NA,Cesarean birth - Non-reassuring fetal status,Percent,NA,None,1,N/A,Non-Hispanic Black,13.5,-99,-99
10.1097/AOG.0000000000004620,2,No,NA,No,NA,Cesarean birth - Non-reassuring fetal status,Percent,NA,None,2,N/A,Hispanic,11.1,-99,-99
10.1097/AOG.0000000000004620,2,No,NA,No,NA,Cesarean birth - Non-reassuring fetal status,Percent,NA,None,3,N/A,Non-Hispanic White,7.2,-99,-99
10.1097/AOG.0000000000004620,3,No,NA,No,NA,Cesarean birth - Labor dystocia,Percent,NA,None,1,N/A,Non-Hispanic Black,7.8,-99,-99
10.1097/AOG.0000000000004620,3,No,NA,No,NA,Cesarean birth - Labor dystocia,Percent,NA,None,2,N/A,Hispanic,9.2,-99,-99
10.1097/AOG.0000000000004620,3,No,NA,No,NA,Cesarean birth - Labor dystocia,Percent,NA,None,3,N/A,Non-Hispanic White,8.9,-99,-99
10.1097/AOG.0000000000004620,4,No,NA,No,NA,Cesarean birth - Other,Percent,NA,None,1,N/A,Non-Hispanic Black,1.4,-99,-99
10.1097/AOG.0000000000004620,4,No,NA,No,NA,Cesarean birth - Other,Percent,NA,None,2,N/A,Hispanic,1.7,-99,-99
10.1097/AOG.0000000000004620,4,No,NA,No,NA,Cesarean birth - Other,Percent,NA,None,3,N/A,Non-Hispanic White,1.5,-99,-99
10.1097/AOG.0000000000004620,5,No,NA,No,NA,Maternal morbidity composite,Percent,NA,None,1,N/A,Non-Hispanic Black,3.1,-99,-99
10.1097/AOG.0000000000004620,5,No,NA,No,NA,Maternal morbidity composite,Percent,NA,None,2,N/A,Hispanic,3.2,-99,-99
10.1097/AOG.0000000000004620,5,No,NA,No,NA,Maternal morbidity composite,Percent,NA,None,3,N/A,Non-Hispanic White,1.3,-99,-99
10.1097/AOG.0000000000004620,6,No,NA,No,NA,Maternal morbidity composite- Transfusion ≥ 4u pRBC,Percent,NA,None,1,N/A,Non-Hispanic Black,0.3,-99,-99
10.1097/AOG.0000000000004620,6,No,NA,No,NA,Maternal morbidity composite- Transfusion ≥ 4u pRBC,Percent,NA,None,2,N/A,Hispanic,0.4,-99,-99
10.1097/AOG.0000000000004620,6,No,NA,No,NA,Maternal morbidity composite- Transfusion ≥ 4u pRBC,Percent,NA,None,3,N/A,Non-Hispanic White,0.2,-99,-99
10.1097/AOG.0000000000004620,7,No,NA,No,NA,Maternal morbidity composite- Transfusion any other products,Percent,NA,None,1,N/A,Non-Hispanic Black,0.4,-99,-99
10.1097/AOG.0000000000004620,7,No,NA,No,NA,Maternal morbidity composite- Transfusion any other products,Percent,NA,None,2,N/A,Hispanic,0.4,-99,-99
10.1097/AOG.0000000000004620,7,No,NA,No,NA,Maternal morbidity composite- Transfusion any other products,Percent,NA,None,3,N/A,Non-Hispanic White,0.2,-99,-99
10.1097/AOG.0000000000004620,8,No,NA,No,NA,Maternal morbidity composite- Postpartum infection,Percent,NA,None,1,N/A,Non-Hispanic Black,2.7,-99,-99
10.1097/AOG.0000000000004620,8,No,NA,No,NA,Maternal morbidity composite- Postpartum infection,Percent,NA,None,2,N/A,Hispanic,2.6,-99,-99
10.1097/AOG.0000000000004620,8,No,NA,No,NA,Maternal morbidity composite- Postpartum infection,Percent,NA,None,3,N/A,Non-Hispanic White,1,-99,-99
10.1097/AOG.0000000000004620,9,No,NA,No,NA,Maternal morbidity composite- ICU admission,Percent,NA,None,1,N/A,Non-Hispanic Black,0.3,-99,-99
10.1097/AOG.0000000000004620,9,No,NA,No,NA,Maternal morbidity composite- ICU admission,Percent,NA,None,2,N/A,Hispanic,0.2,-99,-99
10.1097/AOG.0000000000004620,9,No,NA,No,NA,Maternal morbidity composite- ICU admission,Percent,NA,None,3,N/A,Non-Hispanic White,0.2,-99,-99
10.1097/AOG.0000000000004620,10,No,NA,No,NA,Maternal morbidity composite- Hysterectomy,Percent,NA,None,1,N/A,Hispanic,0.1,-99,-99
10.1097/AOG.0000000000004620,11,No,NA,No,NA,Maternal morbidity composite- Venous thromboembolism,Percent,NA,None,1,N/A,Non-Hispanic Black,0.1,-99,-99
10.1097/AOG.0000000000004620,11,No,NA,No,NA,Maternal morbidity composite- Venous thromboembolism,Percent,NA,None,2,N/A,Hispanic,0.1,-99,-99
10.1097/AOG.0000000000004620,12,No,NA,No,NA,Neonatal outcomes- Small for gestational age,Percent,NA,None,1,N/A,Non-Hispanic Black,8.1,-99,-99
10.1097/AOG.0000000000004620,12,No,NA,No,NA,Neonatal outcomes- Small for gestational age,Percent,NA,None,2,N/A,Hispanic,8.5,-99,-99
10.1097/AOG.0000000000004620,12,No,NA,No,NA,Neonatal outcomes- Small for gestational age,Percent,NA,None,3,N/A,Non-Hispanic White,9.1,-99,-99
10.1097/AOG.0000000000004620,13,No,NA,No,NA,Neonatal outcomes- NICU admission,Percent,NA,None,1,N/A,Non-Hispanic Black,12.4,-99,-99
10.1097/AOG.0000000000004620,13,No,NA,No,NA,Neonatal outcomes- NICU admission,Percent,NA,None,2,N/A,Hispanic,11.9,-99,-99
10.1097/AOG.0000000000004620,13,No,NA,No,NA,Neonatal outcomes- NICU admission,Percent,NA,None,3,N/A,Non-Hispanic White,11.9,-99,-99
10.1097/AOG.0000000000004620,14,No,NA,No,NA,Neonatal outcomes- 1-minute Apgar ≥ 7,Percent,NA,None,1,N/A,Non-Hispanic Black,78.4,-99,-99
10.1097/AOG.0000000000004620,14,No,NA,No,NA,Neonatal outcomes- 1-minute Apgar ≥ 7,Percent,NA,None,2,N/A,Hispanic,82.7,-99,-99
10.1097/AOG.0000000000004620,14,No,NA,No,NA,Neonatal outcomes- 1-minute Apgar ≥ 7,Percent,NA,None,3,N/A,Non-Hispanic White,75.8,-99,-99
10.1097/AOG.0000000000004620,15,No,NA,No,NA,Cesarean birth,RR,NA,None,1,non-Hispanic White,Non-Hispanic Black,1.3,1.14,1.47
10.1097/AOG.0000000000004620,15,No,NA,No,NA,Cesarean birth,RR,NA,None,2,non-Hispanic White,Hispanic,1.25,1.1,1.41
10.1097/AOG.0000000000004620,16,No,NA,No,NA,Cesarean birth,RR,NA,clinical factors,1,non-Hispanic White,Non-Hispanic Black,1.28,1.11,1.47
10.1097/AOG.0000000000004620,16,No,NA,No,NA,Cesarean birth,RR,NA,clinical factors,2,non-Hispanic White,Hispanic,1.29,1.13,1.47
10.1097/AOG.0000000000004620,17,No,NA,No,NA,Cesarean birth,RR,NA,"clinical factors, employment status, insurance status, marital status",1,non-Hispanic White,Non-Hispanic Black,1.21,1.03,1.42
10.1097/AOG.0000000000004620,17,No,NA,No,NA,Cesarean birth,RR,NA,"clinical factors, employment status, insurance status, marital status",2,non-Hispanic White,Hispanic,1.26,1.08,1.46
10.1097/AOG.0000000000004620,18,No,NA,No,NA,Cesarean indication- Non-reassuring fetal status,RR,NA,None,1,non-Hispanic White,Non-Hispanic Black,2,1.62,2.47
10.1097/AOG.0000000000004620,18,No,NA,No,NA,Cesarean indication- Non-reassuring fetal status,RR,NA,None,2,non-Hispanic White,Hispanic,1.62,1.31,2
10.1097/AOG.0000000000004620,19,No,NA,No,NA,Cesarean indication- Non-reassuring fetal status,RR,NA,clinical factors,1,non-Hispanic White,Non-Hispanic Black,1.97,1.55,2.51
10.1097/AOG.0000000000004620,19,No,NA,No,NA,Cesarean indication- Non-reassuring fetal status,RR,NA,clinical factors,2,non-Hispanic White,Hispanic,1.67,1.33,2.11
10.1097/AOG.0000000000004620,20,No,NA,No,NA,Cesarean indication- Non-reassuring fetal status,RR,NA,"clinical factors, employment status, insurance status, marital status",1,non-Hispanic White,Non-Hispanic Black,1.74,1.32,2.29
10.1097/AOG.0000000000004620,20,No,NA,No,NA,Cesarean indication- Non-reassuring fetal status,RR,NA,"clinical factors, employment status, insurance status, marital status",2,non-Hispanic White,Hispanic,1.51,1.16,1.97
10.1097/AOG.0000000000004620,21,No,NA,No,NA,Cesarean indication- Labor Dystocia,RR,NA,None,1,non-Hispanic White,Non-Hispanic Black,0.94,0.74,1.19
10.1097/AOG.0000000000004620,21,No,NA,No,NA,Cesarean indication- Labor Dystocia,RR,NA,None,2,non-Hispanic White,Hispanic,1.09,0.88,1.35
10.1097/AOG.0000000000004620,22,No,NA,No,NA,Cesarean indication- Labor Dystocia,RR,NA,clinical factors,1,non-Hispanic White,Non-Hispanic Black,0.93,0.71,1.21
10.1097/AOG.0000000000004620,22,No,NA,No,NA,Cesarean indication- Labor Dystocia,RR,NA,clinical factors,2,non-Hispanic White,Hispanic,1.16,0.92,1.48
10.1097/AOG.0000000000004620,23,No,NA,No,NA,Cesarean indication- Labor Dystocia,RR,NA,"clinical factors, employment status, insurance status, marital status",1,non-Hispanic White,Non-Hispanic Black,0.9,0.66,1.21
10.1097/AOG.0000000000004620,23,No,NA,No,NA,Cesarean indication- Labor Dystocia,RR,NA,"clinical factors, employment status, insurance status, marital status",2,non-Hispanic White,Hispanic,1.21,0.92,1.59
10.1097/AOG.0000000000004620,24,No,NA,No,NA,Cesarean indication- Other,RR,NA,None,1,non-Hispanic White,Non-Hispanic Black,1.05,0.61,1.8
10.1097/AOG.0000000000004620,24,No,NA,No,NA,Cesarean indication- Other,RR,NA,None,2,non-Hispanic White,Hispanic,1.22,0.75,1.99
10.1097/AOG.0000000000004620,25,No,NA,No,NA,Cesarean indication- Other,RR,NA,clinical factors,1,non-Hispanic White,Non-Hispanic Black,1.21,0.55,2.66
10.1097/AOG.0000000000004620,25,No,NA,No,NA,Cesarean indication- Other,RR,NA,clinical factors,2,non-Hispanic White,Hispanic,1.63,0.85,3.15
10.1097/AOG.0000000000004620,26,No,NA,No,NA,Cesarean indication- Other,RR,NA,"clinical factors, employment status, insurance status, marital status",1,non-Hispanic White,Non-Hispanic Black,1.29,0.53,3.12
10.1097/AOG.0000000000004620,26,No,NA,No,NA,Cesarean indication- Other,RR,NA,"clinical factors, employment status, insurance status, marital status",2,non-Hispanic White,Hispanic,1.66,0.77,3.58
10.1097/AOG.0000000000004620,27,No,NA,No,NA,Maternal morbidity composite,RR,NA,None,1,non-Hispanic White,Non-Hispanic Black,2.35,1.51,3.65
10.1097/AOG.0000000000004620,27,No,NA,No,NA,Maternal morbidity composite,RR,NA,None,2,non-Hispanic White,Hispanic,2.48,1.63,3.78
10.1097/AOG.0000000000004620,28,No,NA,No,NA,Maternal morbidity composite,RR,NA,clinical factors,1,non-Hispanic White,Non-Hispanic Black,2.22,1.41,3.48
10.1097/AOG.0000000000004620,28,No,NA,No,NA,Maternal morbidity composite,RR,NA,clinical factors,2,non-Hispanic White,Hispanic,2.21,1.44,3.37
10.1097/AOG.0000000000004620,29,No,NA,No,NA,Maternal morbidity composite,RR,NA,"clinical factors, employment status, insurance status, marital status",1,non-Hispanic White,Non-Hispanic Black,2.05,1.21,3.47
10.1097/AOG.0000000000004620,29,No,NA,No,NA,Maternal morbidity composite,RR,NA,"clinical factors, employment status, insurance status, marital status",2,non-Hispanic White,Hispanic,1.92,1.17,3.14
10.1097/AOG.0000000000004620,30,No,NA,No,NA,Maternal morbidity composite- Adjusted for cesarean birth,RR,NA,"clinical factors, employment status, insurance status, marital status, cesarean birth",1,non-Hispanic White,Non-Hispanic Black,1.84,1.11,3.05
10.1097/AOG.0000000000004620,30,No,NA,No,NA,Maternal morbidity composite- Adjusted for cesarean birth,RR,NA,"clinical factors, employment status, insurance status, marital status, cesarean birth",2,non-Hispanic White,Hispanic,1.76,1.1,2.83
10.1097/AOG.0000000000004649,1,No,NA,No,NA,Drug-related death during or within 1 year of pregnancy,Incidence,"per 100,000 live births",None,1,N/A,Hispanic,1.6,-99,-99
10.1097/AOG.0000000000004649,1,No,NA,No,NA,Drug-related death during or within 1 year of pregnancy,Incidence,"per 100,000 live births",None,2,N/A,NonHispanic American Indian or Alaska Native,10.1,-99,-99
10.1097/AOG.0000000000004649,1,No,NA,No,NA,Drug-related death during or within 1 year of pregnancy,Incidence,"per 100,000 live births",None,3,N/A,NonHispanic Asian or Pacific Islander,0.6,-99,-99
10.1097/AOG.0000000000004649,1,No,NA,No,NA,Drug-related death during or within 1 year of pregnancy,Incidence,"per 100,000 live births",None,4,N/A,NonHispanic Black,3.4,-99,-99
10.1097/AOG.0000000000004649,1,No,NA,No,NA,Drug-related death during or within 1 year of pregnancy,Incidence,"per 100,000 live births",None,5,N/A,NonHispanic White,7.2,-99,-99
10.1097/AOG.0000000000004649,2,No,NA,No,NA,Death by suicide during or within 1 year of pregnancy,Incidence,"per 100,000 live births",None,1,N/A,Hispanic,1.3,-99,-99
10.1097/AOG.0000000000004649,2,No,NA,No,NA,Death by suicide during or within 1 year of pregnancy,Incidence,"per 100,000 live births",None,2,N/A,NonHispanic American Indian or Alaska Native,7.7,-99,-99
10.1097/AOG.0000000000004649,2,No,NA,No,NA,Death by suicide during or within 1 year of pregnancy,Incidence,"per 100,000 live births",None,3,N/A,NonHispanic Asian or Pacific Islander,2,-99,-99
10.1097/AOG.0000000000004649,2,No,NA,No,NA,Death by suicide during or within 1 year of pregnancy,Incidence,"per 100,000 live births",None,4,N/A,NonHispanic Black,1.6,-99,-99
10.1097/AOG.0000000000004649,2,No,NA,No,NA,Death by suicide during or within 1 year of pregnancy,Incidence,"per 100,000 live births",None,5,N/A,NonHispanic White,2.8,-99,-99
10.1097/AOG.0000000000004649,3,No,NA,No,NA,Death by homicide during or within 1 year of pregnancy,Incidence,"per 100,000 live births",None,1,N/A,Hispanic,1.6,-99,-99
10.1097/AOG.0000000000004649,3,No,NA,No,NA,Death by homicide during or within 1 year of pregnancy,Incidence,"per 100,000 live births",None,2,N/A,NonHispanic American Indian or Alaska Native,2.1,-99,-99
10.1097/AOG.0000000000004649,3,No,NA,No,NA,Death by homicide during or within 1 year of pregnancy,Incidence,"per 100,000 live births",None,3,N/A,NonHispanic Asian or Pacific Islander,0.2,-99,-99
10.1097/AOG.0000000000004649,3,No,NA,No,NA,Death by homicide during or within 1 year of pregnancy,Incidence,"per 100,000 live births",None,4,N/A,NonHispanic Black,7,-99,-99
10.1097/AOG.0000000000004649,3,No,NA,No,NA,Death by homicide during or within 1 year of pregnancy,Incidence,"per 100,000 live births",None,5,N/A,NonHispanic White,1.5,-99,-99
10.1097/AOG.0000000000004649,4,No,NA,No,NA,Drug-related death during or within 1 year of pregnancy,RR,NA,None,1,NonHispanic White,Hispanic,0.2,0.2,0.3
10.1097/AOG.0000000000004649,4,No,NA,No,NA,Drug-related death during or within 1 year of pregnancy,RR,NA,None,2,NonHispanic White,NonHispanic American Indian or Alaska Native,1.4,0.9,2
10.1097/AOG.0000000000004649,4,No,NA,No,NA,Drug-related death during or within 1 year of pregnancy,RR,NA,None,3,NonHispanic White,NonHispanic Asian or Pacific Islander,0.1,0,0.1
10.1097/AOG.0000000000004649,4,No,NA,No,NA,Drug-related death during or within 1 year of pregnancy,RR,NA,None,4,NonHispanic White,NonHispanic Black,0.5,0.4,0.6
10.1097/AOG.0000000000004649,5,No,NA,No,NA,Death by suicide during or within 1 year of pregnancy,RR,NA,None,1,NonHispanic White,Hispanic,0.5,0.4,0.6
10.1097/AOG.0000000000004649,5,No,NA,No,NA,Death by suicide during or within 1 year of pregnancy,RR,NA,None,2,NonHispanic White,NonHispanic American Indian or Alaska Native,2.8,1.7,4.2
10.1097/AOG.0000000000004649,5,No,NA,No,NA,Death by suicide during or within 1 year of pregnancy,RR,NA,None,3,NonHispanic White,NonHispanic Asian or Pacific Islander,0.7,0.5,1
10.1097/AOG.0000000000004649,5,No,NA,No,NA,Death by suicide during or within 1 year of pregnancy,RR,NA,None,4,NonHispanic White,NonHispanic Black,0.6,0.4,0.7
10.1097/AOG.0000000000004649,6,No,NA,No,NA,Death by homicide during or within 1 year of pregnancy,RR,NA,None,1,NonHispanic White,Hispanic,1.1,0.9,1.4
10.1097/AOG.0000000000004649,6,No,NA,No,NA,Death by homicide during or within 1 year of pregnancy,RR,NA,None,2,NonHispanic White,NonHispanic American Indian or Alaska Native,1.4,0.5,3.1
10.1097/AOG.0000000000004649,6,No,NA,No,NA,Death by homicide during or within 1 year of pregnancy,RR,NA,None,3,NonHispanic White,NonHispanic Asian or Pacific Islander,0.2,0.1,0.4
10.1097/AOG.0000000000004649,6,No,NA,No,NA,Death by homicide during or within 1 year of pregnancy,RR,NA,None,4,NonHispanic White,NonHispanic Black,4.8,4,5.7
10.1097/AOG.0000000000004791,1,No,NA,No,NA,Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) seropositivity at the end of pregnancy,OR,NA,None,1,White,Hispanic,8.48,5.91,12.2
10.1097/AOG.0000000000004791,1,No,NA,No,NA,Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) seropositivity at the end of pregnancy,OR,NA,None,2,White,Black,5.84,4.35,7.84
10.1097/AOG.0000000000004791,1,No,NA,No,NA,Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) seropositivity at the end of pregnancy,OR,NA,None,3,White,Another race or ethnicity,1.55,0.93,2.6
10.1097/AOG.0000000000004791,2,No,NA,No,NA,Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) seropositivity at the end of pregnancy,OR,NA,"Age, body mass index, insurance, limited English proficiency",1,White,Hispanic,3.36,2.1,5.38
10.1097/AOG.0000000000004791,2,No,NA,No,NA,Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) seropositivity at the end of pregnancy,OR,NA,"Age, body mass index, insurance, limited English proficiency",2,White,Black,3.98,2.83,5.6
10.1097/AOG.0000000000004791,2,No,NA,No,NA,Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) seropositivity at the end of pregnancy,OR,NA,"Age, body mass index, insurance, limited English proficiency",3,White,Another race or ethnicity,1.36,0.8,2.3
10.1097/AOG.0000000000004791,3,No,NA,No,NA,Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) seropositivity at the end of pregnancy,OR,NA,"Age, body mass index, insurance, limited English proficiency, neighborhood deprivation index",1,White,Hispanic,3.16,1.93,5.15
10.1097/AOG.0000000000004791,3,No,NA,No,NA,Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) seropositivity at the end of pregnancy,OR,NA,"Age, body mass index, insurance, limited English proficiency, neighborhood deprivation index",2,White,Black,3.48,2.41,5.02
10.1097/AOG.0000000000004791,3,No,NA,No,NA,Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) seropositivity at the end of pregnancy,OR,NA,"Age, body mass index, insurance, limited English proficiency, neighborhood deprivation index",3,White,Another race or ethnicity,1.32,0.78,2.21
10.1097/AOG.0000000000004791,4,No,NA,No,NA,Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) seropositivity at the end of pregnancy,OR,NA,"Age, body mass index, insurance, limited English proficiency, neighborhood racial residential segregation",1,White,Hispanic,3.43,2.12,5.54
10.1097/AOG.0000000000004791,4,No,NA,No,NA,Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) seropositivity at the end of pregnancy,OR,NA,"Age, body mass index, insurance, limited English proficiency, neighborhood racial residential segregation",2,White,Black,3.6,2.42,5.36
10.1097/AOG.0000000000004791,4,No,NA,No,NA,Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) seropositivity at the end of pregnancy,OR,NA,"Age, body mass index, insurance, limited English proficiency, neighborhood racial residential segregation",3,White,Another race or ethnicity,1.26,0.73,2.17
10.1097/AOG.0000000000004791,5,No,NA,No,NA,Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) seropositivity at the end of pregnancy,OR,NA,"Age, body mass index, insurance, limited English proficiency, proportion of residences with more humans than rooms in the house",1,White,Hispanic,3.04,1.89,4.87
10.1097/AOG.0000000000004791,5,No,NA,No,NA,Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) seropositivity at the end of pregnancy,OR,NA,"Age, body mass index, insurance, limited English proficiency, proportion of residences with more humans than rooms in the house",2,White,Black,3.89,2.77,5.47
10.1097/AOG.0000000000004791,5,No,NA,No,NA,Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) seropositivity at the end of pregnancy,OR,NA,"Age, body mass index, insurance, limited English proficiency, proportion of residences with more humans than rooms in the house",3,White,Another race or ethnicity,1.35,0.79,2.28
10.1097/AOG.0000000000004791,6,No,NA,No,NA,Racial and ethnic disparity in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seropositivity at the end of pregnancy mediated by neighborhood deprivation,Percent,NA,None,1,White,Hispanic,5.6,-6.5,18
10.1097/AOG.0000000000004791,6,No,NA,No,NA,Racial and ethnic disparity in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seropositivity at the end of pregnancy mediated by neighborhood deprivation,Percent,NA,None,2,White,Black,10.2,0.5,21.1
10.1097/AOG.0000000000004791,7,No,NA,No,NA,Racial and ethnic disparity in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seropositivity at the end of pregnancy mediated by neighborhood segregation,Percent,NA,None,1,White,Hispanic,-2.4,-13.1,5.6
10.1097/AOG.0000000000004791,7,No,NA,No,NA,Racial and ethnic disparity in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seropositivity at the end of pregnancy mediated by neighborhood segregation,Percent,NA,None,2,White,Black,6.9,-7.1,21.5
10.1097/AOG.0000000000004791,8,No,NA,No,NA,Racial and ethnic disparity in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seropositivity at the end of pregnancy mediated by residential crowding,Percent,NA,None,1,White,Hispanic,6.7,2,14.7
10.1097/AOG.0000000000004791,8,No,NA,No,NA,Racial and ethnic disparity in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seropositivity at the end of pregnancy mediated by residential crowding,Percent,NA,None,2,White,Black,1.8,0,4.4
10.1097/AOG.0000000000004834,1,No,NA,No,NA,cannabis users advised not to breastfeed,Percent,NA,None,1,N/A,Hispanic,41.1,25.5,56.7
10.1097/AOG.0000000000004834,1,No,NA,No,NA,cannabis users advised not to breastfeed,Percent,NA,None,2,N/A,Non-Hispanic American Indian,42.6,21,64.2
10.1097/AOG.0000000000004834,1,No,NA,No,NA,cannabis users advised not to breastfeed,Percent,NA,None,3,N/A,Non-Hispanic Asian,9.5,0,23.8
10.1097/AOG.0000000000004834,1,No,NA,No,NA,cannabis users advised not to breastfeed,Percent,NA,None,4,N/A,Non-Hispanic Black,62.7,50.2,75.2
10.1097/AOG.0000000000004834,1,No,NA,No,NA,cannabis users advised not to breastfeed,Percent,NA,None,5,N/A,Non-Hispanic Mixed,52.3,23.8,80.8
10.1097/AOG.0000000000004834,1,No,NA,No,NA,cannabis users advised not to breastfeed,Percent,NA,None,6,N/A,Non-Hispanic White,28.8,23.8,33.8
10.1097/AOG.0000000000004834,1,No,NA,No,NA,cannabis users advised not to breastfeed,Percent,NA,None,7,N/A,"Non-Hispanic, none of the above",9.4,0,32.1
10.1097/AOG.0000000000004834,2,No,NA,No,NA,cannabis users advised not to breastfeed with self-reported prenatal cannabis use,OR,NA,None,1,White,American Indian,1.8,0.7,4.6
10.1097/AOG.0000000000004834,2,No,NA,No,NA,cannabis users advised not to breastfeed with self-reported prenatal cannabis use,OR,NA,None,2,White,Asian,0.3,0.1,1.4
10.1097/AOG.0000000000004834,2,No,NA,No,NA,cannabis users advised not to breastfeed with self-reported prenatal cannabis use,OR,NA,None,3,White,Black,4.2,2.3,7.5
10.1097/AOG.0000000000004834,2,No,NA,No,NA,cannabis users advised not to breastfeed with self-reported prenatal cannabis use,OR,NA,None,4,White,Hispanic,1.7,0.9,3.4
10.1097/AOG.0000000000004834,2,No,NA,No,NA,cannabis users advised not to breastfeed with self-reported prenatal cannabis use,OR,NA,None,5,White,Mixed,2.7,0.9,8.7
10.1097/AOG.0000000000004834,2,No,NA,No,NA,cannabis users advised not to breastfeed with self-reported prenatal cannabis use,OR,NA,None,6,White,None of the above,0.3,0,3.7
10.1097/AOG.0000000000004834,3,No,NA,No,NA,cannabis users advised not to breastfeed with self-reported prenatal cannabis use,OR,NA,"insurance type, state of residence, year of delivery, prenatal smoking, maternal education, maternal age",1,White,American Indian,1.3,0.6,3
10.1097/AOG.0000000000004834,3,No,NA,No,NA,cannabis users advised not to breastfeed with self-reported prenatal cannabis use,OR,NA,"insurance type, state of residence, year of delivery, prenatal smoking, maternal education, maternal age",2,White,Asian,0.4,0.1,2.6
10.1097/AOG.0000000000004834,3,No,NA,No,NA,cannabis users advised not to breastfeed with self-reported prenatal cannabis use,OR,NA,"insurance type, state of residence, year of delivery, prenatal smoking, maternal education, maternal age",3,White,Black,4.1,2.1,8.2
10.1097/AOG.0000000000004834,3,No,NA,No,NA,cannabis users advised not to breastfeed with self-reported prenatal cannabis use,OR,NA,"insurance type, state of residence, year of delivery, prenatal smoking, maternal education, maternal age",4,White,Hispanic,2,1,4.1
10.1097/AOG.0000000000004834,3,No,NA,No,NA,cannabis users advised not to breastfeed with self-reported prenatal cannabis use,OR,NA,"insurance type, state of residence, year of delivery, prenatal smoking, maternal education, maternal age",5,White,Mixed,2.6,0.8,8.2
10.1097/AOG.0000000000004834,3,No,NA,No,NA,cannabis users advised not to breastfeed with self-reported prenatal cannabis use,OR,NA,"insurance type, state of residence, year of delivery, prenatal smoking, maternal education, maternal age",6,White,None of the above,0.2,0,2
10.1097/AOG.0000000000004859,1,Yes,Pre-perinatal collaborative care model implementation,No,NA,Antenatal depression screen completion,OR,NA,None,1,White Individuals,Black Individuals,2.45,1.87,3.21
10.1097/AOG.0000000000004859,2,Yes,Pre-perinatal collaborative care model implementation,No,NA,Antenatal depression treatment recommendation,OR,NA,propensity score and race-by-epoch interaction term,1,White Individuals,Black Individuals,2.44,1.86,3.22
10.1097/AOG.0000000000004859,3,Yes,Pre-perinatal collaborative care model implementation,Yes,those with a positive screen for depression,Antenatal depression screen completion,OR,NA,None,1,White Individuals,Black Individuals,0.07,0.01,0.68
10.1097/AOG.0000000000004859,4,Yes,Pre-perinatal collaborative care model implementation,Yes,those with a positive screen for depression,Antenatal depression treatment recommendation,OR,NA,propensity score and race-by-epoch interaction term,1,White Individuals,Black Individuals,0.05,0.01,0.55
10.1097/AOG.0000000000004859,5,Yes,Post-perinatal collaborative care model implementation,No,NA,Antenatal depression screen completion,OR,NA,None,1,White Individuals,Black Individuals,1.24,0.9,1.7
10.1097/AOG.0000000000004859,6,Yes,Post-perinatal collaborative care model implementation,No,NA,Antenatal depression treatment recommendation,OR,NA,propensity score and race-by-epoch interaction term,1,White Individuals,Black Individuals,1.22,0.89,1.68
10.1097/AOG.0000000000004859,7,Yes,Post-perinatal collaborative care model implementation,Yes,those with a positive screen for depression,Antenatal depression screen completion,OR,NA,None,1,White Individuals,Black Individuals,0.7,0.3,1.62
10.1097/AOG.0000000000004859,8,Yes,Post-perinatal collaborative care model implementation,Yes,those with a positive screen for depression,Antenatal depression treatment recommendation,OR,NA,propensity score and race-by-epoch interaction term,1,White Individuals,Black Individuals,0.64,0.27,1.53
10.1097/AOG.0000000000004917,1,Yes,cancer type - ovarian,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,enrollment ratio (actual participants divided by expected participants),NA,None,1,N/A,American Indian,0.53,0.23,1.26
10.1097/AOG.0000000000004917,1,Yes,cancer type - ovarian,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,enrollment ratio (actual participants divided by expected participants),NA,None,2,N/A,Asian,0.7,0.53,0.93
10.1097/AOG.0000000000004917,1,Yes,cancer type - ovarian,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,enrollment ratio (actual participants divided by expected participants),NA,None,3,N/A,Hispanic,0.23,0.18,0.29
10.1097/AOG.0000000000004917,1,Yes,cancer type - ovarian,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,enrollment ratio (actual participants divided by expected participants),NA,None,4,N/A,Non-Hispanic Black,0.42,0.34,0.52
10.1097/AOG.0000000000004917,1,Yes,cancer type - ovarian,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,enrollment ratio (actual participants divided by expected participants),NA,None,5,N/A,Non-Hispanic White,1.27,1.23,1.31
10.1097/AOG.0000000000004917,2,Yes,cancer type - uterine,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,enrollment ratio (actual participants divided by expected participants),NA,None,1,N/A,American Indian,1.56,0.68,3.58
10.1097/AOG.0000000000004917,2,Yes,cancer type - uterine,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,enrollment ratio (actual participants divided by expected participants),NA,None,2,N/A,Asian,0.44,0.28,0.72
10.1097/AOG.0000000000004917,2,Yes,cancer type - uterine,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,enrollment ratio (actual participants divided by expected participants),NA,None,3,N/A,Hispanic,0.22,0.16,0.3
10.1097/AOG.0000000000004917,2,Yes,cancer type - uterine,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,enrollment ratio (actual participants divided by expected participants),NA,None,4,N/A,Non-Hispanic Black,0.88,0.71,1.09
10.1097/AOG.0000000000004917,2,Yes,cancer type - uterine,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,enrollment ratio (actual participants divided by expected participants),NA,None,5,N/A,Non-Hispanic White,1.29,1.19,1.32
10.1097/AOG.0000000000004917,3,Yes,cancer type - cervical,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,enrollment ratio (actual participants divided by expected participants),NA,None,1,N/A,American Indian,0.5,0.05,5.46
10.1097/AOG.0000000000004917,3,Yes,cancer type - cervical,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,enrollment ratio (actual participants divided by expected participants),NA,None,2,N/A,Asian,0.29,0.06,1.35
10.1097/AOG.0000000000004917,3,Yes,cancer type - cervical,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,enrollment ratio (actual participants divided by expected participants),NA,None,3,N/A,Hispanic,0.15,0.06,0.38
10.1097/AOG.0000000000004917,3,Yes,cancer type - cervical,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,enrollment ratio (actual participants divided by expected participants),NA,None,4,N/A,Non-Hispanic Black,0.74,0.43,1.27
10.1097/AOG.0000000000004917,3,Yes,cancer type - cervical,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,enrollment ratio (actual participants divided by expected participants),NA,None,5,N/A,Non-Hispanic White,1.39,1.19,1.63
10.1097/AOG.0000000000004917,4,Yes,cancer type - ovarian,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,mean enrollment ratio (actual participants divided by expected participants),NA,median year of enrollment,1,N/A,Asian,0.66,0.38,0.93
10.1097/AOG.0000000000004917,4,Yes,cancer type - ovarian,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,mean enrollment ratio (actual participants divided by expected participants),NA,median year of enrollment,2,N/A,Hispanic,0.28,0.16,0.4
10.1097/AOG.0000000000004917,4,Yes,cancer type - ovarian,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,mean enrollment ratio (actual participants divided by expected participants),NA,median year of enrollment,3,N/A,Non-Hispanic Black,0.45,0.19,0.7
10.1097/AOG.0000000000004917,4,Yes,cancer type - ovarian,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,mean enrollment ratio (actual participants divided by expected participants),NA,median year of enrollment,4,N/A,Non-Hispanic White,1.28,1.24,1.33
10.1097/AOG.0000000000004917,5,Yes,cancer type - uterine,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,mean enrollment ratio (actual participants divided by expected participants),NA,median year of enrollment,1,N/A,Asian,0.59,0.19,0.99
10.1097/AOG.0000000000004917,5,Yes,cancer type - uterine,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,mean enrollment ratio (actual participants divided by expected participants),NA,median year of enrollment,2,N/A,Hispanic,0.28,0.16,0.41
10.1097/AOG.0000000000004917,5,Yes,cancer type - uterine,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,mean enrollment ratio (actual participants divided by expected participants),NA,median year of enrollment,3,N/A,Non-Hispanic Black,0.68,0.45,0.91
10.1097/AOG.0000000000004917,5,Yes,cancer type - uterine,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,mean enrollment ratio (actual participants divided by expected participants),NA,median year of enrollment,4,N/A,Non-Hispanic White,1.17,1.03,1.32
10.1097/AOG.0000000000004917,6,Yes,cancer type - cervical,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,mean enrollment ratio (actual participants divided by expected participants),NA,median year of enrollment,1,N/A,Hispanic,0.28,-0.14,0.7
10.1097/AOG.0000000000004917,6,Yes,cancer type - cervical,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,mean enrollment ratio (actual participants divided by expected participants),NA,median year of enrollment,2,N/A,Non-Hispanic Black,0.76,0.05,1.47
10.1097/AOG.0000000000004917,6,Yes,cancer type - cervical,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,mean enrollment ratio (actual participants divided by expected participants),NA,median year of enrollment,3,N/A,Non-Hispanic White,1.38,1.06,1.73
10.1097/AOG.0000000000004917,7,Yes,cancer type - total,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,mean enrollment ratio (actual participants divided by expected participants),NA,median year of enrollment,1,N/A,Asian,0.63,0.41,0.86
10.1097/AOG.0000000000004917,7,Yes,cancer type - total,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,mean enrollment ratio (actual participants divided by expected participants),NA,median year of enrollment,2,N/A,Hispanic,0.3,0.23,0.36
10.1097/AOG.0000000000004917,7,Yes,cancer type - total,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,mean enrollment ratio (actual participants divided by expected participants),NA,median year of enrollment,3,N/A,Non-Hispanic Black,0.51,0.36,0.66
10.1097/AOG.0000000000004917,7,Yes,cancer type - total,No,NA,enrollment in precision oncology clinical trials for gynecologic cancers,mean enrollment ratio (actual participants divided by expected participants),NA,median year of enrollment,4,N/A,Non-Hispanic White,1.26,1.2,1.32
10.1097/AOG.0000000000004953,1,No,NA,No,NA,Primary Cesarean Delivery,RR,NA,None,1,Non-Hispanic White,Hispanic,0.95,0.95,0.96
10.1097/AOG.0000000000004953,1,No,NA,No,NA,Primary Cesarean Delivery,RR,NA,None,2,Non-Hispanic White,Non-Hispanic Black,1.2,1.19,1.2
10.1097/AOG.0000000000004953,2,No,NA,No,NA,Primary Cesarean Delivery,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy BMI, smoking during pregnancy, chorioamnionitis, gestational age, neonatal sex, and year",1,Non-Hispanic White,Hispanic,1.09,1.09,1.1
10.1097/AOG.0000000000004953,2,No,NA,No,NA,Primary Cesarean Delivery,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy BMI, smoking during pregnancy, chorioamnionitis, gestational age, neonatal sex, and year",2,Non-Hispanic White,Non-Hispanic Black,1.24,1.23,1.25
10.1097/AOG.0000000000004953,3,No,NA,No,NA,Composite neonatal adverse outcome,RR,NA,None,1,Non-Hispanic White,Hispanic,0.77,0.75,0.79
10.1097/AOG.0000000000004953,3,No,NA,No,NA,Composite neonatal adverse outcome,RR,NA,None,2,Non-Hispanic White,Non-Hispanic Black,1.12,1.1,1.15
10.1097/AOG.0000000000004953,4,No,NA,No,NA,Composite neonatal adverse outcome,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, primary cesarean birth, neonatal sex, and year",1,Non-Hispanic White,Hispanic,0.74,0.72,0.75
10.1097/AOG.0000000000004953,4,No,NA,No,NA,Composite neonatal adverse outcome,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, primary cesarean birth, neonatal sex, and year",2,Non-Hispanic White,Non-Hispanic Black,1.01,0.98,1.04
10.1097/AOG.0000000000004953,5,No,NA,No,NA,5-min Apgar score less than 5,RR,NA,None,1,Non-Hispanic White,Hispanic,0.73,0.7,0.75
10.1097/AOG.0000000000004953,5,No,NA,No,NA,5-min Apgar score less than 5,RR,NA,None,2,Non-Hispanic White,Non-Hispanic Black,1.35,1.3,1.39
10.1097/AOG.0000000000004953,6,No,NA,No,NA,5-min Apgar score less than 5,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, primary cesarean birth, neonatal sex, and year",1,Non-Hispanic White,Hispanic,0.67,0.64,0.69
10.1097/AOG.0000000000004953,6,No,NA,No,NA,5-min Apgar score less than 5,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, primary cesarean birth, neonatal sex, and year",2,Non-Hispanic White,Non-Hispanic Black,1.17,1.13,1.22
10.1097/AOG.0000000000004953,7,No,NA,No,NA,Assisted ventilation longer than 6 h,RR,NA,None,1,Non-Hispanic White,Hispanic,0.8,0.77,0.82
10.1097/AOG.0000000000004953,7,No,NA,No,NA,Assisted ventilation longer than 6 h,RR,NA,None,2,Non-Hispanic White,Non-Hispanic Black,0.9,0.87,0.94
10.1097/AOG.0000000000004953,8,No,NA,No,NA,Assisted ventilation longer than 6 h,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, primary cesarean birth, neonatal sex, and year",1,Non-Hispanic White,Hispanic,0.8,0.77,0.82
10.1097/AOG.0000000000004953,8,No,NA,No,NA,Assisted ventilation longer than 6 h,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, primary cesarean birth, neonatal sex, and year",2,Non-Hispanic White,Non-Hispanic Black,0.84,0.81,0.88
10.1097/AOG.0000000000004953,9,No,NA,No,NA,Neonatal seizure,RR,NA,None,1,Non-Hispanic White,Hispanic,0.57,0.5,0.65
10.1097/AOG.0000000000004953,9,No,NA,No,NA,Neonatal seizure,RR,NA,None,2,Non-Hispanic White,Non-Hispanic Black,0.75,0.65,0.87
10.1097/AOG.0000000000004953,10,No,NA,No,NA,Neonatal seizure,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, primary cesarean birth, neonatal sex, and year",1,Non-Hispanic White,Hispanic,0.56,0.49,0.65
10.1097/AOG.0000000000004953,10,No,NA,No,NA,Neonatal seizure,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, primary cesarean birth, neonatal sex, and year",2,Non-Hispanic White,Non-Hispanic Black,0.65,0.55,0.76
10.1097/AOG.0000000000004953,11,No,NA,No,NA,Neonatal death,RR,NA,None,1,Non-Hispanic White,Hispanic,0.86,0.76,0.98
10.1097/AOG.0000000000004953,11,No,NA,No,NA,Neonatal death,RR,NA,None,2,Non-Hispanic White,Non-Hispanic Black,1.1,0.96,1.27
10.1097/AOG.0000000000004953,12,No,NA,No,NA,Neonatal death,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, primary cesarean birth, neonatal sex, and year",1,Non-Hispanic White,Hispanic,0.66,0.57,0.76
10.1097/AOG.0000000000004953,12,No,NA,No,NA,Neonatal death,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, primary cesarean birth, neonatal sex, and year",2,Non-Hispanic White,Non-Hispanic Black,0.8,0.69,0.93
10.1097/AOG.0000000000004953,13,No,NA,No,NA,Infant death,RR,NA,None,1,Non-Hispanic White,Hispanic,0.85,0.79,0.91
10.1097/AOG.0000000000004953,13,No,NA,No,NA,Infant death,RR,NA,None,2,Non-Hispanic White,Non-Hispanic Black,1.68,1.57,1.8
10.1097/AOG.0000000000004953,14,No,NA,No,NA,Infant death,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, primary cesarean birth, neonatal sex, and year",1,Non-Hispanic White,Hispanic,0.62,0.57,0.67
10.1097/AOG.0000000000004953,14,No,NA,No,NA,Infant death,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, primary cesarean birth, neonatal sex, and year",2,Non-Hispanic White,Non-Hispanic Black,1.11,1.03,1.19
10.1097/AOG.0000000000004953,15,No,NA,No,NA,Composite maternal adverse outcome,RR,NA,None,1,Non-Hispanic White,Hispanic,1.06,1.02,1.1
10.1097/AOG.0000000000004953,15,No,NA,No,NA,Composite maternal adverse outcome,RR,NA,None,2,Non-Hispanic White,Non-Hispanic Black,0.97,0.92,1.02
10.1097/AOG.0000000000004953,16,No,NA,No,NA,Composite maternal adverse outcome,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, primary cesarean birth, neonatal sex, and year",1,Non-Hispanic White,Hispanic,1,0.96,1.04
10.1097/AOG.0000000000004953,16,No,NA,No,NA,Composite maternal adverse outcome,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, primary cesarean birth, neonatal sex, and year",2,Non-Hispanic White,Non-Hispanic Black,0.85,0.8,0.89
10.1097/AOG.0000000000004953,17,No,NA,No,NA,Admission to ICU,RR,NA,None,1,Non-Hispanic White,Hispanic,1,0.92,1.09
10.1097/AOG.0000000000004953,17,No,NA,No,NA,Admission to ICU,RR,NA,None,2,Non-Hispanic White,Non-Hispanic Black,1.16,1.06,1.28
10.1097/AOG.0000000000004953,18,No,NA,No,NA,Admission to ICU,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, primary cesarean birth, neonatal sex, and year",1,Non-Hispanic White,Hispanic,0.96,0.87,1.05
10.1097/AOG.0000000000004953,18,No,NA,No,NA,Admission to ICU,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, primary cesarean birth, neonatal sex, and year",2,Non-Hispanic White,Non-Hispanic Black,1.06,0.95,1.18
10.1097/AOG.0000000000004953,19,No,NA,No,NA,Maternal transfusion,RR,NA,None,1,Non-Hispanic White,Hispanic,1.04,1,1.09
10.1097/AOG.0000000000004953,19,No,NA,No,NA,Maternal transfusion,RR,NA,None,2,Non-Hispanic White,Non-Hispanic Black,0.87,0.83,0.92
10.1097/AOG.0000000000004953,20,No,NA,No,NA,Maternal transfusion,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, primary cesarean birth, neonatal sex, and year",1,Non-Hispanic White,Hispanic,0.98,0.94,1.03
10.1097/AOG.0000000000004953,20,No,NA,No,NA,Maternal transfusion,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, primary cesarean birth, neonatal sex, and year",2,Non-Hispanic White,Non-Hispanic Black,0.76,0.72,0.81
10.1097/AOG.0000000000004953,21,No,NA,No,NA,Uterine rupture,RR,NA,None,1,Non-Hispanic White,Hispanic,1.43,1.12,1.82
10.1097/AOG.0000000000004953,21,No,NA,No,NA,Uterine rupture,RR,NA,None,2,Non-Hispanic White,Non-Hispanic Black,1.44,1.08,1.92
10.1097/AOG.0000000000004953,22,No,NA,No,NA,Uterine rupture,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, primary cesarean birth, neonatal sex, and year",1,Non-Hispanic White,Hispanic,1.24,0.93,1.64
10.1097/AOG.0000000000004953,22,No,NA,No,NA,Uterine rupture,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, primary cesarean birth, neonatal sex, and year",2,Non-Hispanic White,Non-Hispanic Black,1.35,0.99,1.85
10.1097/AOG.0000000000004953,23,No,NA,No,NA,Unplanned hysterectomy,RR,NA,None,1,Non-Hispanic White,Hispanic,0.82,0.67,1.01
10.1097/AOG.0000000000004953,23,No,NA,No,NA,Unplanned hysterectomy,RR,NA,None,2,Non-Hispanic White,Non-Hispanic Black,0.82,0.63,1.06
10.1097/AOG.0000000000004953,24,No,NA,No,NA,Unplanned hysterectomy,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, primary cesarean birth, neonatal sex, and year",1,Non-Hispanic White,Hispanic,0.94,0.76,1.18
10.1097/AOG.0000000000004953,24,No,NA,No,NA,Unplanned hysterectomy,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, primary cesarean birth, neonatal sex, and year",2,Non-Hispanic White,Non-Hispanic Black,0.92,0.69,1.21
10.1097/AOG.0000000000004953,25,No,NA,No,NA,Composite maternal adverse outcome without transfusion,RR,NA,None,1,Non-Hispanic White,Hispanic,1.02,0.94,1.1
10.1097/AOG.0000000000004953,25,No,NA,No,NA,Composite maternal adverse outcome without transfusion,RR,NA,None,2,Non-Hispanic White,Non-Hispanic Black,1.16,1.06,1.27
10.1097/AOG.0000000000004953,26,No,NA,No,NA,Composite maternal adverse outcome without transfusion,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, primary cesarean birth, neonatal sex, and year",1,Non-Hispanic White,Hispanic,0.99,0.91,1.08
10.1097/AOG.0000000000004953,26,No,NA,No,NA,Composite maternal adverse outcome without transfusion,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, primary cesarean birth, neonatal sex, and year",2,Non-Hispanic White,Non-Hispanic Black,1.07,0.97,1.19
10.1097/AOG.0000000000004953,27,No,NA,Yes,Primary Cesarean Deliveries,Composite neonatal adverse outcome,RR,NA,None,1,Non-Hispanic White,Hispanic,0.81,0.78,0.85
10.1097/AOG.0000000000004953,27,No,NA,Yes,Primary Cesarean Deliveries,Composite neonatal adverse outcome,RR,NA,None,2,Non-Hispanic White,Non-Hispanic Black,1.18,1.13,1.23
10.1097/AOG.0000000000004953,28,No,NA,Yes,Primary Cesarean Deliveries,Composite neonatal adverse outcome,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, neonatal sex, and year",1,Non-Hispanic White,Hispanic,0.73,0.7,0.76
10.1097/AOG.0000000000004953,28,No,NA,Yes,Primary Cesarean Deliveries,Composite neonatal adverse outcome,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, neonatal sex, and year",2,Non-Hispanic White,Non-Hispanic Black,1.06,1.01,1.1
10.1097/AOG.0000000000004953,29,No,NA,Yes,Primary Cesarean Deliveries,Composite maternal adverse outcome,RR,NA,None,1,Non-Hispanic White,Hispanic,1.09,1.03,1.16
10.1097/AOG.0000000000004953,29,No,NA,Yes,Primary Cesarean Deliveries,Composite maternal adverse outcome,RR,NA,None,2,Non-Hispanic White,Non-Hispanic Black,1,0.93,1.08
10.1097/AOG.0000000000004953,30,No,NA,Yes,Primary Cesarean Deliveries,Composite maternal adverse outcome,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, neonatal sex, and year",1,Non-Hispanic White,Hispanic,0.92,0.86,0.99
10.1097/AOG.0000000000004953,30,No,NA,Yes,Primary Cesarean Deliveries,Composite maternal adverse outcome,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, neonatal sex, and year",2,Non-Hispanic White,Non-Hispanic Black,0.89,0.83,0.96
10.1097/AOG.0000000000004953,31,No,NA,Yes,Primary Cesarean Deliveries,Composite maternal adverse outcome without transfusion,RR,NA,None,1,Non-Hispanic White,Hispanic,1.07,0.96,1.19
10.1097/AOG.0000000000004953,31,No,NA,Yes,Primary Cesarean Deliveries,Composite maternal adverse outcome without transfusion,RR,NA,None,2,Non-Hispanic White,Non-Hispanic Black,1.05,0.93,1.19
10.1097/AOG.0000000000004953,32,No,NA,Yes,Primary Cesarean Deliveries,Composite maternal adverse outcome without transfusion,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, neonatal sex, and year",1,Non-Hispanic White,Hispanic,0.95,0.85,1.07
10.1097/AOG.0000000000004953,32,No,NA,Yes,Primary Cesarean Deliveries,Composite maternal adverse outcome without transfusion,RR,NA,"maternal age, education, marital status, insurance, prenatal care, prepregnancy body mass index, smoking during pregnancy, chorioamnionitis, gestational age, neonatal sex, and year",2,Non-Hispanic White,Non-Hispanic Black,1.05,0.92,1.19
10.1097/AOG.0000000000004971,1,Yes,Non-Hispanic Black,No,NA,composite adverse pregnancy outcome,OR,NA,None,1,low allostatic load (index less than 4),high allostatic load (index 4 or higher),1.4,1,2
10.1097/AOG.0000000000004971,2,Yes,Non-Hispanic White and Additional Race and Ethnicity,No,NA,composite adverse pregnancy outcome,OR,NA,None,1,low allostatic load (index less than 4),high allostatic load (index 4 or higher),1.5,1.3,1.8
10.1097/AOG.0000000000004971,3,Yes,Non-Hispanic Black,No,NA,composite adverse pregnancy outcome,OR,NA,"Maternal age, education level, gravidity, smoking status, bleeding in the first trimester, and health insurance type",1,low allostatic load (index less than 4),high allostatic load (index 4 or higher),1.3,0.9,1.9
10.1097/AOG.0000000000004971,4,Yes,Non-Hispanic White and Additional Race and Ethnicity,No,NA,composite adverse pregnancy outcome,OR,NA,"Maternal age, education level, gravidity, smoking status, bleeding in the first trimester, and health insurance type",1,low allostatic load (index less than 4),high allostatic load (index 4 or higher),1.5,1.3,1.8
10.1097/AOG.0000000000004971,5,Yes,Non-Hispanic Black,No,NA,Hypertensive disorders of pregnancy,OR,NA,None,1,low allostatic load (index less than 4),high allostatic load (index 4 or higher),1.6,1,2.4
10.1097/AOG.0000000000004971,6,Yes,Non-Hispanic White and Additional Race and Ethnicity,No,NA,Hypertensive disorders of pregnancy,OR,NA,None,1,low allostatic load (index less than 4),high allostatic load (index 4 or higher),2.7,2.2,3.3
10.1097/AOG.0000000000004971,7,Yes,Non-Hispanic Black,No,NA,Hypertensive disorders of pregnancy,OR,NA,"Maternal age, education level, gravidity, smoking status, bleeding in the first trimester, and health insurance type",1,low allostatic load (index less than 4),high allostatic load (index 4 or higher),1.5,1,2.4
10.1097/AOG.0000000000004971,8,Yes,Non-Hispanic White and Additional Race and Ethnicity,No,NA,Hypertensive disorders of pregnancy,OR,NA,"Maternal age, education level, gravidity, smoking status, bleeding in the first trimester, and health insurance type",1,low allostatic load (index less than 4),high allostatic load (index 4 or higher),2.7,2.2,3.2
10.1097/AOG.0000000000004971,9,Yes,Non-Hispanic Black,No,NA,Preterm birth,OR,NA,None,1,low allostatic load (index less than 4),high allostatic load (index 4 or higher),1.4,0.8,2.3
10.1097/AOG.0000000000004971,10,Yes,Non-Hispanic White and Additional Race and Ethnicity,No,NA,Preterm birth,OR,NA,None,1,low allostatic load (index less than 4),high allostatic load (index 4 or higher),1.3,1,1.6
10.1097/AOG.0000000000004971,11,Yes,Non-Hispanic Black,No,NA,Preterm birth,OR,NA,"Maternal age, education level, gravidity, smoking status, bleeding in the first trimester, and health insurance type",1,low allostatic load (index less than 4),high allostatic load (index 4 or higher),1.4,0.8,2.3
10.1097/AOG.0000000000004971,12,Yes,Non-Hispanic White and Additional Race and Ethnicity,No,NA,Preterm birth,OR,NA,"Maternal age, education level, gravidity, smoking status, bleeding in the first trimester, and health insurance type",1,low allostatic load (index less than 4),high allostatic load (index 4 or higher),1.2,0.9,1.5
10.1097/AOG.0000000000004971,13,Yes,Non-Hispanic Black,No,NA,Small for gestational age,OR,NA,None,1,low allostatic load (index less than 4),high allostatic load (index 4 or higher),0.9,0.6,1.4
10.1097/AOG.0000000000004971,14,Yes,Non-Hispanic White and Additional Race and Ethnicity,No,NA,Small for gestational age,OR,NA,None,1,low allostatic load (index less than 4),high allostatic load (index 4 or higher),0.8,0.6,1
10.1097/AOG.0000000000004971,15,Yes,Non-Hispanic Black,No,NA,Small for gestational age,OR,NA,"Maternal age, education level, gravidity, smoking status, bleeding in the first trimester, and health insurance type",1,low allostatic load (index less than 4),high allostatic load (index 4 or higher),0.8,0.5,1.3
10.1097/AOG.0000000000004971,16,Yes,Non-Hispanic White and Additional Race and Ethnicity,No,NA,Small for gestational age,OR,NA,"Maternal age, education level, gravidity, smoking status, bleeding in the first trimester, and health insurance type",1,low allostatic load (index less than 4),high allostatic load (index 4 or higher),0.8,0.6,1
10.1097/AOG.0000000000005044,1,Yes,Cervical Cancer,No,NA,Fertility-Sparing Treatment,OR,NA,None,1,Non-Hispanic White,American Indian,1.41,0.54,2.41
10.1097/AOG.0000000000005044,1,Yes,Cervical Cancer,No,NA,Fertility-Sparing Treatment,OR,NA,None,2,Non-Hispanic White,Asian or Pacific Islander,1.15,0.91,1.46
10.1097/AOG.0000000000005044,1,Yes,Cervical Cancer,No,NA,Fertility-Sparing Treatment,OR,NA,None,3,Non-Hispanic White,Hispanic,0.74,0.62,0.88
10.1097/AOG.0000000000005044,1,Yes,Cervical Cancer,No,NA,Fertility-Sparing Treatment,OR,NA,None,4,Non-Hispanic White,Non-Hispanic Black,0.97,0.69,1.37
10.1097/AOG.0000000000005044,2,Yes,Cervical Cancer,No,NA,Fertility-Sparing Treatment,OR,NA,"Age, Diagnosis year, Socioeconomic Status, Charlson Comorbidity Index, Insurance, Marital Status, Rurality, Parity, Cancer Stage, Histology",1,Non-Hispanic White,American Indian,1.03,0.37,2.89
10.1097/AOG.0000000000005044,2,Yes,Cervical Cancer,No,NA,Fertility-Sparing Treatment,OR,NA,"Age, Diagnosis year, Socioeconomic Status, Charlson Comorbidity Index, Insurance, Marital Status, Rurality, Parity, Cancer Stage, Histology",2,Non-Hispanic White,Asian or Pacific Islander,1.52,1.12,2.08
10.1097/AOG.0000000000005044,2,Yes,Cervical Cancer,No,NA,Fertility-Sparing Treatment,OR,NA,"Age, Diagnosis year, Socioeconomic Status, Charlson Comorbidity Index, Insurance, Marital Status, Rurality, Parity, Cancer Stage, Histology",3,Non-Hispanic White,Hispanic,0.83,0.66,1.06
10.1097/AOG.0000000000005044,2,Yes,Cervical Cancer,No,NA,Fertility-Sparing Treatment,OR,NA,"Age, Diagnosis year, Socioeconomic Status, Charlson Comorbidity Index, Insurance, Marital Status, Rurality, Parity, Cancer Stage, Histology",4,Non-Hispanic White,Non-Hispanic Black,0.6,0.37,0.99
10.1097/AOG.0000000000005044,3,Yes,Endometrial Cancer,No,NA,Fertility-Sparing Treatment,OR,NA,None,1,Non-Hispanic White,American Indian,2.22,0.49,10.14
10.1097/AOG.0000000000005044,3,Yes,Endometrial Cancer,No,NA,Fertility-Sparing Treatment,OR,NA,None,2,Non-Hispanic White,Asian or Pacific Islander,2.73,1.56,4.76
10.1097/AOG.0000000000005044,3,Yes,Endometrial Cancer,No,NA,Fertility-Sparing Treatment,OR,NA,None,3,Non-Hispanic White,Hispanic,1.55,0.92,2.63
10.1097/AOG.0000000000005044,3,Yes,Endometrial Cancer,No,NA,Fertility-Sparing Treatment,OR,NA,None,4,Non-Hispanic White,Non-Hispanic Black,2.94,1.13,7.65
10.1097/AOG.0000000000005044,4,Yes,Endometrial Cancer,No,NA,Fertility-Sparing Treatment,OR,NA,"Age, Diagnosis year, Socioeconomic Status, Charlson Comorbidity Index, Insurance, Marital Status, Rurality, Parity, Cancer Stage, Histology",1,Non-Hispanic White,American Indian,1.99,0.34,11.64
10.1097/AOG.0000000000005044,4,Yes,Endometrial Cancer,No,NA,Fertility-Sparing Treatment,OR,NA,"Age, Diagnosis year, Socioeconomic Status, Charlson Comorbidity Index, Insurance, Marital Status, Rurality, Parity, Cancer Stage, Histology",2,Non-Hispanic White,Asian or Pacific Islander,2.5,0.97,6.43
10.1097/AOG.0000000000005044,4,Yes,Endometrial Cancer,No,NA,Fertility-Sparing Treatment,OR,NA,"Age, Diagnosis year, Socioeconomic Status, Charlson Comorbidity Index, Insurance, Marital Status, Rurality, Parity, Cancer Stage, Histology",3,Non-Hispanic White,Hispanic,1.7,0.72,4.02
10.1097/AOG.0000000000005044,4,Yes,Endometrial Cancer,No,NA,Fertility-Sparing Treatment,OR,NA,"Age, Diagnosis year, Socioeconomic Status, Charlson Comorbidity Index, Insurance, Marital Status, Rurality, Parity, Cancer Stage, Histology",4,Non-Hispanic White,Non-Hispanic Black,3.88,0.97,15.51
10.1097/AOG.0000000000005044,5,Yes,Ovarian Cancer,No,NA,Fertility-Sparing Treatment,OR,NA,None,1,Non-Hispanic White,American Indian,2.52,0.42,15.2
10.1097/AOG.0000000000005044,5,Yes,Ovarian Cancer,No,NA,Fertility-Sparing Treatment,OR,NA,None,2,Non-Hispanic White,Asian or Pacific Islander,1.31,1.01,1.69
10.1097/AOG.0000000000005044,5,Yes,Ovarian Cancer,No,NA,Fertility-Sparing Treatment,OR,NA,None,3,Non-Hispanic White,Hispanic,1.61,1.29,2.03
10.1097/AOG.0000000000005044,5,Yes,Ovarian Cancer,No,NA,Fertility-Sparing Treatment,OR,NA,None,4,Non-Hispanic White,Non-Hispanic Black,1.93,1.23,3.03
10.1097/AOG.0000000000005044,6,Yes,Ovarian Cancer,No,NA,Fertility-Sparing Treatment,OR,NA,"Age, Diagnosis year, Socioeconomic Status, Charlson Comorbidity Index, Insurance, Marital Status, Rurality, Parity, Cancer Stage, Histology",1,Non-Hispanic White,American Indian,0.98,0.08,11.97
10.1097/AOG.0000000000005044,6,Yes,Ovarian Cancer,No,NA,Fertility-Sparing Treatment,OR,NA,"Age, Diagnosis year, Socioeconomic Status, Charlson Comorbidity Index, Insurance, Marital Status, Rurality, Parity, Cancer Stage, Histology",2,Non-Hispanic White,Asian or Pacific Islander,1.3,0.92,1.82
10.1097/AOG.0000000000005044,6,Yes,Ovarian Cancer,No,NA,Fertility-Sparing Treatment,OR,NA,"Age, Diagnosis year, Socioeconomic Status, Charlson Comorbidity Index, Insurance, Marital Status, Rurality, Parity, Cancer Stage, Histology",3,Non-Hispanic White,Hispanic,1.44,1.04,1.99
10.1097/AOG.0000000000005044,6,Yes,Ovarian Cancer,No,NA,Fertility-Sparing Treatment,OR,NA,"Age, Diagnosis year, Socioeconomic Status, Charlson Comorbidity Index, Insurance, Marital Status, Rurality, Parity, Cancer Stage, Histology",4,Non-Hispanic White,Non-Hispanic Black,2.26,1.22,4.17
10.1097/AOG.0000000000005081,1,Yes,Asian or Pacific Islander,No,NA,Uninsurance at Birth,OR,NA,None,1,Rural Residents,Urban Residents,4.7,1.59,14.15
10.1097/AOG.0000000000005081,2,Yes,"Black, non-Hispanic",No,NA,Uninsurance at Birth,OR,NA,None,1,Rural Residents,Urban Residents,0.6,0.28,1.27
10.1097/AOG.0000000000005081,3,Yes,"Hispanic, English-speaking",No,NA,Uninsurance at Birth,OR,NA,None,1,Rural Residents,Urban Residents,3.08,2.14,4.43
10.1097/AOG.0000000000005081,4,Yes,"Hispanic, Spanish-speaking",No,NA,Uninsurance at Birth,OR,NA,None,1,Rural Residents,Urban Residents,1.94,1.47,2.55
10.1097/AOG.0000000000005081,5,Yes,Indigenous,No,NA,Uninsurance at Birth,OR,NA,None,1,Rural Residents,Urban Residents,2.06,1.5,2.83
10.1097/AOG.0000000000005081,6,Yes,Additional races and ethnicities or mixed,No,NA,Uninsurance at Birth,OR,NA,None,1,Rural Residents,Urban Residents,1.91,0.96,3.82
10.1097/AOG.0000000000005081,7,Yes,"White, non-Hispanic",No,NA,Uninsurance at Birth,OR,NA,None,1,Rural Residents,Urban Residents,2.18,1.87,2.53
10.1097/AOG.0000000000005081,8,Yes,Asian or Pacific Islander,No,NA,Uninsurance at Birth,OR,NA,"maternal age, income, highest level of education achieved, state Medicaid expansion status, marital status, parity, pregnancy intention, and the presence of pre-existing chronic conditions (obesity, diabetes, hypertension, and depression)",1,Rural Residents,Urban Residents,1.74,0.61,5
10.1097/AOG.0000000000005081,9,Yes,"Black, non-Hispanic",No,NA,Uninsurance at Birth,OR,NA,"maternal age, income, highest level of education achieved, state Medicaid expansion status, marital status, parity, pregnancy intention, and the presence of pre-existing chronic conditions (obesity, diabetes, hypertension, and depression)",1,Rural Residents,Urban Residents,0.42,0.2,0.91
10.1097/AOG.0000000000005081,10,Yes,"Hispanic, English-speaking",No,NA,Uninsurance at Birth,OR,NA,"maternal age, income, highest level of education achieved, state Medicaid expansion status, marital status, parity, pregnancy intention, and the presence of pre-existing chronic conditions (obesity, diabetes, hypertension, and depression)",1,Rural Residents,Urban Residents,2.91,1.94,4.38
10.1097/AOG.0000000000005081,11,Yes,"Hispanic, Spanish-speaking",No,NA,Uninsurance at Birth,OR,NA,"maternal age, income, highest level of education achieved, state Medicaid expansion status, marital status, parity, pregnancy intention, and the presence of pre-existing chronic conditions (obesity, diabetes, hypertension, and depression)",1,Rural Residents,Urban Residents,1.33,0.94,1.87
10.1097/AOG.0000000000005081,12,Yes,Indigenous,No,NA,Uninsurance at Birth,OR,NA,"maternal age, income, highest level of education achieved, state Medicaid expansion status, marital status, parity, pregnancy intention, and the presence of pre-existing chronic conditions (obesity, diabetes, hypertension, and depression)",1,Rural Residents,Urban Residents,2.08,1.53,2.82
10.1097/AOG.0000000000005081,13,Yes,Additional races and ethnicities or mixed,No,NA,Uninsurance at Birth,OR,NA,"maternal age, income, highest level of education achieved, state Medicaid expansion status, marital status, parity, pregnancy intention, and the presence of pre-existing chronic conditions (obesity, diabetes, hypertension, and depression)",1,Rural Residents,Urban Residents,1.87,0.91,3.85
10.1097/AOG.0000000000005081,14,Yes,"White, non-Hispanic",No,NA,Uninsurance at Birth,OR,NA,"maternal age, income, highest level of education achieved, state Medicaid expansion status, marital status, parity, pregnancy intention, and the presence of pre-existing chronic conditions (obesity, diabetes, hypertension, and depression)",1,Rural Residents,Urban Residents,1.57,1.33,1.86
10.1097/AOG.0000000000005130,1,No,NA,No,NA,Permanent Contraception Fulfillment at Hospital Discharge,OR,NA,None,1,White,Asian,0.86,0.55,1.34
10.1097/AOG.0000000000005130,1,No,NA,No,NA,Permanent Contraception Fulfillment at Hospital Discharge,OR,NA,None,2,White,Black,0.62,0.53,0.74
10.1097/AOG.0000000000005130,2,No,NA,No,NA,Permanent Contraception Fulfillment at Hospital Discharge,OR,NA,"Private Insurance, Maternal age at delivery, Parity 2 or more, Weeks of gestation at delivery, Cesarean delivery, Adequate prenatal care, Married, BMI",1,White,Asian,0.54,0.31,0.96
10.1097/AOG.0000000000005130,2,No,NA,No,NA,Permanent Contraception Fulfillment at Hospital Discharge,OR,NA,"Private Insurance, Maternal age at delivery, Parity 2 or more, Weeks of gestation at delivery, Cesarean delivery, Adequate prenatal care, Married, BMI",2,White,Black,1.01,0.81,1.27
10.1097/AOG.0000000000005130,3,No,NA,No,NA,Permanent Contraception Fulfillment at Hospital Discharge,OR,NA,None,1,non-Hispanic,Hispanic,1.18,1,1.39
10.1097/AOG.0000000000005130,4,No,NA,No,NA,Permanent Contraception Fulfillment at Hospital Discharge,OR,NA,"Private Insurance, Maternal age at delivery, Parity 2 or more, Weeks of gestation at delivery, Cesarean delivery, Adequate prenatal care, Married, BMI",1,non-Hispanic,Hispanic,1.02,0.74,1.4
10.1097/AOG.0000000000005130,5,No,NA,No,NA,Permanent Contraception Fulfillment at 42 Days Postpartum,OR,NA,None,1,White,Asian,0.86,0.55,1.34
10.1097/AOG.0000000000005130,5,No,NA,No,NA,Permanent Contraception Fulfillment at 42 Days Postpartum,OR,NA,None,2,White,Black,0.62,0.53,0.74
10.1097/AOG.0000000000005130,6,No,NA,No,NA,Permanent Contraception Fulfillment at 42 Days Postpartum,OR,NA,"Private Insurance, Maternal age at delivery, Parity 2 or more, Weeks of gestation at delivery, Cesarean delivery, Adequate prenatal care, Married, BMI",1,White,Asian,0.55,0.31,0.96
10.1097/AOG.0000000000005130,6,No,NA,No,NA,Permanent Contraception Fulfillment at 42 Days Postpartum,OR,NA,"Private Insurance, Maternal age at delivery, Parity 2 or more, Weeks of gestation at delivery, Cesarean delivery, Adequate prenatal care, Married, BMI",2,White,Black,0.97,0.78,1.22
10.1097/AOG.0000000000005130,7,No,NA,No,NA,Permanent Contraception Fulfillment at 42 Days Postpartum,OR,NA,None,1,non-Hispanic,Hispanic,1.18,1,1.39
10.1097/AOG.0000000000005130,8,No,NA,No,NA,Permanent Contraception Fulfillment at 42 Days Postpartum,OR,NA,"Private Insurance, Maternal age at delivery, Parity 2 or more, Weeks of gestation at delivery, Cesarean delivery, Adequate prenatal care, Married, BMI",1,non-Hispanic,Hispanic,0.98,0.71,1.34
10.1097/AOG.0000000000005130,9,No,NA,No,NA,Permanent Contraception Fulfillment at 365 Days Postpartum,OR,NA,None,1,White,Asian,0.9,0.56,1.43
10.1097/AOG.0000000000005130,9,No,NA,No,NA,Permanent Contraception Fulfillment at 365 Days Postpartum,OR,NA,None,2,White,Black,0.57,0.48,0.68
10.1097/AOG.0000000000005130,10,No,NA,No,NA,Permanent Contraception Fulfillment at 365 Days Postpartum,OR,NA,"Private Insurance, Maternal age at delivery, Parity 2 or more, Weeks of gestation at delivery, Cesarean delivery, Adequate prenatal care, Married, BMI",1,White,Asian,0.68,0.39,1.19
10.1097/AOG.0000000000005130,10,No,NA,No,NA,Permanent Contraception Fulfillment at 365 Days Postpartum,OR,NA,"Private Insurance, Maternal age at delivery, Parity 2 or more, Weeks of gestation at delivery, Cesarean delivery, Adequate prenatal care, Married, BMI",2,White,Black,0.82,0.66,1.02
10.1097/AOG.0000000000005130,11,No,NA,No,NA,Permanent Contraception Fulfillment at 365 Days Postpartum,OR,NA,None,1,non-Hispanic,Hispanic,1.24,1.04,1.47
10.1097/AOG.0000000000005130,12,No,NA,No,NA,Permanent Contraception Fulfillment at 365 Days Postpartum,OR,NA,"Private Insurance, Maternal age at delivery, Parity 2 or more, Weeks of gestation at delivery, Cesarean delivery, Adequate prenatal care, Married, BMI",1,non-Hispanic,Hispanic,1.12,0.82,1.53
10.1097/AOG.0000000000005182,1,Yes,Prepandemic (2019 to Q1 2020),No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",none,1,N/A,Hispanic,19.3,-99,-99
10.1097/AOG.0000000000005182,1,Yes,Prepandemic (2019 to Q1 2020),No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",none,2,N/A,Non-Hispanic American Indian Alaska Native,68.6,-99,-99
10.1097/AOG.0000000000005182,1,Yes,Prepandemic (2019 to Q1 2020),No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",none,3,N/A,Non-Hispanic Asian,16.3,-99,-99
10.1097/AOG.0000000000005182,1,Yes,Prepandemic (2019 to Q1 2020),No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",none,4,N/A,Non-Hispanic Black,65.6,-99,-99
10.1097/AOG.0000000000005182,1,Yes,Prepandemic (2019 to Q1 2020),No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",none,5,N/A,Non-Hispanic White,25,-99,-99
10.1097/AOG.0000000000005182,2,Yes,Pandemic (2020),No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",none,1,N/A,Hispanic,29.8,-99,-99
10.1097/AOG.0000000000005182,2,Yes,Pandemic (2020),No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",none,2,N/A,Non-Hispanic American Indian Alaska Native,79,-99,-99
10.1097/AOG.0000000000005182,2,Yes,Pandemic (2020),No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",none,3,N/A,Non-Hispanic Asian,23.3,-99,-99
10.1097/AOG.0000000000005182,2,Yes,Pandemic (2020),No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",none,4,N/A,Non-Hispanic Black,81.2,-99,-99
10.1097/AOG.0000000000005182,2,Yes,Pandemic (2020),No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",none,5,N/A,Non-Hispanic White,29.1,-99,-99
10.1097/AOG.0000000000005182,3,Yes,Pandemic (2021),No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",none,1,N/A,Hispanic,39.7,-99,-99
10.1097/AOG.0000000000005182,3,Yes,Pandemic (2021),No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",none,2,N/A,Non-Hispanic American Indian Alaska Native,160.8,-99,-99
10.1097/AOG.0000000000005182,3,Yes,Pandemic (2021),No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",none,3,N/A,Non-Hispanic Asian,24.3,-99,-99
10.1097/AOG.0000000000005182,3,Yes,Pandemic (2021),No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",none,4,N/A,Non-Hispanic Black,97.7,-99,-99
10.1097/AOG.0000000000005182,3,Yes,Pandemic (2021),No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",none,5,N/A,Non-Hispanic White,36.1,-99,-99
10.1097/AOG.0000000000005182,4,Yes,Prepandemic (2019 to Q1 2020),No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",none,1,N/A,Large metropolitan,25.3,-99,-99
10.1097/AOG.0000000000005182,4,Yes,Prepandemic (2019 to Q1 2020),No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",none,2,N/A,Medium and small metropolitan,29.9,-99,-99
10.1097/AOG.0000000000005182,4,Yes,Prepandemic (2019 to Q1 2020),No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",none,3,N/A,Rural,42.5,-99,-99
10.1097/AOG.0000000000005182,5,Yes,Pandemic (2020),No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",none,1,N/A,Large metropolitan,33.7,-99,-99
10.1097/AOG.0000000000005182,5,Yes,Pandemic (2020),No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",none,2,N/A,Medium and small metropolitan,37.7,-99,-99
10.1097/AOG.0000000000005182,5,Yes,Pandemic (2020),No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",none,3,N/A,Rural,46.5,-99,-99
10.1097/AOG.0000000000005182,6,Yes,Pandemic (2021),No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",none,1,N/A,Large metropolitan,39.1,-99,-99
10.1097/AOG.0000000000005182,6,Yes,Pandemic (2021),No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",none,2,N/A,Medium and small metropolitan,52.4,-99,-99
10.1097/AOG.0000000000005182,6,Yes,Pandemic (2021),No,NA,Pregnancy-related mortality,Incidence,"per 100,000 live births",none,3,N/A,Rural,56.2,-99,-99
10.1097/AOG.0000000000005191,1,Yes,Black participants,No,NA,Ovarian cancer - All histotypes,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No endometriosis,Yes endometriosis,2.12,1.5,3
10.1097/AOG.0000000000005191,2,Yes,Black participants,No,NA,Ovarian cancer - High-grade serous,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No endometriosis,Yes endometriosis,1.63,1.06,2.51
10.1097/AOG.0000000000005191,3,Yes,Black participants,No,NA,Ovarian cancer - Low-grade serous,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No endometriosis,Yes endometriosis,1,0.13,7.99
10.1097/AOG.0000000000005191,4,Yes,Black participants,No,NA,Ovarian cancer - Endometrioid,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No endometriosis,Yes endometriosis,7.06,3.86,12.91
10.1097/AOG.0000000000005191,5,Yes,Black participants,No,NA,Ovarian cancer - Clear cell,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No endometriosis,Yes endometriosis,4.82,1.81,12.83
10.1097/AOG.0000000000005191,6,Yes,Black participants,No,NA,Ovarian cancer - Mucinous,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No endometriosis,Yes endometriosis,0.89,0.21,3.82
10.1097/AOG.0000000000005191,7,Yes,Black participants,No,NA,"Ovarian cancer - Low-grade, serous, endometroid, and clear cell",OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No endometriosis,Yes endometriosis,4.91,2.93,8.23
10.1097/AOG.0000000000005191,8,Yes,White participants,No,NA,Ovarian cancer - All histotypes,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No endometriosis,Yes endometriosis,1.58,1.26,1.98
10.1097/AOG.0000000000005191,9,Yes,White participants,No,NA,Ovarian cancer - High-grade serous,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No endometriosis,Yes endometriosis,1.31,1,1.72
10.1097/AOG.0000000000005191,10,Yes,White participants,No,NA,Ovarian cancer - Low-grade serous,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No endometriosis,Yes endometriosis,0.98,0.38,2.55
10.1097/AOG.0000000000005191,11,Yes,White participants,No,NA,Ovarian cancer - Endometrioid,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No endometriosis,Yes endometriosis,2.17,1.36,3.45
10.1097/AOG.0000000000005191,12,Yes,White participants,No,NA,Ovarian cancer - Clear cell,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No endometriosis,Yes endometriosis,3.48,2.24,5.41
10.1097/AOG.0000000000005191,13,Yes,White participants,No,NA,Ovarian cancer - Mucinous,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No endometriosis,Yes endometriosis,1.41,0.73,2.7
10.1097/AOG.0000000000005191,14,Yes,White participants,No,NA,"Ovarian cancer - Low-grade, serous, endometroid, and clear cell",OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No endometriosis,Yes endometriosis,2.39,1.71,3.34
10.1097/AOG.0000000000005191,15,Yes,Black participants,No,NA,Ovarian cancer,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,"No premenopausal hysterectomy, no endometriosis","Yes premenopausal hysterectomy, no endometriosis",1.09,0.88,1.36
10.1097/AOG.0000000000005191,15,Yes,Black participants,No,NA,Ovarian cancer,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",2,"No premenopausal hysterectomy, no endometriosis","No premenopausal hysterectomy, yes endometriosis",2.28,1.48,3.51
10.1097/AOG.0000000000005191,15,Yes,Black participants,No,NA,Ovarian cancer,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",3,"No premenopausal hysterectomy, no endometriosis","Yes premenopausal hysterectomy, yes endometriosis",2.01,1.15,3.53
10.1097/AOG.0000000000005191,16,Yes,White participants,No,NA,Ovarian cancer,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,"No premenopausal hysterectomy, no endometriosis","Yes premenopausal hysterectomy, no endometriosis",1.24,1.05,1.47
10.1097/AOG.0000000000005191,16,Yes,White participants,No,NA,Ovarian cancer,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",2,"No premenopausal hysterectomy, no endometriosis","No premenopausal hysterectomy, yes endometriosis",1.83,1.39,2.39
10.1097/AOG.0000000000005191,16,Yes,White participants,No,NA,Ovarian cancer,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",3,"No premenopausal hysterectomy, no endometriosis","Yes premenopausal hysterectomy, yes endometriosis",1.42,0.98,2.07
10.1097/AOG.0000000000005191,17,Yes,Black participants,No,NA,Ovarian cancer,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,"No hormone therapy, no endometriosis","Yes hormone therapy, no endometriosis",1.11,0.87,1.41
10.1097/AOG.0000000000005191,17,Yes,Black participants,No,NA,Ovarian cancer,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",2,"No hormone therapy, no endometriosis","No hormone therapy, yes endometriosis",2.03,1.35,3.05
10.1097/AOG.0000000000005191,17,Yes,Black participants,No,NA,Ovarian cancer,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",3,"No hormone therapy, no endometriosis","Yes hormone therapy, yes endometriosis",2.48,1.28,4.78
10.1097/AOG.0000000000005191,18,Yes,White participants,No,NA,Ovarian cancer,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,"No hormone therapy, no endometriosis","Yes hormone therapy, no endometriosis",1.11,0.97,1.27
10.1097/AOG.0000000000005191,18,Yes,White participants,No,NA,Ovarian cancer,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",2,"No hormone therapy, no endometriosis","No hormone therapy, yes endometriosis",1.89,1.39,2.57
10.1097/AOG.0000000000005191,18,Yes,White participants,No,NA,Ovarian cancer,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",3,"No hormone therapy, no endometriosis","Yes hormone therapy, yes endometriosis",1.43,1.03,1.98
10.1097/AOG.0000000000005191,19,Yes,Black participants,No,NA,Ovarian cancer - All histotypes,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No uterine leiomyoma,Yes uterine leiomyoma,1.34,1.11,1.62
10.1097/AOG.0000000000005191,20,Yes,White participants,No,NA,Ovarian cancer - Clear cell,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No uterine leiomyoma,Yes uterine leiomyoma,1.22,1.05,1.41
10.1097/AOG.0000000000005191,21,Yes,Black participants,No,NA,Ovarian cancer - High-grade serous,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No uterine leiomyoma,Yes uterine leiomyoma,1.32,1.06,1.64
10.1097/AOG.0000000000005191,22,Yes,White participants,No,NA,Ovarian cancer - Clear cell,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No uterine leiomyoma,Yes uterine leiomyoma,1.18,0.99,1.41
10.1097/AOG.0000000000005191,23,Yes,Black participants,No,NA,Ovarian cancer - Low-grade serous,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No uterine leiomyoma,Yes uterine leiomyoma,2.05,0.83,5.07
10.1097/AOG.0000000000005191,24,Yes,White participants,No,NA,Ovarian cancer - Clear cell,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No uterine leiomyoma,Yes uterine leiomyoma,0.77,0.39,1.53
10.1097/AOG.0000000000005191,25,Yes,Black participants,No,NA,Ovarian cancer - Endometrioid,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No uterine leiomyoma,Yes uterine leiomyoma,2.05,1.24,3.39
10.1097/AOG.0000000000005191,26,Yes,White participants,No,NA,Ovarian cancer - Clear cell,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No uterine leiomyoma,Yes uterine leiomyoma,1.41,0.95,2.1
10.1097/AOG.0000000000005191,27,Yes,Black participants,No,NA,Ovarian cancer - Clear cell,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No uterine leiomyoma,Yes uterine leiomyoma,1.64,0.77,3.48
10.1097/AOG.0000000000005191,28,Yes,White participants,No,NA,Ovarian cancer - Clear cell,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No uterine leiomyoma,Yes uterine leiomyoma,1.27,0.84,1.9
10.1097/AOG.0000000000005191,29,Yes,Black participants,No,NA,Ovarian cancer - Mucinous,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No uterine leiomyoma,Yes uterine leiomyoma,1.92,0.99,3.69
10.1097/AOG.0000000000005191,30,Yes,White participants,No,NA,Ovarian cancer - Mucinous,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No uterine leiomyoma,Yes uterine leiomyoma,1.45,0.91,2.32
10.1097/AOG.0000000000005191,31,Yes,Black participants,No,NA,"Ovarian cancer - Low-grade, serous, endometroid, and clear cell",OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No uterine leiomyoma,Yes uterine leiomyoma,1.92,1.31,2.8
10.1097/AOG.0000000000005191,32,Yes,White participants,No,NA,"Ovarian cancer - Low-grade, serous, endometroid, and clear cell",OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,No uterine leiomyoma,Yes uterine leiomyoma,1.21,0.92,1.59
10.1097/AOG.0000000000005191,33,Yes,Black participants,No,NA,Ovarian cancer,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",1,"No premenopausal hysterectomy, no uterine leiomyoma","Yes premenopausal hysterectomy, no uterine leiomyoma",1.33,0.95,1.87
10.1097/AOG.0000000000005191,33,Yes,Black participants,No,NA,Ovarian cancer,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",2,"No premenopausal hysterectomy, no uterine leiomyoma",No premenopausal hysterectomy and with uterine leiomyoma,1.48,1.2,1.83
10.1097/AOG.0000000000005191,33,Yes,Black participants,No,NA,Ovarian cancer,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use, body mass index, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, postmenopausal hormone duration, age at menarche, premenopausal hysterectomy",3,"No premenopausal hysterectomy, no uterine leiomyoma",With premenopausal hysterectomy and uterine leiomyoma,1.29,1.01,1.66
10.1097/AOG.0000000000005191,34,Yes,White participants,No,NA,Ovarian cancer,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use duration, body mass index, smoking status, tubal ligation, family history of cancer, menopausal status, hormone therapy duration or premenopausal hysterectomy, age at menarche",1,"No premenopausal hysterectomy, no uterine leiomyoma","Yes premenopausal hysterectomy, no uterine leiomyoma",1.26,1.02,1.55
10.1097/AOG.0000000000005191,34,Yes,White participants,No,NA,Ovarian cancer,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use duration, body mass index, smoking status, tubal ligation, family history of cancer, menopausal status, hormone therapy duration or premenopausal hysterectomy, age at menarche",2,"No premenopausal hysterectomy, no uterine leiomyoma",No premenopausal hysterectomy and with uterine leiomyoma,1.29,1.08,1.53
10.1097/AOG.0000000000005191,34,Yes,White participants,No,NA,Ovarian cancer,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use duration, body mass index, smoking status, tubal ligation, family history of cancer, menopausal status, hormone therapy duration or premenopausal hysterectomy, age at menarche",3,"No premenopausal hysterectomy, no uterine leiomyoma",With premenopausal hysterectomy and uterine leiomyoma,1.31,1.03,1.66
10.1097/AOG.0000000000005191,35,Yes,Black participants,No,NA,Ovarian cancer,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use duration, body mass index, smoking status, tubal ligation, family history of cancer, menopausal status, hormone therapy duration or premenopausal hysterectomy, age at menarche",1,"No hormone therapy, no uterine leiomyoma","Yes hormone therapy, no uterine leiomyoma",1.17,0.85,1.61
10.1097/AOG.0000000000005191,35,Yes,Black participants,No,NA,Ovarian cancer,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use duration, body mass index, smoking status, tubal ligation, family history of cancer, menopausal status, hormone therapy duration or premenopausal hysterectomy, age at menarche",2,"No hormone therapy, no uterine leiomyoma",No hormone therapy and with uterine leiomyoma,1.37,1.11,1.68
10.1097/AOG.0000000000005191,35,Yes,Black participants,No,NA,Ovarian cancer,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use duration, body mass index, smoking status, tubal ligation, family history of cancer, menopausal status, hormone therapy duration or premenopausal hysterectomy, age at menarche",3,"No hormone therapy, no uterine leiomyoma",With hormone therapy and uterine leiomyoma,1.42,1.05,1.92
10.1097/AOG.0000000000005191,36,Yes,White participants,No,NA,Ovarian cancer,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use duration, body mass index, smoking status, tubal ligation, family history of cancer, menopausal status, hormone therapy duration or premenopausal hysterectomy, age at menarche",1,"No hormone therapy, no uterine leiomyoma","Yes hormone therapy, no uterine leiomyoma",1.01,0.87,1.18
10.1097/AOG.0000000000005191,36,Yes,White participants,No,NA,Ovarian cancer,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use duration, body mass index, smoking status, tubal ligation, family history of cancer, menopausal status, hormone therapy duration or premenopausal hysterectomy, age at menarche",2,"No hormone therapy, no uterine leiomyoma",No hormone therapy and with uterine leiomyoma,1.23,1,1.52
10.1097/AOG.0000000000005191,36,Yes,White participants,No,NA,Ovarian cancer,OR,NA,"Site, age at diagnosis, education, parity, oral contraceptive use duration, body mass index, smoking status, tubal ligation, family history of cancer, menopausal status, hormone therapy duration or premenopausal hysterectomy, age at menarche",3,"No hormone therapy, no uterine leiomyoma",With hormone therapy and uterine leiomyoma,1.22,0.99,1.51
10.1097/AOG.0000000000005220,1,No,NA,No,NA,Fully Vaccinated Before Pregnancy,OR,NA,None,1,White,"Asian, non-Hispanic",2.58,1.6,4.17
10.1097/AOG.0000000000005220,1,No,NA,No,NA,Fully Vaccinated Before Pregnancy,OR,NA,None,2,White,"Black, non-Hispanic",4.58,2.55,8.24
10.1097/AOG.0000000000005220,1,No,NA,No,NA,Fully Vaccinated Before Pregnancy,OR,NA,None,3,White,Hispanic,2.48,0.84,7.26
10.1097/AOG.0000000000005220,1,No,NA,No,NA,Fully Vaccinated Before Pregnancy,OR,NA,None,4,White,None of the above,5.1,2.2,11.82
10.1097/AOG.0000000000005220,2,No,NA,No,NA,Fully Vaccinated Before Pregnancy,OR,NA,"Age, Insurance, Language, Marital Status, Obstetric practice",1,White,"Asian, non-Hispanic",4.73,1.42,15.72
10.1097/AOG.0000000000005220,2,No,NA,No,NA,Fully Vaccinated Before Pregnancy,OR,NA,"Age, Insurance, Language, Marital Status, Obstetric practice",2,White,"Black, non-Hispanic",3.75,2.01,6.99
10.1097/AOG.0000000000005220,2,No,NA,No,NA,Fully Vaccinated Before Pregnancy,OR,NA,"Age, Insurance, Language, Marital Status, Obstetric practice",3,White,Hispanic,4.61,2.54,8.38
10.1097/AOG.0000000000005220,2,No,NA,No,NA,Fully Vaccinated Before Pregnancy,OR,NA,"Age, Insurance, Language, Marital Status, Obstetric practice",4,White,None of the above,6.38,2.55,15.96
10.1097/AOG.0000000000005220,3,No,NA,No,NA,Received Inpatient Vaccination,OR,NA,None,1,White,"Asian, non-Hispanic",4.75,1.73,13.1
10.1097/AOG.0000000000005220,3,No,NA,No,NA,Received Inpatient Vaccination,OR,NA,None,2,White,"Black, non-Hispanic",2.67,0.74,9.7
10.1097/AOG.0000000000005220,3,No,NA,No,NA,Received Inpatient Vaccination,OR,NA,None,3,White,Hispanic,1.96,0.19,20.26
10.1097/AOG.0000000000005220,3,No,NA,No,NA,Received Inpatient Vaccination,OR,NA,None,4,White,"None of the above, non-Hispanic",4.9,0.93,25.85
10.1097/AOG.0000000000005220,4,No,NA,No,NA,Received Inpatient Vaccination,OR,NA,"Age, Insurance, Language, Obstetric practice",1,White,"Asian, non-Hispanic",1.7,0.14,20.75
10.1097/AOG.0000000000005220,4,No,NA,No,NA,Received Inpatient Vaccination,OR,NA,"Age, Insurance, Language, Obstetric practice",2,White,"Black, non-Hispanic",1.79,0.44,7.23
10.1097/AOG.0000000000005220,4,No,NA,No,NA,Received Inpatient Vaccination,OR,NA,"Age, Insurance, Language, Obstetric practice",3,White,Hispanic,2.07,0.6,7.21
10.1097/AOG.0000000000005220,4,No,NA,No,NA,Received Inpatient Vaccination,OR,NA,"Age, Insurance, Language, Obstetric practice",4,White,"None of the above, non-Hispanic",2.42,0.4,14.72
10.1111/1471-0528.17239,1,No,NA,No,NA,third or fourth degree perineal laceration,OR,NA,"age, marital status, insurance status, smoking status, parity, gestational age, prior cesarean delivery, prior operative delivery, anemia, cardiovascular disease, gestational diabetes, haematocrit value, white blood cell count, conducted creatinine lab test",1,White,Black,0.66,0.51,0.86
10.1111/1471-0528.17239,1,No,NA,No,NA,third or fourth degree perineal laceration,OR,NA,"age, marital status, insurance status, smoking status, parity, gestational age, prior cesarean delivery, prior operative delivery, anemia, cardiovascular disease, gestational diabetes, haematocrit value, white blood cell count, conducted creatinine lab test",2,White,Other/Unknown,1.66,1.38,2
10.1111/1471-0528.17486,1,Yes,Black,No,NA,Cardiovascular-related outcomes: Composite Outcome,OR,NA,None,1,Low allostatic load,High allostatic load,1.8,1.3,2.7
10.1111/1471-0528.17486,2,Yes,Black,No,NA,Cardiovascular-related outcomes: Composite Outcome,OR,NA,"Maternal age, the time elapsed since index pregnancy, education level, gravidity, smoking status, bleeding at first trimester and health insurance status",1,Low allostatic load,High allostatic load,1.8,1.2,2.6
10.1111/1471-0528.17486,3,Yes,Black,No,NA,Cardiovascular-related outcomes: New Hypertension,OR,NA,None,1,Low allostatic load,High allostatic load,1.8,1.3,2.7
10.1111/1471-0528.17486,4,Yes,Black,No,NA,Cardiovascular-related outcomes: New Hypertension,OR,NA,"Maternal age, the time elapsed since index pregnancy, education level, gravidity, smoking status, bleeding at first trimester and health insurance status",1,Low allostatic load,High allostatic load,1.7,1.2,2.6
10.1111/1471-0528.17486,5,Yes,Black,No,NA,Cardiovascular-related outcomes: Metabolic Disorder,OR,NA,None,1,Low allostatic load,High allostatic load,2.1,1.3,3.3
10.1111/1471-0528.17486,6,Yes,Black,No,NA,Cardiovascular-related outcomes: Metabolic Disorder,OR,NA,"Maternal age, the time elapsed since index pregnancy, education level, gravidity, smoking status, bleeding at first trimester and health insurance status",1,Low allostatic load,High allostatic load,2.2,1.4,3.4
10.1111/1471-0528.17486,7,Yes,Non-Hispanic white and additional race and ethnicities,No,NA,Cardiovascular-related outcomes: Composite Outcome,OR,NA,None,1,Low allostatic load,High allostatic load,2.1,1.8,2.4
10.1111/1471-0528.17486,8,Yes,Non-Hispanic white and additional race and ethnicities,No,NA,Cardiovascular-related outcomes: Composite Outcome,OR,NA,"Maternal age, the time elapsed since index pregnancy, education level, gravidity, smoking status, bleeding at first trimester and health insurance status",1,Low allostatic load,High allostatic load,2.1,1.8,2.4
10.1111/1471-0528.17486,9,Yes,Non-Hispanic white and additional race and ethnicities,No,NA,Cardiovascular-related outcomes: New Hypertension,OR,NA,None,1,Low allostatic load,High allostatic load,2.1,1.8,2.5
10.1111/1471-0528.17486,10,Yes,Non-Hispanic white and additional race and ethnicities,No,NA,Cardiovascular-related outcomes: New Hypertension,OR,NA,"Maternal age, the time elapsed since index pregnancy, education level, gravidity, smoking status, bleeding at first trimester and health insurance status",1,Low allostatic load,High allostatic load,2.1,1.8,2.5
10.1111/1471-0528.17486,11,Yes,Non-Hispanic white and additional race and ethnicities,No,NA,Cardiovascular-related outcomes: Metabolic Disorder,OR,NA,None,1,Low allostatic load,High allostatic load,1.8,1.5,2.2
10.1111/1471-0528.17486,12,Yes,Non-Hispanic white and additional race and ethnicities,No,NA,Cardiovascular-related outcomes: Metabolic Disorder,OR,NA,"Maternal age, the time elapsed since index pregnancy, education level, gravidity, smoking status, bleeding at first trimester and health insurance status",1,Low allostatic load,High allostatic load,1.7,1.5,2.1
10.1111/1471-0528.17587,1,Yes,Rural,No,NA,Pregestational diabetes,average annual percent change,NA,none,1,N/A,American Indian,3.1,0.5,5.7
10.1111/1471-0528.17587,1,Yes,Rural,No,NA,Pregestational diabetes,average annual percent change,NA,none,2,N/A,Asian/Pacific Islander,6,-1.6,14.1
10.1111/1471-0528.17587,1,Yes,Rural,No,NA,Pregestational diabetes,average annual percent change,NA,none,3,N/A,Black,1.6,-1.1,4.4
10.1111/1471-0528.17587,1,Yes,Rural,No,NA,Pregestational diabetes,average annual percent change,NA,none,4,N/A,Hispanic,3.9,1.1,6.7
10.1111/1471-0528.17587,1,Yes,Rural,No,NA,Pregestational diabetes,average annual percent change,NA,none,5,N/A,White,2.2,1.4,3
10.1111/1471-0528.17587,2,Yes,Urban,No,NA,Pregestational diabetes,average annual percent change,NA,none,1,N/A,American Indian,3,-3,9.4
10.1111/1471-0528.17587,2,Yes,Urban,No,NA,Pregestational diabetes,average annual percent change,NA,none,2,N/A,Asian/Pacific Islander,7,4.7,9.3
10.1111/1471-0528.17587,2,Yes,Urban,No,NA,Pregestational diabetes,average annual percent change,NA,none,3,N/A,Black,1.7,0.8,2.7
10.1111/1471-0528.17587,2,Yes,Urban,No,NA,Pregestational diabetes,average annual percent change,NA,none,4,N/A,Hispanic,3.6,1.5,5.8
10.1111/1471-0528.17587,2,Yes,Urban,No,NA,Pregestational diabetes,average annual percent change,NA,none,5,N/A,White,2.9,2,3.8
10.1111/1471-0528.17587,3,Yes,Rural,No,NA,Gestational diabetes,average annual percent change,NA,none,1,N/A,American Indian,7.7,5.3,10
10.1111/1471-0528.17587,3,Yes,Rural,No,NA,Gestational diabetes,average annual percent change,NA,none,2,N/A,Asian/Pacific Islander,4.3,2,6.5
10.1111/1471-0528.17587,3,Yes,Rural,No,NA,Gestational diabetes,average annual percent change,NA,none,3,N/A,Black,-0.2,-2.9,2.6
10.1111/1471-0528.17587,3,Yes,Rural,No,NA,Gestational diabetes,average annual percent change,NA,none,4,N/A,Hispanic,2.8,1.5,4
10.1111/1471-0528.17587,3,Yes,Rural,No,NA,Gestational diabetes,average annual percent change,NA,none,5,N/A,White,3.1,2.7,3.5
10.1111/1471-0528.17587,4,Yes,Urban,No,NA,Gestational diabetes,average annual percent change,NA,none,1,N/A,American Indian,9.7,7.2,12.2
10.1111/1471-0528.17587,4,Yes,Urban,No,NA,Gestational diabetes,average annual percent change,NA,none,2,N/A,Asian/Pacific Islander,5,4.5,5.6
10.1111/1471-0528.17587,4,Yes,Urban,No,NA,Gestational diabetes,average annual percent change,NA,none,3,N/A,Black,1.5,0.9,2.2
10.1111/1471-0528.17587,4,Yes,Urban,No,NA,Gestational diabetes,average annual percent change,NA,none,4,N/A,Hispanic,4.1,3.4,4.7
10.1111/1471-0528.17587,4,Yes,Urban,No,NA,Gestational diabetes,average annual percent change,NA,none,5,N/A,White,3.6,2.5,4.8
10.1111/1471-0528.17587,5,Yes,Race/Ethnicity- White,No,NA,Pregestational diabetes,RR,NA,maternal age at delivery,1,Urban,Rural,1.47,1.44,1.51
10.1111/1471-0528.17587,6,Yes,"Race/Ethnicity- 
American Indian",No,NA,Pregestational diabetes,RR,NA,maternal age at delivery,1,Urban,Rural,1.74,1.57,1.93
10.1111/1471-0528.17587,7,Yes,Race/Ethnicity- Asian/Pacific Islander,No,NA,Pregestational diabetes,RR,NA,maternal age at delivery,1,Urban,Rural,1.23,1.06,1.42
10.1111/1471-0528.17587,8,Yes,Race/Ethnicity- Black,No,NA,Pregestational diabetes,RR,NA,maternal age at delivery,1,Urban,Rural,1.62,1.54,1.7
10.1111/1471-0528.17587,9,Yes,Race/Ethnicity- Hispanic,No,NA,Pregestational diabetes,RR,NA,maternal age at delivery,1,Urban,Rural,1.56,1.48,1.65
10.1111/1471-0528.17587,10,Yes,Race/Ethnicity- White,No,NA,Gestational diabetes,RR,NA,maternal age at delivery,1,Urban,Rural,1.23,1.22,1.24
10.1111/1471-0528.17587,11,Yes,"Race/Ethnicity- 
American Indian",No,NA,Gestational diabetes,RR,NA,maternal age at delivery,1,Urban,Rural,1.14,1.08,1.19
10.1111/1471-0528.17587,12,Yes,Race/Ethnicity- Asian/Pacific Islander,No,NA,Gestational diabetes,RR,NA,maternal age at delivery,1,Urban,Rural,1.12,1.07,1.16
10.1111/1471-0528.17587,13,Yes,Race/Ethnicity- Black,No,NA,Gestational diabetes,RR,NA,maternal age at delivery,1,Urban,Rural,1.12,1.09,1.16
10.1111/1471-0528.17587,14,Yes,Race/Ethnicity- Hispanic,No,NA,Gestational diabetes,RR,NA,maternal age at delivery,1,Urban,Rural,1.28,1.25,1.31
